Curriculum Vitae Paul A Gurbel, MD. Page 1 CURRUCULUM VITAE ____________________________ July, 2017 Paul A Gurbel M.D. DEMOGRAPHIC AND PERSONAL INFORMATION Current Appointments Professor of Medicine, Division of Cardiology, Johns Hopkins University Adjunct Professor of Medicine, Division of Cardiology, Duke University Doctor Honoris Causa, Nicolaus Copernicus University, Poland Director, Interventional Cardiology and Cardiovascular Medicine Research, Inova Health Director, Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute Personal Data Inova Heart and Vascular Institute Inova Fairfax Medical Campus 3300 Gallows Road, Suite 1225 Falls Church, VA, USA, 22042 Phone: (703) 776-7724, (410)-601-9600 Fax: (703)-776-3751, (410)-601-9601 E-mail: [email protected], [email protected]Education and Training: Year Degree/Certificate Discipline 1979 B.A. Natural Sciences Johns Hopkins University 1983 M.D. Medicine University of Maryland School of Medicine 1983-1984 Internship Internal Medicine Duke University Medical Center 1984-1986 Residency Internal Medicine Duke University Medical Center 1985 Assistant Chief Resident Internal Medicine Duke University Medical Center 1986-1987 Fellowship Pulmonary and Critical Care Johns Hopkins Hospital 1987-1988 Fellowship Cardiovascular Disease Duke University Medical Center 1988-1989 Chief Resident Internal Medicine Duke University Medical Center 1989-1990 Fellowship Interventional Cardiology Duke University Medical Center Professional Experience 1988-1990 Associate in Medicine, Duke University Medical Center 1990-1995 Assistant Professor of Medicine, University of Maryland Medical System 1990-1991 Director, Interventional Cardiology Research, University of Maryland Medical System 1991-1995 Director, Interventional Cardiology, University of Maryland Medical System 1995-1997 Interventional Cardiologist, Heart Associates, PA, Baltimore, MD 1995-2000 Staff Physician, Church Hospital, Baltimore, MD 1995-2000 Staff Physician, Liberty Medical Center, Baltimore, MD 1995-2009 Staff Physician, St. Joseph Medical Center, Towson, MD 1995-2009 Staff Physician, Bon Secours Hospital, Baltimore, MD 1995-2009 Staff Physician, Greater Baltimore Medical Center (GBMC), Towson, MD 1995-2009 Staff Physician, St. Agnes Hospital, Baltimore, MD, 1995-2009 Staff Physician, Union Memorial Hospital, Baltimore, MD 1995-present Staff Physician, Sinai Hospital of Baltimore, Baltimore, MD 1997-2006 Staff Physician, Johns Hopkins Hospital, Baltimore, MD 1997-2000 Interventional Cardiologist, Cardivascular Specialists of MD 1999-2003 Assistant Professor of Medicine (part-time), Johns Hopkins Hospital, Baltimore, MD 1999-2005 Staff Physician, Upper Chesapeake Medical Center, Bel Air, MD
Transcript
Curriculum Vitae Paul A Gurbel MD Page 1
CURRUCULUM VITAE ____________________________ July 2017 Paul A Gurbel MD DEMOGRAPHIC AND PERSONAL INFORMATION Current Appointments Professor of Medicine Division of Cardiology Johns Hopkins University Adjunct Professor of Medicine Division of Cardiology Duke University Doctor Honoris Causa Nicolaus Copernicus University Poland Director Interventional Cardiology and Cardiovascular Medicine Research Inova Health Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute Personal Data Inova Heart and Vascular Institute Inova Fairfax Medical Campus 3300 Gallows Road Suite 1225 Falls Church VA USA 22042 Phone (703) 776-7724 (410)-601-9600 Fax (703)-776-3751 (410)-601-9601 E-mail paulgurbelinovaorg pgurbellifebridgehealthorg Education and Training Year DegreeCertificate Discipline 1979 BA Natural Sciences Johns Hopkins University 1983 MD Medicine University of Maryland School of Medicine 1983-1984 Internship Internal Medicine Duke University Medical Center 1984-1986 Residency Internal Medicine Duke University Medical Center 1985 Assistant Chief Resident Internal Medicine Duke University Medical Center 1986-1987 Fellowship Pulmonary and Critical Care Johns Hopkins Hospital 1987-1988 Fellowship Cardiovascular Disease Duke University Medical Center 1988-1989 Chief Resident Internal Medicine Duke University Medical Center 1989-1990 Fellowship Interventional Cardiology Duke University Medical Center Professional Experience 1988-1990 Associate in Medicine Duke University Medical Center 1990-1995 Assistant Professor of Medicine University of Maryland Medical System 1990-1991 Director Interventional Cardiology Research University of Maryland Medical System 1991-1995 Director Interventional Cardiology University of Maryland Medical System 1995-1997 Interventional Cardiologist Heart Associates PA Baltimore MD 1995-2000 Staff Physician Church Hospital Baltimore MD 1995-2000 Staff Physician Liberty Medical Center Baltimore MD 1995-2009 Staff Physician St Joseph Medical Center Towson MD 1995-2009 Staff Physician Bon Secours Hospital Baltimore MD 1995-2009 Staff Physician Greater Baltimore Medical Center (GBMC) Towson MD 1995-2009 Staff Physician St Agnes Hospital Baltimore MD 1995-2009 Staff Physician Union Memorial Hospital Baltimore MD 1995-present Staff Physician Sinai Hospital of Baltimore Baltimore MD 1997-2006 Staff Physician Johns Hopkins Hospital Baltimore MD 1997-2000 Interventional Cardiologist Cardivascular Specialists of MD 1999-2003 Assistant Professor of Medicine (part-time) Johns Hopkins Hospital Baltimore MD 1999-2005 Staff Physician Upper Chesapeake Medical Center Bel Air MD
Curriculum Vitae Paul A Gurbel MD Page 2
2000-2001 Interventional Cardiologist Baltimore Heart Associates 2000-present President Platelet and Thrombosis Research Baltimore MD 2000-present Staff Physician Northwest Medical Center Randallstown MD 2001-2007 Partner and Interventional Cardiologist Baltimore Heart Associates Baltimore MD 2001-2015 Director of Cardiovascular Research Lifebridge Health BaltimoreMD 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital Baltimore MD 2003-2013 Associate Professor of Medicine (part-time) Johns Hopkins Hospital Baltimore MD 2005-2006 Helen Dalsheimer Director Division of Cardiology Sinai Hospital of Baltimore 2007-2009 Interventional Cardiologist Hagerstown Heart PA Hagerstown MD 2007-2010 Staff Physician Washington County Hospital Hagerstown MD 2007-2015 Associate Chief for Research Department of Medicine Sinai Hospital Baltimore MD 2013-present Professor of Medicine Johns Hopkins Hospital Baltimore MD 2013-present Adjunct Professor of Medicine Duke University School of Medicine Durham NC 2015-present Staff physician Inova Fairfax Hospital Falls Church VA 2015-present Director Interventional Cardiology Inova Health Falls Church VA 2015-present Director Cardiovascular Medicine Research Inova Health Falls Church VA 2015-present Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute Falls Church VA
RESEARCH ACTIVITIES Publications Peer Reviewed Original Science Research (articles) 1 Tapson VF Davidson CJ Gurbel PA Sheikh KH Kisslo KB Stack RS Rapid and accurate diagnosis of pulmonary emboli in a canine model using intravascular ultrasound imaging Chest 1991 1001410-3 2 Herzog WR Atar D Gurbel PA Vogel RA Schlossberg ML Serebruany VL Effect magnesium infusion on
platelet aggregation in swine Magnesium Res 1993 4349-353 3 Gurbel PA MacCord CS Anderson RD Scott HJ Atar D Mergner W Herzog WR A canine coronary artery
thrombosis model for the evaluation of reperfusion strategies Cardiology 1994 841-8 4 Gurbel PA Anderson RD MacCord CS Scott H Komjathy SF Poulton J Stafford JL Goddard J Arterial
diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy Circulation 1994 89361-265
5 Tapson VF Gurbel PA Witty LA Pieper KS Stack RS Pharmacomechanical thrombolysis of experimental pulmonary emboli rapid low-dose intraembolic therapy Chest 1994 1061668-1652
6 Ohman EM Marquis J-F Ricci DR Brown RG Knudtson ML Kerejakes DJ Samaha JK Margolis JR Niderman AL Dean LJ Gurbel PA Sketch M for the perfusion balloon catheter study group A randomized comparison of gradual prolonged versus standard primary balloon inflation on early and late outcome results of a multicenter clinical trial Circulation 1994 891118-1125
7 Ohman EM George BS White CJ Kern MJ Gurbel PA Freedman RJ Lundergan C Hartmann JR Talley JD Frey MJ Taylor G Leimberger JD Owens PM Lee KL Stack RS Califf RM for Randomized IABP Study Group The use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction Results of a randomized trial Circulation 1994 90792-799
8 The Epic Investigators Evaluation of chimeric monoclonal antibody C7E2 fab fragment directed against the platelet glycoprotein IIb IIIa receptor for preventing ischemic complications of high risk angioplasty (EPIC) N Engl J Med 1994 330956-957
9 Gurbel PA Anderson RD MacCord CS Scott HJ Serebruany VL Herzog WR Accelerated intravenous dosing of recombinant tissue plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction Coron Artery Dis 1994 5929-936
10 Gurbel PA Serebruany VL Komjathy SF Collins ME Sane DC Scott HJ Schlossberg ML Herzog WR Regional and systemic platelet function is altered by myocardial ischemia-reperfusion J Thromb Thrombolysis 19951187-194
11 Serebruany VL Herzog WR Gurbel PA Schlossberg ML Scott HG Vogel RA NPC15669 an anti-inflammatory leucine derivative reduces in vitro platelet aggregability in both swine and human plasma J Thromb Thrombolysis 19951171-178
12 Herzog WR Gurbel PA Vogel RA Schlossberg ML Scott HJ Schneider AI Serebruany VL Effects of NPC 15669 an anti-inflammatory leucine derivative on myocardial stunning and pre-conditioned infarction size in swine J Thromb Thrombolysis 19951163-170
13 Serebruany VL Herzog WR Gurbel PA Serial changes of natural antithrombotics during myocardial ischemia-
Curriculum Vitae Paul A Gurbel MD Page 3
reperfusion in swine Effects of magnesium diltiazem and a novel Mac-1 inhibitor Blood Coag Fibrinolysis 1996 7632-640
14 Gurbel PA Navetta FI Bates ER Muller DW Tenaglia AN Miller MJ Muhstein B Hermiller JB Davidson CJ Aguirre FV Beauman GJ Berdan LG Leimberger JD Boville EG Christenson RH Ohman EM Lesion-directed administration of tissue plasminogen activator with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty Cathet Cardiovasc Diagn 1996 37382-391
15 Anderson RD Gurbel PA The effect of intra-aortic balloon counterpulsation on coronary blood flow velocity distal to coronary artery stenosis Cardiology 1996 87306-312
16 Serebruany VL Herzog WR Atamas SP Gurbel PA Paulsen G Mortensen SA Folkers K Hemostatic changes after dietary coenzyme Q10 supplementation in swine J Cardiovasc Pharm 1996 28175-181
17 Gurbel PA Serebruany VL Komjathy SF Collins ME Bittar GD Schlossberg ML Mergner W Pretreatment with an inhibitor of Mac-1 alters regional and systemic platelet function during ischemia - reperfusion in swine Pharmacology 1996 5379-86
18 Serebruany VL Solomon SR Edenbaum LR Herzog WR Gurbel PA Mac-1 inhibitor affects certain hemostatic parameters during myocardial stunning in swine Pharmacology 1996 5387-96
19 Serebruany VL Schlossberg ML Edenbaum LR Herzog WR Gurbel PA Intracoronary magnesium and diltiazem affect to a similar extent certain hemostatic factors during acute myocardial infarction in swine Pharmacology 1996 53224-233
20 Serebruany VL Schlossberg ML Edenbaum LR Herzog WR Gurbel PA Hemostatic changes after early versus late intracoronary magnesium during acute myocardial infarction in swine J Cardiovasc Pharm 1996 8817-823
21 Serebruany VL Herzog WR Edenbaum LR Shustov AR Gurbel PA Changes in the haemostatic profile during magnesium deficiency in swine Magnesium Res 1996 9155-163
22 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression J Cardiovasc Pharm 1997 2916-22
23 Serebruany VL Herzog WR Gurbel PA Serial changes of the plasma prostanoids during myocardial ischemia - reperfusion in swine Effects of magnesium diltiazem and a novel Mac-1 inhibitor Prostaglandins Leukot Essent Fatty Acids 1997 56135-142
24 Gurbel PA Anderson RD A new concept in coronary angioplasty Dilatation with a helical balloon which allows simultaneous autoperfusion Cathet Cardiovasc Diagn 1997 40109-116
25 Gurbel PA Anderson RD Pells HO van Boven AJ den Heijer P Coronary artery angioplasty with a helical autoperfusion catheter Cathet Cardiovasc Diagn 1997 40179-185
26 Serebruany VL Gurbel PA Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Could coenzyme Q10 affect hemostasis by inhibiting platelet vitronectin (CD51CD61) receptor Molec Aspects Med 199718 S189-S194
27 Gurbel PA Herzog WR Vogel RA Schlossberg ML Edenbaum LR Scott HJ Serebruany VL Short-term low does intracoronary diltiazem administered at the onset of reperfusion reduces myocardial infarct size Intern J Cardiol 1997 5921-27
28 Serebruany VL Solomon SR Herzog WR Gurbel PA Bolus magnesium infusion in humans is associated with predominantly unfavorable changes in platelet aggregation and certain hemostatic factors Pharm Res 1997 3517-22
29 Serebruany VL Schlossberg ML Edenbaum LR Herzog WR Gurbel PA Effects of intracoronary diltiazem on certain hemostatic parameters during acute myocardial infarction in swine Inter J Cardiol 1997 6121-29
30 Gurbel PA Serebruany VL Soluble vascular cell adhesion molecule and E-Selectin in patients with acute myocardial infarction treated with thrombolytic agents Am J Cardiol 1998 81772-775
31 Serebruany VL Bahr RD OConnor CM Lowry DR Gurbel PA For the GUSTO III Platelet Substudy Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction Cardiology 1998 9037-42
32 Serebruany VL Solomon SR Herzog WR Gurbel PA Plasma fibronectin during myocardial ischemia - reperfusion Effects of magnesium diltiazem and a novel Mac-1 inhibitor Am J Hematol 1998 57309-314
33 Serebruany VL Solomon SR Shustov AR Herzog WR Gurbel PA Survival in acute myocardial infarction induced by coronary artery ligation prognostic relevance of certain hemostatic factors during the occlusion phase J Thromb and Thrombolysis 1998 5 39-35
34 Gurbel PA Shustov AR Bahr RD Carpo C Ohman EM and Topol EJ for the GUSTO III Investigators Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment The GUSTO III Platelet Study J Am Coll Cardiol 1998 311466-1473
35 Serebruany VL Ordonez JV Yrovsky VV Gurbel PA The crossreactivity of human vs swine platelet surface antigens is similar for glycoproteins IIb and IIIa but not for IIb and IIIa complex J Thromb and Thrombolysis 1998
Curriculum Vitae Paul A Gurbel MD Page 4
537-41 36 Serebruany VL Gurbel PA Shustov AR Ohman EM Topol EJ Heterogeneity of platelet aggregation and major
surface receptor expression in patients presenting with acute myocardial infarction Am Heart J 1998 136398-405 37 Serebruany VL Gurbel PA Murugesan SR Lowry Dr Sturm E Svetlov SI Depressed plasma platelet-activating
factor acetylhydrolase in patients presenting with acute myocardial infarction Cardiology 199890127-130 38 Serebruany VL Schlossberg ML Edenbaum LR Herzog WR Gurbel PA Serial changes of soluble endothelin-1
levels during myocardial ischemia-reperfusion Effects of magnesium diltiazem and a novel Mac-1 Inhibitor Pharm Res 199838165-172
39 Gurbel PA Serebruany VL Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Increased baseline platelet P-selectin and PECAM-1 as predictors of unsuccessful thrombolysis in patients with acute myocardial infarction Coron Artery Dis 19989451-456
40 Serebruany VL Gurbel PA Effect of thrombolytic therapy on the plasma concentration and platelet expression of the plateletendothelial cell adhesion molecule in patients with acute myocardial infarction Arterioscl Thromb Vasc Biol 199919153-158
41 Serebruany VL Gurbel PA The relations of major platelet receptor expression during myocardial infarction Monitoring efficacy of GP IIbIIIa inhibitors by measuring P-selectin Thromb Haemost 199980314-316
42 Serebruany VL Gurbel PA Assessment of platelet activity by measuring platelet derived substances in plasma from patients with acute myocardial infarction Surprising lessons from the GUSTO III Platelet Study Thromb Res 199993149-150
43 OConnor CM Gurbel PA Serebruany VL Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure Am J Cardiol 1999831345-1349
44 Serebruany VL Murugesan SR Pothula A Semaan H Gurbel PA Soluble plateletendothelial cellular adhesion molecule-1 but not P-selectin nor osteonectin identify acute myocardial infarctions among patients with chest pain admitted to the Emergency Department Cardiology 1999150-55
45 Serebruany VL Yurovsky VV Gurbel PA Mild myocardial stunning affects platelet aggregation and certain hemostatic factors in swine Clin Appl Thromb Haemost 19995236-42
46 Murugesan SR Gurbel PA Serebruany VL Storing paraformaldehyde fixed whole blood in patient samples after chronic platelet glycoprotein IIb IIIa blockade Core laboratory considerations Thromb Res 19995201-203
47 Serebruany VL Kereiakes DJ Dalesandro MR Gurbel PA The flow cytometer model markedly affects measurement of ex vivo whole blood platelet-bound P-selectin expression in patients with chest pain Are we comparing apples and oranges Thromb Res 19999651-56
48 Serebruany VL Yurovsky VV Gurbel PA Effects of a novel Mac-1 inhibitor NPC 15669 on hemostatic parameters during preconditioned myocardial infarction Life Sciences 1999651503-13
49 Gurbel PA Murugesan SR Lowry DR Serebruany VL Plasma thromboxane and prostacyclin are linearly related and increased in patients presenting with myocardial infarction Prostaglandins Leukot Essent Fatty Acids 1999617-11
50 Gurbel PA Kereiakes DJ Dalesandro MR Bahr RD OConnor CM Serebruany VL The role of soluble and platelet-bound P-selectin in discriminating cardiac from non-cardiac chest pain at presentation in the Emergency Department Am Heart J 2000139320-328
51 McKenzie ME Pothula A Gurbel PA Fuzaylov SY OConnor CM Gaitis WA Serebruany VL Failure of thrombin generation markers to triage patients presenting with chest pain Cardiology 20009253-58
52 Gurbel PA Kerejakes DJ Serebruany VL Soluble P-Selectin is not a surrogate marker for platelet P-Selectin Evidence from a multicenter chest pain study group J Thromb Thrombolysis 20001015-22
53 Serebruany VL Murugesan SR Pothula Atar D Lowry DR OrsquoConnor CM Gurbel PA Increased soluble plateletendothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure Independence of disease etiology and antecedent aspirin therapy Eur J Heart Fall 20001243-9
54 Semann HB Gurbel PA Anderson JL Muhlestein JB Carlquist JV Horne BD Serebruany VL Soluble VCAM-1 and E-selectin but not ICAM-1 discriminate endothelial injury in patients with documented coronary artery disease Cardiology 2000937-10
55 Gurbel PA Kereiakes DJ Serebruany VL Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction Scand Cardiovasc J 20003453-8
56 Serebruany VL Lowry DR Fuzaylov SY Levine DJ OConnor CM Gurbel PA Moderate alcohol consumption is associated with the decreased baseline platelet activity in patients presenting with acute myocardial infarction J Thromb Thrombolysis 20009229-34
57 Serebruany VL Murugesan SR Atar D Jerome S Semann H Gurbel PA Effect coronary thrombolysis on the plasma concentration of osteonectin (SPARC BM40) in patients with acute myocardial infarction J Thromb Thrombolysis 200010197-202
58 Semann HB Gurbel PA Anderson JL Muhlestein JB Carlquist JF Horne BD Serebruany VL The effect of
Curriculum Vitae Paul A Gurbel MD Page 5
chronic azithromycin therapy on soluble endothelium-derived adhesion molecules in patients with coronary artery disease Cardiovasc Pharmacol 200036533-7
59 Gurbel PA OrsquoConnor CM Dalesandro MR Serebruany VL Relation of soluble and platelet P-selectin to early outcome in patients with acute myocardial infarction after thrombolytic therapy Am J Cardiol 200187774-7
60 Serebruany VL Alford AB Meister AF Fuzaylov SY Gattis WA Gurbel PA Clinical utility of the platelet function analyzer (PFA-100) for the Assessment of the Platelet Status in Patients with Congestive Heart Failure (EPCOT trial) Thromb Res 200115427-33
61 Serebruany VL Gurbel PA OrsquoConnor CM Platelet inhibition by sertraline and n-desmethylsertraline A possible missing link between depression coronary events and mortality benefits of selective serotonin reuptake inhibitors Pharmacol Res 200143453-62
62 Serebruany VL OrsquoConnor CM Gurbel PA Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease Am J Cardiol 2001871398-400
63 Serebruany VL Levine DJ Nair GV Meister AF Gurbel PA Usefulness of combining necrosis and platelet markers in triaging patients presenting with chest pain to the emergency department J Thromb and Thrombolysis 200111155-62
64 Serebruany VL Cummings CC Malinin AI Steinhubl SR Gurbel PA Uniform platelet activation exists before coronary stent implantation despite aspirin therapy Am Heart J 2001142611-16
65 Gurbel PA Fusaylov SF Gattis WA Gaulden L Hasselblad V Serebruany VL OrsquoConnor CM Evaluation of platelets in heart failure Is platelet activity related to etiology class or clinical outcomes Am Heart J 20021431068-75
66 Gurbel PA Malinin AI Callahan KP Serebruany VL OrsquoConnor CM Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and GP IIbIIIa expression and platelet-leukocyte aggregate formation Am J Cardiol 200290312-315
67 Bahr RD Gurbel PA Malinin AI Wentz C Christenson RH Roe MT Gibler WB Kitt MM Ohman EM Serebruany VL Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q wave acute myocardial infarction Am J Cardiol 200290310-312
68 Faxon DP Gibbons RJ Chronos NAF Gurbel PA Sheehan F for the HALT ndash MI Investigators The effect of blockade of the CD11CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty The results of the HALT- MI study J Am Coll Cardiol 2002401199-1204
69 Serebruany VL McKenzie M Meister A Fuzaylov S Gurbel P Atar D Gattis W OrsquoConnor C Whole blood impedence aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT Trial) Eur J Heart Fail 20024461
70 Serebruany V McKenzie ME Meister AF Fuzaylov SY Gurbel PA Atar D Gattis WA OrsquoConnor CM Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT Trial with special reference to the Hemodyne hemostatic analyzer Pathophysiol Haemost Thromb 2002328-15
71 Gurbel PA Callahan KP Malinin AI Serebruany VL Gillis J Could stent design affect platelet activation Results of the Platelet Activation in Stenting (PAST) study J Invasive Cardiol 200214584-9
72 Gurbel PA Galbutt B Bliden KP Bahr RD Roe MT Serebruany VL Ohman EM Effect of eptifibatide for acute coronary syndromes Rapid versus late administration-therapeutic yield on platelets (the EARLY platelet substudy) J Thromb Thrombolysis 200314213-219
73 Gurbel PA Cummings CC Alford AB Meister AF Serebruany VL Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting The Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial Am Heart J 2003145239-47
74 Serebruany VL Malinin AI Callahan KP Binbrek A Van de Werf F Alexander JH Granger CB Gurbel PA Effect of tenecteplase versus alteplase on platelets during the first three hours of treatment for acute myocardial infarction The ASSENT-2 Platelet Substudy Am Heart J 2003145636-42
75 Gurbel PA Bliden KP Durability of platelet inhibition by clopidogrel Am J Cardiol 2003911123-5 76 Gurbel PA Bliden KP Hiatt BL The early antiplatelet effects of clopidogrel loading for coronary stenting and the
long term stability of inhibition J Thromb Haemost 200311319-21 77 Gurbel PA Bliden KP Hiatt BL Clopidogrel for coronary stenting Response variability drug resistance and the
effect of pretreatment platelet reactivity Circulation 20031072908-13 78 Serebruany VL Malinin AI OrsquoConnor CM Gurbel PA Effects of roxifiban on platelet aggregation and major
receptor expression in patients with coronary artery disease For the Roxifiban Oral Compound Kinetics Evaluation Trial ndash I Am Heart J 200314691-8
79 Gurbel PA Bliden KP Platelet activation after stenting with heparin-coated versus non-coated stents Am Heart J 2003146E10
Curriculum Vitae Paul A Gurbel MD Page 6
80 Gurbel PA Bliden KP A new method of representing drug-induced platelet inhibition Better description of time course response variability non-response and heightened reactivity Platelets 200314481-3
81 Gurbel PA Bliden KP The stratification of platelet reactivity and activation in patients with stable coronary disease on aspirin therapy Thromb Res 20031129-12
82 Gurbel PA Samara WM Bliden KP Failure of clopidogrel to reduce platelet reactivity an activation following standard dosing in elective stenting Implications for thrombotic events and restenosis Platelets 20031595-99
83 Lau WC Gurbel PA Watkins PB Neer CJ Hopp AS Carville DGM Guyer KE Tait AR Bates ER The contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 200410966-71
84 Joynt KE Gattis WA Hasselblad V Fuzaylov SY Serebruany VL Gurbel PA Gaulden LH Felker GM Whellan DJ OrsquoConnor CM Effect of angiotensin-converting enzyme inhibitors beta blockers statins and aspirin on C-reactive protein levels in outpatients with heart failure Am J Cardiol 200493783-5
85 Samara WM Bliden KP Tantry U Gurbel PA Thrombotic risk The difference between clopidogrel responsiveness and post-treatment platelet reactivity Thromb Res 200411589-94
86 Gurbel PA Hayes KA Bliden KP Yoho J Tantry U The platelet-related effects of tenecteplase vs alteplase vs reteplase Blood Coag Fibrinolysis 2005161-7
87 Gurbel PA Bliden KP Zaman KA Yoho JA Hayes KM Tantry US Clopidogrel loading with eptifibatide to arrest the reactivity of platelets Results of the CLEAR PLATELETS study Circulation 20051111153-9
88 Poston R Gu J Brown J Gammie J White C Manchio J Pierson RN Griffith P Gurbel P Tantry U Gilbert TB Hypercoaguability affecting early vein graft patency does not exist after off-pump coronary artery bypass J Cardiothoracic Vasc Anesth 20051911-18
89 Gurbel PA Bliden KP Hates KM Yoho JA Herzog WR Tantry US The relation of dosing to clopidogrel responsiveness and the incidence of high post-stent platelet aggregation in patients undergoing coronary stenting J Am Coll Cardiol 2005451392-6
90 Hermiller JB Raizner A Cannon L Gurbel PA Kutcher MA Wong SC Russell ME Ellis SG Mehran R Stone GW TAXUS-IV Investigators Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus The TAXUS-IV trial J Am Coll Cardiol 2005451172-9
91 Gurbel PA Bliden KP Samara W Yoho J Hayes K Fissha M Tantry U Clopidogrel Effect on Platelet REactivity in Patients with Stent Thrombosis Results of the CREST Study J Am Coll Cardiol 2005461827-32
92 Gurbel PA Bliden KP Guyer K Cho P Zaman K Kreutz R Bassi A Tantry US Platelet REactivity in Patients And Recurrent Events POST-STENTING Results of the PREPARE POST-STENTING Study J Am Coll Cardiol 2005461820-6
93 Tantry US Bliden KP Gurbel PA Overestimation of platelet aspirin resistance Detection by thrombelastograph platelet mapping and validation by conventional aggregation using arachidonic acid stimulation J Am Coll Cardiol 2005461705-9
94 Kreutz RP Tantry US Bliden KP Gurbel PA Viral respiratory tract infections increase platelet reactivity and activation - an explanation for the higher rates of myocardial infarction and stroke during viral illness J Thromb Haemost 200532108-9
95 Bleske B Nicklas J Bard R Brook R Gurbel PA Bliden K Rajagopalan S Pitt B Neutral effect on markers of heart failure inflammation endothelial activation and function and vagal tone following high dose HMG - coA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low density lipoproteins J Am Coll Cardiol 200647338-41
96 Gurbel PA Bliden KP Tantry US Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting Inflammation results from the CLEAR PLATELETS-1b study J Am Coll Cardiol 2006482186-91
97 Kandzari DE Leon MB Popma JJ Fitzgerald PJ OrsquoShaughnessy C Ball MW Turco M Applegate RJ Gurbel PA et alfor the ENDEAVOR III Investigators Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease a randomized controlled trial J Am Coll Cardiol 2006482440 ndash 2447
98 Gurbel PA Bliden KP Guyer K Aggarwal N Tantry US Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting Thromb Res 2007119563-70
99 Bliden KP DiChiara J Tantry US Bassi AK Chaganti SK Gurbel PA Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention is the current antiplatelet therapy adequate J Am Coll Cardiol 200749657-66
100 Gurbel PA Bliden KP Etherington A Tantry US Assessment of clopidogrel responsiveness measurements of maximum platelet aggregation final platelet aggregation and their correlation with vasodilator stimulated phosphoprotein in resistant patients Thromb Res 2007121107-15
101 Gurbel PA Bliden KP DiChiara J Gesheff T RN Chaganti S Etherington A MD Tantry US Evaluation of
Curriculum Vitae Paul A Gurbel MD Page 7
dose-related effects of aspirin on platelet function results from the ASpirin-Induced Platelet EffeCT (ASPECT) study Circulation 20071153156-64
102 Kreutz RP Tantry US Bliden KP Gurbel PA Inflammatory changes during the common cold are associated with platelet activation and increased reactivity of platelets to agonists Blood Coagul Fibrinolysis 200718713-8
103 Storey R Husted S Harrington R Heptinstall S Wilcox R Peters G Wickens Emanuelsson H Gurbel PA Grande P Cannon C Inhibition of platelet aggregation by AZD6140 a reversible oral P2Y12 receptor antagonist compared with clopidogrel in patients with acute coronary syndromes J Am Coll Cardiol 2007501852-6
104 DiChiara J Bliden KP Tantry US Hamed MS Antonino MJ Suarez TA Bailon O Singla A Gurbel PA The effect of aspirin dosing on platelet function in diabetic and non-diabetic patients an analysis from the aspirin-induced platelet effect (ASPECT) study Diabetes 200756 3014-9
105 DiChiara J Bliden KP Tantry US Chaganti SK Kreutz R Gesheff TB Kreutz Y Gurbel PA Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients Platelets 200718 414-23
106 Gurbel PA Kreutz RP Bliden KP Tantry US Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease a potential approach to identify atherosclerotic disease progression Am Heart J 200815555-61
107 Gurbel PA Bliden KP Cohen E Navickas IA Singla A Antonino MJ Fissha M Kreutz RP Bassi AK Tantry US Race and sex differences in thrombogenicity risk of ischemic events following coronary stenting Blood Coagul Fibrinolysis 200819268-75
108 Nissen SE Nicholls SJ Wolski K Rodeacutes-Cabau J Cannon CP Deanfield JE Despreacutes JP Kastelein JJ Steinhubl SR Kapadia S Yasin M Ruzyllo W Gaudin C Job B Hu B Bhatt DL Lincoff AM Tuzcu EM STRADIVARIUS Investigators Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease the STRADIVARIUS randomized controlled trial JAMA 20082991547-60
109 Bliden KP DiChiara J Lookman L Singla A Antonino MJ Baker BA Bailey WL Tantry US Gurbel PA The association of cigarette smoking with enhanced platelet inhibition by clopidogrel J Am Coll Cardiol 200852531-3
110 Gurbel PA Antonino MJ Bliden KP Dichiara J Suarez TA Singla A Tantry US Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention a potential antiplatelet therapeutic target Platelets 200819595-604
111 Gurbel PA Bliden KP Cohen E Navickas IA Singla A Antonino MJ Fissha M Kreutz RP Bassi AK Tantry US Race and sex differences in thrombogenicity risk of ischemic events following coronary stenting Blood Coagul Fibrinolysis 200819268-75
112 Gurbel PA Antonino MJ Bliden KP Dichiara J Suarez TA Singla A Tantry US Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention a potential antiplatelet therapeutic target Platelets 200819595-604
113 Hamed MS Gambert S Bliden KP Bailon O Anand S Antonino MJ Hamed F Tantry US Gurbel PA Dark chocolate effect on platelet activity C-reactive protein and lipid profile a pilot study S Med J 20081011203-8
114 Gilstad JR Gurbel PA Andersen RE Relationship between age and platelet activation in patients with stable and unstable angina Arch Gerontol Geriatr 200948155-9
115 Gurbel PA Bliden KP Saucedo JF Suarez TA DiChiara J Antonino MJ Mahla E Singla A Herzog WR Bassi AK Hennebry TA Gesheff TB Tantry US Bivalirudin and clopidogrel with and without eptifibatide for elective stenting effects on platelet function thrombelastographic indices and their relation to periprocedural infarctionResults of the CLEAR PLATELETS-2 study J Am Coll Cardiol 200953857-9
116 Gurbel PA Bliden KP Kreutz RP DiChiara J Antonino MJ Tantry US The link between heightened thrombogenicity and inflammation Pre-procedure characterization of the patient at high risk for recurrent events after stenting Platelets 20092097-104
117 Antonino MJ Mahla E Bliden KP Tantry US Gurbel PA Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting Am J Cardiol 20091031546-50
118 Antonino MJ Coppolecchia R Mahla E Bliden KP Tantry US Gurbel PA Antiplatelet effects of aspirin with phytosterols Comparison with non-enteric coated aspirin alone Thromb Res 2009126384-5
119 Pinto Slottow TL Bonello L Gavini R Beauzile P Sushinsky SJ Scheinowitz M Kaneshige K Xue Z Torguson R Tantry U Pichard AD Satler LF Suddath WO Kent K Gurbel P Waksman R Am J Cardiol 2009104525-30
120 Shuldiner AR OConnell JR Bliden KP Gandhi A Ryan K Horenstein RB Damcott CM Pakyz R Tantry US Gibson Q Pollin TI Post W Parsa A Mitchell BD Faraday N Herzog W Gurbel PA Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyJAMA2009302849-57
121 Singla A Antonino MJ Bliden KP Tantry US Gurbel PA The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy Am Heart J 2009158784e1-6
122 Gurbel PA Bliden KP Antonino MJ Stephens G Gretler DD Jurek MM Pakyz RE Shuldiner AR Conley PB
Curriculum Vitae Paul A Gurbel MD Page 8
Tantry US The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP 2C192 genotype First experience in patients J Thromb Haemost 2010843-53
123 Gurbel PA Bliden KP Butler K Tantry US Gesheff T Wei C Teng R Antonino MJ Patil SB Karunakaran A Kereiakes DJ Parris C Purdy D Wilson V Ledley GS Storey RF Randomized double-blind assessment of the ONSET and OFFSet of the antiplatelet Effects of Ticagrelor versus clopidogrel in patients with stable coronary artery disease The ONSETOFFSET Study Circulation 20091202577-85
124 Gurbel PA Bliden K Antonino M Butler K Teng R Rasmussen L Syd A Storey R Nielsen T Eikelboom J Sabe-Affaki G Husted S Kereaikes D Henderson D Patel V Tantry U Response to Ticagrelor in Clopidogrel Non-responders and ReSPONDers and the Effect of Switching Therapies The RESPOND Study Circulation 20101211188-99
125 Tantry US Bliden KP Suarez TA Kreutz RP DiChiara J Gurbel PA Hypercoagulability platelet function inflammation and coronary artery disease acuity results of the Thrombotic Risk Platelets 201021 360-7
126 Hennekens CH Schneuder WR Hebert PR Tantry US Gurbel PA Hypothesis formulation from subgroup analyses non-adherence or non-steroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to ldquoaspirin resistancerdquo Am Heart J 2010159744-8
127 Storey RF Bliden KP Patil SB Karunakaran A Ecob R Butler K Teng R Wei C Tantry US Gurbel PA ONSETOFFSET Investigators Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor clopidogrel or placebo in the ONSETOFFSET study J Am Coll Cardiol 201056185-93
128 Gurbel PA Bliden KP Navickas IA Mahla E Dichiara J Suarez TA Antonino MJ Tantry US Cohen E Adenosine diphosphate-induced platelet-fibrin clot strength a new thrombelastographic indicator of long-term poststenting ischemic events Am Heart J 2010160346-54
129 Angiolillo DJ Saucedo JF Deraad R Frelinger AL Gurbel PA Costigan TM Jakubowski JA Ojeh CK Effron MB SWAP Investigators Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes results of the SWAP (SWitching Anti Platelet) study J Am Coll Cardiol 2010561017-23
130 Mega JL Simon T Collet JP Anderson JL Antman EM Bliden K Cannon CP Danchin N Giusti B Gurbel P Horne BD Hulot JS Kastrati A Montalescot G Neumann FJ Shen L Sibbing D Steg PG Trenk D Wiviott SD Sabatine MS Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI a metaanalysis JAMA 20103041821-30
131 Tantry US Bliden KP Wei C Storey RF Armstrong M Butler K Gurbel PA First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel The ONSETOFFSET and RESPOND Genotype Studies Circ Cardiovasc Genet 20103556-66
132 Lau WC Welch TD Shields T Rubenfire M Tantry US Gurbel PA The Effect of St Johns Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients Increased Platelet Inhibition by Enhancement of CYP 3A4 Metabolic Activity J Cardiovasc Pharmacol 20115786-93
133 Gurbel PA Shuldiner AR Bliden KP Ryan K Pakyz RE Tantry US The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy Am Heart J 2011161598-604
134 Kandzari DE Mauri L Popma JJ Turco MA Gurbel PA Fitzgerald PJ Leon MB Late-Term Clinical Outcomes With Zotarolimus-and Sirolimus-Eluting Stents 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) JACC Cardiovasc Interv 20114543-50
135 Storey RF Bliden KP Ecob R Karunakaran A Butler K Wei C Tantry U Gurbel PA Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared to clopidogrel in patients with high antiplatelet responses J Thromb Haemost 201191730-7
136 Bliden KP Tantry US Storey RF Jeong YH Gesheff M Wei C Gurbel PA The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity Combined analysis of the ONSETOFFSET and RESPOND studies Am Heart J 2011162160-5
137 Lewis JP Fisch AS Ryan K OrsquoConnell JR Gibson Q Mitchell BD Shen H Tanner K Horenstein RB Pakzy R Tantry US Bliden KP Gurbel PA and Shuldiner AR ( equal contribution) Paraoxonase 1 (PON1) Gene Variants Are Not Associated With Clopidogrel Response Clinical Pharm Ther 201190568-74
138 Navarese EP Kozinski M Obonska K Margheri M Gurbel PA Kubica J De Luca G Clinical efficacy and safety of intracoronary vs intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention A meta-analysis of randomized trials Platelets 2011 (in press)
139 Navarese EP De Luca G Castriota F Kozinski M Gurbel P MD Gibson CM Andreotti F Siller-MatulaJM Pafundi T Sukkenik A De Servi S Kubica J Low-molecular-weight heparins vs unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction A meta-analysis J
Curriculum Vitae Paul A Gurbel MD Page 9
Thromb Haemost 201191902-15) 140 Jeong YH Tantry US Kim I-S Koh J-S Kwon TJ Park Y Hwang SJ Bliden KP Kwak CH Hwang J-W
Gurbel PA Effect of CYP2C192 and 3 loss-of-function allele carriage on platelet reactivity and adverse clinical event occurrence in east asian acute myocardial infarction survivors treated with clopidogrel and aspirin Circ Cardiovasc Genet 20114585-94
141 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
142 Gurbel PA Bliden KP Firt J Zhang Y Plachetka JR Antonino M Gesheff M Tantry US Pharmacodynamic evaluation of clopidogrel plus PA32540 The Spaced PA32540 with Clopidogrel INteraction Gauging (SPACING) study Clin Pharmacol Ther 201190860-6
143 Navarese EP Buffon A Andreotti F Gurbel PA Kozinski M Kubica A Musumeci G Cremonesi A Tavazzi L Kubica J Castriota F Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome A meta-analysis of randomized trials Atherosclerosis 20122221-7
144 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 201210487-9
145 Gurbel PA Bliden KP Antonino MJ Gesheff T Cummings CC Dubois BV Herzog WR Tantry US Time dependence of clopidogrel loading effect Platelet activation versus platelet aggregation Thromb Res Thromb Res 20121291-2
146 Mahla E Suarez TA Bliden KP Rehak P Metzler H Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study Circ Cardiovasc Interv 20125261-9
147 Park Y Jeong YH Tantry US Ahn JH Kwon TJ Park JR Hwang SJ Gho EH Bliden KP Kwak CH Hwang JY Kim S Gurbel PA Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study Eur Heart J 2012332151-62
148 Husted SE Storey RF Bliden K Tantry US Hoslashimark L Butler K Wei C Teng R Gurbel PA Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease Results from the ONSET-OFFSET and RESPOND Studies Clin Pharmacokinet 201251397-409
149 Kubica J Koziński M Navarese EP Tantry US Grześk G Fabiszak T Kubica A Swiątkiewicz I Bliden KP Gurbel PA Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction A systematic review and meta-analysis of randomized clinical trials Cardiol J 201219(3)230-42 Jeong YH Bliden KP Antonino MJ Tantry US Gurbel PA Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity Platelets 2012 May 30 [Epub ahead of print]
150 Welsh RC Rao SV Zeymer U Thompson VP Huber K Kochman J McClure MW Gretler DD Bhatt DL Gibson CM Angiolillo DJ Gurbel PA Berdan LG Paynter G Leonardi S Madan M French WJ Harrington RA on behalf of the INNOVATE PCI Investigators A Randomized Double-Blind Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention The INNOVATE-PCI Trial Circ Cardiovasc Interv 20125336-346
151 Angiolillo DJ Welsh RC Trenk D Neumann FJ Conley PB McClure MW Stephens G Kochman J Jennings LK Gurbel PA Woacutejcik J Dabrowski M Saucedo JF Stumpf J Buerke M Broderick S Harrington RA Rao SV Pharmacokinetic and Pharmacodynamic Effects of Elinogrel Results of the Platelet Function Substudy From the Intravenous and Oral Administration of Elinogrel to Evaluate Tolerability and Efficacy in Nonurgent Percutaneous Coronary Intervention Patients (INNOVATE-PCI) Trial Circ Cardiovasc Interv 20125347-56
152 Reny JL Combescure C Daali Y Gurbel PA Fontana P PON1 Meta-Analysis Group Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events a systematic review and meta-analysis J Thromb Haemost 2012101242-1251
153 Jeong YH Bliden KP Antonino MJ Park KS Tantry US Gurbel PA Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies Am Heart J 201216435-42
154 Jeong YH Bliden KP Antonino MJ Tantry US Gurbel PA Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity Platelets 201216435-42
155 Singla A Bliden KP Jeong YH Abadilla K Antonino MJ Muse WC Mathew DP Bailon O Tantry US Gurbel PA Platelet reactivity and thrombogenecity in postmeopausal women Menopause 20132057-63
156 Jeong YH Tantry US Park Y Kwon TJ Park JR Hwang SJ Bliden KP Koh EH Kwak CH Hwang JY Kim S
Curriculum Vitae Paul A Gurbel MD Page 10
Gurbel PA Pharmacodynamic Effect of Cilostazol Plus Standard Clopidogrel Versus Double-Dose Clopidogrel in Patients With Type 2 Diabetes Undergoing Percutaneous Coronary Intervention Diabetes Care 2012352194-7
157 Roe MT Armstrong PW Fox KAA White HD Prabhakaran D Goodman SG Cornel JH Bhatt DL Clemmensen P Martinez F Ardissino D Nicolau JC Boden WE Gurbel PA Ruzyllo W Dalby AJ McGuire DK Leiva-Pons JL Parkhomenko A Gottlieb S Topacio GO Hamm C Pavlides G Goudev AR Oto A Tseng C-D Merkely B Gasparovic V Corbalan R Cinteză M McLendon RC Winters KJ Brown EB Lokhnygina Y Aylward PE Huber K Hochman JS E Magnus Ohman EM for the TRILOGY ACS Investigators Prasugrel versus clopidogrel for ACS patients managed without revascularization N Engl J Med 20123671297-309
158 Gurbel PA Bliden KP Jeong Y-H Antonino M Gesheff T Fort JG Shuldiner A Chai S Gesheff M Zhang Y Tantry US Spaced Administration of PA32540 and Clopidogrel Results in Greater Platelet Inhibition than Synchronous Administration of Enteric-Coated Aspirin and Enteric-Coated Omeprazole and Clopidogrel Am Heart J 2013165176-82
159 Gurbel PA Erlinge D Ohman EM Neely B Neely M Goodman SG Huber K Chan MY Cornel JH Brown E Zhou C Jakubowski JA White HD Fox KA Prabhakaran D Armstrong PW Tantry US Roe MT TRILOGY ACS Platelet Function Substudy Investigators JAMA 20123081785-94
160 Lewis JP Horenstein RB Ryan K OConnell JR Gibson Q Mitchell BD Tanner K Chai S Bliden KP Tantry US Peer CJ Figg WD Spencer SD Pacanowski MA Gurbel PA Shuldiner AR The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response Pharmacogenet Genomics 2012 Pharmacogenet Genomics 2013231-8
161 Jeong YH Tantry US Min JH Park Y Navarese EP Koh JS Park JR Hwang SJ Kho EH Bliden KP Kwak CH Hwang JY Kim S Gurbel PA Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention Int J Cardiol 2012 Oct 12 doipii S0167-5273(12)01253-3 101016
162 Saucedo JF Angiolillo DJ Deraad R Frelinger AL 3rd Gurbel PA Costigan TM Jakubowski JA Ojeh CK Duvvuru S Effron MB for the SWAP Investigators Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel insights from the switching anti-platelet (SWAP) study Thromb Haemost 2012 Dec 6109(2) [Epub ahead of print]
163 Navarese EP Austin D Gurbel PA Andreotti F Tantry U James S Buffon A Kozinski M Obonska K Bliden K Jeong YH Kubica J Kunadian V Drug-coated balloons in treatment of in-stent restenosis a meta-analysis of randomized controlled trials Clin Res Cardiol 2012 Dec 20 [Epub ahead of print]
164 Gurbel PA Bliden KP Fort JG Jeong YH Shuldiner A Chai S Gesheff T Antonino M Gesheff M Zhang Y Tantry US Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel Am Heart J 2013165176-82
165 Lewis JP Ryan K OConnell JR Horenstein RB Damcott CM Gibson Q Pollin TI Mitchell BD Beitelshees AL Pakzy R Tanner K Parsa A Tantry US Bliden KP Post WS Faraday N Herzog W Gong Y Pepine CJ Johnson JA Gurbel PA Shuldiner AR Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes Circ Cardiovasc Genet 2013 Feb 7 [Epub ahead of print]
166 Navarese EP Gurbel PA Andreotti F Tantry U Jeong YH Kozinski M Engstroslashm T Di Pasquale G Kochman W Ardissino D Kedhi E Stone GW Kubica J Optimal Timing of Coronary Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes A Systematic Review and Meta-analysis Ann Intern Med 2013158261-70
167 Jeong YH Abadilla KA Tantry US Park Y Koh JS Kwak CH Hwang JY Gurbel PA Influence of CYP2C192 and 3 loss-of-function alleles on pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention the results of the ACCEL-DOUBLE-2N3 studyJ Thromb Haemost 2013111194-7
168 Gurbel PA Bliden KP Logan DK Kereiakes DJ Lasseter KC White A Angiolillo DJ Nolin TD Maa JF Bailey WL Jakubowski JA Ojeh CK Jeong YH Tantry US Baker BA The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel The PARADOX Study J Am Coll Cardiol 2013 Apr 16 doipii S0735-1097(13)01478-2 101016jjacc201303037 [Epub ahead of print]
169 Grzesk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E4 Jeong Y-H Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 2013 Article ID 928271 httpdxdoiorg1011552013928271
170 Erlinge D Gurbel PA James S Lindahl TL Svensson P Ten Berg JM Foley DP Wagner H Brown PB Luo J Zhou C Moser BA Jakubowski JA Small DS Winters KJ Angiolillo DJ Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains non-inferiority to prasugrel 10-mg in non-elderly patients The GENERATIONS trial a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients J Am Coll Cardiol 201362577-83
Curriculum Vitae Paul A Gurbel MD Page 11
171 Kim IS Jeong YH Tantry US Park Y Lee DH Bliden KP Koh JS Park JR Jang JS Hwang SJ Koh EH Kwak CH Hwang JY Kim S Gurbel PA Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading Am Heart J 201316695-103
172 Grześk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E Jeong YH Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 20132013928271
173 Stone GW Witzenbichler B Weisz G Rinaldi MJ Neumann FJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri E Gurbel PA Xu K Parise H Kirtane AJ Brodie BR Mehran R Stuckey TD for the ADAPT-DES Investigators Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES) a prospective multicentre registry study Lancet 2013382614-23
174 Angiolillo DJ Curzen N Gurbel P Vaitkus P Lipkin F Li W Jakubowski JA Zettler M Effron MB Trenk D Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in subjects with stable coronary artery disease Results of the SWAP-2 Study J Am Coll Cardiol 2014631500-9
175 Jeong YH Bliden KP Shuldiner AR Tantry US Gurbel PA Thrombin-induced platelet-fibrin clot strength Relation to high on-clopidogrel platelet reactivity genotype and post-percutaneous coronary intervention outcomes Thromb Haemost 2014111713-24
176 Gouya G Arrich J Wolzt M Huber K Verheugt FW Gurbel PA Pirker-Kees A Siller-Matula JM Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases a systematic review and meta-analysis Stroke 201445492-503
177 Erlinge D James S Duvvuru S Jakubowski JA Wagner H Varenhorst C Tantry US Brown PB Small D Moser BA Sundseth S Walker JR Winters KJ Gurbel PA Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease Thromb Haemost 2014111943-50
178 Gurbel PA Baker BA Bailey WL Bliden KP Tantry US Unraveling the Smokers Paradox Cigarette smoking high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors Thromb Haemost 20141111187-90
179 Koh JS Kim IS Tantry US Yoon SE Park Y Cho SY Lee EJ Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading The results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study Int J Cardiol 2014174129-32
180 Bliden KP Singla A Gesheff MG Toth PP Tabrizchi A Ens G Guyer K Singh M Franzese CJ Stapleton D Tantry US Gurbel PA Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin Thromb Haemost 2014 Apr 24112(2) [Epub ahead of print]
181 Gurbel PA Gesheff MG Franzese CJ Bliden KP Tantry US Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy Platelets 201526608-9
182 Gurbel PA Bergmeijer TO Tantry US Ten Berg JM Angiolillo DJ James S Lindahl TL Svensson P Jakubowski JA Brown PB Duvvuru S Sundseth S Walker JR Small D Moser BA Winters KJ Erlinge D The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease Thromb Haemost 2014 2014112589-97
183 Cornel JH Ohman EM Neely B Clemmensen P Sritara P Zamoryakhin D Armstrong PW Prabhakaran D White HD Fox KA Gurbel PA Roe MT TRILOGY ACS Investigators Impact of smoking status on platelet function and clinical outcomes with prasugrel vs clopidogrel in patients with acute coronary syndromes managed without revascularization Insights from the TRILOGY ACS trial Am Heart J 201416876-87
184 Park Y Jung JM Tantry US Kim K Koh JS Park JR Hwang SJ Kwak CH Hwang JY Kim S Gurbel PA Jeong YH Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration The ACCEL-PARAZOL Study J Atheroscler Thromb 2014211121-39
185 Park Y Jeong YH Tantry US Ahn JH Kim K Koh J Park J Hwang SJ Kwak CH Hwang JY Gurbel PA Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity The Resultof the ACCEL-DIP Study Thromb Haemost 2014112 [Epub ahead of print]
186 Lev EI Bliden KP Jeong Y-H Pandya S Kang K Franzese C Tantry US Gurbel PA Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients J Am Heart Assoc 20143e001167
187 Alexopoulos D Xanthopoulou I Storey RF Bliden KP Tantry US Angiolillo DJ Gurbel PA Platelet reactivity during ticagrelor maintenance therapy A patient-level data meta-analysis Am Heart J 2014 168530-6
188 Lhermusier T Lipinski MJ Tantry US Escarcega RO Baker N Bliden KP Magalhaes MA Ota H Tian W Pendyala L Minha S Chen F Torguson R Gurbel PA Waksman R Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity Am J Cardiol 2015115716-23
189 Franzese CJ Bliden KP Gesheff MG Pandya S Guyer KE Singla A Tantry US Toth PP Gurbel PA Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy Am J Cardiol 2015 11151204-11
Curriculum Vitae Paul A Gurbel MD Page 12
190 Aradi D Kirtane A Bonello L Gurbel PA Tantry US Huber K Freynhofer MK Ten Berg J Janssen P Angiolillo DJ Siller-Matula JM Marcucci R Patti G Mangiacapra F Valgimigli M Morel O Palmerini T Price MJ Cuisset T Kastrati A Stone GW Sibbing D Bleeding and stent thrombosis on P2Y12-inhibitors collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention Eur Heart J 2015361762-71
191 Navarese EP Kolodziejczak M Schulze V Gurbel PA Tantry U Lin Y Brockmeyer M Kandzari DE Kubica JM DAgostino RB Sr Kubica J Volpe M Agewall S Kereiakes DJ Kelm M Effects of proprotein convertase subtilisinkexin type 9 antibodies in adults with hypercholesterolemia a systematic review and meta-analysis Ann Intern Med 201516340-51
192 Lee K Yoo SY Suh J Park KH Park Y Tantry US Park KS Han SH Kang WC Shin DH Lee C Choi SW Lee JH Cho YH Lee NH Jeong MH Ahn Y Kubica J Gurbel PA Park JH Jeong YH Efficacy of cilostazol on inhibition of platelet aggregation inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study Int J Cardiol 2015190370-5
193 Kowalewski M Schulze V Berti S Waksman R Kubica J Kołodziejczak M Buffon A Suryapranata H Gurbel PA Kelm M Pawliszak W Anisimowicz L Navarese EP Complete revascularisation in ST-elevation myocardial infarction and multivessel disease meta-analysis of randomised controlled trials Heart 2015 1011309-17
194 Baber U Mehran R Kirtane AJ Gurbel PA Christodoulidis G Maehara A Witzenbichler B Weisz G Rinaldi MJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri EL Jr Xu K Parise H Brodie BR Stuckey TD Stone GW Prevalence and impact of high platelet reactivity in chronic kidney disease Results from the assessment of dual antiplatelet therapy with drug-eluting stents registry Circ Cardiovasc Interv 20158e001683
195 Tricoci P DAndrea DM Gurbel PA Yao Z Cuchel M Winston B Schott R Weiss R Blazing MA Cannon L Bailey A Angiolillo DJ Gille A Shear CL Wright SDAlexander JH Infusion of Reconstituted High-Density Lipoprotein CSL112 in Patients With Atherosclerosis Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial J Am Heart Assoc 20154 pii e002171
196 Reny JL Fontana P Hochholzer W Neumann MJ ten Berg J Janssen PF Geisler T Gawaz M Marcucci R Gori A-M Cuisset T Alessi M-S Berdagueacute P Gurbel PA Yong G Angiolillo DJ Aradi D Beigel R Campo G Combescure C Vascular risk levels affect the predictive value of platelet reactivity 1 for the occurrence of major adverse cardiovascular events in patients on clopidogrel Systematic review and collaborative meta-analysis of individual patient data Thromb Haemost 2015 (in press)
197 Chaudhary R Bliden KP Tantry US Mohammed N Mathew D Gesheff MG Franzese CJ Gurbel PA Association of weight gain with coronary artery disease inflammation and thrombogenicity J Thromb Thrombolysis 2015 Dec 29 [Epub ahead of print]
198 Gurbel PA Bliden KP Turner SE Tantry US Gesheff MG Barr TP Covic L Kuliopulos A Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease Arterioscler Thromb Vasc Biol 201636189-97
199 Kwon TJ Tantry US Park Y Choi YM Ahn JH Kim KH Koh JS Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Smith SC Jr Jeong YH Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention Results of the ACCEL-BLEED study Thromb Haemost 2016 Jan 21115(5) [Epub ahead of print]
200 Bliden KP Tantry US Gesheff MG Franzese CJ Pandya S Toth PP Mathew DP Chaudhary R Gurbel PA Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis J Interv Cardiol 201629168-78
201 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin J Diabetes Complications 2016 May 10 pii S1056-8727(16)30127-1
202 Bedeir K Bliden K Tantry U Gurbel PA Mahla E Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel The Role of VerifyNow Can J Cardiol 201632724-5
203 Giustino G Kirtane AJ Baber U Geacuteneacutereux P Witzenbichler B Neumann FJ Weisz G Maehara A Rinaldi MJ Metzger C Henry TD Cox DA Duffy PL Mazzaferri EL Brodie BR Stuckey TD Gurbel PA Dangas GD Francese DP Ozan O Mehran R Stone GW Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study Am J Cardiol 20161171877-83
204 Kubica J Kubica A Jilma B Adamski P Hobl EL Navarese EP Siller-Matula JM Dąbrowska A Fabiszak T Koziński M Gurbel PA Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors Int J Cardiol 2016215201-8
205 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin
Curriculum Vitae Paul A Gurbel MD Page 13
J Diabetes Complications 2016 May 10 [Epub ahead of print] 206 Bliden KP Chaudhary R Lopez LR Damrongwatanasuk R Guyer K Gesheff MG Franzese CJ Kaza H
Tantry US Gurbel PA Oxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease Am J Cardiol 2016 Jun 15 [Epub ahead of print]
207 Mahla E Prueller F Farzi S Pregartner G Raggam RB Beran E Toller W Berghold A Tantry US Gurbel PA Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy Ann Thorac Surg 2016 Jul 1 [Epub ahead of print]
208 Koh JS Park Y Tantry US Ahn JH Kang MG Kim K Jang JY Park HW Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents The ACCEL-COMBO trial Platelets 2016 Aug 251-7 [Epub ahead of print]
209 Chaudhary R Saadin K Bliden KP Harris WS Dinh B Sharma T Tantry US Gurbel PA Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease Prostaglandins Leukot Essent Fatty Acids 201611340-45
210 Gurbel PA Bliden KP Chaudhary R Patrick J Liu F Chen G McLeod C Tantry US Antiplatelet Effect Durability of a Novel 24-Hour Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes MellitusAm J Cardiol 20161181941-1947
211 Gurbel PA Bliden KP Tantry US Monroe AL Muresan AA Brunner NE Lopez-Espina CG Delmenico PR Cohen E Raviv G Haugen DL Ereth MH First report of the point-of-care TEG A technical validation study of the TEG-6S system Platelets 201627642-649
212 Cornel JH Ohman EM Neely B Jakubowski JA Bhatt DL White HD Ardissino D Fox KA Prabhakaran D Armstrong PW Erlinge D Tantry US Gurbel PA Roe MT Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes J Am Heart Assoc 2016 Nov 45(11) pii e003977
213 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 201717109-121
214 Sharma T Bliden K Chaudhary R Tantry U Gurbel PA Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease Expert Opin Pharmacother 201718123-131
215 Park Y Tantry US Koh JS Ahn JH Kang MG Kim KH Jang JY Park HW Park JR Hwang SJ Park KS Kwak CH Hwang JY Gurbel PA Jeong YH Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction The REMODELING Trial Thromb Haemost 2017117911-922
216 Navarese EP Gurbel PA Andreotti F Kołodziejczak MM Palmer SC Dias S Buffon A Kubica J Kowalewski M Jadczyk T Laskiewicz M Jędrzejek M Brockmeyer M Airoldi F Ruospo M De Servi S Wojakowski W O Connor C Strippoli GF Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis PLoS One 201712e0168726
217 Bliden KP Chaudhary R Mohammed N Muresan AA Lopez-Espina CG Cohen E Raviv G Doubleday M Zaman F Mathew B Tantry US Gurbel PA Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system J Thromb Thrombolysis 201743437-445
Publications Peer Reviewed Original Science Research - Reviews 1 Serebruany VL Atar D Dalesandro MR OConnor CM Gurbel PA Changes in hemostasis after parenteral
magnesium in myocardial ischemia reperfusion Animal studies to clinical trials Magnes Res 19981137-42 2 McKenzie ME Gurbel PA Levine DJ Serebruany VL Clinical utility of available methods determining platelet
function Cardiology 199992240-7 3 Gurbel PA OConnor CM Cummings CC Serebruany VL Clopidogrel The future choice for preventing platelet
activation during coronary stenting Pharm Res 199965109-123 4 Nair GV Gurbel PA Fusaylov SY Davis CJ Ohman EM Bahr RD Christensen RH Serebruany VL Combing
necrosis and platelet markers for perfecting myocardial infarction rule out How close are we Cardiology 20009350-5
5 Davis CJ Gurbel PA Gaitis WA Fuzaylov SY Nair GV OrsquoConnor CM Serebruany VL Hemostatic abnormalities in congestive heart failure Diagnostic significance and clinical challenge Int J Cardiol 20007515-21
6 Pothula A Gurbel PA Atar D McKenzie ME Serebruany VL Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease Eur J Pharmacol 20004021-10
7 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Serebruany VL Platelet function and fibrinolytic agents Two sides of a coin Cardiology 20019555-60
Curriculum Vitae Paul A Gurbel MD Page 14
8 Samara WM Gurbel PA The role of platelet receptors and adhesion molecules in coronary artery disease Coron Artery Dis 20031465-79
9 Gurbel PA Tantry U Clopidogrel response variability and the advent of personalised antiplatelet therapy A bench to bedside journey Thromb Haemost 2011106265-71
10 Gurbel PA Roe MT Jakubowski JA Shah S Erlinge D Goodman SG Huber K Chan MY Cornel JH Tantry US Ohman EM Translational platelet research in patients with coronary artery disease What are the major knowledge gaps Thromb Haemost 2012 May 25108 [Epub ahead of print]
11 Bliden KP Baker BA Nolin TD Jeong YH Bailey WL Tantry US Gurbel PA Thienopyridine efficacy and cigarette smoking status Am Heart J 2013165693-703
12 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
13 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013111547-56
14 Gesheff MG Franzese CJ Bliden KP Contino CJ Rafeedheen R Tantry USGurbel PA Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin Expert Rev Clin Pharmacol 2014 7645-53
15 Tantry US Gesheff M Liu F Bliden KP Gurbel PA Resistance to antiplatelet therapy what progress has been made Expert Opin Pharmacother 2014 9 1-12
16 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print]
17 Gurbel PA Myat A Tantry US Platelet-mediated Thrombosis From Bench to Bedside Cir Res 2015 (in press)
18 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 20161245-58
19 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
20 Gurbel PA Tantry US Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes Heart 2016102882-92
21 Navarese EP Kolodziejczak M Kereiakes DJ Tantry US OConnor C Gurbel PA Proprotein Convertase SubtilisinKexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome A Narrative Review Ann Intern Med 2016164600-7
22 Gurbel PA Jeong YH Navarese EP Tantry US Platelet-Mediated Thrombosis From Bench to Bedside Circ Res 20161181380-91
23 Gurbel PA Myat A Kubica J Tantry US State of the art Oral antiplatelet therapy JRSM Cardiovasc Dis 2016 Jun 152048004016652514 doi 1011772048004016652514 eCollection 2016 Jan-Dec
24 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 2016 Nov 17 [Epub ahead of print] Review
25 Winter MP Grove EL De Caterina R Gorog DA Ahrens I Geisler T Gurbel PA Tantry U Navarese EP Siller-Matula JM Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors Eur Heart J Cardiovasc Pharmacother 2017 Feb 15 doi 101093ehjcvppvw044 [Epub ahead of print]
26 Shah P Tantry US Bliden KP Gurbel PA Bleeding and thrombosis associated with ventricular assist device therapy J Heart Lung Transplant 2017 May 11 pii S1053-2498(17)31789-8
Inventions Patents Copyrights 32294 Gurbel PA Anderson RD Autoperfusion dilatation catheter United States Patent 5295959 51501 Dalesandro MR Gurbel PA Serebruany VL Determining a treatment plan for patients undergoing thrombotic
events by monitoring p-Selectin United States Patent 623071 61201 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6245782 13102 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 20020013343 42203 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6552014
Curriculum Vitae Paul A Gurbel MD Page 15
120611 Gurbel PA The detection of restenosis risk in patients receiving a stent by measuring the characteristics of blood clotting including the measurement of maximum thrombin-induced clot strength (patent awarded pending)
6308 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 7381536 2010 Gurbel PA Conley P Andre P Gretler D Jurek M Methods for diagnosis and treatment of thrombotic
disorders mediated bycyp2c192 (patent pending) 41014 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent
20140100167 81815 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 9110062 111715 Gurbel PA Detection of restenosis risk in patients receiving a stent by measuring the characteristics of
blood clotting including the measurement of maximum thrombin-induced clot strength Patent 9188597 Extramural Funding (since 2002) CURRENT 2010-2015 MAGMA (Multianalyte And Genetic Markers of Atherosclerosis)
Haemonetics and Sinai Hospital of Baltimore 2015-present An Observational Study of CORA-Assisted Stroke Identification and Antithrombotic Therapy
2014-2015 Feasibility clinical trial to evaluate the efficacy of an Anticoagulant cartridge to be used in the CORA System Coramed Technologies LLC
2014-2015 Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid Durlaza in CVD Patients at Risk of High Platelet Turnover (DURATION)
New Haven Pharmaceuticals Inc 2015-present Influence of Edoxaban on Coagulability and Thrombin Generation An in Vitro Study Focusing on
Thrombelastography Daiichi Sankyo
2016 Influence of Vorapaxar on Thrombin Generation and Coagulability Merck 2015-present Durlaza GI GI Tolerability Study New Haven Pharamceuticals 2015-present Thrombogenicity in LVAD Recipients Haemonetics 2014-2015 First-in-Man Assessment of PZ-128 National Institutes of Health PREVIOUS 2002 Atorvastatin in the Treatment of Heart Failure
LBH IRB 20030512 NIHThe National Heart Lung and Blood Institute NIH
2002 Asessment of the In Vitro Effects of Tenecteplase Reteplase and Alteplase on Human Platelets TAR STUDY Genetech
2003-2005 Assessment of the Effects of the heparin-coated Cordis Stent versus Non-coated Stents on Platelet and Endothelial Cell Activation and Thrombin Effect in Patients with Coronary Artery Disease (HEPACOAT) Cordis Inc
2004-2005 The Antiplatelet Effects of Eptifibatide with High and Standard Dose Clopidogrel in Low-Moderate Risk Patients Undergoing Coronary Intervention (CLEAR-PLATELETS Study) MilleniumSchering Plough
2004-2005 The Use of The TEG System to Monitor Platelet Inhibition at Bedside 5R44HL059753-03Haemoscope National Institute of Health
2004-2006 Clopidogrel Resistance in Patients with Stent Thrombosis (CREST Study) AstraZeneca
Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study MilleniumSchering Plough
2005 St Johns Wort Decreases ADP Induced Platelet Reactivity in Known Clopidogrel Resistant Post Coronary Intervention Patients after a Loading Dose of Clopidogrel University of Michigan
2008-2009 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST) Sinai Hospital Department of Medicine
2009-2010 Demonstration of the Pharmacodynamic Antiplatelet Effect of PRT060128 in Patients with High Platelet Reactivity during Clopidogrel and Aspirin Maintenance Therapy (PORTOLA) Portola Pharmaceuticals
2008-2009 A Randomised Double-Blind Outpatient Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND] AstraZeneca Pharmaceuticals LP
2008-2009 A Randomized Double-blind Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Background Therapy in Patients with Stable Coronary Artery Disease with Additional Detailed Assessment of Cardiopulmonary Function (ONSET-OFFSET) AstraZeneca Pharmaceuticals LP
2008-2009 A Single Center Randomized Open Label Parallel Group Pharmacodynamic Study of a Novel Combination Form of Aspirin and Phytosterol versus Aspirin in Healthy Adult Subjects (ARMOR) Bayer Healthcare LLC
2008-2009 Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel Plus EC Aspirin (325 mg) and Clopidogrel Plus PA32540 on Platelet Aggregation in Healthy Volunteers POZEN 110 POZEN Inc
2009-2010 Antithrombosis with Clopidogrel Beyond the Concept of Platelet Aggregate Inhibition (SANOFI) Sanofi Inc 2010-2012 A Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel EC
Aspirin 81 mg and EC omeprazole 40 mg all dosed concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers POZEN Inc
Intramural Funding (since 2002) CURRENT 2008-present Time Based Strategy to Reduce Clopidogrel Associated Bleeding Related to CABG (TARGET CABG) Sinai Hospital of Baltimore Department of Medicine 2009-present Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI)
Sinai Hospital of Baltimore Department of Medicine 2011-present Detection of Leukemic Blood and Solid TypE MalignanCies by Urinary 11-DehydroThromboxane B2 (DETECT) Study
Sinai Hospital of Baltimore Department of Medicine PREVIOUS 2001-2002 Platelet Activation in Stenting PAST Study Sinai Hospital of Baltimore 2005-2006 Platelet Reactivity in Patients with Crohnrsquos disease Receiving Infliximab (chimeric anti-TNF alpha antibody) ndash COIN
Sinai Hospital of Baltimore Department of Medicine 2006-2007 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST)
Sinai Hospital of Baltimore Department of Medicine 2008-2011 Platelet Reactivity and Thrombogenecity in Postmenopausal Women
Sinai Hospital Department of Medicine 2008-2010 Platelet Reactivity and Thrombogenecity in Postmenopausal Women (PRIDE Study)
Sinai Hospital Department of Medicine Multicenter Studies since 2001
Curriculum Vitae Paul A Gurbel MD Page 17
CURRENT 2010-present The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and
Clopidogrel in Aspirin-Treated Subjects With Stable Coronary Artery Disease Daiichi Sankyo
2010-present A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly versus Non-Elderly Aspirin-Treated Subjects with Stable Coronary Artery Disease Eli Lilly amp company
2011-present A Prospective Multicenter Randomized Trial of Clopidogrel versus Prasugrel Anti-platelet Therapy in Cytochrome P450 2C19 (CYP2C19) Intermediate Metabolizers Grant No U01HL105198
NIH National Heart Lung and Blood Institute NIH 2011-present A Prospective Randomized Multi-Center Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHERreg Sirolimus-Eluting Coronary stents
HCRI 2012-present A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in
patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)
Bayer Healthcare LLC 2013-present Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in
Patients at a High-Risk for Vascular Outcomes (ACCELERATE) Eli Lilly amp Company 2014-present A Phase 2b Multi-center Randomized Placebo-controlled Dose-ranging Study to Investigate the
Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infarction
AEGIS CSL 2015-2017 A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety of PZ- 128 in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention
National Institute of Health PREVIOUS 2001 A Randomized Double-Blind Placebo-Controlled Study of Two Intravenous Dosing Regimens of
h5G11-scFv in Patients with Acute Myocardial Infarction Undergoing 2001-2002 Prevention of REStenosis with Tranilast and Its Outcomes A Placebo Controlled Trial PRESTO STUDY
SmithKline Beecham 2002-2003 Taxus IV-SR Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
Boston Scientific 2003 MICROVENA Corporation TRAP Vascular Filtration System (VFS) Trial
Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily Pfizer Inc
2003-2004 Phase 3 Multi-Center Double-Blind Randomized Parallel Group Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily (QD) for 24 Months Compared with Atorvastatin Alone in Subjects with Angiographically Documented Coronary Heart Disease Pfizer Inc
2003-2004 A Randomized Controlled Trial of the Medtronic Endeavor Drug Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ldquoENDEAVOR III Studyrdquo)
Medtronic 2009-2010 A Prospective Randomized Open-label Multicenter study in Patients Presenting with Acute Coronary Syndromes SYNERGY STUDY
Aventis Pharmaceuticals 2004 CObalt chromium STent with Antiproliferative for Restenosis II Trialrdquo Costar study
Conor Medsystems
Curriculum Vitae Paul A Gurbel MD Page 18
2004-2005 A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions ENDEAVOR IV Medtronic
2004-2005 A Randomized Trial to evaluate the relative protection against POST-PCI microvasculat obstruction among antiplatelet and anti-thrombotic medications (TIMI-30) TIMI group
2004-2006 A Double-blind Double-dummy Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI 33 AstraZeneca Lp
2005-2006 Strategy To Reduce Atherosclerosis Development Involving Administration of Rimonabant - The Intravascular Ultrasound Study (STRADIVARIUS) EFC5827 Sanofi Synthelabo Research
2006 A Multicenter Randomized Double-Blind Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (TRASM-PCI) Schering Plough
2006-2007 A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel -SWAP (SWitching Anti Platelet study) Eli Lilly amp Company and Sankyo Company Limited
2006-2007 A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2008-2010 A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary InterventionTIMI-38 Eli Lilly Company Daiichi
2009-2010 A Randomized Double-Blind Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128 a Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Interventions (INNOVATE-PCI) Portola Pharmaceuticals
2010-2012 TReatment with ADPreceptor iNhibitorS Longitudinal Assessment ofTreatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS)
Eli Lilly Company 2010-2013 RADAR Randomized Partially-Blinded Multi-Center Active-Controlled Dose-Ranging Study
Assessing the Safety Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome Regado Bioscience Inc
2011-2013 A Phase IIa Multi-center Randomized Sponsor-unblinded Placebo-controlled Single Ascending Dose Study to Investigate the Safety Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Adults Taking Aspirin and a P2Y12 Platelet Inhibitor
AEGIS CSL Research Program BuildingLeadership 1991-1995 Director Interventional Cardiology Research University of Maryland Medical System 1998-2015 Director Sinai Center for Thrombosis Research 2001-2015 Director Cardiovascular Research Lifebridge Health 2002-2015 Director Therapeutics Research and Technology Development for the Cardiac Catheterization Program Sinai Hospital of Baltimore 2007-2015 Associate Chief for Research Department of Medicine Sinai Hospital of Baltimore 2015-current Director Interventional Cardiology and Cardiovascular Medicine Research INOVA Health 2015-Current Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute EDUCATIONAL ACTIVITIES
Curriculum Vitae Paul A Gurbel MD Page 19
Peer Reviewed Publications-Consensus Statements Expert Opinions 1 Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C
Rao AK The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 200531309-11
2 Hoekstra J Cohen M Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Saucedo JF Pollack CV Jr Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention-an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective report on a roundtable discussion Am J Emerg Med 200927720-8
3 Bonello L Tantry US Marcucci R Blindt R Angiolillo DJ Becker R Bhatt DL Cattaneo M Collet JP Cuisset T Gachet C Montalescot G Jennings LK Kereiakes D Sibbing D Trenk D Van Werkum JW Paganelli F Price MJ Waksman R Gurbel PA Working Group on High On Treatment Platelet Reactivity Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 201056919-33
4 Gurbel PA Tantry US Shuldiner AR Kereiakes DJ Genotyping one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 201056112-6
5 Gurbel PA Tantry US Antiplatelet therapy Clopidogrel-PPI interaction an ongoing controversy Nat Rev Cardiol 201187-8
6 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
7 Gurbel PA Nolin TD Tantry US Clopidogrel efficacy and cigarette smoking status JAMA 20123072495-6 8 Tantry US Bonello L Aradi D Price MJ Jeong YH Angiolillo DJ Stone GW Curzen N Geisler T Ten Berg J
Kirtane A Siller-Matula J Mahla E Becker RC Bhatt DL Waksman R Rao SV Alexopoulos D Marcucci R Reny JL Trenk D Sibbing D Gurbel PA Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding J Am Coll Cardiol 2013622261-73
9 Gurbel PA Tantry US Antiplatelet and anticoagulant agents in heart failure Current status and future perspectives JACC Heart Fail 201421-14
10 Gurbel PA Tantry US Antiplatelet therapy What have we learned from the ANTARCTIC trial Nat Rev Cardiol 201613639-640
Invited Review Articles 1 Gurbel PA Midwall JA Brodie BR Angioplasty and adjunctive intra-aortic balloon pump counterpulsation Current
clinical considerations Todays Therapy Trends 19951363-78 2 OrsquoConnor CM Gurbel PA Serebruany VL Depression and ischemic heart disease Am Heart J 200014063-69 3 Gurbel PA Serebruany VL Oral IIbIIIa inhibitors From initial promise to clinical failures J Thromb and
Thrombolysis 200010217-20 4 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Atar D Serebruany VL Platelets and
Thrombolysis Cooperation or Contrariety Heart Drug 20011281-290 5 McKenzie ME Gurbel PA The potential of monoclonal antibodies to reduce reperfusion injury in myocardial
infarction BioDrugs 200115395-404 6 Gurbel PA Bliden KP Hayes K Tantry U Platelet activation in myocardial ischemic syndromes Expert Rev of
Cardiovasc Ther 20052535-45 7 Tantry US Bliden KP Gurbel PA Resistance to antiplatelet drugs Current status and future research Expert
Opin Pharmacother 200562027-45 8 Gurbel PA Lau WC Bliden KP Tantry US Clopidogrel resistance Implications for coronary stenting Curr Pharm
Des 2006121261-9 9 Gurbel PA Tantry US Drug insight Clopidogrel non-responsiveness Nature ClinPract Cardiovasc Med
20063387-95 10 Gurbel PA Tantry US Aspirin and Clopidogrel Resistance Considerations and management J Interv Cardiol
200619439-48 11 Lau WC Gurbel PA Antiplatelet drug resistance and drug-drug interactions Role of cytochrome P450 3A4
Pharm Res 2006232691-708 12 Wiviott SD Tantry US Gurbel PA Clinical applications of antiplatelet therapy Rev Cardiovasc Med 20067
Curriculum Vitae Paul A Gurbel MD Page 20
130-46 13 Tantry US Bliden KP Gurbel PA Prasugrel Expert Opin Investig Drugs 2006151627-33 14 Gurbel PA Tantry US Clopidogrel Resistance Thromb Res 2007120311-21 15 Tantry US Etherington A Bliden KP Gurbel PA Antiplatelet therapy Current strategies and future trends Future
Cardiology 20072343-366 16 Gurbel PA Tantry US The relationship of platelet reactivity to the occurrence of post-stenting ischemic events
emergence of a new cardiovascular risk factor Rev Cardiovasc Med 2006Suppl 4S20-8 17 Tantry US Bliden KP Gurbel PA AZD6140 Expert Opin Investig Drugs 200716225-9 18 Gurbel PA Tantry US Stent thrombosis role of compliance and non-responsiveness to antiplatelet therapy Rev
Cardiovasc Med 20078S19-S26 19 Gurbel PA Kandzari DE Stent thrombosis associated with first-generation drug-eluting stents issues with
antiplatelet therapy Neth Heart J 200715148-50 20 Gurbel PA Tantry US The role of clopidogrel in cardiovascular diseases Pol Arch Med Wewn 2007117207-9 21 Gurbel PA DiChiara J Tantry US Antiplatelet therapy after implantation of drug-eluting stents duration
resistance alternatives and management of surgical patients Am J Cardiol 200710018M-25M 22 Gurbel PA Becker R Mann KG Steinhubl SR Michelson AD Platelet function monitoring in patients with
coronary artery disease J Am Coll Cardiol 2007501822-34 23 Gurbel PA Tantry US Prasugrel a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig
Drugs 20089324-36 24 Gurbel PA Bilden KP Tantry US Diagnostics for aspirin resistance Mol Diagn Ther 20081255-6 25 Gurbel PA Antonino MJ Tantry US Antiplatelet treatment of cardiovascular disease a translational research
perspective Pol Arch Med Wewn 2008118289-97 26 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831I36 27 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention Clin Cardiol 200831I28-I35
28 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches Clin Cardiol 200831I21-I27
29 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention Clin Cardiol 200831I17-I20
30 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Assessing the Current Role of Platelet Function Testing Clin Cardiol 200831I10-I16
31 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831136
32 Keriakes DJ Gurbel PA Periprocedural platelet function in percutaneous coronary intervention JACC Cardiovasc Interv 2008suppl 1111ndash121
33 Gurbel PA Tantry US The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome J Interv Cardiol 200821Suppl 1S10-7
34 Gurbel PA Tantry US Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 20091122-322
35 Gurbel PA Aspirin scope and limitations Br J Cardiol 200917 (Suppl 1)S8-S9 36 Cohen M Hoekstra J Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Pollack CV Jr
Saucedo JF Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion J Interv Cardiol 200821283-99
37 Angiolillo DJ Bhatt DL Gurbel PA Jennings LK Advances in antiplatelet therapy agents in clinical development Am J Cardiol 2009103(3 Suppl)40A-51A
38 Gurbel PA Mahla E Antonino MJ Tantry US Response variability and the role of platelet function testing J Invasive Cardiol 200921172-8
39 Gurbel PA Antonino MJ Tantry US Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug MetabToxicol Expert Opin Drug Metab Toxicol 20095989-1004
40 Gurbel PA Tantry US Antiplatelet resistance- Fact or Myth Am Hosp J 2009750-57 41 Gurbel PA Mahla E Tantry US Aspirin resistance Prog Cardiovasc Dis 200952141-52 42 Tantry US Gurbel PA Platelet monitoring for PCI Is it really necessary Haemostaseologie 200929 368-75 43 Gurbel PA Aspirin-scope and limitations Br J Cardiol 200917(Suppl 1)S8-S9
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 2
2000-2001 Interventional Cardiologist Baltimore Heart Associates 2000-present President Platelet and Thrombosis Research Baltimore MD 2000-present Staff Physician Northwest Medical Center Randallstown MD 2001-2007 Partner and Interventional Cardiologist Baltimore Heart Associates Baltimore MD 2001-2015 Director of Cardiovascular Research Lifebridge Health BaltimoreMD 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital Baltimore MD 2003-2013 Associate Professor of Medicine (part-time) Johns Hopkins Hospital Baltimore MD 2005-2006 Helen Dalsheimer Director Division of Cardiology Sinai Hospital of Baltimore 2007-2009 Interventional Cardiologist Hagerstown Heart PA Hagerstown MD 2007-2010 Staff Physician Washington County Hospital Hagerstown MD 2007-2015 Associate Chief for Research Department of Medicine Sinai Hospital Baltimore MD 2013-present Professor of Medicine Johns Hopkins Hospital Baltimore MD 2013-present Adjunct Professor of Medicine Duke University School of Medicine Durham NC 2015-present Staff physician Inova Fairfax Hospital Falls Church VA 2015-present Director Interventional Cardiology Inova Health Falls Church VA 2015-present Director Cardiovascular Medicine Research Inova Health Falls Church VA 2015-present Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute Falls Church VA
RESEARCH ACTIVITIES Publications Peer Reviewed Original Science Research (articles) 1 Tapson VF Davidson CJ Gurbel PA Sheikh KH Kisslo KB Stack RS Rapid and accurate diagnosis of pulmonary emboli in a canine model using intravascular ultrasound imaging Chest 1991 1001410-3 2 Herzog WR Atar D Gurbel PA Vogel RA Schlossberg ML Serebruany VL Effect magnesium infusion on
platelet aggregation in swine Magnesium Res 1993 4349-353 3 Gurbel PA MacCord CS Anderson RD Scott HJ Atar D Mergner W Herzog WR A canine coronary artery
thrombosis model for the evaluation of reperfusion strategies Cardiology 1994 841-8 4 Gurbel PA Anderson RD MacCord CS Scott H Komjathy SF Poulton J Stafford JL Goddard J Arterial
diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy Circulation 1994 89361-265
5 Tapson VF Gurbel PA Witty LA Pieper KS Stack RS Pharmacomechanical thrombolysis of experimental pulmonary emboli rapid low-dose intraembolic therapy Chest 1994 1061668-1652
6 Ohman EM Marquis J-F Ricci DR Brown RG Knudtson ML Kerejakes DJ Samaha JK Margolis JR Niderman AL Dean LJ Gurbel PA Sketch M for the perfusion balloon catheter study group A randomized comparison of gradual prolonged versus standard primary balloon inflation on early and late outcome results of a multicenter clinical trial Circulation 1994 891118-1125
7 Ohman EM George BS White CJ Kern MJ Gurbel PA Freedman RJ Lundergan C Hartmann JR Talley JD Frey MJ Taylor G Leimberger JD Owens PM Lee KL Stack RS Califf RM for Randomized IABP Study Group The use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction Results of a randomized trial Circulation 1994 90792-799
8 The Epic Investigators Evaluation of chimeric monoclonal antibody C7E2 fab fragment directed against the platelet glycoprotein IIb IIIa receptor for preventing ischemic complications of high risk angioplasty (EPIC) N Engl J Med 1994 330956-957
9 Gurbel PA Anderson RD MacCord CS Scott HJ Serebruany VL Herzog WR Accelerated intravenous dosing of recombinant tissue plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction Coron Artery Dis 1994 5929-936
10 Gurbel PA Serebruany VL Komjathy SF Collins ME Sane DC Scott HJ Schlossberg ML Herzog WR Regional and systemic platelet function is altered by myocardial ischemia-reperfusion J Thromb Thrombolysis 19951187-194
11 Serebruany VL Herzog WR Gurbel PA Schlossberg ML Scott HG Vogel RA NPC15669 an anti-inflammatory leucine derivative reduces in vitro platelet aggregability in both swine and human plasma J Thromb Thrombolysis 19951171-178
12 Herzog WR Gurbel PA Vogel RA Schlossberg ML Scott HJ Schneider AI Serebruany VL Effects of NPC 15669 an anti-inflammatory leucine derivative on myocardial stunning and pre-conditioned infarction size in swine J Thromb Thrombolysis 19951163-170
13 Serebruany VL Herzog WR Gurbel PA Serial changes of natural antithrombotics during myocardial ischemia-
Curriculum Vitae Paul A Gurbel MD Page 3
reperfusion in swine Effects of magnesium diltiazem and a novel Mac-1 inhibitor Blood Coag Fibrinolysis 1996 7632-640
14 Gurbel PA Navetta FI Bates ER Muller DW Tenaglia AN Miller MJ Muhstein B Hermiller JB Davidson CJ Aguirre FV Beauman GJ Berdan LG Leimberger JD Boville EG Christenson RH Ohman EM Lesion-directed administration of tissue plasminogen activator with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty Cathet Cardiovasc Diagn 1996 37382-391
15 Anderson RD Gurbel PA The effect of intra-aortic balloon counterpulsation on coronary blood flow velocity distal to coronary artery stenosis Cardiology 1996 87306-312
16 Serebruany VL Herzog WR Atamas SP Gurbel PA Paulsen G Mortensen SA Folkers K Hemostatic changes after dietary coenzyme Q10 supplementation in swine J Cardiovasc Pharm 1996 28175-181
17 Gurbel PA Serebruany VL Komjathy SF Collins ME Bittar GD Schlossberg ML Mergner W Pretreatment with an inhibitor of Mac-1 alters regional and systemic platelet function during ischemia - reperfusion in swine Pharmacology 1996 5379-86
18 Serebruany VL Solomon SR Edenbaum LR Herzog WR Gurbel PA Mac-1 inhibitor affects certain hemostatic parameters during myocardial stunning in swine Pharmacology 1996 5387-96
19 Serebruany VL Schlossberg ML Edenbaum LR Herzog WR Gurbel PA Intracoronary magnesium and diltiazem affect to a similar extent certain hemostatic factors during acute myocardial infarction in swine Pharmacology 1996 53224-233
20 Serebruany VL Schlossberg ML Edenbaum LR Herzog WR Gurbel PA Hemostatic changes after early versus late intracoronary magnesium during acute myocardial infarction in swine J Cardiovasc Pharm 1996 8817-823
21 Serebruany VL Herzog WR Edenbaum LR Shustov AR Gurbel PA Changes in the haemostatic profile during magnesium deficiency in swine Magnesium Res 1996 9155-163
22 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression J Cardiovasc Pharm 1997 2916-22
23 Serebruany VL Herzog WR Gurbel PA Serial changes of the plasma prostanoids during myocardial ischemia - reperfusion in swine Effects of magnesium diltiazem and a novel Mac-1 inhibitor Prostaglandins Leukot Essent Fatty Acids 1997 56135-142
24 Gurbel PA Anderson RD A new concept in coronary angioplasty Dilatation with a helical balloon which allows simultaneous autoperfusion Cathet Cardiovasc Diagn 1997 40109-116
25 Gurbel PA Anderson RD Pells HO van Boven AJ den Heijer P Coronary artery angioplasty with a helical autoperfusion catheter Cathet Cardiovasc Diagn 1997 40179-185
26 Serebruany VL Gurbel PA Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Could coenzyme Q10 affect hemostasis by inhibiting platelet vitronectin (CD51CD61) receptor Molec Aspects Med 199718 S189-S194
27 Gurbel PA Herzog WR Vogel RA Schlossberg ML Edenbaum LR Scott HJ Serebruany VL Short-term low does intracoronary diltiazem administered at the onset of reperfusion reduces myocardial infarct size Intern J Cardiol 1997 5921-27
28 Serebruany VL Solomon SR Herzog WR Gurbel PA Bolus magnesium infusion in humans is associated with predominantly unfavorable changes in platelet aggregation and certain hemostatic factors Pharm Res 1997 3517-22
29 Serebruany VL Schlossberg ML Edenbaum LR Herzog WR Gurbel PA Effects of intracoronary diltiazem on certain hemostatic parameters during acute myocardial infarction in swine Inter J Cardiol 1997 6121-29
30 Gurbel PA Serebruany VL Soluble vascular cell adhesion molecule and E-Selectin in patients with acute myocardial infarction treated with thrombolytic agents Am J Cardiol 1998 81772-775
31 Serebruany VL Bahr RD OConnor CM Lowry DR Gurbel PA For the GUSTO III Platelet Substudy Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction Cardiology 1998 9037-42
32 Serebruany VL Solomon SR Herzog WR Gurbel PA Plasma fibronectin during myocardial ischemia - reperfusion Effects of magnesium diltiazem and a novel Mac-1 inhibitor Am J Hematol 1998 57309-314
33 Serebruany VL Solomon SR Shustov AR Herzog WR Gurbel PA Survival in acute myocardial infarction induced by coronary artery ligation prognostic relevance of certain hemostatic factors during the occlusion phase J Thromb and Thrombolysis 1998 5 39-35
34 Gurbel PA Shustov AR Bahr RD Carpo C Ohman EM and Topol EJ for the GUSTO III Investigators Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment The GUSTO III Platelet Study J Am Coll Cardiol 1998 311466-1473
35 Serebruany VL Ordonez JV Yrovsky VV Gurbel PA The crossreactivity of human vs swine platelet surface antigens is similar for glycoproteins IIb and IIIa but not for IIb and IIIa complex J Thromb and Thrombolysis 1998
Curriculum Vitae Paul A Gurbel MD Page 4
537-41 36 Serebruany VL Gurbel PA Shustov AR Ohman EM Topol EJ Heterogeneity of platelet aggregation and major
surface receptor expression in patients presenting with acute myocardial infarction Am Heart J 1998 136398-405 37 Serebruany VL Gurbel PA Murugesan SR Lowry Dr Sturm E Svetlov SI Depressed plasma platelet-activating
factor acetylhydrolase in patients presenting with acute myocardial infarction Cardiology 199890127-130 38 Serebruany VL Schlossberg ML Edenbaum LR Herzog WR Gurbel PA Serial changes of soluble endothelin-1
levels during myocardial ischemia-reperfusion Effects of magnesium diltiazem and a novel Mac-1 Inhibitor Pharm Res 199838165-172
39 Gurbel PA Serebruany VL Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Increased baseline platelet P-selectin and PECAM-1 as predictors of unsuccessful thrombolysis in patients with acute myocardial infarction Coron Artery Dis 19989451-456
40 Serebruany VL Gurbel PA Effect of thrombolytic therapy on the plasma concentration and platelet expression of the plateletendothelial cell adhesion molecule in patients with acute myocardial infarction Arterioscl Thromb Vasc Biol 199919153-158
41 Serebruany VL Gurbel PA The relations of major platelet receptor expression during myocardial infarction Monitoring efficacy of GP IIbIIIa inhibitors by measuring P-selectin Thromb Haemost 199980314-316
42 Serebruany VL Gurbel PA Assessment of platelet activity by measuring platelet derived substances in plasma from patients with acute myocardial infarction Surprising lessons from the GUSTO III Platelet Study Thromb Res 199993149-150
43 OConnor CM Gurbel PA Serebruany VL Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure Am J Cardiol 1999831345-1349
44 Serebruany VL Murugesan SR Pothula A Semaan H Gurbel PA Soluble plateletendothelial cellular adhesion molecule-1 but not P-selectin nor osteonectin identify acute myocardial infarctions among patients with chest pain admitted to the Emergency Department Cardiology 1999150-55
45 Serebruany VL Yurovsky VV Gurbel PA Mild myocardial stunning affects platelet aggregation and certain hemostatic factors in swine Clin Appl Thromb Haemost 19995236-42
46 Murugesan SR Gurbel PA Serebruany VL Storing paraformaldehyde fixed whole blood in patient samples after chronic platelet glycoprotein IIb IIIa blockade Core laboratory considerations Thromb Res 19995201-203
47 Serebruany VL Kereiakes DJ Dalesandro MR Gurbel PA The flow cytometer model markedly affects measurement of ex vivo whole blood platelet-bound P-selectin expression in patients with chest pain Are we comparing apples and oranges Thromb Res 19999651-56
48 Serebruany VL Yurovsky VV Gurbel PA Effects of a novel Mac-1 inhibitor NPC 15669 on hemostatic parameters during preconditioned myocardial infarction Life Sciences 1999651503-13
49 Gurbel PA Murugesan SR Lowry DR Serebruany VL Plasma thromboxane and prostacyclin are linearly related and increased in patients presenting with myocardial infarction Prostaglandins Leukot Essent Fatty Acids 1999617-11
50 Gurbel PA Kereiakes DJ Dalesandro MR Bahr RD OConnor CM Serebruany VL The role of soluble and platelet-bound P-selectin in discriminating cardiac from non-cardiac chest pain at presentation in the Emergency Department Am Heart J 2000139320-328
51 McKenzie ME Pothula A Gurbel PA Fuzaylov SY OConnor CM Gaitis WA Serebruany VL Failure of thrombin generation markers to triage patients presenting with chest pain Cardiology 20009253-58
52 Gurbel PA Kerejakes DJ Serebruany VL Soluble P-Selectin is not a surrogate marker for platelet P-Selectin Evidence from a multicenter chest pain study group J Thromb Thrombolysis 20001015-22
53 Serebruany VL Murugesan SR Pothula Atar D Lowry DR OrsquoConnor CM Gurbel PA Increased soluble plateletendothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure Independence of disease etiology and antecedent aspirin therapy Eur J Heart Fall 20001243-9
54 Semann HB Gurbel PA Anderson JL Muhlestein JB Carlquist JV Horne BD Serebruany VL Soluble VCAM-1 and E-selectin but not ICAM-1 discriminate endothelial injury in patients with documented coronary artery disease Cardiology 2000937-10
55 Gurbel PA Kereiakes DJ Serebruany VL Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction Scand Cardiovasc J 20003453-8
56 Serebruany VL Lowry DR Fuzaylov SY Levine DJ OConnor CM Gurbel PA Moderate alcohol consumption is associated with the decreased baseline platelet activity in patients presenting with acute myocardial infarction J Thromb Thrombolysis 20009229-34
57 Serebruany VL Murugesan SR Atar D Jerome S Semann H Gurbel PA Effect coronary thrombolysis on the plasma concentration of osteonectin (SPARC BM40) in patients with acute myocardial infarction J Thromb Thrombolysis 200010197-202
58 Semann HB Gurbel PA Anderson JL Muhlestein JB Carlquist JF Horne BD Serebruany VL The effect of
Curriculum Vitae Paul A Gurbel MD Page 5
chronic azithromycin therapy on soluble endothelium-derived adhesion molecules in patients with coronary artery disease Cardiovasc Pharmacol 200036533-7
59 Gurbel PA OrsquoConnor CM Dalesandro MR Serebruany VL Relation of soluble and platelet P-selectin to early outcome in patients with acute myocardial infarction after thrombolytic therapy Am J Cardiol 200187774-7
60 Serebruany VL Alford AB Meister AF Fuzaylov SY Gattis WA Gurbel PA Clinical utility of the platelet function analyzer (PFA-100) for the Assessment of the Platelet Status in Patients with Congestive Heart Failure (EPCOT trial) Thromb Res 200115427-33
61 Serebruany VL Gurbel PA OrsquoConnor CM Platelet inhibition by sertraline and n-desmethylsertraline A possible missing link between depression coronary events and mortality benefits of selective serotonin reuptake inhibitors Pharmacol Res 200143453-62
62 Serebruany VL OrsquoConnor CM Gurbel PA Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease Am J Cardiol 2001871398-400
63 Serebruany VL Levine DJ Nair GV Meister AF Gurbel PA Usefulness of combining necrosis and platelet markers in triaging patients presenting with chest pain to the emergency department J Thromb and Thrombolysis 200111155-62
64 Serebruany VL Cummings CC Malinin AI Steinhubl SR Gurbel PA Uniform platelet activation exists before coronary stent implantation despite aspirin therapy Am Heart J 2001142611-16
65 Gurbel PA Fusaylov SF Gattis WA Gaulden L Hasselblad V Serebruany VL OrsquoConnor CM Evaluation of platelets in heart failure Is platelet activity related to etiology class or clinical outcomes Am Heart J 20021431068-75
66 Gurbel PA Malinin AI Callahan KP Serebruany VL OrsquoConnor CM Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and GP IIbIIIa expression and platelet-leukocyte aggregate formation Am J Cardiol 200290312-315
67 Bahr RD Gurbel PA Malinin AI Wentz C Christenson RH Roe MT Gibler WB Kitt MM Ohman EM Serebruany VL Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q wave acute myocardial infarction Am J Cardiol 200290310-312
68 Faxon DP Gibbons RJ Chronos NAF Gurbel PA Sheehan F for the HALT ndash MI Investigators The effect of blockade of the CD11CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty The results of the HALT- MI study J Am Coll Cardiol 2002401199-1204
69 Serebruany VL McKenzie M Meister A Fuzaylov S Gurbel P Atar D Gattis W OrsquoConnor C Whole blood impedence aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT Trial) Eur J Heart Fail 20024461
70 Serebruany V McKenzie ME Meister AF Fuzaylov SY Gurbel PA Atar D Gattis WA OrsquoConnor CM Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT Trial with special reference to the Hemodyne hemostatic analyzer Pathophysiol Haemost Thromb 2002328-15
71 Gurbel PA Callahan KP Malinin AI Serebruany VL Gillis J Could stent design affect platelet activation Results of the Platelet Activation in Stenting (PAST) study J Invasive Cardiol 200214584-9
72 Gurbel PA Galbutt B Bliden KP Bahr RD Roe MT Serebruany VL Ohman EM Effect of eptifibatide for acute coronary syndromes Rapid versus late administration-therapeutic yield on platelets (the EARLY platelet substudy) J Thromb Thrombolysis 200314213-219
73 Gurbel PA Cummings CC Alford AB Meister AF Serebruany VL Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting The Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial Am Heart J 2003145239-47
74 Serebruany VL Malinin AI Callahan KP Binbrek A Van de Werf F Alexander JH Granger CB Gurbel PA Effect of tenecteplase versus alteplase on platelets during the first three hours of treatment for acute myocardial infarction The ASSENT-2 Platelet Substudy Am Heart J 2003145636-42
75 Gurbel PA Bliden KP Durability of platelet inhibition by clopidogrel Am J Cardiol 2003911123-5 76 Gurbel PA Bliden KP Hiatt BL The early antiplatelet effects of clopidogrel loading for coronary stenting and the
long term stability of inhibition J Thromb Haemost 200311319-21 77 Gurbel PA Bliden KP Hiatt BL Clopidogrel for coronary stenting Response variability drug resistance and the
effect of pretreatment platelet reactivity Circulation 20031072908-13 78 Serebruany VL Malinin AI OrsquoConnor CM Gurbel PA Effects of roxifiban on platelet aggregation and major
receptor expression in patients with coronary artery disease For the Roxifiban Oral Compound Kinetics Evaluation Trial ndash I Am Heart J 200314691-8
79 Gurbel PA Bliden KP Platelet activation after stenting with heparin-coated versus non-coated stents Am Heart J 2003146E10
Curriculum Vitae Paul A Gurbel MD Page 6
80 Gurbel PA Bliden KP A new method of representing drug-induced platelet inhibition Better description of time course response variability non-response and heightened reactivity Platelets 200314481-3
81 Gurbel PA Bliden KP The stratification of platelet reactivity and activation in patients with stable coronary disease on aspirin therapy Thromb Res 20031129-12
82 Gurbel PA Samara WM Bliden KP Failure of clopidogrel to reduce platelet reactivity an activation following standard dosing in elective stenting Implications for thrombotic events and restenosis Platelets 20031595-99
83 Lau WC Gurbel PA Watkins PB Neer CJ Hopp AS Carville DGM Guyer KE Tait AR Bates ER The contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 200410966-71
84 Joynt KE Gattis WA Hasselblad V Fuzaylov SY Serebruany VL Gurbel PA Gaulden LH Felker GM Whellan DJ OrsquoConnor CM Effect of angiotensin-converting enzyme inhibitors beta blockers statins and aspirin on C-reactive protein levels in outpatients with heart failure Am J Cardiol 200493783-5
85 Samara WM Bliden KP Tantry U Gurbel PA Thrombotic risk The difference between clopidogrel responsiveness and post-treatment platelet reactivity Thromb Res 200411589-94
86 Gurbel PA Hayes KA Bliden KP Yoho J Tantry U The platelet-related effects of tenecteplase vs alteplase vs reteplase Blood Coag Fibrinolysis 2005161-7
87 Gurbel PA Bliden KP Zaman KA Yoho JA Hayes KM Tantry US Clopidogrel loading with eptifibatide to arrest the reactivity of platelets Results of the CLEAR PLATELETS study Circulation 20051111153-9
88 Poston R Gu J Brown J Gammie J White C Manchio J Pierson RN Griffith P Gurbel P Tantry U Gilbert TB Hypercoaguability affecting early vein graft patency does not exist after off-pump coronary artery bypass J Cardiothoracic Vasc Anesth 20051911-18
89 Gurbel PA Bliden KP Hates KM Yoho JA Herzog WR Tantry US The relation of dosing to clopidogrel responsiveness and the incidence of high post-stent platelet aggregation in patients undergoing coronary stenting J Am Coll Cardiol 2005451392-6
90 Hermiller JB Raizner A Cannon L Gurbel PA Kutcher MA Wong SC Russell ME Ellis SG Mehran R Stone GW TAXUS-IV Investigators Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus The TAXUS-IV trial J Am Coll Cardiol 2005451172-9
91 Gurbel PA Bliden KP Samara W Yoho J Hayes K Fissha M Tantry U Clopidogrel Effect on Platelet REactivity in Patients with Stent Thrombosis Results of the CREST Study J Am Coll Cardiol 2005461827-32
92 Gurbel PA Bliden KP Guyer K Cho P Zaman K Kreutz R Bassi A Tantry US Platelet REactivity in Patients And Recurrent Events POST-STENTING Results of the PREPARE POST-STENTING Study J Am Coll Cardiol 2005461820-6
93 Tantry US Bliden KP Gurbel PA Overestimation of platelet aspirin resistance Detection by thrombelastograph platelet mapping and validation by conventional aggregation using arachidonic acid stimulation J Am Coll Cardiol 2005461705-9
94 Kreutz RP Tantry US Bliden KP Gurbel PA Viral respiratory tract infections increase platelet reactivity and activation - an explanation for the higher rates of myocardial infarction and stroke during viral illness J Thromb Haemost 200532108-9
95 Bleske B Nicklas J Bard R Brook R Gurbel PA Bliden K Rajagopalan S Pitt B Neutral effect on markers of heart failure inflammation endothelial activation and function and vagal tone following high dose HMG - coA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low density lipoproteins J Am Coll Cardiol 200647338-41
96 Gurbel PA Bliden KP Tantry US Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting Inflammation results from the CLEAR PLATELETS-1b study J Am Coll Cardiol 2006482186-91
97 Kandzari DE Leon MB Popma JJ Fitzgerald PJ OrsquoShaughnessy C Ball MW Turco M Applegate RJ Gurbel PA et alfor the ENDEAVOR III Investigators Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease a randomized controlled trial J Am Coll Cardiol 2006482440 ndash 2447
98 Gurbel PA Bliden KP Guyer K Aggarwal N Tantry US Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting Thromb Res 2007119563-70
99 Bliden KP DiChiara J Tantry US Bassi AK Chaganti SK Gurbel PA Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention is the current antiplatelet therapy adequate J Am Coll Cardiol 200749657-66
100 Gurbel PA Bliden KP Etherington A Tantry US Assessment of clopidogrel responsiveness measurements of maximum platelet aggregation final platelet aggregation and their correlation with vasodilator stimulated phosphoprotein in resistant patients Thromb Res 2007121107-15
101 Gurbel PA Bliden KP DiChiara J Gesheff T RN Chaganti S Etherington A MD Tantry US Evaluation of
Curriculum Vitae Paul A Gurbel MD Page 7
dose-related effects of aspirin on platelet function results from the ASpirin-Induced Platelet EffeCT (ASPECT) study Circulation 20071153156-64
102 Kreutz RP Tantry US Bliden KP Gurbel PA Inflammatory changes during the common cold are associated with platelet activation and increased reactivity of platelets to agonists Blood Coagul Fibrinolysis 200718713-8
103 Storey R Husted S Harrington R Heptinstall S Wilcox R Peters G Wickens Emanuelsson H Gurbel PA Grande P Cannon C Inhibition of platelet aggregation by AZD6140 a reversible oral P2Y12 receptor antagonist compared with clopidogrel in patients with acute coronary syndromes J Am Coll Cardiol 2007501852-6
104 DiChiara J Bliden KP Tantry US Hamed MS Antonino MJ Suarez TA Bailon O Singla A Gurbel PA The effect of aspirin dosing on platelet function in diabetic and non-diabetic patients an analysis from the aspirin-induced platelet effect (ASPECT) study Diabetes 200756 3014-9
105 DiChiara J Bliden KP Tantry US Chaganti SK Kreutz R Gesheff TB Kreutz Y Gurbel PA Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients Platelets 200718 414-23
106 Gurbel PA Kreutz RP Bliden KP Tantry US Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease a potential approach to identify atherosclerotic disease progression Am Heart J 200815555-61
107 Gurbel PA Bliden KP Cohen E Navickas IA Singla A Antonino MJ Fissha M Kreutz RP Bassi AK Tantry US Race and sex differences in thrombogenicity risk of ischemic events following coronary stenting Blood Coagul Fibrinolysis 200819268-75
108 Nissen SE Nicholls SJ Wolski K Rodeacutes-Cabau J Cannon CP Deanfield JE Despreacutes JP Kastelein JJ Steinhubl SR Kapadia S Yasin M Ruzyllo W Gaudin C Job B Hu B Bhatt DL Lincoff AM Tuzcu EM STRADIVARIUS Investigators Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease the STRADIVARIUS randomized controlled trial JAMA 20082991547-60
109 Bliden KP DiChiara J Lookman L Singla A Antonino MJ Baker BA Bailey WL Tantry US Gurbel PA The association of cigarette smoking with enhanced platelet inhibition by clopidogrel J Am Coll Cardiol 200852531-3
110 Gurbel PA Antonino MJ Bliden KP Dichiara J Suarez TA Singla A Tantry US Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention a potential antiplatelet therapeutic target Platelets 200819595-604
111 Gurbel PA Bliden KP Cohen E Navickas IA Singla A Antonino MJ Fissha M Kreutz RP Bassi AK Tantry US Race and sex differences in thrombogenicity risk of ischemic events following coronary stenting Blood Coagul Fibrinolysis 200819268-75
112 Gurbel PA Antonino MJ Bliden KP Dichiara J Suarez TA Singla A Tantry US Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention a potential antiplatelet therapeutic target Platelets 200819595-604
113 Hamed MS Gambert S Bliden KP Bailon O Anand S Antonino MJ Hamed F Tantry US Gurbel PA Dark chocolate effect on platelet activity C-reactive protein and lipid profile a pilot study S Med J 20081011203-8
114 Gilstad JR Gurbel PA Andersen RE Relationship between age and platelet activation in patients with stable and unstable angina Arch Gerontol Geriatr 200948155-9
115 Gurbel PA Bliden KP Saucedo JF Suarez TA DiChiara J Antonino MJ Mahla E Singla A Herzog WR Bassi AK Hennebry TA Gesheff TB Tantry US Bivalirudin and clopidogrel with and without eptifibatide for elective stenting effects on platelet function thrombelastographic indices and their relation to periprocedural infarctionResults of the CLEAR PLATELETS-2 study J Am Coll Cardiol 200953857-9
116 Gurbel PA Bliden KP Kreutz RP DiChiara J Antonino MJ Tantry US The link between heightened thrombogenicity and inflammation Pre-procedure characterization of the patient at high risk for recurrent events after stenting Platelets 20092097-104
117 Antonino MJ Mahla E Bliden KP Tantry US Gurbel PA Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting Am J Cardiol 20091031546-50
118 Antonino MJ Coppolecchia R Mahla E Bliden KP Tantry US Gurbel PA Antiplatelet effects of aspirin with phytosterols Comparison with non-enteric coated aspirin alone Thromb Res 2009126384-5
119 Pinto Slottow TL Bonello L Gavini R Beauzile P Sushinsky SJ Scheinowitz M Kaneshige K Xue Z Torguson R Tantry U Pichard AD Satler LF Suddath WO Kent K Gurbel P Waksman R Am J Cardiol 2009104525-30
120 Shuldiner AR OConnell JR Bliden KP Gandhi A Ryan K Horenstein RB Damcott CM Pakyz R Tantry US Gibson Q Pollin TI Post W Parsa A Mitchell BD Faraday N Herzog W Gurbel PA Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyJAMA2009302849-57
121 Singla A Antonino MJ Bliden KP Tantry US Gurbel PA The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy Am Heart J 2009158784e1-6
122 Gurbel PA Bliden KP Antonino MJ Stephens G Gretler DD Jurek MM Pakyz RE Shuldiner AR Conley PB
Curriculum Vitae Paul A Gurbel MD Page 8
Tantry US The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP 2C192 genotype First experience in patients J Thromb Haemost 2010843-53
123 Gurbel PA Bliden KP Butler K Tantry US Gesheff T Wei C Teng R Antonino MJ Patil SB Karunakaran A Kereiakes DJ Parris C Purdy D Wilson V Ledley GS Storey RF Randomized double-blind assessment of the ONSET and OFFSet of the antiplatelet Effects of Ticagrelor versus clopidogrel in patients with stable coronary artery disease The ONSETOFFSET Study Circulation 20091202577-85
124 Gurbel PA Bliden K Antonino M Butler K Teng R Rasmussen L Syd A Storey R Nielsen T Eikelboom J Sabe-Affaki G Husted S Kereaikes D Henderson D Patel V Tantry U Response to Ticagrelor in Clopidogrel Non-responders and ReSPONDers and the Effect of Switching Therapies The RESPOND Study Circulation 20101211188-99
125 Tantry US Bliden KP Suarez TA Kreutz RP DiChiara J Gurbel PA Hypercoagulability platelet function inflammation and coronary artery disease acuity results of the Thrombotic Risk Platelets 201021 360-7
126 Hennekens CH Schneuder WR Hebert PR Tantry US Gurbel PA Hypothesis formulation from subgroup analyses non-adherence or non-steroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to ldquoaspirin resistancerdquo Am Heart J 2010159744-8
127 Storey RF Bliden KP Patil SB Karunakaran A Ecob R Butler K Teng R Wei C Tantry US Gurbel PA ONSETOFFSET Investigators Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor clopidogrel or placebo in the ONSETOFFSET study J Am Coll Cardiol 201056185-93
128 Gurbel PA Bliden KP Navickas IA Mahla E Dichiara J Suarez TA Antonino MJ Tantry US Cohen E Adenosine diphosphate-induced platelet-fibrin clot strength a new thrombelastographic indicator of long-term poststenting ischemic events Am Heart J 2010160346-54
129 Angiolillo DJ Saucedo JF Deraad R Frelinger AL Gurbel PA Costigan TM Jakubowski JA Ojeh CK Effron MB SWAP Investigators Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes results of the SWAP (SWitching Anti Platelet) study J Am Coll Cardiol 2010561017-23
130 Mega JL Simon T Collet JP Anderson JL Antman EM Bliden K Cannon CP Danchin N Giusti B Gurbel P Horne BD Hulot JS Kastrati A Montalescot G Neumann FJ Shen L Sibbing D Steg PG Trenk D Wiviott SD Sabatine MS Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI a metaanalysis JAMA 20103041821-30
131 Tantry US Bliden KP Wei C Storey RF Armstrong M Butler K Gurbel PA First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel The ONSETOFFSET and RESPOND Genotype Studies Circ Cardiovasc Genet 20103556-66
132 Lau WC Welch TD Shields T Rubenfire M Tantry US Gurbel PA The Effect of St Johns Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients Increased Platelet Inhibition by Enhancement of CYP 3A4 Metabolic Activity J Cardiovasc Pharmacol 20115786-93
133 Gurbel PA Shuldiner AR Bliden KP Ryan K Pakyz RE Tantry US The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy Am Heart J 2011161598-604
134 Kandzari DE Mauri L Popma JJ Turco MA Gurbel PA Fitzgerald PJ Leon MB Late-Term Clinical Outcomes With Zotarolimus-and Sirolimus-Eluting Stents 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) JACC Cardiovasc Interv 20114543-50
135 Storey RF Bliden KP Ecob R Karunakaran A Butler K Wei C Tantry U Gurbel PA Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared to clopidogrel in patients with high antiplatelet responses J Thromb Haemost 201191730-7
136 Bliden KP Tantry US Storey RF Jeong YH Gesheff M Wei C Gurbel PA The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity Combined analysis of the ONSETOFFSET and RESPOND studies Am Heart J 2011162160-5
137 Lewis JP Fisch AS Ryan K OrsquoConnell JR Gibson Q Mitchell BD Shen H Tanner K Horenstein RB Pakzy R Tantry US Bliden KP Gurbel PA and Shuldiner AR ( equal contribution) Paraoxonase 1 (PON1) Gene Variants Are Not Associated With Clopidogrel Response Clinical Pharm Ther 201190568-74
138 Navarese EP Kozinski M Obonska K Margheri M Gurbel PA Kubica J De Luca G Clinical efficacy and safety of intracoronary vs intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention A meta-analysis of randomized trials Platelets 2011 (in press)
139 Navarese EP De Luca G Castriota F Kozinski M Gurbel P MD Gibson CM Andreotti F Siller-MatulaJM Pafundi T Sukkenik A De Servi S Kubica J Low-molecular-weight heparins vs unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction A meta-analysis J
Curriculum Vitae Paul A Gurbel MD Page 9
Thromb Haemost 201191902-15) 140 Jeong YH Tantry US Kim I-S Koh J-S Kwon TJ Park Y Hwang SJ Bliden KP Kwak CH Hwang J-W
Gurbel PA Effect of CYP2C192 and 3 loss-of-function allele carriage on platelet reactivity and adverse clinical event occurrence in east asian acute myocardial infarction survivors treated with clopidogrel and aspirin Circ Cardiovasc Genet 20114585-94
141 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
142 Gurbel PA Bliden KP Firt J Zhang Y Plachetka JR Antonino M Gesheff M Tantry US Pharmacodynamic evaluation of clopidogrel plus PA32540 The Spaced PA32540 with Clopidogrel INteraction Gauging (SPACING) study Clin Pharmacol Ther 201190860-6
143 Navarese EP Buffon A Andreotti F Gurbel PA Kozinski M Kubica A Musumeci G Cremonesi A Tavazzi L Kubica J Castriota F Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome A meta-analysis of randomized trials Atherosclerosis 20122221-7
144 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 201210487-9
145 Gurbel PA Bliden KP Antonino MJ Gesheff T Cummings CC Dubois BV Herzog WR Tantry US Time dependence of clopidogrel loading effect Platelet activation versus platelet aggregation Thromb Res Thromb Res 20121291-2
146 Mahla E Suarez TA Bliden KP Rehak P Metzler H Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study Circ Cardiovasc Interv 20125261-9
147 Park Y Jeong YH Tantry US Ahn JH Kwon TJ Park JR Hwang SJ Gho EH Bliden KP Kwak CH Hwang JY Kim S Gurbel PA Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study Eur Heart J 2012332151-62
148 Husted SE Storey RF Bliden K Tantry US Hoslashimark L Butler K Wei C Teng R Gurbel PA Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease Results from the ONSET-OFFSET and RESPOND Studies Clin Pharmacokinet 201251397-409
149 Kubica J Koziński M Navarese EP Tantry US Grześk G Fabiszak T Kubica A Swiątkiewicz I Bliden KP Gurbel PA Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction A systematic review and meta-analysis of randomized clinical trials Cardiol J 201219(3)230-42 Jeong YH Bliden KP Antonino MJ Tantry US Gurbel PA Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity Platelets 2012 May 30 [Epub ahead of print]
150 Welsh RC Rao SV Zeymer U Thompson VP Huber K Kochman J McClure MW Gretler DD Bhatt DL Gibson CM Angiolillo DJ Gurbel PA Berdan LG Paynter G Leonardi S Madan M French WJ Harrington RA on behalf of the INNOVATE PCI Investigators A Randomized Double-Blind Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention The INNOVATE-PCI Trial Circ Cardiovasc Interv 20125336-346
151 Angiolillo DJ Welsh RC Trenk D Neumann FJ Conley PB McClure MW Stephens G Kochman J Jennings LK Gurbel PA Woacutejcik J Dabrowski M Saucedo JF Stumpf J Buerke M Broderick S Harrington RA Rao SV Pharmacokinetic and Pharmacodynamic Effects of Elinogrel Results of the Platelet Function Substudy From the Intravenous and Oral Administration of Elinogrel to Evaluate Tolerability and Efficacy in Nonurgent Percutaneous Coronary Intervention Patients (INNOVATE-PCI) Trial Circ Cardiovasc Interv 20125347-56
152 Reny JL Combescure C Daali Y Gurbel PA Fontana P PON1 Meta-Analysis Group Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events a systematic review and meta-analysis J Thromb Haemost 2012101242-1251
153 Jeong YH Bliden KP Antonino MJ Park KS Tantry US Gurbel PA Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies Am Heart J 201216435-42
154 Jeong YH Bliden KP Antonino MJ Tantry US Gurbel PA Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity Platelets 201216435-42
155 Singla A Bliden KP Jeong YH Abadilla K Antonino MJ Muse WC Mathew DP Bailon O Tantry US Gurbel PA Platelet reactivity and thrombogenecity in postmeopausal women Menopause 20132057-63
156 Jeong YH Tantry US Park Y Kwon TJ Park JR Hwang SJ Bliden KP Koh EH Kwak CH Hwang JY Kim S
Curriculum Vitae Paul A Gurbel MD Page 10
Gurbel PA Pharmacodynamic Effect of Cilostazol Plus Standard Clopidogrel Versus Double-Dose Clopidogrel in Patients With Type 2 Diabetes Undergoing Percutaneous Coronary Intervention Diabetes Care 2012352194-7
157 Roe MT Armstrong PW Fox KAA White HD Prabhakaran D Goodman SG Cornel JH Bhatt DL Clemmensen P Martinez F Ardissino D Nicolau JC Boden WE Gurbel PA Ruzyllo W Dalby AJ McGuire DK Leiva-Pons JL Parkhomenko A Gottlieb S Topacio GO Hamm C Pavlides G Goudev AR Oto A Tseng C-D Merkely B Gasparovic V Corbalan R Cinteză M McLendon RC Winters KJ Brown EB Lokhnygina Y Aylward PE Huber K Hochman JS E Magnus Ohman EM for the TRILOGY ACS Investigators Prasugrel versus clopidogrel for ACS patients managed without revascularization N Engl J Med 20123671297-309
158 Gurbel PA Bliden KP Jeong Y-H Antonino M Gesheff T Fort JG Shuldiner A Chai S Gesheff M Zhang Y Tantry US Spaced Administration of PA32540 and Clopidogrel Results in Greater Platelet Inhibition than Synchronous Administration of Enteric-Coated Aspirin and Enteric-Coated Omeprazole and Clopidogrel Am Heart J 2013165176-82
159 Gurbel PA Erlinge D Ohman EM Neely B Neely M Goodman SG Huber K Chan MY Cornel JH Brown E Zhou C Jakubowski JA White HD Fox KA Prabhakaran D Armstrong PW Tantry US Roe MT TRILOGY ACS Platelet Function Substudy Investigators JAMA 20123081785-94
160 Lewis JP Horenstein RB Ryan K OConnell JR Gibson Q Mitchell BD Tanner K Chai S Bliden KP Tantry US Peer CJ Figg WD Spencer SD Pacanowski MA Gurbel PA Shuldiner AR The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response Pharmacogenet Genomics 2012 Pharmacogenet Genomics 2013231-8
161 Jeong YH Tantry US Min JH Park Y Navarese EP Koh JS Park JR Hwang SJ Kho EH Bliden KP Kwak CH Hwang JY Kim S Gurbel PA Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention Int J Cardiol 2012 Oct 12 doipii S0167-5273(12)01253-3 101016
162 Saucedo JF Angiolillo DJ Deraad R Frelinger AL 3rd Gurbel PA Costigan TM Jakubowski JA Ojeh CK Duvvuru S Effron MB for the SWAP Investigators Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel insights from the switching anti-platelet (SWAP) study Thromb Haemost 2012 Dec 6109(2) [Epub ahead of print]
163 Navarese EP Austin D Gurbel PA Andreotti F Tantry U James S Buffon A Kozinski M Obonska K Bliden K Jeong YH Kubica J Kunadian V Drug-coated balloons in treatment of in-stent restenosis a meta-analysis of randomized controlled trials Clin Res Cardiol 2012 Dec 20 [Epub ahead of print]
164 Gurbel PA Bliden KP Fort JG Jeong YH Shuldiner A Chai S Gesheff T Antonino M Gesheff M Zhang Y Tantry US Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel Am Heart J 2013165176-82
165 Lewis JP Ryan K OConnell JR Horenstein RB Damcott CM Gibson Q Pollin TI Mitchell BD Beitelshees AL Pakzy R Tanner K Parsa A Tantry US Bliden KP Post WS Faraday N Herzog W Gong Y Pepine CJ Johnson JA Gurbel PA Shuldiner AR Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes Circ Cardiovasc Genet 2013 Feb 7 [Epub ahead of print]
166 Navarese EP Gurbel PA Andreotti F Tantry U Jeong YH Kozinski M Engstroslashm T Di Pasquale G Kochman W Ardissino D Kedhi E Stone GW Kubica J Optimal Timing of Coronary Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes A Systematic Review and Meta-analysis Ann Intern Med 2013158261-70
167 Jeong YH Abadilla KA Tantry US Park Y Koh JS Kwak CH Hwang JY Gurbel PA Influence of CYP2C192 and 3 loss-of-function alleles on pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention the results of the ACCEL-DOUBLE-2N3 studyJ Thromb Haemost 2013111194-7
168 Gurbel PA Bliden KP Logan DK Kereiakes DJ Lasseter KC White A Angiolillo DJ Nolin TD Maa JF Bailey WL Jakubowski JA Ojeh CK Jeong YH Tantry US Baker BA The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel The PARADOX Study J Am Coll Cardiol 2013 Apr 16 doipii S0735-1097(13)01478-2 101016jjacc201303037 [Epub ahead of print]
169 Grzesk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E4 Jeong Y-H Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 2013 Article ID 928271 httpdxdoiorg1011552013928271
170 Erlinge D Gurbel PA James S Lindahl TL Svensson P Ten Berg JM Foley DP Wagner H Brown PB Luo J Zhou C Moser BA Jakubowski JA Small DS Winters KJ Angiolillo DJ Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains non-inferiority to prasugrel 10-mg in non-elderly patients The GENERATIONS trial a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients J Am Coll Cardiol 201362577-83
Curriculum Vitae Paul A Gurbel MD Page 11
171 Kim IS Jeong YH Tantry US Park Y Lee DH Bliden KP Koh JS Park JR Jang JS Hwang SJ Koh EH Kwak CH Hwang JY Kim S Gurbel PA Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading Am Heart J 201316695-103
172 Grześk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E Jeong YH Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 20132013928271
173 Stone GW Witzenbichler B Weisz G Rinaldi MJ Neumann FJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri E Gurbel PA Xu K Parise H Kirtane AJ Brodie BR Mehran R Stuckey TD for the ADAPT-DES Investigators Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES) a prospective multicentre registry study Lancet 2013382614-23
174 Angiolillo DJ Curzen N Gurbel P Vaitkus P Lipkin F Li W Jakubowski JA Zettler M Effron MB Trenk D Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in subjects with stable coronary artery disease Results of the SWAP-2 Study J Am Coll Cardiol 2014631500-9
175 Jeong YH Bliden KP Shuldiner AR Tantry US Gurbel PA Thrombin-induced platelet-fibrin clot strength Relation to high on-clopidogrel platelet reactivity genotype and post-percutaneous coronary intervention outcomes Thromb Haemost 2014111713-24
176 Gouya G Arrich J Wolzt M Huber K Verheugt FW Gurbel PA Pirker-Kees A Siller-Matula JM Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases a systematic review and meta-analysis Stroke 201445492-503
177 Erlinge D James S Duvvuru S Jakubowski JA Wagner H Varenhorst C Tantry US Brown PB Small D Moser BA Sundseth S Walker JR Winters KJ Gurbel PA Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease Thromb Haemost 2014111943-50
178 Gurbel PA Baker BA Bailey WL Bliden KP Tantry US Unraveling the Smokers Paradox Cigarette smoking high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors Thromb Haemost 20141111187-90
179 Koh JS Kim IS Tantry US Yoon SE Park Y Cho SY Lee EJ Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading The results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study Int J Cardiol 2014174129-32
180 Bliden KP Singla A Gesheff MG Toth PP Tabrizchi A Ens G Guyer K Singh M Franzese CJ Stapleton D Tantry US Gurbel PA Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin Thromb Haemost 2014 Apr 24112(2) [Epub ahead of print]
181 Gurbel PA Gesheff MG Franzese CJ Bliden KP Tantry US Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy Platelets 201526608-9
182 Gurbel PA Bergmeijer TO Tantry US Ten Berg JM Angiolillo DJ James S Lindahl TL Svensson P Jakubowski JA Brown PB Duvvuru S Sundseth S Walker JR Small D Moser BA Winters KJ Erlinge D The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease Thromb Haemost 2014 2014112589-97
183 Cornel JH Ohman EM Neely B Clemmensen P Sritara P Zamoryakhin D Armstrong PW Prabhakaran D White HD Fox KA Gurbel PA Roe MT TRILOGY ACS Investigators Impact of smoking status on platelet function and clinical outcomes with prasugrel vs clopidogrel in patients with acute coronary syndromes managed without revascularization Insights from the TRILOGY ACS trial Am Heart J 201416876-87
184 Park Y Jung JM Tantry US Kim K Koh JS Park JR Hwang SJ Kwak CH Hwang JY Kim S Gurbel PA Jeong YH Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration The ACCEL-PARAZOL Study J Atheroscler Thromb 2014211121-39
185 Park Y Jeong YH Tantry US Ahn JH Kim K Koh J Park J Hwang SJ Kwak CH Hwang JY Gurbel PA Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity The Resultof the ACCEL-DIP Study Thromb Haemost 2014112 [Epub ahead of print]
186 Lev EI Bliden KP Jeong Y-H Pandya S Kang K Franzese C Tantry US Gurbel PA Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients J Am Heart Assoc 20143e001167
187 Alexopoulos D Xanthopoulou I Storey RF Bliden KP Tantry US Angiolillo DJ Gurbel PA Platelet reactivity during ticagrelor maintenance therapy A patient-level data meta-analysis Am Heart J 2014 168530-6
188 Lhermusier T Lipinski MJ Tantry US Escarcega RO Baker N Bliden KP Magalhaes MA Ota H Tian W Pendyala L Minha S Chen F Torguson R Gurbel PA Waksman R Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity Am J Cardiol 2015115716-23
189 Franzese CJ Bliden KP Gesheff MG Pandya S Guyer KE Singla A Tantry US Toth PP Gurbel PA Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy Am J Cardiol 2015 11151204-11
Curriculum Vitae Paul A Gurbel MD Page 12
190 Aradi D Kirtane A Bonello L Gurbel PA Tantry US Huber K Freynhofer MK Ten Berg J Janssen P Angiolillo DJ Siller-Matula JM Marcucci R Patti G Mangiacapra F Valgimigli M Morel O Palmerini T Price MJ Cuisset T Kastrati A Stone GW Sibbing D Bleeding and stent thrombosis on P2Y12-inhibitors collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention Eur Heart J 2015361762-71
191 Navarese EP Kolodziejczak M Schulze V Gurbel PA Tantry U Lin Y Brockmeyer M Kandzari DE Kubica JM DAgostino RB Sr Kubica J Volpe M Agewall S Kereiakes DJ Kelm M Effects of proprotein convertase subtilisinkexin type 9 antibodies in adults with hypercholesterolemia a systematic review and meta-analysis Ann Intern Med 201516340-51
192 Lee K Yoo SY Suh J Park KH Park Y Tantry US Park KS Han SH Kang WC Shin DH Lee C Choi SW Lee JH Cho YH Lee NH Jeong MH Ahn Y Kubica J Gurbel PA Park JH Jeong YH Efficacy of cilostazol on inhibition of platelet aggregation inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study Int J Cardiol 2015190370-5
193 Kowalewski M Schulze V Berti S Waksman R Kubica J Kołodziejczak M Buffon A Suryapranata H Gurbel PA Kelm M Pawliszak W Anisimowicz L Navarese EP Complete revascularisation in ST-elevation myocardial infarction and multivessel disease meta-analysis of randomised controlled trials Heart 2015 1011309-17
194 Baber U Mehran R Kirtane AJ Gurbel PA Christodoulidis G Maehara A Witzenbichler B Weisz G Rinaldi MJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri EL Jr Xu K Parise H Brodie BR Stuckey TD Stone GW Prevalence and impact of high platelet reactivity in chronic kidney disease Results from the assessment of dual antiplatelet therapy with drug-eluting stents registry Circ Cardiovasc Interv 20158e001683
195 Tricoci P DAndrea DM Gurbel PA Yao Z Cuchel M Winston B Schott R Weiss R Blazing MA Cannon L Bailey A Angiolillo DJ Gille A Shear CL Wright SDAlexander JH Infusion of Reconstituted High-Density Lipoprotein CSL112 in Patients With Atherosclerosis Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial J Am Heart Assoc 20154 pii e002171
196 Reny JL Fontana P Hochholzer W Neumann MJ ten Berg J Janssen PF Geisler T Gawaz M Marcucci R Gori A-M Cuisset T Alessi M-S Berdagueacute P Gurbel PA Yong G Angiolillo DJ Aradi D Beigel R Campo G Combescure C Vascular risk levels affect the predictive value of platelet reactivity 1 for the occurrence of major adverse cardiovascular events in patients on clopidogrel Systematic review and collaborative meta-analysis of individual patient data Thromb Haemost 2015 (in press)
197 Chaudhary R Bliden KP Tantry US Mohammed N Mathew D Gesheff MG Franzese CJ Gurbel PA Association of weight gain with coronary artery disease inflammation and thrombogenicity J Thromb Thrombolysis 2015 Dec 29 [Epub ahead of print]
198 Gurbel PA Bliden KP Turner SE Tantry US Gesheff MG Barr TP Covic L Kuliopulos A Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease Arterioscler Thromb Vasc Biol 201636189-97
199 Kwon TJ Tantry US Park Y Choi YM Ahn JH Kim KH Koh JS Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Smith SC Jr Jeong YH Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention Results of the ACCEL-BLEED study Thromb Haemost 2016 Jan 21115(5) [Epub ahead of print]
200 Bliden KP Tantry US Gesheff MG Franzese CJ Pandya S Toth PP Mathew DP Chaudhary R Gurbel PA Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis J Interv Cardiol 201629168-78
201 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin J Diabetes Complications 2016 May 10 pii S1056-8727(16)30127-1
202 Bedeir K Bliden K Tantry U Gurbel PA Mahla E Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel The Role of VerifyNow Can J Cardiol 201632724-5
203 Giustino G Kirtane AJ Baber U Geacuteneacutereux P Witzenbichler B Neumann FJ Weisz G Maehara A Rinaldi MJ Metzger C Henry TD Cox DA Duffy PL Mazzaferri EL Brodie BR Stuckey TD Gurbel PA Dangas GD Francese DP Ozan O Mehran R Stone GW Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study Am J Cardiol 20161171877-83
204 Kubica J Kubica A Jilma B Adamski P Hobl EL Navarese EP Siller-Matula JM Dąbrowska A Fabiszak T Koziński M Gurbel PA Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors Int J Cardiol 2016215201-8
205 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin
Curriculum Vitae Paul A Gurbel MD Page 13
J Diabetes Complications 2016 May 10 [Epub ahead of print] 206 Bliden KP Chaudhary R Lopez LR Damrongwatanasuk R Guyer K Gesheff MG Franzese CJ Kaza H
Tantry US Gurbel PA Oxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease Am J Cardiol 2016 Jun 15 [Epub ahead of print]
207 Mahla E Prueller F Farzi S Pregartner G Raggam RB Beran E Toller W Berghold A Tantry US Gurbel PA Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy Ann Thorac Surg 2016 Jul 1 [Epub ahead of print]
208 Koh JS Park Y Tantry US Ahn JH Kang MG Kim K Jang JY Park HW Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents The ACCEL-COMBO trial Platelets 2016 Aug 251-7 [Epub ahead of print]
209 Chaudhary R Saadin K Bliden KP Harris WS Dinh B Sharma T Tantry US Gurbel PA Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease Prostaglandins Leukot Essent Fatty Acids 201611340-45
210 Gurbel PA Bliden KP Chaudhary R Patrick J Liu F Chen G McLeod C Tantry US Antiplatelet Effect Durability of a Novel 24-Hour Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes MellitusAm J Cardiol 20161181941-1947
211 Gurbel PA Bliden KP Tantry US Monroe AL Muresan AA Brunner NE Lopez-Espina CG Delmenico PR Cohen E Raviv G Haugen DL Ereth MH First report of the point-of-care TEG A technical validation study of the TEG-6S system Platelets 201627642-649
212 Cornel JH Ohman EM Neely B Jakubowski JA Bhatt DL White HD Ardissino D Fox KA Prabhakaran D Armstrong PW Erlinge D Tantry US Gurbel PA Roe MT Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes J Am Heart Assoc 2016 Nov 45(11) pii e003977
213 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 201717109-121
214 Sharma T Bliden K Chaudhary R Tantry U Gurbel PA Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease Expert Opin Pharmacother 201718123-131
215 Park Y Tantry US Koh JS Ahn JH Kang MG Kim KH Jang JY Park HW Park JR Hwang SJ Park KS Kwak CH Hwang JY Gurbel PA Jeong YH Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction The REMODELING Trial Thromb Haemost 2017117911-922
216 Navarese EP Gurbel PA Andreotti F Kołodziejczak MM Palmer SC Dias S Buffon A Kubica J Kowalewski M Jadczyk T Laskiewicz M Jędrzejek M Brockmeyer M Airoldi F Ruospo M De Servi S Wojakowski W O Connor C Strippoli GF Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis PLoS One 201712e0168726
217 Bliden KP Chaudhary R Mohammed N Muresan AA Lopez-Espina CG Cohen E Raviv G Doubleday M Zaman F Mathew B Tantry US Gurbel PA Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system J Thromb Thrombolysis 201743437-445
Publications Peer Reviewed Original Science Research - Reviews 1 Serebruany VL Atar D Dalesandro MR OConnor CM Gurbel PA Changes in hemostasis after parenteral
magnesium in myocardial ischemia reperfusion Animal studies to clinical trials Magnes Res 19981137-42 2 McKenzie ME Gurbel PA Levine DJ Serebruany VL Clinical utility of available methods determining platelet
function Cardiology 199992240-7 3 Gurbel PA OConnor CM Cummings CC Serebruany VL Clopidogrel The future choice for preventing platelet
activation during coronary stenting Pharm Res 199965109-123 4 Nair GV Gurbel PA Fusaylov SY Davis CJ Ohman EM Bahr RD Christensen RH Serebruany VL Combing
necrosis and platelet markers for perfecting myocardial infarction rule out How close are we Cardiology 20009350-5
5 Davis CJ Gurbel PA Gaitis WA Fuzaylov SY Nair GV OrsquoConnor CM Serebruany VL Hemostatic abnormalities in congestive heart failure Diagnostic significance and clinical challenge Int J Cardiol 20007515-21
6 Pothula A Gurbel PA Atar D McKenzie ME Serebruany VL Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease Eur J Pharmacol 20004021-10
7 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Serebruany VL Platelet function and fibrinolytic agents Two sides of a coin Cardiology 20019555-60
Curriculum Vitae Paul A Gurbel MD Page 14
8 Samara WM Gurbel PA The role of platelet receptors and adhesion molecules in coronary artery disease Coron Artery Dis 20031465-79
9 Gurbel PA Tantry U Clopidogrel response variability and the advent of personalised antiplatelet therapy A bench to bedside journey Thromb Haemost 2011106265-71
10 Gurbel PA Roe MT Jakubowski JA Shah S Erlinge D Goodman SG Huber K Chan MY Cornel JH Tantry US Ohman EM Translational platelet research in patients with coronary artery disease What are the major knowledge gaps Thromb Haemost 2012 May 25108 [Epub ahead of print]
11 Bliden KP Baker BA Nolin TD Jeong YH Bailey WL Tantry US Gurbel PA Thienopyridine efficacy and cigarette smoking status Am Heart J 2013165693-703
12 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
13 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013111547-56
14 Gesheff MG Franzese CJ Bliden KP Contino CJ Rafeedheen R Tantry USGurbel PA Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin Expert Rev Clin Pharmacol 2014 7645-53
15 Tantry US Gesheff M Liu F Bliden KP Gurbel PA Resistance to antiplatelet therapy what progress has been made Expert Opin Pharmacother 2014 9 1-12
16 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print]
17 Gurbel PA Myat A Tantry US Platelet-mediated Thrombosis From Bench to Bedside Cir Res 2015 (in press)
18 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 20161245-58
19 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
20 Gurbel PA Tantry US Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes Heart 2016102882-92
21 Navarese EP Kolodziejczak M Kereiakes DJ Tantry US OConnor C Gurbel PA Proprotein Convertase SubtilisinKexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome A Narrative Review Ann Intern Med 2016164600-7
22 Gurbel PA Jeong YH Navarese EP Tantry US Platelet-Mediated Thrombosis From Bench to Bedside Circ Res 20161181380-91
23 Gurbel PA Myat A Kubica J Tantry US State of the art Oral antiplatelet therapy JRSM Cardiovasc Dis 2016 Jun 152048004016652514 doi 1011772048004016652514 eCollection 2016 Jan-Dec
24 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 2016 Nov 17 [Epub ahead of print] Review
25 Winter MP Grove EL De Caterina R Gorog DA Ahrens I Geisler T Gurbel PA Tantry U Navarese EP Siller-Matula JM Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors Eur Heart J Cardiovasc Pharmacother 2017 Feb 15 doi 101093ehjcvppvw044 [Epub ahead of print]
26 Shah P Tantry US Bliden KP Gurbel PA Bleeding and thrombosis associated with ventricular assist device therapy J Heart Lung Transplant 2017 May 11 pii S1053-2498(17)31789-8
Inventions Patents Copyrights 32294 Gurbel PA Anderson RD Autoperfusion dilatation catheter United States Patent 5295959 51501 Dalesandro MR Gurbel PA Serebruany VL Determining a treatment plan for patients undergoing thrombotic
events by monitoring p-Selectin United States Patent 623071 61201 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6245782 13102 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 20020013343 42203 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6552014
Curriculum Vitae Paul A Gurbel MD Page 15
120611 Gurbel PA The detection of restenosis risk in patients receiving a stent by measuring the characteristics of blood clotting including the measurement of maximum thrombin-induced clot strength (patent awarded pending)
6308 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 7381536 2010 Gurbel PA Conley P Andre P Gretler D Jurek M Methods for diagnosis and treatment of thrombotic
disorders mediated bycyp2c192 (patent pending) 41014 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent
20140100167 81815 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 9110062 111715 Gurbel PA Detection of restenosis risk in patients receiving a stent by measuring the characteristics of
blood clotting including the measurement of maximum thrombin-induced clot strength Patent 9188597 Extramural Funding (since 2002) CURRENT 2010-2015 MAGMA (Multianalyte And Genetic Markers of Atherosclerosis)
Haemonetics and Sinai Hospital of Baltimore 2015-present An Observational Study of CORA-Assisted Stroke Identification and Antithrombotic Therapy
2014-2015 Feasibility clinical trial to evaluate the efficacy of an Anticoagulant cartridge to be used in the CORA System Coramed Technologies LLC
2014-2015 Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid Durlaza in CVD Patients at Risk of High Platelet Turnover (DURATION)
New Haven Pharmaceuticals Inc 2015-present Influence of Edoxaban on Coagulability and Thrombin Generation An in Vitro Study Focusing on
Thrombelastography Daiichi Sankyo
2016 Influence of Vorapaxar on Thrombin Generation and Coagulability Merck 2015-present Durlaza GI GI Tolerability Study New Haven Pharamceuticals 2015-present Thrombogenicity in LVAD Recipients Haemonetics 2014-2015 First-in-Man Assessment of PZ-128 National Institutes of Health PREVIOUS 2002 Atorvastatin in the Treatment of Heart Failure
LBH IRB 20030512 NIHThe National Heart Lung and Blood Institute NIH
2002 Asessment of the In Vitro Effects of Tenecteplase Reteplase and Alteplase on Human Platelets TAR STUDY Genetech
2003-2005 Assessment of the Effects of the heparin-coated Cordis Stent versus Non-coated Stents on Platelet and Endothelial Cell Activation and Thrombin Effect in Patients with Coronary Artery Disease (HEPACOAT) Cordis Inc
2004-2005 The Antiplatelet Effects of Eptifibatide with High and Standard Dose Clopidogrel in Low-Moderate Risk Patients Undergoing Coronary Intervention (CLEAR-PLATELETS Study) MilleniumSchering Plough
2004-2005 The Use of The TEG System to Monitor Platelet Inhibition at Bedside 5R44HL059753-03Haemoscope National Institute of Health
2004-2006 Clopidogrel Resistance in Patients with Stent Thrombosis (CREST Study) AstraZeneca
Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study MilleniumSchering Plough
2005 St Johns Wort Decreases ADP Induced Platelet Reactivity in Known Clopidogrel Resistant Post Coronary Intervention Patients after a Loading Dose of Clopidogrel University of Michigan
2008-2009 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST) Sinai Hospital Department of Medicine
2009-2010 Demonstration of the Pharmacodynamic Antiplatelet Effect of PRT060128 in Patients with High Platelet Reactivity during Clopidogrel and Aspirin Maintenance Therapy (PORTOLA) Portola Pharmaceuticals
2008-2009 A Randomised Double-Blind Outpatient Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND] AstraZeneca Pharmaceuticals LP
2008-2009 A Randomized Double-blind Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Background Therapy in Patients with Stable Coronary Artery Disease with Additional Detailed Assessment of Cardiopulmonary Function (ONSET-OFFSET) AstraZeneca Pharmaceuticals LP
2008-2009 A Single Center Randomized Open Label Parallel Group Pharmacodynamic Study of a Novel Combination Form of Aspirin and Phytosterol versus Aspirin in Healthy Adult Subjects (ARMOR) Bayer Healthcare LLC
2008-2009 Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel Plus EC Aspirin (325 mg) and Clopidogrel Plus PA32540 on Platelet Aggregation in Healthy Volunteers POZEN 110 POZEN Inc
2009-2010 Antithrombosis with Clopidogrel Beyond the Concept of Platelet Aggregate Inhibition (SANOFI) Sanofi Inc 2010-2012 A Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel EC
Aspirin 81 mg and EC omeprazole 40 mg all dosed concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers POZEN Inc
Intramural Funding (since 2002) CURRENT 2008-present Time Based Strategy to Reduce Clopidogrel Associated Bleeding Related to CABG (TARGET CABG) Sinai Hospital of Baltimore Department of Medicine 2009-present Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI)
Sinai Hospital of Baltimore Department of Medicine 2011-present Detection of Leukemic Blood and Solid TypE MalignanCies by Urinary 11-DehydroThromboxane B2 (DETECT) Study
Sinai Hospital of Baltimore Department of Medicine PREVIOUS 2001-2002 Platelet Activation in Stenting PAST Study Sinai Hospital of Baltimore 2005-2006 Platelet Reactivity in Patients with Crohnrsquos disease Receiving Infliximab (chimeric anti-TNF alpha antibody) ndash COIN
Sinai Hospital of Baltimore Department of Medicine 2006-2007 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST)
Sinai Hospital of Baltimore Department of Medicine 2008-2011 Platelet Reactivity and Thrombogenecity in Postmenopausal Women
Sinai Hospital Department of Medicine 2008-2010 Platelet Reactivity and Thrombogenecity in Postmenopausal Women (PRIDE Study)
Sinai Hospital Department of Medicine Multicenter Studies since 2001
Curriculum Vitae Paul A Gurbel MD Page 17
CURRENT 2010-present The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and
Clopidogrel in Aspirin-Treated Subjects With Stable Coronary Artery Disease Daiichi Sankyo
2010-present A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly versus Non-Elderly Aspirin-Treated Subjects with Stable Coronary Artery Disease Eli Lilly amp company
2011-present A Prospective Multicenter Randomized Trial of Clopidogrel versus Prasugrel Anti-platelet Therapy in Cytochrome P450 2C19 (CYP2C19) Intermediate Metabolizers Grant No U01HL105198
NIH National Heart Lung and Blood Institute NIH 2011-present A Prospective Randomized Multi-Center Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHERreg Sirolimus-Eluting Coronary stents
HCRI 2012-present A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in
patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)
Bayer Healthcare LLC 2013-present Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in
Patients at a High-Risk for Vascular Outcomes (ACCELERATE) Eli Lilly amp Company 2014-present A Phase 2b Multi-center Randomized Placebo-controlled Dose-ranging Study to Investigate the
Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infarction
AEGIS CSL 2015-2017 A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety of PZ- 128 in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention
National Institute of Health PREVIOUS 2001 A Randomized Double-Blind Placebo-Controlled Study of Two Intravenous Dosing Regimens of
h5G11-scFv in Patients with Acute Myocardial Infarction Undergoing 2001-2002 Prevention of REStenosis with Tranilast and Its Outcomes A Placebo Controlled Trial PRESTO STUDY
SmithKline Beecham 2002-2003 Taxus IV-SR Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
Boston Scientific 2003 MICROVENA Corporation TRAP Vascular Filtration System (VFS) Trial
Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily Pfizer Inc
2003-2004 Phase 3 Multi-Center Double-Blind Randomized Parallel Group Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily (QD) for 24 Months Compared with Atorvastatin Alone in Subjects with Angiographically Documented Coronary Heart Disease Pfizer Inc
2003-2004 A Randomized Controlled Trial of the Medtronic Endeavor Drug Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ldquoENDEAVOR III Studyrdquo)
Medtronic 2009-2010 A Prospective Randomized Open-label Multicenter study in Patients Presenting with Acute Coronary Syndromes SYNERGY STUDY
Aventis Pharmaceuticals 2004 CObalt chromium STent with Antiproliferative for Restenosis II Trialrdquo Costar study
Conor Medsystems
Curriculum Vitae Paul A Gurbel MD Page 18
2004-2005 A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions ENDEAVOR IV Medtronic
2004-2005 A Randomized Trial to evaluate the relative protection against POST-PCI microvasculat obstruction among antiplatelet and anti-thrombotic medications (TIMI-30) TIMI group
2004-2006 A Double-blind Double-dummy Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI 33 AstraZeneca Lp
2005-2006 Strategy To Reduce Atherosclerosis Development Involving Administration of Rimonabant - The Intravascular Ultrasound Study (STRADIVARIUS) EFC5827 Sanofi Synthelabo Research
2006 A Multicenter Randomized Double-Blind Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (TRASM-PCI) Schering Plough
2006-2007 A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel -SWAP (SWitching Anti Platelet study) Eli Lilly amp Company and Sankyo Company Limited
2006-2007 A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2008-2010 A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary InterventionTIMI-38 Eli Lilly Company Daiichi
2009-2010 A Randomized Double-Blind Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128 a Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Interventions (INNOVATE-PCI) Portola Pharmaceuticals
2010-2012 TReatment with ADPreceptor iNhibitorS Longitudinal Assessment ofTreatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS)
Eli Lilly Company 2010-2013 RADAR Randomized Partially-Blinded Multi-Center Active-Controlled Dose-Ranging Study
Assessing the Safety Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome Regado Bioscience Inc
2011-2013 A Phase IIa Multi-center Randomized Sponsor-unblinded Placebo-controlled Single Ascending Dose Study to Investigate the Safety Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Adults Taking Aspirin and a P2Y12 Platelet Inhibitor
AEGIS CSL Research Program BuildingLeadership 1991-1995 Director Interventional Cardiology Research University of Maryland Medical System 1998-2015 Director Sinai Center for Thrombosis Research 2001-2015 Director Cardiovascular Research Lifebridge Health 2002-2015 Director Therapeutics Research and Technology Development for the Cardiac Catheterization Program Sinai Hospital of Baltimore 2007-2015 Associate Chief for Research Department of Medicine Sinai Hospital of Baltimore 2015-current Director Interventional Cardiology and Cardiovascular Medicine Research INOVA Health 2015-Current Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute EDUCATIONAL ACTIVITIES
Curriculum Vitae Paul A Gurbel MD Page 19
Peer Reviewed Publications-Consensus Statements Expert Opinions 1 Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C
Rao AK The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 200531309-11
2 Hoekstra J Cohen M Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Saucedo JF Pollack CV Jr Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention-an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective report on a roundtable discussion Am J Emerg Med 200927720-8
3 Bonello L Tantry US Marcucci R Blindt R Angiolillo DJ Becker R Bhatt DL Cattaneo M Collet JP Cuisset T Gachet C Montalescot G Jennings LK Kereiakes D Sibbing D Trenk D Van Werkum JW Paganelli F Price MJ Waksman R Gurbel PA Working Group on High On Treatment Platelet Reactivity Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 201056919-33
4 Gurbel PA Tantry US Shuldiner AR Kereiakes DJ Genotyping one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 201056112-6
5 Gurbel PA Tantry US Antiplatelet therapy Clopidogrel-PPI interaction an ongoing controversy Nat Rev Cardiol 201187-8
6 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
7 Gurbel PA Nolin TD Tantry US Clopidogrel efficacy and cigarette smoking status JAMA 20123072495-6 8 Tantry US Bonello L Aradi D Price MJ Jeong YH Angiolillo DJ Stone GW Curzen N Geisler T Ten Berg J
Kirtane A Siller-Matula J Mahla E Becker RC Bhatt DL Waksman R Rao SV Alexopoulos D Marcucci R Reny JL Trenk D Sibbing D Gurbel PA Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding J Am Coll Cardiol 2013622261-73
9 Gurbel PA Tantry US Antiplatelet and anticoagulant agents in heart failure Current status and future perspectives JACC Heart Fail 201421-14
10 Gurbel PA Tantry US Antiplatelet therapy What have we learned from the ANTARCTIC trial Nat Rev Cardiol 201613639-640
Invited Review Articles 1 Gurbel PA Midwall JA Brodie BR Angioplasty and adjunctive intra-aortic balloon pump counterpulsation Current
clinical considerations Todays Therapy Trends 19951363-78 2 OrsquoConnor CM Gurbel PA Serebruany VL Depression and ischemic heart disease Am Heart J 200014063-69 3 Gurbel PA Serebruany VL Oral IIbIIIa inhibitors From initial promise to clinical failures J Thromb and
Thrombolysis 200010217-20 4 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Atar D Serebruany VL Platelets and
Thrombolysis Cooperation or Contrariety Heart Drug 20011281-290 5 McKenzie ME Gurbel PA The potential of monoclonal antibodies to reduce reperfusion injury in myocardial
infarction BioDrugs 200115395-404 6 Gurbel PA Bliden KP Hayes K Tantry U Platelet activation in myocardial ischemic syndromes Expert Rev of
Cardiovasc Ther 20052535-45 7 Tantry US Bliden KP Gurbel PA Resistance to antiplatelet drugs Current status and future research Expert
Opin Pharmacother 200562027-45 8 Gurbel PA Lau WC Bliden KP Tantry US Clopidogrel resistance Implications for coronary stenting Curr Pharm
Des 2006121261-9 9 Gurbel PA Tantry US Drug insight Clopidogrel non-responsiveness Nature ClinPract Cardiovasc Med
20063387-95 10 Gurbel PA Tantry US Aspirin and Clopidogrel Resistance Considerations and management J Interv Cardiol
200619439-48 11 Lau WC Gurbel PA Antiplatelet drug resistance and drug-drug interactions Role of cytochrome P450 3A4
Pharm Res 2006232691-708 12 Wiviott SD Tantry US Gurbel PA Clinical applications of antiplatelet therapy Rev Cardiovasc Med 20067
Curriculum Vitae Paul A Gurbel MD Page 20
130-46 13 Tantry US Bliden KP Gurbel PA Prasugrel Expert Opin Investig Drugs 2006151627-33 14 Gurbel PA Tantry US Clopidogrel Resistance Thromb Res 2007120311-21 15 Tantry US Etherington A Bliden KP Gurbel PA Antiplatelet therapy Current strategies and future trends Future
Cardiology 20072343-366 16 Gurbel PA Tantry US The relationship of platelet reactivity to the occurrence of post-stenting ischemic events
emergence of a new cardiovascular risk factor Rev Cardiovasc Med 2006Suppl 4S20-8 17 Tantry US Bliden KP Gurbel PA AZD6140 Expert Opin Investig Drugs 200716225-9 18 Gurbel PA Tantry US Stent thrombosis role of compliance and non-responsiveness to antiplatelet therapy Rev
Cardiovasc Med 20078S19-S26 19 Gurbel PA Kandzari DE Stent thrombosis associated with first-generation drug-eluting stents issues with
antiplatelet therapy Neth Heart J 200715148-50 20 Gurbel PA Tantry US The role of clopidogrel in cardiovascular diseases Pol Arch Med Wewn 2007117207-9 21 Gurbel PA DiChiara J Tantry US Antiplatelet therapy after implantation of drug-eluting stents duration
resistance alternatives and management of surgical patients Am J Cardiol 200710018M-25M 22 Gurbel PA Becker R Mann KG Steinhubl SR Michelson AD Platelet function monitoring in patients with
coronary artery disease J Am Coll Cardiol 2007501822-34 23 Gurbel PA Tantry US Prasugrel a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig
Drugs 20089324-36 24 Gurbel PA Bilden KP Tantry US Diagnostics for aspirin resistance Mol Diagn Ther 20081255-6 25 Gurbel PA Antonino MJ Tantry US Antiplatelet treatment of cardiovascular disease a translational research
perspective Pol Arch Med Wewn 2008118289-97 26 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831I36 27 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention Clin Cardiol 200831I28-I35
28 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches Clin Cardiol 200831I21-I27
29 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention Clin Cardiol 200831I17-I20
30 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Assessing the Current Role of Platelet Function Testing Clin Cardiol 200831I10-I16
31 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831136
32 Keriakes DJ Gurbel PA Periprocedural platelet function in percutaneous coronary intervention JACC Cardiovasc Interv 2008suppl 1111ndash121
33 Gurbel PA Tantry US The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome J Interv Cardiol 200821Suppl 1S10-7
34 Gurbel PA Tantry US Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 20091122-322
35 Gurbel PA Aspirin scope and limitations Br J Cardiol 200917 (Suppl 1)S8-S9 36 Cohen M Hoekstra J Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Pollack CV Jr
Saucedo JF Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion J Interv Cardiol 200821283-99
37 Angiolillo DJ Bhatt DL Gurbel PA Jennings LK Advances in antiplatelet therapy agents in clinical development Am J Cardiol 2009103(3 Suppl)40A-51A
38 Gurbel PA Mahla E Antonino MJ Tantry US Response variability and the role of platelet function testing J Invasive Cardiol 200921172-8
39 Gurbel PA Antonino MJ Tantry US Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug MetabToxicol Expert Opin Drug Metab Toxicol 20095989-1004
40 Gurbel PA Tantry US Antiplatelet resistance- Fact or Myth Am Hosp J 2009750-57 41 Gurbel PA Mahla E Tantry US Aspirin resistance Prog Cardiovasc Dis 200952141-52 42 Tantry US Gurbel PA Platelet monitoring for PCI Is it really necessary Haemostaseologie 200929 368-75 43 Gurbel PA Aspirin-scope and limitations Br J Cardiol 200917(Suppl 1)S8-S9
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 3
reperfusion in swine Effects of magnesium diltiazem and a novel Mac-1 inhibitor Blood Coag Fibrinolysis 1996 7632-640
14 Gurbel PA Navetta FI Bates ER Muller DW Tenaglia AN Miller MJ Muhstein B Hermiller JB Davidson CJ Aguirre FV Beauman GJ Berdan LG Leimberger JD Boville EG Christenson RH Ohman EM Lesion-directed administration of tissue plasminogen activator with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty Cathet Cardiovasc Diagn 1996 37382-391
15 Anderson RD Gurbel PA The effect of intra-aortic balloon counterpulsation on coronary blood flow velocity distal to coronary artery stenosis Cardiology 1996 87306-312
16 Serebruany VL Herzog WR Atamas SP Gurbel PA Paulsen G Mortensen SA Folkers K Hemostatic changes after dietary coenzyme Q10 supplementation in swine J Cardiovasc Pharm 1996 28175-181
17 Gurbel PA Serebruany VL Komjathy SF Collins ME Bittar GD Schlossberg ML Mergner W Pretreatment with an inhibitor of Mac-1 alters regional and systemic platelet function during ischemia - reperfusion in swine Pharmacology 1996 5379-86
18 Serebruany VL Solomon SR Edenbaum LR Herzog WR Gurbel PA Mac-1 inhibitor affects certain hemostatic parameters during myocardial stunning in swine Pharmacology 1996 5387-96
19 Serebruany VL Schlossberg ML Edenbaum LR Herzog WR Gurbel PA Intracoronary magnesium and diltiazem affect to a similar extent certain hemostatic factors during acute myocardial infarction in swine Pharmacology 1996 53224-233
20 Serebruany VL Schlossberg ML Edenbaum LR Herzog WR Gurbel PA Hemostatic changes after early versus late intracoronary magnesium during acute myocardial infarction in swine J Cardiovasc Pharm 1996 8817-823
21 Serebruany VL Herzog WR Edenbaum LR Shustov AR Gurbel PA Changes in the haemostatic profile during magnesium deficiency in swine Magnesium Res 1996 9155-163
22 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression J Cardiovasc Pharm 1997 2916-22
23 Serebruany VL Herzog WR Gurbel PA Serial changes of the plasma prostanoids during myocardial ischemia - reperfusion in swine Effects of magnesium diltiazem and a novel Mac-1 inhibitor Prostaglandins Leukot Essent Fatty Acids 1997 56135-142
24 Gurbel PA Anderson RD A new concept in coronary angioplasty Dilatation with a helical balloon which allows simultaneous autoperfusion Cathet Cardiovasc Diagn 1997 40109-116
25 Gurbel PA Anderson RD Pells HO van Boven AJ den Heijer P Coronary artery angioplasty with a helical autoperfusion catheter Cathet Cardiovasc Diagn 1997 40179-185
26 Serebruany VL Gurbel PA Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Could coenzyme Q10 affect hemostasis by inhibiting platelet vitronectin (CD51CD61) receptor Molec Aspects Med 199718 S189-S194
27 Gurbel PA Herzog WR Vogel RA Schlossberg ML Edenbaum LR Scott HJ Serebruany VL Short-term low does intracoronary diltiazem administered at the onset of reperfusion reduces myocardial infarct size Intern J Cardiol 1997 5921-27
28 Serebruany VL Solomon SR Herzog WR Gurbel PA Bolus magnesium infusion in humans is associated with predominantly unfavorable changes in platelet aggregation and certain hemostatic factors Pharm Res 1997 3517-22
29 Serebruany VL Schlossberg ML Edenbaum LR Herzog WR Gurbel PA Effects of intracoronary diltiazem on certain hemostatic parameters during acute myocardial infarction in swine Inter J Cardiol 1997 6121-29
30 Gurbel PA Serebruany VL Soluble vascular cell adhesion molecule and E-Selectin in patients with acute myocardial infarction treated with thrombolytic agents Am J Cardiol 1998 81772-775
31 Serebruany VL Bahr RD OConnor CM Lowry DR Gurbel PA For the GUSTO III Platelet Substudy Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction Cardiology 1998 9037-42
32 Serebruany VL Solomon SR Herzog WR Gurbel PA Plasma fibronectin during myocardial ischemia - reperfusion Effects of magnesium diltiazem and a novel Mac-1 inhibitor Am J Hematol 1998 57309-314
33 Serebruany VL Solomon SR Shustov AR Herzog WR Gurbel PA Survival in acute myocardial infarction induced by coronary artery ligation prognostic relevance of certain hemostatic factors during the occlusion phase J Thromb and Thrombolysis 1998 5 39-35
34 Gurbel PA Shustov AR Bahr RD Carpo C Ohman EM and Topol EJ for the GUSTO III Investigators Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment The GUSTO III Platelet Study J Am Coll Cardiol 1998 311466-1473
35 Serebruany VL Ordonez JV Yrovsky VV Gurbel PA The crossreactivity of human vs swine platelet surface antigens is similar for glycoproteins IIb and IIIa but not for IIb and IIIa complex J Thromb and Thrombolysis 1998
Curriculum Vitae Paul A Gurbel MD Page 4
537-41 36 Serebruany VL Gurbel PA Shustov AR Ohman EM Topol EJ Heterogeneity of platelet aggregation and major
surface receptor expression in patients presenting with acute myocardial infarction Am Heart J 1998 136398-405 37 Serebruany VL Gurbel PA Murugesan SR Lowry Dr Sturm E Svetlov SI Depressed plasma platelet-activating
factor acetylhydrolase in patients presenting with acute myocardial infarction Cardiology 199890127-130 38 Serebruany VL Schlossberg ML Edenbaum LR Herzog WR Gurbel PA Serial changes of soluble endothelin-1
levels during myocardial ischemia-reperfusion Effects of magnesium diltiazem and a novel Mac-1 Inhibitor Pharm Res 199838165-172
39 Gurbel PA Serebruany VL Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Increased baseline platelet P-selectin and PECAM-1 as predictors of unsuccessful thrombolysis in patients with acute myocardial infarction Coron Artery Dis 19989451-456
40 Serebruany VL Gurbel PA Effect of thrombolytic therapy on the plasma concentration and platelet expression of the plateletendothelial cell adhesion molecule in patients with acute myocardial infarction Arterioscl Thromb Vasc Biol 199919153-158
41 Serebruany VL Gurbel PA The relations of major platelet receptor expression during myocardial infarction Monitoring efficacy of GP IIbIIIa inhibitors by measuring P-selectin Thromb Haemost 199980314-316
42 Serebruany VL Gurbel PA Assessment of platelet activity by measuring platelet derived substances in plasma from patients with acute myocardial infarction Surprising lessons from the GUSTO III Platelet Study Thromb Res 199993149-150
43 OConnor CM Gurbel PA Serebruany VL Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure Am J Cardiol 1999831345-1349
44 Serebruany VL Murugesan SR Pothula A Semaan H Gurbel PA Soluble plateletendothelial cellular adhesion molecule-1 but not P-selectin nor osteonectin identify acute myocardial infarctions among patients with chest pain admitted to the Emergency Department Cardiology 1999150-55
45 Serebruany VL Yurovsky VV Gurbel PA Mild myocardial stunning affects platelet aggregation and certain hemostatic factors in swine Clin Appl Thromb Haemost 19995236-42
46 Murugesan SR Gurbel PA Serebruany VL Storing paraformaldehyde fixed whole blood in patient samples after chronic platelet glycoprotein IIb IIIa blockade Core laboratory considerations Thromb Res 19995201-203
47 Serebruany VL Kereiakes DJ Dalesandro MR Gurbel PA The flow cytometer model markedly affects measurement of ex vivo whole blood platelet-bound P-selectin expression in patients with chest pain Are we comparing apples and oranges Thromb Res 19999651-56
48 Serebruany VL Yurovsky VV Gurbel PA Effects of a novel Mac-1 inhibitor NPC 15669 on hemostatic parameters during preconditioned myocardial infarction Life Sciences 1999651503-13
49 Gurbel PA Murugesan SR Lowry DR Serebruany VL Plasma thromboxane and prostacyclin are linearly related and increased in patients presenting with myocardial infarction Prostaglandins Leukot Essent Fatty Acids 1999617-11
50 Gurbel PA Kereiakes DJ Dalesandro MR Bahr RD OConnor CM Serebruany VL The role of soluble and platelet-bound P-selectin in discriminating cardiac from non-cardiac chest pain at presentation in the Emergency Department Am Heart J 2000139320-328
51 McKenzie ME Pothula A Gurbel PA Fuzaylov SY OConnor CM Gaitis WA Serebruany VL Failure of thrombin generation markers to triage patients presenting with chest pain Cardiology 20009253-58
52 Gurbel PA Kerejakes DJ Serebruany VL Soluble P-Selectin is not a surrogate marker for platelet P-Selectin Evidence from a multicenter chest pain study group J Thromb Thrombolysis 20001015-22
53 Serebruany VL Murugesan SR Pothula Atar D Lowry DR OrsquoConnor CM Gurbel PA Increased soluble plateletendothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure Independence of disease etiology and antecedent aspirin therapy Eur J Heart Fall 20001243-9
54 Semann HB Gurbel PA Anderson JL Muhlestein JB Carlquist JV Horne BD Serebruany VL Soluble VCAM-1 and E-selectin but not ICAM-1 discriminate endothelial injury in patients with documented coronary artery disease Cardiology 2000937-10
55 Gurbel PA Kereiakes DJ Serebruany VL Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction Scand Cardiovasc J 20003453-8
56 Serebruany VL Lowry DR Fuzaylov SY Levine DJ OConnor CM Gurbel PA Moderate alcohol consumption is associated with the decreased baseline platelet activity in patients presenting with acute myocardial infarction J Thromb Thrombolysis 20009229-34
57 Serebruany VL Murugesan SR Atar D Jerome S Semann H Gurbel PA Effect coronary thrombolysis on the plasma concentration of osteonectin (SPARC BM40) in patients with acute myocardial infarction J Thromb Thrombolysis 200010197-202
58 Semann HB Gurbel PA Anderson JL Muhlestein JB Carlquist JF Horne BD Serebruany VL The effect of
Curriculum Vitae Paul A Gurbel MD Page 5
chronic azithromycin therapy on soluble endothelium-derived adhesion molecules in patients with coronary artery disease Cardiovasc Pharmacol 200036533-7
59 Gurbel PA OrsquoConnor CM Dalesandro MR Serebruany VL Relation of soluble and platelet P-selectin to early outcome in patients with acute myocardial infarction after thrombolytic therapy Am J Cardiol 200187774-7
60 Serebruany VL Alford AB Meister AF Fuzaylov SY Gattis WA Gurbel PA Clinical utility of the platelet function analyzer (PFA-100) for the Assessment of the Platelet Status in Patients with Congestive Heart Failure (EPCOT trial) Thromb Res 200115427-33
61 Serebruany VL Gurbel PA OrsquoConnor CM Platelet inhibition by sertraline and n-desmethylsertraline A possible missing link between depression coronary events and mortality benefits of selective serotonin reuptake inhibitors Pharmacol Res 200143453-62
62 Serebruany VL OrsquoConnor CM Gurbel PA Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease Am J Cardiol 2001871398-400
63 Serebruany VL Levine DJ Nair GV Meister AF Gurbel PA Usefulness of combining necrosis and platelet markers in triaging patients presenting with chest pain to the emergency department J Thromb and Thrombolysis 200111155-62
64 Serebruany VL Cummings CC Malinin AI Steinhubl SR Gurbel PA Uniform platelet activation exists before coronary stent implantation despite aspirin therapy Am Heart J 2001142611-16
65 Gurbel PA Fusaylov SF Gattis WA Gaulden L Hasselblad V Serebruany VL OrsquoConnor CM Evaluation of platelets in heart failure Is platelet activity related to etiology class or clinical outcomes Am Heart J 20021431068-75
66 Gurbel PA Malinin AI Callahan KP Serebruany VL OrsquoConnor CM Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and GP IIbIIIa expression and platelet-leukocyte aggregate formation Am J Cardiol 200290312-315
67 Bahr RD Gurbel PA Malinin AI Wentz C Christenson RH Roe MT Gibler WB Kitt MM Ohman EM Serebruany VL Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q wave acute myocardial infarction Am J Cardiol 200290310-312
68 Faxon DP Gibbons RJ Chronos NAF Gurbel PA Sheehan F for the HALT ndash MI Investigators The effect of blockade of the CD11CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty The results of the HALT- MI study J Am Coll Cardiol 2002401199-1204
69 Serebruany VL McKenzie M Meister A Fuzaylov S Gurbel P Atar D Gattis W OrsquoConnor C Whole blood impedence aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT Trial) Eur J Heart Fail 20024461
70 Serebruany V McKenzie ME Meister AF Fuzaylov SY Gurbel PA Atar D Gattis WA OrsquoConnor CM Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT Trial with special reference to the Hemodyne hemostatic analyzer Pathophysiol Haemost Thromb 2002328-15
71 Gurbel PA Callahan KP Malinin AI Serebruany VL Gillis J Could stent design affect platelet activation Results of the Platelet Activation in Stenting (PAST) study J Invasive Cardiol 200214584-9
72 Gurbel PA Galbutt B Bliden KP Bahr RD Roe MT Serebruany VL Ohman EM Effect of eptifibatide for acute coronary syndromes Rapid versus late administration-therapeutic yield on platelets (the EARLY platelet substudy) J Thromb Thrombolysis 200314213-219
73 Gurbel PA Cummings CC Alford AB Meister AF Serebruany VL Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting The Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial Am Heart J 2003145239-47
74 Serebruany VL Malinin AI Callahan KP Binbrek A Van de Werf F Alexander JH Granger CB Gurbel PA Effect of tenecteplase versus alteplase on platelets during the first three hours of treatment for acute myocardial infarction The ASSENT-2 Platelet Substudy Am Heart J 2003145636-42
75 Gurbel PA Bliden KP Durability of platelet inhibition by clopidogrel Am J Cardiol 2003911123-5 76 Gurbel PA Bliden KP Hiatt BL The early antiplatelet effects of clopidogrel loading for coronary stenting and the
long term stability of inhibition J Thromb Haemost 200311319-21 77 Gurbel PA Bliden KP Hiatt BL Clopidogrel for coronary stenting Response variability drug resistance and the
effect of pretreatment platelet reactivity Circulation 20031072908-13 78 Serebruany VL Malinin AI OrsquoConnor CM Gurbel PA Effects of roxifiban on platelet aggregation and major
receptor expression in patients with coronary artery disease For the Roxifiban Oral Compound Kinetics Evaluation Trial ndash I Am Heart J 200314691-8
79 Gurbel PA Bliden KP Platelet activation after stenting with heparin-coated versus non-coated stents Am Heart J 2003146E10
Curriculum Vitae Paul A Gurbel MD Page 6
80 Gurbel PA Bliden KP A new method of representing drug-induced platelet inhibition Better description of time course response variability non-response and heightened reactivity Platelets 200314481-3
81 Gurbel PA Bliden KP The stratification of platelet reactivity and activation in patients with stable coronary disease on aspirin therapy Thromb Res 20031129-12
82 Gurbel PA Samara WM Bliden KP Failure of clopidogrel to reduce platelet reactivity an activation following standard dosing in elective stenting Implications for thrombotic events and restenosis Platelets 20031595-99
83 Lau WC Gurbel PA Watkins PB Neer CJ Hopp AS Carville DGM Guyer KE Tait AR Bates ER The contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 200410966-71
84 Joynt KE Gattis WA Hasselblad V Fuzaylov SY Serebruany VL Gurbel PA Gaulden LH Felker GM Whellan DJ OrsquoConnor CM Effect of angiotensin-converting enzyme inhibitors beta blockers statins and aspirin on C-reactive protein levels in outpatients with heart failure Am J Cardiol 200493783-5
85 Samara WM Bliden KP Tantry U Gurbel PA Thrombotic risk The difference between clopidogrel responsiveness and post-treatment platelet reactivity Thromb Res 200411589-94
86 Gurbel PA Hayes KA Bliden KP Yoho J Tantry U The platelet-related effects of tenecteplase vs alteplase vs reteplase Blood Coag Fibrinolysis 2005161-7
87 Gurbel PA Bliden KP Zaman KA Yoho JA Hayes KM Tantry US Clopidogrel loading with eptifibatide to arrest the reactivity of platelets Results of the CLEAR PLATELETS study Circulation 20051111153-9
88 Poston R Gu J Brown J Gammie J White C Manchio J Pierson RN Griffith P Gurbel P Tantry U Gilbert TB Hypercoaguability affecting early vein graft patency does not exist after off-pump coronary artery bypass J Cardiothoracic Vasc Anesth 20051911-18
89 Gurbel PA Bliden KP Hates KM Yoho JA Herzog WR Tantry US The relation of dosing to clopidogrel responsiveness and the incidence of high post-stent platelet aggregation in patients undergoing coronary stenting J Am Coll Cardiol 2005451392-6
90 Hermiller JB Raizner A Cannon L Gurbel PA Kutcher MA Wong SC Russell ME Ellis SG Mehran R Stone GW TAXUS-IV Investigators Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus The TAXUS-IV trial J Am Coll Cardiol 2005451172-9
91 Gurbel PA Bliden KP Samara W Yoho J Hayes K Fissha M Tantry U Clopidogrel Effect on Platelet REactivity in Patients with Stent Thrombosis Results of the CREST Study J Am Coll Cardiol 2005461827-32
92 Gurbel PA Bliden KP Guyer K Cho P Zaman K Kreutz R Bassi A Tantry US Platelet REactivity in Patients And Recurrent Events POST-STENTING Results of the PREPARE POST-STENTING Study J Am Coll Cardiol 2005461820-6
93 Tantry US Bliden KP Gurbel PA Overestimation of platelet aspirin resistance Detection by thrombelastograph platelet mapping and validation by conventional aggregation using arachidonic acid stimulation J Am Coll Cardiol 2005461705-9
94 Kreutz RP Tantry US Bliden KP Gurbel PA Viral respiratory tract infections increase platelet reactivity and activation - an explanation for the higher rates of myocardial infarction and stroke during viral illness J Thromb Haemost 200532108-9
95 Bleske B Nicklas J Bard R Brook R Gurbel PA Bliden K Rajagopalan S Pitt B Neutral effect on markers of heart failure inflammation endothelial activation and function and vagal tone following high dose HMG - coA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low density lipoproteins J Am Coll Cardiol 200647338-41
96 Gurbel PA Bliden KP Tantry US Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting Inflammation results from the CLEAR PLATELETS-1b study J Am Coll Cardiol 2006482186-91
97 Kandzari DE Leon MB Popma JJ Fitzgerald PJ OrsquoShaughnessy C Ball MW Turco M Applegate RJ Gurbel PA et alfor the ENDEAVOR III Investigators Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease a randomized controlled trial J Am Coll Cardiol 2006482440 ndash 2447
98 Gurbel PA Bliden KP Guyer K Aggarwal N Tantry US Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting Thromb Res 2007119563-70
99 Bliden KP DiChiara J Tantry US Bassi AK Chaganti SK Gurbel PA Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention is the current antiplatelet therapy adequate J Am Coll Cardiol 200749657-66
100 Gurbel PA Bliden KP Etherington A Tantry US Assessment of clopidogrel responsiveness measurements of maximum platelet aggregation final platelet aggregation and their correlation with vasodilator stimulated phosphoprotein in resistant patients Thromb Res 2007121107-15
101 Gurbel PA Bliden KP DiChiara J Gesheff T RN Chaganti S Etherington A MD Tantry US Evaluation of
Curriculum Vitae Paul A Gurbel MD Page 7
dose-related effects of aspirin on platelet function results from the ASpirin-Induced Platelet EffeCT (ASPECT) study Circulation 20071153156-64
102 Kreutz RP Tantry US Bliden KP Gurbel PA Inflammatory changes during the common cold are associated with platelet activation and increased reactivity of platelets to agonists Blood Coagul Fibrinolysis 200718713-8
103 Storey R Husted S Harrington R Heptinstall S Wilcox R Peters G Wickens Emanuelsson H Gurbel PA Grande P Cannon C Inhibition of platelet aggregation by AZD6140 a reversible oral P2Y12 receptor antagonist compared with clopidogrel in patients with acute coronary syndromes J Am Coll Cardiol 2007501852-6
104 DiChiara J Bliden KP Tantry US Hamed MS Antonino MJ Suarez TA Bailon O Singla A Gurbel PA The effect of aspirin dosing on platelet function in diabetic and non-diabetic patients an analysis from the aspirin-induced platelet effect (ASPECT) study Diabetes 200756 3014-9
105 DiChiara J Bliden KP Tantry US Chaganti SK Kreutz R Gesheff TB Kreutz Y Gurbel PA Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients Platelets 200718 414-23
106 Gurbel PA Kreutz RP Bliden KP Tantry US Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease a potential approach to identify atherosclerotic disease progression Am Heart J 200815555-61
107 Gurbel PA Bliden KP Cohen E Navickas IA Singla A Antonino MJ Fissha M Kreutz RP Bassi AK Tantry US Race and sex differences in thrombogenicity risk of ischemic events following coronary stenting Blood Coagul Fibrinolysis 200819268-75
108 Nissen SE Nicholls SJ Wolski K Rodeacutes-Cabau J Cannon CP Deanfield JE Despreacutes JP Kastelein JJ Steinhubl SR Kapadia S Yasin M Ruzyllo W Gaudin C Job B Hu B Bhatt DL Lincoff AM Tuzcu EM STRADIVARIUS Investigators Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease the STRADIVARIUS randomized controlled trial JAMA 20082991547-60
109 Bliden KP DiChiara J Lookman L Singla A Antonino MJ Baker BA Bailey WL Tantry US Gurbel PA The association of cigarette smoking with enhanced platelet inhibition by clopidogrel J Am Coll Cardiol 200852531-3
110 Gurbel PA Antonino MJ Bliden KP Dichiara J Suarez TA Singla A Tantry US Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention a potential antiplatelet therapeutic target Platelets 200819595-604
111 Gurbel PA Bliden KP Cohen E Navickas IA Singla A Antonino MJ Fissha M Kreutz RP Bassi AK Tantry US Race and sex differences in thrombogenicity risk of ischemic events following coronary stenting Blood Coagul Fibrinolysis 200819268-75
112 Gurbel PA Antonino MJ Bliden KP Dichiara J Suarez TA Singla A Tantry US Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention a potential antiplatelet therapeutic target Platelets 200819595-604
113 Hamed MS Gambert S Bliden KP Bailon O Anand S Antonino MJ Hamed F Tantry US Gurbel PA Dark chocolate effect on platelet activity C-reactive protein and lipid profile a pilot study S Med J 20081011203-8
114 Gilstad JR Gurbel PA Andersen RE Relationship between age and platelet activation in patients with stable and unstable angina Arch Gerontol Geriatr 200948155-9
115 Gurbel PA Bliden KP Saucedo JF Suarez TA DiChiara J Antonino MJ Mahla E Singla A Herzog WR Bassi AK Hennebry TA Gesheff TB Tantry US Bivalirudin and clopidogrel with and without eptifibatide for elective stenting effects on platelet function thrombelastographic indices and their relation to periprocedural infarctionResults of the CLEAR PLATELETS-2 study J Am Coll Cardiol 200953857-9
116 Gurbel PA Bliden KP Kreutz RP DiChiara J Antonino MJ Tantry US The link between heightened thrombogenicity and inflammation Pre-procedure characterization of the patient at high risk for recurrent events after stenting Platelets 20092097-104
117 Antonino MJ Mahla E Bliden KP Tantry US Gurbel PA Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting Am J Cardiol 20091031546-50
118 Antonino MJ Coppolecchia R Mahla E Bliden KP Tantry US Gurbel PA Antiplatelet effects of aspirin with phytosterols Comparison with non-enteric coated aspirin alone Thromb Res 2009126384-5
119 Pinto Slottow TL Bonello L Gavini R Beauzile P Sushinsky SJ Scheinowitz M Kaneshige K Xue Z Torguson R Tantry U Pichard AD Satler LF Suddath WO Kent K Gurbel P Waksman R Am J Cardiol 2009104525-30
120 Shuldiner AR OConnell JR Bliden KP Gandhi A Ryan K Horenstein RB Damcott CM Pakyz R Tantry US Gibson Q Pollin TI Post W Parsa A Mitchell BD Faraday N Herzog W Gurbel PA Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyJAMA2009302849-57
121 Singla A Antonino MJ Bliden KP Tantry US Gurbel PA The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy Am Heart J 2009158784e1-6
122 Gurbel PA Bliden KP Antonino MJ Stephens G Gretler DD Jurek MM Pakyz RE Shuldiner AR Conley PB
Curriculum Vitae Paul A Gurbel MD Page 8
Tantry US The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP 2C192 genotype First experience in patients J Thromb Haemost 2010843-53
123 Gurbel PA Bliden KP Butler K Tantry US Gesheff T Wei C Teng R Antonino MJ Patil SB Karunakaran A Kereiakes DJ Parris C Purdy D Wilson V Ledley GS Storey RF Randomized double-blind assessment of the ONSET and OFFSet of the antiplatelet Effects of Ticagrelor versus clopidogrel in patients with stable coronary artery disease The ONSETOFFSET Study Circulation 20091202577-85
124 Gurbel PA Bliden K Antonino M Butler K Teng R Rasmussen L Syd A Storey R Nielsen T Eikelboom J Sabe-Affaki G Husted S Kereaikes D Henderson D Patel V Tantry U Response to Ticagrelor in Clopidogrel Non-responders and ReSPONDers and the Effect of Switching Therapies The RESPOND Study Circulation 20101211188-99
125 Tantry US Bliden KP Suarez TA Kreutz RP DiChiara J Gurbel PA Hypercoagulability platelet function inflammation and coronary artery disease acuity results of the Thrombotic Risk Platelets 201021 360-7
126 Hennekens CH Schneuder WR Hebert PR Tantry US Gurbel PA Hypothesis formulation from subgroup analyses non-adherence or non-steroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to ldquoaspirin resistancerdquo Am Heart J 2010159744-8
127 Storey RF Bliden KP Patil SB Karunakaran A Ecob R Butler K Teng R Wei C Tantry US Gurbel PA ONSETOFFSET Investigators Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor clopidogrel or placebo in the ONSETOFFSET study J Am Coll Cardiol 201056185-93
128 Gurbel PA Bliden KP Navickas IA Mahla E Dichiara J Suarez TA Antonino MJ Tantry US Cohen E Adenosine diphosphate-induced platelet-fibrin clot strength a new thrombelastographic indicator of long-term poststenting ischemic events Am Heart J 2010160346-54
129 Angiolillo DJ Saucedo JF Deraad R Frelinger AL Gurbel PA Costigan TM Jakubowski JA Ojeh CK Effron MB SWAP Investigators Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes results of the SWAP (SWitching Anti Platelet) study J Am Coll Cardiol 2010561017-23
130 Mega JL Simon T Collet JP Anderson JL Antman EM Bliden K Cannon CP Danchin N Giusti B Gurbel P Horne BD Hulot JS Kastrati A Montalescot G Neumann FJ Shen L Sibbing D Steg PG Trenk D Wiviott SD Sabatine MS Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI a metaanalysis JAMA 20103041821-30
131 Tantry US Bliden KP Wei C Storey RF Armstrong M Butler K Gurbel PA First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel The ONSETOFFSET and RESPOND Genotype Studies Circ Cardiovasc Genet 20103556-66
132 Lau WC Welch TD Shields T Rubenfire M Tantry US Gurbel PA The Effect of St Johns Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients Increased Platelet Inhibition by Enhancement of CYP 3A4 Metabolic Activity J Cardiovasc Pharmacol 20115786-93
133 Gurbel PA Shuldiner AR Bliden KP Ryan K Pakyz RE Tantry US The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy Am Heart J 2011161598-604
134 Kandzari DE Mauri L Popma JJ Turco MA Gurbel PA Fitzgerald PJ Leon MB Late-Term Clinical Outcomes With Zotarolimus-and Sirolimus-Eluting Stents 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) JACC Cardiovasc Interv 20114543-50
135 Storey RF Bliden KP Ecob R Karunakaran A Butler K Wei C Tantry U Gurbel PA Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared to clopidogrel in patients with high antiplatelet responses J Thromb Haemost 201191730-7
136 Bliden KP Tantry US Storey RF Jeong YH Gesheff M Wei C Gurbel PA The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity Combined analysis of the ONSETOFFSET and RESPOND studies Am Heart J 2011162160-5
137 Lewis JP Fisch AS Ryan K OrsquoConnell JR Gibson Q Mitchell BD Shen H Tanner K Horenstein RB Pakzy R Tantry US Bliden KP Gurbel PA and Shuldiner AR ( equal contribution) Paraoxonase 1 (PON1) Gene Variants Are Not Associated With Clopidogrel Response Clinical Pharm Ther 201190568-74
138 Navarese EP Kozinski M Obonska K Margheri M Gurbel PA Kubica J De Luca G Clinical efficacy and safety of intracoronary vs intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention A meta-analysis of randomized trials Platelets 2011 (in press)
139 Navarese EP De Luca G Castriota F Kozinski M Gurbel P MD Gibson CM Andreotti F Siller-MatulaJM Pafundi T Sukkenik A De Servi S Kubica J Low-molecular-weight heparins vs unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction A meta-analysis J
Curriculum Vitae Paul A Gurbel MD Page 9
Thromb Haemost 201191902-15) 140 Jeong YH Tantry US Kim I-S Koh J-S Kwon TJ Park Y Hwang SJ Bliden KP Kwak CH Hwang J-W
Gurbel PA Effect of CYP2C192 and 3 loss-of-function allele carriage on platelet reactivity and adverse clinical event occurrence in east asian acute myocardial infarction survivors treated with clopidogrel and aspirin Circ Cardiovasc Genet 20114585-94
141 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
142 Gurbel PA Bliden KP Firt J Zhang Y Plachetka JR Antonino M Gesheff M Tantry US Pharmacodynamic evaluation of clopidogrel plus PA32540 The Spaced PA32540 with Clopidogrel INteraction Gauging (SPACING) study Clin Pharmacol Ther 201190860-6
143 Navarese EP Buffon A Andreotti F Gurbel PA Kozinski M Kubica A Musumeci G Cremonesi A Tavazzi L Kubica J Castriota F Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome A meta-analysis of randomized trials Atherosclerosis 20122221-7
144 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 201210487-9
145 Gurbel PA Bliden KP Antonino MJ Gesheff T Cummings CC Dubois BV Herzog WR Tantry US Time dependence of clopidogrel loading effect Platelet activation versus platelet aggregation Thromb Res Thromb Res 20121291-2
146 Mahla E Suarez TA Bliden KP Rehak P Metzler H Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study Circ Cardiovasc Interv 20125261-9
147 Park Y Jeong YH Tantry US Ahn JH Kwon TJ Park JR Hwang SJ Gho EH Bliden KP Kwak CH Hwang JY Kim S Gurbel PA Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study Eur Heart J 2012332151-62
148 Husted SE Storey RF Bliden K Tantry US Hoslashimark L Butler K Wei C Teng R Gurbel PA Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease Results from the ONSET-OFFSET and RESPOND Studies Clin Pharmacokinet 201251397-409
149 Kubica J Koziński M Navarese EP Tantry US Grześk G Fabiszak T Kubica A Swiątkiewicz I Bliden KP Gurbel PA Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction A systematic review and meta-analysis of randomized clinical trials Cardiol J 201219(3)230-42 Jeong YH Bliden KP Antonino MJ Tantry US Gurbel PA Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity Platelets 2012 May 30 [Epub ahead of print]
150 Welsh RC Rao SV Zeymer U Thompson VP Huber K Kochman J McClure MW Gretler DD Bhatt DL Gibson CM Angiolillo DJ Gurbel PA Berdan LG Paynter G Leonardi S Madan M French WJ Harrington RA on behalf of the INNOVATE PCI Investigators A Randomized Double-Blind Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention The INNOVATE-PCI Trial Circ Cardiovasc Interv 20125336-346
151 Angiolillo DJ Welsh RC Trenk D Neumann FJ Conley PB McClure MW Stephens G Kochman J Jennings LK Gurbel PA Woacutejcik J Dabrowski M Saucedo JF Stumpf J Buerke M Broderick S Harrington RA Rao SV Pharmacokinetic and Pharmacodynamic Effects of Elinogrel Results of the Platelet Function Substudy From the Intravenous and Oral Administration of Elinogrel to Evaluate Tolerability and Efficacy in Nonurgent Percutaneous Coronary Intervention Patients (INNOVATE-PCI) Trial Circ Cardiovasc Interv 20125347-56
152 Reny JL Combescure C Daali Y Gurbel PA Fontana P PON1 Meta-Analysis Group Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events a systematic review and meta-analysis J Thromb Haemost 2012101242-1251
153 Jeong YH Bliden KP Antonino MJ Park KS Tantry US Gurbel PA Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies Am Heart J 201216435-42
154 Jeong YH Bliden KP Antonino MJ Tantry US Gurbel PA Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity Platelets 201216435-42
155 Singla A Bliden KP Jeong YH Abadilla K Antonino MJ Muse WC Mathew DP Bailon O Tantry US Gurbel PA Platelet reactivity and thrombogenecity in postmeopausal women Menopause 20132057-63
156 Jeong YH Tantry US Park Y Kwon TJ Park JR Hwang SJ Bliden KP Koh EH Kwak CH Hwang JY Kim S
Curriculum Vitae Paul A Gurbel MD Page 10
Gurbel PA Pharmacodynamic Effect of Cilostazol Plus Standard Clopidogrel Versus Double-Dose Clopidogrel in Patients With Type 2 Diabetes Undergoing Percutaneous Coronary Intervention Diabetes Care 2012352194-7
157 Roe MT Armstrong PW Fox KAA White HD Prabhakaran D Goodman SG Cornel JH Bhatt DL Clemmensen P Martinez F Ardissino D Nicolau JC Boden WE Gurbel PA Ruzyllo W Dalby AJ McGuire DK Leiva-Pons JL Parkhomenko A Gottlieb S Topacio GO Hamm C Pavlides G Goudev AR Oto A Tseng C-D Merkely B Gasparovic V Corbalan R Cinteză M McLendon RC Winters KJ Brown EB Lokhnygina Y Aylward PE Huber K Hochman JS E Magnus Ohman EM for the TRILOGY ACS Investigators Prasugrel versus clopidogrel for ACS patients managed without revascularization N Engl J Med 20123671297-309
158 Gurbel PA Bliden KP Jeong Y-H Antonino M Gesheff T Fort JG Shuldiner A Chai S Gesheff M Zhang Y Tantry US Spaced Administration of PA32540 and Clopidogrel Results in Greater Platelet Inhibition than Synchronous Administration of Enteric-Coated Aspirin and Enteric-Coated Omeprazole and Clopidogrel Am Heart J 2013165176-82
159 Gurbel PA Erlinge D Ohman EM Neely B Neely M Goodman SG Huber K Chan MY Cornel JH Brown E Zhou C Jakubowski JA White HD Fox KA Prabhakaran D Armstrong PW Tantry US Roe MT TRILOGY ACS Platelet Function Substudy Investigators JAMA 20123081785-94
160 Lewis JP Horenstein RB Ryan K OConnell JR Gibson Q Mitchell BD Tanner K Chai S Bliden KP Tantry US Peer CJ Figg WD Spencer SD Pacanowski MA Gurbel PA Shuldiner AR The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response Pharmacogenet Genomics 2012 Pharmacogenet Genomics 2013231-8
161 Jeong YH Tantry US Min JH Park Y Navarese EP Koh JS Park JR Hwang SJ Kho EH Bliden KP Kwak CH Hwang JY Kim S Gurbel PA Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention Int J Cardiol 2012 Oct 12 doipii S0167-5273(12)01253-3 101016
162 Saucedo JF Angiolillo DJ Deraad R Frelinger AL 3rd Gurbel PA Costigan TM Jakubowski JA Ojeh CK Duvvuru S Effron MB for the SWAP Investigators Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel insights from the switching anti-platelet (SWAP) study Thromb Haemost 2012 Dec 6109(2) [Epub ahead of print]
163 Navarese EP Austin D Gurbel PA Andreotti F Tantry U James S Buffon A Kozinski M Obonska K Bliden K Jeong YH Kubica J Kunadian V Drug-coated balloons in treatment of in-stent restenosis a meta-analysis of randomized controlled trials Clin Res Cardiol 2012 Dec 20 [Epub ahead of print]
164 Gurbel PA Bliden KP Fort JG Jeong YH Shuldiner A Chai S Gesheff T Antonino M Gesheff M Zhang Y Tantry US Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel Am Heart J 2013165176-82
165 Lewis JP Ryan K OConnell JR Horenstein RB Damcott CM Gibson Q Pollin TI Mitchell BD Beitelshees AL Pakzy R Tanner K Parsa A Tantry US Bliden KP Post WS Faraday N Herzog W Gong Y Pepine CJ Johnson JA Gurbel PA Shuldiner AR Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes Circ Cardiovasc Genet 2013 Feb 7 [Epub ahead of print]
166 Navarese EP Gurbel PA Andreotti F Tantry U Jeong YH Kozinski M Engstroslashm T Di Pasquale G Kochman W Ardissino D Kedhi E Stone GW Kubica J Optimal Timing of Coronary Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes A Systematic Review and Meta-analysis Ann Intern Med 2013158261-70
167 Jeong YH Abadilla KA Tantry US Park Y Koh JS Kwak CH Hwang JY Gurbel PA Influence of CYP2C192 and 3 loss-of-function alleles on pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention the results of the ACCEL-DOUBLE-2N3 studyJ Thromb Haemost 2013111194-7
168 Gurbel PA Bliden KP Logan DK Kereiakes DJ Lasseter KC White A Angiolillo DJ Nolin TD Maa JF Bailey WL Jakubowski JA Ojeh CK Jeong YH Tantry US Baker BA The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel The PARADOX Study J Am Coll Cardiol 2013 Apr 16 doipii S0735-1097(13)01478-2 101016jjacc201303037 [Epub ahead of print]
169 Grzesk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E4 Jeong Y-H Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 2013 Article ID 928271 httpdxdoiorg1011552013928271
170 Erlinge D Gurbel PA James S Lindahl TL Svensson P Ten Berg JM Foley DP Wagner H Brown PB Luo J Zhou C Moser BA Jakubowski JA Small DS Winters KJ Angiolillo DJ Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains non-inferiority to prasugrel 10-mg in non-elderly patients The GENERATIONS trial a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients J Am Coll Cardiol 201362577-83
Curriculum Vitae Paul A Gurbel MD Page 11
171 Kim IS Jeong YH Tantry US Park Y Lee DH Bliden KP Koh JS Park JR Jang JS Hwang SJ Koh EH Kwak CH Hwang JY Kim S Gurbel PA Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading Am Heart J 201316695-103
172 Grześk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E Jeong YH Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 20132013928271
173 Stone GW Witzenbichler B Weisz G Rinaldi MJ Neumann FJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri E Gurbel PA Xu K Parise H Kirtane AJ Brodie BR Mehran R Stuckey TD for the ADAPT-DES Investigators Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES) a prospective multicentre registry study Lancet 2013382614-23
174 Angiolillo DJ Curzen N Gurbel P Vaitkus P Lipkin F Li W Jakubowski JA Zettler M Effron MB Trenk D Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in subjects with stable coronary artery disease Results of the SWAP-2 Study J Am Coll Cardiol 2014631500-9
175 Jeong YH Bliden KP Shuldiner AR Tantry US Gurbel PA Thrombin-induced platelet-fibrin clot strength Relation to high on-clopidogrel platelet reactivity genotype and post-percutaneous coronary intervention outcomes Thromb Haemost 2014111713-24
176 Gouya G Arrich J Wolzt M Huber K Verheugt FW Gurbel PA Pirker-Kees A Siller-Matula JM Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases a systematic review and meta-analysis Stroke 201445492-503
177 Erlinge D James S Duvvuru S Jakubowski JA Wagner H Varenhorst C Tantry US Brown PB Small D Moser BA Sundseth S Walker JR Winters KJ Gurbel PA Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease Thromb Haemost 2014111943-50
178 Gurbel PA Baker BA Bailey WL Bliden KP Tantry US Unraveling the Smokers Paradox Cigarette smoking high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors Thromb Haemost 20141111187-90
179 Koh JS Kim IS Tantry US Yoon SE Park Y Cho SY Lee EJ Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading The results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study Int J Cardiol 2014174129-32
180 Bliden KP Singla A Gesheff MG Toth PP Tabrizchi A Ens G Guyer K Singh M Franzese CJ Stapleton D Tantry US Gurbel PA Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin Thromb Haemost 2014 Apr 24112(2) [Epub ahead of print]
181 Gurbel PA Gesheff MG Franzese CJ Bliden KP Tantry US Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy Platelets 201526608-9
182 Gurbel PA Bergmeijer TO Tantry US Ten Berg JM Angiolillo DJ James S Lindahl TL Svensson P Jakubowski JA Brown PB Duvvuru S Sundseth S Walker JR Small D Moser BA Winters KJ Erlinge D The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease Thromb Haemost 2014 2014112589-97
183 Cornel JH Ohman EM Neely B Clemmensen P Sritara P Zamoryakhin D Armstrong PW Prabhakaran D White HD Fox KA Gurbel PA Roe MT TRILOGY ACS Investigators Impact of smoking status on platelet function and clinical outcomes with prasugrel vs clopidogrel in patients with acute coronary syndromes managed without revascularization Insights from the TRILOGY ACS trial Am Heart J 201416876-87
184 Park Y Jung JM Tantry US Kim K Koh JS Park JR Hwang SJ Kwak CH Hwang JY Kim S Gurbel PA Jeong YH Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration The ACCEL-PARAZOL Study J Atheroscler Thromb 2014211121-39
185 Park Y Jeong YH Tantry US Ahn JH Kim K Koh J Park J Hwang SJ Kwak CH Hwang JY Gurbel PA Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity The Resultof the ACCEL-DIP Study Thromb Haemost 2014112 [Epub ahead of print]
186 Lev EI Bliden KP Jeong Y-H Pandya S Kang K Franzese C Tantry US Gurbel PA Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients J Am Heart Assoc 20143e001167
187 Alexopoulos D Xanthopoulou I Storey RF Bliden KP Tantry US Angiolillo DJ Gurbel PA Platelet reactivity during ticagrelor maintenance therapy A patient-level data meta-analysis Am Heart J 2014 168530-6
188 Lhermusier T Lipinski MJ Tantry US Escarcega RO Baker N Bliden KP Magalhaes MA Ota H Tian W Pendyala L Minha S Chen F Torguson R Gurbel PA Waksman R Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity Am J Cardiol 2015115716-23
189 Franzese CJ Bliden KP Gesheff MG Pandya S Guyer KE Singla A Tantry US Toth PP Gurbel PA Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy Am J Cardiol 2015 11151204-11
Curriculum Vitae Paul A Gurbel MD Page 12
190 Aradi D Kirtane A Bonello L Gurbel PA Tantry US Huber K Freynhofer MK Ten Berg J Janssen P Angiolillo DJ Siller-Matula JM Marcucci R Patti G Mangiacapra F Valgimigli M Morel O Palmerini T Price MJ Cuisset T Kastrati A Stone GW Sibbing D Bleeding and stent thrombosis on P2Y12-inhibitors collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention Eur Heart J 2015361762-71
191 Navarese EP Kolodziejczak M Schulze V Gurbel PA Tantry U Lin Y Brockmeyer M Kandzari DE Kubica JM DAgostino RB Sr Kubica J Volpe M Agewall S Kereiakes DJ Kelm M Effects of proprotein convertase subtilisinkexin type 9 antibodies in adults with hypercholesterolemia a systematic review and meta-analysis Ann Intern Med 201516340-51
192 Lee K Yoo SY Suh J Park KH Park Y Tantry US Park KS Han SH Kang WC Shin DH Lee C Choi SW Lee JH Cho YH Lee NH Jeong MH Ahn Y Kubica J Gurbel PA Park JH Jeong YH Efficacy of cilostazol on inhibition of platelet aggregation inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study Int J Cardiol 2015190370-5
193 Kowalewski M Schulze V Berti S Waksman R Kubica J Kołodziejczak M Buffon A Suryapranata H Gurbel PA Kelm M Pawliszak W Anisimowicz L Navarese EP Complete revascularisation in ST-elevation myocardial infarction and multivessel disease meta-analysis of randomised controlled trials Heart 2015 1011309-17
194 Baber U Mehran R Kirtane AJ Gurbel PA Christodoulidis G Maehara A Witzenbichler B Weisz G Rinaldi MJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri EL Jr Xu K Parise H Brodie BR Stuckey TD Stone GW Prevalence and impact of high platelet reactivity in chronic kidney disease Results from the assessment of dual antiplatelet therapy with drug-eluting stents registry Circ Cardiovasc Interv 20158e001683
195 Tricoci P DAndrea DM Gurbel PA Yao Z Cuchel M Winston B Schott R Weiss R Blazing MA Cannon L Bailey A Angiolillo DJ Gille A Shear CL Wright SDAlexander JH Infusion of Reconstituted High-Density Lipoprotein CSL112 in Patients With Atherosclerosis Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial J Am Heart Assoc 20154 pii e002171
196 Reny JL Fontana P Hochholzer W Neumann MJ ten Berg J Janssen PF Geisler T Gawaz M Marcucci R Gori A-M Cuisset T Alessi M-S Berdagueacute P Gurbel PA Yong G Angiolillo DJ Aradi D Beigel R Campo G Combescure C Vascular risk levels affect the predictive value of platelet reactivity 1 for the occurrence of major adverse cardiovascular events in patients on clopidogrel Systematic review and collaborative meta-analysis of individual patient data Thromb Haemost 2015 (in press)
197 Chaudhary R Bliden KP Tantry US Mohammed N Mathew D Gesheff MG Franzese CJ Gurbel PA Association of weight gain with coronary artery disease inflammation and thrombogenicity J Thromb Thrombolysis 2015 Dec 29 [Epub ahead of print]
198 Gurbel PA Bliden KP Turner SE Tantry US Gesheff MG Barr TP Covic L Kuliopulos A Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease Arterioscler Thromb Vasc Biol 201636189-97
199 Kwon TJ Tantry US Park Y Choi YM Ahn JH Kim KH Koh JS Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Smith SC Jr Jeong YH Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention Results of the ACCEL-BLEED study Thromb Haemost 2016 Jan 21115(5) [Epub ahead of print]
200 Bliden KP Tantry US Gesheff MG Franzese CJ Pandya S Toth PP Mathew DP Chaudhary R Gurbel PA Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis J Interv Cardiol 201629168-78
201 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin J Diabetes Complications 2016 May 10 pii S1056-8727(16)30127-1
202 Bedeir K Bliden K Tantry U Gurbel PA Mahla E Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel The Role of VerifyNow Can J Cardiol 201632724-5
203 Giustino G Kirtane AJ Baber U Geacuteneacutereux P Witzenbichler B Neumann FJ Weisz G Maehara A Rinaldi MJ Metzger C Henry TD Cox DA Duffy PL Mazzaferri EL Brodie BR Stuckey TD Gurbel PA Dangas GD Francese DP Ozan O Mehran R Stone GW Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study Am J Cardiol 20161171877-83
204 Kubica J Kubica A Jilma B Adamski P Hobl EL Navarese EP Siller-Matula JM Dąbrowska A Fabiszak T Koziński M Gurbel PA Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors Int J Cardiol 2016215201-8
205 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin
Curriculum Vitae Paul A Gurbel MD Page 13
J Diabetes Complications 2016 May 10 [Epub ahead of print] 206 Bliden KP Chaudhary R Lopez LR Damrongwatanasuk R Guyer K Gesheff MG Franzese CJ Kaza H
Tantry US Gurbel PA Oxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease Am J Cardiol 2016 Jun 15 [Epub ahead of print]
207 Mahla E Prueller F Farzi S Pregartner G Raggam RB Beran E Toller W Berghold A Tantry US Gurbel PA Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy Ann Thorac Surg 2016 Jul 1 [Epub ahead of print]
208 Koh JS Park Y Tantry US Ahn JH Kang MG Kim K Jang JY Park HW Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents The ACCEL-COMBO trial Platelets 2016 Aug 251-7 [Epub ahead of print]
209 Chaudhary R Saadin K Bliden KP Harris WS Dinh B Sharma T Tantry US Gurbel PA Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease Prostaglandins Leukot Essent Fatty Acids 201611340-45
210 Gurbel PA Bliden KP Chaudhary R Patrick J Liu F Chen G McLeod C Tantry US Antiplatelet Effect Durability of a Novel 24-Hour Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes MellitusAm J Cardiol 20161181941-1947
211 Gurbel PA Bliden KP Tantry US Monroe AL Muresan AA Brunner NE Lopez-Espina CG Delmenico PR Cohen E Raviv G Haugen DL Ereth MH First report of the point-of-care TEG A technical validation study of the TEG-6S system Platelets 201627642-649
212 Cornel JH Ohman EM Neely B Jakubowski JA Bhatt DL White HD Ardissino D Fox KA Prabhakaran D Armstrong PW Erlinge D Tantry US Gurbel PA Roe MT Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes J Am Heart Assoc 2016 Nov 45(11) pii e003977
213 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 201717109-121
214 Sharma T Bliden K Chaudhary R Tantry U Gurbel PA Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease Expert Opin Pharmacother 201718123-131
215 Park Y Tantry US Koh JS Ahn JH Kang MG Kim KH Jang JY Park HW Park JR Hwang SJ Park KS Kwak CH Hwang JY Gurbel PA Jeong YH Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction The REMODELING Trial Thromb Haemost 2017117911-922
216 Navarese EP Gurbel PA Andreotti F Kołodziejczak MM Palmer SC Dias S Buffon A Kubica J Kowalewski M Jadczyk T Laskiewicz M Jędrzejek M Brockmeyer M Airoldi F Ruospo M De Servi S Wojakowski W O Connor C Strippoli GF Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis PLoS One 201712e0168726
217 Bliden KP Chaudhary R Mohammed N Muresan AA Lopez-Espina CG Cohen E Raviv G Doubleday M Zaman F Mathew B Tantry US Gurbel PA Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system J Thromb Thrombolysis 201743437-445
Publications Peer Reviewed Original Science Research - Reviews 1 Serebruany VL Atar D Dalesandro MR OConnor CM Gurbel PA Changes in hemostasis after parenteral
magnesium in myocardial ischemia reperfusion Animal studies to clinical trials Magnes Res 19981137-42 2 McKenzie ME Gurbel PA Levine DJ Serebruany VL Clinical utility of available methods determining platelet
function Cardiology 199992240-7 3 Gurbel PA OConnor CM Cummings CC Serebruany VL Clopidogrel The future choice for preventing platelet
activation during coronary stenting Pharm Res 199965109-123 4 Nair GV Gurbel PA Fusaylov SY Davis CJ Ohman EM Bahr RD Christensen RH Serebruany VL Combing
necrosis and platelet markers for perfecting myocardial infarction rule out How close are we Cardiology 20009350-5
5 Davis CJ Gurbel PA Gaitis WA Fuzaylov SY Nair GV OrsquoConnor CM Serebruany VL Hemostatic abnormalities in congestive heart failure Diagnostic significance and clinical challenge Int J Cardiol 20007515-21
6 Pothula A Gurbel PA Atar D McKenzie ME Serebruany VL Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease Eur J Pharmacol 20004021-10
7 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Serebruany VL Platelet function and fibrinolytic agents Two sides of a coin Cardiology 20019555-60
Curriculum Vitae Paul A Gurbel MD Page 14
8 Samara WM Gurbel PA The role of platelet receptors and adhesion molecules in coronary artery disease Coron Artery Dis 20031465-79
9 Gurbel PA Tantry U Clopidogrel response variability and the advent of personalised antiplatelet therapy A bench to bedside journey Thromb Haemost 2011106265-71
10 Gurbel PA Roe MT Jakubowski JA Shah S Erlinge D Goodman SG Huber K Chan MY Cornel JH Tantry US Ohman EM Translational platelet research in patients with coronary artery disease What are the major knowledge gaps Thromb Haemost 2012 May 25108 [Epub ahead of print]
11 Bliden KP Baker BA Nolin TD Jeong YH Bailey WL Tantry US Gurbel PA Thienopyridine efficacy and cigarette smoking status Am Heart J 2013165693-703
12 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
13 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013111547-56
14 Gesheff MG Franzese CJ Bliden KP Contino CJ Rafeedheen R Tantry USGurbel PA Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin Expert Rev Clin Pharmacol 2014 7645-53
15 Tantry US Gesheff M Liu F Bliden KP Gurbel PA Resistance to antiplatelet therapy what progress has been made Expert Opin Pharmacother 2014 9 1-12
16 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print]
17 Gurbel PA Myat A Tantry US Platelet-mediated Thrombosis From Bench to Bedside Cir Res 2015 (in press)
18 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 20161245-58
19 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
20 Gurbel PA Tantry US Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes Heart 2016102882-92
21 Navarese EP Kolodziejczak M Kereiakes DJ Tantry US OConnor C Gurbel PA Proprotein Convertase SubtilisinKexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome A Narrative Review Ann Intern Med 2016164600-7
22 Gurbel PA Jeong YH Navarese EP Tantry US Platelet-Mediated Thrombosis From Bench to Bedside Circ Res 20161181380-91
23 Gurbel PA Myat A Kubica J Tantry US State of the art Oral antiplatelet therapy JRSM Cardiovasc Dis 2016 Jun 152048004016652514 doi 1011772048004016652514 eCollection 2016 Jan-Dec
24 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 2016 Nov 17 [Epub ahead of print] Review
25 Winter MP Grove EL De Caterina R Gorog DA Ahrens I Geisler T Gurbel PA Tantry U Navarese EP Siller-Matula JM Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors Eur Heart J Cardiovasc Pharmacother 2017 Feb 15 doi 101093ehjcvppvw044 [Epub ahead of print]
26 Shah P Tantry US Bliden KP Gurbel PA Bleeding and thrombosis associated with ventricular assist device therapy J Heart Lung Transplant 2017 May 11 pii S1053-2498(17)31789-8
Inventions Patents Copyrights 32294 Gurbel PA Anderson RD Autoperfusion dilatation catheter United States Patent 5295959 51501 Dalesandro MR Gurbel PA Serebruany VL Determining a treatment plan for patients undergoing thrombotic
events by monitoring p-Selectin United States Patent 623071 61201 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6245782 13102 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 20020013343 42203 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6552014
Curriculum Vitae Paul A Gurbel MD Page 15
120611 Gurbel PA The detection of restenosis risk in patients receiving a stent by measuring the characteristics of blood clotting including the measurement of maximum thrombin-induced clot strength (patent awarded pending)
6308 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 7381536 2010 Gurbel PA Conley P Andre P Gretler D Jurek M Methods for diagnosis and treatment of thrombotic
disorders mediated bycyp2c192 (patent pending) 41014 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent
20140100167 81815 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 9110062 111715 Gurbel PA Detection of restenosis risk in patients receiving a stent by measuring the characteristics of
blood clotting including the measurement of maximum thrombin-induced clot strength Patent 9188597 Extramural Funding (since 2002) CURRENT 2010-2015 MAGMA (Multianalyte And Genetic Markers of Atherosclerosis)
Haemonetics and Sinai Hospital of Baltimore 2015-present An Observational Study of CORA-Assisted Stroke Identification and Antithrombotic Therapy
2014-2015 Feasibility clinical trial to evaluate the efficacy of an Anticoagulant cartridge to be used in the CORA System Coramed Technologies LLC
2014-2015 Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid Durlaza in CVD Patients at Risk of High Platelet Turnover (DURATION)
New Haven Pharmaceuticals Inc 2015-present Influence of Edoxaban on Coagulability and Thrombin Generation An in Vitro Study Focusing on
Thrombelastography Daiichi Sankyo
2016 Influence of Vorapaxar on Thrombin Generation and Coagulability Merck 2015-present Durlaza GI GI Tolerability Study New Haven Pharamceuticals 2015-present Thrombogenicity in LVAD Recipients Haemonetics 2014-2015 First-in-Man Assessment of PZ-128 National Institutes of Health PREVIOUS 2002 Atorvastatin in the Treatment of Heart Failure
LBH IRB 20030512 NIHThe National Heart Lung and Blood Institute NIH
2002 Asessment of the In Vitro Effects of Tenecteplase Reteplase and Alteplase on Human Platelets TAR STUDY Genetech
2003-2005 Assessment of the Effects of the heparin-coated Cordis Stent versus Non-coated Stents on Platelet and Endothelial Cell Activation and Thrombin Effect in Patients with Coronary Artery Disease (HEPACOAT) Cordis Inc
2004-2005 The Antiplatelet Effects of Eptifibatide with High and Standard Dose Clopidogrel in Low-Moderate Risk Patients Undergoing Coronary Intervention (CLEAR-PLATELETS Study) MilleniumSchering Plough
2004-2005 The Use of The TEG System to Monitor Platelet Inhibition at Bedside 5R44HL059753-03Haemoscope National Institute of Health
2004-2006 Clopidogrel Resistance in Patients with Stent Thrombosis (CREST Study) AstraZeneca
Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study MilleniumSchering Plough
2005 St Johns Wort Decreases ADP Induced Platelet Reactivity in Known Clopidogrel Resistant Post Coronary Intervention Patients after a Loading Dose of Clopidogrel University of Michigan
2008-2009 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST) Sinai Hospital Department of Medicine
2009-2010 Demonstration of the Pharmacodynamic Antiplatelet Effect of PRT060128 in Patients with High Platelet Reactivity during Clopidogrel and Aspirin Maintenance Therapy (PORTOLA) Portola Pharmaceuticals
2008-2009 A Randomised Double-Blind Outpatient Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND] AstraZeneca Pharmaceuticals LP
2008-2009 A Randomized Double-blind Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Background Therapy in Patients with Stable Coronary Artery Disease with Additional Detailed Assessment of Cardiopulmonary Function (ONSET-OFFSET) AstraZeneca Pharmaceuticals LP
2008-2009 A Single Center Randomized Open Label Parallel Group Pharmacodynamic Study of a Novel Combination Form of Aspirin and Phytosterol versus Aspirin in Healthy Adult Subjects (ARMOR) Bayer Healthcare LLC
2008-2009 Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel Plus EC Aspirin (325 mg) and Clopidogrel Plus PA32540 on Platelet Aggregation in Healthy Volunteers POZEN 110 POZEN Inc
2009-2010 Antithrombosis with Clopidogrel Beyond the Concept of Platelet Aggregate Inhibition (SANOFI) Sanofi Inc 2010-2012 A Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel EC
Aspirin 81 mg and EC omeprazole 40 mg all dosed concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers POZEN Inc
Intramural Funding (since 2002) CURRENT 2008-present Time Based Strategy to Reduce Clopidogrel Associated Bleeding Related to CABG (TARGET CABG) Sinai Hospital of Baltimore Department of Medicine 2009-present Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI)
Sinai Hospital of Baltimore Department of Medicine 2011-present Detection of Leukemic Blood and Solid TypE MalignanCies by Urinary 11-DehydroThromboxane B2 (DETECT) Study
Sinai Hospital of Baltimore Department of Medicine PREVIOUS 2001-2002 Platelet Activation in Stenting PAST Study Sinai Hospital of Baltimore 2005-2006 Platelet Reactivity in Patients with Crohnrsquos disease Receiving Infliximab (chimeric anti-TNF alpha antibody) ndash COIN
Sinai Hospital of Baltimore Department of Medicine 2006-2007 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST)
Sinai Hospital of Baltimore Department of Medicine 2008-2011 Platelet Reactivity and Thrombogenecity in Postmenopausal Women
Sinai Hospital Department of Medicine 2008-2010 Platelet Reactivity and Thrombogenecity in Postmenopausal Women (PRIDE Study)
Sinai Hospital Department of Medicine Multicenter Studies since 2001
Curriculum Vitae Paul A Gurbel MD Page 17
CURRENT 2010-present The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and
Clopidogrel in Aspirin-Treated Subjects With Stable Coronary Artery Disease Daiichi Sankyo
2010-present A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly versus Non-Elderly Aspirin-Treated Subjects with Stable Coronary Artery Disease Eli Lilly amp company
2011-present A Prospective Multicenter Randomized Trial of Clopidogrel versus Prasugrel Anti-platelet Therapy in Cytochrome P450 2C19 (CYP2C19) Intermediate Metabolizers Grant No U01HL105198
NIH National Heart Lung and Blood Institute NIH 2011-present A Prospective Randomized Multi-Center Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHERreg Sirolimus-Eluting Coronary stents
HCRI 2012-present A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in
patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)
Bayer Healthcare LLC 2013-present Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in
Patients at a High-Risk for Vascular Outcomes (ACCELERATE) Eli Lilly amp Company 2014-present A Phase 2b Multi-center Randomized Placebo-controlled Dose-ranging Study to Investigate the
Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infarction
AEGIS CSL 2015-2017 A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety of PZ- 128 in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention
National Institute of Health PREVIOUS 2001 A Randomized Double-Blind Placebo-Controlled Study of Two Intravenous Dosing Regimens of
h5G11-scFv in Patients with Acute Myocardial Infarction Undergoing 2001-2002 Prevention of REStenosis with Tranilast and Its Outcomes A Placebo Controlled Trial PRESTO STUDY
SmithKline Beecham 2002-2003 Taxus IV-SR Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
Boston Scientific 2003 MICROVENA Corporation TRAP Vascular Filtration System (VFS) Trial
Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily Pfizer Inc
2003-2004 Phase 3 Multi-Center Double-Blind Randomized Parallel Group Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily (QD) for 24 Months Compared with Atorvastatin Alone in Subjects with Angiographically Documented Coronary Heart Disease Pfizer Inc
2003-2004 A Randomized Controlled Trial of the Medtronic Endeavor Drug Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ldquoENDEAVOR III Studyrdquo)
Medtronic 2009-2010 A Prospective Randomized Open-label Multicenter study in Patients Presenting with Acute Coronary Syndromes SYNERGY STUDY
Aventis Pharmaceuticals 2004 CObalt chromium STent with Antiproliferative for Restenosis II Trialrdquo Costar study
Conor Medsystems
Curriculum Vitae Paul A Gurbel MD Page 18
2004-2005 A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions ENDEAVOR IV Medtronic
2004-2005 A Randomized Trial to evaluate the relative protection against POST-PCI microvasculat obstruction among antiplatelet and anti-thrombotic medications (TIMI-30) TIMI group
2004-2006 A Double-blind Double-dummy Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI 33 AstraZeneca Lp
2005-2006 Strategy To Reduce Atherosclerosis Development Involving Administration of Rimonabant - The Intravascular Ultrasound Study (STRADIVARIUS) EFC5827 Sanofi Synthelabo Research
2006 A Multicenter Randomized Double-Blind Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (TRASM-PCI) Schering Plough
2006-2007 A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel -SWAP (SWitching Anti Platelet study) Eli Lilly amp Company and Sankyo Company Limited
2006-2007 A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2008-2010 A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary InterventionTIMI-38 Eli Lilly Company Daiichi
2009-2010 A Randomized Double-Blind Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128 a Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Interventions (INNOVATE-PCI) Portola Pharmaceuticals
2010-2012 TReatment with ADPreceptor iNhibitorS Longitudinal Assessment ofTreatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS)
Eli Lilly Company 2010-2013 RADAR Randomized Partially-Blinded Multi-Center Active-Controlled Dose-Ranging Study
Assessing the Safety Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome Regado Bioscience Inc
2011-2013 A Phase IIa Multi-center Randomized Sponsor-unblinded Placebo-controlled Single Ascending Dose Study to Investigate the Safety Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Adults Taking Aspirin and a P2Y12 Platelet Inhibitor
AEGIS CSL Research Program BuildingLeadership 1991-1995 Director Interventional Cardiology Research University of Maryland Medical System 1998-2015 Director Sinai Center for Thrombosis Research 2001-2015 Director Cardiovascular Research Lifebridge Health 2002-2015 Director Therapeutics Research and Technology Development for the Cardiac Catheterization Program Sinai Hospital of Baltimore 2007-2015 Associate Chief for Research Department of Medicine Sinai Hospital of Baltimore 2015-current Director Interventional Cardiology and Cardiovascular Medicine Research INOVA Health 2015-Current Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute EDUCATIONAL ACTIVITIES
Curriculum Vitae Paul A Gurbel MD Page 19
Peer Reviewed Publications-Consensus Statements Expert Opinions 1 Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C
Rao AK The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 200531309-11
2 Hoekstra J Cohen M Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Saucedo JF Pollack CV Jr Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention-an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective report on a roundtable discussion Am J Emerg Med 200927720-8
3 Bonello L Tantry US Marcucci R Blindt R Angiolillo DJ Becker R Bhatt DL Cattaneo M Collet JP Cuisset T Gachet C Montalescot G Jennings LK Kereiakes D Sibbing D Trenk D Van Werkum JW Paganelli F Price MJ Waksman R Gurbel PA Working Group on High On Treatment Platelet Reactivity Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 201056919-33
4 Gurbel PA Tantry US Shuldiner AR Kereiakes DJ Genotyping one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 201056112-6
5 Gurbel PA Tantry US Antiplatelet therapy Clopidogrel-PPI interaction an ongoing controversy Nat Rev Cardiol 201187-8
6 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
7 Gurbel PA Nolin TD Tantry US Clopidogrel efficacy and cigarette smoking status JAMA 20123072495-6 8 Tantry US Bonello L Aradi D Price MJ Jeong YH Angiolillo DJ Stone GW Curzen N Geisler T Ten Berg J
Kirtane A Siller-Matula J Mahla E Becker RC Bhatt DL Waksman R Rao SV Alexopoulos D Marcucci R Reny JL Trenk D Sibbing D Gurbel PA Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding J Am Coll Cardiol 2013622261-73
9 Gurbel PA Tantry US Antiplatelet and anticoagulant agents in heart failure Current status and future perspectives JACC Heart Fail 201421-14
10 Gurbel PA Tantry US Antiplatelet therapy What have we learned from the ANTARCTIC trial Nat Rev Cardiol 201613639-640
Invited Review Articles 1 Gurbel PA Midwall JA Brodie BR Angioplasty and adjunctive intra-aortic balloon pump counterpulsation Current
clinical considerations Todays Therapy Trends 19951363-78 2 OrsquoConnor CM Gurbel PA Serebruany VL Depression and ischemic heart disease Am Heart J 200014063-69 3 Gurbel PA Serebruany VL Oral IIbIIIa inhibitors From initial promise to clinical failures J Thromb and
Thrombolysis 200010217-20 4 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Atar D Serebruany VL Platelets and
Thrombolysis Cooperation or Contrariety Heart Drug 20011281-290 5 McKenzie ME Gurbel PA The potential of monoclonal antibodies to reduce reperfusion injury in myocardial
infarction BioDrugs 200115395-404 6 Gurbel PA Bliden KP Hayes K Tantry U Platelet activation in myocardial ischemic syndromes Expert Rev of
Cardiovasc Ther 20052535-45 7 Tantry US Bliden KP Gurbel PA Resistance to antiplatelet drugs Current status and future research Expert
Opin Pharmacother 200562027-45 8 Gurbel PA Lau WC Bliden KP Tantry US Clopidogrel resistance Implications for coronary stenting Curr Pharm
Des 2006121261-9 9 Gurbel PA Tantry US Drug insight Clopidogrel non-responsiveness Nature ClinPract Cardiovasc Med
20063387-95 10 Gurbel PA Tantry US Aspirin and Clopidogrel Resistance Considerations and management J Interv Cardiol
200619439-48 11 Lau WC Gurbel PA Antiplatelet drug resistance and drug-drug interactions Role of cytochrome P450 3A4
Pharm Res 2006232691-708 12 Wiviott SD Tantry US Gurbel PA Clinical applications of antiplatelet therapy Rev Cardiovasc Med 20067
Curriculum Vitae Paul A Gurbel MD Page 20
130-46 13 Tantry US Bliden KP Gurbel PA Prasugrel Expert Opin Investig Drugs 2006151627-33 14 Gurbel PA Tantry US Clopidogrel Resistance Thromb Res 2007120311-21 15 Tantry US Etherington A Bliden KP Gurbel PA Antiplatelet therapy Current strategies and future trends Future
Cardiology 20072343-366 16 Gurbel PA Tantry US The relationship of platelet reactivity to the occurrence of post-stenting ischemic events
emergence of a new cardiovascular risk factor Rev Cardiovasc Med 2006Suppl 4S20-8 17 Tantry US Bliden KP Gurbel PA AZD6140 Expert Opin Investig Drugs 200716225-9 18 Gurbel PA Tantry US Stent thrombosis role of compliance and non-responsiveness to antiplatelet therapy Rev
Cardiovasc Med 20078S19-S26 19 Gurbel PA Kandzari DE Stent thrombosis associated with first-generation drug-eluting stents issues with
antiplatelet therapy Neth Heart J 200715148-50 20 Gurbel PA Tantry US The role of clopidogrel in cardiovascular diseases Pol Arch Med Wewn 2007117207-9 21 Gurbel PA DiChiara J Tantry US Antiplatelet therapy after implantation of drug-eluting stents duration
resistance alternatives and management of surgical patients Am J Cardiol 200710018M-25M 22 Gurbel PA Becker R Mann KG Steinhubl SR Michelson AD Platelet function monitoring in patients with
coronary artery disease J Am Coll Cardiol 2007501822-34 23 Gurbel PA Tantry US Prasugrel a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig
Drugs 20089324-36 24 Gurbel PA Bilden KP Tantry US Diagnostics for aspirin resistance Mol Diagn Ther 20081255-6 25 Gurbel PA Antonino MJ Tantry US Antiplatelet treatment of cardiovascular disease a translational research
perspective Pol Arch Med Wewn 2008118289-97 26 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831I36 27 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention Clin Cardiol 200831I28-I35
28 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches Clin Cardiol 200831I21-I27
29 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention Clin Cardiol 200831I17-I20
30 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Assessing the Current Role of Platelet Function Testing Clin Cardiol 200831I10-I16
31 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831136
32 Keriakes DJ Gurbel PA Periprocedural platelet function in percutaneous coronary intervention JACC Cardiovasc Interv 2008suppl 1111ndash121
33 Gurbel PA Tantry US The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome J Interv Cardiol 200821Suppl 1S10-7
34 Gurbel PA Tantry US Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 20091122-322
35 Gurbel PA Aspirin scope and limitations Br J Cardiol 200917 (Suppl 1)S8-S9 36 Cohen M Hoekstra J Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Pollack CV Jr
Saucedo JF Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion J Interv Cardiol 200821283-99
37 Angiolillo DJ Bhatt DL Gurbel PA Jennings LK Advances in antiplatelet therapy agents in clinical development Am J Cardiol 2009103(3 Suppl)40A-51A
38 Gurbel PA Mahla E Antonino MJ Tantry US Response variability and the role of platelet function testing J Invasive Cardiol 200921172-8
39 Gurbel PA Antonino MJ Tantry US Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug MetabToxicol Expert Opin Drug Metab Toxicol 20095989-1004
40 Gurbel PA Tantry US Antiplatelet resistance- Fact or Myth Am Hosp J 2009750-57 41 Gurbel PA Mahla E Tantry US Aspirin resistance Prog Cardiovasc Dis 200952141-52 42 Tantry US Gurbel PA Platelet monitoring for PCI Is it really necessary Haemostaseologie 200929 368-75 43 Gurbel PA Aspirin-scope and limitations Br J Cardiol 200917(Suppl 1)S8-S9
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 4
537-41 36 Serebruany VL Gurbel PA Shustov AR Ohman EM Topol EJ Heterogeneity of platelet aggregation and major
surface receptor expression in patients presenting with acute myocardial infarction Am Heart J 1998 136398-405 37 Serebruany VL Gurbel PA Murugesan SR Lowry Dr Sturm E Svetlov SI Depressed plasma platelet-activating
factor acetylhydrolase in patients presenting with acute myocardial infarction Cardiology 199890127-130 38 Serebruany VL Schlossberg ML Edenbaum LR Herzog WR Gurbel PA Serial changes of soluble endothelin-1
levels during myocardial ischemia-reperfusion Effects of magnesium diltiazem and a novel Mac-1 Inhibitor Pharm Res 199838165-172
39 Gurbel PA Serebruany VL Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Increased baseline platelet P-selectin and PECAM-1 as predictors of unsuccessful thrombolysis in patients with acute myocardial infarction Coron Artery Dis 19989451-456
40 Serebruany VL Gurbel PA Effect of thrombolytic therapy on the plasma concentration and platelet expression of the plateletendothelial cell adhesion molecule in patients with acute myocardial infarction Arterioscl Thromb Vasc Biol 199919153-158
41 Serebruany VL Gurbel PA The relations of major platelet receptor expression during myocardial infarction Monitoring efficacy of GP IIbIIIa inhibitors by measuring P-selectin Thromb Haemost 199980314-316
42 Serebruany VL Gurbel PA Assessment of platelet activity by measuring platelet derived substances in plasma from patients with acute myocardial infarction Surprising lessons from the GUSTO III Platelet Study Thromb Res 199993149-150
43 OConnor CM Gurbel PA Serebruany VL Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure Am J Cardiol 1999831345-1349
44 Serebruany VL Murugesan SR Pothula A Semaan H Gurbel PA Soluble plateletendothelial cellular adhesion molecule-1 but not P-selectin nor osteonectin identify acute myocardial infarctions among patients with chest pain admitted to the Emergency Department Cardiology 1999150-55
45 Serebruany VL Yurovsky VV Gurbel PA Mild myocardial stunning affects platelet aggregation and certain hemostatic factors in swine Clin Appl Thromb Haemost 19995236-42
46 Murugesan SR Gurbel PA Serebruany VL Storing paraformaldehyde fixed whole blood in patient samples after chronic platelet glycoprotein IIb IIIa blockade Core laboratory considerations Thromb Res 19995201-203
47 Serebruany VL Kereiakes DJ Dalesandro MR Gurbel PA The flow cytometer model markedly affects measurement of ex vivo whole blood platelet-bound P-selectin expression in patients with chest pain Are we comparing apples and oranges Thromb Res 19999651-56
48 Serebruany VL Yurovsky VV Gurbel PA Effects of a novel Mac-1 inhibitor NPC 15669 on hemostatic parameters during preconditioned myocardial infarction Life Sciences 1999651503-13
49 Gurbel PA Murugesan SR Lowry DR Serebruany VL Plasma thromboxane and prostacyclin are linearly related and increased in patients presenting with myocardial infarction Prostaglandins Leukot Essent Fatty Acids 1999617-11
50 Gurbel PA Kereiakes DJ Dalesandro MR Bahr RD OConnor CM Serebruany VL The role of soluble and platelet-bound P-selectin in discriminating cardiac from non-cardiac chest pain at presentation in the Emergency Department Am Heart J 2000139320-328
51 McKenzie ME Pothula A Gurbel PA Fuzaylov SY OConnor CM Gaitis WA Serebruany VL Failure of thrombin generation markers to triage patients presenting with chest pain Cardiology 20009253-58
52 Gurbel PA Kerejakes DJ Serebruany VL Soluble P-Selectin is not a surrogate marker for platelet P-Selectin Evidence from a multicenter chest pain study group J Thromb Thrombolysis 20001015-22
53 Serebruany VL Murugesan SR Pothula Atar D Lowry DR OrsquoConnor CM Gurbel PA Increased soluble plateletendothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure Independence of disease etiology and antecedent aspirin therapy Eur J Heart Fall 20001243-9
54 Semann HB Gurbel PA Anderson JL Muhlestein JB Carlquist JV Horne BD Serebruany VL Soluble VCAM-1 and E-selectin but not ICAM-1 discriminate endothelial injury in patients with documented coronary artery disease Cardiology 2000937-10
55 Gurbel PA Kereiakes DJ Serebruany VL Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction Scand Cardiovasc J 20003453-8
56 Serebruany VL Lowry DR Fuzaylov SY Levine DJ OConnor CM Gurbel PA Moderate alcohol consumption is associated with the decreased baseline platelet activity in patients presenting with acute myocardial infarction J Thromb Thrombolysis 20009229-34
57 Serebruany VL Murugesan SR Atar D Jerome S Semann H Gurbel PA Effect coronary thrombolysis on the plasma concentration of osteonectin (SPARC BM40) in patients with acute myocardial infarction J Thromb Thrombolysis 200010197-202
58 Semann HB Gurbel PA Anderson JL Muhlestein JB Carlquist JF Horne BD Serebruany VL The effect of
Curriculum Vitae Paul A Gurbel MD Page 5
chronic azithromycin therapy on soluble endothelium-derived adhesion molecules in patients with coronary artery disease Cardiovasc Pharmacol 200036533-7
59 Gurbel PA OrsquoConnor CM Dalesandro MR Serebruany VL Relation of soluble and platelet P-selectin to early outcome in patients with acute myocardial infarction after thrombolytic therapy Am J Cardiol 200187774-7
60 Serebruany VL Alford AB Meister AF Fuzaylov SY Gattis WA Gurbel PA Clinical utility of the platelet function analyzer (PFA-100) for the Assessment of the Platelet Status in Patients with Congestive Heart Failure (EPCOT trial) Thromb Res 200115427-33
61 Serebruany VL Gurbel PA OrsquoConnor CM Platelet inhibition by sertraline and n-desmethylsertraline A possible missing link between depression coronary events and mortality benefits of selective serotonin reuptake inhibitors Pharmacol Res 200143453-62
62 Serebruany VL OrsquoConnor CM Gurbel PA Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease Am J Cardiol 2001871398-400
63 Serebruany VL Levine DJ Nair GV Meister AF Gurbel PA Usefulness of combining necrosis and platelet markers in triaging patients presenting with chest pain to the emergency department J Thromb and Thrombolysis 200111155-62
64 Serebruany VL Cummings CC Malinin AI Steinhubl SR Gurbel PA Uniform platelet activation exists before coronary stent implantation despite aspirin therapy Am Heart J 2001142611-16
65 Gurbel PA Fusaylov SF Gattis WA Gaulden L Hasselblad V Serebruany VL OrsquoConnor CM Evaluation of platelets in heart failure Is platelet activity related to etiology class or clinical outcomes Am Heart J 20021431068-75
66 Gurbel PA Malinin AI Callahan KP Serebruany VL OrsquoConnor CM Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and GP IIbIIIa expression and platelet-leukocyte aggregate formation Am J Cardiol 200290312-315
67 Bahr RD Gurbel PA Malinin AI Wentz C Christenson RH Roe MT Gibler WB Kitt MM Ohman EM Serebruany VL Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q wave acute myocardial infarction Am J Cardiol 200290310-312
68 Faxon DP Gibbons RJ Chronos NAF Gurbel PA Sheehan F for the HALT ndash MI Investigators The effect of blockade of the CD11CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty The results of the HALT- MI study J Am Coll Cardiol 2002401199-1204
69 Serebruany VL McKenzie M Meister A Fuzaylov S Gurbel P Atar D Gattis W OrsquoConnor C Whole blood impedence aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT Trial) Eur J Heart Fail 20024461
70 Serebruany V McKenzie ME Meister AF Fuzaylov SY Gurbel PA Atar D Gattis WA OrsquoConnor CM Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT Trial with special reference to the Hemodyne hemostatic analyzer Pathophysiol Haemost Thromb 2002328-15
71 Gurbel PA Callahan KP Malinin AI Serebruany VL Gillis J Could stent design affect platelet activation Results of the Platelet Activation in Stenting (PAST) study J Invasive Cardiol 200214584-9
72 Gurbel PA Galbutt B Bliden KP Bahr RD Roe MT Serebruany VL Ohman EM Effect of eptifibatide for acute coronary syndromes Rapid versus late administration-therapeutic yield on platelets (the EARLY platelet substudy) J Thromb Thrombolysis 200314213-219
73 Gurbel PA Cummings CC Alford AB Meister AF Serebruany VL Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting The Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial Am Heart J 2003145239-47
74 Serebruany VL Malinin AI Callahan KP Binbrek A Van de Werf F Alexander JH Granger CB Gurbel PA Effect of tenecteplase versus alteplase on platelets during the first three hours of treatment for acute myocardial infarction The ASSENT-2 Platelet Substudy Am Heart J 2003145636-42
75 Gurbel PA Bliden KP Durability of platelet inhibition by clopidogrel Am J Cardiol 2003911123-5 76 Gurbel PA Bliden KP Hiatt BL The early antiplatelet effects of clopidogrel loading for coronary stenting and the
long term stability of inhibition J Thromb Haemost 200311319-21 77 Gurbel PA Bliden KP Hiatt BL Clopidogrel for coronary stenting Response variability drug resistance and the
effect of pretreatment platelet reactivity Circulation 20031072908-13 78 Serebruany VL Malinin AI OrsquoConnor CM Gurbel PA Effects of roxifiban on platelet aggregation and major
receptor expression in patients with coronary artery disease For the Roxifiban Oral Compound Kinetics Evaluation Trial ndash I Am Heart J 200314691-8
79 Gurbel PA Bliden KP Platelet activation after stenting with heparin-coated versus non-coated stents Am Heart J 2003146E10
Curriculum Vitae Paul A Gurbel MD Page 6
80 Gurbel PA Bliden KP A new method of representing drug-induced platelet inhibition Better description of time course response variability non-response and heightened reactivity Platelets 200314481-3
81 Gurbel PA Bliden KP The stratification of platelet reactivity and activation in patients with stable coronary disease on aspirin therapy Thromb Res 20031129-12
82 Gurbel PA Samara WM Bliden KP Failure of clopidogrel to reduce platelet reactivity an activation following standard dosing in elective stenting Implications for thrombotic events and restenosis Platelets 20031595-99
83 Lau WC Gurbel PA Watkins PB Neer CJ Hopp AS Carville DGM Guyer KE Tait AR Bates ER The contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 200410966-71
84 Joynt KE Gattis WA Hasselblad V Fuzaylov SY Serebruany VL Gurbel PA Gaulden LH Felker GM Whellan DJ OrsquoConnor CM Effect of angiotensin-converting enzyme inhibitors beta blockers statins and aspirin on C-reactive protein levels in outpatients with heart failure Am J Cardiol 200493783-5
85 Samara WM Bliden KP Tantry U Gurbel PA Thrombotic risk The difference between clopidogrel responsiveness and post-treatment platelet reactivity Thromb Res 200411589-94
86 Gurbel PA Hayes KA Bliden KP Yoho J Tantry U The platelet-related effects of tenecteplase vs alteplase vs reteplase Blood Coag Fibrinolysis 2005161-7
87 Gurbel PA Bliden KP Zaman KA Yoho JA Hayes KM Tantry US Clopidogrel loading with eptifibatide to arrest the reactivity of platelets Results of the CLEAR PLATELETS study Circulation 20051111153-9
88 Poston R Gu J Brown J Gammie J White C Manchio J Pierson RN Griffith P Gurbel P Tantry U Gilbert TB Hypercoaguability affecting early vein graft patency does not exist after off-pump coronary artery bypass J Cardiothoracic Vasc Anesth 20051911-18
89 Gurbel PA Bliden KP Hates KM Yoho JA Herzog WR Tantry US The relation of dosing to clopidogrel responsiveness and the incidence of high post-stent platelet aggregation in patients undergoing coronary stenting J Am Coll Cardiol 2005451392-6
90 Hermiller JB Raizner A Cannon L Gurbel PA Kutcher MA Wong SC Russell ME Ellis SG Mehran R Stone GW TAXUS-IV Investigators Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus The TAXUS-IV trial J Am Coll Cardiol 2005451172-9
91 Gurbel PA Bliden KP Samara W Yoho J Hayes K Fissha M Tantry U Clopidogrel Effect on Platelet REactivity in Patients with Stent Thrombosis Results of the CREST Study J Am Coll Cardiol 2005461827-32
92 Gurbel PA Bliden KP Guyer K Cho P Zaman K Kreutz R Bassi A Tantry US Platelet REactivity in Patients And Recurrent Events POST-STENTING Results of the PREPARE POST-STENTING Study J Am Coll Cardiol 2005461820-6
93 Tantry US Bliden KP Gurbel PA Overestimation of platelet aspirin resistance Detection by thrombelastograph platelet mapping and validation by conventional aggregation using arachidonic acid stimulation J Am Coll Cardiol 2005461705-9
94 Kreutz RP Tantry US Bliden KP Gurbel PA Viral respiratory tract infections increase platelet reactivity and activation - an explanation for the higher rates of myocardial infarction and stroke during viral illness J Thromb Haemost 200532108-9
95 Bleske B Nicklas J Bard R Brook R Gurbel PA Bliden K Rajagopalan S Pitt B Neutral effect on markers of heart failure inflammation endothelial activation and function and vagal tone following high dose HMG - coA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low density lipoproteins J Am Coll Cardiol 200647338-41
96 Gurbel PA Bliden KP Tantry US Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting Inflammation results from the CLEAR PLATELETS-1b study J Am Coll Cardiol 2006482186-91
97 Kandzari DE Leon MB Popma JJ Fitzgerald PJ OrsquoShaughnessy C Ball MW Turco M Applegate RJ Gurbel PA et alfor the ENDEAVOR III Investigators Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease a randomized controlled trial J Am Coll Cardiol 2006482440 ndash 2447
98 Gurbel PA Bliden KP Guyer K Aggarwal N Tantry US Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting Thromb Res 2007119563-70
99 Bliden KP DiChiara J Tantry US Bassi AK Chaganti SK Gurbel PA Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention is the current antiplatelet therapy adequate J Am Coll Cardiol 200749657-66
100 Gurbel PA Bliden KP Etherington A Tantry US Assessment of clopidogrel responsiveness measurements of maximum platelet aggregation final platelet aggregation and their correlation with vasodilator stimulated phosphoprotein in resistant patients Thromb Res 2007121107-15
101 Gurbel PA Bliden KP DiChiara J Gesheff T RN Chaganti S Etherington A MD Tantry US Evaluation of
Curriculum Vitae Paul A Gurbel MD Page 7
dose-related effects of aspirin on platelet function results from the ASpirin-Induced Platelet EffeCT (ASPECT) study Circulation 20071153156-64
102 Kreutz RP Tantry US Bliden KP Gurbel PA Inflammatory changes during the common cold are associated with platelet activation and increased reactivity of platelets to agonists Blood Coagul Fibrinolysis 200718713-8
103 Storey R Husted S Harrington R Heptinstall S Wilcox R Peters G Wickens Emanuelsson H Gurbel PA Grande P Cannon C Inhibition of platelet aggregation by AZD6140 a reversible oral P2Y12 receptor antagonist compared with clopidogrel in patients with acute coronary syndromes J Am Coll Cardiol 2007501852-6
104 DiChiara J Bliden KP Tantry US Hamed MS Antonino MJ Suarez TA Bailon O Singla A Gurbel PA The effect of aspirin dosing on platelet function in diabetic and non-diabetic patients an analysis from the aspirin-induced platelet effect (ASPECT) study Diabetes 200756 3014-9
105 DiChiara J Bliden KP Tantry US Chaganti SK Kreutz R Gesheff TB Kreutz Y Gurbel PA Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients Platelets 200718 414-23
106 Gurbel PA Kreutz RP Bliden KP Tantry US Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease a potential approach to identify atherosclerotic disease progression Am Heart J 200815555-61
107 Gurbel PA Bliden KP Cohen E Navickas IA Singla A Antonino MJ Fissha M Kreutz RP Bassi AK Tantry US Race and sex differences in thrombogenicity risk of ischemic events following coronary stenting Blood Coagul Fibrinolysis 200819268-75
108 Nissen SE Nicholls SJ Wolski K Rodeacutes-Cabau J Cannon CP Deanfield JE Despreacutes JP Kastelein JJ Steinhubl SR Kapadia S Yasin M Ruzyllo W Gaudin C Job B Hu B Bhatt DL Lincoff AM Tuzcu EM STRADIVARIUS Investigators Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease the STRADIVARIUS randomized controlled trial JAMA 20082991547-60
109 Bliden KP DiChiara J Lookman L Singla A Antonino MJ Baker BA Bailey WL Tantry US Gurbel PA The association of cigarette smoking with enhanced platelet inhibition by clopidogrel J Am Coll Cardiol 200852531-3
110 Gurbel PA Antonino MJ Bliden KP Dichiara J Suarez TA Singla A Tantry US Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention a potential antiplatelet therapeutic target Platelets 200819595-604
111 Gurbel PA Bliden KP Cohen E Navickas IA Singla A Antonino MJ Fissha M Kreutz RP Bassi AK Tantry US Race and sex differences in thrombogenicity risk of ischemic events following coronary stenting Blood Coagul Fibrinolysis 200819268-75
112 Gurbel PA Antonino MJ Bliden KP Dichiara J Suarez TA Singla A Tantry US Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention a potential antiplatelet therapeutic target Platelets 200819595-604
113 Hamed MS Gambert S Bliden KP Bailon O Anand S Antonino MJ Hamed F Tantry US Gurbel PA Dark chocolate effect on platelet activity C-reactive protein and lipid profile a pilot study S Med J 20081011203-8
114 Gilstad JR Gurbel PA Andersen RE Relationship between age and platelet activation in patients with stable and unstable angina Arch Gerontol Geriatr 200948155-9
115 Gurbel PA Bliden KP Saucedo JF Suarez TA DiChiara J Antonino MJ Mahla E Singla A Herzog WR Bassi AK Hennebry TA Gesheff TB Tantry US Bivalirudin and clopidogrel with and without eptifibatide for elective stenting effects on platelet function thrombelastographic indices and their relation to periprocedural infarctionResults of the CLEAR PLATELETS-2 study J Am Coll Cardiol 200953857-9
116 Gurbel PA Bliden KP Kreutz RP DiChiara J Antonino MJ Tantry US The link between heightened thrombogenicity and inflammation Pre-procedure characterization of the patient at high risk for recurrent events after stenting Platelets 20092097-104
117 Antonino MJ Mahla E Bliden KP Tantry US Gurbel PA Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting Am J Cardiol 20091031546-50
118 Antonino MJ Coppolecchia R Mahla E Bliden KP Tantry US Gurbel PA Antiplatelet effects of aspirin with phytosterols Comparison with non-enteric coated aspirin alone Thromb Res 2009126384-5
119 Pinto Slottow TL Bonello L Gavini R Beauzile P Sushinsky SJ Scheinowitz M Kaneshige K Xue Z Torguson R Tantry U Pichard AD Satler LF Suddath WO Kent K Gurbel P Waksman R Am J Cardiol 2009104525-30
120 Shuldiner AR OConnell JR Bliden KP Gandhi A Ryan K Horenstein RB Damcott CM Pakyz R Tantry US Gibson Q Pollin TI Post W Parsa A Mitchell BD Faraday N Herzog W Gurbel PA Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyJAMA2009302849-57
121 Singla A Antonino MJ Bliden KP Tantry US Gurbel PA The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy Am Heart J 2009158784e1-6
122 Gurbel PA Bliden KP Antonino MJ Stephens G Gretler DD Jurek MM Pakyz RE Shuldiner AR Conley PB
Curriculum Vitae Paul A Gurbel MD Page 8
Tantry US The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP 2C192 genotype First experience in patients J Thromb Haemost 2010843-53
123 Gurbel PA Bliden KP Butler K Tantry US Gesheff T Wei C Teng R Antonino MJ Patil SB Karunakaran A Kereiakes DJ Parris C Purdy D Wilson V Ledley GS Storey RF Randomized double-blind assessment of the ONSET and OFFSet of the antiplatelet Effects of Ticagrelor versus clopidogrel in patients with stable coronary artery disease The ONSETOFFSET Study Circulation 20091202577-85
124 Gurbel PA Bliden K Antonino M Butler K Teng R Rasmussen L Syd A Storey R Nielsen T Eikelboom J Sabe-Affaki G Husted S Kereaikes D Henderson D Patel V Tantry U Response to Ticagrelor in Clopidogrel Non-responders and ReSPONDers and the Effect of Switching Therapies The RESPOND Study Circulation 20101211188-99
125 Tantry US Bliden KP Suarez TA Kreutz RP DiChiara J Gurbel PA Hypercoagulability platelet function inflammation and coronary artery disease acuity results of the Thrombotic Risk Platelets 201021 360-7
126 Hennekens CH Schneuder WR Hebert PR Tantry US Gurbel PA Hypothesis formulation from subgroup analyses non-adherence or non-steroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to ldquoaspirin resistancerdquo Am Heart J 2010159744-8
127 Storey RF Bliden KP Patil SB Karunakaran A Ecob R Butler K Teng R Wei C Tantry US Gurbel PA ONSETOFFSET Investigators Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor clopidogrel or placebo in the ONSETOFFSET study J Am Coll Cardiol 201056185-93
128 Gurbel PA Bliden KP Navickas IA Mahla E Dichiara J Suarez TA Antonino MJ Tantry US Cohen E Adenosine diphosphate-induced platelet-fibrin clot strength a new thrombelastographic indicator of long-term poststenting ischemic events Am Heart J 2010160346-54
129 Angiolillo DJ Saucedo JF Deraad R Frelinger AL Gurbel PA Costigan TM Jakubowski JA Ojeh CK Effron MB SWAP Investigators Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes results of the SWAP (SWitching Anti Platelet) study J Am Coll Cardiol 2010561017-23
130 Mega JL Simon T Collet JP Anderson JL Antman EM Bliden K Cannon CP Danchin N Giusti B Gurbel P Horne BD Hulot JS Kastrati A Montalescot G Neumann FJ Shen L Sibbing D Steg PG Trenk D Wiviott SD Sabatine MS Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI a metaanalysis JAMA 20103041821-30
131 Tantry US Bliden KP Wei C Storey RF Armstrong M Butler K Gurbel PA First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel The ONSETOFFSET and RESPOND Genotype Studies Circ Cardiovasc Genet 20103556-66
132 Lau WC Welch TD Shields T Rubenfire M Tantry US Gurbel PA The Effect of St Johns Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients Increased Platelet Inhibition by Enhancement of CYP 3A4 Metabolic Activity J Cardiovasc Pharmacol 20115786-93
133 Gurbel PA Shuldiner AR Bliden KP Ryan K Pakyz RE Tantry US The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy Am Heart J 2011161598-604
134 Kandzari DE Mauri L Popma JJ Turco MA Gurbel PA Fitzgerald PJ Leon MB Late-Term Clinical Outcomes With Zotarolimus-and Sirolimus-Eluting Stents 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) JACC Cardiovasc Interv 20114543-50
135 Storey RF Bliden KP Ecob R Karunakaran A Butler K Wei C Tantry U Gurbel PA Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared to clopidogrel in patients with high antiplatelet responses J Thromb Haemost 201191730-7
136 Bliden KP Tantry US Storey RF Jeong YH Gesheff M Wei C Gurbel PA The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity Combined analysis of the ONSETOFFSET and RESPOND studies Am Heart J 2011162160-5
137 Lewis JP Fisch AS Ryan K OrsquoConnell JR Gibson Q Mitchell BD Shen H Tanner K Horenstein RB Pakzy R Tantry US Bliden KP Gurbel PA and Shuldiner AR ( equal contribution) Paraoxonase 1 (PON1) Gene Variants Are Not Associated With Clopidogrel Response Clinical Pharm Ther 201190568-74
138 Navarese EP Kozinski M Obonska K Margheri M Gurbel PA Kubica J De Luca G Clinical efficacy and safety of intracoronary vs intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention A meta-analysis of randomized trials Platelets 2011 (in press)
139 Navarese EP De Luca G Castriota F Kozinski M Gurbel P MD Gibson CM Andreotti F Siller-MatulaJM Pafundi T Sukkenik A De Servi S Kubica J Low-molecular-weight heparins vs unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction A meta-analysis J
Curriculum Vitae Paul A Gurbel MD Page 9
Thromb Haemost 201191902-15) 140 Jeong YH Tantry US Kim I-S Koh J-S Kwon TJ Park Y Hwang SJ Bliden KP Kwak CH Hwang J-W
Gurbel PA Effect of CYP2C192 and 3 loss-of-function allele carriage on platelet reactivity and adverse clinical event occurrence in east asian acute myocardial infarction survivors treated with clopidogrel and aspirin Circ Cardiovasc Genet 20114585-94
141 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
142 Gurbel PA Bliden KP Firt J Zhang Y Plachetka JR Antonino M Gesheff M Tantry US Pharmacodynamic evaluation of clopidogrel plus PA32540 The Spaced PA32540 with Clopidogrel INteraction Gauging (SPACING) study Clin Pharmacol Ther 201190860-6
143 Navarese EP Buffon A Andreotti F Gurbel PA Kozinski M Kubica A Musumeci G Cremonesi A Tavazzi L Kubica J Castriota F Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome A meta-analysis of randomized trials Atherosclerosis 20122221-7
144 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 201210487-9
145 Gurbel PA Bliden KP Antonino MJ Gesheff T Cummings CC Dubois BV Herzog WR Tantry US Time dependence of clopidogrel loading effect Platelet activation versus platelet aggregation Thromb Res Thromb Res 20121291-2
146 Mahla E Suarez TA Bliden KP Rehak P Metzler H Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study Circ Cardiovasc Interv 20125261-9
147 Park Y Jeong YH Tantry US Ahn JH Kwon TJ Park JR Hwang SJ Gho EH Bliden KP Kwak CH Hwang JY Kim S Gurbel PA Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study Eur Heart J 2012332151-62
148 Husted SE Storey RF Bliden K Tantry US Hoslashimark L Butler K Wei C Teng R Gurbel PA Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease Results from the ONSET-OFFSET and RESPOND Studies Clin Pharmacokinet 201251397-409
149 Kubica J Koziński M Navarese EP Tantry US Grześk G Fabiszak T Kubica A Swiątkiewicz I Bliden KP Gurbel PA Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction A systematic review and meta-analysis of randomized clinical trials Cardiol J 201219(3)230-42 Jeong YH Bliden KP Antonino MJ Tantry US Gurbel PA Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity Platelets 2012 May 30 [Epub ahead of print]
150 Welsh RC Rao SV Zeymer U Thompson VP Huber K Kochman J McClure MW Gretler DD Bhatt DL Gibson CM Angiolillo DJ Gurbel PA Berdan LG Paynter G Leonardi S Madan M French WJ Harrington RA on behalf of the INNOVATE PCI Investigators A Randomized Double-Blind Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention The INNOVATE-PCI Trial Circ Cardiovasc Interv 20125336-346
151 Angiolillo DJ Welsh RC Trenk D Neumann FJ Conley PB McClure MW Stephens G Kochman J Jennings LK Gurbel PA Woacutejcik J Dabrowski M Saucedo JF Stumpf J Buerke M Broderick S Harrington RA Rao SV Pharmacokinetic and Pharmacodynamic Effects of Elinogrel Results of the Platelet Function Substudy From the Intravenous and Oral Administration of Elinogrel to Evaluate Tolerability and Efficacy in Nonurgent Percutaneous Coronary Intervention Patients (INNOVATE-PCI) Trial Circ Cardiovasc Interv 20125347-56
152 Reny JL Combescure C Daali Y Gurbel PA Fontana P PON1 Meta-Analysis Group Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events a systematic review and meta-analysis J Thromb Haemost 2012101242-1251
153 Jeong YH Bliden KP Antonino MJ Park KS Tantry US Gurbel PA Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies Am Heart J 201216435-42
154 Jeong YH Bliden KP Antonino MJ Tantry US Gurbel PA Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity Platelets 201216435-42
155 Singla A Bliden KP Jeong YH Abadilla K Antonino MJ Muse WC Mathew DP Bailon O Tantry US Gurbel PA Platelet reactivity and thrombogenecity in postmeopausal women Menopause 20132057-63
156 Jeong YH Tantry US Park Y Kwon TJ Park JR Hwang SJ Bliden KP Koh EH Kwak CH Hwang JY Kim S
Curriculum Vitae Paul A Gurbel MD Page 10
Gurbel PA Pharmacodynamic Effect of Cilostazol Plus Standard Clopidogrel Versus Double-Dose Clopidogrel in Patients With Type 2 Diabetes Undergoing Percutaneous Coronary Intervention Diabetes Care 2012352194-7
157 Roe MT Armstrong PW Fox KAA White HD Prabhakaran D Goodman SG Cornel JH Bhatt DL Clemmensen P Martinez F Ardissino D Nicolau JC Boden WE Gurbel PA Ruzyllo W Dalby AJ McGuire DK Leiva-Pons JL Parkhomenko A Gottlieb S Topacio GO Hamm C Pavlides G Goudev AR Oto A Tseng C-D Merkely B Gasparovic V Corbalan R Cinteză M McLendon RC Winters KJ Brown EB Lokhnygina Y Aylward PE Huber K Hochman JS E Magnus Ohman EM for the TRILOGY ACS Investigators Prasugrel versus clopidogrel for ACS patients managed without revascularization N Engl J Med 20123671297-309
158 Gurbel PA Bliden KP Jeong Y-H Antonino M Gesheff T Fort JG Shuldiner A Chai S Gesheff M Zhang Y Tantry US Spaced Administration of PA32540 and Clopidogrel Results in Greater Platelet Inhibition than Synchronous Administration of Enteric-Coated Aspirin and Enteric-Coated Omeprazole and Clopidogrel Am Heart J 2013165176-82
159 Gurbel PA Erlinge D Ohman EM Neely B Neely M Goodman SG Huber K Chan MY Cornel JH Brown E Zhou C Jakubowski JA White HD Fox KA Prabhakaran D Armstrong PW Tantry US Roe MT TRILOGY ACS Platelet Function Substudy Investigators JAMA 20123081785-94
160 Lewis JP Horenstein RB Ryan K OConnell JR Gibson Q Mitchell BD Tanner K Chai S Bliden KP Tantry US Peer CJ Figg WD Spencer SD Pacanowski MA Gurbel PA Shuldiner AR The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response Pharmacogenet Genomics 2012 Pharmacogenet Genomics 2013231-8
161 Jeong YH Tantry US Min JH Park Y Navarese EP Koh JS Park JR Hwang SJ Kho EH Bliden KP Kwak CH Hwang JY Kim S Gurbel PA Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention Int J Cardiol 2012 Oct 12 doipii S0167-5273(12)01253-3 101016
162 Saucedo JF Angiolillo DJ Deraad R Frelinger AL 3rd Gurbel PA Costigan TM Jakubowski JA Ojeh CK Duvvuru S Effron MB for the SWAP Investigators Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel insights from the switching anti-platelet (SWAP) study Thromb Haemost 2012 Dec 6109(2) [Epub ahead of print]
163 Navarese EP Austin D Gurbel PA Andreotti F Tantry U James S Buffon A Kozinski M Obonska K Bliden K Jeong YH Kubica J Kunadian V Drug-coated balloons in treatment of in-stent restenosis a meta-analysis of randomized controlled trials Clin Res Cardiol 2012 Dec 20 [Epub ahead of print]
164 Gurbel PA Bliden KP Fort JG Jeong YH Shuldiner A Chai S Gesheff T Antonino M Gesheff M Zhang Y Tantry US Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel Am Heart J 2013165176-82
165 Lewis JP Ryan K OConnell JR Horenstein RB Damcott CM Gibson Q Pollin TI Mitchell BD Beitelshees AL Pakzy R Tanner K Parsa A Tantry US Bliden KP Post WS Faraday N Herzog W Gong Y Pepine CJ Johnson JA Gurbel PA Shuldiner AR Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes Circ Cardiovasc Genet 2013 Feb 7 [Epub ahead of print]
166 Navarese EP Gurbel PA Andreotti F Tantry U Jeong YH Kozinski M Engstroslashm T Di Pasquale G Kochman W Ardissino D Kedhi E Stone GW Kubica J Optimal Timing of Coronary Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes A Systematic Review and Meta-analysis Ann Intern Med 2013158261-70
167 Jeong YH Abadilla KA Tantry US Park Y Koh JS Kwak CH Hwang JY Gurbel PA Influence of CYP2C192 and 3 loss-of-function alleles on pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention the results of the ACCEL-DOUBLE-2N3 studyJ Thromb Haemost 2013111194-7
168 Gurbel PA Bliden KP Logan DK Kereiakes DJ Lasseter KC White A Angiolillo DJ Nolin TD Maa JF Bailey WL Jakubowski JA Ojeh CK Jeong YH Tantry US Baker BA The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel The PARADOX Study J Am Coll Cardiol 2013 Apr 16 doipii S0735-1097(13)01478-2 101016jjacc201303037 [Epub ahead of print]
169 Grzesk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E4 Jeong Y-H Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 2013 Article ID 928271 httpdxdoiorg1011552013928271
170 Erlinge D Gurbel PA James S Lindahl TL Svensson P Ten Berg JM Foley DP Wagner H Brown PB Luo J Zhou C Moser BA Jakubowski JA Small DS Winters KJ Angiolillo DJ Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains non-inferiority to prasugrel 10-mg in non-elderly patients The GENERATIONS trial a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients J Am Coll Cardiol 201362577-83
Curriculum Vitae Paul A Gurbel MD Page 11
171 Kim IS Jeong YH Tantry US Park Y Lee DH Bliden KP Koh JS Park JR Jang JS Hwang SJ Koh EH Kwak CH Hwang JY Kim S Gurbel PA Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading Am Heart J 201316695-103
172 Grześk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E Jeong YH Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 20132013928271
173 Stone GW Witzenbichler B Weisz G Rinaldi MJ Neumann FJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri E Gurbel PA Xu K Parise H Kirtane AJ Brodie BR Mehran R Stuckey TD for the ADAPT-DES Investigators Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES) a prospective multicentre registry study Lancet 2013382614-23
174 Angiolillo DJ Curzen N Gurbel P Vaitkus P Lipkin F Li W Jakubowski JA Zettler M Effron MB Trenk D Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in subjects with stable coronary artery disease Results of the SWAP-2 Study J Am Coll Cardiol 2014631500-9
175 Jeong YH Bliden KP Shuldiner AR Tantry US Gurbel PA Thrombin-induced platelet-fibrin clot strength Relation to high on-clopidogrel platelet reactivity genotype and post-percutaneous coronary intervention outcomes Thromb Haemost 2014111713-24
176 Gouya G Arrich J Wolzt M Huber K Verheugt FW Gurbel PA Pirker-Kees A Siller-Matula JM Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases a systematic review and meta-analysis Stroke 201445492-503
177 Erlinge D James S Duvvuru S Jakubowski JA Wagner H Varenhorst C Tantry US Brown PB Small D Moser BA Sundseth S Walker JR Winters KJ Gurbel PA Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease Thromb Haemost 2014111943-50
178 Gurbel PA Baker BA Bailey WL Bliden KP Tantry US Unraveling the Smokers Paradox Cigarette smoking high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors Thromb Haemost 20141111187-90
179 Koh JS Kim IS Tantry US Yoon SE Park Y Cho SY Lee EJ Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading The results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study Int J Cardiol 2014174129-32
180 Bliden KP Singla A Gesheff MG Toth PP Tabrizchi A Ens G Guyer K Singh M Franzese CJ Stapleton D Tantry US Gurbel PA Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin Thromb Haemost 2014 Apr 24112(2) [Epub ahead of print]
181 Gurbel PA Gesheff MG Franzese CJ Bliden KP Tantry US Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy Platelets 201526608-9
182 Gurbel PA Bergmeijer TO Tantry US Ten Berg JM Angiolillo DJ James S Lindahl TL Svensson P Jakubowski JA Brown PB Duvvuru S Sundseth S Walker JR Small D Moser BA Winters KJ Erlinge D The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease Thromb Haemost 2014 2014112589-97
183 Cornel JH Ohman EM Neely B Clemmensen P Sritara P Zamoryakhin D Armstrong PW Prabhakaran D White HD Fox KA Gurbel PA Roe MT TRILOGY ACS Investigators Impact of smoking status on platelet function and clinical outcomes with prasugrel vs clopidogrel in patients with acute coronary syndromes managed without revascularization Insights from the TRILOGY ACS trial Am Heart J 201416876-87
184 Park Y Jung JM Tantry US Kim K Koh JS Park JR Hwang SJ Kwak CH Hwang JY Kim S Gurbel PA Jeong YH Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration The ACCEL-PARAZOL Study J Atheroscler Thromb 2014211121-39
185 Park Y Jeong YH Tantry US Ahn JH Kim K Koh J Park J Hwang SJ Kwak CH Hwang JY Gurbel PA Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity The Resultof the ACCEL-DIP Study Thromb Haemost 2014112 [Epub ahead of print]
186 Lev EI Bliden KP Jeong Y-H Pandya S Kang K Franzese C Tantry US Gurbel PA Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients J Am Heart Assoc 20143e001167
187 Alexopoulos D Xanthopoulou I Storey RF Bliden KP Tantry US Angiolillo DJ Gurbel PA Platelet reactivity during ticagrelor maintenance therapy A patient-level data meta-analysis Am Heart J 2014 168530-6
188 Lhermusier T Lipinski MJ Tantry US Escarcega RO Baker N Bliden KP Magalhaes MA Ota H Tian W Pendyala L Minha S Chen F Torguson R Gurbel PA Waksman R Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity Am J Cardiol 2015115716-23
189 Franzese CJ Bliden KP Gesheff MG Pandya S Guyer KE Singla A Tantry US Toth PP Gurbel PA Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy Am J Cardiol 2015 11151204-11
Curriculum Vitae Paul A Gurbel MD Page 12
190 Aradi D Kirtane A Bonello L Gurbel PA Tantry US Huber K Freynhofer MK Ten Berg J Janssen P Angiolillo DJ Siller-Matula JM Marcucci R Patti G Mangiacapra F Valgimigli M Morel O Palmerini T Price MJ Cuisset T Kastrati A Stone GW Sibbing D Bleeding and stent thrombosis on P2Y12-inhibitors collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention Eur Heart J 2015361762-71
191 Navarese EP Kolodziejczak M Schulze V Gurbel PA Tantry U Lin Y Brockmeyer M Kandzari DE Kubica JM DAgostino RB Sr Kubica J Volpe M Agewall S Kereiakes DJ Kelm M Effects of proprotein convertase subtilisinkexin type 9 antibodies in adults with hypercholesterolemia a systematic review and meta-analysis Ann Intern Med 201516340-51
192 Lee K Yoo SY Suh J Park KH Park Y Tantry US Park KS Han SH Kang WC Shin DH Lee C Choi SW Lee JH Cho YH Lee NH Jeong MH Ahn Y Kubica J Gurbel PA Park JH Jeong YH Efficacy of cilostazol on inhibition of platelet aggregation inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study Int J Cardiol 2015190370-5
193 Kowalewski M Schulze V Berti S Waksman R Kubica J Kołodziejczak M Buffon A Suryapranata H Gurbel PA Kelm M Pawliszak W Anisimowicz L Navarese EP Complete revascularisation in ST-elevation myocardial infarction and multivessel disease meta-analysis of randomised controlled trials Heart 2015 1011309-17
194 Baber U Mehran R Kirtane AJ Gurbel PA Christodoulidis G Maehara A Witzenbichler B Weisz G Rinaldi MJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri EL Jr Xu K Parise H Brodie BR Stuckey TD Stone GW Prevalence and impact of high platelet reactivity in chronic kidney disease Results from the assessment of dual antiplatelet therapy with drug-eluting stents registry Circ Cardiovasc Interv 20158e001683
195 Tricoci P DAndrea DM Gurbel PA Yao Z Cuchel M Winston B Schott R Weiss R Blazing MA Cannon L Bailey A Angiolillo DJ Gille A Shear CL Wright SDAlexander JH Infusion of Reconstituted High-Density Lipoprotein CSL112 in Patients With Atherosclerosis Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial J Am Heart Assoc 20154 pii e002171
196 Reny JL Fontana P Hochholzer W Neumann MJ ten Berg J Janssen PF Geisler T Gawaz M Marcucci R Gori A-M Cuisset T Alessi M-S Berdagueacute P Gurbel PA Yong G Angiolillo DJ Aradi D Beigel R Campo G Combescure C Vascular risk levels affect the predictive value of platelet reactivity 1 for the occurrence of major adverse cardiovascular events in patients on clopidogrel Systematic review and collaborative meta-analysis of individual patient data Thromb Haemost 2015 (in press)
197 Chaudhary R Bliden KP Tantry US Mohammed N Mathew D Gesheff MG Franzese CJ Gurbel PA Association of weight gain with coronary artery disease inflammation and thrombogenicity J Thromb Thrombolysis 2015 Dec 29 [Epub ahead of print]
198 Gurbel PA Bliden KP Turner SE Tantry US Gesheff MG Barr TP Covic L Kuliopulos A Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease Arterioscler Thromb Vasc Biol 201636189-97
199 Kwon TJ Tantry US Park Y Choi YM Ahn JH Kim KH Koh JS Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Smith SC Jr Jeong YH Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention Results of the ACCEL-BLEED study Thromb Haemost 2016 Jan 21115(5) [Epub ahead of print]
200 Bliden KP Tantry US Gesheff MG Franzese CJ Pandya S Toth PP Mathew DP Chaudhary R Gurbel PA Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis J Interv Cardiol 201629168-78
201 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin J Diabetes Complications 2016 May 10 pii S1056-8727(16)30127-1
202 Bedeir K Bliden K Tantry U Gurbel PA Mahla E Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel The Role of VerifyNow Can J Cardiol 201632724-5
203 Giustino G Kirtane AJ Baber U Geacuteneacutereux P Witzenbichler B Neumann FJ Weisz G Maehara A Rinaldi MJ Metzger C Henry TD Cox DA Duffy PL Mazzaferri EL Brodie BR Stuckey TD Gurbel PA Dangas GD Francese DP Ozan O Mehran R Stone GW Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study Am J Cardiol 20161171877-83
204 Kubica J Kubica A Jilma B Adamski P Hobl EL Navarese EP Siller-Matula JM Dąbrowska A Fabiszak T Koziński M Gurbel PA Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors Int J Cardiol 2016215201-8
205 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin
Curriculum Vitae Paul A Gurbel MD Page 13
J Diabetes Complications 2016 May 10 [Epub ahead of print] 206 Bliden KP Chaudhary R Lopez LR Damrongwatanasuk R Guyer K Gesheff MG Franzese CJ Kaza H
Tantry US Gurbel PA Oxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease Am J Cardiol 2016 Jun 15 [Epub ahead of print]
207 Mahla E Prueller F Farzi S Pregartner G Raggam RB Beran E Toller W Berghold A Tantry US Gurbel PA Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy Ann Thorac Surg 2016 Jul 1 [Epub ahead of print]
208 Koh JS Park Y Tantry US Ahn JH Kang MG Kim K Jang JY Park HW Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents The ACCEL-COMBO trial Platelets 2016 Aug 251-7 [Epub ahead of print]
209 Chaudhary R Saadin K Bliden KP Harris WS Dinh B Sharma T Tantry US Gurbel PA Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease Prostaglandins Leukot Essent Fatty Acids 201611340-45
210 Gurbel PA Bliden KP Chaudhary R Patrick J Liu F Chen G McLeod C Tantry US Antiplatelet Effect Durability of a Novel 24-Hour Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes MellitusAm J Cardiol 20161181941-1947
211 Gurbel PA Bliden KP Tantry US Monroe AL Muresan AA Brunner NE Lopez-Espina CG Delmenico PR Cohen E Raviv G Haugen DL Ereth MH First report of the point-of-care TEG A technical validation study of the TEG-6S system Platelets 201627642-649
212 Cornel JH Ohman EM Neely B Jakubowski JA Bhatt DL White HD Ardissino D Fox KA Prabhakaran D Armstrong PW Erlinge D Tantry US Gurbel PA Roe MT Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes J Am Heart Assoc 2016 Nov 45(11) pii e003977
213 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 201717109-121
214 Sharma T Bliden K Chaudhary R Tantry U Gurbel PA Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease Expert Opin Pharmacother 201718123-131
215 Park Y Tantry US Koh JS Ahn JH Kang MG Kim KH Jang JY Park HW Park JR Hwang SJ Park KS Kwak CH Hwang JY Gurbel PA Jeong YH Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction The REMODELING Trial Thromb Haemost 2017117911-922
216 Navarese EP Gurbel PA Andreotti F Kołodziejczak MM Palmer SC Dias S Buffon A Kubica J Kowalewski M Jadczyk T Laskiewicz M Jędrzejek M Brockmeyer M Airoldi F Ruospo M De Servi S Wojakowski W O Connor C Strippoli GF Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis PLoS One 201712e0168726
217 Bliden KP Chaudhary R Mohammed N Muresan AA Lopez-Espina CG Cohen E Raviv G Doubleday M Zaman F Mathew B Tantry US Gurbel PA Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system J Thromb Thrombolysis 201743437-445
Publications Peer Reviewed Original Science Research - Reviews 1 Serebruany VL Atar D Dalesandro MR OConnor CM Gurbel PA Changes in hemostasis after parenteral
magnesium in myocardial ischemia reperfusion Animal studies to clinical trials Magnes Res 19981137-42 2 McKenzie ME Gurbel PA Levine DJ Serebruany VL Clinical utility of available methods determining platelet
function Cardiology 199992240-7 3 Gurbel PA OConnor CM Cummings CC Serebruany VL Clopidogrel The future choice for preventing platelet
activation during coronary stenting Pharm Res 199965109-123 4 Nair GV Gurbel PA Fusaylov SY Davis CJ Ohman EM Bahr RD Christensen RH Serebruany VL Combing
necrosis and platelet markers for perfecting myocardial infarction rule out How close are we Cardiology 20009350-5
5 Davis CJ Gurbel PA Gaitis WA Fuzaylov SY Nair GV OrsquoConnor CM Serebruany VL Hemostatic abnormalities in congestive heart failure Diagnostic significance and clinical challenge Int J Cardiol 20007515-21
6 Pothula A Gurbel PA Atar D McKenzie ME Serebruany VL Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease Eur J Pharmacol 20004021-10
7 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Serebruany VL Platelet function and fibrinolytic agents Two sides of a coin Cardiology 20019555-60
Curriculum Vitae Paul A Gurbel MD Page 14
8 Samara WM Gurbel PA The role of platelet receptors and adhesion molecules in coronary artery disease Coron Artery Dis 20031465-79
9 Gurbel PA Tantry U Clopidogrel response variability and the advent of personalised antiplatelet therapy A bench to bedside journey Thromb Haemost 2011106265-71
10 Gurbel PA Roe MT Jakubowski JA Shah S Erlinge D Goodman SG Huber K Chan MY Cornel JH Tantry US Ohman EM Translational platelet research in patients with coronary artery disease What are the major knowledge gaps Thromb Haemost 2012 May 25108 [Epub ahead of print]
11 Bliden KP Baker BA Nolin TD Jeong YH Bailey WL Tantry US Gurbel PA Thienopyridine efficacy and cigarette smoking status Am Heart J 2013165693-703
12 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
13 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013111547-56
14 Gesheff MG Franzese CJ Bliden KP Contino CJ Rafeedheen R Tantry USGurbel PA Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin Expert Rev Clin Pharmacol 2014 7645-53
15 Tantry US Gesheff M Liu F Bliden KP Gurbel PA Resistance to antiplatelet therapy what progress has been made Expert Opin Pharmacother 2014 9 1-12
16 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print]
17 Gurbel PA Myat A Tantry US Platelet-mediated Thrombosis From Bench to Bedside Cir Res 2015 (in press)
18 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 20161245-58
19 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
20 Gurbel PA Tantry US Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes Heart 2016102882-92
21 Navarese EP Kolodziejczak M Kereiakes DJ Tantry US OConnor C Gurbel PA Proprotein Convertase SubtilisinKexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome A Narrative Review Ann Intern Med 2016164600-7
22 Gurbel PA Jeong YH Navarese EP Tantry US Platelet-Mediated Thrombosis From Bench to Bedside Circ Res 20161181380-91
23 Gurbel PA Myat A Kubica J Tantry US State of the art Oral antiplatelet therapy JRSM Cardiovasc Dis 2016 Jun 152048004016652514 doi 1011772048004016652514 eCollection 2016 Jan-Dec
24 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 2016 Nov 17 [Epub ahead of print] Review
25 Winter MP Grove EL De Caterina R Gorog DA Ahrens I Geisler T Gurbel PA Tantry U Navarese EP Siller-Matula JM Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors Eur Heart J Cardiovasc Pharmacother 2017 Feb 15 doi 101093ehjcvppvw044 [Epub ahead of print]
26 Shah P Tantry US Bliden KP Gurbel PA Bleeding and thrombosis associated with ventricular assist device therapy J Heart Lung Transplant 2017 May 11 pii S1053-2498(17)31789-8
Inventions Patents Copyrights 32294 Gurbel PA Anderson RD Autoperfusion dilatation catheter United States Patent 5295959 51501 Dalesandro MR Gurbel PA Serebruany VL Determining a treatment plan for patients undergoing thrombotic
events by monitoring p-Selectin United States Patent 623071 61201 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6245782 13102 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 20020013343 42203 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6552014
Curriculum Vitae Paul A Gurbel MD Page 15
120611 Gurbel PA The detection of restenosis risk in patients receiving a stent by measuring the characteristics of blood clotting including the measurement of maximum thrombin-induced clot strength (patent awarded pending)
6308 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 7381536 2010 Gurbel PA Conley P Andre P Gretler D Jurek M Methods for diagnosis and treatment of thrombotic
disorders mediated bycyp2c192 (patent pending) 41014 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent
20140100167 81815 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 9110062 111715 Gurbel PA Detection of restenosis risk in patients receiving a stent by measuring the characteristics of
blood clotting including the measurement of maximum thrombin-induced clot strength Patent 9188597 Extramural Funding (since 2002) CURRENT 2010-2015 MAGMA (Multianalyte And Genetic Markers of Atherosclerosis)
Haemonetics and Sinai Hospital of Baltimore 2015-present An Observational Study of CORA-Assisted Stroke Identification and Antithrombotic Therapy
2014-2015 Feasibility clinical trial to evaluate the efficacy of an Anticoagulant cartridge to be used in the CORA System Coramed Technologies LLC
2014-2015 Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid Durlaza in CVD Patients at Risk of High Platelet Turnover (DURATION)
New Haven Pharmaceuticals Inc 2015-present Influence of Edoxaban on Coagulability and Thrombin Generation An in Vitro Study Focusing on
Thrombelastography Daiichi Sankyo
2016 Influence of Vorapaxar on Thrombin Generation and Coagulability Merck 2015-present Durlaza GI GI Tolerability Study New Haven Pharamceuticals 2015-present Thrombogenicity in LVAD Recipients Haemonetics 2014-2015 First-in-Man Assessment of PZ-128 National Institutes of Health PREVIOUS 2002 Atorvastatin in the Treatment of Heart Failure
LBH IRB 20030512 NIHThe National Heart Lung and Blood Institute NIH
2002 Asessment of the In Vitro Effects of Tenecteplase Reteplase and Alteplase on Human Platelets TAR STUDY Genetech
2003-2005 Assessment of the Effects of the heparin-coated Cordis Stent versus Non-coated Stents on Platelet and Endothelial Cell Activation and Thrombin Effect in Patients with Coronary Artery Disease (HEPACOAT) Cordis Inc
2004-2005 The Antiplatelet Effects of Eptifibatide with High and Standard Dose Clopidogrel in Low-Moderate Risk Patients Undergoing Coronary Intervention (CLEAR-PLATELETS Study) MilleniumSchering Plough
2004-2005 The Use of The TEG System to Monitor Platelet Inhibition at Bedside 5R44HL059753-03Haemoscope National Institute of Health
2004-2006 Clopidogrel Resistance in Patients with Stent Thrombosis (CREST Study) AstraZeneca
Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study MilleniumSchering Plough
2005 St Johns Wort Decreases ADP Induced Platelet Reactivity in Known Clopidogrel Resistant Post Coronary Intervention Patients after a Loading Dose of Clopidogrel University of Michigan
2008-2009 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST) Sinai Hospital Department of Medicine
2009-2010 Demonstration of the Pharmacodynamic Antiplatelet Effect of PRT060128 in Patients with High Platelet Reactivity during Clopidogrel and Aspirin Maintenance Therapy (PORTOLA) Portola Pharmaceuticals
2008-2009 A Randomised Double-Blind Outpatient Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND] AstraZeneca Pharmaceuticals LP
2008-2009 A Randomized Double-blind Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Background Therapy in Patients with Stable Coronary Artery Disease with Additional Detailed Assessment of Cardiopulmonary Function (ONSET-OFFSET) AstraZeneca Pharmaceuticals LP
2008-2009 A Single Center Randomized Open Label Parallel Group Pharmacodynamic Study of a Novel Combination Form of Aspirin and Phytosterol versus Aspirin in Healthy Adult Subjects (ARMOR) Bayer Healthcare LLC
2008-2009 Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel Plus EC Aspirin (325 mg) and Clopidogrel Plus PA32540 on Platelet Aggregation in Healthy Volunteers POZEN 110 POZEN Inc
2009-2010 Antithrombosis with Clopidogrel Beyond the Concept of Platelet Aggregate Inhibition (SANOFI) Sanofi Inc 2010-2012 A Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel EC
Aspirin 81 mg and EC omeprazole 40 mg all dosed concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers POZEN Inc
Intramural Funding (since 2002) CURRENT 2008-present Time Based Strategy to Reduce Clopidogrel Associated Bleeding Related to CABG (TARGET CABG) Sinai Hospital of Baltimore Department of Medicine 2009-present Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI)
Sinai Hospital of Baltimore Department of Medicine 2011-present Detection of Leukemic Blood and Solid TypE MalignanCies by Urinary 11-DehydroThromboxane B2 (DETECT) Study
Sinai Hospital of Baltimore Department of Medicine PREVIOUS 2001-2002 Platelet Activation in Stenting PAST Study Sinai Hospital of Baltimore 2005-2006 Platelet Reactivity in Patients with Crohnrsquos disease Receiving Infliximab (chimeric anti-TNF alpha antibody) ndash COIN
Sinai Hospital of Baltimore Department of Medicine 2006-2007 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST)
Sinai Hospital of Baltimore Department of Medicine 2008-2011 Platelet Reactivity and Thrombogenecity in Postmenopausal Women
Sinai Hospital Department of Medicine 2008-2010 Platelet Reactivity and Thrombogenecity in Postmenopausal Women (PRIDE Study)
Sinai Hospital Department of Medicine Multicenter Studies since 2001
Curriculum Vitae Paul A Gurbel MD Page 17
CURRENT 2010-present The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and
Clopidogrel in Aspirin-Treated Subjects With Stable Coronary Artery Disease Daiichi Sankyo
2010-present A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly versus Non-Elderly Aspirin-Treated Subjects with Stable Coronary Artery Disease Eli Lilly amp company
2011-present A Prospective Multicenter Randomized Trial of Clopidogrel versus Prasugrel Anti-platelet Therapy in Cytochrome P450 2C19 (CYP2C19) Intermediate Metabolizers Grant No U01HL105198
NIH National Heart Lung and Blood Institute NIH 2011-present A Prospective Randomized Multi-Center Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHERreg Sirolimus-Eluting Coronary stents
HCRI 2012-present A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in
patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)
Bayer Healthcare LLC 2013-present Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in
Patients at a High-Risk for Vascular Outcomes (ACCELERATE) Eli Lilly amp Company 2014-present A Phase 2b Multi-center Randomized Placebo-controlled Dose-ranging Study to Investigate the
Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infarction
AEGIS CSL 2015-2017 A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety of PZ- 128 in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention
National Institute of Health PREVIOUS 2001 A Randomized Double-Blind Placebo-Controlled Study of Two Intravenous Dosing Regimens of
h5G11-scFv in Patients with Acute Myocardial Infarction Undergoing 2001-2002 Prevention of REStenosis with Tranilast and Its Outcomes A Placebo Controlled Trial PRESTO STUDY
SmithKline Beecham 2002-2003 Taxus IV-SR Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
Boston Scientific 2003 MICROVENA Corporation TRAP Vascular Filtration System (VFS) Trial
Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily Pfizer Inc
2003-2004 Phase 3 Multi-Center Double-Blind Randomized Parallel Group Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily (QD) for 24 Months Compared with Atorvastatin Alone in Subjects with Angiographically Documented Coronary Heart Disease Pfizer Inc
2003-2004 A Randomized Controlled Trial of the Medtronic Endeavor Drug Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ldquoENDEAVOR III Studyrdquo)
Medtronic 2009-2010 A Prospective Randomized Open-label Multicenter study in Patients Presenting with Acute Coronary Syndromes SYNERGY STUDY
Aventis Pharmaceuticals 2004 CObalt chromium STent with Antiproliferative for Restenosis II Trialrdquo Costar study
Conor Medsystems
Curriculum Vitae Paul A Gurbel MD Page 18
2004-2005 A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions ENDEAVOR IV Medtronic
2004-2005 A Randomized Trial to evaluate the relative protection against POST-PCI microvasculat obstruction among antiplatelet and anti-thrombotic medications (TIMI-30) TIMI group
2004-2006 A Double-blind Double-dummy Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI 33 AstraZeneca Lp
2005-2006 Strategy To Reduce Atherosclerosis Development Involving Administration of Rimonabant - The Intravascular Ultrasound Study (STRADIVARIUS) EFC5827 Sanofi Synthelabo Research
2006 A Multicenter Randomized Double-Blind Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (TRASM-PCI) Schering Plough
2006-2007 A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel -SWAP (SWitching Anti Platelet study) Eli Lilly amp Company and Sankyo Company Limited
2006-2007 A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2008-2010 A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary InterventionTIMI-38 Eli Lilly Company Daiichi
2009-2010 A Randomized Double-Blind Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128 a Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Interventions (INNOVATE-PCI) Portola Pharmaceuticals
2010-2012 TReatment with ADPreceptor iNhibitorS Longitudinal Assessment ofTreatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS)
Eli Lilly Company 2010-2013 RADAR Randomized Partially-Blinded Multi-Center Active-Controlled Dose-Ranging Study
Assessing the Safety Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome Regado Bioscience Inc
2011-2013 A Phase IIa Multi-center Randomized Sponsor-unblinded Placebo-controlled Single Ascending Dose Study to Investigate the Safety Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Adults Taking Aspirin and a P2Y12 Platelet Inhibitor
AEGIS CSL Research Program BuildingLeadership 1991-1995 Director Interventional Cardiology Research University of Maryland Medical System 1998-2015 Director Sinai Center for Thrombosis Research 2001-2015 Director Cardiovascular Research Lifebridge Health 2002-2015 Director Therapeutics Research and Technology Development for the Cardiac Catheterization Program Sinai Hospital of Baltimore 2007-2015 Associate Chief for Research Department of Medicine Sinai Hospital of Baltimore 2015-current Director Interventional Cardiology and Cardiovascular Medicine Research INOVA Health 2015-Current Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute EDUCATIONAL ACTIVITIES
Curriculum Vitae Paul A Gurbel MD Page 19
Peer Reviewed Publications-Consensus Statements Expert Opinions 1 Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C
Rao AK The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 200531309-11
2 Hoekstra J Cohen M Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Saucedo JF Pollack CV Jr Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention-an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective report on a roundtable discussion Am J Emerg Med 200927720-8
3 Bonello L Tantry US Marcucci R Blindt R Angiolillo DJ Becker R Bhatt DL Cattaneo M Collet JP Cuisset T Gachet C Montalescot G Jennings LK Kereiakes D Sibbing D Trenk D Van Werkum JW Paganelli F Price MJ Waksman R Gurbel PA Working Group on High On Treatment Platelet Reactivity Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 201056919-33
4 Gurbel PA Tantry US Shuldiner AR Kereiakes DJ Genotyping one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 201056112-6
5 Gurbel PA Tantry US Antiplatelet therapy Clopidogrel-PPI interaction an ongoing controversy Nat Rev Cardiol 201187-8
6 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
7 Gurbel PA Nolin TD Tantry US Clopidogrel efficacy and cigarette smoking status JAMA 20123072495-6 8 Tantry US Bonello L Aradi D Price MJ Jeong YH Angiolillo DJ Stone GW Curzen N Geisler T Ten Berg J
Kirtane A Siller-Matula J Mahla E Becker RC Bhatt DL Waksman R Rao SV Alexopoulos D Marcucci R Reny JL Trenk D Sibbing D Gurbel PA Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding J Am Coll Cardiol 2013622261-73
9 Gurbel PA Tantry US Antiplatelet and anticoagulant agents in heart failure Current status and future perspectives JACC Heart Fail 201421-14
10 Gurbel PA Tantry US Antiplatelet therapy What have we learned from the ANTARCTIC trial Nat Rev Cardiol 201613639-640
Invited Review Articles 1 Gurbel PA Midwall JA Brodie BR Angioplasty and adjunctive intra-aortic balloon pump counterpulsation Current
clinical considerations Todays Therapy Trends 19951363-78 2 OrsquoConnor CM Gurbel PA Serebruany VL Depression and ischemic heart disease Am Heart J 200014063-69 3 Gurbel PA Serebruany VL Oral IIbIIIa inhibitors From initial promise to clinical failures J Thromb and
Thrombolysis 200010217-20 4 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Atar D Serebruany VL Platelets and
Thrombolysis Cooperation or Contrariety Heart Drug 20011281-290 5 McKenzie ME Gurbel PA The potential of monoclonal antibodies to reduce reperfusion injury in myocardial
infarction BioDrugs 200115395-404 6 Gurbel PA Bliden KP Hayes K Tantry U Platelet activation in myocardial ischemic syndromes Expert Rev of
Cardiovasc Ther 20052535-45 7 Tantry US Bliden KP Gurbel PA Resistance to antiplatelet drugs Current status and future research Expert
Opin Pharmacother 200562027-45 8 Gurbel PA Lau WC Bliden KP Tantry US Clopidogrel resistance Implications for coronary stenting Curr Pharm
Des 2006121261-9 9 Gurbel PA Tantry US Drug insight Clopidogrel non-responsiveness Nature ClinPract Cardiovasc Med
20063387-95 10 Gurbel PA Tantry US Aspirin and Clopidogrel Resistance Considerations and management J Interv Cardiol
200619439-48 11 Lau WC Gurbel PA Antiplatelet drug resistance and drug-drug interactions Role of cytochrome P450 3A4
Pharm Res 2006232691-708 12 Wiviott SD Tantry US Gurbel PA Clinical applications of antiplatelet therapy Rev Cardiovasc Med 20067
Curriculum Vitae Paul A Gurbel MD Page 20
130-46 13 Tantry US Bliden KP Gurbel PA Prasugrel Expert Opin Investig Drugs 2006151627-33 14 Gurbel PA Tantry US Clopidogrel Resistance Thromb Res 2007120311-21 15 Tantry US Etherington A Bliden KP Gurbel PA Antiplatelet therapy Current strategies and future trends Future
Cardiology 20072343-366 16 Gurbel PA Tantry US The relationship of platelet reactivity to the occurrence of post-stenting ischemic events
emergence of a new cardiovascular risk factor Rev Cardiovasc Med 2006Suppl 4S20-8 17 Tantry US Bliden KP Gurbel PA AZD6140 Expert Opin Investig Drugs 200716225-9 18 Gurbel PA Tantry US Stent thrombosis role of compliance and non-responsiveness to antiplatelet therapy Rev
Cardiovasc Med 20078S19-S26 19 Gurbel PA Kandzari DE Stent thrombosis associated with first-generation drug-eluting stents issues with
antiplatelet therapy Neth Heart J 200715148-50 20 Gurbel PA Tantry US The role of clopidogrel in cardiovascular diseases Pol Arch Med Wewn 2007117207-9 21 Gurbel PA DiChiara J Tantry US Antiplatelet therapy after implantation of drug-eluting stents duration
resistance alternatives and management of surgical patients Am J Cardiol 200710018M-25M 22 Gurbel PA Becker R Mann KG Steinhubl SR Michelson AD Platelet function monitoring in patients with
coronary artery disease J Am Coll Cardiol 2007501822-34 23 Gurbel PA Tantry US Prasugrel a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig
Drugs 20089324-36 24 Gurbel PA Bilden KP Tantry US Diagnostics for aspirin resistance Mol Diagn Ther 20081255-6 25 Gurbel PA Antonino MJ Tantry US Antiplatelet treatment of cardiovascular disease a translational research
perspective Pol Arch Med Wewn 2008118289-97 26 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831I36 27 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention Clin Cardiol 200831I28-I35
28 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches Clin Cardiol 200831I21-I27
29 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention Clin Cardiol 200831I17-I20
30 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Assessing the Current Role of Platelet Function Testing Clin Cardiol 200831I10-I16
31 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831136
32 Keriakes DJ Gurbel PA Periprocedural platelet function in percutaneous coronary intervention JACC Cardiovasc Interv 2008suppl 1111ndash121
33 Gurbel PA Tantry US The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome J Interv Cardiol 200821Suppl 1S10-7
34 Gurbel PA Tantry US Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 20091122-322
35 Gurbel PA Aspirin scope and limitations Br J Cardiol 200917 (Suppl 1)S8-S9 36 Cohen M Hoekstra J Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Pollack CV Jr
Saucedo JF Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion J Interv Cardiol 200821283-99
37 Angiolillo DJ Bhatt DL Gurbel PA Jennings LK Advances in antiplatelet therapy agents in clinical development Am J Cardiol 2009103(3 Suppl)40A-51A
38 Gurbel PA Mahla E Antonino MJ Tantry US Response variability and the role of platelet function testing J Invasive Cardiol 200921172-8
39 Gurbel PA Antonino MJ Tantry US Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug MetabToxicol Expert Opin Drug Metab Toxicol 20095989-1004
40 Gurbel PA Tantry US Antiplatelet resistance- Fact or Myth Am Hosp J 2009750-57 41 Gurbel PA Mahla E Tantry US Aspirin resistance Prog Cardiovasc Dis 200952141-52 42 Tantry US Gurbel PA Platelet monitoring for PCI Is it really necessary Haemostaseologie 200929 368-75 43 Gurbel PA Aspirin-scope and limitations Br J Cardiol 200917(Suppl 1)S8-S9
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 5
chronic azithromycin therapy on soluble endothelium-derived adhesion molecules in patients with coronary artery disease Cardiovasc Pharmacol 200036533-7
59 Gurbel PA OrsquoConnor CM Dalesandro MR Serebruany VL Relation of soluble and platelet P-selectin to early outcome in patients with acute myocardial infarction after thrombolytic therapy Am J Cardiol 200187774-7
60 Serebruany VL Alford AB Meister AF Fuzaylov SY Gattis WA Gurbel PA Clinical utility of the platelet function analyzer (PFA-100) for the Assessment of the Platelet Status in Patients with Congestive Heart Failure (EPCOT trial) Thromb Res 200115427-33
61 Serebruany VL Gurbel PA OrsquoConnor CM Platelet inhibition by sertraline and n-desmethylsertraline A possible missing link between depression coronary events and mortality benefits of selective serotonin reuptake inhibitors Pharmacol Res 200143453-62
62 Serebruany VL OrsquoConnor CM Gurbel PA Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease Am J Cardiol 2001871398-400
63 Serebruany VL Levine DJ Nair GV Meister AF Gurbel PA Usefulness of combining necrosis and platelet markers in triaging patients presenting with chest pain to the emergency department J Thromb and Thrombolysis 200111155-62
64 Serebruany VL Cummings CC Malinin AI Steinhubl SR Gurbel PA Uniform platelet activation exists before coronary stent implantation despite aspirin therapy Am Heart J 2001142611-16
65 Gurbel PA Fusaylov SF Gattis WA Gaulden L Hasselblad V Serebruany VL OrsquoConnor CM Evaluation of platelets in heart failure Is platelet activity related to etiology class or clinical outcomes Am Heart J 20021431068-75
66 Gurbel PA Malinin AI Callahan KP Serebruany VL OrsquoConnor CM Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and GP IIbIIIa expression and platelet-leukocyte aggregate formation Am J Cardiol 200290312-315
67 Bahr RD Gurbel PA Malinin AI Wentz C Christenson RH Roe MT Gibler WB Kitt MM Ohman EM Serebruany VL Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q wave acute myocardial infarction Am J Cardiol 200290310-312
68 Faxon DP Gibbons RJ Chronos NAF Gurbel PA Sheehan F for the HALT ndash MI Investigators The effect of blockade of the CD11CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty The results of the HALT- MI study J Am Coll Cardiol 2002401199-1204
69 Serebruany VL McKenzie M Meister A Fuzaylov S Gurbel P Atar D Gattis W OrsquoConnor C Whole blood impedence aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT Trial) Eur J Heart Fail 20024461
70 Serebruany V McKenzie ME Meister AF Fuzaylov SY Gurbel PA Atar D Gattis WA OrsquoConnor CM Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT Trial with special reference to the Hemodyne hemostatic analyzer Pathophysiol Haemost Thromb 2002328-15
71 Gurbel PA Callahan KP Malinin AI Serebruany VL Gillis J Could stent design affect platelet activation Results of the Platelet Activation in Stenting (PAST) study J Invasive Cardiol 200214584-9
72 Gurbel PA Galbutt B Bliden KP Bahr RD Roe MT Serebruany VL Ohman EM Effect of eptifibatide for acute coronary syndromes Rapid versus late administration-therapeutic yield on platelets (the EARLY platelet substudy) J Thromb Thrombolysis 200314213-219
73 Gurbel PA Cummings CC Alford AB Meister AF Serebruany VL Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting The Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial Am Heart J 2003145239-47
74 Serebruany VL Malinin AI Callahan KP Binbrek A Van de Werf F Alexander JH Granger CB Gurbel PA Effect of tenecteplase versus alteplase on platelets during the first three hours of treatment for acute myocardial infarction The ASSENT-2 Platelet Substudy Am Heart J 2003145636-42
75 Gurbel PA Bliden KP Durability of platelet inhibition by clopidogrel Am J Cardiol 2003911123-5 76 Gurbel PA Bliden KP Hiatt BL The early antiplatelet effects of clopidogrel loading for coronary stenting and the
long term stability of inhibition J Thromb Haemost 200311319-21 77 Gurbel PA Bliden KP Hiatt BL Clopidogrel for coronary stenting Response variability drug resistance and the
effect of pretreatment platelet reactivity Circulation 20031072908-13 78 Serebruany VL Malinin AI OrsquoConnor CM Gurbel PA Effects of roxifiban on platelet aggregation and major
receptor expression in patients with coronary artery disease For the Roxifiban Oral Compound Kinetics Evaluation Trial ndash I Am Heart J 200314691-8
79 Gurbel PA Bliden KP Platelet activation after stenting with heparin-coated versus non-coated stents Am Heart J 2003146E10
Curriculum Vitae Paul A Gurbel MD Page 6
80 Gurbel PA Bliden KP A new method of representing drug-induced platelet inhibition Better description of time course response variability non-response and heightened reactivity Platelets 200314481-3
81 Gurbel PA Bliden KP The stratification of platelet reactivity and activation in patients with stable coronary disease on aspirin therapy Thromb Res 20031129-12
82 Gurbel PA Samara WM Bliden KP Failure of clopidogrel to reduce platelet reactivity an activation following standard dosing in elective stenting Implications for thrombotic events and restenosis Platelets 20031595-99
83 Lau WC Gurbel PA Watkins PB Neer CJ Hopp AS Carville DGM Guyer KE Tait AR Bates ER The contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 200410966-71
84 Joynt KE Gattis WA Hasselblad V Fuzaylov SY Serebruany VL Gurbel PA Gaulden LH Felker GM Whellan DJ OrsquoConnor CM Effect of angiotensin-converting enzyme inhibitors beta blockers statins and aspirin on C-reactive protein levels in outpatients with heart failure Am J Cardiol 200493783-5
85 Samara WM Bliden KP Tantry U Gurbel PA Thrombotic risk The difference between clopidogrel responsiveness and post-treatment platelet reactivity Thromb Res 200411589-94
86 Gurbel PA Hayes KA Bliden KP Yoho J Tantry U The platelet-related effects of tenecteplase vs alteplase vs reteplase Blood Coag Fibrinolysis 2005161-7
87 Gurbel PA Bliden KP Zaman KA Yoho JA Hayes KM Tantry US Clopidogrel loading with eptifibatide to arrest the reactivity of platelets Results of the CLEAR PLATELETS study Circulation 20051111153-9
88 Poston R Gu J Brown J Gammie J White C Manchio J Pierson RN Griffith P Gurbel P Tantry U Gilbert TB Hypercoaguability affecting early vein graft patency does not exist after off-pump coronary artery bypass J Cardiothoracic Vasc Anesth 20051911-18
89 Gurbel PA Bliden KP Hates KM Yoho JA Herzog WR Tantry US The relation of dosing to clopidogrel responsiveness and the incidence of high post-stent platelet aggregation in patients undergoing coronary stenting J Am Coll Cardiol 2005451392-6
90 Hermiller JB Raizner A Cannon L Gurbel PA Kutcher MA Wong SC Russell ME Ellis SG Mehran R Stone GW TAXUS-IV Investigators Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus The TAXUS-IV trial J Am Coll Cardiol 2005451172-9
91 Gurbel PA Bliden KP Samara W Yoho J Hayes K Fissha M Tantry U Clopidogrel Effect on Platelet REactivity in Patients with Stent Thrombosis Results of the CREST Study J Am Coll Cardiol 2005461827-32
92 Gurbel PA Bliden KP Guyer K Cho P Zaman K Kreutz R Bassi A Tantry US Platelet REactivity in Patients And Recurrent Events POST-STENTING Results of the PREPARE POST-STENTING Study J Am Coll Cardiol 2005461820-6
93 Tantry US Bliden KP Gurbel PA Overestimation of platelet aspirin resistance Detection by thrombelastograph platelet mapping and validation by conventional aggregation using arachidonic acid stimulation J Am Coll Cardiol 2005461705-9
94 Kreutz RP Tantry US Bliden KP Gurbel PA Viral respiratory tract infections increase platelet reactivity and activation - an explanation for the higher rates of myocardial infarction and stroke during viral illness J Thromb Haemost 200532108-9
95 Bleske B Nicklas J Bard R Brook R Gurbel PA Bliden K Rajagopalan S Pitt B Neutral effect on markers of heart failure inflammation endothelial activation and function and vagal tone following high dose HMG - coA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low density lipoproteins J Am Coll Cardiol 200647338-41
96 Gurbel PA Bliden KP Tantry US Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting Inflammation results from the CLEAR PLATELETS-1b study J Am Coll Cardiol 2006482186-91
97 Kandzari DE Leon MB Popma JJ Fitzgerald PJ OrsquoShaughnessy C Ball MW Turco M Applegate RJ Gurbel PA et alfor the ENDEAVOR III Investigators Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease a randomized controlled trial J Am Coll Cardiol 2006482440 ndash 2447
98 Gurbel PA Bliden KP Guyer K Aggarwal N Tantry US Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting Thromb Res 2007119563-70
99 Bliden KP DiChiara J Tantry US Bassi AK Chaganti SK Gurbel PA Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention is the current antiplatelet therapy adequate J Am Coll Cardiol 200749657-66
100 Gurbel PA Bliden KP Etherington A Tantry US Assessment of clopidogrel responsiveness measurements of maximum platelet aggregation final platelet aggregation and their correlation with vasodilator stimulated phosphoprotein in resistant patients Thromb Res 2007121107-15
101 Gurbel PA Bliden KP DiChiara J Gesheff T RN Chaganti S Etherington A MD Tantry US Evaluation of
Curriculum Vitae Paul A Gurbel MD Page 7
dose-related effects of aspirin on platelet function results from the ASpirin-Induced Platelet EffeCT (ASPECT) study Circulation 20071153156-64
102 Kreutz RP Tantry US Bliden KP Gurbel PA Inflammatory changes during the common cold are associated with platelet activation and increased reactivity of platelets to agonists Blood Coagul Fibrinolysis 200718713-8
103 Storey R Husted S Harrington R Heptinstall S Wilcox R Peters G Wickens Emanuelsson H Gurbel PA Grande P Cannon C Inhibition of platelet aggregation by AZD6140 a reversible oral P2Y12 receptor antagonist compared with clopidogrel in patients with acute coronary syndromes J Am Coll Cardiol 2007501852-6
104 DiChiara J Bliden KP Tantry US Hamed MS Antonino MJ Suarez TA Bailon O Singla A Gurbel PA The effect of aspirin dosing on platelet function in diabetic and non-diabetic patients an analysis from the aspirin-induced platelet effect (ASPECT) study Diabetes 200756 3014-9
105 DiChiara J Bliden KP Tantry US Chaganti SK Kreutz R Gesheff TB Kreutz Y Gurbel PA Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients Platelets 200718 414-23
106 Gurbel PA Kreutz RP Bliden KP Tantry US Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease a potential approach to identify atherosclerotic disease progression Am Heart J 200815555-61
107 Gurbel PA Bliden KP Cohen E Navickas IA Singla A Antonino MJ Fissha M Kreutz RP Bassi AK Tantry US Race and sex differences in thrombogenicity risk of ischemic events following coronary stenting Blood Coagul Fibrinolysis 200819268-75
108 Nissen SE Nicholls SJ Wolski K Rodeacutes-Cabau J Cannon CP Deanfield JE Despreacutes JP Kastelein JJ Steinhubl SR Kapadia S Yasin M Ruzyllo W Gaudin C Job B Hu B Bhatt DL Lincoff AM Tuzcu EM STRADIVARIUS Investigators Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease the STRADIVARIUS randomized controlled trial JAMA 20082991547-60
109 Bliden KP DiChiara J Lookman L Singla A Antonino MJ Baker BA Bailey WL Tantry US Gurbel PA The association of cigarette smoking with enhanced platelet inhibition by clopidogrel J Am Coll Cardiol 200852531-3
110 Gurbel PA Antonino MJ Bliden KP Dichiara J Suarez TA Singla A Tantry US Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention a potential antiplatelet therapeutic target Platelets 200819595-604
111 Gurbel PA Bliden KP Cohen E Navickas IA Singla A Antonino MJ Fissha M Kreutz RP Bassi AK Tantry US Race and sex differences in thrombogenicity risk of ischemic events following coronary stenting Blood Coagul Fibrinolysis 200819268-75
112 Gurbel PA Antonino MJ Bliden KP Dichiara J Suarez TA Singla A Tantry US Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention a potential antiplatelet therapeutic target Platelets 200819595-604
113 Hamed MS Gambert S Bliden KP Bailon O Anand S Antonino MJ Hamed F Tantry US Gurbel PA Dark chocolate effect on platelet activity C-reactive protein and lipid profile a pilot study S Med J 20081011203-8
114 Gilstad JR Gurbel PA Andersen RE Relationship between age and platelet activation in patients with stable and unstable angina Arch Gerontol Geriatr 200948155-9
115 Gurbel PA Bliden KP Saucedo JF Suarez TA DiChiara J Antonino MJ Mahla E Singla A Herzog WR Bassi AK Hennebry TA Gesheff TB Tantry US Bivalirudin and clopidogrel with and without eptifibatide for elective stenting effects on platelet function thrombelastographic indices and their relation to periprocedural infarctionResults of the CLEAR PLATELETS-2 study J Am Coll Cardiol 200953857-9
116 Gurbel PA Bliden KP Kreutz RP DiChiara J Antonino MJ Tantry US The link between heightened thrombogenicity and inflammation Pre-procedure characterization of the patient at high risk for recurrent events after stenting Platelets 20092097-104
117 Antonino MJ Mahla E Bliden KP Tantry US Gurbel PA Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting Am J Cardiol 20091031546-50
118 Antonino MJ Coppolecchia R Mahla E Bliden KP Tantry US Gurbel PA Antiplatelet effects of aspirin with phytosterols Comparison with non-enteric coated aspirin alone Thromb Res 2009126384-5
119 Pinto Slottow TL Bonello L Gavini R Beauzile P Sushinsky SJ Scheinowitz M Kaneshige K Xue Z Torguson R Tantry U Pichard AD Satler LF Suddath WO Kent K Gurbel P Waksman R Am J Cardiol 2009104525-30
120 Shuldiner AR OConnell JR Bliden KP Gandhi A Ryan K Horenstein RB Damcott CM Pakyz R Tantry US Gibson Q Pollin TI Post W Parsa A Mitchell BD Faraday N Herzog W Gurbel PA Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyJAMA2009302849-57
121 Singla A Antonino MJ Bliden KP Tantry US Gurbel PA The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy Am Heart J 2009158784e1-6
122 Gurbel PA Bliden KP Antonino MJ Stephens G Gretler DD Jurek MM Pakyz RE Shuldiner AR Conley PB
Curriculum Vitae Paul A Gurbel MD Page 8
Tantry US The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP 2C192 genotype First experience in patients J Thromb Haemost 2010843-53
123 Gurbel PA Bliden KP Butler K Tantry US Gesheff T Wei C Teng R Antonino MJ Patil SB Karunakaran A Kereiakes DJ Parris C Purdy D Wilson V Ledley GS Storey RF Randomized double-blind assessment of the ONSET and OFFSet of the antiplatelet Effects of Ticagrelor versus clopidogrel in patients with stable coronary artery disease The ONSETOFFSET Study Circulation 20091202577-85
124 Gurbel PA Bliden K Antonino M Butler K Teng R Rasmussen L Syd A Storey R Nielsen T Eikelboom J Sabe-Affaki G Husted S Kereaikes D Henderson D Patel V Tantry U Response to Ticagrelor in Clopidogrel Non-responders and ReSPONDers and the Effect of Switching Therapies The RESPOND Study Circulation 20101211188-99
125 Tantry US Bliden KP Suarez TA Kreutz RP DiChiara J Gurbel PA Hypercoagulability platelet function inflammation and coronary artery disease acuity results of the Thrombotic Risk Platelets 201021 360-7
126 Hennekens CH Schneuder WR Hebert PR Tantry US Gurbel PA Hypothesis formulation from subgroup analyses non-adherence or non-steroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to ldquoaspirin resistancerdquo Am Heart J 2010159744-8
127 Storey RF Bliden KP Patil SB Karunakaran A Ecob R Butler K Teng R Wei C Tantry US Gurbel PA ONSETOFFSET Investigators Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor clopidogrel or placebo in the ONSETOFFSET study J Am Coll Cardiol 201056185-93
128 Gurbel PA Bliden KP Navickas IA Mahla E Dichiara J Suarez TA Antonino MJ Tantry US Cohen E Adenosine diphosphate-induced platelet-fibrin clot strength a new thrombelastographic indicator of long-term poststenting ischemic events Am Heart J 2010160346-54
129 Angiolillo DJ Saucedo JF Deraad R Frelinger AL Gurbel PA Costigan TM Jakubowski JA Ojeh CK Effron MB SWAP Investigators Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes results of the SWAP (SWitching Anti Platelet) study J Am Coll Cardiol 2010561017-23
130 Mega JL Simon T Collet JP Anderson JL Antman EM Bliden K Cannon CP Danchin N Giusti B Gurbel P Horne BD Hulot JS Kastrati A Montalescot G Neumann FJ Shen L Sibbing D Steg PG Trenk D Wiviott SD Sabatine MS Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI a metaanalysis JAMA 20103041821-30
131 Tantry US Bliden KP Wei C Storey RF Armstrong M Butler K Gurbel PA First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel The ONSETOFFSET and RESPOND Genotype Studies Circ Cardiovasc Genet 20103556-66
132 Lau WC Welch TD Shields T Rubenfire M Tantry US Gurbel PA The Effect of St Johns Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients Increased Platelet Inhibition by Enhancement of CYP 3A4 Metabolic Activity J Cardiovasc Pharmacol 20115786-93
133 Gurbel PA Shuldiner AR Bliden KP Ryan K Pakyz RE Tantry US The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy Am Heart J 2011161598-604
134 Kandzari DE Mauri L Popma JJ Turco MA Gurbel PA Fitzgerald PJ Leon MB Late-Term Clinical Outcomes With Zotarolimus-and Sirolimus-Eluting Stents 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) JACC Cardiovasc Interv 20114543-50
135 Storey RF Bliden KP Ecob R Karunakaran A Butler K Wei C Tantry U Gurbel PA Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared to clopidogrel in patients with high antiplatelet responses J Thromb Haemost 201191730-7
136 Bliden KP Tantry US Storey RF Jeong YH Gesheff M Wei C Gurbel PA The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity Combined analysis of the ONSETOFFSET and RESPOND studies Am Heart J 2011162160-5
137 Lewis JP Fisch AS Ryan K OrsquoConnell JR Gibson Q Mitchell BD Shen H Tanner K Horenstein RB Pakzy R Tantry US Bliden KP Gurbel PA and Shuldiner AR ( equal contribution) Paraoxonase 1 (PON1) Gene Variants Are Not Associated With Clopidogrel Response Clinical Pharm Ther 201190568-74
138 Navarese EP Kozinski M Obonska K Margheri M Gurbel PA Kubica J De Luca G Clinical efficacy and safety of intracoronary vs intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention A meta-analysis of randomized trials Platelets 2011 (in press)
139 Navarese EP De Luca G Castriota F Kozinski M Gurbel P MD Gibson CM Andreotti F Siller-MatulaJM Pafundi T Sukkenik A De Servi S Kubica J Low-molecular-weight heparins vs unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction A meta-analysis J
Curriculum Vitae Paul A Gurbel MD Page 9
Thromb Haemost 201191902-15) 140 Jeong YH Tantry US Kim I-S Koh J-S Kwon TJ Park Y Hwang SJ Bliden KP Kwak CH Hwang J-W
Gurbel PA Effect of CYP2C192 and 3 loss-of-function allele carriage on platelet reactivity and adverse clinical event occurrence in east asian acute myocardial infarction survivors treated with clopidogrel and aspirin Circ Cardiovasc Genet 20114585-94
141 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
142 Gurbel PA Bliden KP Firt J Zhang Y Plachetka JR Antonino M Gesheff M Tantry US Pharmacodynamic evaluation of clopidogrel plus PA32540 The Spaced PA32540 with Clopidogrel INteraction Gauging (SPACING) study Clin Pharmacol Ther 201190860-6
143 Navarese EP Buffon A Andreotti F Gurbel PA Kozinski M Kubica A Musumeci G Cremonesi A Tavazzi L Kubica J Castriota F Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome A meta-analysis of randomized trials Atherosclerosis 20122221-7
144 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 201210487-9
145 Gurbel PA Bliden KP Antonino MJ Gesheff T Cummings CC Dubois BV Herzog WR Tantry US Time dependence of clopidogrel loading effect Platelet activation versus platelet aggregation Thromb Res Thromb Res 20121291-2
146 Mahla E Suarez TA Bliden KP Rehak P Metzler H Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study Circ Cardiovasc Interv 20125261-9
147 Park Y Jeong YH Tantry US Ahn JH Kwon TJ Park JR Hwang SJ Gho EH Bliden KP Kwak CH Hwang JY Kim S Gurbel PA Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study Eur Heart J 2012332151-62
148 Husted SE Storey RF Bliden K Tantry US Hoslashimark L Butler K Wei C Teng R Gurbel PA Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease Results from the ONSET-OFFSET and RESPOND Studies Clin Pharmacokinet 201251397-409
149 Kubica J Koziński M Navarese EP Tantry US Grześk G Fabiszak T Kubica A Swiątkiewicz I Bliden KP Gurbel PA Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction A systematic review and meta-analysis of randomized clinical trials Cardiol J 201219(3)230-42 Jeong YH Bliden KP Antonino MJ Tantry US Gurbel PA Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity Platelets 2012 May 30 [Epub ahead of print]
150 Welsh RC Rao SV Zeymer U Thompson VP Huber K Kochman J McClure MW Gretler DD Bhatt DL Gibson CM Angiolillo DJ Gurbel PA Berdan LG Paynter G Leonardi S Madan M French WJ Harrington RA on behalf of the INNOVATE PCI Investigators A Randomized Double-Blind Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention The INNOVATE-PCI Trial Circ Cardiovasc Interv 20125336-346
151 Angiolillo DJ Welsh RC Trenk D Neumann FJ Conley PB McClure MW Stephens G Kochman J Jennings LK Gurbel PA Woacutejcik J Dabrowski M Saucedo JF Stumpf J Buerke M Broderick S Harrington RA Rao SV Pharmacokinetic and Pharmacodynamic Effects of Elinogrel Results of the Platelet Function Substudy From the Intravenous and Oral Administration of Elinogrel to Evaluate Tolerability and Efficacy in Nonurgent Percutaneous Coronary Intervention Patients (INNOVATE-PCI) Trial Circ Cardiovasc Interv 20125347-56
152 Reny JL Combescure C Daali Y Gurbel PA Fontana P PON1 Meta-Analysis Group Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events a systematic review and meta-analysis J Thromb Haemost 2012101242-1251
153 Jeong YH Bliden KP Antonino MJ Park KS Tantry US Gurbel PA Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies Am Heart J 201216435-42
154 Jeong YH Bliden KP Antonino MJ Tantry US Gurbel PA Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity Platelets 201216435-42
155 Singla A Bliden KP Jeong YH Abadilla K Antonino MJ Muse WC Mathew DP Bailon O Tantry US Gurbel PA Platelet reactivity and thrombogenecity in postmeopausal women Menopause 20132057-63
156 Jeong YH Tantry US Park Y Kwon TJ Park JR Hwang SJ Bliden KP Koh EH Kwak CH Hwang JY Kim S
Curriculum Vitae Paul A Gurbel MD Page 10
Gurbel PA Pharmacodynamic Effect of Cilostazol Plus Standard Clopidogrel Versus Double-Dose Clopidogrel in Patients With Type 2 Diabetes Undergoing Percutaneous Coronary Intervention Diabetes Care 2012352194-7
157 Roe MT Armstrong PW Fox KAA White HD Prabhakaran D Goodman SG Cornel JH Bhatt DL Clemmensen P Martinez F Ardissino D Nicolau JC Boden WE Gurbel PA Ruzyllo W Dalby AJ McGuire DK Leiva-Pons JL Parkhomenko A Gottlieb S Topacio GO Hamm C Pavlides G Goudev AR Oto A Tseng C-D Merkely B Gasparovic V Corbalan R Cinteză M McLendon RC Winters KJ Brown EB Lokhnygina Y Aylward PE Huber K Hochman JS E Magnus Ohman EM for the TRILOGY ACS Investigators Prasugrel versus clopidogrel for ACS patients managed without revascularization N Engl J Med 20123671297-309
158 Gurbel PA Bliden KP Jeong Y-H Antonino M Gesheff T Fort JG Shuldiner A Chai S Gesheff M Zhang Y Tantry US Spaced Administration of PA32540 and Clopidogrel Results in Greater Platelet Inhibition than Synchronous Administration of Enteric-Coated Aspirin and Enteric-Coated Omeprazole and Clopidogrel Am Heart J 2013165176-82
159 Gurbel PA Erlinge D Ohman EM Neely B Neely M Goodman SG Huber K Chan MY Cornel JH Brown E Zhou C Jakubowski JA White HD Fox KA Prabhakaran D Armstrong PW Tantry US Roe MT TRILOGY ACS Platelet Function Substudy Investigators JAMA 20123081785-94
160 Lewis JP Horenstein RB Ryan K OConnell JR Gibson Q Mitchell BD Tanner K Chai S Bliden KP Tantry US Peer CJ Figg WD Spencer SD Pacanowski MA Gurbel PA Shuldiner AR The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response Pharmacogenet Genomics 2012 Pharmacogenet Genomics 2013231-8
161 Jeong YH Tantry US Min JH Park Y Navarese EP Koh JS Park JR Hwang SJ Kho EH Bliden KP Kwak CH Hwang JY Kim S Gurbel PA Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention Int J Cardiol 2012 Oct 12 doipii S0167-5273(12)01253-3 101016
162 Saucedo JF Angiolillo DJ Deraad R Frelinger AL 3rd Gurbel PA Costigan TM Jakubowski JA Ojeh CK Duvvuru S Effron MB for the SWAP Investigators Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel insights from the switching anti-platelet (SWAP) study Thromb Haemost 2012 Dec 6109(2) [Epub ahead of print]
163 Navarese EP Austin D Gurbel PA Andreotti F Tantry U James S Buffon A Kozinski M Obonska K Bliden K Jeong YH Kubica J Kunadian V Drug-coated balloons in treatment of in-stent restenosis a meta-analysis of randomized controlled trials Clin Res Cardiol 2012 Dec 20 [Epub ahead of print]
164 Gurbel PA Bliden KP Fort JG Jeong YH Shuldiner A Chai S Gesheff T Antonino M Gesheff M Zhang Y Tantry US Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel Am Heart J 2013165176-82
165 Lewis JP Ryan K OConnell JR Horenstein RB Damcott CM Gibson Q Pollin TI Mitchell BD Beitelshees AL Pakzy R Tanner K Parsa A Tantry US Bliden KP Post WS Faraday N Herzog W Gong Y Pepine CJ Johnson JA Gurbel PA Shuldiner AR Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes Circ Cardiovasc Genet 2013 Feb 7 [Epub ahead of print]
166 Navarese EP Gurbel PA Andreotti F Tantry U Jeong YH Kozinski M Engstroslashm T Di Pasquale G Kochman W Ardissino D Kedhi E Stone GW Kubica J Optimal Timing of Coronary Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes A Systematic Review and Meta-analysis Ann Intern Med 2013158261-70
167 Jeong YH Abadilla KA Tantry US Park Y Koh JS Kwak CH Hwang JY Gurbel PA Influence of CYP2C192 and 3 loss-of-function alleles on pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention the results of the ACCEL-DOUBLE-2N3 studyJ Thromb Haemost 2013111194-7
168 Gurbel PA Bliden KP Logan DK Kereiakes DJ Lasseter KC White A Angiolillo DJ Nolin TD Maa JF Bailey WL Jakubowski JA Ojeh CK Jeong YH Tantry US Baker BA The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel The PARADOX Study J Am Coll Cardiol 2013 Apr 16 doipii S0735-1097(13)01478-2 101016jjacc201303037 [Epub ahead of print]
169 Grzesk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E4 Jeong Y-H Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 2013 Article ID 928271 httpdxdoiorg1011552013928271
170 Erlinge D Gurbel PA James S Lindahl TL Svensson P Ten Berg JM Foley DP Wagner H Brown PB Luo J Zhou C Moser BA Jakubowski JA Small DS Winters KJ Angiolillo DJ Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains non-inferiority to prasugrel 10-mg in non-elderly patients The GENERATIONS trial a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients J Am Coll Cardiol 201362577-83
Curriculum Vitae Paul A Gurbel MD Page 11
171 Kim IS Jeong YH Tantry US Park Y Lee DH Bliden KP Koh JS Park JR Jang JS Hwang SJ Koh EH Kwak CH Hwang JY Kim S Gurbel PA Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading Am Heart J 201316695-103
172 Grześk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E Jeong YH Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 20132013928271
173 Stone GW Witzenbichler B Weisz G Rinaldi MJ Neumann FJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri E Gurbel PA Xu K Parise H Kirtane AJ Brodie BR Mehran R Stuckey TD for the ADAPT-DES Investigators Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES) a prospective multicentre registry study Lancet 2013382614-23
174 Angiolillo DJ Curzen N Gurbel P Vaitkus P Lipkin F Li W Jakubowski JA Zettler M Effron MB Trenk D Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in subjects with stable coronary artery disease Results of the SWAP-2 Study J Am Coll Cardiol 2014631500-9
175 Jeong YH Bliden KP Shuldiner AR Tantry US Gurbel PA Thrombin-induced platelet-fibrin clot strength Relation to high on-clopidogrel platelet reactivity genotype and post-percutaneous coronary intervention outcomes Thromb Haemost 2014111713-24
176 Gouya G Arrich J Wolzt M Huber K Verheugt FW Gurbel PA Pirker-Kees A Siller-Matula JM Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases a systematic review and meta-analysis Stroke 201445492-503
177 Erlinge D James S Duvvuru S Jakubowski JA Wagner H Varenhorst C Tantry US Brown PB Small D Moser BA Sundseth S Walker JR Winters KJ Gurbel PA Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease Thromb Haemost 2014111943-50
178 Gurbel PA Baker BA Bailey WL Bliden KP Tantry US Unraveling the Smokers Paradox Cigarette smoking high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors Thromb Haemost 20141111187-90
179 Koh JS Kim IS Tantry US Yoon SE Park Y Cho SY Lee EJ Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading The results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study Int J Cardiol 2014174129-32
180 Bliden KP Singla A Gesheff MG Toth PP Tabrizchi A Ens G Guyer K Singh M Franzese CJ Stapleton D Tantry US Gurbel PA Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin Thromb Haemost 2014 Apr 24112(2) [Epub ahead of print]
181 Gurbel PA Gesheff MG Franzese CJ Bliden KP Tantry US Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy Platelets 201526608-9
182 Gurbel PA Bergmeijer TO Tantry US Ten Berg JM Angiolillo DJ James S Lindahl TL Svensson P Jakubowski JA Brown PB Duvvuru S Sundseth S Walker JR Small D Moser BA Winters KJ Erlinge D The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease Thromb Haemost 2014 2014112589-97
183 Cornel JH Ohman EM Neely B Clemmensen P Sritara P Zamoryakhin D Armstrong PW Prabhakaran D White HD Fox KA Gurbel PA Roe MT TRILOGY ACS Investigators Impact of smoking status on platelet function and clinical outcomes with prasugrel vs clopidogrel in patients with acute coronary syndromes managed without revascularization Insights from the TRILOGY ACS trial Am Heart J 201416876-87
184 Park Y Jung JM Tantry US Kim K Koh JS Park JR Hwang SJ Kwak CH Hwang JY Kim S Gurbel PA Jeong YH Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration The ACCEL-PARAZOL Study J Atheroscler Thromb 2014211121-39
185 Park Y Jeong YH Tantry US Ahn JH Kim K Koh J Park J Hwang SJ Kwak CH Hwang JY Gurbel PA Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity The Resultof the ACCEL-DIP Study Thromb Haemost 2014112 [Epub ahead of print]
186 Lev EI Bliden KP Jeong Y-H Pandya S Kang K Franzese C Tantry US Gurbel PA Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients J Am Heart Assoc 20143e001167
187 Alexopoulos D Xanthopoulou I Storey RF Bliden KP Tantry US Angiolillo DJ Gurbel PA Platelet reactivity during ticagrelor maintenance therapy A patient-level data meta-analysis Am Heart J 2014 168530-6
188 Lhermusier T Lipinski MJ Tantry US Escarcega RO Baker N Bliden KP Magalhaes MA Ota H Tian W Pendyala L Minha S Chen F Torguson R Gurbel PA Waksman R Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity Am J Cardiol 2015115716-23
189 Franzese CJ Bliden KP Gesheff MG Pandya S Guyer KE Singla A Tantry US Toth PP Gurbel PA Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy Am J Cardiol 2015 11151204-11
Curriculum Vitae Paul A Gurbel MD Page 12
190 Aradi D Kirtane A Bonello L Gurbel PA Tantry US Huber K Freynhofer MK Ten Berg J Janssen P Angiolillo DJ Siller-Matula JM Marcucci R Patti G Mangiacapra F Valgimigli M Morel O Palmerini T Price MJ Cuisset T Kastrati A Stone GW Sibbing D Bleeding and stent thrombosis on P2Y12-inhibitors collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention Eur Heart J 2015361762-71
191 Navarese EP Kolodziejczak M Schulze V Gurbel PA Tantry U Lin Y Brockmeyer M Kandzari DE Kubica JM DAgostino RB Sr Kubica J Volpe M Agewall S Kereiakes DJ Kelm M Effects of proprotein convertase subtilisinkexin type 9 antibodies in adults with hypercholesterolemia a systematic review and meta-analysis Ann Intern Med 201516340-51
192 Lee K Yoo SY Suh J Park KH Park Y Tantry US Park KS Han SH Kang WC Shin DH Lee C Choi SW Lee JH Cho YH Lee NH Jeong MH Ahn Y Kubica J Gurbel PA Park JH Jeong YH Efficacy of cilostazol on inhibition of platelet aggregation inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study Int J Cardiol 2015190370-5
193 Kowalewski M Schulze V Berti S Waksman R Kubica J Kołodziejczak M Buffon A Suryapranata H Gurbel PA Kelm M Pawliszak W Anisimowicz L Navarese EP Complete revascularisation in ST-elevation myocardial infarction and multivessel disease meta-analysis of randomised controlled trials Heart 2015 1011309-17
194 Baber U Mehran R Kirtane AJ Gurbel PA Christodoulidis G Maehara A Witzenbichler B Weisz G Rinaldi MJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri EL Jr Xu K Parise H Brodie BR Stuckey TD Stone GW Prevalence and impact of high platelet reactivity in chronic kidney disease Results from the assessment of dual antiplatelet therapy with drug-eluting stents registry Circ Cardiovasc Interv 20158e001683
195 Tricoci P DAndrea DM Gurbel PA Yao Z Cuchel M Winston B Schott R Weiss R Blazing MA Cannon L Bailey A Angiolillo DJ Gille A Shear CL Wright SDAlexander JH Infusion of Reconstituted High-Density Lipoprotein CSL112 in Patients With Atherosclerosis Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial J Am Heart Assoc 20154 pii e002171
196 Reny JL Fontana P Hochholzer W Neumann MJ ten Berg J Janssen PF Geisler T Gawaz M Marcucci R Gori A-M Cuisset T Alessi M-S Berdagueacute P Gurbel PA Yong G Angiolillo DJ Aradi D Beigel R Campo G Combescure C Vascular risk levels affect the predictive value of platelet reactivity 1 for the occurrence of major adverse cardiovascular events in patients on clopidogrel Systematic review and collaborative meta-analysis of individual patient data Thromb Haemost 2015 (in press)
197 Chaudhary R Bliden KP Tantry US Mohammed N Mathew D Gesheff MG Franzese CJ Gurbel PA Association of weight gain with coronary artery disease inflammation and thrombogenicity J Thromb Thrombolysis 2015 Dec 29 [Epub ahead of print]
198 Gurbel PA Bliden KP Turner SE Tantry US Gesheff MG Barr TP Covic L Kuliopulos A Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease Arterioscler Thromb Vasc Biol 201636189-97
199 Kwon TJ Tantry US Park Y Choi YM Ahn JH Kim KH Koh JS Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Smith SC Jr Jeong YH Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention Results of the ACCEL-BLEED study Thromb Haemost 2016 Jan 21115(5) [Epub ahead of print]
200 Bliden KP Tantry US Gesheff MG Franzese CJ Pandya S Toth PP Mathew DP Chaudhary R Gurbel PA Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis J Interv Cardiol 201629168-78
201 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin J Diabetes Complications 2016 May 10 pii S1056-8727(16)30127-1
202 Bedeir K Bliden K Tantry U Gurbel PA Mahla E Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel The Role of VerifyNow Can J Cardiol 201632724-5
203 Giustino G Kirtane AJ Baber U Geacuteneacutereux P Witzenbichler B Neumann FJ Weisz G Maehara A Rinaldi MJ Metzger C Henry TD Cox DA Duffy PL Mazzaferri EL Brodie BR Stuckey TD Gurbel PA Dangas GD Francese DP Ozan O Mehran R Stone GW Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study Am J Cardiol 20161171877-83
204 Kubica J Kubica A Jilma B Adamski P Hobl EL Navarese EP Siller-Matula JM Dąbrowska A Fabiszak T Koziński M Gurbel PA Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors Int J Cardiol 2016215201-8
205 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin
Curriculum Vitae Paul A Gurbel MD Page 13
J Diabetes Complications 2016 May 10 [Epub ahead of print] 206 Bliden KP Chaudhary R Lopez LR Damrongwatanasuk R Guyer K Gesheff MG Franzese CJ Kaza H
Tantry US Gurbel PA Oxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease Am J Cardiol 2016 Jun 15 [Epub ahead of print]
207 Mahla E Prueller F Farzi S Pregartner G Raggam RB Beran E Toller W Berghold A Tantry US Gurbel PA Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy Ann Thorac Surg 2016 Jul 1 [Epub ahead of print]
208 Koh JS Park Y Tantry US Ahn JH Kang MG Kim K Jang JY Park HW Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents The ACCEL-COMBO trial Platelets 2016 Aug 251-7 [Epub ahead of print]
209 Chaudhary R Saadin K Bliden KP Harris WS Dinh B Sharma T Tantry US Gurbel PA Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease Prostaglandins Leukot Essent Fatty Acids 201611340-45
210 Gurbel PA Bliden KP Chaudhary R Patrick J Liu F Chen G McLeod C Tantry US Antiplatelet Effect Durability of a Novel 24-Hour Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes MellitusAm J Cardiol 20161181941-1947
211 Gurbel PA Bliden KP Tantry US Monroe AL Muresan AA Brunner NE Lopez-Espina CG Delmenico PR Cohen E Raviv G Haugen DL Ereth MH First report of the point-of-care TEG A technical validation study of the TEG-6S system Platelets 201627642-649
212 Cornel JH Ohman EM Neely B Jakubowski JA Bhatt DL White HD Ardissino D Fox KA Prabhakaran D Armstrong PW Erlinge D Tantry US Gurbel PA Roe MT Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes J Am Heart Assoc 2016 Nov 45(11) pii e003977
213 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 201717109-121
214 Sharma T Bliden K Chaudhary R Tantry U Gurbel PA Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease Expert Opin Pharmacother 201718123-131
215 Park Y Tantry US Koh JS Ahn JH Kang MG Kim KH Jang JY Park HW Park JR Hwang SJ Park KS Kwak CH Hwang JY Gurbel PA Jeong YH Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction The REMODELING Trial Thromb Haemost 2017117911-922
216 Navarese EP Gurbel PA Andreotti F Kołodziejczak MM Palmer SC Dias S Buffon A Kubica J Kowalewski M Jadczyk T Laskiewicz M Jędrzejek M Brockmeyer M Airoldi F Ruospo M De Servi S Wojakowski W O Connor C Strippoli GF Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis PLoS One 201712e0168726
217 Bliden KP Chaudhary R Mohammed N Muresan AA Lopez-Espina CG Cohen E Raviv G Doubleday M Zaman F Mathew B Tantry US Gurbel PA Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system J Thromb Thrombolysis 201743437-445
Publications Peer Reviewed Original Science Research - Reviews 1 Serebruany VL Atar D Dalesandro MR OConnor CM Gurbel PA Changes in hemostasis after parenteral
magnesium in myocardial ischemia reperfusion Animal studies to clinical trials Magnes Res 19981137-42 2 McKenzie ME Gurbel PA Levine DJ Serebruany VL Clinical utility of available methods determining platelet
function Cardiology 199992240-7 3 Gurbel PA OConnor CM Cummings CC Serebruany VL Clopidogrel The future choice for preventing platelet
activation during coronary stenting Pharm Res 199965109-123 4 Nair GV Gurbel PA Fusaylov SY Davis CJ Ohman EM Bahr RD Christensen RH Serebruany VL Combing
necrosis and platelet markers for perfecting myocardial infarction rule out How close are we Cardiology 20009350-5
5 Davis CJ Gurbel PA Gaitis WA Fuzaylov SY Nair GV OrsquoConnor CM Serebruany VL Hemostatic abnormalities in congestive heart failure Diagnostic significance and clinical challenge Int J Cardiol 20007515-21
6 Pothula A Gurbel PA Atar D McKenzie ME Serebruany VL Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease Eur J Pharmacol 20004021-10
7 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Serebruany VL Platelet function and fibrinolytic agents Two sides of a coin Cardiology 20019555-60
Curriculum Vitae Paul A Gurbel MD Page 14
8 Samara WM Gurbel PA The role of platelet receptors and adhesion molecules in coronary artery disease Coron Artery Dis 20031465-79
9 Gurbel PA Tantry U Clopidogrel response variability and the advent of personalised antiplatelet therapy A bench to bedside journey Thromb Haemost 2011106265-71
10 Gurbel PA Roe MT Jakubowski JA Shah S Erlinge D Goodman SG Huber K Chan MY Cornel JH Tantry US Ohman EM Translational platelet research in patients with coronary artery disease What are the major knowledge gaps Thromb Haemost 2012 May 25108 [Epub ahead of print]
11 Bliden KP Baker BA Nolin TD Jeong YH Bailey WL Tantry US Gurbel PA Thienopyridine efficacy and cigarette smoking status Am Heart J 2013165693-703
12 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
13 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013111547-56
14 Gesheff MG Franzese CJ Bliden KP Contino CJ Rafeedheen R Tantry USGurbel PA Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin Expert Rev Clin Pharmacol 2014 7645-53
15 Tantry US Gesheff M Liu F Bliden KP Gurbel PA Resistance to antiplatelet therapy what progress has been made Expert Opin Pharmacother 2014 9 1-12
16 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print]
17 Gurbel PA Myat A Tantry US Platelet-mediated Thrombosis From Bench to Bedside Cir Res 2015 (in press)
18 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 20161245-58
19 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
20 Gurbel PA Tantry US Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes Heart 2016102882-92
21 Navarese EP Kolodziejczak M Kereiakes DJ Tantry US OConnor C Gurbel PA Proprotein Convertase SubtilisinKexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome A Narrative Review Ann Intern Med 2016164600-7
22 Gurbel PA Jeong YH Navarese EP Tantry US Platelet-Mediated Thrombosis From Bench to Bedside Circ Res 20161181380-91
23 Gurbel PA Myat A Kubica J Tantry US State of the art Oral antiplatelet therapy JRSM Cardiovasc Dis 2016 Jun 152048004016652514 doi 1011772048004016652514 eCollection 2016 Jan-Dec
24 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 2016 Nov 17 [Epub ahead of print] Review
25 Winter MP Grove EL De Caterina R Gorog DA Ahrens I Geisler T Gurbel PA Tantry U Navarese EP Siller-Matula JM Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors Eur Heart J Cardiovasc Pharmacother 2017 Feb 15 doi 101093ehjcvppvw044 [Epub ahead of print]
26 Shah P Tantry US Bliden KP Gurbel PA Bleeding and thrombosis associated with ventricular assist device therapy J Heart Lung Transplant 2017 May 11 pii S1053-2498(17)31789-8
Inventions Patents Copyrights 32294 Gurbel PA Anderson RD Autoperfusion dilatation catheter United States Patent 5295959 51501 Dalesandro MR Gurbel PA Serebruany VL Determining a treatment plan for patients undergoing thrombotic
events by monitoring p-Selectin United States Patent 623071 61201 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6245782 13102 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 20020013343 42203 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6552014
Curriculum Vitae Paul A Gurbel MD Page 15
120611 Gurbel PA The detection of restenosis risk in patients receiving a stent by measuring the characteristics of blood clotting including the measurement of maximum thrombin-induced clot strength (patent awarded pending)
6308 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 7381536 2010 Gurbel PA Conley P Andre P Gretler D Jurek M Methods for diagnosis and treatment of thrombotic
disorders mediated bycyp2c192 (patent pending) 41014 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent
20140100167 81815 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 9110062 111715 Gurbel PA Detection of restenosis risk in patients receiving a stent by measuring the characteristics of
blood clotting including the measurement of maximum thrombin-induced clot strength Patent 9188597 Extramural Funding (since 2002) CURRENT 2010-2015 MAGMA (Multianalyte And Genetic Markers of Atherosclerosis)
Haemonetics and Sinai Hospital of Baltimore 2015-present An Observational Study of CORA-Assisted Stroke Identification and Antithrombotic Therapy
2014-2015 Feasibility clinical trial to evaluate the efficacy of an Anticoagulant cartridge to be used in the CORA System Coramed Technologies LLC
2014-2015 Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid Durlaza in CVD Patients at Risk of High Platelet Turnover (DURATION)
New Haven Pharmaceuticals Inc 2015-present Influence of Edoxaban on Coagulability and Thrombin Generation An in Vitro Study Focusing on
Thrombelastography Daiichi Sankyo
2016 Influence of Vorapaxar on Thrombin Generation and Coagulability Merck 2015-present Durlaza GI GI Tolerability Study New Haven Pharamceuticals 2015-present Thrombogenicity in LVAD Recipients Haemonetics 2014-2015 First-in-Man Assessment of PZ-128 National Institutes of Health PREVIOUS 2002 Atorvastatin in the Treatment of Heart Failure
LBH IRB 20030512 NIHThe National Heart Lung and Blood Institute NIH
2002 Asessment of the In Vitro Effects of Tenecteplase Reteplase and Alteplase on Human Platelets TAR STUDY Genetech
2003-2005 Assessment of the Effects of the heparin-coated Cordis Stent versus Non-coated Stents on Platelet and Endothelial Cell Activation and Thrombin Effect in Patients with Coronary Artery Disease (HEPACOAT) Cordis Inc
2004-2005 The Antiplatelet Effects of Eptifibatide with High and Standard Dose Clopidogrel in Low-Moderate Risk Patients Undergoing Coronary Intervention (CLEAR-PLATELETS Study) MilleniumSchering Plough
2004-2005 The Use of The TEG System to Monitor Platelet Inhibition at Bedside 5R44HL059753-03Haemoscope National Institute of Health
2004-2006 Clopidogrel Resistance in Patients with Stent Thrombosis (CREST Study) AstraZeneca
Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study MilleniumSchering Plough
2005 St Johns Wort Decreases ADP Induced Platelet Reactivity in Known Clopidogrel Resistant Post Coronary Intervention Patients after a Loading Dose of Clopidogrel University of Michigan
2008-2009 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST) Sinai Hospital Department of Medicine
2009-2010 Demonstration of the Pharmacodynamic Antiplatelet Effect of PRT060128 in Patients with High Platelet Reactivity during Clopidogrel and Aspirin Maintenance Therapy (PORTOLA) Portola Pharmaceuticals
2008-2009 A Randomised Double-Blind Outpatient Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND] AstraZeneca Pharmaceuticals LP
2008-2009 A Randomized Double-blind Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Background Therapy in Patients with Stable Coronary Artery Disease with Additional Detailed Assessment of Cardiopulmonary Function (ONSET-OFFSET) AstraZeneca Pharmaceuticals LP
2008-2009 A Single Center Randomized Open Label Parallel Group Pharmacodynamic Study of a Novel Combination Form of Aspirin and Phytosterol versus Aspirin in Healthy Adult Subjects (ARMOR) Bayer Healthcare LLC
2008-2009 Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel Plus EC Aspirin (325 mg) and Clopidogrel Plus PA32540 on Platelet Aggregation in Healthy Volunteers POZEN 110 POZEN Inc
2009-2010 Antithrombosis with Clopidogrel Beyond the Concept of Platelet Aggregate Inhibition (SANOFI) Sanofi Inc 2010-2012 A Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel EC
Aspirin 81 mg and EC omeprazole 40 mg all dosed concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers POZEN Inc
Intramural Funding (since 2002) CURRENT 2008-present Time Based Strategy to Reduce Clopidogrel Associated Bleeding Related to CABG (TARGET CABG) Sinai Hospital of Baltimore Department of Medicine 2009-present Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI)
Sinai Hospital of Baltimore Department of Medicine 2011-present Detection of Leukemic Blood and Solid TypE MalignanCies by Urinary 11-DehydroThromboxane B2 (DETECT) Study
Sinai Hospital of Baltimore Department of Medicine PREVIOUS 2001-2002 Platelet Activation in Stenting PAST Study Sinai Hospital of Baltimore 2005-2006 Platelet Reactivity in Patients with Crohnrsquos disease Receiving Infliximab (chimeric anti-TNF alpha antibody) ndash COIN
Sinai Hospital of Baltimore Department of Medicine 2006-2007 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST)
Sinai Hospital of Baltimore Department of Medicine 2008-2011 Platelet Reactivity and Thrombogenecity in Postmenopausal Women
Sinai Hospital Department of Medicine 2008-2010 Platelet Reactivity and Thrombogenecity in Postmenopausal Women (PRIDE Study)
Sinai Hospital Department of Medicine Multicenter Studies since 2001
Curriculum Vitae Paul A Gurbel MD Page 17
CURRENT 2010-present The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and
Clopidogrel in Aspirin-Treated Subjects With Stable Coronary Artery Disease Daiichi Sankyo
2010-present A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly versus Non-Elderly Aspirin-Treated Subjects with Stable Coronary Artery Disease Eli Lilly amp company
2011-present A Prospective Multicenter Randomized Trial of Clopidogrel versus Prasugrel Anti-platelet Therapy in Cytochrome P450 2C19 (CYP2C19) Intermediate Metabolizers Grant No U01HL105198
NIH National Heart Lung and Blood Institute NIH 2011-present A Prospective Randomized Multi-Center Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHERreg Sirolimus-Eluting Coronary stents
HCRI 2012-present A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in
patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)
Bayer Healthcare LLC 2013-present Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in
Patients at a High-Risk for Vascular Outcomes (ACCELERATE) Eli Lilly amp Company 2014-present A Phase 2b Multi-center Randomized Placebo-controlled Dose-ranging Study to Investigate the
Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infarction
AEGIS CSL 2015-2017 A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety of PZ- 128 in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention
National Institute of Health PREVIOUS 2001 A Randomized Double-Blind Placebo-Controlled Study of Two Intravenous Dosing Regimens of
h5G11-scFv in Patients with Acute Myocardial Infarction Undergoing 2001-2002 Prevention of REStenosis with Tranilast and Its Outcomes A Placebo Controlled Trial PRESTO STUDY
SmithKline Beecham 2002-2003 Taxus IV-SR Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
Boston Scientific 2003 MICROVENA Corporation TRAP Vascular Filtration System (VFS) Trial
Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily Pfizer Inc
2003-2004 Phase 3 Multi-Center Double-Blind Randomized Parallel Group Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily (QD) for 24 Months Compared with Atorvastatin Alone in Subjects with Angiographically Documented Coronary Heart Disease Pfizer Inc
2003-2004 A Randomized Controlled Trial of the Medtronic Endeavor Drug Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ldquoENDEAVOR III Studyrdquo)
Medtronic 2009-2010 A Prospective Randomized Open-label Multicenter study in Patients Presenting with Acute Coronary Syndromes SYNERGY STUDY
Aventis Pharmaceuticals 2004 CObalt chromium STent with Antiproliferative for Restenosis II Trialrdquo Costar study
Conor Medsystems
Curriculum Vitae Paul A Gurbel MD Page 18
2004-2005 A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions ENDEAVOR IV Medtronic
2004-2005 A Randomized Trial to evaluate the relative protection against POST-PCI microvasculat obstruction among antiplatelet and anti-thrombotic medications (TIMI-30) TIMI group
2004-2006 A Double-blind Double-dummy Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI 33 AstraZeneca Lp
2005-2006 Strategy To Reduce Atherosclerosis Development Involving Administration of Rimonabant - The Intravascular Ultrasound Study (STRADIVARIUS) EFC5827 Sanofi Synthelabo Research
2006 A Multicenter Randomized Double-Blind Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (TRASM-PCI) Schering Plough
2006-2007 A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel -SWAP (SWitching Anti Platelet study) Eli Lilly amp Company and Sankyo Company Limited
2006-2007 A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2008-2010 A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary InterventionTIMI-38 Eli Lilly Company Daiichi
2009-2010 A Randomized Double-Blind Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128 a Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Interventions (INNOVATE-PCI) Portola Pharmaceuticals
2010-2012 TReatment with ADPreceptor iNhibitorS Longitudinal Assessment ofTreatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS)
Eli Lilly Company 2010-2013 RADAR Randomized Partially-Blinded Multi-Center Active-Controlled Dose-Ranging Study
Assessing the Safety Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome Regado Bioscience Inc
2011-2013 A Phase IIa Multi-center Randomized Sponsor-unblinded Placebo-controlled Single Ascending Dose Study to Investigate the Safety Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Adults Taking Aspirin and a P2Y12 Platelet Inhibitor
AEGIS CSL Research Program BuildingLeadership 1991-1995 Director Interventional Cardiology Research University of Maryland Medical System 1998-2015 Director Sinai Center for Thrombosis Research 2001-2015 Director Cardiovascular Research Lifebridge Health 2002-2015 Director Therapeutics Research and Technology Development for the Cardiac Catheterization Program Sinai Hospital of Baltimore 2007-2015 Associate Chief for Research Department of Medicine Sinai Hospital of Baltimore 2015-current Director Interventional Cardiology and Cardiovascular Medicine Research INOVA Health 2015-Current Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute EDUCATIONAL ACTIVITIES
Curriculum Vitae Paul A Gurbel MD Page 19
Peer Reviewed Publications-Consensus Statements Expert Opinions 1 Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C
Rao AK The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 200531309-11
2 Hoekstra J Cohen M Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Saucedo JF Pollack CV Jr Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention-an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective report on a roundtable discussion Am J Emerg Med 200927720-8
3 Bonello L Tantry US Marcucci R Blindt R Angiolillo DJ Becker R Bhatt DL Cattaneo M Collet JP Cuisset T Gachet C Montalescot G Jennings LK Kereiakes D Sibbing D Trenk D Van Werkum JW Paganelli F Price MJ Waksman R Gurbel PA Working Group on High On Treatment Platelet Reactivity Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 201056919-33
4 Gurbel PA Tantry US Shuldiner AR Kereiakes DJ Genotyping one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 201056112-6
5 Gurbel PA Tantry US Antiplatelet therapy Clopidogrel-PPI interaction an ongoing controversy Nat Rev Cardiol 201187-8
6 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
7 Gurbel PA Nolin TD Tantry US Clopidogrel efficacy and cigarette smoking status JAMA 20123072495-6 8 Tantry US Bonello L Aradi D Price MJ Jeong YH Angiolillo DJ Stone GW Curzen N Geisler T Ten Berg J
Kirtane A Siller-Matula J Mahla E Becker RC Bhatt DL Waksman R Rao SV Alexopoulos D Marcucci R Reny JL Trenk D Sibbing D Gurbel PA Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding J Am Coll Cardiol 2013622261-73
9 Gurbel PA Tantry US Antiplatelet and anticoagulant agents in heart failure Current status and future perspectives JACC Heart Fail 201421-14
10 Gurbel PA Tantry US Antiplatelet therapy What have we learned from the ANTARCTIC trial Nat Rev Cardiol 201613639-640
Invited Review Articles 1 Gurbel PA Midwall JA Brodie BR Angioplasty and adjunctive intra-aortic balloon pump counterpulsation Current
clinical considerations Todays Therapy Trends 19951363-78 2 OrsquoConnor CM Gurbel PA Serebruany VL Depression and ischemic heart disease Am Heart J 200014063-69 3 Gurbel PA Serebruany VL Oral IIbIIIa inhibitors From initial promise to clinical failures J Thromb and
Thrombolysis 200010217-20 4 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Atar D Serebruany VL Platelets and
Thrombolysis Cooperation or Contrariety Heart Drug 20011281-290 5 McKenzie ME Gurbel PA The potential of monoclonal antibodies to reduce reperfusion injury in myocardial
infarction BioDrugs 200115395-404 6 Gurbel PA Bliden KP Hayes K Tantry U Platelet activation in myocardial ischemic syndromes Expert Rev of
Cardiovasc Ther 20052535-45 7 Tantry US Bliden KP Gurbel PA Resistance to antiplatelet drugs Current status and future research Expert
Opin Pharmacother 200562027-45 8 Gurbel PA Lau WC Bliden KP Tantry US Clopidogrel resistance Implications for coronary stenting Curr Pharm
Des 2006121261-9 9 Gurbel PA Tantry US Drug insight Clopidogrel non-responsiveness Nature ClinPract Cardiovasc Med
20063387-95 10 Gurbel PA Tantry US Aspirin and Clopidogrel Resistance Considerations and management J Interv Cardiol
200619439-48 11 Lau WC Gurbel PA Antiplatelet drug resistance and drug-drug interactions Role of cytochrome P450 3A4
Pharm Res 2006232691-708 12 Wiviott SD Tantry US Gurbel PA Clinical applications of antiplatelet therapy Rev Cardiovasc Med 20067
Curriculum Vitae Paul A Gurbel MD Page 20
130-46 13 Tantry US Bliden KP Gurbel PA Prasugrel Expert Opin Investig Drugs 2006151627-33 14 Gurbel PA Tantry US Clopidogrel Resistance Thromb Res 2007120311-21 15 Tantry US Etherington A Bliden KP Gurbel PA Antiplatelet therapy Current strategies and future trends Future
Cardiology 20072343-366 16 Gurbel PA Tantry US The relationship of platelet reactivity to the occurrence of post-stenting ischemic events
emergence of a new cardiovascular risk factor Rev Cardiovasc Med 2006Suppl 4S20-8 17 Tantry US Bliden KP Gurbel PA AZD6140 Expert Opin Investig Drugs 200716225-9 18 Gurbel PA Tantry US Stent thrombosis role of compliance and non-responsiveness to antiplatelet therapy Rev
Cardiovasc Med 20078S19-S26 19 Gurbel PA Kandzari DE Stent thrombosis associated with first-generation drug-eluting stents issues with
antiplatelet therapy Neth Heart J 200715148-50 20 Gurbel PA Tantry US The role of clopidogrel in cardiovascular diseases Pol Arch Med Wewn 2007117207-9 21 Gurbel PA DiChiara J Tantry US Antiplatelet therapy after implantation of drug-eluting stents duration
resistance alternatives and management of surgical patients Am J Cardiol 200710018M-25M 22 Gurbel PA Becker R Mann KG Steinhubl SR Michelson AD Platelet function monitoring in patients with
coronary artery disease J Am Coll Cardiol 2007501822-34 23 Gurbel PA Tantry US Prasugrel a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig
Drugs 20089324-36 24 Gurbel PA Bilden KP Tantry US Diagnostics for aspirin resistance Mol Diagn Ther 20081255-6 25 Gurbel PA Antonino MJ Tantry US Antiplatelet treatment of cardiovascular disease a translational research
perspective Pol Arch Med Wewn 2008118289-97 26 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831I36 27 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention Clin Cardiol 200831I28-I35
28 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches Clin Cardiol 200831I21-I27
29 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention Clin Cardiol 200831I17-I20
30 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Assessing the Current Role of Platelet Function Testing Clin Cardiol 200831I10-I16
31 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831136
32 Keriakes DJ Gurbel PA Periprocedural platelet function in percutaneous coronary intervention JACC Cardiovasc Interv 2008suppl 1111ndash121
33 Gurbel PA Tantry US The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome J Interv Cardiol 200821Suppl 1S10-7
34 Gurbel PA Tantry US Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 20091122-322
35 Gurbel PA Aspirin scope and limitations Br J Cardiol 200917 (Suppl 1)S8-S9 36 Cohen M Hoekstra J Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Pollack CV Jr
Saucedo JF Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion J Interv Cardiol 200821283-99
37 Angiolillo DJ Bhatt DL Gurbel PA Jennings LK Advances in antiplatelet therapy agents in clinical development Am J Cardiol 2009103(3 Suppl)40A-51A
38 Gurbel PA Mahla E Antonino MJ Tantry US Response variability and the role of platelet function testing J Invasive Cardiol 200921172-8
39 Gurbel PA Antonino MJ Tantry US Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug MetabToxicol Expert Opin Drug Metab Toxicol 20095989-1004
40 Gurbel PA Tantry US Antiplatelet resistance- Fact or Myth Am Hosp J 2009750-57 41 Gurbel PA Mahla E Tantry US Aspirin resistance Prog Cardiovasc Dis 200952141-52 42 Tantry US Gurbel PA Platelet monitoring for PCI Is it really necessary Haemostaseologie 200929 368-75 43 Gurbel PA Aspirin-scope and limitations Br J Cardiol 200917(Suppl 1)S8-S9
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 6
80 Gurbel PA Bliden KP A new method of representing drug-induced platelet inhibition Better description of time course response variability non-response and heightened reactivity Platelets 200314481-3
81 Gurbel PA Bliden KP The stratification of platelet reactivity and activation in patients with stable coronary disease on aspirin therapy Thromb Res 20031129-12
82 Gurbel PA Samara WM Bliden KP Failure of clopidogrel to reduce platelet reactivity an activation following standard dosing in elective stenting Implications for thrombotic events and restenosis Platelets 20031595-99
83 Lau WC Gurbel PA Watkins PB Neer CJ Hopp AS Carville DGM Guyer KE Tait AR Bates ER The contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 200410966-71
84 Joynt KE Gattis WA Hasselblad V Fuzaylov SY Serebruany VL Gurbel PA Gaulden LH Felker GM Whellan DJ OrsquoConnor CM Effect of angiotensin-converting enzyme inhibitors beta blockers statins and aspirin on C-reactive protein levels in outpatients with heart failure Am J Cardiol 200493783-5
85 Samara WM Bliden KP Tantry U Gurbel PA Thrombotic risk The difference between clopidogrel responsiveness and post-treatment platelet reactivity Thromb Res 200411589-94
86 Gurbel PA Hayes KA Bliden KP Yoho J Tantry U The platelet-related effects of tenecteplase vs alteplase vs reteplase Blood Coag Fibrinolysis 2005161-7
87 Gurbel PA Bliden KP Zaman KA Yoho JA Hayes KM Tantry US Clopidogrel loading with eptifibatide to arrest the reactivity of platelets Results of the CLEAR PLATELETS study Circulation 20051111153-9
88 Poston R Gu J Brown J Gammie J White C Manchio J Pierson RN Griffith P Gurbel P Tantry U Gilbert TB Hypercoaguability affecting early vein graft patency does not exist after off-pump coronary artery bypass J Cardiothoracic Vasc Anesth 20051911-18
89 Gurbel PA Bliden KP Hates KM Yoho JA Herzog WR Tantry US The relation of dosing to clopidogrel responsiveness and the incidence of high post-stent platelet aggregation in patients undergoing coronary stenting J Am Coll Cardiol 2005451392-6
90 Hermiller JB Raizner A Cannon L Gurbel PA Kutcher MA Wong SC Russell ME Ellis SG Mehran R Stone GW TAXUS-IV Investigators Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus The TAXUS-IV trial J Am Coll Cardiol 2005451172-9
91 Gurbel PA Bliden KP Samara W Yoho J Hayes K Fissha M Tantry U Clopidogrel Effect on Platelet REactivity in Patients with Stent Thrombosis Results of the CREST Study J Am Coll Cardiol 2005461827-32
92 Gurbel PA Bliden KP Guyer K Cho P Zaman K Kreutz R Bassi A Tantry US Platelet REactivity in Patients And Recurrent Events POST-STENTING Results of the PREPARE POST-STENTING Study J Am Coll Cardiol 2005461820-6
93 Tantry US Bliden KP Gurbel PA Overestimation of platelet aspirin resistance Detection by thrombelastograph platelet mapping and validation by conventional aggregation using arachidonic acid stimulation J Am Coll Cardiol 2005461705-9
94 Kreutz RP Tantry US Bliden KP Gurbel PA Viral respiratory tract infections increase platelet reactivity and activation - an explanation for the higher rates of myocardial infarction and stroke during viral illness J Thromb Haemost 200532108-9
95 Bleske B Nicklas J Bard R Brook R Gurbel PA Bliden K Rajagopalan S Pitt B Neutral effect on markers of heart failure inflammation endothelial activation and function and vagal tone following high dose HMG - coA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low density lipoproteins J Am Coll Cardiol 200647338-41
96 Gurbel PA Bliden KP Tantry US Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting Inflammation results from the CLEAR PLATELETS-1b study J Am Coll Cardiol 2006482186-91
97 Kandzari DE Leon MB Popma JJ Fitzgerald PJ OrsquoShaughnessy C Ball MW Turco M Applegate RJ Gurbel PA et alfor the ENDEAVOR III Investigators Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease a randomized controlled trial J Am Coll Cardiol 2006482440 ndash 2447
98 Gurbel PA Bliden KP Guyer K Aggarwal N Tantry US Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting Thromb Res 2007119563-70
99 Bliden KP DiChiara J Tantry US Bassi AK Chaganti SK Gurbel PA Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention is the current antiplatelet therapy adequate J Am Coll Cardiol 200749657-66
100 Gurbel PA Bliden KP Etherington A Tantry US Assessment of clopidogrel responsiveness measurements of maximum platelet aggregation final platelet aggregation and their correlation with vasodilator stimulated phosphoprotein in resistant patients Thromb Res 2007121107-15
101 Gurbel PA Bliden KP DiChiara J Gesheff T RN Chaganti S Etherington A MD Tantry US Evaluation of
Curriculum Vitae Paul A Gurbel MD Page 7
dose-related effects of aspirin on platelet function results from the ASpirin-Induced Platelet EffeCT (ASPECT) study Circulation 20071153156-64
102 Kreutz RP Tantry US Bliden KP Gurbel PA Inflammatory changes during the common cold are associated with platelet activation and increased reactivity of platelets to agonists Blood Coagul Fibrinolysis 200718713-8
103 Storey R Husted S Harrington R Heptinstall S Wilcox R Peters G Wickens Emanuelsson H Gurbel PA Grande P Cannon C Inhibition of platelet aggregation by AZD6140 a reversible oral P2Y12 receptor antagonist compared with clopidogrel in patients with acute coronary syndromes J Am Coll Cardiol 2007501852-6
104 DiChiara J Bliden KP Tantry US Hamed MS Antonino MJ Suarez TA Bailon O Singla A Gurbel PA The effect of aspirin dosing on platelet function in diabetic and non-diabetic patients an analysis from the aspirin-induced platelet effect (ASPECT) study Diabetes 200756 3014-9
105 DiChiara J Bliden KP Tantry US Chaganti SK Kreutz R Gesheff TB Kreutz Y Gurbel PA Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients Platelets 200718 414-23
106 Gurbel PA Kreutz RP Bliden KP Tantry US Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease a potential approach to identify atherosclerotic disease progression Am Heart J 200815555-61
107 Gurbel PA Bliden KP Cohen E Navickas IA Singla A Antonino MJ Fissha M Kreutz RP Bassi AK Tantry US Race and sex differences in thrombogenicity risk of ischemic events following coronary stenting Blood Coagul Fibrinolysis 200819268-75
108 Nissen SE Nicholls SJ Wolski K Rodeacutes-Cabau J Cannon CP Deanfield JE Despreacutes JP Kastelein JJ Steinhubl SR Kapadia S Yasin M Ruzyllo W Gaudin C Job B Hu B Bhatt DL Lincoff AM Tuzcu EM STRADIVARIUS Investigators Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease the STRADIVARIUS randomized controlled trial JAMA 20082991547-60
109 Bliden KP DiChiara J Lookman L Singla A Antonino MJ Baker BA Bailey WL Tantry US Gurbel PA The association of cigarette smoking with enhanced platelet inhibition by clopidogrel J Am Coll Cardiol 200852531-3
110 Gurbel PA Antonino MJ Bliden KP Dichiara J Suarez TA Singla A Tantry US Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention a potential antiplatelet therapeutic target Platelets 200819595-604
111 Gurbel PA Bliden KP Cohen E Navickas IA Singla A Antonino MJ Fissha M Kreutz RP Bassi AK Tantry US Race and sex differences in thrombogenicity risk of ischemic events following coronary stenting Blood Coagul Fibrinolysis 200819268-75
112 Gurbel PA Antonino MJ Bliden KP Dichiara J Suarez TA Singla A Tantry US Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention a potential antiplatelet therapeutic target Platelets 200819595-604
113 Hamed MS Gambert S Bliden KP Bailon O Anand S Antonino MJ Hamed F Tantry US Gurbel PA Dark chocolate effect on platelet activity C-reactive protein and lipid profile a pilot study S Med J 20081011203-8
114 Gilstad JR Gurbel PA Andersen RE Relationship between age and platelet activation in patients with stable and unstable angina Arch Gerontol Geriatr 200948155-9
115 Gurbel PA Bliden KP Saucedo JF Suarez TA DiChiara J Antonino MJ Mahla E Singla A Herzog WR Bassi AK Hennebry TA Gesheff TB Tantry US Bivalirudin and clopidogrel with and without eptifibatide for elective stenting effects on platelet function thrombelastographic indices and their relation to periprocedural infarctionResults of the CLEAR PLATELETS-2 study J Am Coll Cardiol 200953857-9
116 Gurbel PA Bliden KP Kreutz RP DiChiara J Antonino MJ Tantry US The link between heightened thrombogenicity and inflammation Pre-procedure characterization of the patient at high risk for recurrent events after stenting Platelets 20092097-104
117 Antonino MJ Mahla E Bliden KP Tantry US Gurbel PA Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting Am J Cardiol 20091031546-50
118 Antonino MJ Coppolecchia R Mahla E Bliden KP Tantry US Gurbel PA Antiplatelet effects of aspirin with phytosterols Comparison with non-enteric coated aspirin alone Thromb Res 2009126384-5
119 Pinto Slottow TL Bonello L Gavini R Beauzile P Sushinsky SJ Scheinowitz M Kaneshige K Xue Z Torguson R Tantry U Pichard AD Satler LF Suddath WO Kent K Gurbel P Waksman R Am J Cardiol 2009104525-30
120 Shuldiner AR OConnell JR Bliden KP Gandhi A Ryan K Horenstein RB Damcott CM Pakyz R Tantry US Gibson Q Pollin TI Post W Parsa A Mitchell BD Faraday N Herzog W Gurbel PA Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyJAMA2009302849-57
121 Singla A Antonino MJ Bliden KP Tantry US Gurbel PA The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy Am Heart J 2009158784e1-6
122 Gurbel PA Bliden KP Antonino MJ Stephens G Gretler DD Jurek MM Pakyz RE Shuldiner AR Conley PB
Curriculum Vitae Paul A Gurbel MD Page 8
Tantry US The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP 2C192 genotype First experience in patients J Thromb Haemost 2010843-53
123 Gurbel PA Bliden KP Butler K Tantry US Gesheff T Wei C Teng R Antonino MJ Patil SB Karunakaran A Kereiakes DJ Parris C Purdy D Wilson V Ledley GS Storey RF Randomized double-blind assessment of the ONSET and OFFSet of the antiplatelet Effects of Ticagrelor versus clopidogrel in patients with stable coronary artery disease The ONSETOFFSET Study Circulation 20091202577-85
124 Gurbel PA Bliden K Antonino M Butler K Teng R Rasmussen L Syd A Storey R Nielsen T Eikelboom J Sabe-Affaki G Husted S Kereaikes D Henderson D Patel V Tantry U Response to Ticagrelor in Clopidogrel Non-responders and ReSPONDers and the Effect of Switching Therapies The RESPOND Study Circulation 20101211188-99
125 Tantry US Bliden KP Suarez TA Kreutz RP DiChiara J Gurbel PA Hypercoagulability platelet function inflammation and coronary artery disease acuity results of the Thrombotic Risk Platelets 201021 360-7
126 Hennekens CH Schneuder WR Hebert PR Tantry US Gurbel PA Hypothesis formulation from subgroup analyses non-adherence or non-steroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to ldquoaspirin resistancerdquo Am Heart J 2010159744-8
127 Storey RF Bliden KP Patil SB Karunakaran A Ecob R Butler K Teng R Wei C Tantry US Gurbel PA ONSETOFFSET Investigators Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor clopidogrel or placebo in the ONSETOFFSET study J Am Coll Cardiol 201056185-93
128 Gurbel PA Bliden KP Navickas IA Mahla E Dichiara J Suarez TA Antonino MJ Tantry US Cohen E Adenosine diphosphate-induced platelet-fibrin clot strength a new thrombelastographic indicator of long-term poststenting ischemic events Am Heart J 2010160346-54
129 Angiolillo DJ Saucedo JF Deraad R Frelinger AL Gurbel PA Costigan TM Jakubowski JA Ojeh CK Effron MB SWAP Investigators Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes results of the SWAP (SWitching Anti Platelet) study J Am Coll Cardiol 2010561017-23
130 Mega JL Simon T Collet JP Anderson JL Antman EM Bliden K Cannon CP Danchin N Giusti B Gurbel P Horne BD Hulot JS Kastrati A Montalescot G Neumann FJ Shen L Sibbing D Steg PG Trenk D Wiviott SD Sabatine MS Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI a metaanalysis JAMA 20103041821-30
131 Tantry US Bliden KP Wei C Storey RF Armstrong M Butler K Gurbel PA First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel The ONSETOFFSET and RESPOND Genotype Studies Circ Cardiovasc Genet 20103556-66
132 Lau WC Welch TD Shields T Rubenfire M Tantry US Gurbel PA The Effect of St Johns Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients Increased Platelet Inhibition by Enhancement of CYP 3A4 Metabolic Activity J Cardiovasc Pharmacol 20115786-93
133 Gurbel PA Shuldiner AR Bliden KP Ryan K Pakyz RE Tantry US The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy Am Heart J 2011161598-604
134 Kandzari DE Mauri L Popma JJ Turco MA Gurbel PA Fitzgerald PJ Leon MB Late-Term Clinical Outcomes With Zotarolimus-and Sirolimus-Eluting Stents 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) JACC Cardiovasc Interv 20114543-50
135 Storey RF Bliden KP Ecob R Karunakaran A Butler K Wei C Tantry U Gurbel PA Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared to clopidogrel in patients with high antiplatelet responses J Thromb Haemost 201191730-7
136 Bliden KP Tantry US Storey RF Jeong YH Gesheff M Wei C Gurbel PA The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity Combined analysis of the ONSETOFFSET and RESPOND studies Am Heart J 2011162160-5
137 Lewis JP Fisch AS Ryan K OrsquoConnell JR Gibson Q Mitchell BD Shen H Tanner K Horenstein RB Pakzy R Tantry US Bliden KP Gurbel PA and Shuldiner AR ( equal contribution) Paraoxonase 1 (PON1) Gene Variants Are Not Associated With Clopidogrel Response Clinical Pharm Ther 201190568-74
138 Navarese EP Kozinski M Obonska K Margheri M Gurbel PA Kubica J De Luca G Clinical efficacy and safety of intracoronary vs intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention A meta-analysis of randomized trials Platelets 2011 (in press)
139 Navarese EP De Luca G Castriota F Kozinski M Gurbel P MD Gibson CM Andreotti F Siller-MatulaJM Pafundi T Sukkenik A De Servi S Kubica J Low-molecular-weight heparins vs unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction A meta-analysis J
Curriculum Vitae Paul A Gurbel MD Page 9
Thromb Haemost 201191902-15) 140 Jeong YH Tantry US Kim I-S Koh J-S Kwon TJ Park Y Hwang SJ Bliden KP Kwak CH Hwang J-W
Gurbel PA Effect of CYP2C192 and 3 loss-of-function allele carriage on platelet reactivity and adverse clinical event occurrence in east asian acute myocardial infarction survivors treated with clopidogrel and aspirin Circ Cardiovasc Genet 20114585-94
141 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
142 Gurbel PA Bliden KP Firt J Zhang Y Plachetka JR Antonino M Gesheff M Tantry US Pharmacodynamic evaluation of clopidogrel plus PA32540 The Spaced PA32540 with Clopidogrel INteraction Gauging (SPACING) study Clin Pharmacol Ther 201190860-6
143 Navarese EP Buffon A Andreotti F Gurbel PA Kozinski M Kubica A Musumeci G Cremonesi A Tavazzi L Kubica J Castriota F Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome A meta-analysis of randomized trials Atherosclerosis 20122221-7
144 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 201210487-9
145 Gurbel PA Bliden KP Antonino MJ Gesheff T Cummings CC Dubois BV Herzog WR Tantry US Time dependence of clopidogrel loading effect Platelet activation versus platelet aggregation Thromb Res Thromb Res 20121291-2
146 Mahla E Suarez TA Bliden KP Rehak P Metzler H Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study Circ Cardiovasc Interv 20125261-9
147 Park Y Jeong YH Tantry US Ahn JH Kwon TJ Park JR Hwang SJ Gho EH Bliden KP Kwak CH Hwang JY Kim S Gurbel PA Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study Eur Heart J 2012332151-62
148 Husted SE Storey RF Bliden K Tantry US Hoslashimark L Butler K Wei C Teng R Gurbel PA Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease Results from the ONSET-OFFSET and RESPOND Studies Clin Pharmacokinet 201251397-409
149 Kubica J Koziński M Navarese EP Tantry US Grześk G Fabiszak T Kubica A Swiątkiewicz I Bliden KP Gurbel PA Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction A systematic review and meta-analysis of randomized clinical trials Cardiol J 201219(3)230-42 Jeong YH Bliden KP Antonino MJ Tantry US Gurbel PA Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity Platelets 2012 May 30 [Epub ahead of print]
150 Welsh RC Rao SV Zeymer U Thompson VP Huber K Kochman J McClure MW Gretler DD Bhatt DL Gibson CM Angiolillo DJ Gurbel PA Berdan LG Paynter G Leonardi S Madan M French WJ Harrington RA on behalf of the INNOVATE PCI Investigators A Randomized Double-Blind Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention The INNOVATE-PCI Trial Circ Cardiovasc Interv 20125336-346
151 Angiolillo DJ Welsh RC Trenk D Neumann FJ Conley PB McClure MW Stephens G Kochman J Jennings LK Gurbel PA Woacutejcik J Dabrowski M Saucedo JF Stumpf J Buerke M Broderick S Harrington RA Rao SV Pharmacokinetic and Pharmacodynamic Effects of Elinogrel Results of the Platelet Function Substudy From the Intravenous and Oral Administration of Elinogrel to Evaluate Tolerability and Efficacy in Nonurgent Percutaneous Coronary Intervention Patients (INNOVATE-PCI) Trial Circ Cardiovasc Interv 20125347-56
152 Reny JL Combescure C Daali Y Gurbel PA Fontana P PON1 Meta-Analysis Group Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events a systematic review and meta-analysis J Thromb Haemost 2012101242-1251
153 Jeong YH Bliden KP Antonino MJ Park KS Tantry US Gurbel PA Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies Am Heart J 201216435-42
154 Jeong YH Bliden KP Antonino MJ Tantry US Gurbel PA Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity Platelets 201216435-42
155 Singla A Bliden KP Jeong YH Abadilla K Antonino MJ Muse WC Mathew DP Bailon O Tantry US Gurbel PA Platelet reactivity and thrombogenecity in postmeopausal women Menopause 20132057-63
156 Jeong YH Tantry US Park Y Kwon TJ Park JR Hwang SJ Bliden KP Koh EH Kwak CH Hwang JY Kim S
Curriculum Vitae Paul A Gurbel MD Page 10
Gurbel PA Pharmacodynamic Effect of Cilostazol Plus Standard Clopidogrel Versus Double-Dose Clopidogrel in Patients With Type 2 Diabetes Undergoing Percutaneous Coronary Intervention Diabetes Care 2012352194-7
157 Roe MT Armstrong PW Fox KAA White HD Prabhakaran D Goodman SG Cornel JH Bhatt DL Clemmensen P Martinez F Ardissino D Nicolau JC Boden WE Gurbel PA Ruzyllo W Dalby AJ McGuire DK Leiva-Pons JL Parkhomenko A Gottlieb S Topacio GO Hamm C Pavlides G Goudev AR Oto A Tseng C-D Merkely B Gasparovic V Corbalan R Cinteză M McLendon RC Winters KJ Brown EB Lokhnygina Y Aylward PE Huber K Hochman JS E Magnus Ohman EM for the TRILOGY ACS Investigators Prasugrel versus clopidogrel for ACS patients managed without revascularization N Engl J Med 20123671297-309
158 Gurbel PA Bliden KP Jeong Y-H Antonino M Gesheff T Fort JG Shuldiner A Chai S Gesheff M Zhang Y Tantry US Spaced Administration of PA32540 and Clopidogrel Results in Greater Platelet Inhibition than Synchronous Administration of Enteric-Coated Aspirin and Enteric-Coated Omeprazole and Clopidogrel Am Heart J 2013165176-82
159 Gurbel PA Erlinge D Ohman EM Neely B Neely M Goodman SG Huber K Chan MY Cornel JH Brown E Zhou C Jakubowski JA White HD Fox KA Prabhakaran D Armstrong PW Tantry US Roe MT TRILOGY ACS Platelet Function Substudy Investigators JAMA 20123081785-94
160 Lewis JP Horenstein RB Ryan K OConnell JR Gibson Q Mitchell BD Tanner K Chai S Bliden KP Tantry US Peer CJ Figg WD Spencer SD Pacanowski MA Gurbel PA Shuldiner AR The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response Pharmacogenet Genomics 2012 Pharmacogenet Genomics 2013231-8
161 Jeong YH Tantry US Min JH Park Y Navarese EP Koh JS Park JR Hwang SJ Kho EH Bliden KP Kwak CH Hwang JY Kim S Gurbel PA Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention Int J Cardiol 2012 Oct 12 doipii S0167-5273(12)01253-3 101016
162 Saucedo JF Angiolillo DJ Deraad R Frelinger AL 3rd Gurbel PA Costigan TM Jakubowski JA Ojeh CK Duvvuru S Effron MB for the SWAP Investigators Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel insights from the switching anti-platelet (SWAP) study Thromb Haemost 2012 Dec 6109(2) [Epub ahead of print]
163 Navarese EP Austin D Gurbel PA Andreotti F Tantry U James S Buffon A Kozinski M Obonska K Bliden K Jeong YH Kubica J Kunadian V Drug-coated balloons in treatment of in-stent restenosis a meta-analysis of randomized controlled trials Clin Res Cardiol 2012 Dec 20 [Epub ahead of print]
164 Gurbel PA Bliden KP Fort JG Jeong YH Shuldiner A Chai S Gesheff T Antonino M Gesheff M Zhang Y Tantry US Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel Am Heart J 2013165176-82
165 Lewis JP Ryan K OConnell JR Horenstein RB Damcott CM Gibson Q Pollin TI Mitchell BD Beitelshees AL Pakzy R Tanner K Parsa A Tantry US Bliden KP Post WS Faraday N Herzog W Gong Y Pepine CJ Johnson JA Gurbel PA Shuldiner AR Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes Circ Cardiovasc Genet 2013 Feb 7 [Epub ahead of print]
166 Navarese EP Gurbel PA Andreotti F Tantry U Jeong YH Kozinski M Engstroslashm T Di Pasquale G Kochman W Ardissino D Kedhi E Stone GW Kubica J Optimal Timing of Coronary Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes A Systematic Review and Meta-analysis Ann Intern Med 2013158261-70
167 Jeong YH Abadilla KA Tantry US Park Y Koh JS Kwak CH Hwang JY Gurbel PA Influence of CYP2C192 and 3 loss-of-function alleles on pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention the results of the ACCEL-DOUBLE-2N3 studyJ Thromb Haemost 2013111194-7
168 Gurbel PA Bliden KP Logan DK Kereiakes DJ Lasseter KC White A Angiolillo DJ Nolin TD Maa JF Bailey WL Jakubowski JA Ojeh CK Jeong YH Tantry US Baker BA The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel The PARADOX Study J Am Coll Cardiol 2013 Apr 16 doipii S0735-1097(13)01478-2 101016jjacc201303037 [Epub ahead of print]
169 Grzesk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E4 Jeong Y-H Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 2013 Article ID 928271 httpdxdoiorg1011552013928271
170 Erlinge D Gurbel PA James S Lindahl TL Svensson P Ten Berg JM Foley DP Wagner H Brown PB Luo J Zhou C Moser BA Jakubowski JA Small DS Winters KJ Angiolillo DJ Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains non-inferiority to prasugrel 10-mg in non-elderly patients The GENERATIONS trial a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients J Am Coll Cardiol 201362577-83
Curriculum Vitae Paul A Gurbel MD Page 11
171 Kim IS Jeong YH Tantry US Park Y Lee DH Bliden KP Koh JS Park JR Jang JS Hwang SJ Koh EH Kwak CH Hwang JY Kim S Gurbel PA Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading Am Heart J 201316695-103
172 Grześk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E Jeong YH Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 20132013928271
173 Stone GW Witzenbichler B Weisz G Rinaldi MJ Neumann FJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri E Gurbel PA Xu K Parise H Kirtane AJ Brodie BR Mehran R Stuckey TD for the ADAPT-DES Investigators Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES) a prospective multicentre registry study Lancet 2013382614-23
174 Angiolillo DJ Curzen N Gurbel P Vaitkus P Lipkin F Li W Jakubowski JA Zettler M Effron MB Trenk D Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in subjects with stable coronary artery disease Results of the SWAP-2 Study J Am Coll Cardiol 2014631500-9
175 Jeong YH Bliden KP Shuldiner AR Tantry US Gurbel PA Thrombin-induced platelet-fibrin clot strength Relation to high on-clopidogrel platelet reactivity genotype and post-percutaneous coronary intervention outcomes Thromb Haemost 2014111713-24
176 Gouya G Arrich J Wolzt M Huber K Verheugt FW Gurbel PA Pirker-Kees A Siller-Matula JM Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases a systematic review and meta-analysis Stroke 201445492-503
177 Erlinge D James S Duvvuru S Jakubowski JA Wagner H Varenhorst C Tantry US Brown PB Small D Moser BA Sundseth S Walker JR Winters KJ Gurbel PA Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease Thromb Haemost 2014111943-50
178 Gurbel PA Baker BA Bailey WL Bliden KP Tantry US Unraveling the Smokers Paradox Cigarette smoking high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors Thromb Haemost 20141111187-90
179 Koh JS Kim IS Tantry US Yoon SE Park Y Cho SY Lee EJ Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading The results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study Int J Cardiol 2014174129-32
180 Bliden KP Singla A Gesheff MG Toth PP Tabrizchi A Ens G Guyer K Singh M Franzese CJ Stapleton D Tantry US Gurbel PA Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin Thromb Haemost 2014 Apr 24112(2) [Epub ahead of print]
181 Gurbel PA Gesheff MG Franzese CJ Bliden KP Tantry US Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy Platelets 201526608-9
182 Gurbel PA Bergmeijer TO Tantry US Ten Berg JM Angiolillo DJ James S Lindahl TL Svensson P Jakubowski JA Brown PB Duvvuru S Sundseth S Walker JR Small D Moser BA Winters KJ Erlinge D The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease Thromb Haemost 2014 2014112589-97
183 Cornel JH Ohman EM Neely B Clemmensen P Sritara P Zamoryakhin D Armstrong PW Prabhakaran D White HD Fox KA Gurbel PA Roe MT TRILOGY ACS Investigators Impact of smoking status on platelet function and clinical outcomes with prasugrel vs clopidogrel in patients with acute coronary syndromes managed without revascularization Insights from the TRILOGY ACS trial Am Heart J 201416876-87
184 Park Y Jung JM Tantry US Kim K Koh JS Park JR Hwang SJ Kwak CH Hwang JY Kim S Gurbel PA Jeong YH Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration The ACCEL-PARAZOL Study J Atheroscler Thromb 2014211121-39
185 Park Y Jeong YH Tantry US Ahn JH Kim K Koh J Park J Hwang SJ Kwak CH Hwang JY Gurbel PA Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity The Resultof the ACCEL-DIP Study Thromb Haemost 2014112 [Epub ahead of print]
186 Lev EI Bliden KP Jeong Y-H Pandya S Kang K Franzese C Tantry US Gurbel PA Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients J Am Heart Assoc 20143e001167
187 Alexopoulos D Xanthopoulou I Storey RF Bliden KP Tantry US Angiolillo DJ Gurbel PA Platelet reactivity during ticagrelor maintenance therapy A patient-level data meta-analysis Am Heart J 2014 168530-6
188 Lhermusier T Lipinski MJ Tantry US Escarcega RO Baker N Bliden KP Magalhaes MA Ota H Tian W Pendyala L Minha S Chen F Torguson R Gurbel PA Waksman R Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity Am J Cardiol 2015115716-23
189 Franzese CJ Bliden KP Gesheff MG Pandya S Guyer KE Singla A Tantry US Toth PP Gurbel PA Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy Am J Cardiol 2015 11151204-11
Curriculum Vitae Paul A Gurbel MD Page 12
190 Aradi D Kirtane A Bonello L Gurbel PA Tantry US Huber K Freynhofer MK Ten Berg J Janssen P Angiolillo DJ Siller-Matula JM Marcucci R Patti G Mangiacapra F Valgimigli M Morel O Palmerini T Price MJ Cuisset T Kastrati A Stone GW Sibbing D Bleeding and stent thrombosis on P2Y12-inhibitors collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention Eur Heart J 2015361762-71
191 Navarese EP Kolodziejczak M Schulze V Gurbel PA Tantry U Lin Y Brockmeyer M Kandzari DE Kubica JM DAgostino RB Sr Kubica J Volpe M Agewall S Kereiakes DJ Kelm M Effects of proprotein convertase subtilisinkexin type 9 antibodies in adults with hypercholesterolemia a systematic review and meta-analysis Ann Intern Med 201516340-51
192 Lee K Yoo SY Suh J Park KH Park Y Tantry US Park KS Han SH Kang WC Shin DH Lee C Choi SW Lee JH Cho YH Lee NH Jeong MH Ahn Y Kubica J Gurbel PA Park JH Jeong YH Efficacy of cilostazol on inhibition of platelet aggregation inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study Int J Cardiol 2015190370-5
193 Kowalewski M Schulze V Berti S Waksman R Kubica J Kołodziejczak M Buffon A Suryapranata H Gurbel PA Kelm M Pawliszak W Anisimowicz L Navarese EP Complete revascularisation in ST-elevation myocardial infarction and multivessel disease meta-analysis of randomised controlled trials Heart 2015 1011309-17
194 Baber U Mehran R Kirtane AJ Gurbel PA Christodoulidis G Maehara A Witzenbichler B Weisz G Rinaldi MJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri EL Jr Xu K Parise H Brodie BR Stuckey TD Stone GW Prevalence and impact of high platelet reactivity in chronic kidney disease Results from the assessment of dual antiplatelet therapy with drug-eluting stents registry Circ Cardiovasc Interv 20158e001683
195 Tricoci P DAndrea DM Gurbel PA Yao Z Cuchel M Winston B Schott R Weiss R Blazing MA Cannon L Bailey A Angiolillo DJ Gille A Shear CL Wright SDAlexander JH Infusion of Reconstituted High-Density Lipoprotein CSL112 in Patients With Atherosclerosis Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial J Am Heart Assoc 20154 pii e002171
196 Reny JL Fontana P Hochholzer W Neumann MJ ten Berg J Janssen PF Geisler T Gawaz M Marcucci R Gori A-M Cuisset T Alessi M-S Berdagueacute P Gurbel PA Yong G Angiolillo DJ Aradi D Beigel R Campo G Combescure C Vascular risk levels affect the predictive value of platelet reactivity 1 for the occurrence of major adverse cardiovascular events in patients on clopidogrel Systematic review and collaborative meta-analysis of individual patient data Thromb Haemost 2015 (in press)
197 Chaudhary R Bliden KP Tantry US Mohammed N Mathew D Gesheff MG Franzese CJ Gurbel PA Association of weight gain with coronary artery disease inflammation and thrombogenicity J Thromb Thrombolysis 2015 Dec 29 [Epub ahead of print]
198 Gurbel PA Bliden KP Turner SE Tantry US Gesheff MG Barr TP Covic L Kuliopulos A Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease Arterioscler Thromb Vasc Biol 201636189-97
199 Kwon TJ Tantry US Park Y Choi YM Ahn JH Kim KH Koh JS Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Smith SC Jr Jeong YH Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention Results of the ACCEL-BLEED study Thromb Haemost 2016 Jan 21115(5) [Epub ahead of print]
200 Bliden KP Tantry US Gesheff MG Franzese CJ Pandya S Toth PP Mathew DP Chaudhary R Gurbel PA Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis J Interv Cardiol 201629168-78
201 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin J Diabetes Complications 2016 May 10 pii S1056-8727(16)30127-1
202 Bedeir K Bliden K Tantry U Gurbel PA Mahla E Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel The Role of VerifyNow Can J Cardiol 201632724-5
203 Giustino G Kirtane AJ Baber U Geacuteneacutereux P Witzenbichler B Neumann FJ Weisz G Maehara A Rinaldi MJ Metzger C Henry TD Cox DA Duffy PL Mazzaferri EL Brodie BR Stuckey TD Gurbel PA Dangas GD Francese DP Ozan O Mehran R Stone GW Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study Am J Cardiol 20161171877-83
204 Kubica J Kubica A Jilma B Adamski P Hobl EL Navarese EP Siller-Matula JM Dąbrowska A Fabiszak T Koziński M Gurbel PA Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors Int J Cardiol 2016215201-8
205 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin
Curriculum Vitae Paul A Gurbel MD Page 13
J Diabetes Complications 2016 May 10 [Epub ahead of print] 206 Bliden KP Chaudhary R Lopez LR Damrongwatanasuk R Guyer K Gesheff MG Franzese CJ Kaza H
Tantry US Gurbel PA Oxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease Am J Cardiol 2016 Jun 15 [Epub ahead of print]
207 Mahla E Prueller F Farzi S Pregartner G Raggam RB Beran E Toller W Berghold A Tantry US Gurbel PA Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy Ann Thorac Surg 2016 Jul 1 [Epub ahead of print]
208 Koh JS Park Y Tantry US Ahn JH Kang MG Kim K Jang JY Park HW Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents The ACCEL-COMBO trial Platelets 2016 Aug 251-7 [Epub ahead of print]
209 Chaudhary R Saadin K Bliden KP Harris WS Dinh B Sharma T Tantry US Gurbel PA Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease Prostaglandins Leukot Essent Fatty Acids 201611340-45
210 Gurbel PA Bliden KP Chaudhary R Patrick J Liu F Chen G McLeod C Tantry US Antiplatelet Effect Durability of a Novel 24-Hour Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes MellitusAm J Cardiol 20161181941-1947
211 Gurbel PA Bliden KP Tantry US Monroe AL Muresan AA Brunner NE Lopez-Espina CG Delmenico PR Cohen E Raviv G Haugen DL Ereth MH First report of the point-of-care TEG A technical validation study of the TEG-6S system Platelets 201627642-649
212 Cornel JH Ohman EM Neely B Jakubowski JA Bhatt DL White HD Ardissino D Fox KA Prabhakaran D Armstrong PW Erlinge D Tantry US Gurbel PA Roe MT Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes J Am Heart Assoc 2016 Nov 45(11) pii e003977
213 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 201717109-121
214 Sharma T Bliden K Chaudhary R Tantry U Gurbel PA Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease Expert Opin Pharmacother 201718123-131
215 Park Y Tantry US Koh JS Ahn JH Kang MG Kim KH Jang JY Park HW Park JR Hwang SJ Park KS Kwak CH Hwang JY Gurbel PA Jeong YH Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction The REMODELING Trial Thromb Haemost 2017117911-922
216 Navarese EP Gurbel PA Andreotti F Kołodziejczak MM Palmer SC Dias S Buffon A Kubica J Kowalewski M Jadczyk T Laskiewicz M Jędrzejek M Brockmeyer M Airoldi F Ruospo M De Servi S Wojakowski W O Connor C Strippoli GF Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis PLoS One 201712e0168726
217 Bliden KP Chaudhary R Mohammed N Muresan AA Lopez-Espina CG Cohen E Raviv G Doubleday M Zaman F Mathew B Tantry US Gurbel PA Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system J Thromb Thrombolysis 201743437-445
Publications Peer Reviewed Original Science Research - Reviews 1 Serebruany VL Atar D Dalesandro MR OConnor CM Gurbel PA Changes in hemostasis after parenteral
magnesium in myocardial ischemia reperfusion Animal studies to clinical trials Magnes Res 19981137-42 2 McKenzie ME Gurbel PA Levine DJ Serebruany VL Clinical utility of available methods determining platelet
function Cardiology 199992240-7 3 Gurbel PA OConnor CM Cummings CC Serebruany VL Clopidogrel The future choice for preventing platelet
activation during coronary stenting Pharm Res 199965109-123 4 Nair GV Gurbel PA Fusaylov SY Davis CJ Ohman EM Bahr RD Christensen RH Serebruany VL Combing
necrosis and platelet markers for perfecting myocardial infarction rule out How close are we Cardiology 20009350-5
5 Davis CJ Gurbel PA Gaitis WA Fuzaylov SY Nair GV OrsquoConnor CM Serebruany VL Hemostatic abnormalities in congestive heart failure Diagnostic significance and clinical challenge Int J Cardiol 20007515-21
6 Pothula A Gurbel PA Atar D McKenzie ME Serebruany VL Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease Eur J Pharmacol 20004021-10
7 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Serebruany VL Platelet function and fibrinolytic agents Two sides of a coin Cardiology 20019555-60
Curriculum Vitae Paul A Gurbel MD Page 14
8 Samara WM Gurbel PA The role of platelet receptors and adhesion molecules in coronary artery disease Coron Artery Dis 20031465-79
9 Gurbel PA Tantry U Clopidogrel response variability and the advent of personalised antiplatelet therapy A bench to bedside journey Thromb Haemost 2011106265-71
10 Gurbel PA Roe MT Jakubowski JA Shah S Erlinge D Goodman SG Huber K Chan MY Cornel JH Tantry US Ohman EM Translational platelet research in patients with coronary artery disease What are the major knowledge gaps Thromb Haemost 2012 May 25108 [Epub ahead of print]
11 Bliden KP Baker BA Nolin TD Jeong YH Bailey WL Tantry US Gurbel PA Thienopyridine efficacy and cigarette smoking status Am Heart J 2013165693-703
12 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
13 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013111547-56
14 Gesheff MG Franzese CJ Bliden KP Contino CJ Rafeedheen R Tantry USGurbel PA Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin Expert Rev Clin Pharmacol 2014 7645-53
15 Tantry US Gesheff M Liu F Bliden KP Gurbel PA Resistance to antiplatelet therapy what progress has been made Expert Opin Pharmacother 2014 9 1-12
16 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print]
17 Gurbel PA Myat A Tantry US Platelet-mediated Thrombosis From Bench to Bedside Cir Res 2015 (in press)
18 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 20161245-58
19 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
20 Gurbel PA Tantry US Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes Heart 2016102882-92
21 Navarese EP Kolodziejczak M Kereiakes DJ Tantry US OConnor C Gurbel PA Proprotein Convertase SubtilisinKexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome A Narrative Review Ann Intern Med 2016164600-7
22 Gurbel PA Jeong YH Navarese EP Tantry US Platelet-Mediated Thrombosis From Bench to Bedside Circ Res 20161181380-91
23 Gurbel PA Myat A Kubica J Tantry US State of the art Oral antiplatelet therapy JRSM Cardiovasc Dis 2016 Jun 152048004016652514 doi 1011772048004016652514 eCollection 2016 Jan-Dec
24 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 2016 Nov 17 [Epub ahead of print] Review
25 Winter MP Grove EL De Caterina R Gorog DA Ahrens I Geisler T Gurbel PA Tantry U Navarese EP Siller-Matula JM Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors Eur Heart J Cardiovasc Pharmacother 2017 Feb 15 doi 101093ehjcvppvw044 [Epub ahead of print]
26 Shah P Tantry US Bliden KP Gurbel PA Bleeding and thrombosis associated with ventricular assist device therapy J Heart Lung Transplant 2017 May 11 pii S1053-2498(17)31789-8
Inventions Patents Copyrights 32294 Gurbel PA Anderson RD Autoperfusion dilatation catheter United States Patent 5295959 51501 Dalesandro MR Gurbel PA Serebruany VL Determining a treatment plan for patients undergoing thrombotic
events by monitoring p-Selectin United States Patent 623071 61201 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6245782 13102 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 20020013343 42203 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6552014
Curriculum Vitae Paul A Gurbel MD Page 15
120611 Gurbel PA The detection of restenosis risk in patients receiving a stent by measuring the characteristics of blood clotting including the measurement of maximum thrombin-induced clot strength (patent awarded pending)
6308 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 7381536 2010 Gurbel PA Conley P Andre P Gretler D Jurek M Methods for diagnosis and treatment of thrombotic
disorders mediated bycyp2c192 (patent pending) 41014 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent
20140100167 81815 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 9110062 111715 Gurbel PA Detection of restenosis risk in patients receiving a stent by measuring the characteristics of
blood clotting including the measurement of maximum thrombin-induced clot strength Patent 9188597 Extramural Funding (since 2002) CURRENT 2010-2015 MAGMA (Multianalyte And Genetic Markers of Atherosclerosis)
Haemonetics and Sinai Hospital of Baltimore 2015-present An Observational Study of CORA-Assisted Stroke Identification and Antithrombotic Therapy
2014-2015 Feasibility clinical trial to evaluate the efficacy of an Anticoagulant cartridge to be used in the CORA System Coramed Technologies LLC
2014-2015 Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid Durlaza in CVD Patients at Risk of High Platelet Turnover (DURATION)
New Haven Pharmaceuticals Inc 2015-present Influence of Edoxaban on Coagulability and Thrombin Generation An in Vitro Study Focusing on
Thrombelastography Daiichi Sankyo
2016 Influence of Vorapaxar on Thrombin Generation and Coagulability Merck 2015-present Durlaza GI GI Tolerability Study New Haven Pharamceuticals 2015-present Thrombogenicity in LVAD Recipients Haemonetics 2014-2015 First-in-Man Assessment of PZ-128 National Institutes of Health PREVIOUS 2002 Atorvastatin in the Treatment of Heart Failure
LBH IRB 20030512 NIHThe National Heart Lung and Blood Institute NIH
2002 Asessment of the In Vitro Effects of Tenecteplase Reteplase and Alteplase on Human Platelets TAR STUDY Genetech
2003-2005 Assessment of the Effects of the heparin-coated Cordis Stent versus Non-coated Stents on Platelet and Endothelial Cell Activation and Thrombin Effect in Patients with Coronary Artery Disease (HEPACOAT) Cordis Inc
2004-2005 The Antiplatelet Effects of Eptifibatide with High and Standard Dose Clopidogrel in Low-Moderate Risk Patients Undergoing Coronary Intervention (CLEAR-PLATELETS Study) MilleniumSchering Plough
2004-2005 The Use of The TEG System to Monitor Platelet Inhibition at Bedside 5R44HL059753-03Haemoscope National Institute of Health
2004-2006 Clopidogrel Resistance in Patients with Stent Thrombosis (CREST Study) AstraZeneca
Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study MilleniumSchering Plough
2005 St Johns Wort Decreases ADP Induced Platelet Reactivity in Known Clopidogrel Resistant Post Coronary Intervention Patients after a Loading Dose of Clopidogrel University of Michigan
2008-2009 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST) Sinai Hospital Department of Medicine
2009-2010 Demonstration of the Pharmacodynamic Antiplatelet Effect of PRT060128 in Patients with High Platelet Reactivity during Clopidogrel and Aspirin Maintenance Therapy (PORTOLA) Portola Pharmaceuticals
2008-2009 A Randomised Double-Blind Outpatient Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND] AstraZeneca Pharmaceuticals LP
2008-2009 A Randomized Double-blind Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Background Therapy in Patients with Stable Coronary Artery Disease with Additional Detailed Assessment of Cardiopulmonary Function (ONSET-OFFSET) AstraZeneca Pharmaceuticals LP
2008-2009 A Single Center Randomized Open Label Parallel Group Pharmacodynamic Study of a Novel Combination Form of Aspirin and Phytosterol versus Aspirin in Healthy Adult Subjects (ARMOR) Bayer Healthcare LLC
2008-2009 Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel Plus EC Aspirin (325 mg) and Clopidogrel Plus PA32540 on Platelet Aggregation in Healthy Volunteers POZEN 110 POZEN Inc
2009-2010 Antithrombosis with Clopidogrel Beyond the Concept of Platelet Aggregate Inhibition (SANOFI) Sanofi Inc 2010-2012 A Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel EC
Aspirin 81 mg and EC omeprazole 40 mg all dosed concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers POZEN Inc
Intramural Funding (since 2002) CURRENT 2008-present Time Based Strategy to Reduce Clopidogrel Associated Bleeding Related to CABG (TARGET CABG) Sinai Hospital of Baltimore Department of Medicine 2009-present Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI)
Sinai Hospital of Baltimore Department of Medicine 2011-present Detection of Leukemic Blood and Solid TypE MalignanCies by Urinary 11-DehydroThromboxane B2 (DETECT) Study
Sinai Hospital of Baltimore Department of Medicine PREVIOUS 2001-2002 Platelet Activation in Stenting PAST Study Sinai Hospital of Baltimore 2005-2006 Platelet Reactivity in Patients with Crohnrsquos disease Receiving Infliximab (chimeric anti-TNF alpha antibody) ndash COIN
Sinai Hospital of Baltimore Department of Medicine 2006-2007 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST)
Sinai Hospital of Baltimore Department of Medicine 2008-2011 Platelet Reactivity and Thrombogenecity in Postmenopausal Women
Sinai Hospital Department of Medicine 2008-2010 Platelet Reactivity and Thrombogenecity in Postmenopausal Women (PRIDE Study)
Sinai Hospital Department of Medicine Multicenter Studies since 2001
Curriculum Vitae Paul A Gurbel MD Page 17
CURRENT 2010-present The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and
Clopidogrel in Aspirin-Treated Subjects With Stable Coronary Artery Disease Daiichi Sankyo
2010-present A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly versus Non-Elderly Aspirin-Treated Subjects with Stable Coronary Artery Disease Eli Lilly amp company
2011-present A Prospective Multicenter Randomized Trial of Clopidogrel versus Prasugrel Anti-platelet Therapy in Cytochrome P450 2C19 (CYP2C19) Intermediate Metabolizers Grant No U01HL105198
NIH National Heart Lung and Blood Institute NIH 2011-present A Prospective Randomized Multi-Center Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHERreg Sirolimus-Eluting Coronary stents
HCRI 2012-present A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in
patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)
Bayer Healthcare LLC 2013-present Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in
Patients at a High-Risk for Vascular Outcomes (ACCELERATE) Eli Lilly amp Company 2014-present A Phase 2b Multi-center Randomized Placebo-controlled Dose-ranging Study to Investigate the
Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infarction
AEGIS CSL 2015-2017 A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety of PZ- 128 in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention
National Institute of Health PREVIOUS 2001 A Randomized Double-Blind Placebo-Controlled Study of Two Intravenous Dosing Regimens of
h5G11-scFv in Patients with Acute Myocardial Infarction Undergoing 2001-2002 Prevention of REStenosis with Tranilast and Its Outcomes A Placebo Controlled Trial PRESTO STUDY
SmithKline Beecham 2002-2003 Taxus IV-SR Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
Boston Scientific 2003 MICROVENA Corporation TRAP Vascular Filtration System (VFS) Trial
Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily Pfizer Inc
2003-2004 Phase 3 Multi-Center Double-Blind Randomized Parallel Group Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily (QD) for 24 Months Compared with Atorvastatin Alone in Subjects with Angiographically Documented Coronary Heart Disease Pfizer Inc
2003-2004 A Randomized Controlled Trial of the Medtronic Endeavor Drug Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ldquoENDEAVOR III Studyrdquo)
Medtronic 2009-2010 A Prospective Randomized Open-label Multicenter study in Patients Presenting with Acute Coronary Syndromes SYNERGY STUDY
Aventis Pharmaceuticals 2004 CObalt chromium STent with Antiproliferative for Restenosis II Trialrdquo Costar study
Conor Medsystems
Curriculum Vitae Paul A Gurbel MD Page 18
2004-2005 A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions ENDEAVOR IV Medtronic
2004-2005 A Randomized Trial to evaluate the relative protection against POST-PCI microvasculat obstruction among antiplatelet and anti-thrombotic medications (TIMI-30) TIMI group
2004-2006 A Double-blind Double-dummy Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI 33 AstraZeneca Lp
2005-2006 Strategy To Reduce Atherosclerosis Development Involving Administration of Rimonabant - The Intravascular Ultrasound Study (STRADIVARIUS) EFC5827 Sanofi Synthelabo Research
2006 A Multicenter Randomized Double-Blind Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (TRASM-PCI) Schering Plough
2006-2007 A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel -SWAP (SWitching Anti Platelet study) Eli Lilly amp Company and Sankyo Company Limited
2006-2007 A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2008-2010 A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary InterventionTIMI-38 Eli Lilly Company Daiichi
2009-2010 A Randomized Double-Blind Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128 a Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Interventions (INNOVATE-PCI) Portola Pharmaceuticals
2010-2012 TReatment with ADPreceptor iNhibitorS Longitudinal Assessment ofTreatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS)
Eli Lilly Company 2010-2013 RADAR Randomized Partially-Blinded Multi-Center Active-Controlled Dose-Ranging Study
Assessing the Safety Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome Regado Bioscience Inc
2011-2013 A Phase IIa Multi-center Randomized Sponsor-unblinded Placebo-controlled Single Ascending Dose Study to Investigate the Safety Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Adults Taking Aspirin and a P2Y12 Platelet Inhibitor
AEGIS CSL Research Program BuildingLeadership 1991-1995 Director Interventional Cardiology Research University of Maryland Medical System 1998-2015 Director Sinai Center for Thrombosis Research 2001-2015 Director Cardiovascular Research Lifebridge Health 2002-2015 Director Therapeutics Research and Technology Development for the Cardiac Catheterization Program Sinai Hospital of Baltimore 2007-2015 Associate Chief for Research Department of Medicine Sinai Hospital of Baltimore 2015-current Director Interventional Cardiology and Cardiovascular Medicine Research INOVA Health 2015-Current Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute EDUCATIONAL ACTIVITIES
Curriculum Vitae Paul A Gurbel MD Page 19
Peer Reviewed Publications-Consensus Statements Expert Opinions 1 Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C
Rao AK The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 200531309-11
2 Hoekstra J Cohen M Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Saucedo JF Pollack CV Jr Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention-an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective report on a roundtable discussion Am J Emerg Med 200927720-8
3 Bonello L Tantry US Marcucci R Blindt R Angiolillo DJ Becker R Bhatt DL Cattaneo M Collet JP Cuisset T Gachet C Montalescot G Jennings LK Kereiakes D Sibbing D Trenk D Van Werkum JW Paganelli F Price MJ Waksman R Gurbel PA Working Group on High On Treatment Platelet Reactivity Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 201056919-33
4 Gurbel PA Tantry US Shuldiner AR Kereiakes DJ Genotyping one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 201056112-6
5 Gurbel PA Tantry US Antiplatelet therapy Clopidogrel-PPI interaction an ongoing controversy Nat Rev Cardiol 201187-8
6 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
7 Gurbel PA Nolin TD Tantry US Clopidogrel efficacy and cigarette smoking status JAMA 20123072495-6 8 Tantry US Bonello L Aradi D Price MJ Jeong YH Angiolillo DJ Stone GW Curzen N Geisler T Ten Berg J
Kirtane A Siller-Matula J Mahla E Becker RC Bhatt DL Waksman R Rao SV Alexopoulos D Marcucci R Reny JL Trenk D Sibbing D Gurbel PA Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding J Am Coll Cardiol 2013622261-73
9 Gurbel PA Tantry US Antiplatelet and anticoagulant agents in heart failure Current status and future perspectives JACC Heart Fail 201421-14
10 Gurbel PA Tantry US Antiplatelet therapy What have we learned from the ANTARCTIC trial Nat Rev Cardiol 201613639-640
Invited Review Articles 1 Gurbel PA Midwall JA Brodie BR Angioplasty and adjunctive intra-aortic balloon pump counterpulsation Current
clinical considerations Todays Therapy Trends 19951363-78 2 OrsquoConnor CM Gurbel PA Serebruany VL Depression and ischemic heart disease Am Heart J 200014063-69 3 Gurbel PA Serebruany VL Oral IIbIIIa inhibitors From initial promise to clinical failures J Thromb and
Thrombolysis 200010217-20 4 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Atar D Serebruany VL Platelets and
Thrombolysis Cooperation or Contrariety Heart Drug 20011281-290 5 McKenzie ME Gurbel PA The potential of monoclonal antibodies to reduce reperfusion injury in myocardial
infarction BioDrugs 200115395-404 6 Gurbel PA Bliden KP Hayes K Tantry U Platelet activation in myocardial ischemic syndromes Expert Rev of
Cardiovasc Ther 20052535-45 7 Tantry US Bliden KP Gurbel PA Resistance to antiplatelet drugs Current status and future research Expert
Opin Pharmacother 200562027-45 8 Gurbel PA Lau WC Bliden KP Tantry US Clopidogrel resistance Implications for coronary stenting Curr Pharm
Des 2006121261-9 9 Gurbel PA Tantry US Drug insight Clopidogrel non-responsiveness Nature ClinPract Cardiovasc Med
20063387-95 10 Gurbel PA Tantry US Aspirin and Clopidogrel Resistance Considerations and management J Interv Cardiol
200619439-48 11 Lau WC Gurbel PA Antiplatelet drug resistance and drug-drug interactions Role of cytochrome P450 3A4
Pharm Res 2006232691-708 12 Wiviott SD Tantry US Gurbel PA Clinical applications of antiplatelet therapy Rev Cardiovasc Med 20067
Curriculum Vitae Paul A Gurbel MD Page 20
130-46 13 Tantry US Bliden KP Gurbel PA Prasugrel Expert Opin Investig Drugs 2006151627-33 14 Gurbel PA Tantry US Clopidogrel Resistance Thromb Res 2007120311-21 15 Tantry US Etherington A Bliden KP Gurbel PA Antiplatelet therapy Current strategies and future trends Future
Cardiology 20072343-366 16 Gurbel PA Tantry US The relationship of platelet reactivity to the occurrence of post-stenting ischemic events
emergence of a new cardiovascular risk factor Rev Cardiovasc Med 2006Suppl 4S20-8 17 Tantry US Bliden KP Gurbel PA AZD6140 Expert Opin Investig Drugs 200716225-9 18 Gurbel PA Tantry US Stent thrombosis role of compliance and non-responsiveness to antiplatelet therapy Rev
Cardiovasc Med 20078S19-S26 19 Gurbel PA Kandzari DE Stent thrombosis associated with first-generation drug-eluting stents issues with
antiplatelet therapy Neth Heart J 200715148-50 20 Gurbel PA Tantry US The role of clopidogrel in cardiovascular diseases Pol Arch Med Wewn 2007117207-9 21 Gurbel PA DiChiara J Tantry US Antiplatelet therapy after implantation of drug-eluting stents duration
resistance alternatives and management of surgical patients Am J Cardiol 200710018M-25M 22 Gurbel PA Becker R Mann KG Steinhubl SR Michelson AD Platelet function monitoring in patients with
coronary artery disease J Am Coll Cardiol 2007501822-34 23 Gurbel PA Tantry US Prasugrel a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig
Drugs 20089324-36 24 Gurbel PA Bilden KP Tantry US Diagnostics for aspirin resistance Mol Diagn Ther 20081255-6 25 Gurbel PA Antonino MJ Tantry US Antiplatelet treatment of cardiovascular disease a translational research
perspective Pol Arch Med Wewn 2008118289-97 26 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831I36 27 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention Clin Cardiol 200831I28-I35
28 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches Clin Cardiol 200831I21-I27
29 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention Clin Cardiol 200831I17-I20
30 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Assessing the Current Role of Platelet Function Testing Clin Cardiol 200831I10-I16
31 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831136
32 Keriakes DJ Gurbel PA Periprocedural platelet function in percutaneous coronary intervention JACC Cardiovasc Interv 2008suppl 1111ndash121
33 Gurbel PA Tantry US The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome J Interv Cardiol 200821Suppl 1S10-7
34 Gurbel PA Tantry US Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 20091122-322
35 Gurbel PA Aspirin scope and limitations Br J Cardiol 200917 (Suppl 1)S8-S9 36 Cohen M Hoekstra J Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Pollack CV Jr
Saucedo JF Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion J Interv Cardiol 200821283-99
37 Angiolillo DJ Bhatt DL Gurbel PA Jennings LK Advances in antiplatelet therapy agents in clinical development Am J Cardiol 2009103(3 Suppl)40A-51A
38 Gurbel PA Mahla E Antonino MJ Tantry US Response variability and the role of platelet function testing J Invasive Cardiol 200921172-8
39 Gurbel PA Antonino MJ Tantry US Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug MetabToxicol Expert Opin Drug Metab Toxicol 20095989-1004
40 Gurbel PA Tantry US Antiplatelet resistance- Fact or Myth Am Hosp J 2009750-57 41 Gurbel PA Mahla E Tantry US Aspirin resistance Prog Cardiovasc Dis 200952141-52 42 Tantry US Gurbel PA Platelet monitoring for PCI Is it really necessary Haemostaseologie 200929 368-75 43 Gurbel PA Aspirin-scope and limitations Br J Cardiol 200917(Suppl 1)S8-S9
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 7
dose-related effects of aspirin on platelet function results from the ASpirin-Induced Platelet EffeCT (ASPECT) study Circulation 20071153156-64
102 Kreutz RP Tantry US Bliden KP Gurbel PA Inflammatory changes during the common cold are associated with platelet activation and increased reactivity of platelets to agonists Blood Coagul Fibrinolysis 200718713-8
103 Storey R Husted S Harrington R Heptinstall S Wilcox R Peters G Wickens Emanuelsson H Gurbel PA Grande P Cannon C Inhibition of platelet aggregation by AZD6140 a reversible oral P2Y12 receptor antagonist compared with clopidogrel in patients with acute coronary syndromes J Am Coll Cardiol 2007501852-6
104 DiChiara J Bliden KP Tantry US Hamed MS Antonino MJ Suarez TA Bailon O Singla A Gurbel PA The effect of aspirin dosing on platelet function in diabetic and non-diabetic patients an analysis from the aspirin-induced platelet effect (ASPECT) study Diabetes 200756 3014-9
105 DiChiara J Bliden KP Tantry US Chaganti SK Kreutz R Gesheff TB Kreutz Y Gurbel PA Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients Platelets 200718 414-23
106 Gurbel PA Kreutz RP Bliden KP Tantry US Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease a potential approach to identify atherosclerotic disease progression Am Heart J 200815555-61
107 Gurbel PA Bliden KP Cohen E Navickas IA Singla A Antonino MJ Fissha M Kreutz RP Bassi AK Tantry US Race and sex differences in thrombogenicity risk of ischemic events following coronary stenting Blood Coagul Fibrinolysis 200819268-75
108 Nissen SE Nicholls SJ Wolski K Rodeacutes-Cabau J Cannon CP Deanfield JE Despreacutes JP Kastelein JJ Steinhubl SR Kapadia S Yasin M Ruzyllo W Gaudin C Job B Hu B Bhatt DL Lincoff AM Tuzcu EM STRADIVARIUS Investigators Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease the STRADIVARIUS randomized controlled trial JAMA 20082991547-60
109 Bliden KP DiChiara J Lookman L Singla A Antonino MJ Baker BA Bailey WL Tantry US Gurbel PA The association of cigarette smoking with enhanced platelet inhibition by clopidogrel J Am Coll Cardiol 200852531-3
110 Gurbel PA Antonino MJ Bliden KP Dichiara J Suarez TA Singla A Tantry US Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention a potential antiplatelet therapeutic target Platelets 200819595-604
111 Gurbel PA Bliden KP Cohen E Navickas IA Singla A Antonino MJ Fissha M Kreutz RP Bassi AK Tantry US Race and sex differences in thrombogenicity risk of ischemic events following coronary stenting Blood Coagul Fibrinolysis 200819268-75
112 Gurbel PA Antonino MJ Bliden KP Dichiara J Suarez TA Singla A Tantry US Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention a potential antiplatelet therapeutic target Platelets 200819595-604
113 Hamed MS Gambert S Bliden KP Bailon O Anand S Antonino MJ Hamed F Tantry US Gurbel PA Dark chocolate effect on platelet activity C-reactive protein and lipid profile a pilot study S Med J 20081011203-8
114 Gilstad JR Gurbel PA Andersen RE Relationship between age and platelet activation in patients with stable and unstable angina Arch Gerontol Geriatr 200948155-9
115 Gurbel PA Bliden KP Saucedo JF Suarez TA DiChiara J Antonino MJ Mahla E Singla A Herzog WR Bassi AK Hennebry TA Gesheff TB Tantry US Bivalirudin and clopidogrel with and without eptifibatide for elective stenting effects on platelet function thrombelastographic indices and their relation to periprocedural infarctionResults of the CLEAR PLATELETS-2 study J Am Coll Cardiol 200953857-9
116 Gurbel PA Bliden KP Kreutz RP DiChiara J Antonino MJ Tantry US The link between heightened thrombogenicity and inflammation Pre-procedure characterization of the patient at high risk for recurrent events after stenting Platelets 20092097-104
117 Antonino MJ Mahla E Bliden KP Tantry US Gurbel PA Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting Am J Cardiol 20091031546-50
118 Antonino MJ Coppolecchia R Mahla E Bliden KP Tantry US Gurbel PA Antiplatelet effects of aspirin with phytosterols Comparison with non-enteric coated aspirin alone Thromb Res 2009126384-5
119 Pinto Slottow TL Bonello L Gavini R Beauzile P Sushinsky SJ Scheinowitz M Kaneshige K Xue Z Torguson R Tantry U Pichard AD Satler LF Suddath WO Kent K Gurbel P Waksman R Am J Cardiol 2009104525-30
120 Shuldiner AR OConnell JR Bliden KP Gandhi A Ryan K Horenstein RB Damcott CM Pakyz R Tantry US Gibson Q Pollin TI Post W Parsa A Mitchell BD Faraday N Herzog W Gurbel PA Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyJAMA2009302849-57
121 Singla A Antonino MJ Bliden KP Tantry US Gurbel PA The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy Am Heart J 2009158784e1-6
122 Gurbel PA Bliden KP Antonino MJ Stephens G Gretler DD Jurek MM Pakyz RE Shuldiner AR Conley PB
Curriculum Vitae Paul A Gurbel MD Page 8
Tantry US The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP 2C192 genotype First experience in patients J Thromb Haemost 2010843-53
123 Gurbel PA Bliden KP Butler K Tantry US Gesheff T Wei C Teng R Antonino MJ Patil SB Karunakaran A Kereiakes DJ Parris C Purdy D Wilson V Ledley GS Storey RF Randomized double-blind assessment of the ONSET and OFFSet of the antiplatelet Effects of Ticagrelor versus clopidogrel in patients with stable coronary artery disease The ONSETOFFSET Study Circulation 20091202577-85
124 Gurbel PA Bliden K Antonino M Butler K Teng R Rasmussen L Syd A Storey R Nielsen T Eikelboom J Sabe-Affaki G Husted S Kereaikes D Henderson D Patel V Tantry U Response to Ticagrelor in Clopidogrel Non-responders and ReSPONDers and the Effect of Switching Therapies The RESPOND Study Circulation 20101211188-99
125 Tantry US Bliden KP Suarez TA Kreutz RP DiChiara J Gurbel PA Hypercoagulability platelet function inflammation and coronary artery disease acuity results of the Thrombotic Risk Platelets 201021 360-7
126 Hennekens CH Schneuder WR Hebert PR Tantry US Gurbel PA Hypothesis formulation from subgroup analyses non-adherence or non-steroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to ldquoaspirin resistancerdquo Am Heart J 2010159744-8
127 Storey RF Bliden KP Patil SB Karunakaran A Ecob R Butler K Teng R Wei C Tantry US Gurbel PA ONSETOFFSET Investigators Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor clopidogrel or placebo in the ONSETOFFSET study J Am Coll Cardiol 201056185-93
128 Gurbel PA Bliden KP Navickas IA Mahla E Dichiara J Suarez TA Antonino MJ Tantry US Cohen E Adenosine diphosphate-induced platelet-fibrin clot strength a new thrombelastographic indicator of long-term poststenting ischemic events Am Heart J 2010160346-54
129 Angiolillo DJ Saucedo JF Deraad R Frelinger AL Gurbel PA Costigan TM Jakubowski JA Ojeh CK Effron MB SWAP Investigators Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes results of the SWAP (SWitching Anti Platelet) study J Am Coll Cardiol 2010561017-23
130 Mega JL Simon T Collet JP Anderson JL Antman EM Bliden K Cannon CP Danchin N Giusti B Gurbel P Horne BD Hulot JS Kastrati A Montalescot G Neumann FJ Shen L Sibbing D Steg PG Trenk D Wiviott SD Sabatine MS Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI a metaanalysis JAMA 20103041821-30
131 Tantry US Bliden KP Wei C Storey RF Armstrong M Butler K Gurbel PA First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel The ONSETOFFSET and RESPOND Genotype Studies Circ Cardiovasc Genet 20103556-66
132 Lau WC Welch TD Shields T Rubenfire M Tantry US Gurbel PA The Effect of St Johns Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients Increased Platelet Inhibition by Enhancement of CYP 3A4 Metabolic Activity J Cardiovasc Pharmacol 20115786-93
133 Gurbel PA Shuldiner AR Bliden KP Ryan K Pakyz RE Tantry US The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy Am Heart J 2011161598-604
134 Kandzari DE Mauri L Popma JJ Turco MA Gurbel PA Fitzgerald PJ Leon MB Late-Term Clinical Outcomes With Zotarolimus-and Sirolimus-Eluting Stents 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) JACC Cardiovasc Interv 20114543-50
135 Storey RF Bliden KP Ecob R Karunakaran A Butler K Wei C Tantry U Gurbel PA Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared to clopidogrel in patients with high antiplatelet responses J Thromb Haemost 201191730-7
136 Bliden KP Tantry US Storey RF Jeong YH Gesheff M Wei C Gurbel PA The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity Combined analysis of the ONSETOFFSET and RESPOND studies Am Heart J 2011162160-5
137 Lewis JP Fisch AS Ryan K OrsquoConnell JR Gibson Q Mitchell BD Shen H Tanner K Horenstein RB Pakzy R Tantry US Bliden KP Gurbel PA and Shuldiner AR ( equal contribution) Paraoxonase 1 (PON1) Gene Variants Are Not Associated With Clopidogrel Response Clinical Pharm Ther 201190568-74
138 Navarese EP Kozinski M Obonska K Margheri M Gurbel PA Kubica J De Luca G Clinical efficacy and safety of intracoronary vs intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention A meta-analysis of randomized trials Platelets 2011 (in press)
139 Navarese EP De Luca G Castriota F Kozinski M Gurbel P MD Gibson CM Andreotti F Siller-MatulaJM Pafundi T Sukkenik A De Servi S Kubica J Low-molecular-weight heparins vs unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction A meta-analysis J
Curriculum Vitae Paul A Gurbel MD Page 9
Thromb Haemost 201191902-15) 140 Jeong YH Tantry US Kim I-S Koh J-S Kwon TJ Park Y Hwang SJ Bliden KP Kwak CH Hwang J-W
Gurbel PA Effect of CYP2C192 and 3 loss-of-function allele carriage on platelet reactivity and adverse clinical event occurrence in east asian acute myocardial infarction survivors treated with clopidogrel and aspirin Circ Cardiovasc Genet 20114585-94
141 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
142 Gurbel PA Bliden KP Firt J Zhang Y Plachetka JR Antonino M Gesheff M Tantry US Pharmacodynamic evaluation of clopidogrel plus PA32540 The Spaced PA32540 with Clopidogrel INteraction Gauging (SPACING) study Clin Pharmacol Ther 201190860-6
143 Navarese EP Buffon A Andreotti F Gurbel PA Kozinski M Kubica A Musumeci G Cremonesi A Tavazzi L Kubica J Castriota F Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome A meta-analysis of randomized trials Atherosclerosis 20122221-7
144 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 201210487-9
145 Gurbel PA Bliden KP Antonino MJ Gesheff T Cummings CC Dubois BV Herzog WR Tantry US Time dependence of clopidogrel loading effect Platelet activation versus platelet aggregation Thromb Res Thromb Res 20121291-2
146 Mahla E Suarez TA Bliden KP Rehak P Metzler H Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study Circ Cardiovasc Interv 20125261-9
147 Park Y Jeong YH Tantry US Ahn JH Kwon TJ Park JR Hwang SJ Gho EH Bliden KP Kwak CH Hwang JY Kim S Gurbel PA Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study Eur Heart J 2012332151-62
148 Husted SE Storey RF Bliden K Tantry US Hoslashimark L Butler K Wei C Teng R Gurbel PA Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease Results from the ONSET-OFFSET and RESPOND Studies Clin Pharmacokinet 201251397-409
149 Kubica J Koziński M Navarese EP Tantry US Grześk G Fabiszak T Kubica A Swiątkiewicz I Bliden KP Gurbel PA Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction A systematic review and meta-analysis of randomized clinical trials Cardiol J 201219(3)230-42 Jeong YH Bliden KP Antonino MJ Tantry US Gurbel PA Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity Platelets 2012 May 30 [Epub ahead of print]
150 Welsh RC Rao SV Zeymer U Thompson VP Huber K Kochman J McClure MW Gretler DD Bhatt DL Gibson CM Angiolillo DJ Gurbel PA Berdan LG Paynter G Leonardi S Madan M French WJ Harrington RA on behalf of the INNOVATE PCI Investigators A Randomized Double-Blind Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention The INNOVATE-PCI Trial Circ Cardiovasc Interv 20125336-346
151 Angiolillo DJ Welsh RC Trenk D Neumann FJ Conley PB McClure MW Stephens G Kochman J Jennings LK Gurbel PA Woacutejcik J Dabrowski M Saucedo JF Stumpf J Buerke M Broderick S Harrington RA Rao SV Pharmacokinetic and Pharmacodynamic Effects of Elinogrel Results of the Platelet Function Substudy From the Intravenous and Oral Administration of Elinogrel to Evaluate Tolerability and Efficacy in Nonurgent Percutaneous Coronary Intervention Patients (INNOVATE-PCI) Trial Circ Cardiovasc Interv 20125347-56
152 Reny JL Combescure C Daali Y Gurbel PA Fontana P PON1 Meta-Analysis Group Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events a systematic review and meta-analysis J Thromb Haemost 2012101242-1251
153 Jeong YH Bliden KP Antonino MJ Park KS Tantry US Gurbel PA Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies Am Heart J 201216435-42
154 Jeong YH Bliden KP Antonino MJ Tantry US Gurbel PA Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity Platelets 201216435-42
155 Singla A Bliden KP Jeong YH Abadilla K Antonino MJ Muse WC Mathew DP Bailon O Tantry US Gurbel PA Platelet reactivity and thrombogenecity in postmeopausal women Menopause 20132057-63
156 Jeong YH Tantry US Park Y Kwon TJ Park JR Hwang SJ Bliden KP Koh EH Kwak CH Hwang JY Kim S
Curriculum Vitae Paul A Gurbel MD Page 10
Gurbel PA Pharmacodynamic Effect of Cilostazol Plus Standard Clopidogrel Versus Double-Dose Clopidogrel in Patients With Type 2 Diabetes Undergoing Percutaneous Coronary Intervention Diabetes Care 2012352194-7
157 Roe MT Armstrong PW Fox KAA White HD Prabhakaran D Goodman SG Cornel JH Bhatt DL Clemmensen P Martinez F Ardissino D Nicolau JC Boden WE Gurbel PA Ruzyllo W Dalby AJ McGuire DK Leiva-Pons JL Parkhomenko A Gottlieb S Topacio GO Hamm C Pavlides G Goudev AR Oto A Tseng C-D Merkely B Gasparovic V Corbalan R Cinteză M McLendon RC Winters KJ Brown EB Lokhnygina Y Aylward PE Huber K Hochman JS E Magnus Ohman EM for the TRILOGY ACS Investigators Prasugrel versus clopidogrel for ACS patients managed without revascularization N Engl J Med 20123671297-309
158 Gurbel PA Bliden KP Jeong Y-H Antonino M Gesheff T Fort JG Shuldiner A Chai S Gesheff M Zhang Y Tantry US Spaced Administration of PA32540 and Clopidogrel Results in Greater Platelet Inhibition than Synchronous Administration of Enteric-Coated Aspirin and Enteric-Coated Omeprazole and Clopidogrel Am Heart J 2013165176-82
159 Gurbel PA Erlinge D Ohman EM Neely B Neely M Goodman SG Huber K Chan MY Cornel JH Brown E Zhou C Jakubowski JA White HD Fox KA Prabhakaran D Armstrong PW Tantry US Roe MT TRILOGY ACS Platelet Function Substudy Investigators JAMA 20123081785-94
160 Lewis JP Horenstein RB Ryan K OConnell JR Gibson Q Mitchell BD Tanner K Chai S Bliden KP Tantry US Peer CJ Figg WD Spencer SD Pacanowski MA Gurbel PA Shuldiner AR The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response Pharmacogenet Genomics 2012 Pharmacogenet Genomics 2013231-8
161 Jeong YH Tantry US Min JH Park Y Navarese EP Koh JS Park JR Hwang SJ Kho EH Bliden KP Kwak CH Hwang JY Kim S Gurbel PA Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention Int J Cardiol 2012 Oct 12 doipii S0167-5273(12)01253-3 101016
162 Saucedo JF Angiolillo DJ Deraad R Frelinger AL 3rd Gurbel PA Costigan TM Jakubowski JA Ojeh CK Duvvuru S Effron MB for the SWAP Investigators Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel insights from the switching anti-platelet (SWAP) study Thromb Haemost 2012 Dec 6109(2) [Epub ahead of print]
163 Navarese EP Austin D Gurbel PA Andreotti F Tantry U James S Buffon A Kozinski M Obonska K Bliden K Jeong YH Kubica J Kunadian V Drug-coated balloons in treatment of in-stent restenosis a meta-analysis of randomized controlled trials Clin Res Cardiol 2012 Dec 20 [Epub ahead of print]
164 Gurbel PA Bliden KP Fort JG Jeong YH Shuldiner A Chai S Gesheff T Antonino M Gesheff M Zhang Y Tantry US Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel Am Heart J 2013165176-82
165 Lewis JP Ryan K OConnell JR Horenstein RB Damcott CM Gibson Q Pollin TI Mitchell BD Beitelshees AL Pakzy R Tanner K Parsa A Tantry US Bliden KP Post WS Faraday N Herzog W Gong Y Pepine CJ Johnson JA Gurbel PA Shuldiner AR Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes Circ Cardiovasc Genet 2013 Feb 7 [Epub ahead of print]
166 Navarese EP Gurbel PA Andreotti F Tantry U Jeong YH Kozinski M Engstroslashm T Di Pasquale G Kochman W Ardissino D Kedhi E Stone GW Kubica J Optimal Timing of Coronary Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes A Systematic Review and Meta-analysis Ann Intern Med 2013158261-70
167 Jeong YH Abadilla KA Tantry US Park Y Koh JS Kwak CH Hwang JY Gurbel PA Influence of CYP2C192 and 3 loss-of-function alleles on pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention the results of the ACCEL-DOUBLE-2N3 studyJ Thromb Haemost 2013111194-7
168 Gurbel PA Bliden KP Logan DK Kereiakes DJ Lasseter KC White A Angiolillo DJ Nolin TD Maa JF Bailey WL Jakubowski JA Ojeh CK Jeong YH Tantry US Baker BA The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel The PARADOX Study J Am Coll Cardiol 2013 Apr 16 doipii S0735-1097(13)01478-2 101016jjacc201303037 [Epub ahead of print]
169 Grzesk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E4 Jeong Y-H Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 2013 Article ID 928271 httpdxdoiorg1011552013928271
170 Erlinge D Gurbel PA James S Lindahl TL Svensson P Ten Berg JM Foley DP Wagner H Brown PB Luo J Zhou C Moser BA Jakubowski JA Small DS Winters KJ Angiolillo DJ Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains non-inferiority to prasugrel 10-mg in non-elderly patients The GENERATIONS trial a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients J Am Coll Cardiol 201362577-83
Curriculum Vitae Paul A Gurbel MD Page 11
171 Kim IS Jeong YH Tantry US Park Y Lee DH Bliden KP Koh JS Park JR Jang JS Hwang SJ Koh EH Kwak CH Hwang JY Kim S Gurbel PA Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading Am Heart J 201316695-103
172 Grześk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E Jeong YH Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 20132013928271
173 Stone GW Witzenbichler B Weisz G Rinaldi MJ Neumann FJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri E Gurbel PA Xu K Parise H Kirtane AJ Brodie BR Mehran R Stuckey TD for the ADAPT-DES Investigators Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES) a prospective multicentre registry study Lancet 2013382614-23
174 Angiolillo DJ Curzen N Gurbel P Vaitkus P Lipkin F Li W Jakubowski JA Zettler M Effron MB Trenk D Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in subjects with stable coronary artery disease Results of the SWAP-2 Study J Am Coll Cardiol 2014631500-9
175 Jeong YH Bliden KP Shuldiner AR Tantry US Gurbel PA Thrombin-induced platelet-fibrin clot strength Relation to high on-clopidogrel platelet reactivity genotype and post-percutaneous coronary intervention outcomes Thromb Haemost 2014111713-24
176 Gouya G Arrich J Wolzt M Huber K Verheugt FW Gurbel PA Pirker-Kees A Siller-Matula JM Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases a systematic review and meta-analysis Stroke 201445492-503
177 Erlinge D James S Duvvuru S Jakubowski JA Wagner H Varenhorst C Tantry US Brown PB Small D Moser BA Sundseth S Walker JR Winters KJ Gurbel PA Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease Thromb Haemost 2014111943-50
178 Gurbel PA Baker BA Bailey WL Bliden KP Tantry US Unraveling the Smokers Paradox Cigarette smoking high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors Thromb Haemost 20141111187-90
179 Koh JS Kim IS Tantry US Yoon SE Park Y Cho SY Lee EJ Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading The results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study Int J Cardiol 2014174129-32
180 Bliden KP Singla A Gesheff MG Toth PP Tabrizchi A Ens G Guyer K Singh M Franzese CJ Stapleton D Tantry US Gurbel PA Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin Thromb Haemost 2014 Apr 24112(2) [Epub ahead of print]
181 Gurbel PA Gesheff MG Franzese CJ Bliden KP Tantry US Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy Platelets 201526608-9
182 Gurbel PA Bergmeijer TO Tantry US Ten Berg JM Angiolillo DJ James S Lindahl TL Svensson P Jakubowski JA Brown PB Duvvuru S Sundseth S Walker JR Small D Moser BA Winters KJ Erlinge D The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease Thromb Haemost 2014 2014112589-97
183 Cornel JH Ohman EM Neely B Clemmensen P Sritara P Zamoryakhin D Armstrong PW Prabhakaran D White HD Fox KA Gurbel PA Roe MT TRILOGY ACS Investigators Impact of smoking status on platelet function and clinical outcomes with prasugrel vs clopidogrel in patients with acute coronary syndromes managed without revascularization Insights from the TRILOGY ACS trial Am Heart J 201416876-87
184 Park Y Jung JM Tantry US Kim K Koh JS Park JR Hwang SJ Kwak CH Hwang JY Kim S Gurbel PA Jeong YH Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration The ACCEL-PARAZOL Study J Atheroscler Thromb 2014211121-39
185 Park Y Jeong YH Tantry US Ahn JH Kim K Koh J Park J Hwang SJ Kwak CH Hwang JY Gurbel PA Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity The Resultof the ACCEL-DIP Study Thromb Haemost 2014112 [Epub ahead of print]
186 Lev EI Bliden KP Jeong Y-H Pandya S Kang K Franzese C Tantry US Gurbel PA Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients J Am Heart Assoc 20143e001167
187 Alexopoulos D Xanthopoulou I Storey RF Bliden KP Tantry US Angiolillo DJ Gurbel PA Platelet reactivity during ticagrelor maintenance therapy A patient-level data meta-analysis Am Heart J 2014 168530-6
188 Lhermusier T Lipinski MJ Tantry US Escarcega RO Baker N Bliden KP Magalhaes MA Ota H Tian W Pendyala L Minha S Chen F Torguson R Gurbel PA Waksman R Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity Am J Cardiol 2015115716-23
189 Franzese CJ Bliden KP Gesheff MG Pandya S Guyer KE Singla A Tantry US Toth PP Gurbel PA Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy Am J Cardiol 2015 11151204-11
Curriculum Vitae Paul A Gurbel MD Page 12
190 Aradi D Kirtane A Bonello L Gurbel PA Tantry US Huber K Freynhofer MK Ten Berg J Janssen P Angiolillo DJ Siller-Matula JM Marcucci R Patti G Mangiacapra F Valgimigli M Morel O Palmerini T Price MJ Cuisset T Kastrati A Stone GW Sibbing D Bleeding and stent thrombosis on P2Y12-inhibitors collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention Eur Heart J 2015361762-71
191 Navarese EP Kolodziejczak M Schulze V Gurbel PA Tantry U Lin Y Brockmeyer M Kandzari DE Kubica JM DAgostino RB Sr Kubica J Volpe M Agewall S Kereiakes DJ Kelm M Effects of proprotein convertase subtilisinkexin type 9 antibodies in adults with hypercholesterolemia a systematic review and meta-analysis Ann Intern Med 201516340-51
192 Lee K Yoo SY Suh J Park KH Park Y Tantry US Park KS Han SH Kang WC Shin DH Lee C Choi SW Lee JH Cho YH Lee NH Jeong MH Ahn Y Kubica J Gurbel PA Park JH Jeong YH Efficacy of cilostazol on inhibition of platelet aggregation inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study Int J Cardiol 2015190370-5
193 Kowalewski M Schulze V Berti S Waksman R Kubica J Kołodziejczak M Buffon A Suryapranata H Gurbel PA Kelm M Pawliszak W Anisimowicz L Navarese EP Complete revascularisation in ST-elevation myocardial infarction and multivessel disease meta-analysis of randomised controlled trials Heart 2015 1011309-17
194 Baber U Mehran R Kirtane AJ Gurbel PA Christodoulidis G Maehara A Witzenbichler B Weisz G Rinaldi MJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri EL Jr Xu K Parise H Brodie BR Stuckey TD Stone GW Prevalence and impact of high platelet reactivity in chronic kidney disease Results from the assessment of dual antiplatelet therapy with drug-eluting stents registry Circ Cardiovasc Interv 20158e001683
195 Tricoci P DAndrea DM Gurbel PA Yao Z Cuchel M Winston B Schott R Weiss R Blazing MA Cannon L Bailey A Angiolillo DJ Gille A Shear CL Wright SDAlexander JH Infusion of Reconstituted High-Density Lipoprotein CSL112 in Patients With Atherosclerosis Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial J Am Heart Assoc 20154 pii e002171
196 Reny JL Fontana P Hochholzer W Neumann MJ ten Berg J Janssen PF Geisler T Gawaz M Marcucci R Gori A-M Cuisset T Alessi M-S Berdagueacute P Gurbel PA Yong G Angiolillo DJ Aradi D Beigel R Campo G Combescure C Vascular risk levels affect the predictive value of platelet reactivity 1 for the occurrence of major adverse cardiovascular events in patients on clopidogrel Systematic review and collaborative meta-analysis of individual patient data Thromb Haemost 2015 (in press)
197 Chaudhary R Bliden KP Tantry US Mohammed N Mathew D Gesheff MG Franzese CJ Gurbel PA Association of weight gain with coronary artery disease inflammation and thrombogenicity J Thromb Thrombolysis 2015 Dec 29 [Epub ahead of print]
198 Gurbel PA Bliden KP Turner SE Tantry US Gesheff MG Barr TP Covic L Kuliopulos A Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease Arterioscler Thromb Vasc Biol 201636189-97
199 Kwon TJ Tantry US Park Y Choi YM Ahn JH Kim KH Koh JS Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Smith SC Jr Jeong YH Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention Results of the ACCEL-BLEED study Thromb Haemost 2016 Jan 21115(5) [Epub ahead of print]
200 Bliden KP Tantry US Gesheff MG Franzese CJ Pandya S Toth PP Mathew DP Chaudhary R Gurbel PA Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis J Interv Cardiol 201629168-78
201 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin J Diabetes Complications 2016 May 10 pii S1056-8727(16)30127-1
202 Bedeir K Bliden K Tantry U Gurbel PA Mahla E Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel The Role of VerifyNow Can J Cardiol 201632724-5
203 Giustino G Kirtane AJ Baber U Geacuteneacutereux P Witzenbichler B Neumann FJ Weisz G Maehara A Rinaldi MJ Metzger C Henry TD Cox DA Duffy PL Mazzaferri EL Brodie BR Stuckey TD Gurbel PA Dangas GD Francese DP Ozan O Mehran R Stone GW Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study Am J Cardiol 20161171877-83
204 Kubica J Kubica A Jilma B Adamski P Hobl EL Navarese EP Siller-Matula JM Dąbrowska A Fabiszak T Koziński M Gurbel PA Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors Int J Cardiol 2016215201-8
205 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin
Curriculum Vitae Paul A Gurbel MD Page 13
J Diabetes Complications 2016 May 10 [Epub ahead of print] 206 Bliden KP Chaudhary R Lopez LR Damrongwatanasuk R Guyer K Gesheff MG Franzese CJ Kaza H
Tantry US Gurbel PA Oxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease Am J Cardiol 2016 Jun 15 [Epub ahead of print]
207 Mahla E Prueller F Farzi S Pregartner G Raggam RB Beran E Toller W Berghold A Tantry US Gurbel PA Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy Ann Thorac Surg 2016 Jul 1 [Epub ahead of print]
208 Koh JS Park Y Tantry US Ahn JH Kang MG Kim K Jang JY Park HW Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents The ACCEL-COMBO trial Platelets 2016 Aug 251-7 [Epub ahead of print]
209 Chaudhary R Saadin K Bliden KP Harris WS Dinh B Sharma T Tantry US Gurbel PA Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease Prostaglandins Leukot Essent Fatty Acids 201611340-45
210 Gurbel PA Bliden KP Chaudhary R Patrick J Liu F Chen G McLeod C Tantry US Antiplatelet Effect Durability of a Novel 24-Hour Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes MellitusAm J Cardiol 20161181941-1947
211 Gurbel PA Bliden KP Tantry US Monroe AL Muresan AA Brunner NE Lopez-Espina CG Delmenico PR Cohen E Raviv G Haugen DL Ereth MH First report of the point-of-care TEG A technical validation study of the TEG-6S system Platelets 201627642-649
212 Cornel JH Ohman EM Neely B Jakubowski JA Bhatt DL White HD Ardissino D Fox KA Prabhakaran D Armstrong PW Erlinge D Tantry US Gurbel PA Roe MT Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes J Am Heart Assoc 2016 Nov 45(11) pii e003977
213 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 201717109-121
214 Sharma T Bliden K Chaudhary R Tantry U Gurbel PA Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease Expert Opin Pharmacother 201718123-131
215 Park Y Tantry US Koh JS Ahn JH Kang MG Kim KH Jang JY Park HW Park JR Hwang SJ Park KS Kwak CH Hwang JY Gurbel PA Jeong YH Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction The REMODELING Trial Thromb Haemost 2017117911-922
216 Navarese EP Gurbel PA Andreotti F Kołodziejczak MM Palmer SC Dias S Buffon A Kubica J Kowalewski M Jadczyk T Laskiewicz M Jędrzejek M Brockmeyer M Airoldi F Ruospo M De Servi S Wojakowski W O Connor C Strippoli GF Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis PLoS One 201712e0168726
217 Bliden KP Chaudhary R Mohammed N Muresan AA Lopez-Espina CG Cohen E Raviv G Doubleday M Zaman F Mathew B Tantry US Gurbel PA Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system J Thromb Thrombolysis 201743437-445
Publications Peer Reviewed Original Science Research - Reviews 1 Serebruany VL Atar D Dalesandro MR OConnor CM Gurbel PA Changes in hemostasis after parenteral
magnesium in myocardial ischemia reperfusion Animal studies to clinical trials Magnes Res 19981137-42 2 McKenzie ME Gurbel PA Levine DJ Serebruany VL Clinical utility of available methods determining platelet
function Cardiology 199992240-7 3 Gurbel PA OConnor CM Cummings CC Serebruany VL Clopidogrel The future choice for preventing platelet
activation during coronary stenting Pharm Res 199965109-123 4 Nair GV Gurbel PA Fusaylov SY Davis CJ Ohman EM Bahr RD Christensen RH Serebruany VL Combing
necrosis and platelet markers for perfecting myocardial infarction rule out How close are we Cardiology 20009350-5
5 Davis CJ Gurbel PA Gaitis WA Fuzaylov SY Nair GV OrsquoConnor CM Serebruany VL Hemostatic abnormalities in congestive heart failure Diagnostic significance and clinical challenge Int J Cardiol 20007515-21
6 Pothula A Gurbel PA Atar D McKenzie ME Serebruany VL Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease Eur J Pharmacol 20004021-10
7 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Serebruany VL Platelet function and fibrinolytic agents Two sides of a coin Cardiology 20019555-60
Curriculum Vitae Paul A Gurbel MD Page 14
8 Samara WM Gurbel PA The role of platelet receptors and adhesion molecules in coronary artery disease Coron Artery Dis 20031465-79
9 Gurbel PA Tantry U Clopidogrel response variability and the advent of personalised antiplatelet therapy A bench to bedside journey Thromb Haemost 2011106265-71
10 Gurbel PA Roe MT Jakubowski JA Shah S Erlinge D Goodman SG Huber K Chan MY Cornel JH Tantry US Ohman EM Translational platelet research in patients with coronary artery disease What are the major knowledge gaps Thromb Haemost 2012 May 25108 [Epub ahead of print]
11 Bliden KP Baker BA Nolin TD Jeong YH Bailey WL Tantry US Gurbel PA Thienopyridine efficacy and cigarette smoking status Am Heart J 2013165693-703
12 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
13 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013111547-56
14 Gesheff MG Franzese CJ Bliden KP Contino CJ Rafeedheen R Tantry USGurbel PA Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin Expert Rev Clin Pharmacol 2014 7645-53
15 Tantry US Gesheff M Liu F Bliden KP Gurbel PA Resistance to antiplatelet therapy what progress has been made Expert Opin Pharmacother 2014 9 1-12
16 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print]
17 Gurbel PA Myat A Tantry US Platelet-mediated Thrombosis From Bench to Bedside Cir Res 2015 (in press)
18 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 20161245-58
19 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
20 Gurbel PA Tantry US Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes Heart 2016102882-92
21 Navarese EP Kolodziejczak M Kereiakes DJ Tantry US OConnor C Gurbel PA Proprotein Convertase SubtilisinKexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome A Narrative Review Ann Intern Med 2016164600-7
22 Gurbel PA Jeong YH Navarese EP Tantry US Platelet-Mediated Thrombosis From Bench to Bedside Circ Res 20161181380-91
23 Gurbel PA Myat A Kubica J Tantry US State of the art Oral antiplatelet therapy JRSM Cardiovasc Dis 2016 Jun 152048004016652514 doi 1011772048004016652514 eCollection 2016 Jan-Dec
24 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 2016 Nov 17 [Epub ahead of print] Review
25 Winter MP Grove EL De Caterina R Gorog DA Ahrens I Geisler T Gurbel PA Tantry U Navarese EP Siller-Matula JM Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors Eur Heart J Cardiovasc Pharmacother 2017 Feb 15 doi 101093ehjcvppvw044 [Epub ahead of print]
26 Shah P Tantry US Bliden KP Gurbel PA Bleeding and thrombosis associated with ventricular assist device therapy J Heart Lung Transplant 2017 May 11 pii S1053-2498(17)31789-8
Inventions Patents Copyrights 32294 Gurbel PA Anderson RD Autoperfusion dilatation catheter United States Patent 5295959 51501 Dalesandro MR Gurbel PA Serebruany VL Determining a treatment plan for patients undergoing thrombotic
events by monitoring p-Selectin United States Patent 623071 61201 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6245782 13102 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 20020013343 42203 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6552014
Curriculum Vitae Paul A Gurbel MD Page 15
120611 Gurbel PA The detection of restenosis risk in patients receiving a stent by measuring the characteristics of blood clotting including the measurement of maximum thrombin-induced clot strength (patent awarded pending)
6308 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 7381536 2010 Gurbel PA Conley P Andre P Gretler D Jurek M Methods for diagnosis and treatment of thrombotic
disorders mediated bycyp2c192 (patent pending) 41014 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent
20140100167 81815 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 9110062 111715 Gurbel PA Detection of restenosis risk in patients receiving a stent by measuring the characteristics of
blood clotting including the measurement of maximum thrombin-induced clot strength Patent 9188597 Extramural Funding (since 2002) CURRENT 2010-2015 MAGMA (Multianalyte And Genetic Markers of Atherosclerosis)
Haemonetics and Sinai Hospital of Baltimore 2015-present An Observational Study of CORA-Assisted Stroke Identification and Antithrombotic Therapy
2014-2015 Feasibility clinical trial to evaluate the efficacy of an Anticoagulant cartridge to be used in the CORA System Coramed Technologies LLC
2014-2015 Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid Durlaza in CVD Patients at Risk of High Platelet Turnover (DURATION)
New Haven Pharmaceuticals Inc 2015-present Influence of Edoxaban on Coagulability and Thrombin Generation An in Vitro Study Focusing on
Thrombelastography Daiichi Sankyo
2016 Influence of Vorapaxar on Thrombin Generation and Coagulability Merck 2015-present Durlaza GI GI Tolerability Study New Haven Pharamceuticals 2015-present Thrombogenicity in LVAD Recipients Haemonetics 2014-2015 First-in-Man Assessment of PZ-128 National Institutes of Health PREVIOUS 2002 Atorvastatin in the Treatment of Heart Failure
LBH IRB 20030512 NIHThe National Heart Lung and Blood Institute NIH
2002 Asessment of the In Vitro Effects of Tenecteplase Reteplase and Alteplase on Human Platelets TAR STUDY Genetech
2003-2005 Assessment of the Effects of the heparin-coated Cordis Stent versus Non-coated Stents on Platelet and Endothelial Cell Activation and Thrombin Effect in Patients with Coronary Artery Disease (HEPACOAT) Cordis Inc
2004-2005 The Antiplatelet Effects of Eptifibatide with High and Standard Dose Clopidogrel in Low-Moderate Risk Patients Undergoing Coronary Intervention (CLEAR-PLATELETS Study) MilleniumSchering Plough
2004-2005 The Use of The TEG System to Monitor Platelet Inhibition at Bedside 5R44HL059753-03Haemoscope National Institute of Health
2004-2006 Clopidogrel Resistance in Patients with Stent Thrombosis (CREST Study) AstraZeneca
Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study MilleniumSchering Plough
2005 St Johns Wort Decreases ADP Induced Platelet Reactivity in Known Clopidogrel Resistant Post Coronary Intervention Patients after a Loading Dose of Clopidogrel University of Michigan
2008-2009 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST) Sinai Hospital Department of Medicine
2009-2010 Demonstration of the Pharmacodynamic Antiplatelet Effect of PRT060128 in Patients with High Platelet Reactivity during Clopidogrel and Aspirin Maintenance Therapy (PORTOLA) Portola Pharmaceuticals
2008-2009 A Randomised Double-Blind Outpatient Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND] AstraZeneca Pharmaceuticals LP
2008-2009 A Randomized Double-blind Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Background Therapy in Patients with Stable Coronary Artery Disease with Additional Detailed Assessment of Cardiopulmonary Function (ONSET-OFFSET) AstraZeneca Pharmaceuticals LP
2008-2009 A Single Center Randomized Open Label Parallel Group Pharmacodynamic Study of a Novel Combination Form of Aspirin and Phytosterol versus Aspirin in Healthy Adult Subjects (ARMOR) Bayer Healthcare LLC
2008-2009 Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel Plus EC Aspirin (325 mg) and Clopidogrel Plus PA32540 on Platelet Aggregation in Healthy Volunteers POZEN 110 POZEN Inc
2009-2010 Antithrombosis with Clopidogrel Beyond the Concept of Platelet Aggregate Inhibition (SANOFI) Sanofi Inc 2010-2012 A Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel EC
Aspirin 81 mg and EC omeprazole 40 mg all dosed concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers POZEN Inc
Intramural Funding (since 2002) CURRENT 2008-present Time Based Strategy to Reduce Clopidogrel Associated Bleeding Related to CABG (TARGET CABG) Sinai Hospital of Baltimore Department of Medicine 2009-present Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI)
Sinai Hospital of Baltimore Department of Medicine 2011-present Detection of Leukemic Blood and Solid TypE MalignanCies by Urinary 11-DehydroThromboxane B2 (DETECT) Study
Sinai Hospital of Baltimore Department of Medicine PREVIOUS 2001-2002 Platelet Activation in Stenting PAST Study Sinai Hospital of Baltimore 2005-2006 Platelet Reactivity in Patients with Crohnrsquos disease Receiving Infliximab (chimeric anti-TNF alpha antibody) ndash COIN
Sinai Hospital of Baltimore Department of Medicine 2006-2007 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST)
Sinai Hospital of Baltimore Department of Medicine 2008-2011 Platelet Reactivity and Thrombogenecity in Postmenopausal Women
Sinai Hospital Department of Medicine 2008-2010 Platelet Reactivity and Thrombogenecity in Postmenopausal Women (PRIDE Study)
Sinai Hospital Department of Medicine Multicenter Studies since 2001
Curriculum Vitae Paul A Gurbel MD Page 17
CURRENT 2010-present The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and
Clopidogrel in Aspirin-Treated Subjects With Stable Coronary Artery Disease Daiichi Sankyo
2010-present A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly versus Non-Elderly Aspirin-Treated Subjects with Stable Coronary Artery Disease Eli Lilly amp company
2011-present A Prospective Multicenter Randomized Trial of Clopidogrel versus Prasugrel Anti-platelet Therapy in Cytochrome P450 2C19 (CYP2C19) Intermediate Metabolizers Grant No U01HL105198
NIH National Heart Lung and Blood Institute NIH 2011-present A Prospective Randomized Multi-Center Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHERreg Sirolimus-Eluting Coronary stents
HCRI 2012-present A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in
patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)
Bayer Healthcare LLC 2013-present Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in
Patients at a High-Risk for Vascular Outcomes (ACCELERATE) Eli Lilly amp Company 2014-present A Phase 2b Multi-center Randomized Placebo-controlled Dose-ranging Study to Investigate the
Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infarction
AEGIS CSL 2015-2017 A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety of PZ- 128 in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention
National Institute of Health PREVIOUS 2001 A Randomized Double-Blind Placebo-Controlled Study of Two Intravenous Dosing Regimens of
h5G11-scFv in Patients with Acute Myocardial Infarction Undergoing 2001-2002 Prevention of REStenosis with Tranilast and Its Outcomes A Placebo Controlled Trial PRESTO STUDY
SmithKline Beecham 2002-2003 Taxus IV-SR Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
Boston Scientific 2003 MICROVENA Corporation TRAP Vascular Filtration System (VFS) Trial
Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily Pfizer Inc
2003-2004 Phase 3 Multi-Center Double-Blind Randomized Parallel Group Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily (QD) for 24 Months Compared with Atorvastatin Alone in Subjects with Angiographically Documented Coronary Heart Disease Pfizer Inc
2003-2004 A Randomized Controlled Trial of the Medtronic Endeavor Drug Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ldquoENDEAVOR III Studyrdquo)
Medtronic 2009-2010 A Prospective Randomized Open-label Multicenter study in Patients Presenting with Acute Coronary Syndromes SYNERGY STUDY
Aventis Pharmaceuticals 2004 CObalt chromium STent with Antiproliferative for Restenosis II Trialrdquo Costar study
Conor Medsystems
Curriculum Vitae Paul A Gurbel MD Page 18
2004-2005 A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions ENDEAVOR IV Medtronic
2004-2005 A Randomized Trial to evaluate the relative protection against POST-PCI microvasculat obstruction among antiplatelet and anti-thrombotic medications (TIMI-30) TIMI group
2004-2006 A Double-blind Double-dummy Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI 33 AstraZeneca Lp
2005-2006 Strategy To Reduce Atherosclerosis Development Involving Administration of Rimonabant - The Intravascular Ultrasound Study (STRADIVARIUS) EFC5827 Sanofi Synthelabo Research
2006 A Multicenter Randomized Double-Blind Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (TRASM-PCI) Schering Plough
2006-2007 A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel -SWAP (SWitching Anti Platelet study) Eli Lilly amp Company and Sankyo Company Limited
2006-2007 A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2008-2010 A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary InterventionTIMI-38 Eli Lilly Company Daiichi
2009-2010 A Randomized Double-Blind Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128 a Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Interventions (INNOVATE-PCI) Portola Pharmaceuticals
2010-2012 TReatment with ADPreceptor iNhibitorS Longitudinal Assessment ofTreatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS)
Eli Lilly Company 2010-2013 RADAR Randomized Partially-Blinded Multi-Center Active-Controlled Dose-Ranging Study
Assessing the Safety Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome Regado Bioscience Inc
2011-2013 A Phase IIa Multi-center Randomized Sponsor-unblinded Placebo-controlled Single Ascending Dose Study to Investigate the Safety Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Adults Taking Aspirin and a P2Y12 Platelet Inhibitor
AEGIS CSL Research Program BuildingLeadership 1991-1995 Director Interventional Cardiology Research University of Maryland Medical System 1998-2015 Director Sinai Center for Thrombosis Research 2001-2015 Director Cardiovascular Research Lifebridge Health 2002-2015 Director Therapeutics Research and Technology Development for the Cardiac Catheterization Program Sinai Hospital of Baltimore 2007-2015 Associate Chief for Research Department of Medicine Sinai Hospital of Baltimore 2015-current Director Interventional Cardiology and Cardiovascular Medicine Research INOVA Health 2015-Current Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute EDUCATIONAL ACTIVITIES
Curriculum Vitae Paul A Gurbel MD Page 19
Peer Reviewed Publications-Consensus Statements Expert Opinions 1 Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C
Rao AK The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 200531309-11
2 Hoekstra J Cohen M Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Saucedo JF Pollack CV Jr Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention-an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective report on a roundtable discussion Am J Emerg Med 200927720-8
3 Bonello L Tantry US Marcucci R Blindt R Angiolillo DJ Becker R Bhatt DL Cattaneo M Collet JP Cuisset T Gachet C Montalescot G Jennings LK Kereiakes D Sibbing D Trenk D Van Werkum JW Paganelli F Price MJ Waksman R Gurbel PA Working Group on High On Treatment Platelet Reactivity Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 201056919-33
4 Gurbel PA Tantry US Shuldiner AR Kereiakes DJ Genotyping one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 201056112-6
5 Gurbel PA Tantry US Antiplatelet therapy Clopidogrel-PPI interaction an ongoing controversy Nat Rev Cardiol 201187-8
6 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
7 Gurbel PA Nolin TD Tantry US Clopidogrel efficacy and cigarette smoking status JAMA 20123072495-6 8 Tantry US Bonello L Aradi D Price MJ Jeong YH Angiolillo DJ Stone GW Curzen N Geisler T Ten Berg J
Kirtane A Siller-Matula J Mahla E Becker RC Bhatt DL Waksman R Rao SV Alexopoulos D Marcucci R Reny JL Trenk D Sibbing D Gurbel PA Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding J Am Coll Cardiol 2013622261-73
9 Gurbel PA Tantry US Antiplatelet and anticoagulant agents in heart failure Current status and future perspectives JACC Heart Fail 201421-14
10 Gurbel PA Tantry US Antiplatelet therapy What have we learned from the ANTARCTIC trial Nat Rev Cardiol 201613639-640
Invited Review Articles 1 Gurbel PA Midwall JA Brodie BR Angioplasty and adjunctive intra-aortic balloon pump counterpulsation Current
clinical considerations Todays Therapy Trends 19951363-78 2 OrsquoConnor CM Gurbel PA Serebruany VL Depression and ischemic heart disease Am Heart J 200014063-69 3 Gurbel PA Serebruany VL Oral IIbIIIa inhibitors From initial promise to clinical failures J Thromb and
Thrombolysis 200010217-20 4 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Atar D Serebruany VL Platelets and
Thrombolysis Cooperation or Contrariety Heart Drug 20011281-290 5 McKenzie ME Gurbel PA The potential of monoclonal antibodies to reduce reperfusion injury in myocardial
infarction BioDrugs 200115395-404 6 Gurbel PA Bliden KP Hayes K Tantry U Platelet activation in myocardial ischemic syndromes Expert Rev of
Cardiovasc Ther 20052535-45 7 Tantry US Bliden KP Gurbel PA Resistance to antiplatelet drugs Current status and future research Expert
Opin Pharmacother 200562027-45 8 Gurbel PA Lau WC Bliden KP Tantry US Clopidogrel resistance Implications for coronary stenting Curr Pharm
Des 2006121261-9 9 Gurbel PA Tantry US Drug insight Clopidogrel non-responsiveness Nature ClinPract Cardiovasc Med
20063387-95 10 Gurbel PA Tantry US Aspirin and Clopidogrel Resistance Considerations and management J Interv Cardiol
200619439-48 11 Lau WC Gurbel PA Antiplatelet drug resistance and drug-drug interactions Role of cytochrome P450 3A4
Pharm Res 2006232691-708 12 Wiviott SD Tantry US Gurbel PA Clinical applications of antiplatelet therapy Rev Cardiovasc Med 20067
Curriculum Vitae Paul A Gurbel MD Page 20
130-46 13 Tantry US Bliden KP Gurbel PA Prasugrel Expert Opin Investig Drugs 2006151627-33 14 Gurbel PA Tantry US Clopidogrel Resistance Thromb Res 2007120311-21 15 Tantry US Etherington A Bliden KP Gurbel PA Antiplatelet therapy Current strategies and future trends Future
Cardiology 20072343-366 16 Gurbel PA Tantry US The relationship of platelet reactivity to the occurrence of post-stenting ischemic events
emergence of a new cardiovascular risk factor Rev Cardiovasc Med 2006Suppl 4S20-8 17 Tantry US Bliden KP Gurbel PA AZD6140 Expert Opin Investig Drugs 200716225-9 18 Gurbel PA Tantry US Stent thrombosis role of compliance and non-responsiveness to antiplatelet therapy Rev
Cardiovasc Med 20078S19-S26 19 Gurbel PA Kandzari DE Stent thrombosis associated with first-generation drug-eluting stents issues with
antiplatelet therapy Neth Heart J 200715148-50 20 Gurbel PA Tantry US The role of clopidogrel in cardiovascular diseases Pol Arch Med Wewn 2007117207-9 21 Gurbel PA DiChiara J Tantry US Antiplatelet therapy after implantation of drug-eluting stents duration
resistance alternatives and management of surgical patients Am J Cardiol 200710018M-25M 22 Gurbel PA Becker R Mann KG Steinhubl SR Michelson AD Platelet function monitoring in patients with
coronary artery disease J Am Coll Cardiol 2007501822-34 23 Gurbel PA Tantry US Prasugrel a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig
Drugs 20089324-36 24 Gurbel PA Bilden KP Tantry US Diagnostics for aspirin resistance Mol Diagn Ther 20081255-6 25 Gurbel PA Antonino MJ Tantry US Antiplatelet treatment of cardiovascular disease a translational research
perspective Pol Arch Med Wewn 2008118289-97 26 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831I36 27 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention Clin Cardiol 200831I28-I35
28 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches Clin Cardiol 200831I21-I27
29 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention Clin Cardiol 200831I17-I20
30 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Assessing the Current Role of Platelet Function Testing Clin Cardiol 200831I10-I16
31 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831136
32 Keriakes DJ Gurbel PA Periprocedural platelet function in percutaneous coronary intervention JACC Cardiovasc Interv 2008suppl 1111ndash121
33 Gurbel PA Tantry US The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome J Interv Cardiol 200821Suppl 1S10-7
34 Gurbel PA Tantry US Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 20091122-322
35 Gurbel PA Aspirin scope and limitations Br J Cardiol 200917 (Suppl 1)S8-S9 36 Cohen M Hoekstra J Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Pollack CV Jr
Saucedo JF Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion J Interv Cardiol 200821283-99
37 Angiolillo DJ Bhatt DL Gurbel PA Jennings LK Advances in antiplatelet therapy agents in clinical development Am J Cardiol 2009103(3 Suppl)40A-51A
38 Gurbel PA Mahla E Antonino MJ Tantry US Response variability and the role of platelet function testing J Invasive Cardiol 200921172-8
39 Gurbel PA Antonino MJ Tantry US Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug MetabToxicol Expert Opin Drug Metab Toxicol 20095989-1004
40 Gurbel PA Tantry US Antiplatelet resistance- Fact or Myth Am Hosp J 2009750-57 41 Gurbel PA Mahla E Tantry US Aspirin resistance Prog Cardiovasc Dis 200952141-52 42 Tantry US Gurbel PA Platelet monitoring for PCI Is it really necessary Haemostaseologie 200929 368-75 43 Gurbel PA Aspirin-scope and limitations Br J Cardiol 200917(Suppl 1)S8-S9
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 8
Tantry US The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP 2C192 genotype First experience in patients J Thromb Haemost 2010843-53
123 Gurbel PA Bliden KP Butler K Tantry US Gesheff T Wei C Teng R Antonino MJ Patil SB Karunakaran A Kereiakes DJ Parris C Purdy D Wilson V Ledley GS Storey RF Randomized double-blind assessment of the ONSET and OFFSet of the antiplatelet Effects of Ticagrelor versus clopidogrel in patients with stable coronary artery disease The ONSETOFFSET Study Circulation 20091202577-85
124 Gurbel PA Bliden K Antonino M Butler K Teng R Rasmussen L Syd A Storey R Nielsen T Eikelboom J Sabe-Affaki G Husted S Kereaikes D Henderson D Patel V Tantry U Response to Ticagrelor in Clopidogrel Non-responders and ReSPONDers and the Effect of Switching Therapies The RESPOND Study Circulation 20101211188-99
125 Tantry US Bliden KP Suarez TA Kreutz RP DiChiara J Gurbel PA Hypercoagulability platelet function inflammation and coronary artery disease acuity results of the Thrombotic Risk Platelets 201021 360-7
126 Hennekens CH Schneuder WR Hebert PR Tantry US Gurbel PA Hypothesis formulation from subgroup analyses non-adherence or non-steroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to ldquoaspirin resistancerdquo Am Heart J 2010159744-8
127 Storey RF Bliden KP Patil SB Karunakaran A Ecob R Butler K Teng R Wei C Tantry US Gurbel PA ONSETOFFSET Investigators Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor clopidogrel or placebo in the ONSETOFFSET study J Am Coll Cardiol 201056185-93
128 Gurbel PA Bliden KP Navickas IA Mahla E Dichiara J Suarez TA Antonino MJ Tantry US Cohen E Adenosine diphosphate-induced platelet-fibrin clot strength a new thrombelastographic indicator of long-term poststenting ischemic events Am Heart J 2010160346-54
129 Angiolillo DJ Saucedo JF Deraad R Frelinger AL Gurbel PA Costigan TM Jakubowski JA Ojeh CK Effron MB SWAP Investigators Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes results of the SWAP (SWitching Anti Platelet) study J Am Coll Cardiol 2010561017-23
130 Mega JL Simon T Collet JP Anderson JL Antman EM Bliden K Cannon CP Danchin N Giusti B Gurbel P Horne BD Hulot JS Kastrati A Montalescot G Neumann FJ Shen L Sibbing D Steg PG Trenk D Wiviott SD Sabatine MS Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI a metaanalysis JAMA 20103041821-30
131 Tantry US Bliden KP Wei C Storey RF Armstrong M Butler K Gurbel PA First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel The ONSETOFFSET and RESPOND Genotype Studies Circ Cardiovasc Genet 20103556-66
132 Lau WC Welch TD Shields T Rubenfire M Tantry US Gurbel PA The Effect of St Johns Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients Increased Platelet Inhibition by Enhancement of CYP 3A4 Metabolic Activity J Cardiovasc Pharmacol 20115786-93
133 Gurbel PA Shuldiner AR Bliden KP Ryan K Pakyz RE Tantry US The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy Am Heart J 2011161598-604
134 Kandzari DE Mauri L Popma JJ Turco MA Gurbel PA Fitzgerald PJ Leon MB Late-Term Clinical Outcomes With Zotarolimus-and Sirolimus-Eluting Stents 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) JACC Cardiovasc Interv 20114543-50
135 Storey RF Bliden KP Ecob R Karunakaran A Butler K Wei C Tantry U Gurbel PA Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared to clopidogrel in patients with high antiplatelet responses J Thromb Haemost 201191730-7
136 Bliden KP Tantry US Storey RF Jeong YH Gesheff M Wei C Gurbel PA The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity Combined analysis of the ONSETOFFSET and RESPOND studies Am Heart J 2011162160-5
137 Lewis JP Fisch AS Ryan K OrsquoConnell JR Gibson Q Mitchell BD Shen H Tanner K Horenstein RB Pakzy R Tantry US Bliden KP Gurbel PA and Shuldiner AR ( equal contribution) Paraoxonase 1 (PON1) Gene Variants Are Not Associated With Clopidogrel Response Clinical Pharm Ther 201190568-74
138 Navarese EP Kozinski M Obonska K Margheri M Gurbel PA Kubica J De Luca G Clinical efficacy and safety of intracoronary vs intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention A meta-analysis of randomized trials Platelets 2011 (in press)
139 Navarese EP De Luca G Castriota F Kozinski M Gurbel P MD Gibson CM Andreotti F Siller-MatulaJM Pafundi T Sukkenik A De Servi S Kubica J Low-molecular-weight heparins vs unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction A meta-analysis J
Curriculum Vitae Paul A Gurbel MD Page 9
Thromb Haemost 201191902-15) 140 Jeong YH Tantry US Kim I-S Koh J-S Kwon TJ Park Y Hwang SJ Bliden KP Kwak CH Hwang J-W
Gurbel PA Effect of CYP2C192 and 3 loss-of-function allele carriage on platelet reactivity and adverse clinical event occurrence in east asian acute myocardial infarction survivors treated with clopidogrel and aspirin Circ Cardiovasc Genet 20114585-94
141 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
142 Gurbel PA Bliden KP Firt J Zhang Y Plachetka JR Antonino M Gesheff M Tantry US Pharmacodynamic evaluation of clopidogrel plus PA32540 The Spaced PA32540 with Clopidogrel INteraction Gauging (SPACING) study Clin Pharmacol Ther 201190860-6
143 Navarese EP Buffon A Andreotti F Gurbel PA Kozinski M Kubica A Musumeci G Cremonesi A Tavazzi L Kubica J Castriota F Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome A meta-analysis of randomized trials Atherosclerosis 20122221-7
144 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 201210487-9
145 Gurbel PA Bliden KP Antonino MJ Gesheff T Cummings CC Dubois BV Herzog WR Tantry US Time dependence of clopidogrel loading effect Platelet activation versus platelet aggregation Thromb Res Thromb Res 20121291-2
146 Mahla E Suarez TA Bliden KP Rehak P Metzler H Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study Circ Cardiovasc Interv 20125261-9
147 Park Y Jeong YH Tantry US Ahn JH Kwon TJ Park JR Hwang SJ Gho EH Bliden KP Kwak CH Hwang JY Kim S Gurbel PA Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study Eur Heart J 2012332151-62
148 Husted SE Storey RF Bliden K Tantry US Hoslashimark L Butler K Wei C Teng R Gurbel PA Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease Results from the ONSET-OFFSET and RESPOND Studies Clin Pharmacokinet 201251397-409
149 Kubica J Koziński M Navarese EP Tantry US Grześk G Fabiszak T Kubica A Swiątkiewicz I Bliden KP Gurbel PA Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction A systematic review and meta-analysis of randomized clinical trials Cardiol J 201219(3)230-42 Jeong YH Bliden KP Antonino MJ Tantry US Gurbel PA Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity Platelets 2012 May 30 [Epub ahead of print]
150 Welsh RC Rao SV Zeymer U Thompson VP Huber K Kochman J McClure MW Gretler DD Bhatt DL Gibson CM Angiolillo DJ Gurbel PA Berdan LG Paynter G Leonardi S Madan M French WJ Harrington RA on behalf of the INNOVATE PCI Investigators A Randomized Double-Blind Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention The INNOVATE-PCI Trial Circ Cardiovasc Interv 20125336-346
151 Angiolillo DJ Welsh RC Trenk D Neumann FJ Conley PB McClure MW Stephens G Kochman J Jennings LK Gurbel PA Woacutejcik J Dabrowski M Saucedo JF Stumpf J Buerke M Broderick S Harrington RA Rao SV Pharmacokinetic and Pharmacodynamic Effects of Elinogrel Results of the Platelet Function Substudy From the Intravenous and Oral Administration of Elinogrel to Evaluate Tolerability and Efficacy in Nonurgent Percutaneous Coronary Intervention Patients (INNOVATE-PCI) Trial Circ Cardiovasc Interv 20125347-56
152 Reny JL Combescure C Daali Y Gurbel PA Fontana P PON1 Meta-Analysis Group Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events a systematic review and meta-analysis J Thromb Haemost 2012101242-1251
153 Jeong YH Bliden KP Antonino MJ Park KS Tantry US Gurbel PA Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies Am Heart J 201216435-42
154 Jeong YH Bliden KP Antonino MJ Tantry US Gurbel PA Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity Platelets 201216435-42
155 Singla A Bliden KP Jeong YH Abadilla K Antonino MJ Muse WC Mathew DP Bailon O Tantry US Gurbel PA Platelet reactivity and thrombogenecity in postmeopausal women Menopause 20132057-63
156 Jeong YH Tantry US Park Y Kwon TJ Park JR Hwang SJ Bliden KP Koh EH Kwak CH Hwang JY Kim S
Curriculum Vitae Paul A Gurbel MD Page 10
Gurbel PA Pharmacodynamic Effect of Cilostazol Plus Standard Clopidogrel Versus Double-Dose Clopidogrel in Patients With Type 2 Diabetes Undergoing Percutaneous Coronary Intervention Diabetes Care 2012352194-7
157 Roe MT Armstrong PW Fox KAA White HD Prabhakaran D Goodman SG Cornel JH Bhatt DL Clemmensen P Martinez F Ardissino D Nicolau JC Boden WE Gurbel PA Ruzyllo W Dalby AJ McGuire DK Leiva-Pons JL Parkhomenko A Gottlieb S Topacio GO Hamm C Pavlides G Goudev AR Oto A Tseng C-D Merkely B Gasparovic V Corbalan R Cinteză M McLendon RC Winters KJ Brown EB Lokhnygina Y Aylward PE Huber K Hochman JS E Magnus Ohman EM for the TRILOGY ACS Investigators Prasugrel versus clopidogrel for ACS patients managed without revascularization N Engl J Med 20123671297-309
158 Gurbel PA Bliden KP Jeong Y-H Antonino M Gesheff T Fort JG Shuldiner A Chai S Gesheff M Zhang Y Tantry US Spaced Administration of PA32540 and Clopidogrel Results in Greater Platelet Inhibition than Synchronous Administration of Enteric-Coated Aspirin and Enteric-Coated Omeprazole and Clopidogrel Am Heart J 2013165176-82
159 Gurbel PA Erlinge D Ohman EM Neely B Neely M Goodman SG Huber K Chan MY Cornel JH Brown E Zhou C Jakubowski JA White HD Fox KA Prabhakaran D Armstrong PW Tantry US Roe MT TRILOGY ACS Platelet Function Substudy Investigators JAMA 20123081785-94
160 Lewis JP Horenstein RB Ryan K OConnell JR Gibson Q Mitchell BD Tanner K Chai S Bliden KP Tantry US Peer CJ Figg WD Spencer SD Pacanowski MA Gurbel PA Shuldiner AR The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response Pharmacogenet Genomics 2012 Pharmacogenet Genomics 2013231-8
161 Jeong YH Tantry US Min JH Park Y Navarese EP Koh JS Park JR Hwang SJ Kho EH Bliden KP Kwak CH Hwang JY Kim S Gurbel PA Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention Int J Cardiol 2012 Oct 12 doipii S0167-5273(12)01253-3 101016
162 Saucedo JF Angiolillo DJ Deraad R Frelinger AL 3rd Gurbel PA Costigan TM Jakubowski JA Ojeh CK Duvvuru S Effron MB for the SWAP Investigators Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel insights from the switching anti-platelet (SWAP) study Thromb Haemost 2012 Dec 6109(2) [Epub ahead of print]
163 Navarese EP Austin D Gurbel PA Andreotti F Tantry U James S Buffon A Kozinski M Obonska K Bliden K Jeong YH Kubica J Kunadian V Drug-coated balloons in treatment of in-stent restenosis a meta-analysis of randomized controlled trials Clin Res Cardiol 2012 Dec 20 [Epub ahead of print]
164 Gurbel PA Bliden KP Fort JG Jeong YH Shuldiner A Chai S Gesheff T Antonino M Gesheff M Zhang Y Tantry US Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel Am Heart J 2013165176-82
165 Lewis JP Ryan K OConnell JR Horenstein RB Damcott CM Gibson Q Pollin TI Mitchell BD Beitelshees AL Pakzy R Tanner K Parsa A Tantry US Bliden KP Post WS Faraday N Herzog W Gong Y Pepine CJ Johnson JA Gurbel PA Shuldiner AR Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes Circ Cardiovasc Genet 2013 Feb 7 [Epub ahead of print]
166 Navarese EP Gurbel PA Andreotti F Tantry U Jeong YH Kozinski M Engstroslashm T Di Pasquale G Kochman W Ardissino D Kedhi E Stone GW Kubica J Optimal Timing of Coronary Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes A Systematic Review and Meta-analysis Ann Intern Med 2013158261-70
167 Jeong YH Abadilla KA Tantry US Park Y Koh JS Kwak CH Hwang JY Gurbel PA Influence of CYP2C192 and 3 loss-of-function alleles on pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention the results of the ACCEL-DOUBLE-2N3 studyJ Thromb Haemost 2013111194-7
168 Gurbel PA Bliden KP Logan DK Kereiakes DJ Lasseter KC White A Angiolillo DJ Nolin TD Maa JF Bailey WL Jakubowski JA Ojeh CK Jeong YH Tantry US Baker BA The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel The PARADOX Study J Am Coll Cardiol 2013 Apr 16 doipii S0735-1097(13)01478-2 101016jjacc201303037 [Epub ahead of print]
169 Grzesk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E4 Jeong Y-H Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 2013 Article ID 928271 httpdxdoiorg1011552013928271
170 Erlinge D Gurbel PA James S Lindahl TL Svensson P Ten Berg JM Foley DP Wagner H Brown PB Luo J Zhou C Moser BA Jakubowski JA Small DS Winters KJ Angiolillo DJ Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains non-inferiority to prasugrel 10-mg in non-elderly patients The GENERATIONS trial a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients J Am Coll Cardiol 201362577-83
Curriculum Vitae Paul A Gurbel MD Page 11
171 Kim IS Jeong YH Tantry US Park Y Lee DH Bliden KP Koh JS Park JR Jang JS Hwang SJ Koh EH Kwak CH Hwang JY Kim S Gurbel PA Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading Am Heart J 201316695-103
172 Grześk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E Jeong YH Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 20132013928271
173 Stone GW Witzenbichler B Weisz G Rinaldi MJ Neumann FJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri E Gurbel PA Xu K Parise H Kirtane AJ Brodie BR Mehran R Stuckey TD for the ADAPT-DES Investigators Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES) a prospective multicentre registry study Lancet 2013382614-23
174 Angiolillo DJ Curzen N Gurbel P Vaitkus P Lipkin F Li W Jakubowski JA Zettler M Effron MB Trenk D Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in subjects with stable coronary artery disease Results of the SWAP-2 Study J Am Coll Cardiol 2014631500-9
175 Jeong YH Bliden KP Shuldiner AR Tantry US Gurbel PA Thrombin-induced platelet-fibrin clot strength Relation to high on-clopidogrel platelet reactivity genotype and post-percutaneous coronary intervention outcomes Thromb Haemost 2014111713-24
176 Gouya G Arrich J Wolzt M Huber K Verheugt FW Gurbel PA Pirker-Kees A Siller-Matula JM Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases a systematic review and meta-analysis Stroke 201445492-503
177 Erlinge D James S Duvvuru S Jakubowski JA Wagner H Varenhorst C Tantry US Brown PB Small D Moser BA Sundseth S Walker JR Winters KJ Gurbel PA Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease Thromb Haemost 2014111943-50
178 Gurbel PA Baker BA Bailey WL Bliden KP Tantry US Unraveling the Smokers Paradox Cigarette smoking high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors Thromb Haemost 20141111187-90
179 Koh JS Kim IS Tantry US Yoon SE Park Y Cho SY Lee EJ Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading The results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study Int J Cardiol 2014174129-32
180 Bliden KP Singla A Gesheff MG Toth PP Tabrizchi A Ens G Guyer K Singh M Franzese CJ Stapleton D Tantry US Gurbel PA Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin Thromb Haemost 2014 Apr 24112(2) [Epub ahead of print]
181 Gurbel PA Gesheff MG Franzese CJ Bliden KP Tantry US Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy Platelets 201526608-9
182 Gurbel PA Bergmeijer TO Tantry US Ten Berg JM Angiolillo DJ James S Lindahl TL Svensson P Jakubowski JA Brown PB Duvvuru S Sundseth S Walker JR Small D Moser BA Winters KJ Erlinge D The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease Thromb Haemost 2014 2014112589-97
183 Cornel JH Ohman EM Neely B Clemmensen P Sritara P Zamoryakhin D Armstrong PW Prabhakaran D White HD Fox KA Gurbel PA Roe MT TRILOGY ACS Investigators Impact of smoking status on platelet function and clinical outcomes with prasugrel vs clopidogrel in patients with acute coronary syndromes managed without revascularization Insights from the TRILOGY ACS trial Am Heart J 201416876-87
184 Park Y Jung JM Tantry US Kim K Koh JS Park JR Hwang SJ Kwak CH Hwang JY Kim S Gurbel PA Jeong YH Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration The ACCEL-PARAZOL Study J Atheroscler Thromb 2014211121-39
185 Park Y Jeong YH Tantry US Ahn JH Kim K Koh J Park J Hwang SJ Kwak CH Hwang JY Gurbel PA Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity The Resultof the ACCEL-DIP Study Thromb Haemost 2014112 [Epub ahead of print]
186 Lev EI Bliden KP Jeong Y-H Pandya S Kang K Franzese C Tantry US Gurbel PA Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients J Am Heart Assoc 20143e001167
187 Alexopoulos D Xanthopoulou I Storey RF Bliden KP Tantry US Angiolillo DJ Gurbel PA Platelet reactivity during ticagrelor maintenance therapy A patient-level data meta-analysis Am Heart J 2014 168530-6
188 Lhermusier T Lipinski MJ Tantry US Escarcega RO Baker N Bliden KP Magalhaes MA Ota H Tian W Pendyala L Minha S Chen F Torguson R Gurbel PA Waksman R Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity Am J Cardiol 2015115716-23
189 Franzese CJ Bliden KP Gesheff MG Pandya S Guyer KE Singla A Tantry US Toth PP Gurbel PA Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy Am J Cardiol 2015 11151204-11
Curriculum Vitae Paul A Gurbel MD Page 12
190 Aradi D Kirtane A Bonello L Gurbel PA Tantry US Huber K Freynhofer MK Ten Berg J Janssen P Angiolillo DJ Siller-Matula JM Marcucci R Patti G Mangiacapra F Valgimigli M Morel O Palmerini T Price MJ Cuisset T Kastrati A Stone GW Sibbing D Bleeding and stent thrombosis on P2Y12-inhibitors collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention Eur Heart J 2015361762-71
191 Navarese EP Kolodziejczak M Schulze V Gurbel PA Tantry U Lin Y Brockmeyer M Kandzari DE Kubica JM DAgostino RB Sr Kubica J Volpe M Agewall S Kereiakes DJ Kelm M Effects of proprotein convertase subtilisinkexin type 9 antibodies in adults with hypercholesterolemia a systematic review and meta-analysis Ann Intern Med 201516340-51
192 Lee K Yoo SY Suh J Park KH Park Y Tantry US Park KS Han SH Kang WC Shin DH Lee C Choi SW Lee JH Cho YH Lee NH Jeong MH Ahn Y Kubica J Gurbel PA Park JH Jeong YH Efficacy of cilostazol on inhibition of platelet aggregation inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study Int J Cardiol 2015190370-5
193 Kowalewski M Schulze V Berti S Waksman R Kubica J Kołodziejczak M Buffon A Suryapranata H Gurbel PA Kelm M Pawliszak W Anisimowicz L Navarese EP Complete revascularisation in ST-elevation myocardial infarction and multivessel disease meta-analysis of randomised controlled trials Heart 2015 1011309-17
194 Baber U Mehran R Kirtane AJ Gurbel PA Christodoulidis G Maehara A Witzenbichler B Weisz G Rinaldi MJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri EL Jr Xu K Parise H Brodie BR Stuckey TD Stone GW Prevalence and impact of high platelet reactivity in chronic kidney disease Results from the assessment of dual antiplatelet therapy with drug-eluting stents registry Circ Cardiovasc Interv 20158e001683
195 Tricoci P DAndrea DM Gurbel PA Yao Z Cuchel M Winston B Schott R Weiss R Blazing MA Cannon L Bailey A Angiolillo DJ Gille A Shear CL Wright SDAlexander JH Infusion of Reconstituted High-Density Lipoprotein CSL112 in Patients With Atherosclerosis Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial J Am Heart Assoc 20154 pii e002171
196 Reny JL Fontana P Hochholzer W Neumann MJ ten Berg J Janssen PF Geisler T Gawaz M Marcucci R Gori A-M Cuisset T Alessi M-S Berdagueacute P Gurbel PA Yong G Angiolillo DJ Aradi D Beigel R Campo G Combescure C Vascular risk levels affect the predictive value of platelet reactivity 1 for the occurrence of major adverse cardiovascular events in patients on clopidogrel Systematic review and collaborative meta-analysis of individual patient data Thromb Haemost 2015 (in press)
197 Chaudhary R Bliden KP Tantry US Mohammed N Mathew D Gesheff MG Franzese CJ Gurbel PA Association of weight gain with coronary artery disease inflammation and thrombogenicity J Thromb Thrombolysis 2015 Dec 29 [Epub ahead of print]
198 Gurbel PA Bliden KP Turner SE Tantry US Gesheff MG Barr TP Covic L Kuliopulos A Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease Arterioscler Thromb Vasc Biol 201636189-97
199 Kwon TJ Tantry US Park Y Choi YM Ahn JH Kim KH Koh JS Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Smith SC Jr Jeong YH Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention Results of the ACCEL-BLEED study Thromb Haemost 2016 Jan 21115(5) [Epub ahead of print]
200 Bliden KP Tantry US Gesheff MG Franzese CJ Pandya S Toth PP Mathew DP Chaudhary R Gurbel PA Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis J Interv Cardiol 201629168-78
201 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin J Diabetes Complications 2016 May 10 pii S1056-8727(16)30127-1
202 Bedeir K Bliden K Tantry U Gurbel PA Mahla E Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel The Role of VerifyNow Can J Cardiol 201632724-5
203 Giustino G Kirtane AJ Baber U Geacuteneacutereux P Witzenbichler B Neumann FJ Weisz G Maehara A Rinaldi MJ Metzger C Henry TD Cox DA Duffy PL Mazzaferri EL Brodie BR Stuckey TD Gurbel PA Dangas GD Francese DP Ozan O Mehran R Stone GW Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study Am J Cardiol 20161171877-83
204 Kubica J Kubica A Jilma B Adamski P Hobl EL Navarese EP Siller-Matula JM Dąbrowska A Fabiszak T Koziński M Gurbel PA Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors Int J Cardiol 2016215201-8
205 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin
Curriculum Vitae Paul A Gurbel MD Page 13
J Diabetes Complications 2016 May 10 [Epub ahead of print] 206 Bliden KP Chaudhary R Lopez LR Damrongwatanasuk R Guyer K Gesheff MG Franzese CJ Kaza H
Tantry US Gurbel PA Oxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease Am J Cardiol 2016 Jun 15 [Epub ahead of print]
207 Mahla E Prueller F Farzi S Pregartner G Raggam RB Beran E Toller W Berghold A Tantry US Gurbel PA Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy Ann Thorac Surg 2016 Jul 1 [Epub ahead of print]
208 Koh JS Park Y Tantry US Ahn JH Kang MG Kim K Jang JY Park HW Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents The ACCEL-COMBO trial Platelets 2016 Aug 251-7 [Epub ahead of print]
209 Chaudhary R Saadin K Bliden KP Harris WS Dinh B Sharma T Tantry US Gurbel PA Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease Prostaglandins Leukot Essent Fatty Acids 201611340-45
210 Gurbel PA Bliden KP Chaudhary R Patrick J Liu F Chen G McLeod C Tantry US Antiplatelet Effect Durability of a Novel 24-Hour Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes MellitusAm J Cardiol 20161181941-1947
211 Gurbel PA Bliden KP Tantry US Monroe AL Muresan AA Brunner NE Lopez-Espina CG Delmenico PR Cohen E Raviv G Haugen DL Ereth MH First report of the point-of-care TEG A technical validation study of the TEG-6S system Platelets 201627642-649
212 Cornel JH Ohman EM Neely B Jakubowski JA Bhatt DL White HD Ardissino D Fox KA Prabhakaran D Armstrong PW Erlinge D Tantry US Gurbel PA Roe MT Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes J Am Heart Assoc 2016 Nov 45(11) pii e003977
213 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 201717109-121
214 Sharma T Bliden K Chaudhary R Tantry U Gurbel PA Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease Expert Opin Pharmacother 201718123-131
215 Park Y Tantry US Koh JS Ahn JH Kang MG Kim KH Jang JY Park HW Park JR Hwang SJ Park KS Kwak CH Hwang JY Gurbel PA Jeong YH Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction The REMODELING Trial Thromb Haemost 2017117911-922
216 Navarese EP Gurbel PA Andreotti F Kołodziejczak MM Palmer SC Dias S Buffon A Kubica J Kowalewski M Jadczyk T Laskiewicz M Jędrzejek M Brockmeyer M Airoldi F Ruospo M De Servi S Wojakowski W O Connor C Strippoli GF Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis PLoS One 201712e0168726
217 Bliden KP Chaudhary R Mohammed N Muresan AA Lopez-Espina CG Cohen E Raviv G Doubleday M Zaman F Mathew B Tantry US Gurbel PA Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system J Thromb Thrombolysis 201743437-445
Publications Peer Reviewed Original Science Research - Reviews 1 Serebruany VL Atar D Dalesandro MR OConnor CM Gurbel PA Changes in hemostasis after parenteral
magnesium in myocardial ischemia reperfusion Animal studies to clinical trials Magnes Res 19981137-42 2 McKenzie ME Gurbel PA Levine DJ Serebruany VL Clinical utility of available methods determining platelet
function Cardiology 199992240-7 3 Gurbel PA OConnor CM Cummings CC Serebruany VL Clopidogrel The future choice for preventing platelet
activation during coronary stenting Pharm Res 199965109-123 4 Nair GV Gurbel PA Fusaylov SY Davis CJ Ohman EM Bahr RD Christensen RH Serebruany VL Combing
necrosis and platelet markers for perfecting myocardial infarction rule out How close are we Cardiology 20009350-5
5 Davis CJ Gurbel PA Gaitis WA Fuzaylov SY Nair GV OrsquoConnor CM Serebruany VL Hemostatic abnormalities in congestive heart failure Diagnostic significance and clinical challenge Int J Cardiol 20007515-21
6 Pothula A Gurbel PA Atar D McKenzie ME Serebruany VL Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease Eur J Pharmacol 20004021-10
7 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Serebruany VL Platelet function and fibrinolytic agents Two sides of a coin Cardiology 20019555-60
Curriculum Vitae Paul A Gurbel MD Page 14
8 Samara WM Gurbel PA The role of platelet receptors and adhesion molecules in coronary artery disease Coron Artery Dis 20031465-79
9 Gurbel PA Tantry U Clopidogrel response variability and the advent of personalised antiplatelet therapy A bench to bedside journey Thromb Haemost 2011106265-71
10 Gurbel PA Roe MT Jakubowski JA Shah S Erlinge D Goodman SG Huber K Chan MY Cornel JH Tantry US Ohman EM Translational platelet research in patients with coronary artery disease What are the major knowledge gaps Thromb Haemost 2012 May 25108 [Epub ahead of print]
11 Bliden KP Baker BA Nolin TD Jeong YH Bailey WL Tantry US Gurbel PA Thienopyridine efficacy and cigarette smoking status Am Heart J 2013165693-703
12 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
13 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013111547-56
14 Gesheff MG Franzese CJ Bliden KP Contino CJ Rafeedheen R Tantry USGurbel PA Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin Expert Rev Clin Pharmacol 2014 7645-53
15 Tantry US Gesheff M Liu F Bliden KP Gurbel PA Resistance to antiplatelet therapy what progress has been made Expert Opin Pharmacother 2014 9 1-12
16 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print]
17 Gurbel PA Myat A Tantry US Platelet-mediated Thrombosis From Bench to Bedside Cir Res 2015 (in press)
18 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 20161245-58
19 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
20 Gurbel PA Tantry US Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes Heart 2016102882-92
21 Navarese EP Kolodziejczak M Kereiakes DJ Tantry US OConnor C Gurbel PA Proprotein Convertase SubtilisinKexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome A Narrative Review Ann Intern Med 2016164600-7
22 Gurbel PA Jeong YH Navarese EP Tantry US Platelet-Mediated Thrombosis From Bench to Bedside Circ Res 20161181380-91
23 Gurbel PA Myat A Kubica J Tantry US State of the art Oral antiplatelet therapy JRSM Cardiovasc Dis 2016 Jun 152048004016652514 doi 1011772048004016652514 eCollection 2016 Jan-Dec
24 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 2016 Nov 17 [Epub ahead of print] Review
25 Winter MP Grove EL De Caterina R Gorog DA Ahrens I Geisler T Gurbel PA Tantry U Navarese EP Siller-Matula JM Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors Eur Heart J Cardiovasc Pharmacother 2017 Feb 15 doi 101093ehjcvppvw044 [Epub ahead of print]
26 Shah P Tantry US Bliden KP Gurbel PA Bleeding and thrombosis associated with ventricular assist device therapy J Heart Lung Transplant 2017 May 11 pii S1053-2498(17)31789-8
Inventions Patents Copyrights 32294 Gurbel PA Anderson RD Autoperfusion dilatation catheter United States Patent 5295959 51501 Dalesandro MR Gurbel PA Serebruany VL Determining a treatment plan for patients undergoing thrombotic
events by monitoring p-Selectin United States Patent 623071 61201 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6245782 13102 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 20020013343 42203 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6552014
Curriculum Vitae Paul A Gurbel MD Page 15
120611 Gurbel PA The detection of restenosis risk in patients receiving a stent by measuring the characteristics of blood clotting including the measurement of maximum thrombin-induced clot strength (patent awarded pending)
6308 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 7381536 2010 Gurbel PA Conley P Andre P Gretler D Jurek M Methods for diagnosis and treatment of thrombotic
disorders mediated bycyp2c192 (patent pending) 41014 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent
20140100167 81815 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 9110062 111715 Gurbel PA Detection of restenosis risk in patients receiving a stent by measuring the characteristics of
blood clotting including the measurement of maximum thrombin-induced clot strength Patent 9188597 Extramural Funding (since 2002) CURRENT 2010-2015 MAGMA (Multianalyte And Genetic Markers of Atherosclerosis)
Haemonetics and Sinai Hospital of Baltimore 2015-present An Observational Study of CORA-Assisted Stroke Identification and Antithrombotic Therapy
2014-2015 Feasibility clinical trial to evaluate the efficacy of an Anticoagulant cartridge to be used in the CORA System Coramed Technologies LLC
2014-2015 Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid Durlaza in CVD Patients at Risk of High Platelet Turnover (DURATION)
New Haven Pharmaceuticals Inc 2015-present Influence of Edoxaban on Coagulability and Thrombin Generation An in Vitro Study Focusing on
Thrombelastography Daiichi Sankyo
2016 Influence of Vorapaxar on Thrombin Generation and Coagulability Merck 2015-present Durlaza GI GI Tolerability Study New Haven Pharamceuticals 2015-present Thrombogenicity in LVAD Recipients Haemonetics 2014-2015 First-in-Man Assessment of PZ-128 National Institutes of Health PREVIOUS 2002 Atorvastatin in the Treatment of Heart Failure
LBH IRB 20030512 NIHThe National Heart Lung and Blood Institute NIH
2002 Asessment of the In Vitro Effects of Tenecteplase Reteplase and Alteplase on Human Platelets TAR STUDY Genetech
2003-2005 Assessment of the Effects of the heparin-coated Cordis Stent versus Non-coated Stents on Platelet and Endothelial Cell Activation and Thrombin Effect in Patients with Coronary Artery Disease (HEPACOAT) Cordis Inc
2004-2005 The Antiplatelet Effects of Eptifibatide with High and Standard Dose Clopidogrel in Low-Moderate Risk Patients Undergoing Coronary Intervention (CLEAR-PLATELETS Study) MilleniumSchering Plough
2004-2005 The Use of The TEG System to Monitor Platelet Inhibition at Bedside 5R44HL059753-03Haemoscope National Institute of Health
2004-2006 Clopidogrel Resistance in Patients with Stent Thrombosis (CREST Study) AstraZeneca
Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study MilleniumSchering Plough
2005 St Johns Wort Decreases ADP Induced Platelet Reactivity in Known Clopidogrel Resistant Post Coronary Intervention Patients after a Loading Dose of Clopidogrel University of Michigan
2008-2009 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST) Sinai Hospital Department of Medicine
2009-2010 Demonstration of the Pharmacodynamic Antiplatelet Effect of PRT060128 in Patients with High Platelet Reactivity during Clopidogrel and Aspirin Maintenance Therapy (PORTOLA) Portola Pharmaceuticals
2008-2009 A Randomised Double-Blind Outpatient Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND] AstraZeneca Pharmaceuticals LP
2008-2009 A Randomized Double-blind Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Background Therapy in Patients with Stable Coronary Artery Disease with Additional Detailed Assessment of Cardiopulmonary Function (ONSET-OFFSET) AstraZeneca Pharmaceuticals LP
2008-2009 A Single Center Randomized Open Label Parallel Group Pharmacodynamic Study of a Novel Combination Form of Aspirin and Phytosterol versus Aspirin in Healthy Adult Subjects (ARMOR) Bayer Healthcare LLC
2008-2009 Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel Plus EC Aspirin (325 mg) and Clopidogrel Plus PA32540 on Platelet Aggregation in Healthy Volunteers POZEN 110 POZEN Inc
2009-2010 Antithrombosis with Clopidogrel Beyond the Concept of Platelet Aggregate Inhibition (SANOFI) Sanofi Inc 2010-2012 A Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel EC
Aspirin 81 mg and EC omeprazole 40 mg all dosed concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers POZEN Inc
Intramural Funding (since 2002) CURRENT 2008-present Time Based Strategy to Reduce Clopidogrel Associated Bleeding Related to CABG (TARGET CABG) Sinai Hospital of Baltimore Department of Medicine 2009-present Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI)
Sinai Hospital of Baltimore Department of Medicine 2011-present Detection of Leukemic Blood and Solid TypE MalignanCies by Urinary 11-DehydroThromboxane B2 (DETECT) Study
Sinai Hospital of Baltimore Department of Medicine PREVIOUS 2001-2002 Platelet Activation in Stenting PAST Study Sinai Hospital of Baltimore 2005-2006 Platelet Reactivity in Patients with Crohnrsquos disease Receiving Infliximab (chimeric anti-TNF alpha antibody) ndash COIN
Sinai Hospital of Baltimore Department of Medicine 2006-2007 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST)
Sinai Hospital of Baltimore Department of Medicine 2008-2011 Platelet Reactivity and Thrombogenecity in Postmenopausal Women
Sinai Hospital Department of Medicine 2008-2010 Platelet Reactivity and Thrombogenecity in Postmenopausal Women (PRIDE Study)
Sinai Hospital Department of Medicine Multicenter Studies since 2001
Curriculum Vitae Paul A Gurbel MD Page 17
CURRENT 2010-present The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and
Clopidogrel in Aspirin-Treated Subjects With Stable Coronary Artery Disease Daiichi Sankyo
2010-present A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly versus Non-Elderly Aspirin-Treated Subjects with Stable Coronary Artery Disease Eli Lilly amp company
2011-present A Prospective Multicenter Randomized Trial of Clopidogrel versus Prasugrel Anti-platelet Therapy in Cytochrome P450 2C19 (CYP2C19) Intermediate Metabolizers Grant No U01HL105198
NIH National Heart Lung and Blood Institute NIH 2011-present A Prospective Randomized Multi-Center Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHERreg Sirolimus-Eluting Coronary stents
HCRI 2012-present A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in
patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)
Bayer Healthcare LLC 2013-present Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in
Patients at a High-Risk for Vascular Outcomes (ACCELERATE) Eli Lilly amp Company 2014-present A Phase 2b Multi-center Randomized Placebo-controlled Dose-ranging Study to Investigate the
Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infarction
AEGIS CSL 2015-2017 A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety of PZ- 128 in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention
National Institute of Health PREVIOUS 2001 A Randomized Double-Blind Placebo-Controlled Study of Two Intravenous Dosing Regimens of
h5G11-scFv in Patients with Acute Myocardial Infarction Undergoing 2001-2002 Prevention of REStenosis with Tranilast and Its Outcomes A Placebo Controlled Trial PRESTO STUDY
SmithKline Beecham 2002-2003 Taxus IV-SR Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
Boston Scientific 2003 MICROVENA Corporation TRAP Vascular Filtration System (VFS) Trial
Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily Pfizer Inc
2003-2004 Phase 3 Multi-Center Double-Blind Randomized Parallel Group Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily (QD) for 24 Months Compared with Atorvastatin Alone in Subjects with Angiographically Documented Coronary Heart Disease Pfizer Inc
2003-2004 A Randomized Controlled Trial of the Medtronic Endeavor Drug Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ldquoENDEAVOR III Studyrdquo)
Medtronic 2009-2010 A Prospective Randomized Open-label Multicenter study in Patients Presenting with Acute Coronary Syndromes SYNERGY STUDY
Aventis Pharmaceuticals 2004 CObalt chromium STent with Antiproliferative for Restenosis II Trialrdquo Costar study
Conor Medsystems
Curriculum Vitae Paul A Gurbel MD Page 18
2004-2005 A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions ENDEAVOR IV Medtronic
2004-2005 A Randomized Trial to evaluate the relative protection against POST-PCI microvasculat obstruction among antiplatelet and anti-thrombotic medications (TIMI-30) TIMI group
2004-2006 A Double-blind Double-dummy Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI 33 AstraZeneca Lp
2005-2006 Strategy To Reduce Atherosclerosis Development Involving Administration of Rimonabant - The Intravascular Ultrasound Study (STRADIVARIUS) EFC5827 Sanofi Synthelabo Research
2006 A Multicenter Randomized Double-Blind Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (TRASM-PCI) Schering Plough
2006-2007 A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel -SWAP (SWitching Anti Platelet study) Eli Lilly amp Company and Sankyo Company Limited
2006-2007 A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2008-2010 A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary InterventionTIMI-38 Eli Lilly Company Daiichi
2009-2010 A Randomized Double-Blind Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128 a Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Interventions (INNOVATE-PCI) Portola Pharmaceuticals
2010-2012 TReatment with ADPreceptor iNhibitorS Longitudinal Assessment ofTreatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS)
Eli Lilly Company 2010-2013 RADAR Randomized Partially-Blinded Multi-Center Active-Controlled Dose-Ranging Study
Assessing the Safety Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome Regado Bioscience Inc
2011-2013 A Phase IIa Multi-center Randomized Sponsor-unblinded Placebo-controlled Single Ascending Dose Study to Investigate the Safety Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Adults Taking Aspirin and a P2Y12 Platelet Inhibitor
AEGIS CSL Research Program BuildingLeadership 1991-1995 Director Interventional Cardiology Research University of Maryland Medical System 1998-2015 Director Sinai Center for Thrombosis Research 2001-2015 Director Cardiovascular Research Lifebridge Health 2002-2015 Director Therapeutics Research and Technology Development for the Cardiac Catheterization Program Sinai Hospital of Baltimore 2007-2015 Associate Chief for Research Department of Medicine Sinai Hospital of Baltimore 2015-current Director Interventional Cardiology and Cardiovascular Medicine Research INOVA Health 2015-Current Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute EDUCATIONAL ACTIVITIES
Curriculum Vitae Paul A Gurbel MD Page 19
Peer Reviewed Publications-Consensus Statements Expert Opinions 1 Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C
Rao AK The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 200531309-11
2 Hoekstra J Cohen M Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Saucedo JF Pollack CV Jr Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention-an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective report on a roundtable discussion Am J Emerg Med 200927720-8
3 Bonello L Tantry US Marcucci R Blindt R Angiolillo DJ Becker R Bhatt DL Cattaneo M Collet JP Cuisset T Gachet C Montalescot G Jennings LK Kereiakes D Sibbing D Trenk D Van Werkum JW Paganelli F Price MJ Waksman R Gurbel PA Working Group on High On Treatment Platelet Reactivity Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 201056919-33
4 Gurbel PA Tantry US Shuldiner AR Kereiakes DJ Genotyping one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 201056112-6
5 Gurbel PA Tantry US Antiplatelet therapy Clopidogrel-PPI interaction an ongoing controversy Nat Rev Cardiol 201187-8
6 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
7 Gurbel PA Nolin TD Tantry US Clopidogrel efficacy and cigarette smoking status JAMA 20123072495-6 8 Tantry US Bonello L Aradi D Price MJ Jeong YH Angiolillo DJ Stone GW Curzen N Geisler T Ten Berg J
Kirtane A Siller-Matula J Mahla E Becker RC Bhatt DL Waksman R Rao SV Alexopoulos D Marcucci R Reny JL Trenk D Sibbing D Gurbel PA Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding J Am Coll Cardiol 2013622261-73
9 Gurbel PA Tantry US Antiplatelet and anticoagulant agents in heart failure Current status and future perspectives JACC Heart Fail 201421-14
10 Gurbel PA Tantry US Antiplatelet therapy What have we learned from the ANTARCTIC trial Nat Rev Cardiol 201613639-640
Invited Review Articles 1 Gurbel PA Midwall JA Brodie BR Angioplasty and adjunctive intra-aortic balloon pump counterpulsation Current
clinical considerations Todays Therapy Trends 19951363-78 2 OrsquoConnor CM Gurbel PA Serebruany VL Depression and ischemic heart disease Am Heart J 200014063-69 3 Gurbel PA Serebruany VL Oral IIbIIIa inhibitors From initial promise to clinical failures J Thromb and
Thrombolysis 200010217-20 4 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Atar D Serebruany VL Platelets and
Thrombolysis Cooperation or Contrariety Heart Drug 20011281-290 5 McKenzie ME Gurbel PA The potential of monoclonal antibodies to reduce reperfusion injury in myocardial
infarction BioDrugs 200115395-404 6 Gurbel PA Bliden KP Hayes K Tantry U Platelet activation in myocardial ischemic syndromes Expert Rev of
Cardiovasc Ther 20052535-45 7 Tantry US Bliden KP Gurbel PA Resistance to antiplatelet drugs Current status and future research Expert
Opin Pharmacother 200562027-45 8 Gurbel PA Lau WC Bliden KP Tantry US Clopidogrel resistance Implications for coronary stenting Curr Pharm
Des 2006121261-9 9 Gurbel PA Tantry US Drug insight Clopidogrel non-responsiveness Nature ClinPract Cardiovasc Med
20063387-95 10 Gurbel PA Tantry US Aspirin and Clopidogrel Resistance Considerations and management J Interv Cardiol
200619439-48 11 Lau WC Gurbel PA Antiplatelet drug resistance and drug-drug interactions Role of cytochrome P450 3A4
Pharm Res 2006232691-708 12 Wiviott SD Tantry US Gurbel PA Clinical applications of antiplatelet therapy Rev Cardiovasc Med 20067
Curriculum Vitae Paul A Gurbel MD Page 20
130-46 13 Tantry US Bliden KP Gurbel PA Prasugrel Expert Opin Investig Drugs 2006151627-33 14 Gurbel PA Tantry US Clopidogrel Resistance Thromb Res 2007120311-21 15 Tantry US Etherington A Bliden KP Gurbel PA Antiplatelet therapy Current strategies and future trends Future
Cardiology 20072343-366 16 Gurbel PA Tantry US The relationship of platelet reactivity to the occurrence of post-stenting ischemic events
emergence of a new cardiovascular risk factor Rev Cardiovasc Med 2006Suppl 4S20-8 17 Tantry US Bliden KP Gurbel PA AZD6140 Expert Opin Investig Drugs 200716225-9 18 Gurbel PA Tantry US Stent thrombosis role of compliance and non-responsiveness to antiplatelet therapy Rev
Cardiovasc Med 20078S19-S26 19 Gurbel PA Kandzari DE Stent thrombosis associated with first-generation drug-eluting stents issues with
antiplatelet therapy Neth Heart J 200715148-50 20 Gurbel PA Tantry US The role of clopidogrel in cardiovascular diseases Pol Arch Med Wewn 2007117207-9 21 Gurbel PA DiChiara J Tantry US Antiplatelet therapy after implantation of drug-eluting stents duration
resistance alternatives and management of surgical patients Am J Cardiol 200710018M-25M 22 Gurbel PA Becker R Mann KG Steinhubl SR Michelson AD Platelet function monitoring in patients with
coronary artery disease J Am Coll Cardiol 2007501822-34 23 Gurbel PA Tantry US Prasugrel a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig
Drugs 20089324-36 24 Gurbel PA Bilden KP Tantry US Diagnostics for aspirin resistance Mol Diagn Ther 20081255-6 25 Gurbel PA Antonino MJ Tantry US Antiplatelet treatment of cardiovascular disease a translational research
perspective Pol Arch Med Wewn 2008118289-97 26 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831I36 27 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention Clin Cardiol 200831I28-I35
28 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches Clin Cardiol 200831I21-I27
29 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention Clin Cardiol 200831I17-I20
30 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Assessing the Current Role of Platelet Function Testing Clin Cardiol 200831I10-I16
31 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831136
32 Keriakes DJ Gurbel PA Periprocedural platelet function in percutaneous coronary intervention JACC Cardiovasc Interv 2008suppl 1111ndash121
33 Gurbel PA Tantry US The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome J Interv Cardiol 200821Suppl 1S10-7
34 Gurbel PA Tantry US Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 20091122-322
35 Gurbel PA Aspirin scope and limitations Br J Cardiol 200917 (Suppl 1)S8-S9 36 Cohen M Hoekstra J Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Pollack CV Jr
Saucedo JF Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion J Interv Cardiol 200821283-99
37 Angiolillo DJ Bhatt DL Gurbel PA Jennings LK Advances in antiplatelet therapy agents in clinical development Am J Cardiol 2009103(3 Suppl)40A-51A
38 Gurbel PA Mahla E Antonino MJ Tantry US Response variability and the role of platelet function testing J Invasive Cardiol 200921172-8
39 Gurbel PA Antonino MJ Tantry US Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug MetabToxicol Expert Opin Drug Metab Toxicol 20095989-1004
40 Gurbel PA Tantry US Antiplatelet resistance- Fact or Myth Am Hosp J 2009750-57 41 Gurbel PA Mahla E Tantry US Aspirin resistance Prog Cardiovasc Dis 200952141-52 42 Tantry US Gurbel PA Platelet monitoring for PCI Is it really necessary Haemostaseologie 200929 368-75 43 Gurbel PA Aspirin-scope and limitations Br J Cardiol 200917(Suppl 1)S8-S9
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 9
Thromb Haemost 201191902-15) 140 Jeong YH Tantry US Kim I-S Koh J-S Kwon TJ Park Y Hwang SJ Bliden KP Kwak CH Hwang J-W
Gurbel PA Effect of CYP2C192 and 3 loss-of-function allele carriage on platelet reactivity and adverse clinical event occurrence in east asian acute myocardial infarction survivors treated with clopidogrel and aspirin Circ Cardiovasc Genet 20114585-94
141 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
142 Gurbel PA Bliden KP Firt J Zhang Y Plachetka JR Antonino M Gesheff M Tantry US Pharmacodynamic evaluation of clopidogrel plus PA32540 The Spaced PA32540 with Clopidogrel INteraction Gauging (SPACING) study Clin Pharmacol Ther 201190860-6
143 Navarese EP Buffon A Andreotti F Gurbel PA Kozinski M Kubica A Musumeci G Cremonesi A Tavazzi L Kubica J Castriota F Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome A meta-analysis of randomized trials Atherosclerosis 20122221-7
144 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 201210487-9
145 Gurbel PA Bliden KP Antonino MJ Gesheff T Cummings CC Dubois BV Herzog WR Tantry US Time dependence of clopidogrel loading effect Platelet activation versus platelet aggregation Thromb Res Thromb Res 20121291-2
146 Mahla E Suarez TA Bliden KP Rehak P Metzler H Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study Circ Cardiovasc Interv 20125261-9
147 Park Y Jeong YH Tantry US Ahn JH Kwon TJ Park JR Hwang SJ Gho EH Bliden KP Kwak CH Hwang JY Kim S Gurbel PA Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study Eur Heart J 2012332151-62
148 Husted SE Storey RF Bliden K Tantry US Hoslashimark L Butler K Wei C Teng R Gurbel PA Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease Results from the ONSET-OFFSET and RESPOND Studies Clin Pharmacokinet 201251397-409
149 Kubica J Koziński M Navarese EP Tantry US Grześk G Fabiszak T Kubica A Swiątkiewicz I Bliden KP Gurbel PA Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction A systematic review and meta-analysis of randomized clinical trials Cardiol J 201219(3)230-42 Jeong YH Bliden KP Antonino MJ Tantry US Gurbel PA Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity Platelets 2012 May 30 [Epub ahead of print]
150 Welsh RC Rao SV Zeymer U Thompson VP Huber K Kochman J McClure MW Gretler DD Bhatt DL Gibson CM Angiolillo DJ Gurbel PA Berdan LG Paynter G Leonardi S Madan M French WJ Harrington RA on behalf of the INNOVATE PCI Investigators A Randomized Double-Blind Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention The INNOVATE-PCI Trial Circ Cardiovasc Interv 20125336-346
151 Angiolillo DJ Welsh RC Trenk D Neumann FJ Conley PB McClure MW Stephens G Kochman J Jennings LK Gurbel PA Woacutejcik J Dabrowski M Saucedo JF Stumpf J Buerke M Broderick S Harrington RA Rao SV Pharmacokinetic and Pharmacodynamic Effects of Elinogrel Results of the Platelet Function Substudy From the Intravenous and Oral Administration of Elinogrel to Evaluate Tolerability and Efficacy in Nonurgent Percutaneous Coronary Intervention Patients (INNOVATE-PCI) Trial Circ Cardiovasc Interv 20125347-56
152 Reny JL Combescure C Daali Y Gurbel PA Fontana P PON1 Meta-Analysis Group Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events a systematic review and meta-analysis J Thromb Haemost 2012101242-1251
153 Jeong YH Bliden KP Antonino MJ Park KS Tantry US Gurbel PA Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies Am Heart J 201216435-42
154 Jeong YH Bliden KP Antonino MJ Tantry US Gurbel PA Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity Platelets 201216435-42
155 Singla A Bliden KP Jeong YH Abadilla K Antonino MJ Muse WC Mathew DP Bailon O Tantry US Gurbel PA Platelet reactivity and thrombogenecity in postmeopausal women Menopause 20132057-63
156 Jeong YH Tantry US Park Y Kwon TJ Park JR Hwang SJ Bliden KP Koh EH Kwak CH Hwang JY Kim S
Curriculum Vitae Paul A Gurbel MD Page 10
Gurbel PA Pharmacodynamic Effect of Cilostazol Plus Standard Clopidogrel Versus Double-Dose Clopidogrel in Patients With Type 2 Diabetes Undergoing Percutaneous Coronary Intervention Diabetes Care 2012352194-7
157 Roe MT Armstrong PW Fox KAA White HD Prabhakaran D Goodman SG Cornel JH Bhatt DL Clemmensen P Martinez F Ardissino D Nicolau JC Boden WE Gurbel PA Ruzyllo W Dalby AJ McGuire DK Leiva-Pons JL Parkhomenko A Gottlieb S Topacio GO Hamm C Pavlides G Goudev AR Oto A Tseng C-D Merkely B Gasparovic V Corbalan R Cinteză M McLendon RC Winters KJ Brown EB Lokhnygina Y Aylward PE Huber K Hochman JS E Magnus Ohman EM for the TRILOGY ACS Investigators Prasugrel versus clopidogrel for ACS patients managed without revascularization N Engl J Med 20123671297-309
158 Gurbel PA Bliden KP Jeong Y-H Antonino M Gesheff T Fort JG Shuldiner A Chai S Gesheff M Zhang Y Tantry US Spaced Administration of PA32540 and Clopidogrel Results in Greater Platelet Inhibition than Synchronous Administration of Enteric-Coated Aspirin and Enteric-Coated Omeprazole and Clopidogrel Am Heart J 2013165176-82
159 Gurbel PA Erlinge D Ohman EM Neely B Neely M Goodman SG Huber K Chan MY Cornel JH Brown E Zhou C Jakubowski JA White HD Fox KA Prabhakaran D Armstrong PW Tantry US Roe MT TRILOGY ACS Platelet Function Substudy Investigators JAMA 20123081785-94
160 Lewis JP Horenstein RB Ryan K OConnell JR Gibson Q Mitchell BD Tanner K Chai S Bliden KP Tantry US Peer CJ Figg WD Spencer SD Pacanowski MA Gurbel PA Shuldiner AR The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response Pharmacogenet Genomics 2012 Pharmacogenet Genomics 2013231-8
161 Jeong YH Tantry US Min JH Park Y Navarese EP Koh JS Park JR Hwang SJ Kho EH Bliden KP Kwak CH Hwang JY Kim S Gurbel PA Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention Int J Cardiol 2012 Oct 12 doipii S0167-5273(12)01253-3 101016
162 Saucedo JF Angiolillo DJ Deraad R Frelinger AL 3rd Gurbel PA Costigan TM Jakubowski JA Ojeh CK Duvvuru S Effron MB for the SWAP Investigators Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel insights from the switching anti-platelet (SWAP) study Thromb Haemost 2012 Dec 6109(2) [Epub ahead of print]
163 Navarese EP Austin D Gurbel PA Andreotti F Tantry U James S Buffon A Kozinski M Obonska K Bliden K Jeong YH Kubica J Kunadian V Drug-coated balloons in treatment of in-stent restenosis a meta-analysis of randomized controlled trials Clin Res Cardiol 2012 Dec 20 [Epub ahead of print]
164 Gurbel PA Bliden KP Fort JG Jeong YH Shuldiner A Chai S Gesheff T Antonino M Gesheff M Zhang Y Tantry US Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel Am Heart J 2013165176-82
165 Lewis JP Ryan K OConnell JR Horenstein RB Damcott CM Gibson Q Pollin TI Mitchell BD Beitelshees AL Pakzy R Tanner K Parsa A Tantry US Bliden KP Post WS Faraday N Herzog W Gong Y Pepine CJ Johnson JA Gurbel PA Shuldiner AR Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes Circ Cardiovasc Genet 2013 Feb 7 [Epub ahead of print]
166 Navarese EP Gurbel PA Andreotti F Tantry U Jeong YH Kozinski M Engstroslashm T Di Pasquale G Kochman W Ardissino D Kedhi E Stone GW Kubica J Optimal Timing of Coronary Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes A Systematic Review and Meta-analysis Ann Intern Med 2013158261-70
167 Jeong YH Abadilla KA Tantry US Park Y Koh JS Kwak CH Hwang JY Gurbel PA Influence of CYP2C192 and 3 loss-of-function alleles on pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention the results of the ACCEL-DOUBLE-2N3 studyJ Thromb Haemost 2013111194-7
168 Gurbel PA Bliden KP Logan DK Kereiakes DJ Lasseter KC White A Angiolillo DJ Nolin TD Maa JF Bailey WL Jakubowski JA Ojeh CK Jeong YH Tantry US Baker BA The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel The PARADOX Study J Am Coll Cardiol 2013 Apr 16 doipii S0735-1097(13)01478-2 101016jjacc201303037 [Epub ahead of print]
169 Grzesk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E4 Jeong Y-H Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 2013 Article ID 928271 httpdxdoiorg1011552013928271
170 Erlinge D Gurbel PA James S Lindahl TL Svensson P Ten Berg JM Foley DP Wagner H Brown PB Luo J Zhou C Moser BA Jakubowski JA Small DS Winters KJ Angiolillo DJ Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains non-inferiority to prasugrel 10-mg in non-elderly patients The GENERATIONS trial a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients J Am Coll Cardiol 201362577-83
Curriculum Vitae Paul A Gurbel MD Page 11
171 Kim IS Jeong YH Tantry US Park Y Lee DH Bliden KP Koh JS Park JR Jang JS Hwang SJ Koh EH Kwak CH Hwang JY Kim S Gurbel PA Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading Am Heart J 201316695-103
172 Grześk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E Jeong YH Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 20132013928271
173 Stone GW Witzenbichler B Weisz G Rinaldi MJ Neumann FJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri E Gurbel PA Xu K Parise H Kirtane AJ Brodie BR Mehran R Stuckey TD for the ADAPT-DES Investigators Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES) a prospective multicentre registry study Lancet 2013382614-23
174 Angiolillo DJ Curzen N Gurbel P Vaitkus P Lipkin F Li W Jakubowski JA Zettler M Effron MB Trenk D Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in subjects with stable coronary artery disease Results of the SWAP-2 Study J Am Coll Cardiol 2014631500-9
175 Jeong YH Bliden KP Shuldiner AR Tantry US Gurbel PA Thrombin-induced platelet-fibrin clot strength Relation to high on-clopidogrel platelet reactivity genotype and post-percutaneous coronary intervention outcomes Thromb Haemost 2014111713-24
176 Gouya G Arrich J Wolzt M Huber K Verheugt FW Gurbel PA Pirker-Kees A Siller-Matula JM Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases a systematic review and meta-analysis Stroke 201445492-503
177 Erlinge D James S Duvvuru S Jakubowski JA Wagner H Varenhorst C Tantry US Brown PB Small D Moser BA Sundseth S Walker JR Winters KJ Gurbel PA Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease Thromb Haemost 2014111943-50
178 Gurbel PA Baker BA Bailey WL Bliden KP Tantry US Unraveling the Smokers Paradox Cigarette smoking high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors Thromb Haemost 20141111187-90
179 Koh JS Kim IS Tantry US Yoon SE Park Y Cho SY Lee EJ Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading The results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study Int J Cardiol 2014174129-32
180 Bliden KP Singla A Gesheff MG Toth PP Tabrizchi A Ens G Guyer K Singh M Franzese CJ Stapleton D Tantry US Gurbel PA Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin Thromb Haemost 2014 Apr 24112(2) [Epub ahead of print]
181 Gurbel PA Gesheff MG Franzese CJ Bliden KP Tantry US Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy Platelets 201526608-9
182 Gurbel PA Bergmeijer TO Tantry US Ten Berg JM Angiolillo DJ James S Lindahl TL Svensson P Jakubowski JA Brown PB Duvvuru S Sundseth S Walker JR Small D Moser BA Winters KJ Erlinge D The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease Thromb Haemost 2014 2014112589-97
183 Cornel JH Ohman EM Neely B Clemmensen P Sritara P Zamoryakhin D Armstrong PW Prabhakaran D White HD Fox KA Gurbel PA Roe MT TRILOGY ACS Investigators Impact of smoking status on platelet function and clinical outcomes with prasugrel vs clopidogrel in patients with acute coronary syndromes managed without revascularization Insights from the TRILOGY ACS trial Am Heart J 201416876-87
184 Park Y Jung JM Tantry US Kim K Koh JS Park JR Hwang SJ Kwak CH Hwang JY Kim S Gurbel PA Jeong YH Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration The ACCEL-PARAZOL Study J Atheroscler Thromb 2014211121-39
185 Park Y Jeong YH Tantry US Ahn JH Kim K Koh J Park J Hwang SJ Kwak CH Hwang JY Gurbel PA Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity The Resultof the ACCEL-DIP Study Thromb Haemost 2014112 [Epub ahead of print]
186 Lev EI Bliden KP Jeong Y-H Pandya S Kang K Franzese C Tantry US Gurbel PA Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients J Am Heart Assoc 20143e001167
187 Alexopoulos D Xanthopoulou I Storey RF Bliden KP Tantry US Angiolillo DJ Gurbel PA Platelet reactivity during ticagrelor maintenance therapy A patient-level data meta-analysis Am Heart J 2014 168530-6
188 Lhermusier T Lipinski MJ Tantry US Escarcega RO Baker N Bliden KP Magalhaes MA Ota H Tian W Pendyala L Minha S Chen F Torguson R Gurbel PA Waksman R Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity Am J Cardiol 2015115716-23
189 Franzese CJ Bliden KP Gesheff MG Pandya S Guyer KE Singla A Tantry US Toth PP Gurbel PA Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy Am J Cardiol 2015 11151204-11
Curriculum Vitae Paul A Gurbel MD Page 12
190 Aradi D Kirtane A Bonello L Gurbel PA Tantry US Huber K Freynhofer MK Ten Berg J Janssen P Angiolillo DJ Siller-Matula JM Marcucci R Patti G Mangiacapra F Valgimigli M Morel O Palmerini T Price MJ Cuisset T Kastrati A Stone GW Sibbing D Bleeding and stent thrombosis on P2Y12-inhibitors collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention Eur Heart J 2015361762-71
191 Navarese EP Kolodziejczak M Schulze V Gurbel PA Tantry U Lin Y Brockmeyer M Kandzari DE Kubica JM DAgostino RB Sr Kubica J Volpe M Agewall S Kereiakes DJ Kelm M Effects of proprotein convertase subtilisinkexin type 9 antibodies in adults with hypercholesterolemia a systematic review and meta-analysis Ann Intern Med 201516340-51
192 Lee K Yoo SY Suh J Park KH Park Y Tantry US Park KS Han SH Kang WC Shin DH Lee C Choi SW Lee JH Cho YH Lee NH Jeong MH Ahn Y Kubica J Gurbel PA Park JH Jeong YH Efficacy of cilostazol on inhibition of platelet aggregation inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study Int J Cardiol 2015190370-5
193 Kowalewski M Schulze V Berti S Waksman R Kubica J Kołodziejczak M Buffon A Suryapranata H Gurbel PA Kelm M Pawliszak W Anisimowicz L Navarese EP Complete revascularisation in ST-elevation myocardial infarction and multivessel disease meta-analysis of randomised controlled trials Heart 2015 1011309-17
194 Baber U Mehran R Kirtane AJ Gurbel PA Christodoulidis G Maehara A Witzenbichler B Weisz G Rinaldi MJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri EL Jr Xu K Parise H Brodie BR Stuckey TD Stone GW Prevalence and impact of high platelet reactivity in chronic kidney disease Results from the assessment of dual antiplatelet therapy with drug-eluting stents registry Circ Cardiovasc Interv 20158e001683
195 Tricoci P DAndrea DM Gurbel PA Yao Z Cuchel M Winston B Schott R Weiss R Blazing MA Cannon L Bailey A Angiolillo DJ Gille A Shear CL Wright SDAlexander JH Infusion of Reconstituted High-Density Lipoprotein CSL112 in Patients With Atherosclerosis Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial J Am Heart Assoc 20154 pii e002171
196 Reny JL Fontana P Hochholzer W Neumann MJ ten Berg J Janssen PF Geisler T Gawaz M Marcucci R Gori A-M Cuisset T Alessi M-S Berdagueacute P Gurbel PA Yong G Angiolillo DJ Aradi D Beigel R Campo G Combescure C Vascular risk levels affect the predictive value of platelet reactivity 1 for the occurrence of major adverse cardiovascular events in patients on clopidogrel Systematic review and collaborative meta-analysis of individual patient data Thromb Haemost 2015 (in press)
197 Chaudhary R Bliden KP Tantry US Mohammed N Mathew D Gesheff MG Franzese CJ Gurbel PA Association of weight gain with coronary artery disease inflammation and thrombogenicity J Thromb Thrombolysis 2015 Dec 29 [Epub ahead of print]
198 Gurbel PA Bliden KP Turner SE Tantry US Gesheff MG Barr TP Covic L Kuliopulos A Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease Arterioscler Thromb Vasc Biol 201636189-97
199 Kwon TJ Tantry US Park Y Choi YM Ahn JH Kim KH Koh JS Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Smith SC Jr Jeong YH Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention Results of the ACCEL-BLEED study Thromb Haemost 2016 Jan 21115(5) [Epub ahead of print]
200 Bliden KP Tantry US Gesheff MG Franzese CJ Pandya S Toth PP Mathew DP Chaudhary R Gurbel PA Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis J Interv Cardiol 201629168-78
201 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin J Diabetes Complications 2016 May 10 pii S1056-8727(16)30127-1
202 Bedeir K Bliden K Tantry U Gurbel PA Mahla E Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel The Role of VerifyNow Can J Cardiol 201632724-5
203 Giustino G Kirtane AJ Baber U Geacuteneacutereux P Witzenbichler B Neumann FJ Weisz G Maehara A Rinaldi MJ Metzger C Henry TD Cox DA Duffy PL Mazzaferri EL Brodie BR Stuckey TD Gurbel PA Dangas GD Francese DP Ozan O Mehran R Stone GW Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study Am J Cardiol 20161171877-83
204 Kubica J Kubica A Jilma B Adamski P Hobl EL Navarese EP Siller-Matula JM Dąbrowska A Fabiszak T Koziński M Gurbel PA Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors Int J Cardiol 2016215201-8
205 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin
Curriculum Vitae Paul A Gurbel MD Page 13
J Diabetes Complications 2016 May 10 [Epub ahead of print] 206 Bliden KP Chaudhary R Lopez LR Damrongwatanasuk R Guyer K Gesheff MG Franzese CJ Kaza H
Tantry US Gurbel PA Oxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease Am J Cardiol 2016 Jun 15 [Epub ahead of print]
207 Mahla E Prueller F Farzi S Pregartner G Raggam RB Beran E Toller W Berghold A Tantry US Gurbel PA Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy Ann Thorac Surg 2016 Jul 1 [Epub ahead of print]
208 Koh JS Park Y Tantry US Ahn JH Kang MG Kim K Jang JY Park HW Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents The ACCEL-COMBO trial Platelets 2016 Aug 251-7 [Epub ahead of print]
209 Chaudhary R Saadin K Bliden KP Harris WS Dinh B Sharma T Tantry US Gurbel PA Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease Prostaglandins Leukot Essent Fatty Acids 201611340-45
210 Gurbel PA Bliden KP Chaudhary R Patrick J Liu F Chen G McLeod C Tantry US Antiplatelet Effect Durability of a Novel 24-Hour Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes MellitusAm J Cardiol 20161181941-1947
211 Gurbel PA Bliden KP Tantry US Monroe AL Muresan AA Brunner NE Lopez-Espina CG Delmenico PR Cohen E Raviv G Haugen DL Ereth MH First report of the point-of-care TEG A technical validation study of the TEG-6S system Platelets 201627642-649
212 Cornel JH Ohman EM Neely B Jakubowski JA Bhatt DL White HD Ardissino D Fox KA Prabhakaran D Armstrong PW Erlinge D Tantry US Gurbel PA Roe MT Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes J Am Heart Assoc 2016 Nov 45(11) pii e003977
213 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 201717109-121
214 Sharma T Bliden K Chaudhary R Tantry U Gurbel PA Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease Expert Opin Pharmacother 201718123-131
215 Park Y Tantry US Koh JS Ahn JH Kang MG Kim KH Jang JY Park HW Park JR Hwang SJ Park KS Kwak CH Hwang JY Gurbel PA Jeong YH Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction The REMODELING Trial Thromb Haemost 2017117911-922
216 Navarese EP Gurbel PA Andreotti F Kołodziejczak MM Palmer SC Dias S Buffon A Kubica J Kowalewski M Jadczyk T Laskiewicz M Jędrzejek M Brockmeyer M Airoldi F Ruospo M De Servi S Wojakowski W O Connor C Strippoli GF Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis PLoS One 201712e0168726
217 Bliden KP Chaudhary R Mohammed N Muresan AA Lopez-Espina CG Cohen E Raviv G Doubleday M Zaman F Mathew B Tantry US Gurbel PA Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system J Thromb Thrombolysis 201743437-445
Publications Peer Reviewed Original Science Research - Reviews 1 Serebruany VL Atar D Dalesandro MR OConnor CM Gurbel PA Changes in hemostasis after parenteral
magnesium in myocardial ischemia reperfusion Animal studies to clinical trials Magnes Res 19981137-42 2 McKenzie ME Gurbel PA Levine DJ Serebruany VL Clinical utility of available methods determining platelet
function Cardiology 199992240-7 3 Gurbel PA OConnor CM Cummings CC Serebruany VL Clopidogrel The future choice for preventing platelet
activation during coronary stenting Pharm Res 199965109-123 4 Nair GV Gurbel PA Fusaylov SY Davis CJ Ohman EM Bahr RD Christensen RH Serebruany VL Combing
necrosis and platelet markers for perfecting myocardial infarction rule out How close are we Cardiology 20009350-5
5 Davis CJ Gurbel PA Gaitis WA Fuzaylov SY Nair GV OrsquoConnor CM Serebruany VL Hemostatic abnormalities in congestive heart failure Diagnostic significance and clinical challenge Int J Cardiol 20007515-21
6 Pothula A Gurbel PA Atar D McKenzie ME Serebruany VL Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease Eur J Pharmacol 20004021-10
7 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Serebruany VL Platelet function and fibrinolytic agents Two sides of a coin Cardiology 20019555-60
Curriculum Vitae Paul A Gurbel MD Page 14
8 Samara WM Gurbel PA The role of platelet receptors and adhesion molecules in coronary artery disease Coron Artery Dis 20031465-79
9 Gurbel PA Tantry U Clopidogrel response variability and the advent of personalised antiplatelet therapy A bench to bedside journey Thromb Haemost 2011106265-71
10 Gurbel PA Roe MT Jakubowski JA Shah S Erlinge D Goodman SG Huber K Chan MY Cornel JH Tantry US Ohman EM Translational platelet research in patients with coronary artery disease What are the major knowledge gaps Thromb Haemost 2012 May 25108 [Epub ahead of print]
11 Bliden KP Baker BA Nolin TD Jeong YH Bailey WL Tantry US Gurbel PA Thienopyridine efficacy and cigarette smoking status Am Heart J 2013165693-703
12 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
13 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013111547-56
14 Gesheff MG Franzese CJ Bliden KP Contino CJ Rafeedheen R Tantry USGurbel PA Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin Expert Rev Clin Pharmacol 2014 7645-53
15 Tantry US Gesheff M Liu F Bliden KP Gurbel PA Resistance to antiplatelet therapy what progress has been made Expert Opin Pharmacother 2014 9 1-12
16 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print]
17 Gurbel PA Myat A Tantry US Platelet-mediated Thrombosis From Bench to Bedside Cir Res 2015 (in press)
18 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 20161245-58
19 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
20 Gurbel PA Tantry US Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes Heart 2016102882-92
21 Navarese EP Kolodziejczak M Kereiakes DJ Tantry US OConnor C Gurbel PA Proprotein Convertase SubtilisinKexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome A Narrative Review Ann Intern Med 2016164600-7
22 Gurbel PA Jeong YH Navarese EP Tantry US Platelet-Mediated Thrombosis From Bench to Bedside Circ Res 20161181380-91
23 Gurbel PA Myat A Kubica J Tantry US State of the art Oral antiplatelet therapy JRSM Cardiovasc Dis 2016 Jun 152048004016652514 doi 1011772048004016652514 eCollection 2016 Jan-Dec
24 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 2016 Nov 17 [Epub ahead of print] Review
25 Winter MP Grove EL De Caterina R Gorog DA Ahrens I Geisler T Gurbel PA Tantry U Navarese EP Siller-Matula JM Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors Eur Heart J Cardiovasc Pharmacother 2017 Feb 15 doi 101093ehjcvppvw044 [Epub ahead of print]
26 Shah P Tantry US Bliden KP Gurbel PA Bleeding and thrombosis associated with ventricular assist device therapy J Heart Lung Transplant 2017 May 11 pii S1053-2498(17)31789-8
Inventions Patents Copyrights 32294 Gurbel PA Anderson RD Autoperfusion dilatation catheter United States Patent 5295959 51501 Dalesandro MR Gurbel PA Serebruany VL Determining a treatment plan for patients undergoing thrombotic
events by monitoring p-Selectin United States Patent 623071 61201 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6245782 13102 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 20020013343 42203 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6552014
Curriculum Vitae Paul A Gurbel MD Page 15
120611 Gurbel PA The detection of restenosis risk in patients receiving a stent by measuring the characteristics of blood clotting including the measurement of maximum thrombin-induced clot strength (patent awarded pending)
6308 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 7381536 2010 Gurbel PA Conley P Andre P Gretler D Jurek M Methods for diagnosis and treatment of thrombotic
disorders mediated bycyp2c192 (patent pending) 41014 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent
20140100167 81815 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 9110062 111715 Gurbel PA Detection of restenosis risk in patients receiving a stent by measuring the characteristics of
blood clotting including the measurement of maximum thrombin-induced clot strength Patent 9188597 Extramural Funding (since 2002) CURRENT 2010-2015 MAGMA (Multianalyte And Genetic Markers of Atherosclerosis)
Haemonetics and Sinai Hospital of Baltimore 2015-present An Observational Study of CORA-Assisted Stroke Identification and Antithrombotic Therapy
2014-2015 Feasibility clinical trial to evaluate the efficacy of an Anticoagulant cartridge to be used in the CORA System Coramed Technologies LLC
2014-2015 Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid Durlaza in CVD Patients at Risk of High Platelet Turnover (DURATION)
New Haven Pharmaceuticals Inc 2015-present Influence of Edoxaban on Coagulability and Thrombin Generation An in Vitro Study Focusing on
Thrombelastography Daiichi Sankyo
2016 Influence of Vorapaxar on Thrombin Generation and Coagulability Merck 2015-present Durlaza GI GI Tolerability Study New Haven Pharamceuticals 2015-present Thrombogenicity in LVAD Recipients Haemonetics 2014-2015 First-in-Man Assessment of PZ-128 National Institutes of Health PREVIOUS 2002 Atorvastatin in the Treatment of Heart Failure
LBH IRB 20030512 NIHThe National Heart Lung and Blood Institute NIH
2002 Asessment of the In Vitro Effects of Tenecteplase Reteplase and Alteplase on Human Platelets TAR STUDY Genetech
2003-2005 Assessment of the Effects of the heparin-coated Cordis Stent versus Non-coated Stents on Platelet and Endothelial Cell Activation and Thrombin Effect in Patients with Coronary Artery Disease (HEPACOAT) Cordis Inc
2004-2005 The Antiplatelet Effects of Eptifibatide with High and Standard Dose Clopidogrel in Low-Moderate Risk Patients Undergoing Coronary Intervention (CLEAR-PLATELETS Study) MilleniumSchering Plough
2004-2005 The Use of The TEG System to Monitor Platelet Inhibition at Bedside 5R44HL059753-03Haemoscope National Institute of Health
2004-2006 Clopidogrel Resistance in Patients with Stent Thrombosis (CREST Study) AstraZeneca
Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study MilleniumSchering Plough
2005 St Johns Wort Decreases ADP Induced Platelet Reactivity in Known Clopidogrel Resistant Post Coronary Intervention Patients after a Loading Dose of Clopidogrel University of Michigan
2008-2009 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST) Sinai Hospital Department of Medicine
2009-2010 Demonstration of the Pharmacodynamic Antiplatelet Effect of PRT060128 in Patients with High Platelet Reactivity during Clopidogrel and Aspirin Maintenance Therapy (PORTOLA) Portola Pharmaceuticals
2008-2009 A Randomised Double-Blind Outpatient Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND] AstraZeneca Pharmaceuticals LP
2008-2009 A Randomized Double-blind Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Background Therapy in Patients with Stable Coronary Artery Disease with Additional Detailed Assessment of Cardiopulmonary Function (ONSET-OFFSET) AstraZeneca Pharmaceuticals LP
2008-2009 A Single Center Randomized Open Label Parallel Group Pharmacodynamic Study of a Novel Combination Form of Aspirin and Phytosterol versus Aspirin in Healthy Adult Subjects (ARMOR) Bayer Healthcare LLC
2008-2009 Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel Plus EC Aspirin (325 mg) and Clopidogrel Plus PA32540 on Platelet Aggregation in Healthy Volunteers POZEN 110 POZEN Inc
2009-2010 Antithrombosis with Clopidogrel Beyond the Concept of Platelet Aggregate Inhibition (SANOFI) Sanofi Inc 2010-2012 A Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel EC
Aspirin 81 mg and EC omeprazole 40 mg all dosed concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers POZEN Inc
Intramural Funding (since 2002) CURRENT 2008-present Time Based Strategy to Reduce Clopidogrel Associated Bleeding Related to CABG (TARGET CABG) Sinai Hospital of Baltimore Department of Medicine 2009-present Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI)
Sinai Hospital of Baltimore Department of Medicine 2011-present Detection of Leukemic Blood and Solid TypE MalignanCies by Urinary 11-DehydroThromboxane B2 (DETECT) Study
Sinai Hospital of Baltimore Department of Medicine PREVIOUS 2001-2002 Platelet Activation in Stenting PAST Study Sinai Hospital of Baltimore 2005-2006 Platelet Reactivity in Patients with Crohnrsquos disease Receiving Infliximab (chimeric anti-TNF alpha antibody) ndash COIN
Sinai Hospital of Baltimore Department of Medicine 2006-2007 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST)
Sinai Hospital of Baltimore Department of Medicine 2008-2011 Platelet Reactivity and Thrombogenecity in Postmenopausal Women
Sinai Hospital Department of Medicine 2008-2010 Platelet Reactivity and Thrombogenecity in Postmenopausal Women (PRIDE Study)
Sinai Hospital Department of Medicine Multicenter Studies since 2001
Curriculum Vitae Paul A Gurbel MD Page 17
CURRENT 2010-present The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and
Clopidogrel in Aspirin-Treated Subjects With Stable Coronary Artery Disease Daiichi Sankyo
2010-present A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly versus Non-Elderly Aspirin-Treated Subjects with Stable Coronary Artery Disease Eli Lilly amp company
2011-present A Prospective Multicenter Randomized Trial of Clopidogrel versus Prasugrel Anti-platelet Therapy in Cytochrome P450 2C19 (CYP2C19) Intermediate Metabolizers Grant No U01HL105198
NIH National Heart Lung and Blood Institute NIH 2011-present A Prospective Randomized Multi-Center Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHERreg Sirolimus-Eluting Coronary stents
HCRI 2012-present A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in
patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)
Bayer Healthcare LLC 2013-present Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in
Patients at a High-Risk for Vascular Outcomes (ACCELERATE) Eli Lilly amp Company 2014-present A Phase 2b Multi-center Randomized Placebo-controlled Dose-ranging Study to Investigate the
Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infarction
AEGIS CSL 2015-2017 A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety of PZ- 128 in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention
National Institute of Health PREVIOUS 2001 A Randomized Double-Blind Placebo-Controlled Study of Two Intravenous Dosing Regimens of
h5G11-scFv in Patients with Acute Myocardial Infarction Undergoing 2001-2002 Prevention of REStenosis with Tranilast and Its Outcomes A Placebo Controlled Trial PRESTO STUDY
SmithKline Beecham 2002-2003 Taxus IV-SR Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
Boston Scientific 2003 MICROVENA Corporation TRAP Vascular Filtration System (VFS) Trial
Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily Pfizer Inc
2003-2004 Phase 3 Multi-Center Double-Blind Randomized Parallel Group Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily (QD) for 24 Months Compared with Atorvastatin Alone in Subjects with Angiographically Documented Coronary Heart Disease Pfizer Inc
2003-2004 A Randomized Controlled Trial of the Medtronic Endeavor Drug Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ldquoENDEAVOR III Studyrdquo)
Medtronic 2009-2010 A Prospective Randomized Open-label Multicenter study in Patients Presenting with Acute Coronary Syndromes SYNERGY STUDY
Aventis Pharmaceuticals 2004 CObalt chromium STent with Antiproliferative for Restenosis II Trialrdquo Costar study
Conor Medsystems
Curriculum Vitae Paul A Gurbel MD Page 18
2004-2005 A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions ENDEAVOR IV Medtronic
2004-2005 A Randomized Trial to evaluate the relative protection against POST-PCI microvasculat obstruction among antiplatelet and anti-thrombotic medications (TIMI-30) TIMI group
2004-2006 A Double-blind Double-dummy Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI 33 AstraZeneca Lp
2005-2006 Strategy To Reduce Atherosclerosis Development Involving Administration of Rimonabant - The Intravascular Ultrasound Study (STRADIVARIUS) EFC5827 Sanofi Synthelabo Research
2006 A Multicenter Randomized Double-Blind Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (TRASM-PCI) Schering Plough
2006-2007 A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel -SWAP (SWitching Anti Platelet study) Eli Lilly amp Company and Sankyo Company Limited
2006-2007 A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2008-2010 A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary InterventionTIMI-38 Eli Lilly Company Daiichi
2009-2010 A Randomized Double-Blind Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128 a Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Interventions (INNOVATE-PCI) Portola Pharmaceuticals
2010-2012 TReatment with ADPreceptor iNhibitorS Longitudinal Assessment ofTreatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS)
Eli Lilly Company 2010-2013 RADAR Randomized Partially-Blinded Multi-Center Active-Controlled Dose-Ranging Study
Assessing the Safety Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome Regado Bioscience Inc
2011-2013 A Phase IIa Multi-center Randomized Sponsor-unblinded Placebo-controlled Single Ascending Dose Study to Investigate the Safety Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Adults Taking Aspirin and a P2Y12 Platelet Inhibitor
AEGIS CSL Research Program BuildingLeadership 1991-1995 Director Interventional Cardiology Research University of Maryland Medical System 1998-2015 Director Sinai Center for Thrombosis Research 2001-2015 Director Cardiovascular Research Lifebridge Health 2002-2015 Director Therapeutics Research and Technology Development for the Cardiac Catheterization Program Sinai Hospital of Baltimore 2007-2015 Associate Chief for Research Department of Medicine Sinai Hospital of Baltimore 2015-current Director Interventional Cardiology and Cardiovascular Medicine Research INOVA Health 2015-Current Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute EDUCATIONAL ACTIVITIES
Curriculum Vitae Paul A Gurbel MD Page 19
Peer Reviewed Publications-Consensus Statements Expert Opinions 1 Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C
Rao AK The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 200531309-11
2 Hoekstra J Cohen M Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Saucedo JF Pollack CV Jr Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention-an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective report on a roundtable discussion Am J Emerg Med 200927720-8
3 Bonello L Tantry US Marcucci R Blindt R Angiolillo DJ Becker R Bhatt DL Cattaneo M Collet JP Cuisset T Gachet C Montalescot G Jennings LK Kereiakes D Sibbing D Trenk D Van Werkum JW Paganelli F Price MJ Waksman R Gurbel PA Working Group on High On Treatment Platelet Reactivity Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 201056919-33
4 Gurbel PA Tantry US Shuldiner AR Kereiakes DJ Genotyping one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 201056112-6
5 Gurbel PA Tantry US Antiplatelet therapy Clopidogrel-PPI interaction an ongoing controversy Nat Rev Cardiol 201187-8
6 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
7 Gurbel PA Nolin TD Tantry US Clopidogrel efficacy and cigarette smoking status JAMA 20123072495-6 8 Tantry US Bonello L Aradi D Price MJ Jeong YH Angiolillo DJ Stone GW Curzen N Geisler T Ten Berg J
Kirtane A Siller-Matula J Mahla E Becker RC Bhatt DL Waksman R Rao SV Alexopoulos D Marcucci R Reny JL Trenk D Sibbing D Gurbel PA Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding J Am Coll Cardiol 2013622261-73
9 Gurbel PA Tantry US Antiplatelet and anticoagulant agents in heart failure Current status and future perspectives JACC Heart Fail 201421-14
10 Gurbel PA Tantry US Antiplatelet therapy What have we learned from the ANTARCTIC trial Nat Rev Cardiol 201613639-640
Invited Review Articles 1 Gurbel PA Midwall JA Brodie BR Angioplasty and adjunctive intra-aortic balloon pump counterpulsation Current
clinical considerations Todays Therapy Trends 19951363-78 2 OrsquoConnor CM Gurbel PA Serebruany VL Depression and ischemic heart disease Am Heart J 200014063-69 3 Gurbel PA Serebruany VL Oral IIbIIIa inhibitors From initial promise to clinical failures J Thromb and
Thrombolysis 200010217-20 4 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Atar D Serebruany VL Platelets and
Thrombolysis Cooperation or Contrariety Heart Drug 20011281-290 5 McKenzie ME Gurbel PA The potential of monoclonal antibodies to reduce reperfusion injury in myocardial
infarction BioDrugs 200115395-404 6 Gurbel PA Bliden KP Hayes K Tantry U Platelet activation in myocardial ischemic syndromes Expert Rev of
Cardiovasc Ther 20052535-45 7 Tantry US Bliden KP Gurbel PA Resistance to antiplatelet drugs Current status and future research Expert
Opin Pharmacother 200562027-45 8 Gurbel PA Lau WC Bliden KP Tantry US Clopidogrel resistance Implications for coronary stenting Curr Pharm
Des 2006121261-9 9 Gurbel PA Tantry US Drug insight Clopidogrel non-responsiveness Nature ClinPract Cardiovasc Med
20063387-95 10 Gurbel PA Tantry US Aspirin and Clopidogrel Resistance Considerations and management J Interv Cardiol
200619439-48 11 Lau WC Gurbel PA Antiplatelet drug resistance and drug-drug interactions Role of cytochrome P450 3A4
Pharm Res 2006232691-708 12 Wiviott SD Tantry US Gurbel PA Clinical applications of antiplatelet therapy Rev Cardiovasc Med 20067
Curriculum Vitae Paul A Gurbel MD Page 20
130-46 13 Tantry US Bliden KP Gurbel PA Prasugrel Expert Opin Investig Drugs 2006151627-33 14 Gurbel PA Tantry US Clopidogrel Resistance Thromb Res 2007120311-21 15 Tantry US Etherington A Bliden KP Gurbel PA Antiplatelet therapy Current strategies and future trends Future
Cardiology 20072343-366 16 Gurbel PA Tantry US The relationship of platelet reactivity to the occurrence of post-stenting ischemic events
emergence of a new cardiovascular risk factor Rev Cardiovasc Med 2006Suppl 4S20-8 17 Tantry US Bliden KP Gurbel PA AZD6140 Expert Opin Investig Drugs 200716225-9 18 Gurbel PA Tantry US Stent thrombosis role of compliance and non-responsiveness to antiplatelet therapy Rev
Cardiovasc Med 20078S19-S26 19 Gurbel PA Kandzari DE Stent thrombosis associated with first-generation drug-eluting stents issues with
antiplatelet therapy Neth Heart J 200715148-50 20 Gurbel PA Tantry US The role of clopidogrel in cardiovascular diseases Pol Arch Med Wewn 2007117207-9 21 Gurbel PA DiChiara J Tantry US Antiplatelet therapy after implantation of drug-eluting stents duration
resistance alternatives and management of surgical patients Am J Cardiol 200710018M-25M 22 Gurbel PA Becker R Mann KG Steinhubl SR Michelson AD Platelet function monitoring in patients with
coronary artery disease J Am Coll Cardiol 2007501822-34 23 Gurbel PA Tantry US Prasugrel a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig
Drugs 20089324-36 24 Gurbel PA Bilden KP Tantry US Diagnostics for aspirin resistance Mol Diagn Ther 20081255-6 25 Gurbel PA Antonino MJ Tantry US Antiplatelet treatment of cardiovascular disease a translational research
perspective Pol Arch Med Wewn 2008118289-97 26 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831I36 27 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention Clin Cardiol 200831I28-I35
28 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches Clin Cardiol 200831I21-I27
29 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention Clin Cardiol 200831I17-I20
30 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Assessing the Current Role of Platelet Function Testing Clin Cardiol 200831I10-I16
31 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831136
32 Keriakes DJ Gurbel PA Periprocedural platelet function in percutaneous coronary intervention JACC Cardiovasc Interv 2008suppl 1111ndash121
33 Gurbel PA Tantry US The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome J Interv Cardiol 200821Suppl 1S10-7
34 Gurbel PA Tantry US Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 20091122-322
35 Gurbel PA Aspirin scope and limitations Br J Cardiol 200917 (Suppl 1)S8-S9 36 Cohen M Hoekstra J Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Pollack CV Jr
Saucedo JF Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion J Interv Cardiol 200821283-99
37 Angiolillo DJ Bhatt DL Gurbel PA Jennings LK Advances in antiplatelet therapy agents in clinical development Am J Cardiol 2009103(3 Suppl)40A-51A
38 Gurbel PA Mahla E Antonino MJ Tantry US Response variability and the role of platelet function testing J Invasive Cardiol 200921172-8
39 Gurbel PA Antonino MJ Tantry US Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug MetabToxicol Expert Opin Drug Metab Toxicol 20095989-1004
40 Gurbel PA Tantry US Antiplatelet resistance- Fact or Myth Am Hosp J 2009750-57 41 Gurbel PA Mahla E Tantry US Aspirin resistance Prog Cardiovasc Dis 200952141-52 42 Tantry US Gurbel PA Platelet monitoring for PCI Is it really necessary Haemostaseologie 200929 368-75 43 Gurbel PA Aspirin-scope and limitations Br J Cardiol 200917(Suppl 1)S8-S9
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 10
Gurbel PA Pharmacodynamic Effect of Cilostazol Plus Standard Clopidogrel Versus Double-Dose Clopidogrel in Patients With Type 2 Diabetes Undergoing Percutaneous Coronary Intervention Diabetes Care 2012352194-7
157 Roe MT Armstrong PW Fox KAA White HD Prabhakaran D Goodman SG Cornel JH Bhatt DL Clemmensen P Martinez F Ardissino D Nicolau JC Boden WE Gurbel PA Ruzyllo W Dalby AJ McGuire DK Leiva-Pons JL Parkhomenko A Gottlieb S Topacio GO Hamm C Pavlides G Goudev AR Oto A Tseng C-D Merkely B Gasparovic V Corbalan R Cinteză M McLendon RC Winters KJ Brown EB Lokhnygina Y Aylward PE Huber K Hochman JS E Magnus Ohman EM for the TRILOGY ACS Investigators Prasugrel versus clopidogrel for ACS patients managed without revascularization N Engl J Med 20123671297-309
158 Gurbel PA Bliden KP Jeong Y-H Antonino M Gesheff T Fort JG Shuldiner A Chai S Gesheff M Zhang Y Tantry US Spaced Administration of PA32540 and Clopidogrel Results in Greater Platelet Inhibition than Synchronous Administration of Enteric-Coated Aspirin and Enteric-Coated Omeprazole and Clopidogrel Am Heart J 2013165176-82
159 Gurbel PA Erlinge D Ohman EM Neely B Neely M Goodman SG Huber K Chan MY Cornel JH Brown E Zhou C Jakubowski JA White HD Fox KA Prabhakaran D Armstrong PW Tantry US Roe MT TRILOGY ACS Platelet Function Substudy Investigators JAMA 20123081785-94
160 Lewis JP Horenstein RB Ryan K OConnell JR Gibson Q Mitchell BD Tanner K Chai S Bliden KP Tantry US Peer CJ Figg WD Spencer SD Pacanowski MA Gurbel PA Shuldiner AR The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response Pharmacogenet Genomics 2012 Pharmacogenet Genomics 2013231-8
161 Jeong YH Tantry US Min JH Park Y Navarese EP Koh JS Park JR Hwang SJ Kho EH Bliden KP Kwak CH Hwang JY Kim S Gurbel PA Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention Int J Cardiol 2012 Oct 12 doipii S0167-5273(12)01253-3 101016
162 Saucedo JF Angiolillo DJ Deraad R Frelinger AL 3rd Gurbel PA Costigan TM Jakubowski JA Ojeh CK Duvvuru S Effron MB for the SWAP Investigators Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel insights from the switching anti-platelet (SWAP) study Thromb Haemost 2012 Dec 6109(2) [Epub ahead of print]
163 Navarese EP Austin D Gurbel PA Andreotti F Tantry U James S Buffon A Kozinski M Obonska K Bliden K Jeong YH Kubica J Kunadian V Drug-coated balloons in treatment of in-stent restenosis a meta-analysis of randomized controlled trials Clin Res Cardiol 2012 Dec 20 [Epub ahead of print]
164 Gurbel PA Bliden KP Fort JG Jeong YH Shuldiner A Chai S Gesheff T Antonino M Gesheff M Zhang Y Tantry US Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel Am Heart J 2013165176-82
165 Lewis JP Ryan K OConnell JR Horenstein RB Damcott CM Gibson Q Pollin TI Mitchell BD Beitelshees AL Pakzy R Tanner K Parsa A Tantry US Bliden KP Post WS Faraday N Herzog W Gong Y Pepine CJ Johnson JA Gurbel PA Shuldiner AR Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes Circ Cardiovasc Genet 2013 Feb 7 [Epub ahead of print]
166 Navarese EP Gurbel PA Andreotti F Tantry U Jeong YH Kozinski M Engstroslashm T Di Pasquale G Kochman W Ardissino D Kedhi E Stone GW Kubica J Optimal Timing of Coronary Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes A Systematic Review and Meta-analysis Ann Intern Med 2013158261-70
167 Jeong YH Abadilla KA Tantry US Park Y Koh JS Kwak CH Hwang JY Gurbel PA Influence of CYP2C192 and 3 loss-of-function alleles on pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention the results of the ACCEL-DOUBLE-2N3 studyJ Thromb Haemost 2013111194-7
168 Gurbel PA Bliden KP Logan DK Kereiakes DJ Lasseter KC White A Angiolillo DJ Nolin TD Maa JF Bailey WL Jakubowski JA Ojeh CK Jeong YH Tantry US Baker BA The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel The PARADOX Study J Am Coll Cardiol 2013 Apr 16 doipii S0735-1097(13)01478-2 101016jjacc201303037 [Epub ahead of print]
169 Grzesk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E4 Jeong Y-H Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 2013 Article ID 928271 httpdxdoiorg1011552013928271
170 Erlinge D Gurbel PA James S Lindahl TL Svensson P Ten Berg JM Foley DP Wagner H Brown PB Luo J Zhou C Moser BA Jakubowski JA Small DS Winters KJ Angiolillo DJ Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains non-inferiority to prasugrel 10-mg in non-elderly patients The GENERATIONS trial a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients J Am Coll Cardiol 201362577-83
Curriculum Vitae Paul A Gurbel MD Page 11
171 Kim IS Jeong YH Tantry US Park Y Lee DH Bliden KP Koh JS Park JR Jang JS Hwang SJ Koh EH Kwak CH Hwang JY Kim S Gurbel PA Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading Am Heart J 201316695-103
172 Grześk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E Jeong YH Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 20132013928271
173 Stone GW Witzenbichler B Weisz G Rinaldi MJ Neumann FJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri E Gurbel PA Xu K Parise H Kirtane AJ Brodie BR Mehran R Stuckey TD for the ADAPT-DES Investigators Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES) a prospective multicentre registry study Lancet 2013382614-23
174 Angiolillo DJ Curzen N Gurbel P Vaitkus P Lipkin F Li W Jakubowski JA Zettler M Effron MB Trenk D Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in subjects with stable coronary artery disease Results of the SWAP-2 Study J Am Coll Cardiol 2014631500-9
175 Jeong YH Bliden KP Shuldiner AR Tantry US Gurbel PA Thrombin-induced platelet-fibrin clot strength Relation to high on-clopidogrel platelet reactivity genotype and post-percutaneous coronary intervention outcomes Thromb Haemost 2014111713-24
176 Gouya G Arrich J Wolzt M Huber K Verheugt FW Gurbel PA Pirker-Kees A Siller-Matula JM Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases a systematic review and meta-analysis Stroke 201445492-503
177 Erlinge D James S Duvvuru S Jakubowski JA Wagner H Varenhorst C Tantry US Brown PB Small D Moser BA Sundseth S Walker JR Winters KJ Gurbel PA Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease Thromb Haemost 2014111943-50
178 Gurbel PA Baker BA Bailey WL Bliden KP Tantry US Unraveling the Smokers Paradox Cigarette smoking high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors Thromb Haemost 20141111187-90
179 Koh JS Kim IS Tantry US Yoon SE Park Y Cho SY Lee EJ Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading The results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study Int J Cardiol 2014174129-32
180 Bliden KP Singla A Gesheff MG Toth PP Tabrizchi A Ens G Guyer K Singh M Franzese CJ Stapleton D Tantry US Gurbel PA Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin Thromb Haemost 2014 Apr 24112(2) [Epub ahead of print]
181 Gurbel PA Gesheff MG Franzese CJ Bliden KP Tantry US Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy Platelets 201526608-9
182 Gurbel PA Bergmeijer TO Tantry US Ten Berg JM Angiolillo DJ James S Lindahl TL Svensson P Jakubowski JA Brown PB Duvvuru S Sundseth S Walker JR Small D Moser BA Winters KJ Erlinge D The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease Thromb Haemost 2014 2014112589-97
183 Cornel JH Ohman EM Neely B Clemmensen P Sritara P Zamoryakhin D Armstrong PW Prabhakaran D White HD Fox KA Gurbel PA Roe MT TRILOGY ACS Investigators Impact of smoking status on platelet function and clinical outcomes with prasugrel vs clopidogrel in patients with acute coronary syndromes managed without revascularization Insights from the TRILOGY ACS trial Am Heart J 201416876-87
184 Park Y Jung JM Tantry US Kim K Koh JS Park JR Hwang SJ Kwak CH Hwang JY Kim S Gurbel PA Jeong YH Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration The ACCEL-PARAZOL Study J Atheroscler Thromb 2014211121-39
185 Park Y Jeong YH Tantry US Ahn JH Kim K Koh J Park J Hwang SJ Kwak CH Hwang JY Gurbel PA Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity The Resultof the ACCEL-DIP Study Thromb Haemost 2014112 [Epub ahead of print]
186 Lev EI Bliden KP Jeong Y-H Pandya S Kang K Franzese C Tantry US Gurbel PA Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients J Am Heart Assoc 20143e001167
187 Alexopoulos D Xanthopoulou I Storey RF Bliden KP Tantry US Angiolillo DJ Gurbel PA Platelet reactivity during ticagrelor maintenance therapy A patient-level data meta-analysis Am Heart J 2014 168530-6
188 Lhermusier T Lipinski MJ Tantry US Escarcega RO Baker N Bliden KP Magalhaes MA Ota H Tian W Pendyala L Minha S Chen F Torguson R Gurbel PA Waksman R Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity Am J Cardiol 2015115716-23
189 Franzese CJ Bliden KP Gesheff MG Pandya S Guyer KE Singla A Tantry US Toth PP Gurbel PA Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy Am J Cardiol 2015 11151204-11
Curriculum Vitae Paul A Gurbel MD Page 12
190 Aradi D Kirtane A Bonello L Gurbel PA Tantry US Huber K Freynhofer MK Ten Berg J Janssen P Angiolillo DJ Siller-Matula JM Marcucci R Patti G Mangiacapra F Valgimigli M Morel O Palmerini T Price MJ Cuisset T Kastrati A Stone GW Sibbing D Bleeding and stent thrombosis on P2Y12-inhibitors collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention Eur Heart J 2015361762-71
191 Navarese EP Kolodziejczak M Schulze V Gurbel PA Tantry U Lin Y Brockmeyer M Kandzari DE Kubica JM DAgostino RB Sr Kubica J Volpe M Agewall S Kereiakes DJ Kelm M Effects of proprotein convertase subtilisinkexin type 9 antibodies in adults with hypercholesterolemia a systematic review and meta-analysis Ann Intern Med 201516340-51
192 Lee K Yoo SY Suh J Park KH Park Y Tantry US Park KS Han SH Kang WC Shin DH Lee C Choi SW Lee JH Cho YH Lee NH Jeong MH Ahn Y Kubica J Gurbel PA Park JH Jeong YH Efficacy of cilostazol on inhibition of platelet aggregation inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study Int J Cardiol 2015190370-5
193 Kowalewski M Schulze V Berti S Waksman R Kubica J Kołodziejczak M Buffon A Suryapranata H Gurbel PA Kelm M Pawliszak W Anisimowicz L Navarese EP Complete revascularisation in ST-elevation myocardial infarction and multivessel disease meta-analysis of randomised controlled trials Heart 2015 1011309-17
194 Baber U Mehran R Kirtane AJ Gurbel PA Christodoulidis G Maehara A Witzenbichler B Weisz G Rinaldi MJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri EL Jr Xu K Parise H Brodie BR Stuckey TD Stone GW Prevalence and impact of high platelet reactivity in chronic kidney disease Results from the assessment of dual antiplatelet therapy with drug-eluting stents registry Circ Cardiovasc Interv 20158e001683
195 Tricoci P DAndrea DM Gurbel PA Yao Z Cuchel M Winston B Schott R Weiss R Blazing MA Cannon L Bailey A Angiolillo DJ Gille A Shear CL Wright SDAlexander JH Infusion of Reconstituted High-Density Lipoprotein CSL112 in Patients With Atherosclerosis Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial J Am Heart Assoc 20154 pii e002171
196 Reny JL Fontana P Hochholzer W Neumann MJ ten Berg J Janssen PF Geisler T Gawaz M Marcucci R Gori A-M Cuisset T Alessi M-S Berdagueacute P Gurbel PA Yong G Angiolillo DJ Aradi D Beigel R Campo G Combescure C Vascular risk levels affect the predictive value of platelet reactivity 1 for the occurrence of major adverse cardiovascular events in patients on clopidogrel Systematic review and collaborative meta-analysis of individual patient data Thromb Haemost 2015 (in press)
197 Chaudhary R Bliden KP Tantry US Mohammed N Mathew D Gesheff MG Franzese CJ Gurbel PA Association of weight gain with coronary artery disease inflammation and thrombogenicity J Thromb Thrombolysis 2015 Dec 29 [Epub ahead of print]
198 Gurbel PA Bliden KP Turner SE Tantry US Gesheff MG Barr TP Covic L Kuliopulos A Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease Arterioscler Thromb Vasc Biol 201636189-97
199 Kwon TJ Tantry US Park Y Choi YM Ahn JH Kim KH Koh JS Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Smith SC Jr Jeong YH Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention Results of the ACCEL-BLEED study Thromb Haemost 2016 Jan 21115(5) [Epub ahead of print]
200 Bliden KP Tantry US Gesheff MG Franzese CJ Pandya S Toth PP Mathew DP Chaudhary R Gurbel PA Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis J Interv Cardiol 201629168-78
201 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin J Diabetes Complications 2016 May 10 pii S1056-8727(16)30127-1
202 Bedeir K Bliden K Tantry U Gurbel PA Mahla E Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel The Role of VerifyNow Can J Cardiol 201632724-5
203 Giustino G Kirtane AJ Baber U Geacuteneacutereux P Witzenbichler B Neumann FJ Weisz G Maehara A Rinaldi MJ Metzger C Henry TD Cox DA Duffy PL Mazzaferri EL Brodie BR Stuckey TD Gurbel PA Dangas GD Francese DP Ozan O Mehran R Stone GW Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study Am J Cardiol 20161171877-83
204 Kubica J Kubica A Jilma B Adamski P Hobl EL Navarese EP Siller-Matula JM Dąbrowska A Fabiszak T Koziński M Gurbel PA Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors Int J Cardiol 2016215201-8
205 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin
Curriculum Vitae Paul A Gurbel MD Page 13
J Diabetes Complications 2016 May 10 [Epub ahead of print] 206 Bliden KP Chaudhary R Lopez LR Damrongwatanasuk R Guyer K Gesheff MG Franzese CJ Kaza H
Tantry US Gurbel PA Oxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease Am J Cardiol 2016 Jun 15 [Epub ahead of print]
207 Mahla E Prueller F Farzi S Pregartner G Raggam RB Beran E Toller W Berghold A Tantry US Gurbel PA Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy Ann Thorac Surg 2016 Jul 1 [Epub ahead of print]
208 Koh JS Park Y Tantry US Ahn JH Kang MG Kim K Jang JY Park HW Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents The ACCEL-COMBO trial Platelets 2016 Aug 251-7 [Epub ahead of print]
209 Chaudhary R Saadin K Bliden KP Harris WS Dinh B Sharma T Tantry US Gurbel PA Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease Prostaglandins Leukot Essent Fatty Acids 201611340-45
210 Gurbel PA Bliden KP Chaudhary R Patrick J Liu F Chen G McLeod C Tantry US Antiplatelet Effect Durability of a Novel 24-Hour Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes MellitusAm J Cardiol 20161181941-1947
211 Gurbel PA Bliden KP Tantry US Monroe AL Muresan AA Brunner NE Lopez-Espina CG Delmenico PR Cohen E Raviv G Haugen DL Ereth MH First report of the point-of-care TEG A technical validation study of the TEG-6S system Platelets 201627642-649
212 Cornel JH Ohman EM Neely B Jakubowski JA Bhatt DL White HD Ardissino D Fox KA Prabhakaran D Armstrong PW Erlinge D Tantry US Gurbel PA Roe MT Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes J Am Heart Assoc 2016 Nov 45(11) pii e003977
213 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 201717109-121
214 Sharma T Bliden K Chaudhary R Tantry U Gurbel PA Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease Expert Opin Pharmacother 201718123-131
215 Park Y Tantry US Koh JS Ahn JH Kang MG Kim KH Jang JY Park HW Park JR Hwang SJ Park KS Kwak CH Hwang JY Gurbel PA Jeong YH Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction The REMODELING Trial Thromb Haemost 2017117911-922
216 Navarese EP Gurbel PA Andreotti F Kołodziejczak MM Palmer SC Dias S Buffon A Kubica J Kowalewski M Jadczyk T Laskiewicz M Jędrzejek M Brockmeyer M Airoldi F Ruospo M De Servi S Wojakowski W O Connor C Strippoli GF Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis PLoS One 201712e0168726
217 Bliden KP Chaudhary R Mohammed N Muresan AA Lopez-Espina CG Cohen E Raviv G Doubleday M Zaman F Mathew B Tantry US Gurbel PA Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system J Thromb Thrombolysis 201743437-445
Publications Peer Reviewed Original Science Research - Reviews 1 Serebruany VL Atar D Dalesandro MR OConnor CM Gurbel PA Changes in hemostasis after parenteral
magnesium in myocardial ischemia reperfusion Animal studies to clinical trials Magnes Res 19981137-42 2 McKenzie ME Gurbel PA Levine DJ Serebruany VL Clinical utility of available methods determining platelet
function Cardiology 199992240-7 3 Gurbel PA OConnor CM Cummings CC Serebruany VL Clopidogrel The future choice for preventing platelet
activation during coronary stenting Pharm Res 199965109-123 4 Nair GV Gurbel PA Fusaylov SY Davis CJ Ohman EM Bahr RD Christensen RH Serebruany VL Combing
necrosis and platelet markers for perfecting myocardial infarction rule out How close are we Cardiology 20009350-5
5 Davis CJ Gurbel PA Gaitis WA Fuzaylov SY Nair GV OrsquoConnor CM Serebruany VL Hemostatic abnormalities in congestive heart failure Diagnostic significance and clinical challenge Int J Cardiol 20007515-21
6 Pothula A Gurbel PA Atar D McKenzie ME Serebruany VL Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease Eur J Pharmacol 20004021-10
7 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Serebruany VL Platelet function and fibrinolytic agents Two sides of a coin Cardiology 20019555-60
Curriculum Vitae Paul A Gurbel MD Page 14
8 Samara WM Gurbel PA The role of platelet receptors and adhesion molecules in coronary artery disease Coron Artery Dis 20031465-79
9 Gurbel PA Tantry U Clopidogrel response variability and the advent of personalised antiplatelet therapy A bench to bedside journey Thromb Haemost 2011106265-71
10 Gurbel PA Roe MT Jakubowski JA Shah S Erlinge D Goodman SG Huber K Chan MY Cornel JH Tantry US Ohman EM Translational platelet research in patients with coronary artery disease What are the major knowledge gaps Thromb Haemost 2012 May 25108 [Epub ahead of print]
11 Bliden KP Baker BA Nolin TD Jeong YH Bailey WL Tantry US Gurbel PA Thienopyridine efficacy and cigarette smoking status Am Heart J 2013165693-703
12 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
13 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013111547-56
14 Gesheff MG Franzese CJ Bliden KP Contino CJ Rafeedheen R Tantry USGurbel PA Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin Expert Rev Clin Pharmacol 2014 7645-53
15 Tantry US Gesheff M Liu F Bliden KP Gurbel PA Resistance to antiplatelet therapy what progress has been made Expert Opin Pharmacother 2014 9 1-12
16 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print]
17 Gurbel PA Myat A Tantry US Platelet-mediated Thrombosis From Bench to Bedside Cir Res 2015 (in press)
18 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 20161245-58
19 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
20 Gurbel PA Tantry US Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes Heart 2016102882-92
21 Navarese EP Kolodziejczak M Kereiakes DJ Tantry US OConnor C Gurbel PA Proprotein Convertase SubtilisinKexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome A Narrative Review Ann Intern Med 2016164600-7
22 Gurbel PA Jeong YH Navarese EP Tantry US Platelet-Mediated Thrombosis From Bench to Bedside Circ Res 20161181380-91
23 Gurbel PA Myat A Kubica J Tantry US State of the art Oral antiplatelet therapy JRSM Cardiovasc Dis 2016 Jun 152048004016652514 doi 1011772048004016652514 eCollection 2016 Jan-Dec
24 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 2016 Nov 17 [Epub ahead of print] Review
25 Winter MP Grove EL De Caterina R Gorog DA Ahrens I Geisler T Gurbel PA Tantry U Navarese EP Siller-Matula JM Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors Eur Heart J Cardiovasc Pharmacother 2017 Feb 15 doi 101093ehjcvppvw044 [Epub ahead of print]
26 Shah P Tantry US Bliden KP Gurbel PA Bleeding and thrombosis associated with ventricular assist device therapy J Heart Lung Transplant 2017 May 11 pii S1053-2498(17)31789-8
Inventions Patents Copyrights 32294 Gurbel PA Anderson RD Autoperfusion dilatation catheter United States Patent 5295959 51501 Dalesandro MR Gurbel PA Serebruany VL Determining a treatment plan for patients undergoing thrombotic
events by monitoring p-Selectin United States Patent 623071 61201 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6245782 13102 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 20020013343 42203 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6552014
Curriculum Vitae Paul A Gurbel MD Page 15
120611 Gurbel PA The detection of restenosis risk in patients receiving a stent by measuring the characteristics of blood clotting including the measurement of maximum thrombin-induced clot strength (patent awarded pending)
6308 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 7381536 2010 Gurbel PA Conley P Andre P Gretler D Jurek M Methods for diagnosis and treatment of thrombotic
disorders mediated bycyp2c192 (patent pending) 41014 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent
20140100167 81815 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 9110062 111715 Gurbel PA Detection of restenosis risk in patients receiving a stent by measuring the characteristics of
blood clotting including the measurement of maximum thrombin-induced clot strength Patent 9188597 Extramural Funding (since 2002) CURRENT 2010-2015 MAGMA (Multianalyte And Genetic Markers of Atherosclerosis)
Haemonetics and Sinai Hospital of Baltimore 2015-present An Observational Study of CORA-Assisted Stroke Identification and Antithrombotic Therapy
2014-2015 Feasibility clinical trial to evaluate the efficacy of an Anticoagulant cartridge to be used in the CORA System Coramed Technologies LLC
2014-2015 Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid Durlaza in CVD Patients at Risk of High Platelet Turnover (DURATION)
New Haven Pharmaceuticals Inc 2015-present Influence of Edoxaban on Coagulability and Thrombin Generation An in Vitro Study Focusing on
Thrombelastography Daiichi Sankyo
2016 Influence of Vorapaxar on Thrombin Generation and Coagulability Merck 2015-present Durlaza GI GI Tolerability Study New Haven Pharamceuticals 2015-present Thrombogenicity in LVAD Recipients Haemonetics 2014-2015 First-in-Man Assessment of PZ-128 National Institutes of Health PREVIOUS 2002 Atorvastatin in the Treatment of Heart Failure
LBH IRB 20030512 NIHThe National Heart Lung and Blood Institute NIH
2002 Asessment of the In Vitro Effects of Tenecteplase Reteplase and Alteplase on Human Platelets TAR STUDY Genetech
2003-2005 Assessment of the Effects of the heparin-coated Cordis Stent versus Non-coated Stents on Platelet and Endothelial Cell Activation and Thrombin Effect in Patients with Coronary Artery Disease (HEPACOAT) Cordis Inc
2004-2005 The Antiplatelet Effects of Eptifibatide with High and Standard Dose Clopidogrel in Low-Moderate Risk Patients Undergoing Coronary Intervention (CLEAR-PLATELETS Study) MilleniumSchering Plough
2004-2005 The Use of The TEG System to Monitor Platelet Inhibition at Bedside 5R44HL059753-03Haemoscope National Institute of Health
2004-2006 Clopidogrel Resistance in Patients with Stent Thrombosis (CREST Study) AstraZeneca
Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study MilleniumSchering Plough
2005 St Johns Wort Decreases ADP Induced Platelet Reactivity in Known Clopidogrel Resistant Post Coronary Intervention Patients after a Loading Dose of Clopidogrel University of Michigan
2008-2009 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST) Sinai Hospital Department of Medicine
2009-2010 Demonstration of the Pharmacodynamic Antiplatelet Effect of PRT060128 in Patients with High Platelet Reactivity during Clopidogrel and Aspirin Maintenance Therapy (PORTOLA) Portola Pharmaceuticals
2008-2009 A Randomised Double-Blind Outpatient Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND] AstraZeneca Pharmaceuticals LP
2008-2009 A Randomized Double-blind Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Background Therapy in Patients with Stable Coronary Artery Disease with Additional Detailed Assessment of Cardiopulmonary Function (ONSET-OFFSET) AstraZeneca Pharmaceuticals LP
2008-2009 A Single Center Randomized Open Label Parallel Group Pharmacodynamic Study of a Novel Combination Form of Aspirin and Phytosterol versus Aspirin in Healthy Adult Subjects (ARMOR) Bayer Healthcare LLC
2008-2009 Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel Plus EC Aspirin (325 mg) and Clopidogrel Plus PA32540 on Platelet Aggregation in Healthy Volunteers POZEN 110 POZEN Inc
2009-2010 Antithrombosis with Clopidogrel Beyond the Concept of Platelet Aggregate Inhibition (SANOFI) Sanofi Inc 2010-2012 A Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel EC
Aspirin 81 mg and EC omeprazole 40 mg all dosed concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers POZEN Inc
Intramural Funding (since 2002) CURRENT 2008-present Time Based Strategy to Reduce Clopidogrel Associated Bleeding Related to CABG (TARGET CABG) Sinai Hospital of Baltimore Department of Medicine 2009-present Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI)
Sinai Hospital of Baltimore Department of Medicine 2011-present Detection of Leukemic Blood and Solid TypE MalignanCies by Urinary 11-DehydroThromboxane B2 (DETECT) Study
Sinai Hospital of Baltimore Department of Medicine PREVIOUS 2001-2002 Platelet Activation in Stenting PAST Study Sinai Hospital of Baltimore 2005-2006 Platelet Reactivity in Patients with Crohnrsquos disease Receiving Infliximab (chimeric anti-TNF alpha antibody) ndash COIN
Sinai Hospital of Baltimore Department of Medicine 2006-2007 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST)
Sinai Hospital of Baltimore Department of Medicine 2008-2011 Platelet Reactivity and Thrombogenecity in Postmenopausal Women
Sinai Hospital Department of Medicine 2008-2010 Platelet Reactivity and Thrombogenecity in Postmenopausal Women (PRIDE Study)
Sinai Hospital Department of Medicine Multicenter Studies since 2001
Curriculum Vitae Paul A Gurbel MD Page 17
CURRENT 2010-present The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and
Clopidogrel in Aspirin-Treated Subjects With Stable Coronary Artery Disease Daiichi Sankyo
2010-present A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly versus Non-Elderly Aspirin-Treated Subjects with Stable Coronary Artery Disease Eli Lilly amp company
2011-present A Prospective Multicenter Randomized Trial of Clopidogrel versus Prasugrel Anti-platelet Therapy in Cytochrome P450 2C19 (CYP2C19) Intermediate Metabolizers Grant No U01HL105198
NIH National Heart Lung and Blood Institute NIH 2011-present A Prospective Randomized Multi-Center Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHERreg Sirolimus-Eluting Coronary stents
HCRI 2012-present A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in
patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)
Bayer Healthcare LLC 2013-present Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in
Patients at a High-Risk for Vascular Outcomes (ACCELERATE) Eli Lilly amp Company 2014-present A Phase 2b Multi-center Randomized Placebo-controlled Dose-ranging Study to Investigate the
Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infarction
AEGIS CSL 2015-2017 A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety of PZ- 128 in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention
National Institute of Health PREVIOUS 2001 A Randomized Double-Blind Placebo-Controlled Study of Two Intravenous Dosing Regimens of
h5G11-scFv in Patients with Acute Myocardial Infarction Undergoing 2001-2002 Prevention of REStenosis with Tranilast and Its Outcomes A Placebo Controlled Trial PRESTO STUDY
SmithKline Beecham 2002-2003 Taxus IV-SR Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
Boston Scientific 2003 MICROVENA Corporation TRAP Vascular Filtration System (VFS) Trial
Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily Pfizer Inc
2003-2004 Phase 3 Multi-Center Double-Blind Randomized Parallel Group Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily (QD) for 24 Months Compared with Atorvastatin Alone in Subjects with Angiographically Documented Coronary Heart Disease Pfizer Inc
2003-2004 A Randomized Controlled Trial of the Medtronic Endeavor Drug Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ldquoENDEAVOR III Studyrdquo)
Medtronic 2009-2010 A Prospective Randomized Open-label Multicenter study in Patients Presenting with Acute Coronary Syndromes SYNERGY STUDY
Aventis Pharmaceuticals 2004 CObalt chromium STent with Antiproliferative for Restenosis II Trialrdquo Costar study
Conor Medsystems
Curriculum Vitae Paul A Gurbel MD Page 18
2004-2005 A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions ENDEAVOR IV Medtronic
2004-2005 A Randomized Trial to evaluate the relative protection against POST-PCI microvasculat obstruction among antiplatelet and anti-thrombotic medications (TIMI-30) TIMI group
2004-2006 A Double-blind Double-dummy Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI 33 AstraZeneca Lp
2005-2006 Strategy To Reduce Atherosclerosis Development Involving Administration of Rimonabant - The Intravascular Ultrasound Study (STRADIVARIUS) EFC5827 Sanofi Synthelabo Research
2006 A Multicenter Randomized Double-Blind Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (TRASM-PCI) Schering Plough
2006-2007 A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel -SWAP (SWitching Anti Platelet study) Eli Lilly amp Company and Sankyo Company Limited
2006-2007 A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2008-2010 A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary InterventionTIMI-38 Eli Lilly Company Daiichi
2009-2010 A Randomized Double-Blind Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128 a Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Interventions (INNOVATE-PCI) Portola Pharmaceuticals
2010-2012 TReatment with ADPreceptor iNhibitorS Longitudinal Assessment ofTreatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS)
Eli Lilly Company 2010-2013 RADAR Randomized Partially-Blinded Multi-Center Active-Controlled Dose-Ranging Study
Assessing the Safety Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome Regado Bioscience Inc
2011-2013 A Phase IIa Multi-center Randomized Sponsor-unblinded Placebo-controlled Single Ascending Dose Study to Investigate the Safety Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Adults Taking Aspirin and a P2Y12 Platelet Inhibitor
AEGIS CSL Research Program BuildingLeadership 1991-1995 Director Interventional Cardiology Research University of Maryland Medical System 1998-2015 Director Sinai Center for Thrombosis Research 2001-2015 Director Cardiovascular Research Lifebridge Health 2002-2015 Director Therapeutics Research and Technology Development for the Cardiac Catheterization Program Sinai Hospital of Baltimore 2007-2015 Associate Chief for Research Department of Medicine Sinai Hospital of Baltimore 2015-current Director Interventional Cardiology and Cardiovascular Medicine Research INOVA Health 2015-Current Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute EDUCATIONAL ACTIVITIES
Curriculum Vitae Paul A Gurbel MD Page 19
Peer Reviewed Publications-Consensus Statements Expert Opinions 1 Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C
Rao AK The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 200531309-11
2 Hoekstra J Cohen M Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Saucedo JF Pollack CV Jr Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention-an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective report on a roundtable discussion Am J Emerg Med 200927720-8
3 Bonello L Tantry US Marcucci R Blindt R Angiolillo DJ Becker R Bhatt DL Cattaneo M Collet JP Cuisset T Gachet C Montalescot G Jennings LK Kereiakes D Sibbing D Trenk D Van Werkum JW Paganelli F Price MJ Waksman R Gurbel PA Working Group on High On Treatment Platelet Reactivity Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 201056919-33
4 Gurbel PA Tantry US Shuldiner AR Kereiakes DJ Genotyping one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 201056112-6
5 Gurbel PA Tantry US Antiplatelet therapy Clopidogrel-PPI interaction an ongoing controversy Nat Rev Cardiol 201187-8
6 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
7 Gurbel PA Nolin TD Tantry US Clopidogrel efficacy and cigarette smoking status JAMA 20123072495-6 8 Tantry US Bonello L Aradi D Price MJ Jeong YH Angiolillo DJ Stone GW Curzen N Geisler T Ten Berg J
Kirtane A Siller-Matula J Mahla E Becker RC Bhatt DL Waksman R Rao SV Alexopoulos D Marcucci R Reny JL Trenk D Sibbing D Gurbel PA Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding J Am Coll Cardiol 2013622261-73
9 Gurbel PA Tantry US Antiplatelet and anticoagulant agents in heart failure Current status and future perspectives JACC Heart Fail 201421-14
10 Gurbel PA Tantry US Antiplatelet therapy What have we learned from the ANTARCTIC trial Nat Rev Cardiol 201613639-640
Invited Review Articles 1 Gurbel PA Midwall JA Brodie BR Angioplasty and adjunctive intra-aortic balloon pump counterpulsation Current
clinical considerations Todays Therapy Trends 19951363-78 2 OrsquoConnor CM Gurbel PA Serebruany VL Depression and ischemic heart disease Am Heart J 200014063-69 3 Gurbel PA Serebruany VL Oral IIbIIIa inhibitors From initial promise to clinical failures J Thromb and
Thrombolysis 200010217-20 4 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Atar D Serebruany VL Platelets and
Thrombolysis Cooperation or Contrariety Heart Drug 20011281-290 5 McKenzie ME Gurbel PA The potential of monoclonal antibodies to reduce reperfusion injury in myocardial
infarction BioDrugs 200115395-404 6 Gurbel PA Bliden KP Hayes K Tantry U Platelet activation in myocardial ischemic syndromes Expert Rev of
Cardiovasc Ther 20052535-45 7 Tantry US Bliden KP Gurbel PA Resistance to antiplatelet drugs Current status and future research Expert
Opin Pharmacother 200562027-45 8 Gurbel PA Lau WC Bliden KP Tantry US Clopidogrel resistance Implications for coronary stenting Curr Pharm
Des 2006121261-9 9 Gurbel PA Tantry US Drug insight Clopidogrel non-responsiveness Nature ClinPract Cardiovasc Med
20063387-95 10 Gurbel PA Tantry US Aspirin and Clopidogrel Resistance Considerations and management J Interv Cardiol
200619439-48 11 Lau WC Gurbel PA Antiplatelet drug resistance and drug-drug interactions Role of cytochrome P450 3A4
Pharm Res 2006232691-708 12 Wiviott SD Tantry US Gurbel PA Clinical applications of antiplatelet therapy Rev Cardiovasc Med 20067
Curriculum Vitae Paul A Gurbel MD Page 20
130-46 13 Tantry US Bliden KP Gurbel PA Prasugrel Expert Opin Investig Drugs 2006151627-33 14 Gurbel PA Tantry US Clopidogrel Resistance Thromb Res 2007120311-21 15 Tantry US Etherington A Bliden KP Gurbel PA Antiplatelet therapy Current strategies and future trends Future
Cardiology 20072343-366 16 Gurbel PA Tantry US The relationship of platelet reactivity to the occurrence of post-stenting ischemic events
emergence of a new cardiovascular risk factor Rev Cardiovasc Med 2006Suppl 4S20-8 17 Tantry US Bliden KP Gurbel PA AZD6140 Expert Opin Investig Drugs 200716225-9 18 Gurbel PA Tantry US Stent thrombosis role of compliance and non-responsiveness to antiplatelet therapy Rev
Cardiovasc Med 20078S19-S26 19 Gurbel PA Kandzari DE Stent thrombosis associated with first-generation drug-eluting stents issues with
antiplatelet therapy Neth Heart J 200715148-50 20 Gurbel PA Tantry US The role of clopidogrel in cardiovascular diseases Pol Arch Med Wewn 2007117207-9 21 Gurbel PA DiChiara J Tantry US Antiplatelet therapy after implantation of drug-eluting stents duration
resistance alternatives and management of surgical patients Am J Cardiol 200710018M-25M 22 Gurbel PA Becker R Mann KG Steinhubl SR Michelson AD Platelet function monitoring in patients with
coronary artery disease J Am Coll Cardiol 2007501822-34 23 Gurbel PA Tantry US Prasugrel a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig
Drugs 20089324-36 24 Gurbel PA Bilden KP Tantry US Diagnostics for aspirin resistance Mol Diagn Ther 20081255-6 25 Gurbel PA Antonino MJ Tantry US Antiplatelet treatment of cardiovascular disease a translational research
perspective Pol Arch Med Wewn 2008118289-97 26 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831I36 27 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention Clin Cardiol 200831I28-I35
28 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches Clin Cardiol 200831I21-I27
29 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention Clin Cardiol 200831I17-I20
30 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Assessing the Current Role of Platelet Function Testing Clin Cardiol 200831I10-I16
31 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831136
32 Keriakes DJ Gurbel PA Periprocedural platelet function in percutaneous coronary intervention JACC Cardiovasc Interv 2008suppl 1111ndash121
33 Gurbel PA Tantry US The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome J Interv Cardiol 200821Suppl 1S10-7
34 Gurbel PA Tantry US Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 20091122-322
35 Gurbel PA Aspirin scope and limitations Br J Cardiol 200917 (Suppl 1)S8-S9 36 Cohen M Hoekstra J Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Pollack CV Jr
Saucedo JF Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion J Interv Cardiol 200821283-99
37 Angiolillo DJ Bhatt DL Gurbel PA Jennings LK Advances in antiplatelet therapy agents in clinical development Am J Cardiol 2009103(3 Suppl)40A-51A
38 Gurbel PA Mahla E Antonino MJ Tantry US Response variability and the role of platelet function testing J Invasive Cardiol 200921172-8
39 Gurbel PA Antonino MJ Tantry US Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug MetabToxicol Expert Opin Drug Metab Toxicol 20095989-1004
40 Gurbel PA Tantry US Antiplatelet resistance- Fact or Myth Am Hosp J 2009750-57 41 Gurbel PA Mahla E Tantry US Aspirin resistance Prog Cardiovasc Dis 200952141-52 42 Tantry US Gurbel PA Platelet monitoring for PCI Is it really necessary Haemostaseologie 200929 368-75 43 Gurbel PA Aspirin-scope and limitations Br J Cardiol 200917(Suppl 1)S8-S9
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 11
171 Kim IS Jeong YH Tantry US Park Y Lee DH Bliden KP Koh JS Park JR Jang JS Hwang SJ Koh EH Kwak CH Hwang JY Kim S Gurbel PA Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading Am Heart J 201316695-103
172 Grześk G Kozinski M Tantry US Wicinski M Fabiszak T Navarese EP Grzesk E Jeong YH Gurbel PA Kubica J High-dose but not low-dose aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells Biomed Res Int 20132013928271
173 Stone GW Witzenbichler B Weisz G Rinaldi MJ Neumann FJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri E Gurbel PA Xu K Parise H Kirtane AJ Brodie BR Mehran R Stuckey TD for the ADAPT-DES Investigators Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES) a prospective multicentre registry study Lancet 2013382614-23
174 Angiolillo DJ Curzen N Gurbel P Vaitkus P Lipkin F Li W Jakubowski JA Zettler M Effron MB Trenk D Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in subjects with stable coronary artery disease Results of the SWAP-2 Study J Am Coll Cardiol 2014631500-9
175 Jeong YH Bliden KP Shuldiner AR Tantry US Gurbel PA Thrombin-induced platelet-fibrin clot strength Relation to high on-clopidogrel platelet reactivity genotype and post-percutaneous coronary intervention outcomes Thromb Haemost 2014111713-24
176 Gouya G Arrich J Wolzt M Huber K Verheugt FW Gurbel PA Pirker-Kees A Siller-Matula JM Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases a systematic review and meta-analysis Stroke 201445492-503
177 Erlinge D James S Duvvuru S Jakubowski JA Wagner H Varenhorst C Tantry US Brown PB Small D Moser BA Sundseth S Walker JR Winters KJ Gurbel PA Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease Thromb Haemost 2014111943-50
178 Gurbel PA Baker BA Bailey WL Bliden KP Tantry US Unraveling the Smokers Paradox Cigarette smoking high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors Thromb Haemost 20141111187-90
179 Koh JS Kim IS Tantry US Yoon SE Park Y Cho SY Lee EJ Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading The results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study Int J Cardiol 2014174129-32
180 Bliden KP Singla A Gesheff MG Toth PP Tabrizchi A Ens G Guyer K Singh M Franzese CJ Stapleton D Tantry US Gurbel PA Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin Thromb Haemost 2014 Apr 24112(2) [Epub ahead of print]
181 Gurbel PA Gesheff MG Franzese CJ Bliden KP Tantry US Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy Platelets 201526608-9
182 Gurbel PA Bergmeijer TO Tantry US Ten Berg JM Angiolillo DJ James S Lindahl TL Svensson P Jakubowski JA Brown PB Duvvuru S Sundseth S Walker JR Small D Moser BA Winters KJ Erlinge D The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease Thromb Haemost 2014 2014112589-97
183 Cornel JH Ohman EM Neely B Clemmensen P Sritara P Zamoryakhin D Armstrong PW Prabhakaran D White HD Fox KA Gurbel PA Roe MT TRILOGY ACS Investigators Impact of smoking status on platelet function and clinical outcomes with prasugrel vs clopidogrel in patients with acute coronary syndromes managed without revascularization Insights from the TRILOGY ACS trial Am Heart J 201416876-87
184 Park Y Jung JM Tantry US Kim K Koh JS Park JR Hwang SJ Kwak CH Hwang JY Kim S Gurbel PA Jeong YH Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration The ACCEL-PARAZOL Study J Atheroscler Thromb 2014211121-39
185 Park Y Jeong YH Tantry US Ahn JH Kim K Koh J Park J Hwang SJ Kwak CH Hwang JY Gurbel PA Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity The Resultof the ACCEL-DIP Study Thromb Haemost 2014112 [Epub ahead of print]
186 Lev EI Bliden KP Jeong Y-H Pandya S Kang K Franzese C Tantry US Gurbel PA Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients J Am Heart Assoc 20143e001167
187 Alexopoulos D Xanthopoulou I Storey RF Bliden KP Tantry US Angiolillo DJ Gurbel PA Platelet reactivity during ticagrelor maintenance therapy A patient-level data meta-analysis Am Heart J 2014 168530-6
188 Lhermusier T Lipinski MJ Tantry US Escarcega RO Baker N Bliden KP Magalhaes MA Ota H Tian W Pendyala L Minha S Chen F Torguson R Gurbel PA Waksman R Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity Am J Cardiol 2015115716-23
189 Franzese CJ Bliden KP Gesheff MG Pandya S Guyer KE Singla A Tantry US Toth PP Gurbel PA Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy Am J Cardiol 2015 11151204-11
Curriculum Vitae Paul A Gurbel MD Page 12
190 Aradi D Kirtane A Bonello L Gurbel PA Tantry US Huber K Freynhofer MK Ten Berg J Janssen P Angiolillo DJ Siller-Matula JM Marcucci R Patti G Mangiacapra F Valgimigli M Morel O Palmerini T Price MJ Cuisset T Kastrati A Stone GW Sibbing D Bleeding and stent thrombosis on P2Y12-inhibitors collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention Eur Heart J 2015361762-71
191 Navarese EP Kolodziejczak M Schulze V Gurbel PA Tantry U Lin Y Brockmeyer M Kandzari DE Kubica JM DAgostino RB Sr Kubica J Volpe M Agewall S Kereiakes DJ Kelm M Effects of proprotein convertase subtilisinkexin type 9 antibodies in adults with hypercholesterolemia a systematic review and meta-analysis Ann Intern Med 201516340-51
192 Lee K Yoo SY Suh J Park KH Park Y Tantry US Park KS Han SH Kang WC Shin DH Lee C Choi SW Lee JH Cho YH Lee NH Jeong MH Ahn Y Kubica J Gurbel PA Park JH Jeong YH Efficacy of cilostazol on inhibition of platelet aggregation inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study Int J Cardiol 2015190370-5
193 Kowalewski M Schulze V Berti S Waksman R Kubica J Kołodziejczak M Buffon A Suryapranata H Gurbel PA Kelm M Pawliszak W Anisimowicz L Navarese EP Complete revascularisation in ST-elevation myocardial infarction and multivessel disease meta-analysis of randomised controlled trials Heart 2015 1011309-17
194 Baber U Mehran R Kirtane AJ Gurbel PA Christodoulidis G Maehara A Witzenbichler B Weisz G Rinaldi MJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri EL Jr Xu K Parise H Brodie BR Stuckey TD Stone GW Prevalence and impact of high platelet reactivity in chronic kidney disease Results from the assessment of dual antiplatelet therapy with drug-eluting stents registry Circ Cardiovasc Interv 20158e001683
195 Tricoci P DAndrea DM Gurbel PA Yao Z Cuchel M Winston B Schott R Weiss R Blazing MA Cannon L Bailey A Angiolillo DJ Gille A Shear CL Wright SDAlexander JH Infusion of Reconstituted High-Density Lipoprotein CSL112 in Patients With Atherosclerosis Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial J Am Heart Assoc 20154 pii e002171
196 Reny JL Fontana P Hochholzer W Neumann MJ ten Berg J Janssen PF Geisler T Gawaz M Marcucci R Gori A-M Cuisset T Alessi M-S Berdagueacute P Gurbel PA Yong G Angiolillo DJ Aradi D Beigel R Campo G Combescure C Vascular risk levels affect the predictive value of platelet reactivity 1 for the occurrence of major adverse cardiovascular events in patients on clopidogrel Systematic review and collaborative meta-analysis of individual patient data Thromb Haemost 2015 (in press)
197 Chaudhary R Bliden KP Tantry US Mohammed N Mathew D Gesheff MG Franzese CJ Gurbel PA Association of weight gain with coronary artery disease inflammation and thrombogenicity J Thromb Thrombolysis 2015 Dec 29 [Epub ahead of print]
198 Gurbel PA Bliden KP Turner SE Tantry US Gesheff MG Barr TP Covic L Kuliopulos A Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease Arterioscler Thromb Vasc Biol 201636189-97
199 Kwon TJ Tantry US Park Y Choi YM Ahn JH Kim KH Koh JS Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Smith SC Jr Jeong YH Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention Results of the ACCEL-BLEED study Thromb Haemost 2016 Jan 21115(5) [Epub ahead of print]
200 Bliden KP Tantry US Gesheff MG Franzese CJ Pandya S Toth PP Mathew DP Chaudhary R Gurbel PA Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis J Interv Cardiol 201629168-78
201 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin J Diabetes Complications 2016 May 10 pii S1056-8727(16)30127-1
202 Bedeir K Bliden K Tantry U Gurbel PA Mahla E Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel The Role of VerifyNow Can J Cardiol 201632724-5
203 Giustino G Kirtane AJ Baber U Geacuteneacutereux P Witzenbichler B Neumann FJ Weisz G Maehara A Rinaldi MJ Metzger C Henry TD Cox DA Duffy PL Mazzaferri EL Brodie BR Stuckey TD Gurbel PA Dangas GD Francese DP Ozan O Mehran R Stone GW Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study Am J Cardiol 20161171877-83
204 Kubica J Kubica A Jilma B Adamski P Hobl EL Navarese EP Siller-Matula JM Dąbrowska A Fabiszak T Koziński M Gurbel PA Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors Int J Cardiol 2016215201-8
205 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin
Curriculum Vitae Paul A Gurbel MD Page 13
J Diabetes Complications 2016 May 10 [Epub ahead of print] 206 Bliden KP Chaudhary R Lopez LR Damrongwatanasuk R Guyer K Gesheff MG Franzese CJ Kaza H
Tantry US Gurbel PA Oxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease Am J Cardiol 2016 Jun 15 [Epub ahead of print]
207 Mahla E Prueller F Farzi S Pregartner G Raggam RB Beran E Toller W Berghold A Tantry US Gurbel PA Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy Ann Thorac Surg 2016 Jul 1 [Epub ahead of print]
208 Koh JS Park Y Tantry US Ahn JH Kang MG Kim K Jang JY Park HW Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents The ACCEL-COMBO trial Platelets 2016 Aug 251-7 [Epub ahead of print]
209 Chaudhary R Saadin K Bliden KP Harris WS Dinh B Sharma T Tantry US Gurbel PA Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease Prostaglandins Leukot Essent Fatty Acids 201611340-45
210 Gurbel PA Bliden KP Chaudhary R Patrick J Liu F Chen G McLeod C Tantry US Antiplatelet Effect Durability of a Novel 24-Hour Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes MellitusAm J Cardiol 20161181941-1947
211 Gurbel PA Bliden KP Tantry US Monroe AL Muresan AA Brunner NE Lopez-Espina CG Delmenico PR Cohen E Raviv G Haugen DL Ereth MH First report of the point-of-care TEG A technical validation study of the TEG-6S system Platelets 201627642-649
212 Cornel JH Ohman EM Neely B Jakubowski JA Bhatt DL White HD Ardissino D Fox KA Prabhakaran D Armstrong PW Erlinge D Tantry US Gurbel PA Roe MT Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes J Am Heart Assoc 2016 Nov 45(11) pii e003977
213 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 201717109-121
214 Sharma T Bliden K Chaudhary R Tantry U Gurbel PA Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease Expert Opin Pharmacother 201718123-131
215 Park Y Tantry US Koh JS Ahn JH Kang MG Kim KH Jang JY Park HW Park JR Hwang SJ Park KS Kwak CH Hwang JY Gurbel PA Jeong YH Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction The REMODELING Trial Thromb Haemost 2017117911-922
216 Navarese EP Gurbel PA Andreotti F Kołodziejczak MM Palmer SC Dias S Buffon A Kubica J Kowalewski M Jadczyk T Laskiewicz M Jędrzejek M Brockmeyer M Airoldi F Ruospo M De Servi S Wojakowski W O Connor C Strippoli GF Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis PLoS One 201712e0168726
217 Bliden KP Chaudhary R Mohammed N Muresan AA Lopez-Espina CG Cohen E Raviv G Doubleday M Zaman F Mathew B Tantry US Gurbel PA Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system J Thromb Thrombolysis 201743437-445
Publications Peer Reviewed Original Science Research - Reviews 1 Serebruany VL Atar D Dalesandro MR OConnor CM Gurbel PA Changes in hemostasis after parenteral
magnesium in myocardial ischemia reperfusion Animal studies to clinical trials Magnes Res 19981137-42 2 McKenzie ME Gurbel PA Levine DJ Serebruany VL Clinical utility of available methods determining platelet
function Cardiology 199992240-7 3 Gurbel PA OConnor CM Cummings CC Serebruany VL Clopidogrel The future choice for preventing platelet
activation during coronary stenting Pharm Res 199965109-123 4 Nair GV Gurbel PA Fusaylov SY Davis CJ Ohman EM Bahr RD Christensen RH Serebruany VL Combing
necrosis and platelet markers for perfecting myocardial infarction rule out How close are we Cardiology 20009350-5
5 Davis CJ Gurbel PA Gaitis WA Fuzaylov SY Nair GV OrsquoConnor CM Serebruany VL Hemostatic abnormalities in congestive heart failure Diagnostic significance and clinical challenge Int J Cardiol 20007515-21
6 Pothula A Gurbel PA Atar D McKenzie ME Serebruany VL Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease Eur J Pharmacol 20004021-10
7 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Serebruany VL Platelet function and fibrinolytic agents Two sides of a coin Cardiology 20019555-60
Curriculum Vitae Paul A Gurbel MD Page 14
8 Samara WM Gurbel PA The role of platelet receptors and adhesion molecules in coronary artery disease Coron Artery Dis 20031465-79
9 Gurbel PA Tantry U Clopidogrel response variability and the advent of personalised antiplatelet therapy A bench to bedside journey Thromb Haemost 2011106265-71
10 Gurbel PA Roe MT Jakubowski JA Shah S Erlinge D Goodman SG Huber K Chan MY Cornel JH Tantry US Ohman EM Translational platelet research in patients with coronary artery disease What are the major knowledge gaps Thromb Haemost 2012 May 25108 [Epub ahead of print]
11 Bliden KP Baker BA Nolin TD Jeong YH Bailey WL Tantry US Gurbel PA Thienopyridine efficacy and cigarette smoking status Am Heart J 2013165693-703
12 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
13 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013111547-56
14 Gesheff MG Franzese CJ Bliden KP Contino CJ Rafeedheen R Tantry USGurbel PA Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin Expert Rev Clin Pharmacol 2014 7645-53
15 Tantry US Gesheff M Liu F Bliden KP Gurbel PA Resistance to antiplatelet therapy what progress has been made Expert Opin Pharmacother 2014 9 1-12
16 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print]
17 Gurbel PA Myat A Tantry US Platelet-mediated Thrombosis From Bench to Bedside Cir Res 2015 (in press)
18 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 20161245-58
19 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
20 Gurbel PA Tantry US Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes Heart 2016102882-92
21 Navarese EP Kolodziejczak M Kereiakes DJ Tantry US OConnor C Gurbel PA Proprotein Convertase SubtilisinKexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome A Narrative Review Ann Intern Med 2016164600-7
22 Gurbel PA Jeong YH Navarese EP Tantry US Platelet-Mediated Thrombosis From Bench to Bedside Circ Res 20161181380-91
23 Gurbel PA Myat A Kubica J Tantry US State of the art Oral antiplatelet therapy JRSM Cardiovasc Dis 2016 Jun 152048004016652514 doi 1011772048004016652514 eCollection 2016 Jan-Dec
24 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 2016 Nov 17 [Epub ahead of print] Review
25 Winter MP Grove EL De Caterina R Gorog DA Ahrens I Geisler T Gurbel PA Tantry U Navarese EP Siller-Matula JM Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors Eur Heart J Cardiovasc Pharmacother 2017 Feb 15 doi 101093ehjcvppvw044 [Epub ahead of print]
26 Shah P Tantry US Bliden KP Gurbel PA Bleeding and thrombosis associated with ventricular assist device therapy J Heart Lung Transplant 2017 May 11 pii S1053-2498(17)31789-8
Inventions Patents Copyrights 32294 Gurbel PA Anderson RD Autoperfusion dilatation catheter United States Patent 5295959 51501 Dalesandro MR Gurbel PA Serebruany VL Determining a treatment plan for patients undergoing thrombotic
events by monitoring p-Selectin United States Patent 623071 61201 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6245782 13102 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 20020013343 42203 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6552014
Curriculum Vitae Paul A Gurbel MD Page 15
120611 Gurbel PA The detection of restenosis risk in patients receiving a stent by measuring the characteristics of blood clotting including the measurement of maximum thrombin-induced clot strength (patent awarded pending)
6308 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 7381536 2010 Gurbel PA Conley P Andre P Gretler D Jurek M Methods for diagnosis and treatment of thrombotic
disorders mediated bycyp2c192 (patent pending) 41014 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent
20140100167 81815 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 9110062 111715 Gurbel PA Detection of restenosis risk in patients receiving a stent by measuring the characteristics of
blood clotting including the measurement of maximum thrombin-induced clot strength Patent 9188597 Extramural Funding (since 2002) CURRENT 2010-2015 MAGMA (Multianalyte And Genetic Markers of Atherosclerosis)
Haemonetics and Sinai Hospital of Baltimore 2015-present An Observational Study of CORA-Assisted Stroke Identification and Antithrombotic Therapy
2014-2015 Feasibility clinical trial to evaluate the efficacy of an Anticoagulant cartridge to be used in the CORA System Coramed Technologies LLC
2014-2015 Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid Durlaza in CVD Patients at Risk of High Platelet Turnover (DURATION)
New Haven Pharmaceuticals Inc 2015-present Influence of Edoxaban on Coagulability and Thrombin Generation An in Vitro Study Focusing on
Thrombelastography Daiichi Sankyo
2016 Influence of Vorapaxar on Thrombin Generation and Coagulability Merck 2015-present Durlaza GI GI Tolerability Study New Haven Pharamceuticals 2015-present Thrombogenicity in LVAD Recipients Haemonetics 2014-2015 First-in-Man Assessment of PZ-128 National Institutes of Health PREVIOUS 2002 Atorvastatin in the Treatment of Heart Failure
LBH IRB 20030512 NIHThe National Heart Lung and Blood Institute NIH
2002 Asessment of the In Vitro Effects of Tenecteplase Reteplase and Alteplase on Human Platelets TAR STUDY Genetech
2003-2005 Assessment of the Effects of the heparin-coated Cordis Stent versus Non-coated Stents on Platelet and Endothelial Cell Activation and Thrombin Effect in Patients with Coronary Artery Disease (HEPACOAT) Cordis Inc
2004-2005 The Antiplatelet Effects of Eptifibatide with High and Standard Dose Clopidogrel in Low-Moderate Risk Patients Undergoing Coronary Intervention (CLEAR-PLATELETS Study) MilleniumSchering Plough
2004-2005 The Use of The TEG System to Monitor Platelet Inhibition at Bedside 5R44HL059753-03Haemoscope National Institute of Health
2004-2006 Clopidogrel Resistance in Patients with Stent Thrombosis (CREST Study) AstraZeneca
Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study MilleniumSchering Plough
2005 St Johns Wort Decreases ADP Induced Platelet Reactivity in Known Clopidogrel Resistant Post Coronary Intervention Patients after a Loading Dose of Clopidogrel University of Michigan
2008-2009 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST) Sinai Hospital Department of Medicine
2009-2010 Demonstration of the Pharmacodynamic Antiplatelet Effect of PRT060128 in Patients with High Platelet Reactivity during Clopidogrel and Aspirin Maintenance Therapy (PORTOLA) Portola Pharmaceuticals
2008-2009 A Randomised Double-Blind Outpatient Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND] AstraZeneca Pharmaceuticals LP
2008-2009 A Randomized Double-blind Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Background Therapy in Patients with Stable Coronary Artery Disease with Additional Detailed Assessment of Cardiopulmonary Function (ONSET-OFFSET) AstraZeneca Pharmaceuticals LP
2008-2009 A Single Center Randomized Open Label Parallel Group Pharmacodynamic Study of a Novel Combination Form of Aspirin and Phytosterol versus Aspirin in Healthy Adult Subjects (ARMOR) Bayer Healthcare LLC
2008-2009 Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel Plus EC Aspirin (325 mg) and Clopidogrel Plus PA32540 on Platelet Aggregation in Healthy Volunteers POZEN 110 POZEN Inc
2009-2010 Antithrombosis with Clopidogrel Beyond the Concept of Platelet Aggregate Inhibition (SANOFI) Sanofi Inc 2010-2012 A Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel EC
Aspirin 81 mg and EC omeprazole 40 mg all dosed concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers POZEN Inc
Intramural Funding (since 2002) CURRENT 2008-present Time Based Strategy to Reduce Clopidogrel Associated Bleeding Related to CABG (TARGET CABG) Sinai Hospital of Baltimore Department of Medicine 2009-present Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI)
Sinai Hospital of Baltimore Department of Medicine 2011-present Detection of Leukemic Blood and Solid TypE MalignanCies by Urinary 11-DehydroThromboxane B2 (DETECT) Study
Sinai Hospital of Baltimore Department of Medicine PREVIOUS 2001-2002 Platelet Activation in Stenting PAST Study Sinai Hospital of Baltimore 2005-2006 Platelet Reactivity in Patients with Crohnrsquos disease Receiving Infliximab (chimeric anti-TNF alpha antibody) ndash COIN
Sinai Hospital of Baltimore Department of Medicine 2006-2007 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST)
Sinai Hospital of Baltimore Department of Medicine 2008-2011 Platelet Reactivity and Thrombogenecity in Postmenopausal Women
Sinai Hospital Department of Medicine 2008-2010 Platelet Reactivity and Thrombogenecity in Postmenopausal Women (PRIDE Study)
Sinai Hospital Department of Medicine Multicenter Studies since 2001
Curriculum Vitae Paul A Gurbel MD Page 17
CURRENT 2010-present The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and
Clopidogrel in Aspirin-Treated Subjects With Stable Coronary Artery Disease Daiichi Sankyo
2010-present A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly versus Non-Elderly Aspirin-Treated Subjects with Stable Coronary Artery Disease Eli Lilly amp company
2011-present A Prospective Multicenter Randomized Trial of Clopidogrel versus Prasugrel Anti-platelet Therapy in Cytochrome P450 2C19 (CYP2C19) Intermediate Metabolizers Grant No U01HL105198
NIH National Heart Lung and Blood Institute NIH 2011-present A Prospective Randomized Multi-Center Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHERreg Sirolimus-Eluting Coronary stents
HCRI 2012-present A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in
patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)
Bayer Healthcare LLC 2013-present Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in
Patients at a High-Risk for Vascular Outcomes (ACCELERATE) Eli Lilly amp Company 2014-present A Phase 2b Multi-center Randomized Placebo-controlled Dose-ranging Study to Investigate the
Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infarction
AEGIS CSL 2015-2017 A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety of PZ- 128 in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention
National Institute of Health PREVIOUS 2001 A Randomized Double-Blind Placebo-Controlled Study of Two Intravenous Dosing Regimens of
h5G11-scFv in Patients with Acute Myocardial Infarction Undergoing 2001-2002 Prevention of REStenosis with Tranilast and Its Outcomes A Placebo Controlled Trial PRESTO STUDY
SmithKline Beecham 2002-2003 Taxus IV-SR Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
Boston Scientific 2003 MICROVENA Corporation TRAP Vascular Filtration System (VFS) Trial
Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily Pfizer Inc
2003-2004 Phase 3 Multi-Center Double-Blind Randomized Parallel Group Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily (QD) for 24 Months Compared with Atorvastatin Alone in Subjects with Angiographically Documented Coronary Heart Disease Pfizer Inc
2003-2004 A Randomized Controlled Trial of the Medtronic Endeavor Drug Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ldquoENDEAVOR III Studyrdquo)
Medtronic 2009-2010 A Prospective Randomized Open-label Multicenter study in Patients Presenting with Acute Coronary Syndromes SYNERGY STUDY
Aventis Pharmaceuticals 2004 CObalt chromium STent with Antiproliferative for Restenosis II Trialrdquo Costar study
Conor Medsystems
Curriculum Vitae Paul A Gurbel MD Page 18
2004-2005 A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions ENDEAVOR IV Medtronic
2004-2005 A Randomized Trial to evaluate the relative protection against POST-PCI microvasculat obstruction among antiplatelet and anti-thrombotic medications (TIMI-30) TIMI group
2004-2006 A Double-blind Double-dummy Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI 33 AstraZeneca Lp
2005-2006 Strategy To Reduce Atherosclerosis Development Involving Administration of Rimonabant - The Intravascular Ultrasound Study (STRADIVARIUS) EFC5827 Sanofi Synthelabo Research
2006 A Multicenter Randomized Double-Blind Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (TRASM-PCI) Schering Plough
2006-2007 A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel -SWAP (SWitching Anti Platelet study) Eli Lilly amp Company and Sankyo Company Limited
2006-2007 A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2008-2010 A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary InterventionTIMI-38 Eli Lilly Company Daiichi
2009-2010 A Randomized Double-Blind Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128 a Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Interventions (INNOVATE-PCI) Portola Pharmaceuticals
2010-2012 TReatment with ADPreceptor iNhibitorS Longitudinal Assessment ofTreatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS)
Eli Lilly Company 2010-2013 RADAR Randomized Partially-Blinded Multi-Center Active-Controlled Dose-Ranging Study
Assessing the Safety Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome Regado Bioscience Inc
2011-2013 A Phase IIa Multi-center Randomized Sponsor-unblinded Placebo-controlled Single Ascending Dose Study to Investigate the Safety Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Adults Taking Aspirin and a P2Y12 Platelet Inhibitor
AEGIS CSL Research Program BuildingLeadership 1991-1995 Director Interventional Cardiology Research University of Maryland Medical System 1998-2015 Director Sinai Center for Thrombosis Research 2001-2015 Director Cardiovascular Research Lifebridge Health 2002-2015 Director Therapeutics Research and Technology Development for the Cardiac Catheterization Program Sinai Hospital of Baltimore 2007-2015 Associate Chief for Research Department of Medicine Sinai Hospital of Baltimore 2015-current Director Interventional Cardiology and Cardiovascular Medicine Research INOVA Health 2015-Current Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute EDUCATIONAL ACTIVITIES
Curriculum Vitae Paul A Gurbel MD Page 19
Peer Reviewed Publications-Consensus Statements Expert Opinions 1 Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C
Rao AK The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 200531309-11
2 Hoekstra J Cohen M Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Saucedo JF Pollack CV Jr Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention-an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective report on a roundtable discussion Am J Emerg Med 200927720-8
3 Bonello L Tantry US Marcucci R Blindt R Angiolillo DJ Becker R Bhatt DL Cattaneo M Collet JP Cuisset T Gachet C Montalescot G Jennings LK Kereiakes D Sibbing D Trenk D Van Werkum JW Paganelli F Price MJ Waksman R Gurbel PA Working Group on High On Treatment Platelet Reactivity Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 201056919-33
4 Gurbel PA Tantry US Shuldiner AR Kereiakes DJ Genotyping one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 201056112-6
5 Gurbel PA Tantry US Antiplatelet therapy Clopidogrel-PPI interaction an ongoing controversy Nat Rev Cardiol 201187-8
6 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
7 Gurbel PA Nolin TD Tantry US Clopidogrel efficacy and cigarette smoking status JAMA 20123072495-6 8 Tantry US Bonello L Aradi D Price MJ Jeong YH Angiolillo DJ Stone GW Curzen N Geisler T Ten Berg J
Kirtane A Siller-Matula J Mahla E Becker RC Bhatt DL Waksman R Rao SV Alexopoulos D Marcucci R Reny JL Trenk D Sibbing D Gurbel PA Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding J Am Coll Cardiol 2013622261-73
9 Gurbel PA Tantry US Antiplatelet and anticoagulant agents in heart failure Current status and future perspectives JACC Heart Fail 201421-14
10 Gurbel PA Tantry US Antiplatelet therapy What have we learned from the ANTARCTIC trial Nat Rev Cardiol 201613639-640
Invited Review Articles 1 Gurbel PA Midwall JA Brodie BR Angioplasty and adjunctive intra-aortic balloon pump counterpulsation Current
clinical considerations Todays Therapy Trends 19951363-78 2 OrsquoConnor CM Gurbel PA Serebruany VL Depression and ischemic heart disease Am Heart J 200014063-69 3 Gurbel PA Serebruany VL Oral IIbIIIa inhibitors From initial promise to clinical failures J Thromb and
Thrombolysis 200010217-20 4 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Atar D Serebruany VL Platelets and
Thrombolysis Cooperation or Contrariety Heart Drug 20011281-290 5 McKenzie ME Gurbel PA The potential of monoclonal antibodies to reduce reperfusion injury in myocardial
infarction BioDrugs 200115395-404 6 Gurbel PA Bliden KP Hayes K Tantry U Platelet activation in myocardial ischemic syndromes Expert Rev of
Cardiovasc Ther 20052535-45 7 Tantry US Bliden KP Gurbel PA Resistance to antiplatelet drugs Current status and future research Expert
Opin Pharmacother 200562027-45 8 Gurbel PA Lau WC Bliden KP Tantry US Clopidogrel resistance Implications for coronary stenting Curr Pharm
Des 2006121261-9 9 Gurbel PA Tantry US Drug insight Clopidogrel non-responsiveness Nature ClinPract Cardiovasc Med
20063387-95 10 Gurbel PA Tantry US Aspirin and Clopidogrel Resistance Considerations and management J Interv Cardiol
200619439-48 11 Lau WC Gurbel PA Antiplatelet drug resistance and drug-drug interactions Role of cytochrome P450 3A4
Pharm Res 2006232691-708 12 Wiviott SD Tantry US Gurbel PA Clinical applications of antiplatelet therapy Rev Cardiovasc Med 20067
Curriculum Vitae Paul A Gurbel MD Page 20
130-46 13 Tantry US Bliden KP Gurbel PA Prasugrel Expert Opin Investig Drugs 2006151627-33 14 Gurbel PA Tantry US Clopidogrel Resistance Thromb Res 2007120311-21 15 Tantry US Etherington A Bliden KP Gurbel PA Antiplatelet therapy Current strategies and future trends Future
Cardiology 20072343-366 16 Gurbel PA Tantry US The relationship of platelet reactivity to the occurrence of post-stenting ischemic events
emergence of a new cardiovascular risk factor Rev Cardiovasc Med 2006Suppl 4S20-8 17 Tantry US Bliden KP Gurbel PA AZD6140 Expert Opin Investig Drugs 200716225-9 18 Gurbel PA Tantry US Stent thrombosis role of compliance and non-responsiveness to antiplatelet therapy Rev
Cardiovasc Med 20078S19-S26 19 Gurbel PA Kandzari DE Stent thrombosis associated with first-generation drug-eluting stents issues with
antiplatelet therapy Neth Heart J 200715148-50 20 Gurbel PA Tantry US The role of clopidogrel in cardiovascular diseases Pol Arch Med Wewn 2007117207-9 21 Gurbel PA DiChiara J Tantry US Antiplatelet therapy after implantation of drug-eluting stents duration
resistance alternatives and management of surgical patients Am J Cardiol 200710018M-25M 22 Gurbel PA Becker R Mann KG Steinhubl SR Michelson AD Platelet function monitoring in patients with
coronary artery disease J Am Coll Cardiol 2007501822-34 23 Gurbel PA Tantry US Prasugrel a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig
Drugs 20089324-36 24 Gurbel PA Bilden KP Tantry US Diagnostics for aspirin resistance Mol Diagn Ther 20081255-6 25 Gurbel PA Antonino MJ Tantry US Antiplatelet treatment of cardiovascular disease a translational research
perspective Pol Arch Med Wewn 2008118289-97 26 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831I36 27 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention Clin Cardiol 200831I28-I35
28 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches Clin Cardiol 200831I21-I27
29 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention Clin Cardiol 200831I17-I20
30 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Assessing the Current Role of Platelet Function Testing Clin Cardiol 200831I10-I16
31 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831136
32 Keriakes DJ Gurbel PA Periprocedural platelet function in percutaneous coronary intervention JACC Cardiovasc Interv 2008suppl 1111ndash121
33 Gurbel PA Tantry US The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome J Interv Cardiol 200821Suppl 1S10-7
34 Gurbel PA Tantry US Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 20091122-322
35 Gurbel PA Aspirin scope and limitations Br J Cardiol 200917 (Suppl 1)S8-S9 36 Cohen M Hoekstra J Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Pollack CV Jr
Saucedo JF Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion J Interv Cardiol 200821283-99
37 Angiolillo DJ Bhatt DL Gurbel PA Jennings LK Advances in antiplatelet therapy agents in clinical development Am J Cardiol 2009103(3 Suppl)40A-51A
38 Gurbel PA Mahla E Antonino MJ Tantry US Response variability and the role of platelet function testing J Invasive Cardiol 200921172-8
39 Gurbel PA Antonino MJ Tantry US Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug MetabToxicol Expert Opin Drug Metab Toxicol 20095989-1004
40 Gurbel PA Tantry US Antiplatelet resistance- Fact or Myth Am Hosp J 2009750-57 41 Gurbel PA Mahla E Tantry US Aspirin resistance Prog Cardiovasc Dis 200952141-52 42 Tantry US Gurbel PA Platelet monitoring for PCI Is it really necessary Haemostaseologie 200929 368-75 43 Gurbel PA Aspirin-scope and limitations Br J Cardiol 200917(Suppl 1)S8-S9
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 12
190 Aradi D Kirtane A Bonello L Gurbel PA Tantry US Huber K Freynhofer MK Ten Berg J Janssen P Angiolillo DJ Siller-Matula JM Marcucci R Patti G Mangiacapra F Valgimigli M Morel O Palmerini T Price MJ Cuisset T Kastrati A Stone GW Sibbing D Bleeding and stent thrombosis on P2Y12-inhibitors collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention Eur Heart J 2015361762-71
191 Navarese EP Kolodziejczak M Schulze V Gurbel PA Tantry U Lin Y Brockmeyer M Kandzari DE Kubica JM DAgostino RB Sr Kubica J Volpe M Agewall S Kereiakes DJ Kelm M Effects of proprotein convertase subtilisinkexin type 9 antibodies in adults with hypercholesterolemia a systematic review and meta-analysis Ann Intern Med 201516340-51
192 Lee K Yoo SY Suh J Park KH Park Y Tantry US Park KS Han SH Kang WC Shin DH Lee C Choi SW Lee JH Cho YH Lee NH Jeong MH Ahn Y Kubica J Gurbel PA Park JH Jeong YH Efficacy of cilostazol on inhibition of platelet aggregation inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study Int J Cardiol 2015190370-5
193 Kowalewski M Schulze V Berti S Waksman R Kubica J Kołodziejczak M Buffon A Suryapranata H Gurbel PA Kelm M Pawliszak W Anisimowicz L Navarese EP Complete revascularisation in ST-elevation myocardial infarction and multivessel disease meta-analysis of randomised controlled trials Heart 2015 1011309-17
194 Baber U Mehran R Kirtane AJ Gurbel PA Christodoulidis G Maehara A Witzenbichler B Weisz G Rinaldi MJ Metzger DC Henry TD Cox DA Duffy PL Mazzaferri EL Jr Xu K Parise H Brodie BR Stuckey TD Stone GW Prevalence and impact of high platelet reactivity in chronic kidney disease Results from the assessment of dual antiplatelet therapy with drug-eluting stents registry Circ Cardiovasc Interv 20158e001683
195 Tricoci P DAndrea DM Gurbel PA Yao Z Cuchel M Winston B Schott R Weiss R Blazing MA Cannon L Bailey A Angiolillo DJ Gille A Shear CL Wright SDAlexander JH Infusion of Reconstituted High-Density Lipoprotein CSL112 in Patients With Atherosclerosis Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial J Am Heart Assoc 20154 pii e002171
196 Reny JL Fontana P Hochholzer W Neumann MJ ten Berg J Janssen PF Geisler T Gawaz M Marcucci R Gori A-M Cuisset T Alessi M-S Berdagueacute P Gurbel PA Yong G Angiolillo DJ Aradi D Beigel R Campo G Combescure C Vascular risk levels affect the predictive value of platelet reactivity 1 for the occurrence of major adverse cardiovascular events in patients on clopidogrel Systematic review and collaborative meta-analysis of individual patient data Thromb Haemost 2015 (in press)
197 Chaudhary R Bliden KP Tantry US Mohammed N Mathew D Gesheff MG Franzese CJ Gurbel PA Association of weight gain with coronary artery disease inflammation and thrombogenicity J Thromb Thrombolysis 2015 Dec 29 [Epub ahead of print]
198 Gurbel PA Bliden KP Turner SE Tantry US Gesheff MG Barr TP Covic L Kuliopulos A Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease Arterioscler Thromb Vasc Biol 201636189-97
199 Kwon TJ Tantry US Park Y Choi YM Ahn JH Kim KH Koh JS Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Smith SC Jr Jeong YH Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention Results of the ACCEL-BLEED study Thromb Haemost 2016 Jan 21115(5) [Epub ahead of print]
200 Bliden KP Tantry US Gesheff MG Franzese CJ Pandya S Toth PP Mathew DP Chaudhary R Gurbel PA Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis J Interv Cardiol 201629168-78
201 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin J Diabetes Complications 2016 May 10 pii S1056-8727(16)30127-1
202 Bedeir K Bliden K Tantry U Gurbel PA Mahla E Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel The Role of VerifyNow Can J Cardiol 201632724-5
203 Giustino G Kirtane AJ Baber U Geacuteneacutereux P Witzenbichler B Neumann FJ Weisz G Maehara A Rinaldi MJ Metzger C Henry TD Cox DA Duffy PL Mazzaferri EL Brodie BR Stuckey TD Gurbel PA Dangas GD Francese DP Ozan O Mehran R Stone GW Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study Am J Cardiol 20161171877-83
204 Kubica J Kubica A Jilma B Adamski P Hobl EL Navarese EP Siller-Matula JM Dąbrowska A Fabiszak T Koziński M Gurbel PA Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors Int J Cardiol 2016215201-8
205 Chaudhary R Bliden KP Garg J Mohammed N Tantry U Mathew D Toth PP Franzese C Gesheff M Pandya S Gurbel P Statin therapy and inflammation in patients with diabetes treated with high dose aspirin
Curriculum Vitae Paul A Gurbel MD Page 13
J Diabetes Complications 2016 May 10 [Epub ahead of print] 206 Bliden KP Chaudhary R Lopez LR Damrongwatanasuk R Guyer K Gesheff MG Franzese CJ Kaza H
Tantry US Gurbel PA Oxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease Am J Cardiol 2016 Jun 15 [Epub ahead of print]
207 Mahla E Prueller F Farzi S Pregartner G Raggam RB Beran E Toller W Berghold A Tantry US Gurbel PA Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy Ann Thorac Surg 2016 Jul 1 [Epub ahead of print]
208 Koh JS Park Y Tantry US Ahn JH Kang MG Kim K Jang JY Park HW Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents The ACCEL-COMBO trial Platelets 2016 Aug 251-7 [Epub ahead of print]
209 Chaudhary R Saadin K Bliden KP Harris WS Dinh B Sharma T Tantry US Gurbel PA Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease Prostaglandins Leukot Essent Fatty Acids 201611340-45
210 Gurbel PA Bliden KP Chaudhary R Patrick J Liu F Chen G McLeod C Tantry US Antiplatelet Effect Durability of a Novel 24-Hour Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes MellitusAm J Cardiol 20161181941-1947
211 Gurbel PA Bliden KP Tantry US Monroe AL Muresan AA Brunner NE Lopez-Espina CG Delmenico PR Cohen E Raviv G Haugen DL Ereth MH First report of the point-of-care TEG A technical validation study of the TEG-6S system Platelets 201627642-649
212 Cornel JH Ohman EM Neely B Jakubowski JA Bhatt DL White HD Ardissino D Fox KA Prabhakaran D Armstrong PW Erlinge D Tantry US Gurbel PA Roe MT Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes J Am Heart Assoc 2016 Nov 45(11) pii e003977
213 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 201717109-121
214 Sharma T Bliden K Chaudhary R Tantry U Gurbel PA Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease Expert Opin Pharmacother 201718123-131
215 Park Y Tantry US Koh JS Ahn JH Kang MG Kim KH Jang JY Park HW Park JR Hwang SJ Park KS Kwak CH Hwang JY Gurbel PA Jeong YH Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction The REMODELING Trial Thromb Haemost 2017117911-922
216 Navarese EP Gurbel PA Andreotti F Kołodziejczak MM Palmer SC Dias S Buffon A Kubica J Kowalewski M Jadczyk T Laskiewicz M Jędrzejek M Brockmeyer M Airoldi F Ruospo M De Servi S Wojakowski W O Connor C Strippoli GF Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis PLoS One 201712e0168726
217 Bliden KP Chaudhary R Mohammed N Muresan AA Lopez-Espina CG Cohen E Raviv G Doubleday M Zaman F Mathew B Tantry US Gurbel PA Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system J Thromb Thrombolysis 201743437-445
Publications Peer Reviewed Original Science Research - Reviews 1 Serebruany VL Atar D Dalesandro MR OConnor CM Gurbel PA Changes in hemostasis after parenteral
magnesium in myocardial ischemia reperfusion Animal studies to clinical trials Magnes Res 19981137-42 2 McKenzie ME Gurbel PA Levine DJ Serebruany VL Clinical utility of available methods determining platelet
function Cardiology 199992240-7 3 Gurbel PA OConnor CM Cummings CC Serebruany VL Clopidogrel The future choice for preventing platelet
activation during coronary stenting Pharm Res 199965109-123 4 Nair GV Gurbel PA Fusaylov SY Davis CJ Ohman EM Bahr RD Christensen RH Serebruany VL Combing
necrosis and platelet markers for perfecting myocardial infarction rule out How close are we Cardiology 20009350-5
5 Davis CJ Gurbel PA Gaitis WA Fuzaylov SY Nair GV OrsquoConnor CM Serebruany VL Hemostatic abnormalities in congestive heart failure Diagnostic significance and clinical challenge Int J Cardiol 20007515-21
6 Pothula A Gurbel PA Atar D McKenzie ME Serebruany VL Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease Eur J Pharmacol 20004021-10
7 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Serebruany VL Platelet function and fibrinolytic agents Two sides of a coin Cardiology 20019555-60
Curriculum Vitae Paul A Gurbel MD Page 14
8 Samara WM Gurbel PA The role of platelet receptors and adhesion molecules in coronary artery disease Coron Artery Dis 20031465-79
9 Gurbel PA Tantry U Clopidogrel response variability and the advent of personalised antiplatelet therapy A bench to bedside journey Thromb Haemost 2011106265-71
10 Gurbel PA Roe MT Jakubowski JA Shah S Erlinge D Goodman SG Huber K Chan MY Cornel JH Tantry US Ohman EM Translational platelet research in patients with coronary artery disease What are the major knowledge gaps Thromb Haemost 2012 May 25108 [Epub ahead of print]
11 Bliden KP Baker BA Nolin TD Jeong YH Bailey WL Tantry US Gurbel PA Thienopyridine efficacy and cigarette smoking status Am Heart J 2013165693-703
12 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
13 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013111547-56
14 Gesheff MG Franzese CJ Bliden KP Contino CJ Rafeedheen R Tantry USGurbel PA Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin Expert Rev Clin Pharmacol 2014 7645-53
15 Tantry US Gesheff M Liu F Bliden KP Gurbel PA Resistance to antiplatelet therapy what progress has been made Expert Opin Pharmacother 2014 9 1-12
16 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print]
17 Gurbel PA Myat A Tantry US Platelet-mediated Thrombosis From Bench to Bedside Cir Res 2015 (in press)
18 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 20161245-58
19 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
20 Gurbel PA Tantry US Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes Heart 2016102882-92
21 Navarese EP Kolodziejczak M Kereiakes DJ Tantry US OConnor C Gurbel PA Proprotein Convertase SubtilisinKexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome A Narrative Review Ann Intern Med 2016164600-7
22 Gurbel PA Jeong YH Navarese EP Tantry US Platelet-Mediated Thrombosis From Bench to Bedside Circ Res 20161181380-91
23 Gurbel PA Myat A Kubica J Tantry US State of the art Oral antiplatelet therapy JRSM Cardiovasc Dis 2016 Jun 152048004016652514 doi 1011772048004016652514 eCollection 2016 Jan-Dec
24 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 2016 Nov 17 [Epub ahead of print] Review
25 Winter MP Grove EL De Caterina R Gorog DA Ahrens I Geisler T Gurbel PA Tantry U Navarese EP Siller-Matula JM Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors Eur Heart J Cardiovasc Pharmacother 2017 Feb 15 doi 101093ehjcvppvw044 [Epub ahead of print]
26 Shah P Tantry US Bliden KP Gurbel PA Bleeding and thrombosis associated with ventricular assist device therapy J Heart Lung Transplant 2017 May 11 pii S1053-2498(17)31789-8
Inventions Patents Copyrights 32294 Gurbel PA Anderson RD Autoperfusion dilatation catheter United States Patent 5295959 51501 Dalesandro MR Gurbel PA Serebruany VL Determining a treatment plan for patients undergoing thrombotic
events by monitoring p-Selectin United States Patent 623071 61201 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6245782 13102 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 20020013343 42203 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6552014
Curriculum Vitae Paul A Gurbel MD Page 15
120611 Gurbel PA The detection of restenosis risk in patients receiving a stent by measuring the characteristics of blood clotting including the measurement of maximum thrombin-induced clot strength (patent awarded pending)
6308 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 7381536 2010 Gurbel PA Conley P Andre P Gretler D Jurek M Methods for diagnosis and treatment of thrombotic
disorders mediated bycyp2c192 (patent pending) 41014 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent
20140100167 81815 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 9110062 111715 Gurbel PA Detection of restenosis risk in patients receiving a stent by measuring the characteristics of
blood clotting including the measurement of maximum thrombin-induced clot strength Patent 9188597 Extramural Funding (since 2002) CURRENT 2010-2015 MAGMA (Multianalyte And Genetic Markers of Atherosclerosis)
Haemonetics and Sinai Hospital of Baltimore 2015-present An Observational Study of CORA-Assisted Stroke Identification and Antithrombotic Therapy
2014-2015 Feasibility clinical trial to evaluate the efficacy of an Anticoagulant cartridge to be used in the CORA System Coramed Technologies LLC
2014-2015 Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid Durlaza in CVD Patients at Risk of High Platelet Turnover (DURATION)
New Haven Pharmaceuticals Inc 2015-present Influence of Edoxaban on Coagulability and Thrombin Generation An in Vitro Study Focusing on
Thrombelastography Daiichi Sankyo
2016 Influence of Vorapaxar on Thrombin Generation and Coagulability Merck 2015-present Durlaza GI GI Tolerability Study New Haven Pharamceuticals 2015-present Thrombogenicity in LVAD Recipients Haemonetics 2014-2015 First-in-Man Assessment of PZ-128 National Institutes of Health PREVIOUS 2002 Atorvastatin in the Treatment of Heart Failure
LBH IRB 20030512 NIHThe National Heart Lung and Blood Institute NIH
2002 Asessment of the In Vitro Effects of Tenecteplase Reteplase and Alteplase on Human Platelets TAR STUDY Genetech
2003-2005 Assessment of the Effects of the heparin-coated Cordis Stent versus Non-coated Stents on Platelet and Endothelial Cell Activation and Thrombin Effect in Patients with Coronary Artery Disease (HEPACOAT) Cordis Inc
2004-2005 The Antiplatelet Effects of Eptifibatide with High and Standard Dose Clopidogrel in Low-Moderate Risk Patients Undergoing Coronary Intervention (CLEAR-PLATELETS Study) MilleniumSchering Plough
2004-2005 The Use of The TEG System to Monitor Platelet Inhibition at Bedside 5R44HL059753-03Haemoscope National Institute of Health
2004-2006 Clopidogrel Resistance in Patients with Stent Thrombosis (CREST Study) AstraZeneca
Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study MilleniumSchering Plough
2005 St Johns Wort Decreases ADP Induced Platelet Reactivity in Known Clopidogrel Resistant Post Coronary Intervention Patients after a Loading Dose of Clopidogrel University of Michigan
2008-2009 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST) Sinai Hospital Department of Medicine
2009-2010 Demonstration of the Pharmacodynamic Antiplatelet Effect of PRT060128 in Patients with High Platelet Reactivity during Clopidogrel and Aspirin Maintenance Therapy (PORTOLA) Portola Pharmaceuticals
2008-2009 A Randomised Double-Blind Outpatient Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND] AstraZeneca Pharmaceuticals LP
2008-2009 A Randomized Double-blind Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Background Therapy in Patients with Stable Coronary Artery Disease with Additional Detailed Assessment of Cardiopulmonary Function (ONSET-OFFSET) AstraZeneca Pharmaceuticals LP
2008-2009 A Single Center Randomized Open Label Parallel Group Pharmacodynamic Study of a Novel Combination Form of Aspirin and Phytosterol versus Aspirin in Healthy Adult Subjects (ARMOR) Bayer Healthcare LLC
2008-2009 Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel Plus EC Aspirin (325 mg) and Clopidogrel Plus PA32540 on Platelet Aggregation in Healthy Volunteers POZEN 110 POZEN Inc
2009-2010 Antithrombosis with Clopidogrel Beyond the Concept of Platelet Aggregate Inhibition (SANOFI) Sanofi Inc 2010-2012 A Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel EC
Aspirin 81 mg and EC omeprazole 40 mg all dosed concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers POZEN Inc
Intramural Funding (since 2002) CURRENT 2008-present Time Based Strategy to Reduce Clopidogrel Associated Bleeding Related to CABG (TARGET CABG) Sinai Hospital of Baltimore Department of Medicine 2009-present Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI)
Sinai Hospital of Baltimore Department of Medicine 2011-present Detection of Leukemic Blood and Solid TypE MalignanCies by Urinary 11-DehydroThromboxane B2 (DETECT) Study
Sinai Hospital of Baltimore Department of Medicine PREVIOUS 2001-2002 Platelet Activation in Stenting PAST Study Sinai Hospital of Baltimore 2005-2006 Platelet Reactivity in Patients with Crohnrsquos disease Receiving Infliximab (chimeric anti-TNF alpha antibody) ndash COIN
Sinai Hospital of Baltimore Department of Medicine 2006-2007 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST)
Sinai Hospital of Baltimore Department of Medicine 2008-2011 Platelet Reactivity and Thrombogenecity in Postmenopausal Women
Sinai Hospital Department of Medicine 2008-2010 Platelet Reactivity and Thrombogenecity in Postmenopausal Women (PRIDE Study)
Sinai Hospital Department of Medicine Multicenter Studies since 2001
Curriculum Vitae Paul A Gurbel MD Page 17
CURRENT 2010-present The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and
Clopidogrel in Aspirin-Treated Subjects With Stable Coronary Artery Disease Daiichi Sankyo
2010-present A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly versus Non-Elderly Aspirin-Treated Subjects with Stable Coronary Artery Disease Eli Lilly amp company
2011-present A Prospective Multicenter Randomized Trial of Clopidogrel versus Prasugrel Anti-platelet Therapy in Cytochrome P450 2C19 (CYP2C19) Intermediate Metabolizers Grant No U01HL105198
NIH National Heart Lung and Blood Institute NIH 2011-present A Prospective Randomized Multi-Center Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHERreg Sirolimus-Eluting Coronary stents
HCRI 2012-present A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in
patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)
Bayer Healthcare LLC 2013-present Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in
Patients at a High-Risk for Vascular Outcomes (ACCELERATE) Eli Lilly amp Company 2014-present A Phase 2b Multi-center Randomized Placebo-controlled Dose-ranging Study to Investigate the
Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infarction
AEGIS CSL 2015-2017 A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety of PZ- 128 in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention
National Institute of Health PREVIOUS 2001 A Randomized Double-Blind Placebo-Controlled Study of Two Intravenous Dosing Regimens of
h5G11-scFv in Patients with Acute Myocardial Infarction Undergoing 2001-2002 Prevention of REStenosis with Tranilast and Its Outcomes A Placebo Controlled Trial PRESTO STUDY
SmithKline Beecham 2002-2003 Taxus IV-SR Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
Boston Scientific 2003 MICROVENA Corporation TRAP Vascular Filtration System (VFS) Trial
Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily Pfizer Inc
2003-2004 Phase 3 Multi-Center Double-Blind Randomized Parallel Group Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily (QD) for 24 Months Compared with Atorvastatin Alone in Subjects with Angiographically Documented Coronary Heart Disease Pfizer Inc
2003-2004 A Randomized Controlled Trial of the Medtronic Endeavor Drug Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ldquoENDEAVOR III Studyrdquo)
Medtronic 2009-2010 A Prospective Randomized Open-label Multicenter study in Patients Presenting with Acute Coronary Syndromes SYNERGY STUDY
Aventis Pharmaceuticals 2004 CObalt chromium STent with Antiproliferative for Restenosis II Trialrdquo Costar study
Conor Medsystems
Curriculum Vitae Paul A Gurbel MD Page 18
2004-2005 A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions ENDEAVOR IV Medtronic
2004-2005 A Randomized Trial to evaluate the relative protection against POST-PCI microvasculat obstruction among antiplatelet and anti-thrombotic medications (TIMI-30) TIMI group
2004-2006 A Double-blind Double-dummy Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI 33 AstraZeneca Lp
2005-2006 Strategy To Reduce Atherosclerosis Development Involving Administration of Rimonabant - The Intravascular Ultrasound Study (STRADIVARIUS) EFC5827 Sanofi Synthelabo Research
2006 A Multicenter Randomized Double-Blind Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (TRASM-PCI) Schering Plough
2006-2007 A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel -SWAP (SWitching Anti Platelet study) Eli Lilly amp Company and Sankyo Company Limited
2006-2007 A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2008-2010 A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary InterventionTIMI-38 Eli Lilly Company Daiichi
2009-2010 A Randomized Double-Blind Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128 a Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Interventions (INNOVATE-PCI) Portola Pharmaceuticals
2010-2012 TReatment with ADPreceptor iNhibitorS Longitudinal Assessment ofTreatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS)
Eli Lilly Company 2010-2013 RADAR Randomized Partially-Blinded Multi-Center Active-Controlled Dose-Ranging Study
Assessing the Safety Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome Regado Bioscience Inc
2011-2013 A Phase IIa Multi-center Randomized Sponsor-unblinded Placebo-controlled Single Ascending Dose Study to Investigate the Safety Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Adults Taking Aspirin and a P2Y12 Platelet Inhibitor
AEGIS CSL Research Program BuildingLeadership 1991-1995 Director Interventional Cardiology Research University of Maryland Medical System 1998-2015 Director Sinai Center for Thrombosis Research 2001-2015 Director Cardiovascular Research Lifebridge Health 2002-2015 Director Therapeutics Research and Technology Development for the Cardiac Catheterization Program Sinai Hospital of Baltimore 2007-2015 Associate Chief for Research Department of Medicine Sinai Hospital of Baltimore 2015-current Director Interventional Cardiology and Cardiovascular Medicine Research INOVA Health 2015-Current Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute EDUCATIONAL ACTIVITIES
Curriculum Vitae Paul A Gurbel MD Page 19
Peer Reviewed Publications-Consensus Statements Expert Opinions 1 Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C
Rao AK The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 200531309-11
2 Hoekstra J Cohen M Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Saucedo JF Pollack CV Jr Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention-an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective report on a roundtable discussion Am J Emerg Med 200927720-8
3 Bonello L Tantry US Marcucci R Blindt R Angiolillo DJ Becker R Bhatt DL Cattaneo M Collet JP Cuisset T Gachet C Montalescot G Jennings LK Kereiakes D Sibbing D Trenk D Van Werkum JW Paganelli F Price MJ Waksman R Gurbel PA Working Group on High On Treatment Platelet Reactivity Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 201056919-33
4 Gurbel PA Tantry US Shuldiner AR Kereiakes DJ Genotyping one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 201056112-6
5 Gurbel PA Tantry US Antiplatelet therapy Clopidogrel-PPI interaction an ongoing controversy Nat Rev Cardiol 201187-8
6 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
7 Gurbel PA Nolin TD Tantry US Clopidogrel efficacy and cigarette smoking status JAMA 20123072495-6 8 Tantry US Bonello L Aradi D Price MJ Jeong YH Angiolillo DJ Stone GW Curzen N Geisler T Ten Berg J
Kirtane A Siller-Matula J Mahla E Becker RC Bhatt DL Waksman R Rao SV Alexopoulos D Marcucci R Reny JL Trenk D Sibbing D Gurbel PA Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding J Am Coll Cardiol 2013622261-73
9 Gurbel PA Tantry US Antiplatelet and anticoagulant agents in heart failure Current status and future perspectives JACC Heart Fail 201421-14
10 Gurbel PA Tantry US Antiplatelet therapy What have we learned from the ANTARCTIC trial Nat Rev Cardiol 201613639-640
Invited Review Articles 1 Gurbel PA Midwall JA Brodie BR Angioplasty and adjunctive intra-aortic balloon pump counterpulsation Current
clinical considerations Todays Therapy Trends 19951363-78 2 OrsquoConnor CM Gurbel PA Serebruany VL Depression and ischemic heart disease Am Heart J 200014063-69 3 Gurbel PA Serebruany VL Oral IIbIIIa inhibitors From initial promise to clinical failures J Thromb and
Thrombolysis 200010217-20 4 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Atar D Serebruany VL Platelets and
Thrombolysis Cooperation or Contrariety Heart Drug 20011281-290 5 McKenzie ME Gurbel PA The potential of monoclonal antibodies to reduce reperfusion injury in myocardial
infarction BioDrugs 200115395-404 6 Gurbel PA Bliden KP Hayes K Tantry U Platelet activation in myocardial ischemic syndromes Expert Rev of
Cardiovasc Ther 20052535-45 7 Tantry US Bliden KP Gurbel PA Resistance to antiplatelet drugs Current status and future research Expert
Opin Pharmacother 200562027-45 8 Gurbel PA Lau WC Bliden KP Tantry US Clopidogrel resistance Implications for coronary stenting Curr Pharm
Des 2006121261-9 9 Gurbel PA Tantry US Drug insight Clopidogrel non-responsiveness Nature ClinPract Cardiovasc Med
20063387-95 10 Gurbel PA Tantry US Aspirin and Clopidogrel Resistance Considerations and management J Interv Cardiol
200619439-48 11 Lau WC Gurbel PA Antiplatelet drug resistance and drug-drug interactions Role of cytochrome P450 3A4
Pharm Res 2006232691-708 12 Wiviott SD Tantry US Gurbel PA Clinical applications of antiplatelet therapy Rev Cardiovasc Med 20067
Curriculum Vitae Paul A Gurbel MD Page 20
130-46 13 Tantry US Bliden KP Gurbel PA Prasugrel Expert Opin Investig Drugs 2006151627-33 14 Gurbel PA Tantry US Clopidogrel Resistance Thromb Res 2007120311-21 15 Tantry US Etherington A Bliden KP Gurbel PA Antiplatelet therapy Current strategies and future trends Future
Cardiology 20072343-366 16 Gurbel PA Tantry US The relationship of platelet reactivity to the occurrence of post-stenting ischemic events
emergence of a new cardiovascular risk factor Rev Cardiovasc Med 2006Suppl 4S20-8 17 Tantry US Bliden KP Gurbel PA AZD6140 Expert Opin Investig Drugs 200716225-9 18 Gurbel PA Tantry US Stent thrombosis role of compliance and non-responsiveness to antiplatelet therapy Rev
Cardiovasc Med 20078S19-S26 19 Gurbel PA Kandzari DE Stent thrombosis associated with first-generation drug-eluting stents issues with
antiplatelet therapy Neth Heart J 200715148-50 20 Gurbel PA Tantry US The role of clopidogrel in cardiovascular diseases Pol Arch Med Wewn 2007117207-9 21 Gurbel PA DiChiara J Tantry US Antiplatelet therapy after implantation of drug-eluting stents duration
resistance alternatives and management of surgical patients Am J Cardiol 200710018M-25M 22 Gurbel PA Becker R Mann KG Steinhubl SR Michelson AD Platelet function monitoring in patients with
coronary artery disease J Am Coll Cardiol 2007501822-34 23 Gurbel PA Tantry US Prasugrel a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig
Drugs 20089324-36 24 Gurbel PA Bilden KP Tantry US Diagnostics for aspirin resistance Mol Diagn Ther 20081255-6 25 Gurbel PA Antonino MJ Tantry US Antiplatelet treatment of cardiovascular disease a translational research
perspective Pol Arch Med Wewn 2008118289-97 26 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831I36 27 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention Clin Cardiol 200831I28-I35
28 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches Clin Cardiol 200831I21-I27
29 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention Clin Cardiol 200831I17-I20
30 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Assessing the Current Role of Platelet Function Testing Clin Cardiol 200831I10-I16
31 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831136
32 Keriakes DJ Gurbel PA Periprocedural platelet function in percutaneous coronary intervention JACC Cardiovasc Interv 2008suppl 1111ndash121
33 Gurbel PA Tantry US The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome J Interv Cardiol 200821Suppl 1S10-7
34 Gurbel PA Tantry US Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 20091122-322
35 Gurbel PA Aspirin scope and limitations Br J Cardiol 200917 (Suppl 1)S8-S9 36 Cohen M Hoekstra J Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Pollack CV Jr
Saucedo JF Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion J Interv Cardiol 200821283-99
37 Angiolillo DJ Bhatt DL Gurbel PA Jennings LK Advances in antiplatelet therapy agents in clinical development Am J Cardiol 2009103(3 Suppl)40A-51A
38 Gurbel PA Mahla E Antonino MJ Tantry US Response variability and the role of platelet function testing J Invasive Cardiol 200921172-8
39 Gurbel PA Antonino MJ Tantry US Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug MetabToxicol Expert Opin Drug Metab Toxicol 20095989-1004
40 Gurbel PA Tantry US Antiplatelet resistance- Fact or Myth Am Hosp J 2009750-57 41 Gurbel PA Mahla E Tantry US Aspirin resistance Prog Cardiovasc Dis 200952141-52 42 Tantry US Gurbel PA Platelet monitoring for PCI Is it really necessary Haemostaseologie 200929 368-75 43 Gurbel PA Aspirin-scope and limitations Br J Cardiol 200917(Suppl 1)S8-S9
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 13
J Diabetes Complications 2016 May 10 [Epub ahead of print] 206 Bliden KP Chaudhary R Lopez LR Damrongwatanasuk R Guyer K Gesheff MG Franzese CJ Kaza H
Tantry US Gurbel PA Oxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease Am J Cardiol 2016 Jun 15 [Epub ahead of print]
207 Mahla E Prueller F Farzi S Pregartner G Raggam RB Beran E Toller W Berghold A Tantry US Gurbel PA Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy Ann Thorac Surg 2016 Jul 1 [Epub ahead of print]
208 Koh JS Park Y Tantry US Ahn JH Kang MG Kim K Jang JY Park HW Park JR Hwang SJ Kwak CH Hwang JY Gurbel PA Jeong YH Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents The ACCEL-COMBO trial Platelets 2016 Aug 251-7 [Epub ahead of print]
209 Chaudhary R Saadin K Bliden KP Harris WS Dinh B Sharma T Tantry US Gurbel PA Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease Prostaglandins Leukot Essent Fatty Acids 201611340-45
210 Gurbel PA Bliden KP Chaudhary R Patrick J Liu F Chen G McLeod C Tantry US Antiplatelet Effect Durability of a Novel 24-Hour Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes MellitusAm J Cardiol 20161181941-1947
211 Gurbel PA Bliden KP Tantry US Monroe AL Muresan AA Brunner NE Lopez-Espina CG Delmenico PR Cohen E Raviv G Haugen DL Ereth MH First report of the point-of-care TEG A technical validation study of the TEG-6S system Platelets 201627642-649
212 Cornel JH Ohman EM Neely B Jakubowski JA Bhatt DL White HD Ardissino D Fox KA Prabhakaran D Armstrong PW Erlinge D Tantry US Gurbel PA Roe MT Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes J Am Heart Assoc 2016 Nov 45(11) pii e003977
213 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 201717109-121
214 Sharma T Bliden K Chaudhary R Tantry U Gurbel PA Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease Expert Opin Pharmacother 201718123-131
215 Park Y Tantry US Koh JS Ahn JH Kang MG Kim KH Jang JY Park HW Park JR Hwang SJ Park KS Kwak CH Hwang JY Gurbel PA Jeong YH Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction The REMODELING Trial Thromb Haemost 2017117911-922
216 Navarese EP Gurbel PA Andreotti F Kołodziejczak MM Palmer SC Dias S Buffon A Kubica J Kowalewski M Jadczyk T Laskiewicz M Jędrzejek M Brockmeyer M Airoldi F Ruospo M De Servi S Wojakowski W O Connor C Strippoli GF Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis PLoS One 201712e0168726
217 Bliden KP Chaudhary R Mohammed N Muresan AA Lopez-Espina CG Cohen E Raviv G Doubleday M Zaman F Mathew B Tantry US Gurbel PA Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system J Thromb Thrombolysis 201743437-445
Publications Peer Reviewed Original Science Research - Reviews 1 Serebruany VL Atar D Dalesandro MR OConnor CM Gurbel PA Changes in hemostasis after parenteral
magnesium in myocardial ischemia reperfusion Animal studies to clinical trials Magnes Res 19981137-42 2 McKenzie ME Gurbel PA Levine DJ Serebruany VL Clinical utility of available methods determining platelet
function Cardiology 199992240-7 3 Gurbel PA OConnor CM Cummings CC Serebruany VL Clopidogrel The future choice for preventing platelet
activation during coronary stenting Pharm Res 199965109-123 4 Nair GV Gurbel PA Fusaylov SY Davis CJ Ohman EM Bahr RD Christensen RH Serebruany VL Combing
necrosis and platelet markers for perfecting myocardial infarction rule out How close are we Cardiology 20009350-5
5 Davis CJ Gurbel PA Gaitis WA Fuzaylov SY Nair GV OrsquoConnor CM Serebruany VL Hemostatic abnormalities in congestive heart failure Diagnostic significance and clinical challenge Int J Cardiol 20007515-21
6 Pothula A Gurbel PA Atar D McKenzie ME Serebruany VL Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease Eur J Pharmacol 20004021-10
7 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Serebruany VL Platelet function and fibrinolytic agents Two sides of a coin Cardiology 20019555-60
Curriculum Vitae Paul A Gurbel MD Page 14
8 Samara WM Gurbel PA The role of platelet receptors and adhesion molecules in coronary artery disease Coron Artery Dis 20031465-79
9 Gurbel PA Tantry U Clopidogrel response variability and the advent of personalised antiplatelet therapy A bench to bedside journey Thromb Haemost 2011106265-71
10 Gurbel PA Roe MT Jakubowski JA Shah S Erlinge D Goodman SG Huber K Chan MY Cornel JH Tantry US Ohman EM Translational platelet research in patients with coronary artery disease What are the major knowledge gaps Thromb Haemost 2012 May 25108 [Epub ahead of print]
11 Bliden KP Baker BA Nolin TD Jeong YH Bailey WL Tantry US Gurbel PA Thienopyridine efficacy and cigarette smoking status Am Heart J 2013165693-703
12 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
13 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013111547-56
14 Gesheff MG Franzese CJ Bliden KP Contino CJ Rafeedheen R Tantry USGurbel PA Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin Expert Rev Clin Pharmacol 2014 7645-53
15 Tantry US Gesheff M Liu F Bliden KP Gurbel PA Resistance to antiplatelet therapy what progress has been made Expert Opin Pharmacother 2014 9 1-12
16 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print]
17 Gurbel PA Myat A Tantry US Platelet-mediated Thrombosis From Bench to Bedside Cir Res 2015 (in press)
18 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 20161245-58
19 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
20 Gurbel PA Tantry US Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes Heart 2016102882-92
21 Navarese EP Kolodziejczak M Kereiakes DJ Tantry US OConnor C Gurbel PA Proprotein Convertase SubtilisinKexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome A Narrative Review Ann Intern Med 2016164600-7
22 Gurbel PA Jeong YH Navarese EP Tantry US Platelet-Mediated Thrombosis From Bench to Bedside Circ Res 20161181380-91
23 Gurbel PA Myat A Kubica J Tantry US State of the art Oral antiplatelet therapy JRSM Cardiovasc Dis 2016 Jun 152048004016652514 doi 1011772048004016652514 eCollection 2016 Jan-Dec
24 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 2016 Nov 17 [Epub ahead of print] Review
25 Winter MP Grove EL De Caterina R Gorog DA Ahrens I Geisler T Gurbel PA Tantry U Navarese EP Siller-Matula JM Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors Eur Heart J Cardiovasc Pharmacother 2017 Feb 15 doi 101093ehjcvppvw044 [Epub ahead of print]
26 Shah P Tantry US Bliden KP Gurbel PA Bleeding and thrombosis associated with ventricular assist device therapy J Heart Lung Transplant 2017 May 11 pii S1053-2498(17)31789-8
Inventions Patents Copyrights 32294 Gurbel PA Anderson RD Autoperfusion dilatation catheter United States Patent 5295959 51501 Dalesandro MR Gurbel PA Serebruany VL Determining a treatment plan for patients undergoing thrombotic
events by monitoring p-Selectin United States Patent 623071 61201 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6245782 13102 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 20020013343 42203 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6552014
Curriculum Vitae Paul A Gurbel MD Page 15
120611 Gurbel PA The detection of restenosis risk in patients receiving a stent by measuring the characteristics of blood clotting including the measurement of maximum thrombin-induced clot strength (patent awarded pending)
6308 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 7381536 2010 Gurbel PA Conley P Andre P Gretler D Jurek M Methods for diagnosis and treatment of thrombotic
disorders mediated bycyp2c192 (patent pending) 41014 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent
20140100167 81815 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 9110062 111715 Gurbel PA Detection of restenosis risk in patients receiving a stent by measuring the characteristics of
blood clotting including the measurement of maximum thrombin-induced clot strength Patent 9188597 Extramural Funding (since 2002) CURRENT 2010-2015 MAGMA (Multianalyte And Genetic Markers of Atherosclerosis)
Haemonetics and Sinai Hospital of Baltimore 2015-present An Observational Study of CORA-Assisted Stroke Identification and Antithrombotic Therapy
2014-2015 Feasibility clinical trial to evaluate the efficacy of an Anticoagulant cartridge to be used in the CORA System Coramed Technologies LLC
2014-2015 Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid Durlaza in CVD Patients at Risk of High Platelet Turnover (DURATION)
New Haven Pharmaceuticals Inc 2015-present Influence of Edoxaban on Coagulability and Thrombin Generation An in Vitro Study Focusing on
Thrombelastography Daiichi Sankyo
2016 Influence of Vorapaxar on Thrombin Generation and Coagulability Merck 2015-present Durlaza GI GI Tolerability Study New Haven Pharamceuticals 2015-present Thrombogenicity in LVAD Recipients Haemonetics 2014-2015 First-in-Man Assessment of PZ-128 National Institutes of Health PREVIOUS 2002 Atorvastatin in the Treatment of Heart Failure
LBH IRB 20030512 NIHThe National Heart Lung and Blood Institute NIH
2002 Asessment of the In Vitro Effects of Tenecteplase Reteplase and Alteplase on Human Platelets TAR STUDY Genetech
2003-2005 Assessment of the Effects of the heparin-coated Cordis Stent versus Non-coated Stents on Platelet and Endothelial Cell Activation and Thrombin Effect in Patients with Coronary Artery Disease (HEPACOAT) Cordis Inc
2004-2005 The Antiplatelet Effects of Eptifibatide with High and Standard Dose Clopidogrel in Low-Moderate Risk Patients Undergoing Coronary Intervention (CLEAR-PLATELETS Study) MilleniumSchering Plough
2004-2005 The Use of The TEG System to Monitor Platelet Inhibition at Bedside 5R44HL059753-03Haemoscope National Institute of Health
2004-2006 Clopidogrel Resistance in Patients with Stent Thrombosis (CREST Study) AstraZeneca
Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study MilleniumSchering Plough
2005 St Johns Wort Decreases ADP Induced Platelet Reactivity in Known Clopidogrel Resistant Post Coronary Intervention Patients after a Loading Dose of Clopidogrel University of Michigan
2008-2009 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST) Sinai Hospital Department of Medicine
2009-2010 Demonstration of the Pharmacodynamic Antiplatelet Effect of PRT060128 in Patients with High Platelet Reactivity during Clopidogrel and Aspirin Maintenance Therapy (PORTOLA) Portola Pharmaceuticals
2008-2009 A Randomised Double-Blind Outpatient Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND] AstraZeneca Pharmaceuticals LP
2008-2009 A Randomized Double-blind Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Background Therapy in Patients with Stable Coronary Artery Disease with Additional Detailed Assessment of Cardiopulmonary Function (ONSET-OFFSET) AstraZeneca Pharmaceuticals LP
2008-2009 A Single Center Randomized Open Label Parallel Group Pharmacodynamic Study of a Novel Combination Form of Aspirin and Phytosterol versus Aspirin in Healthy Adult Subjects (ARMOR) Bayer Healthcare LLC
2008-2009 Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel Plus EC Aspirin (325 mg) and Clopidogrel Plus PA32540 on Platelet Aggregation in Healthy Volunteers POZEN 110 POZEN Inc
2009-2010 Antithrombosis with Clopidogrel Beyond the Concept of Platelet Aggregate Inhibition (SANOFI) Sanofi Inc 2010-2012 A Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel EC
Aspirin 81 mg and EC omeprazole 40 mg all dosed concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers POZEN Inc
Intramural Funding (since 2002) CURRENT 2008-present Time Based Strategy to Reduce Clopidogrel Associated Bleeding Related to CABG (TARGET CABG) Sinai Hospital of Baltimore Department of Medicine 2009-present Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI)
Sinai Hospital of Baltimore Department of Medicine 2011-present Detection of Leukemic Blood and Solid TypE MalignanCies by Urinary 11-DehydroThromboxane B2 (DETECT) Study
Sinai Hospital of Baltimore Department of Medicine PREVIOUS 2001-2002 Platelet Activation in Stenting PAST Study Sinai Hospital of Baltimore 2005-2006 Platelet Reactivity in Patients with Crohnrsquos disease Receiving Infliximab (chimeric anti-TNF alpha antibody) ndash COIN
Sinai Hospital of Baltimore Department of Medicine 2006-2007 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST)
Sinai Hospital of Baltimore Department of Medicine 2008-2011 Platelet Reactivity and Thrombogenecity in Postmenopausal Women
Sinai Hospital Department of Medicine 2008-2010 Platelet Reactivity and Thrombogenecity in Postmenopausal Women (PRIDE Study)
Sinai Hospital Department of Medicine Multicenter Studies since 2001
Curriculum Vitae Paul A Gurbel MD Page 17
CURRENT 2010-present The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and
Clopidogrel in Aspirin-Treated Subjects With Stable Coronary Artery Disease Daiichi Sankyo
2010-present A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly versus Non-Elderly Aspirin-Treated Subjects with Stable Coronary Artery Disease Eli Lilly amp company
2011-present A Prospective Multicenter Randomized Trial of Clopidogrel versus Prasugrel Anti-platelet Therapy in Cytochrome P450 2C19 (CYP2C19) Intermediate Metabolizers Grant No U01HL105198
NIH National Heart Lung and Blood Institute NIH 2011-present A Prospective Randomized Multi-Center Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHERreg Sirolimus-Eluting Coronary stents
HCRI 2012-present A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in
patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)
Bayer Healthcare LLC 2013-present Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in
Patients at a High-Risk for Vascular Outcomes (ACCELERATE) Eli Lilly amp Company 2014-present A Phase 2b Multi-center Randomized Placebo-controlled Dose-ranging Study to Investigate the
Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infarction
AEGIS CSL 2015-2017 A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety of PZ- 128 in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention
National Institute of Health PREVIOUS 2001 A Randomized Double-Blind Placebo-Controlled Study of Two Intravenous Dosing Regimens of
h5G11-scFv in Patients with Acute Myocardial Infarction Undergoing 2001-2002 Prevention of REStenosis with Tranilast and Its Outcomes A Placebo Controlled Trial PRESTO STUDY
SmithKline Beecham 2002-2003 Taxus IV-SR Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
Boston Scientific 2003 MICROVENA Corporation TRAP Vascular Filtration System (VFS) Trial
Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily Pfizer Inc
2003-2004 Phase 3 Multi-Center Double-Blind Randomized Parallel Group Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily (QD) for 24 Months Compared with Atorvastatin Alone in Subjects with Angiographically Documented Coronary Heart Disease Pfizer Inc
2003-2004 A Randomized Controlled Trial of the Medtronic Endeavor Drug Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ldquoENDEAVOR III Studyrdquo)
Medtronic 2009-2010 A Prospective Randomized Open-label Multicenter study in Patients Presenting with Acute Coronary Syndromes SYNERGY STUDY
Aventis Pharmaceuticals 2004 CObalt chromium STent with Antiproliferative for Restenosis II Trialrdquo Costar study
Conor Medsystems
Curriculum Vitae Paul A Gurbel MD Page 18
2004-2005 A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions ENDEAVOR IV Medtronic
2004-2005 A Randomized Trial to evaluate the relative protection against POST-PCI microvasculat obstruction among antiplatelet and anti-thrombotic medications (TIMI-30) TIMI group
2004-2006 A Double-blind Double-dummy Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI 33 AstraZeneca Lp
2005-2006 Strategy To Reduce Atherosclerosis Development Involving Administration of Rimonabant - The Intravascular Ultrasound Study (STRADIVARIUS) EFC5827 Sanofi Synthelabo Research
2006 A Multicenter Randomized Double-Blind Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (TRASM-PCI) Schering Plough
2006-2007 A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel -SWAP (SWitching Anti Platelet study) Eli Lilly amp Company and Sankyo Company Limited
2006-2007 A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2008-2010 A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary InterventionTIMI-38 Eli Lilly Company Daiichi
2009-2010 A Randomized Double-Blind Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128 a Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Interventions (INNOVATE-PCI) Portola Pharmaceuticals
2010-2012 TReatment with ADPreceptor iNhibitorS Longitudinal Assessment ofTreatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS)
Eli Lilly Company 2010-2013 RADAR Randomized Partially-Blinded Multi-Center Active-Controlled Dose-Ranging Study
Assessing the Safety Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome Regado Bioscience Inc
2011-2013 A Phase IIa Multi-center Randomized Sponsor-unblinded Placebo-controlled Single Ascending Dose Study to Investigate the Safety Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Adults Taking Aspirin and a P2Y12 Platelet Inhibitor
AEGIS CSL Research Program BuildingLeadership 1991-1995 Director Interventional Cardiology Research University of Maryland Medical System 1998-2015 Director Sinai Center for Thrombosis Research 2001-2015 Director Cardiovascular Research Lifebridge Health 2002-2015 Director Therapeutics Research and Technology Development for the Cardiac Catheterization Program Sinai Hospital of Baltimore 2007-2015 Associate Chief for Research Department of Medicine Sinai Hospital of Baltimore 2015-current Director Interventional Cardiology and Cardiovascular Medicine Research INOVA Health 2015-Current Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute EDUCATIONAL ACTIVITIES
Curriculum Vitae Paul A Gurbel MD Page 19
Peer Reviewed Publications-Consensus Statements Expert Opinions 1 Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C
Rao AK The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 200531309-11
2 Hoekstra J Cohen M Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Saucedo JF Pollack CV Jr Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention-an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective report on a roundtable discussion Am J Emerg Med 200927720-8
3 Bonello L Tantry US Marcucci R Blindt R Angiolillo DJ Becker R Bhatt DL Cattaneo M Collet JP Cuisset T Gachet C Montalescot G Jennings LK Kereiakes D Sibbing D Trenk D Van Werkum JW Paganelli F Price MJ Waksman R Gurbel PA Working Group on High On Treatment Platelet Reactivity Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 201056919-33
4 Gurbel PA Tantry US Shuldiner AR Kereiakes DJ Genotyping one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 201056112-6
5 Gurbel PA Tantry US Antiplatelet therapy Clopidogrel-PPI interaction an ongoing controversy Nat Rev Cardiol 201187-8
6 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
7 Gurbel PA Nolin TD Tantry US Clopidogrel efficacy and cigarette smoking status JAMA 20123072495-6 8 Tantry US Bonello L Aradi D Price MJ Jeong YH Angiolillo DJ Stone GW Curzen N Geisler T Ten Berg J
Kirtane A Siller-Matula J Mahla E Becker RC Bhatt DL Waksman R Rao SV Alexopoulos D Marcucci R Reny JL Trenk D Sibbing D Gurbel PA Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding J Am Coll Cardiol 2013622261-73
9 Gurbel PA Tantry US Antiplatelet and anticoagulant agents in heart failure Current status and future perspectives JACC Heart Fail 201421-14
10 Gurbel PA Tantry US Antiplatelet therapy What have we learned from the ANTARCTIC trial Nat Rev Cardiol 201613639-640
Invited Review Articles 1 Gurbel PA Midwall JA Brodie BR Angioplasty and adjunctive intra-aortic balloon pump counterpulsation Current
clinical considerations Todays Therapy Trends 19951363-78 2 OrsquoConnor CM Gurbel PA Serebruany VL Depression and ischemic heart disease Am Heart J 200014063-69 3 Gurbel PA Serebruany VL Oral IIbIIIa inhibitors From initial promise to clinical failures J Thromb and
Thrombolysis 200010217-20 4 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Atar D Serebruany VL Platelets and
Thrombolysis Cooperation or Contrariety Heart Drug 20011281-290 5 McKenzie ME Gurbel PA The potential of monoclonal antibodies to reduce reperfusion injury in myocardial
infarction BioDrugs 200115395-404 6 Gurbel PA Bliden KP Hayes K Tantry U Platelet activation in myocardial ischemic syndromes Expert Rev of
Cardiovasc Ther 20052535-45 7 Tantry US Bliden KP Gurbel PA Resistance to antiplatelet drugs Current status and future research Expert
Opin Pharmacother 200562027-45 8 Gurbel PA Lau WC Bliden KP Tantry US Clopidogrel resistance Implications for coronary stenting Curr Pharm
Des 2006121261-9 9 Gurbel PA Tantry US Drug insight Clopidogrel non-responsiveness Nature ClinPract Cardiovasc Med
20063387-95 10 Gurbel PA Tantry US Aspirin and Clopidogrel Resistance Considerations and management J Interv Cardiol
200619439-48 11 Lau WC Gurbel PA Antiplatelet drug resistance and drug-drug interactions Role of cytochrome P450 3A4
Pharm Res 2006232691-708 12 Wiviott SD Tantry US Gurbel PA Clinical applications of antiplatelet therapy Rev Cardiovasc Med 20067
Curriculum Vitae Paul A Gurbel MD Page 20
130-46 13 Tantry US Bliden KP Gurbel PA Prasugrel Expert Opin Investig Drugs 2006151627-33 14 Gurbel PA Tantry US Clopidogrel Resistance Thromb Res 2007120311-21 15 Tantry US Etherington A Bliden KP Gurbel PA Antiplatelet therapy Current strategies and future trends Future
Cardiology 20072343-366 16 Gurbel PA Tantry US The relationship of platelet reactivity to the occurrence of post-stenting ischemic events
emergence of a new cardiovascular risk factor Rev Cardiovasc Med 2006Suppl 4S20-8 17 Tantry US Bliden KP Gurbel PA AZD6140 Expert Opin Investig Drugs 200716225-9 18 Gurbel PA Tantry US Stent thrombosis role of compliance and non-responsiveness to antiplatelet therapy Rev
Cardiovasc Med 20078S19-S26 19 Gurbel PA Kandzari DE Stent thrombosis associated with first-generation drug-eluting stents issues with
antiplatelet therapy Neth Heart J 200715148-50 20 Gurbel PA Tantry US The role of clopidogrel in cardiovascular diseases Pol Arch Med Wewn 2007117207-9 21 Gurbel PA DiChiara J Tantry US Antiplatelet therapy after implantation of drug-eluting stents duration
resistance alternatives and management of surgical patients Am J Cardiol 200710018M-25M 22 Gurbel PA Becker R Mann KG Steinhubl SR Michelson AD Platelet function monitoring in patients with
coronary artery disease J Am Coll Cardiol 2007501822-34 23 Gurbel PA Tantry US Prasugrel a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig
Drugs 20089324-36 24 Gurbel PA Bilden KP Tantry US Diagnostics for aspirin resistance Mol Diagn Ther 20081255-6 25 Gurbel PA Antonino MJ Tantry US Antiplatelet treatment of cardiovascular disease a translational research
perspective Pol Arch Med Wewn 2008118289-97 26 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831I36 27 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention Clin Cardiol 200831I28-I35
28 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches Clin Cardiol 200831I21-I27
29 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention Clin Cardiol 200831I17-I20
30 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Assessing the Current Role of Platelet Function Testing Clin Cardiol 200831I10-I16
31 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831136
32 Keriakes DJ Gurbel PA Periprocedural platelet function in percutaneous coronary intervention JACC Cardiovasc Interv 2008suppl 1111ndash121
33 Gurbel PA Tantry US The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome J Interv Cardiol 200821Suppl 1S10-7
34 Gurbel PA Tantry US Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 20091122-322
35 Gurbel PA Aspirin scope and limitations Br J Cardiol 200917 (Suppl 1)S8-S9 36 Cohen M Hoekstra J Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Pollack CV Jr
Saucedo JF Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion J Interv Cardiol 200821283-99
37 Angiolillo DJ Bhatt DL Gurbel PA Jennings LK Advances in antiplatelet therapy agents in clinical development Am J Cardiol 2009103(3 Suppl)40A-51A
38 Gurbel PA Mahla E Antonino MJ Tantry US Response variability and the role of platelet function testing J Invasive Cardiol 200921172-8
39 Gurbel PA Antonino MJ Tantry US Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug MetabToxicol Expert Opin Drug Metab Toxicol 20095989-1004
40 Gurbel PA Tantry US Antiplatelet resistance- Fact or Myth Am Hosp J 2009750-57 41 Gurbel PA Mahla E Tantry US Aspirin resistance Prog Cardiovasc Dis 200952141-52 42 Tantry US Gurbel PA Platelet monitoring for PCI Is it really necessary Haemostaseologie 200929 368-75 43 Gurbel PA Aspirin-scope and limitations Br J Cardiol 200917(Suppl 1)S8-S9
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 14
8 Samara WM Gurbel PA The role of platelet receptors and adhesion molecules in coronary artery disease Coron Artery Dis 20031465-79
9 Gurbel PA Tantry U Clopidogrel response variability and the advent of personalised antiplatelet therapy A bench to bedside journey Thromb Haemost 2011106265-71
10 Gurbel PA Roe MT Jakubowski JA Shah S Erlinge D Goodman SG Huber K Chan MY Cornel JH Tantry US Ohman EM Translational platelet research in patients with coronary artery disease What are the major knowledge gaps Thromb Haemost 2012 May 25108 [Epub ahead of print]
11 Bliden KP Baker BA Nolin TD Jeong YH Bailey WL Tantry US Gurbel PA Thienopyridine efficacy and cigarette smoking status Am Heart J 2013165693-703
12 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
13 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013111547-56
14 Gesheff MG Franzese CJ Bliden KP Contino CJ Rafeedheen R Tantry USGurbel PA Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin Expert Rev Clin Pharmacol 2014 7645-53
15 Tantry US Gesheff M Liu F Bliden KP Gurbel PA Resistance to antiplatelet therapy what progress has been made Expert Opin Pharmacother 2014 9 1-12
16 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print]
17 Gurbel PA Myat A Tantry US Platelet-mediated Thrombosis From Bench to Bedside Cir Res 2015 (in press)
18 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-release acetylsalicylic acid Future Cardiol 20161245-58
19 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
20 Gurbel PA Tantry US Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes Heart 2016102882-92
21 Navarese EP Kolodziejczak M Kereiakes DJ Tantry US OConnor C Gurbel PA Proprotein Convertase SubtilisinKexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome A Narrative Review Ann Intern Med 2016164600-7
22 Gurbel PA Jeong YH Navarese EP Tantry US Platelet-Mediated Thrombosis From Bench to Bedside Circ Res 20161181380-91
23 Gurbel PA Myat A Kubica J Tantry US State of the art Oral antiplatelet therapy JRSM Cardiovasc Dis 2016 Jun 152048004016652514 doi 1011772048004016652514 eCollection 2016 Jan-Dec
24 Jakubowski JA Erlinge D Alexopoulos D Small DS Winters KJ Gurbel PA Angiolillo DJ The Rationale for and Clinical Pharmacology of Prasugrel 5 mg Am J Cardiovasc Drugs 2016 Nov 17 [Epub ahead of print] Review
25 Winter MP Grove EL De Caterina R Gorog DA Ahrens I Geisler T Gurbel PA Tantry U Navarese EP Siller-Matula JM Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors Eur Heart J Cardiovasc Pharmacother 2017 Feb 15 doi 101093ehjcvppvw044 [Epub ahead of print]
26 Shah P Tantry US Bliden KP Gurbel PA Bleeding and thrombosis associated with ventricular assist device therapy J Heart Lung Transplant 2017 May 11 pii S1053-2498(17)31789-8
Inventions Patents Copyrights 32294 Gurbel PA Anderson RD Autoperfusion dilatation catheter United States Patent 5295959 51501 Dalesandro MR Gurbel PA Serebruany VL Determining a treatment plan for patients undergoing thrombotic
events by monitoring p-Selectin United States Patent 623071 61201 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6245782 13102 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 20020013343 42203 Serebruany VL Gurbel PA OrsquoConnor CM Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors United States Patent 6552014
Curriculum Vitae Paul A Gurbel MD Page 15
120611 Gurbel PA The detection of restenosis risk in patients receiving a stent by measuring the characteristics of blood clotting including the measurement of maximum thrombin-induced clot strength (patent awarded pending)
6308 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 7381536 2010 Gurbel PA Conley P Andre P Gretler D Jurek M Methods for diagnosis and treatment of thrombotic
disorders mediated bycyp2c192 (patent pending) 41014 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent
20140100167 81815 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 9110062 111715 Gurbel PA Detection of restenosis risk in patients receiving a stent by measuring the characteristics of
blood clotting including the measurement of maximum thrombin-induced clot strength Patent 9188597 Extramural Funding (since 2002) CURRENT 2010-2015 MAGMA (Multianalyte And Genetic Markers of Atherosclerosis)
Haemonetics and Sinai Hospital of Baltimore 2015-present An Observational Study of CORA-Assisted Stroke Identification and Antithrombotic Therapy
2014-2015 Feasibility clinical trial to evaluate the efficacy of an Anticoagulant cartridge to be used in the CORA System Coramed Technologies LLC
2014-2015 Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid Durlaza in CVD Patients at Risk of High Platelet Turnover (DURATION)
New Haven Pharmaceuticals Inc 2015-present Influence of Edoxaban on Coagulability and Thrombin Generation An in Vitro Study Focusing on
Thrombelastography Daiichi Sankyo
2016 Influence of Vorapaxar on Thrombin Generation and Coagulability Merck 2015-present Durlaza GI GI Tolerability Study New Haven Pharamceuticals 2015-present Thrombogenicity in LVAD Recipients Haemonetics 2014-2015 First-in-Man Assessment of PZ-128 National Institutes of Health PREVIOUS 2002 Atorvastatin in the Treatment of Heart Failure
LBH IRB 20030512 NIHThe National Heart Lung and Blood Institute NIH
2002 Asessment of the In Vitro Effects of Tenecteplase Reteplase and Alteplase on Human Platelets TAR STUDY Genetech
2003-2005 Assessment of the Effects of the heparin-coated Cordis Stent versus Non-coated Stents on Platelet and Endothelial Cell Activation and Thrombin Effect in Patients with Coronary Artery Disease (HEPACOAT) Cordis Inc
2004-2005 The Antiplatelet Effects of Eptifibatide with High and Standard Dose Clopidogrel in Low-Moderate Risk Patients Undergoing Coronary Intervention (CLEAR-PLATELETS Study) MilleniumSchering Plough
2004-2005 The Use of The TEG System to Monitor Platelet Inhibition at Bedside 5R44HL059753-03Haemoscope National Institute of Health
2004-2006 Clopidogrel Resistance in Patients with Stent Thrombosis (CREST Study) AstraZeneca
Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study MilleniumSchering Plough
2005 St Johns Wort Decreases ADP Induced Platelet Reactivity in Known Clopidogrel Resistant Post Coronary Intervention Patients after a Loading Dose of Clopidogrel University of Michigan
2008-2009 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST) Sinai Hospital Department of Medicine
2009-2010 Demonstration of the Pharmacodynamic Antiplatelet Effect of PRT060128 in Patients with High Platelet Reactivity during Clopidogrel and Aspirin Maintenance Therapy (PORTOLA) Portola Pharmaceuticals
2008-2009 A Randomised Double-Blind Outpatient Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND] AstraZeneca Pharmaceuticals LP
2008-2009 A Randomized Double-blind Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Background Therapy in Patients with Stable Coronary Artery Disease with Additional Detailed Assessment of Cardiopulmonary Function (ONSET-OFFSET) AstraZeneca Pharmaceuticals LP
2008-2009 A Single Center Randomized Open Label Parallel Group Pharmacodynamic Study of a Novel Combination Form of Aspirin and Phytosterol versus Aspirin in Healthy Adult Subjects (ARMOR) Bayer Healthcare LLC
2008-2009 Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel Plus EC Aspirin (325 mg) and Clopidogrel Plus PA32540 on Platelet Aggregation in Healthy Volunteers POZEN 110 POZEN Inc
2009-2010 Antithrombosis with Clopidogrel Beyond the Concept of Platelet Aggregate Inhibition (SANOFI) Sanofi Inc 2010-2012 A Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel EC
Aspirin 81 mg and EC omeprazole 40 mg all dosed concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers POZEN Inc
Intramural Funding (since 2002) CURRENT 2008-present Time Based Strategy to Reduce Clopidogrel Associated Bleeding Related to CABG (TARGET CABG) Sinai Hospital of Baltimore Department of Medicine 2009-present Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI)
Sinai Hospital of Baltimore Department of Medicine 2011-present Detection of Leukemic Blood and Solid TypE MalignanCies by Urinary 11-DehydroThromboxane B2 (DETECT) Study
Sinai Hospital of Baltimore Department of Medicine PREVIOUS 2001-2002 Platelet Activation in Stenting PAST Study Sinai Hospital of Baltimore 2005-2006 Platelet Reactivity in Patients with Crohnrsquos disease Receiving Infliximab (chimeric anti-TNF alpha antibody) ndash COIN
Sinai Hospital of Baltimore Department of Medicine 2006-2007 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST)
Sinai Hospital of Baltimore Department of Medicine 2008-2011 Platelet Reactivity and Thrombogenecity in Postmenopausal Women
Sinai Hospital Department of Medicine 2008-2010 Platelet Reactivity and Thrombogenecity in Postmenopausal Women (PRIDE Study)
Sinai Hospital Department of Medicine Multicenter Studies since 2001
Curriculum Vitae Paul A Gurbel MD Page 17
CURRENT 2010-present The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and
Clopidogrel in Aspirin-Treated Subjects With Stable Coronary Artery Disease Daiichi Sankyo
2010-present A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly versus Non-Elderly Aspirin-Treated Subjects with Stable Coronary Artery Disease Eli Lilly amp company
2011-present A Prospective Multicenter Randomized Trial of Clopidogrel versus Prasugrel Anti-platelet Therapy in Cytochrome P450 2C19 (CYP2C19) Intermediate Metabolizers Grant No U01HL105198
NIH National Heart Lung and Blood Institute NIH 2011-present A Prospective Randomized Multi-Center Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHERreg Sirolimus-Eluting Coronary stents
HCRI 2012-present A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in
patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)
Bayer Healthcare LLC 2013-present Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in
Patients at a High-Risk for Vascular Outcomes (ACCELERATE) Eli Lilly amp Company 2014-present A Phase 2b Multi-center Randomized Placebo-controlled Dose-ranging Study to Investigate the
Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infarction
AEGIS CSL 2015-2017 A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety of PZ- 128 in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention
National Institute of Health PREVIOUS 2001 A Randomized Double-Blind Placebo-Controlled Study of Two Intravenous Dosing Regimens of
h5G11-scFv in Patients with Acute Myocardial Infarction Undergoing 2001-2002 Prevention of REStenosis with Tranilast and Its Outcomes A Placebo Controlled Trial PRESTO STUDY
SmithKline Beecham 2002-2003 Taxus IV-SR Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
Boston Scientific 2003 MICROVENA Corporation TRAP Vascular Filtration System (VFS) Trial
Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily Pfizer Inc
2003-2004 Phase 3 Multi-Center Double-Blind Randomized Parallel Group Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily (QD) for 24 Months Compared with Atorvastatin Alone in Subjects with Angiographically Documented Coronary Heart Disease Pfizer Inc
2003-2004 A Randomized Controlled Trial of the Medtronic Endeavor Drug Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ldquoENDEAVOR III Studyrdquo)
Medtronic 2009-2010 A Prospective Randomized Open-label Multicenter study in Patients Presenting with Acute Coronary Syndromes SYNERGY STUDY
Aventis Pharmaceuticals 2004 CObalt chromium STent with Antiproliferative for Restenosis II Trialrdquo Costar study
Conor Medsystems
Curriculum Vitae Paul A Gurbel MD Page 18
2004-2005 A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions ENDEAVOR IV Medtronic
2004-2005 A Randomized Trial to evaluate the relative protection against POST-PCI microvasculat obstruction among antiplatelet and anti-thrombotic medications (TIMI-30) TIMI group
2004-2006 A Double-blind Double-dummy Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI 33 AstraZeneca Lp
2005-2006 Strategy To Reduce Atherosclerosis Development Involving Administration of Rimonabant - The Intravascular Ultrasound Study (STRADIVARIUS) EFC5827 Sanofi Synthelabo Research
2006 A Multicenter Randomized Double-Blind Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (TRASM-PCI) Schering Plough
2006-2007 A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel -SWAP (SWitching Anti Platelet study) Eli Lilly amp Company and Sankyo Company Limited
2006-2007 A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2008-2010 A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary InterventionTIMI-38 Eli Lilly Company Daiichi
2009-2010 A Randomized Double-Blind Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128 a Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Interventions (INNOVATE-PCI) Portola Pharmaceuticals
2010-2012 TReatment with ADPreceptor iNhibitorS Longitudinal Assessment ofTreatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS)
Eli Lilly Company 2010-2013 RADAR Randomized Partially-Blinded Multi-Center Active-Controlled Dose-Ranging Study
Assessing the Safety Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome Regado Bioscience Inc
2011-2013 A Phase IIa Multi-center Randomized Sponsor-unblinded Placebo-controlled Single Ascending Dose Study to Investigate the Safety Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Adults Taking Aspirin and a P2Y12 Platelet Inhibitor
AEGIS CSL Research Program BuildingLeadership 1991-1995 Director Interventional Cardiology Research University of Maryland Medical System 1998-2015 Director Sinai Center for Thrombosis Research 2001-2015 Director Cardiovascular Research Lifebridge Health 2002-2015 Director Therapeutics Research and Technology Development for the Cardiac Catheterization Program Sinai Hospital of Baltimore 2007-2015 Associate Chief for Research Department of Medicine Sinai Hospital of Baltimore 2015-current Director Interventional Cardiology and Cardiovascular Medicine Research INOVA Health 2015-Current Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute EDUCATIONAL ACTIVITIES
Curriculum Vitae Paul A Gurbel MD Page 19
Peer Reviewed Publications-Consensus Statements Expert Opinions 1 Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C
Rao AK The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 200531309-11
2 Hoekstra J Cohen M Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Saucedo JF Pollack CV Jr Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention-an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective report on a roundtable discussion Am J Emerg Med 200927720-8
3 Bonello L Tantry US Marcucci R Blindt R Angiolillo DJ Becker R Bhatt DL Cattaneo M Collet JP Cuisset T Gachet C Montalescot G Jennings LK Kereiakes D Sibbing D Trenk D Van Werkum JW Paganelli F Price MJ Waksman R Gurbel PA Working Group on High On Treatment Platelet Reactivity Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 201056919-33
4 Gurbel PA Tantry US Shuldiner AR Kereiakes DJ Genotyping one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 201056112-6
5 Gurbel PA Tantry US Antiplatelet therapy Clopidogrel-PPI interaction an ongoing controversy Nat Rev Cardiol 201187-8
6 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
7 Gurbel PA Nolin TD Tantry US Clopidogrel efficacy and cigarette smoking status JAMA 20123072495-6 8 Tantry US Bonello L Aradi D Price MJ Jeong YH Angiolillo DJ Stone GW Curzen N Geisler T Ten Berg J
Kirtane A Siller-Matula J Mahla E Becker RC Bhatt DL Waksman R Rao SV Alexopoulos D Marcucci R Reny JL Trenk D Sibbing D Gurbel PA Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding J Am Coll Cardiol 2013622261-73
9 Gurbel PA Tantry US Antiplatelet and anticoagulant agents in heart failure Current status and future perspectives JACC Heart Fail 201421-14
10 Gurbel PA Tantry US Antiplatelet therapy What have we learned from the ANTARCTIC trial Nat Rev Cardiol 201613639-640
Invited Review Articles 1 Gurbel PA Midwall JA Brodie BR Angioplasty and adjunctive intra-aortic balloon pump counterpulsation Current
clinical considerations Todays Therapy Trends 19951363-78 2 OrsquoConnor CM Gurbel PA Serebruany VL Depression and ischemic heart disease Am Heart J 200014063-69 3 Gurbel PA Serebruany VL Oral IIbIIIa inhibitors From initial promise to clinical failures J Thromb and
Thrombolysis 200010217-20 4 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Atar D Serebruany VL Platelets and
Thrombolysis Cooperation or Contrariety Heart Drug 20011281-290 5 McKenzie ME Gurbel PA The potential of monoclonal antibodies to reduce reperfusion injury in myocardial
infarction BioDrugs 200115395-404 6 Gurbel PA Bliden KP Hayes K Tantry U Platelet activation in myocardial ischemic syndromes Expert Rev of
Cardiovasc Ther 20052535-45 7 Tantry US Bliden KP Gurbel PA Resistance to antiplatelet drugs Current status and future research Expert
Opin Pharmacother 200562027-45 8 Gurbel PA Lau WC Bliden KP Tantry US Clopidogrel resistance Implications for coronary stenting Curr Pharm
Des 2006121261-9 9 Gurbel PA Tantry US Drug insight Clopidogrel non-responsiveness Nature ClinPract Cardiovasc Med
20063387-95 10 Gurbel PA Tantry US Aspirin and Clopidogrel Resistance Considerations and management J Interv Cardiol
200619439-48 11 Lau WC Gurbel PA Antiplatelet drug resistance and drug-drug interactions Role of cytochrome P450 3A4
Pharm Res 2006232691-708 12 Wiviott SD Tantry US Gurbel PA Clinical applications of antiplatelet therapy Rev Cardiovasc Med 20067
Curriculum Vitae Paul A Gurbel MD Page 20
130-46 13 Tantry US Bliden KP Gurbel PA Prasugrel Expert Opin Investig Drugs 2006151627-33 14 Gurbel PA Tantry US Clopidogrel Resistance Thromb Res 2007120311-21 15 Tantry US Etherington A Bliden KP Gurbel PA Antiplatelet therapy Current strategies and future trends Future
Cardiology 20072343-366 16 Gurbel PA Tantry US The relationship of platelet reactivity to the occurrence of post-stenting ischemic events
emergence of a new cardiovascular risk factor Rev Cardiovasc Med 2006Suppl 4S20-8 17 Tantry US Bliden KP Gurbel PA AZD6140 Expert Opin Investig Drugs 200716225-9 18 Gurbel PA Tantry US Stent thrombosis role of compliance and non-responsiveness to antiplatelet therapy Rev
Cardiovasc Med 20078S19-S26 19 Gurbel PA Kandzari DE Stent thrombosis associated with first-generation drug-eluting stents issues with
antiplatelet therapy Neth Heart J 200715148-50 20 Gurbel PA Tantry US The role of clopidogrel in cardiovascular diseases Pol Arch Med Wewn 2007117207-9 21 Gurbel PA DiChiara J Tantry US Antiplatelet therapy after implantation of drug-eluting stents duration
resistance alternatives and management of surgical patients Am J Cardiol 200710018M-25M 22 Gurbel PA Becker R Mann KG Steinhubl SR Michelson AD Platelet function monitoring in patients with
coronary artery disease J Am Coll Cardiol 2007501822-34 23 Gurbel PA Tantry US Prasugrel a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig
Drugs 20089324-36 24 Gurbel PA Bilden KP Tantry US Diagnostics for aspirin resistance Mol Diagn Ther 20081255-6 25 Gurbel PA Antonino MJ Tantry US Antiplatelet treatment of cardiovascular disease a translational research
perspective Pol Arch Med Wewn 2008118289-97 26 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831I36 27 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention Clin Cardiol 200831I28-I35
28 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches Clin Cardiol 200831I21-I27
29 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention Clin Cardiol 200831I17-I20
30 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Assessing the Current Role of Platelet Function Testing Clin Cardiol 200831I10-I16
31 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831136
32 Keriakes DJ Gurbel PA Periprocedural platelet function in percutaneous coronary intervention JACC Cardiovasc Interv 2008suppl 1111ndash121
33 Gurbel PA Tantry US The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome J Interv Cardiol 200821Suppl 1S10-7
34 Gurbel PA Tantry US Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 20091122-322
35 Gurbel PA Aspirin scope and limitations Br J Cardiol 200917 (Suppl 1)S8-S9 36 Cohen M Hoekstra J Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Pollack CV Jr
Saucedo JF Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion J Interv Cardiol 200821283-99
37 Angiolillo DJ Bhatt DL Gurbel PA Jennings LK Advances in antiplatelet therapy agents in clinical development Am J Cardiol 2009103(3 Suppl)40A-51A
38 Gurbel PA Mahla E Antonino MJ Tantry US Response variability and the role of platelet function testing J Invasive Cardiol 200921172-8
39 Gurbel PA Antonino MJ Tantry US Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug MetabToxicol Expert Opin Drug Metab Toxicol 20095989-1004
40 Gurbel PA Tantry US Antiplatelet resistance- Fact or Myth Am Hosp J 2009750-57 41 Gurbel PA Mahla E Tantry US Aspirin resistance Prog Cardiovasc Dis 200952141-52 42 Tantry US Gurbel PA Platelet monitoring for PCI Is it really necessary Haemostaseologie 200929 368-75 43 Gurbel PA Aspirin-scope and limitations Br J Cardiol 200917(Suppl 1)S8-S9
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 15
120611 Gurbel PA The detection of restenosis risk in patients receiving a stent by measuring the characteristics of blood clotting including the measurement of maximum thrombin-induced clot strength (patent awarded pending)
6308 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 7381536 2010 Gurbel PA Conley P Andre P Gretler D Jurek M Methods for diagnosis and treatment of thrombotic
disorders mediated bycyp2c192 (patent pending) 41014 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent
20140100167 81815 Gurbel PA Assessment of cardiac health and thrombotic risk in a patient United States Patent 9110062 111715 Gurbel PA Detection of restenosis risk in patients receiving a stent by measuring the characteristics of
blood clotting including the measurement of maximum thrombin-induced clot strength Patent 9188597 Extramural Funding (since 2002) CURRENT 2010-2015 MAGMA (Multianalyte And Genetic Markers of Atherosclerosis)
Haemonetics and Sinai Hospital of Baltimore 2015-present An Observational Study of CORA-Assisted Stroke Identification and Antithrombotic Therapy
2014-2015 Feasibility clinical trial to evaluate the efficacy of an Anticoagulant cartridge to be used in the CORA System Coramed Technologies LLC
2014-2015 Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid Durlaza in CVD Patients at Risk of High Platelet Turnover (DURATION)
New Haven Pharmaceuticals Inc 2015-present Influence of Edoxaban on Coagulability and Thrombin Generation An in Vitro Study Focusing on
Thrombelastography Daiichi Sankyo
2016 Influence of Vorapaxar on Thrombin Generation and Coagulability Merck 2015-present Durlaza GI GI Tolerability Study New Haven Pharamceuticals 2015-present Thrombogenicity in LVAD Recipients Haemonetics 2014-2015 First-in-Man Assessment of PZ-128 National Institutes of Health PREVIOUS 2002 Atorvastatin in the Treatment of Heart Failure
LBH IRB 20030512 NIHThe National Heart Lung and Blood Institute NIH
2002 Asessment of the In Vitro Effects of Tenecteplase Reteplase and Alteplase on Human Platelets TAR STUDY Genetech
2003-2005 Assessment of the Effects of the heparin-coated Cordis Stent versus Non-coated Stents on Platelet and Endothelial Cell Activation and Thrombin Effect in Patients with Coronary Artery Disease (HEPACOAT) Cordis Inc
2004-2005 The Antiplatelet Effects of Eptifibatide with High and Standard Dose Clopidogrel in Low-Moderate Risk Patients Undergoing Coronary Intervention (CLEAR-PLATELETS Study) MilleniumSchering Plough
2004-2005 The Use of The TEG System to Monitor Platelet Inhibition at Bedside 5R44HL059753-03Haemoscope National Institute of Health
2004-2006 Clopidogrel Resistance in Patients with Stent Thrombosis (CREST Study) AstraZeneca
Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study MilleniumSchering Plough
2005 St Johns Wort Decreases ADP Induced Platelet Reactivity in Known Clopidogrel Resistant Post Coronary Intervention Patients after a Loading Dose of Clopidogrel University of Michigan
2008-2009 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST) Sinai Hospital Department of Medicine
2009-2010 Demonstration of the Pharmacodynamic Antiplatelet Effect of PRT060128 in Patients with High Platelet Reactivity during Clopidogrel and Aspirin Maintenance Therapy (PORTOLA) Portola Pharmaceuticals
2008-2009 A Randomised Double-Blind Outpatient Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND] AstraZeneca Pharmaceuticals LP
2008-2009 A Randomized Double-blind Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Background Therapy in Patients with Stable Coronary Artery Disease with Additional Detailed Assessment of Cardiopulmonary Function (ONSET-OFFSET) AstraZeneca Pharmaceuticals LP
2008-2009 A Single Center Randomized Open Label Parallel Group Pharmacodynamic Study of a Novel Combination Form of Aspirin and Phytosterol versus Aspirin in Healthy Adult Subjects (ARMOR) Bayer Healthcare LLC
2008-2009 Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel Plus EC Aspirin (325 mg) and Clopidogrel Plus PA32540 on Platelet Aggregation in Healthy Volunteers POZEN 110 POZEN Inc
2009-2010 Antithrombosis with Clopidogrel Beyond the Concept of Platelet Aggregate Inhibition (SANOFI) Sanofi Inc 2010-2012 A Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel EC
Aspirin 81 mg and EC omeprazole 40 mg all dosed concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers POZEN Inc
Intramural Funding (since 2002) CURRENT 2008-present Time Based Strategy to Reduce Clopidogrel Associated Bleeding Related to CABG (TARGET CABG) Sinai Hospital of Baltimore Department of Medicine 2009-present Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI)
Sinai Hospital of Baltimore Department of Medicine 2011-present Detection of Leukemic Blood and Solid TypE MalignanCies by Urinary 11-DehydroThromboxane B2 (DETECT) Study
Sinai Hospital of Baltimore Department of Medicine PREVIOUS 2001-2002 Platelet Activation in Stenting PAST Study Sinai Hospital of Baltimore 2005-2006 Platelet Reactivity in Patients with Crohnrsquos disease Receiving Infliximab (chimeric anti-TNF alpha antibody) ndash COIN
Sinai Hospital of Baltimore Department of Medicine 2006-2007 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST)
Sinai Hospital of Baltimore Department of Medicine 2008-2011 Platelet Reactivity and Thrombogenecity in Postmenopausal Women
Sinai Hospital Department of Medicine 2008-2010 Platelet Reactivity and Thrombogenecity in Postmenopausal Women (PRIDE Study)
Sinai Hospital Department of Medicine Multicenter Studies since 2001
Curriculum Vitae Paul A Gurbel MD Page 17
CURRENT 2010-present The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and
Clopidogrel in Aspirin-Treated Subjects With Stable Coronary Artery Disease Daiichi Sankyo
2010-present A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly versus Non-Elderly Aspirin-Treated Subjects with Stable Coronary Artery Disease Eli Lilly amp company
2011-present A Prospective Multicenter Randomized Trial of Clopidogrel versus Prasugrel Anti-platelet Therapy in Cytochrome P450 2C19 (CYP2C19) Intermediate Metabolizers Grant No U01HL105198
NIH National Heart Lung and Blood Institute NIH 2011-present A Prospective Randomized Multi-Center Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHERreg Sirolimus-Eluting Coronary stents
HCRI 2012-present A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in
patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)
Bayer Healthcare LLC 2013-present Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in
Patients at a High-Risk for Vascular Outcomes (ACCELERATE) Eli Lilly amp Company 2014-present A Phase 2b Multi-center Randomized Placebo-controlled Dose-ranging Study to Investigate the
Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infarction
AEGIS CSL 2015-2017 A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety of PZ- 128 in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention
National Institute of Health PREVIOUS 2001 A Randomized Double-Blind Placebo-Controlled Study of Two Intravenous Dosing Regimens of
h5G11-scFv in Patients with Acute Myocardial Infarction Undergoing 2001-2002 Prevention of REStenosis with Tranilast and Its Outcomes A Placebo Controlled Trial PRESTO STUDY
SmithKline Beecham 2002-2003 Taxus IV-SR Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
Boston Scientific 2003 MICROVENA Corporation TRAP Vascular Filtration System (VFS) Trial
Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily Pfizer Inc
2003-2004 Phase 3 Multi-Center Double-Blind Randomized Parallel Group Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily (QD) for 24 Months Compared with Atorvastatin Alone in Subjects with Angiographically Documented Coronary Heart Disease Pfizer Inc
2003-2004 A Randomized Controlled Trial of the Medtronic Endeavor Drug Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ldquoENDEAVOR III Studyrdquo)
Medtronic 2009-2010 A Prospective Randomized Open-label Multicenter study in Patients Presenting with Acute Coronary Syndromes SYNERGY STUDY
Aventis Pharmaceuticals 2004 CObalt chromium STent with Antiproliferative for Restenosis II Trialrdquo Costar study
Conor Medsystems
Curriculum Vitae Paul A Gurbel MD Page 18
2004-2005 A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions ENDEAVOR IV Medtronic
2004-2005 A Randomized Trial to evaluate the relative protection against POST-PCI microvasculat obstruction among antiplatelet and anti-thrombotic medications (TIMI-30) TIMI group
2004-2006 A Double-blind Double-dummy Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI 33 AstraZeneca Lp
2005-2006 Strategy To Reduce Atherosclerosis Development Involving Administration of Rimonabant - The Intravascular Ultrasound Study (STRADIVARIUS) EFC5827 Sanofi Synthelabo Research
2006 A Multicenter Randomized Double-Blind Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (TRASM-PCI) Schering Plough
2006-2007 A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel -SWAP (SWitching Anti Platelet study) Eli Lilly amp Company and Sankyo Company Limited
2006-2007 A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2008-2010 A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary InterventionTIMI-38 Eli Lilly Company Daiichi
2009-2010 A Randomized Double-Blind Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128 a Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Interventions (INNOVATE-PCI) Portola Pharmaceuticals
2010-2012 TReatment with ADPreceptor iNhibitorS Longitudinal Assessment ofTreatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS)
Eli Lilly Company 2010-2013 RADAR Randomized Partially-Blinded Multi-Center Active-Controlled Dose-Ranging Study
Assessing the Safety Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome Regado Bioscience Inc
2011-2013 A Phase IIa Multi-center Randomized Sponsor-unblinded Placebo-controlled Single Ascending Dose Study to Investigate the Safety Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Adults Taking Aspirin and a P2Y12 Platelet Inhibitor
AEGIS CSL Research Program BuildingLeadership 1991-1995 Director Interventional Cardiology Research University of Maryland Medical System 1998-2015 Director Sinai Center for Thrombosis Research 2001-2015 Director Cardiovascular Research Lifebridge Health 2002-2015 Director Therapeutics Research and Technology Development for the Cardiac Catheterization Program Sinai Hospital of Baltimore 2007-2015 Associate Chief for Research Department of Medicine Sinai Hospital of Baltimore 2015-current Director Interventional Cardiology and Cardiovascular Medicine Research INOVA Health 2015-Current Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute EDUCATIONAL ACTIVITIES
Curriculum Vitae Paul A Gurbel MD Page 19
Peer Reviewed Publications-Consensus Statements Expert Opinions 1 Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C
Rao AK The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 200531309-11
2 Hoekstra J Cohen M Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Saucedo JF Pollack CV Jr Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention-an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective report on a roundtable discussion Am J Emerg Med 200927720-8
3 Bonello L Tantry US Marcucci R Blindt R Angiolillo DJ Becker R Bhatt DL Cattaneo M Collet JP Cuisset T Gachet C Montalescot G Jennings LK Kereiakes D Sibbing D Trenk D Van Werkum JW Paganelli F Price MJ Waksman R Gurbel PA Working Group on High On Treatment Platelet Reactivity Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 201056919-33
4 Gurbel PA Tantry US Shuldiner AR Kereiakes DJ Genotyping one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 201056112-6
5 Gurbel PA Tantry US Antiplatelet therapy Clopidogrel-PPI interaction an ongoing controversy Nat Rev Cardiol 201187-8
6 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
7 Gurbel PA Nolin TD Tantry US Clopidogrel efficacy and cigarette smoking status JAMA 20123072495-6 8 Tantry US Bonello L Aradi D Price MJ Jeong YH Angiolillo DJ Stone GW Curzen N Geisler T Ten Berg J
Kirtane A Siller-Matula J Mahla E Becker RC Bhatt DL Waksman R Rao SV Alexopoulos D Marcucci R Reny JL Trenk D Sibbing D Gurbel PA Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding J Am Coll Cardiol 2013622261-73
9 Gurbel PA Tantry US Antiplatelet and anticoagulant agents in heart failure Current status and future perspectives JACC Heart Fail 201421-14
10 Gurbel PA Tantry US Antiplatelet therapy What have we learned from the ANTARCTIC trial Nat Rev Cardiol 201613639-640
Invited Review Articles 1 Gurbel PA Midwall JA Brodie BR Angioplasty and adjunctive intra-aortic balloon pump counterpulsation Current
clinical considerations Todays Therapy Trends 19951363-78 2 OrsquoConnor CM Gurbel PA Serebruany VL Depression and ischemic heart disease Am Heart J 200014063-69 3 Gurbel PA Serebruany VL Oral IIbIIIa inhibitors From initial promise to clinical failures J Thromb and
Thrombolysis 200010217-20 4 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Atar D Serebruany VL Platelets and
Thrombolysis Cooperation or Contrariety Heart Drug 20011281-290 5 McKenzie ME Gurbel PA The potential of monoclonal antibodies to reduce reperfusion injury in myocardial
infarction BioDrugs 200115395-404 6 Gurbel PA Bliden KP Hayes K Tantry U Platelet activation in myocardial ischemic syndromes Expert Rev of
Cardiovasc Ther 20052535-45 7 Tantry US Bliden KP Gurbel PA Resistance to antiplatelet drugs Current status and future research Expert
Opin Pharmacother 200562027-45 8 Gurbel PA Lau WC Bliden KP Tantry US Clopidogrel resistance Implications for coronary stenting Curr Pharm
Des 2006121261-9 9 Gurbel PA Tantry US Drug insight Clopidogrel non-responsiveness Nature ClinPract Cardiovasc Med
20063387-95 10 Gurbel PA Tantry US Aspirin and Clopidogrel Resistance Considerations and management J Interv Cardiol
200619439-48 11 Lau WC Gurbel PA Antiplatelet drug resistance and drug-drug interactions Role of cytochrome P450 3A4
Pharm Res 2006232691-708 12 Wiviott SD Tantry US Gurbel PA Clinical applications of antiplatelet therapy Rev Cardiovasc Med 20067
Curriculum Vitae Paul A Gurbel MD Page 20
130-46 13 Tantry US Bliden KP Gurbel PA Prasugrel Expert Opin Investig Drugs 2006151627-33 14 Gurbel PA Tantry US Clopidogrel Resistance Thromb Res 2007120311-21 15 Tantry US Etherington A Bliden KP Gurbel PA Antiplatelet therapy Current strategies and future trends Future
Cardiology 20072343-366 16 Gurbel PA Tantry US The relationship of platelet reactivity to the occurrence of post-stenting ischemic events
emergence of a new cardiovascular risk factor Rev Cardiovasc Med 2006Suppl 4S20-8 17 Tantry US Bliden KP Gurbel PA AZD6140 Expert Opin Investig Drugs 200716225-9 18 Gurbel PA Tantry US Stent thrombosis role of compliance and non-responsiveness to antiplatelet therapy Rev
Cardiovasc Med 20078S19-S26 19 Gurbel PA Kandzari DE Stent thrombosis associated with first-generation drug-eluting stents issues with
antiplatelet therapy Neth Heart J 200715148-50 20 Gurbel PA Tantry US The role of clopidogrel in cardiovascular diseases Pol Arch Med Wewn 2007117207-9 21 Gurbel PA DiChiara J Tantry US Antiplatelet therapy after implantation of drug-eluting stents duration
resistance alternatives and management of surgical patients Am J Cardiol 200710018M-25M 22 Gurbel PA Becker R Mann KG Steinhubl SR Michelson AD Platelet function monitoring in patients with
coronary artery disease J Am Coll Cardiol 2007501822-34 23 Gurbel PA Tantry US Prasugrel a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig
Drugs 20089324-36 24 Gurbel PA Bilden KP Tantry US Diagnostics for aspirin resistance Mol Diagn Ther 20081255-6 25 Gurbel PA Antonino MJ Tantry US Antiplatelet treatment of cardiovascular disease a translational research
perspective Pol Arch Med Wewn 2008118289-97 26 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831I36 27 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention Clin Cardiol 200831I28-I35
28 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches Clin Cardiol 200831I21-I27
29 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention Clin Cardiol 200831I17-I20
30 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Assessing the Current Role of Platelet Function Testing Clin Cardiol 200831I10-I16
31 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831136
32 Keriakes DJ Gurbel PA Periprocedural platelet function in percutaneous coronary intervention JACC Cardiovasc Interv 2008suppl 1111ndash121
33 Gurbel PA Tantry US The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome J Interv Cardiol 200821Suppl 1S10-7
34 Gurbel PA Tantry US Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 20091122-322
35 Gurbel PA Aspirin scope and limitations Br J Cardiol 200917 (Suppl 1)S8-S9 36 Cohen M Hoekstra J Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Pollack CV Jr
Saucedo JF Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion J Interv Cardiol 200821283-99
37 Angiolillo DJ Bhatt DL Gurbel PA Jennings LK Advances in antiplatelet therapy agents in clinical development Am J Cardiol 2009103(3 Suppl)40A-51A
38 Gurbel PA Mahla E Antonino MJ Tantry US Response variability and the role of platelet function testing J Invasive Cardiol 200921172-8
39 Gurbel PA Antonino MJ Tantry US Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug MetabToxicol Expert Opin Drug Metab Toxicol 20095989-1004
40 Gurbel PA Tantry US Antiplatelet resistance- Fact or Myth Am Hosp J 2009750-57 41 Gurbel PA Mahla E Tantry US Aspirin resistance Prog Cardiovasc Dis 200952141-52 42 Tantry US Gurbel PA Platelet monitoring for PCI Is it really necessary Haemostaseologie 200929 368-75 43 Gurbel PA Aspirin-scope and limitations Br J Cardiol 200917(Suppl 1)S8-S9
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study MilleniumSchering Plough
2005 St Johns Wort Decreases ADP Induced Platelet Reactivity in Known Clopidogrel Resistant Post Coronary Intervention Patients after a Loading Dose of Clopidogrel University of Michigan
2008-2009 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST) Sinai Hospital Department of Medicine
2009-2010 Demonstration of the Pharmacodynamic Antiplatelet Effect of PRT060128 in Patients with High Platelet Reactivity during Clopidogrel and Aspirin Maintenance Therapy (PORTOLA) Portola Pharmaceuticals
2008-2009 A Randomised Double-Blind Outpatient Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND] AstraZeneca Pharmaceuticals LP
2008-2009 A Randomized Double-blind Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Background Therapy in Patients with Stable Coronary Artery Disease with Additional Detailed Assessment of Cardiopulmonary Function (ONSET-OFFSET) AstraZeneca Pharmaceuticals LP
2008-2009 A Single Center Randomized Open Label Parallel Group Pharmacodynamic Study of a Novel Combination Form of Aspirin and Phytosterol versus Aspirin in Healthy Adult Subjects (ARMOR) Bayer Healthcare LLC
2008-2009 Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel Plus EC Aspirin (325 mg) and Clopidogrel Plus PA32540 on Platelet Aggregation in Healthy Volunteers POZEN 110 POZEN Inc
2009-2010 Antithrombosis with Clopidogrel Beyond the Concept of Platelet Aggregate Inhibition (SANOFI) Sanofi Inc 2010-2012 A Randomized Open-Label Cross-Over Study to Evaluate the Inhibitory Effect of Clopidogrel EC
Aspirin 81 mg and EC omeprazole 40 mg all dosed concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers POZEN Inc
Intramural Funding (since 2002) CURRENT 2008-present Time Based Strategy to Reduce Clopidogrel Associated Bleeding Related to CABG (TARGET CABG) Sinai Hospital of Baltimore Department of Medicine 2009-present Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI)
Sinai Hospital of Baltimore Department of Medicine 2011-present Detection of Leukemic Blood and Solid TypE MalignanCies by Urinary 11-DehydroThromboxane B2 (DETECT) Study
Sinai Hospital of Baltimore Department of Medicine PREVIOUS 2001-2002 Platelet Activation in Stenting PAST Study Sinai Hospital of Baltimore 2005-2006 Platelet Reactivity in Patients with Crohnrsquos disease Receiving Infliximab (chimeric anti-TNF alpha antibody) ndash COIN
Sinai Hospital of Baltimore Department of Medicine 2006-2007 Flavonoid Effect on Stimulation and Aggregation of Thrombocytes (FEAST)
Sinai Hospital of Baltimore Department of Medicine 2008-2011 Platelet Reactivity and Thrombogenecity in Postmenopausal Women
Sinai Hospital Department of Medicine 2008-2010 Platelet Reactivity and Thrombogenecity in Postmenopausal Women (PRIDE Study)
Sinai Hospital Department of Medicine Multicenter Studies since 2001
Curriculum Vitae Paul A Gurbel MD Page 17
CURRENT 2010-present The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and
Clopidogrel in Aspirin-Treated Subjects With Stable Coronary Artery Disease Daiichi Sankyo
2010-present A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly versus Non-Elderly Aspirin-Treated Subjects with Stable Coronary Artery Disease Eli Lilly amp company
2011-present A Prospective Multicenter Randomized Trial of Clopidogrel versus Prasugrel Anti-platelet Therapy in Cytochrome P450 2C19 (CYP2C19) Intermediate Metabolizers Grant No U01HL105198
NIH National Heart Lung and Blood Institute NIH 2011-present A Prospective Randomized Multi-Center Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHERreg Sirolimus-Eluting Coronary stents
HCRI 2012-present A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in
patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)
Bayer Healthcare LLC 2013-present Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in
Patients at a High-Risk for Vascular Outcomes (ACCELERATE) Eli Lilly amp Company 2014-present A Phase 2b Multi-center Randomized Placebo-controlled Dose-ranging Study to Investigate the
Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infarction
AEGIS CSL 2015-2017 A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety of PZ- 128 in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention
National Institute of Health PREVIOUS 2001 A Randomized Double-Blind Placebo-Controlled Study of Two Intravenous Dosing Regimens of
h5G11-scFv in Patients with Acute Myocardial Infarction Undergoing 2001-2002 Prevention of REStenosis with Tranilast and Its Outcomes A Placebo Controlled Trial PRESTO STUDY
SmithKline Beecham 2002-2003 Taxus IV-SR Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
Boston Scientific 2003 MICROVENA Corporation TRAP Vascular Filtration System (VFS) Trial
Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily Pfizer Inc
2003-2004 Phase 3 Multi-Center Double-Blind Randomized Parallel Group Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily (QD) for 24 Months Compared with Atorvastatin Alone in Subjects with Angiographically Documented Coronary Heart Disease Pfizer Inc
2003-2004 A Randomized Controlled Trial of the Medtronic Endeavor Drug Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ldquoENDEAVOR III Studyrdquo)
Medtronic 2009-2010 A Prospective Randomized Open-label Multicenter study in Patients Presenting with Acute Coronary Syndromes SYNERGY STUDY
Aventis Pharmaceuticals 2004 CObalt chromium STent with Antiproliferative for Restenosis II Trialrdquo Costar study
Conor Medsystems
Curriculum Vitae Paul A Gurbel MD Page 18
2004-2005 A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions ENDEAVOR IV Medtronic
2004-2005 A Randomized Trial to evaluate the relative protection against POST-PCI microvasculat obstruction among antiplatelet and anti-thrombotic medications (TIMI-30) TIMI group
2004-2006 A Double-blind Double-dummy Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI 33 AstraZeneca Lp
2005-2006 Strategy To Reduce Atherosclerosis Development Involving Administration of Rimonabant - The Intravascular Ultrasound Study (STRADIVARIUS) EFC5827 Sanofi Synthelabo Research
2006 A Multicenter Randomized Double-Blind Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (TRASM-PCI) Schering Plough
2006-2007 A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel -SWAP (SWitching Anti Platelet study) Eli Lilly amp Company and Sankyo Company Limited
2006-2007 A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2008-2010 A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary InterventionTIMI-38 Eli Lilly Company Daiichi
2009-2010 A Randomized Double-Blind Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128 a Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Interventions (INNOVATE-PCI) Portola Pharmaceuticals
2010-2012 TReatment with ADPreceptor iNhibitorS Longitudinal Assessment ofTreatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS)
Eli Lilly Company 2010-2013 RADAR Randomized Partially-Blinded Multi-Center Active-Controlled Dose-Ranging Study
Assessing the Safety Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome Regado Bioscience Inc
2011-2013 A Phase IIa Multi-center Randomized Sponsor-unblinded Placebo-controlled Single Ascending Dose Study to Investigate the Safety Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Adults Taking Aspirin and a P2Y12 Platelet Inhibitor
AEGIS CSL Research Program BuildingLeadership 1991-1995 Director Interventional Cardiology Research University of Maryland Medical System 1998-2015 Director Sinai Center for Thrombosis Research 2001-2015 Director Cardiovascular Research Lifebridge Health 2002-2015 Director Therapeutics Research and Technology Development for the Cardiac Catheterization Program Sinai Hospital of Baltimore 2007-2015 Associate Chief for Research Department of Medicine Sinai Hospital of Baltimore 2015-current Director Interventional Cardiology and Cardiovascular Medicine Research INOVA Health 2015-Current Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute EDUCATIONAL ACTIVITIES
Curriculum Vitae Paul A Gurbel MD Page 19
Peer Reviewed Publications-Consensus Statements Expert Opinions 1 Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C
Rao AK The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 200531309-11
2 Hoekstra J Cohen M Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Saucedo JF Pollack CV Jr Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention-an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective report on a roundtable discussion Am J Emerg Med 200927720-8
3 Bonello L Tantry US Marcucci R Blindt R Angiolillo DJ Becker R Bhatt DL Cattaneo M Collet JP Cuisset T Gachet C Montalescot G Jennings LK Kereiakes D Sibbing D Trenk D Van Werkum JW Paganelli F Price MJ Waksman R Gurbel PA Working Group on High On Treatment Platelet Reactivity Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 201056919-33
4 Gurbel PA Tantry US Shuldiner AR Kereiakes DJ Genotyping one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 201056112-6
5 Gurbel PA Tantry US Antiplatelet therapy Clopidogrel-PPI interaction an ongoing controversy Nat Rev Cardiol 201187-8
6 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
7 Gurbel PA Nolin TD Tantry US Clopidogrel efficacy and cigarette smoking status JAMA 20123072495-6 8 Tantry US Bonello L Aradi D Price MJ Jeong YH Angiolillo DJ Stone GW Curzen N Geisler T Ten Berg J
Kirtane A Siller-Matula J Mahla E Becker RC Bhatt DL Waksman R Rao SV Alexopoulos D Marcucci R Reny JL Trenk D Sibbing D Gurbel PA Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding J Am Coll Cardiol 2013622261-73
9 Gurbel PA Tantry US Antiplatelet and anticoagulant agents in heart failure Current status and future perspectives JACC Heart Fail 201421-14
10 Gurbel PA Tantry US Antiplatelet therapy What have we learned from the ANTARCTIC trial Nat Rev Cardiol 201613639-640
Invited Review Articles 1 Gurbel PA Midwall JA Brodie BR Angioplasty and adjunctive intra-aortic balloon pump counterpulsation Current
clinical considerations Todays Therapy Trends 19951363-78 2 OrsquoConnor CM Gurbel PA Serebruany VL Depression and ischemic heart disease Am Heart J 200014063-69 3 Gurbel PA Serebruany VL Oral IIbIIIa inhibitors From initial promise to clinical failures J Thromb and
Thrombolysis 200010217-20 4 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Atar D Serebruany VL Platelets and
Thrombolysis Cooperation or Contrariety Heart Drug 20011281-290 5 McKenzie ME Gurbel PA The potential of monoclonal antibodies to reduce reperfusion injury in myocardial
infarction BioDrugs 200115395-404 6 Gurbel PA Bliden KP Hayes K Tantry U Platelet activation in myocardial ischemic syndromes Expert Rev of
Cardiovasc Ther 20052535-45 7 Tantry US Bliden KP Gurbel PA Resistance to antiplatelet drugs Current status and future research Expert
Opin Pharmacother 200562027-45 8 Gurbel PA Lau WC Bliden KP Tantry US Clopidogrel resistance Implications for coronary stenting Curr Pharm
Des 2006121261-9 9 Gurbel PA Tantry US Drug insight Clopidogrel non-responsiveness Nature ClinPract Cardiovasc Med
20063387-95 10 Gurbel PA Tantry US Aspirin and Clopidogrel Resistance Considerations and management J Interv Cardiol
200619439-48 11 Lau WC Gurbel PA Antiplatelet drug resistance and drug-drug interactions Role of cytochrome P450 3A4
Pharm Res 2006232691-708 12 Wiviott SD Tantry US Gurbel PA Clinical applications of antiplatelet therapy Rev Cardiovasc Med 20067
Curriculum Vitae Paul A Gurbel MD Page 20
130-46 13 Tantry US Bliden KP Gurbel PA Prasugrel Expert Opin Investig Drugs 2006151627-33 14 Gurbel PA Tantry US Clopidogrel Resistance Thromb Res 2007120311-21 15 Tantry US Etherington A Bliden KP Gurbel PA Antiplatelet therapy Current strategies and future trends Future
Cardiology 20072343-366 16 Gurbel PA Tantry US The relationship of platelet reactivity to the occurrence of post-stenting ischemic events
emergence of a new cardiovascular risk factor Rev Cardiovasc Med 2006Suppl 4S20-8 17 Tantry US Bliden KP Gurbel PA AZD6140 Expert Opin Investig Drugs 200716225-9 18 Gurbel PA Tantry US Stent thrombosis role of compliance and non-responsiveness to antiplatelet therapy Rev
Cardiovasc Med 20078S19-S26 19 Gurbel PA Kandzari DE Stent thrombosis associated with first-generation drug-eluting stents issues with
antiplatelet therapy Neth Heart J 200715148-50 20 Gurbel PA Tantry US The role of clopidogrel in cardiovascular diseases Pol Arch Med Wewn 2007117207-9 21 Gurbel PA DiChiara J Tantry US Antiplatelet therapy after implantation of drug-eluting stents duration
resistance alternatives and management of surgical patients Am J Cardiol 200710018M-25M 22 Gurbel PA Becker R Mann KG Steinhubl SR Michelson AD Platelet function monitoring in patients with
coronary artery disease J Am Coll Cardiol 2007501822-34 23 Gurbel PA Tantry US Prasugrel a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig
Drugs 20089324-36 24 Gurbel PA Bilden KP Tantry US Diagnostics for aspirin resistance Mol Diagn Ther 20081255-6 25 Gurbel PA Antonino MJ Tantry US Antiplatelet treatment of cardiovascular disease a translational research
perspective Pol Arch Med Wewn 2008118289-97 26 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831I36 27 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention Clin Cardiol 200831I28-I35
28 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches Clin Cardiol 200831I21-I27
29 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention Clin Cardiol 200831I17-I20
30 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Assessing the Current Role of Platelet Function Testing Clin Cardiol 200831I10-I16
31 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831136
32 Keriakes DJ Gurbel PA Periprocedural platelet function in percutaneous coronary intervention JACC Cardiovasc Interv 2008suppl 1111ndash121
33 Gurbel PA Tantry US The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome J Interv Cardiol 200821Suppl 1S10-7
34 Gurbel PA Tantry US Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 20091122-322
35 Gurbel PA Aspirin scope and limitations Br J Cardiol 200917 (Suppl 1)S8-S9 36 Cohen M Hoekstra J Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Pollack CV Jr
Saucedo JF Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion J Interv Cardiol 200821283-99
37 Angiolillo DJ Bhatt DL Gurbel PA Jennings LK Advances in antiplatelet therapy agents in clinical development Am J Cardiol 2009103(3 Suppl)40A-51A
38 Gurbel PA Mahla E Antonino MJ Tantry US Response variability and the role of platelet function testing J Invasive Cardiol 200921172-8
39 Gurbel PA Antonino MJ Tantry US Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug MetabToxicol Expert Opin Drug Metab Toxicol 20095989-1004
40 Gurbel PA Tantry US Antiplatelet resistance- Fact or Myth Am Hosp J 2009750-57 41 Gurbel PA Mahla E Tantry US Aspirin resistance Prog Cardiovasc Dis 200952141-52 42 Tantry US Gurbel PA Platelet monitoring for PCI Is it really necessary Haemostaseologie 200929 368-75 43 Gurbel PA Aspirin-scope and limitations Br J Cardiol 200917(Suppl 1)S8-S9
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 17
CURRENT 2010-present The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and
Clopidogrel in Aspirin-Treated Subjects With Stable Coronary Artery Disease Daiichi Sankyo
2010-present A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly versus Non-Elderly Aspirin-Treated Subjects with Stable Coronary Artery Disease Eli Lilly amp company
2011-present A Prospective Multicenter Randomized Trial of Clopidogrel versus Prasugrel Anti-platelet Therapy in Cytochrome P450 2C19 (CYP2C19) Intermediate Metabolizers Grant No U01HL105198
NIH National Heart Lung and Blood Institute NIH 2011-present A Prospective Randomized Multi-Center Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHERreg Sirolimus-Eluting Coronary stents
HCRI 2012-present A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in
patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)
Bayer Healthcare LLC 2013-present Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in
Patients at a High-Risk for Vascular Outcomes (ACCELERATE) Eli Lilly amp Company 2014-present A Phase 2b Multi-center Randomized Placebo-controlled Dose-ranging Study to Investigate the
Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infarction
AEGIS CSL 2015-2017 A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety of PZ- 128 in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention
National Institute of Health PREVIOUS 2001 A Randomized Double-Blind Placebo-Controlled Study of Two Intravenous Dosing Regimens of
h5G11-scFv in Patients with Acute Myocardial Infarction Undergoing 2001-2002 Prevention of REStenosis with Tranilast and Its Outcomes A Placebo Controlled Trial PRESTO STUDY
SmithKline Beecham 2002-2003 Taxus IV-SR Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
Boston Scientific 2003 MICROVENA Corporation TRAP Vascular Filtration System (VFS) Trial
Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily Pfizer Inc
2003-2004 Phase 3 Multi-Center Double-Blind Randomized Parallel Group Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy Safety and Tolerability of Fixed Combination CP-529414 Atorvastatin Administered Orally Once Daily (QD) for 24 Months Compared with Atorvastatin Alone in Subjects with Angiographically Documented Coronary Heart Disease Pfizer Inc
2003-2004 A Randomized Controlled Trial of the Medtronic Endeavor Drug Eluting Stent System versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ldquoENDEAVOR III Studyrdquo)
Medtronic 2009-2010 A Prospective Randomized Open-label Multicenter study in Patients Presenting with Acute Coronary Syndromes SYNERGY STUDY
Aventis Pharmaceuticals 2004 CObalt chromium STent with Antiproliferative for Restenosis II Trialrdquo Costar study
Conor Medsystems
Curriculum Vitae Paul A Gurbel MD Page 18
2004-2005 A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions ENDEAVOR IV Medtronic
2004-2005 A Randomized Trial to evaluate the relative protection against POST-PCI microvasculat obstruction among antiplatelet and anti-thrombotic medications (TIMI-30) TIMI group
2004-2006 A Double-blind Double-dummy Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI 33 AstraZeneca Lp
2005-2006 Strategy To Reduce Atherosclerosis Development Involving Administration of Rimonabant - The Intravascular Ultrasound Study (STRADIVARIUS) EFC5827 Sanofi Synthelabo Research
2006 A Multicenter Randomized Double-Blind Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (TRASM-PCI) Schering Plough
2006-2007 A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel -SWAP (SWitching Anti Platelet study) Eli Lilly amp Company and Sankyo Company Limited
2006-2007 A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2008-2010 A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary InterventionTIMI-38 Eli Lilly Company Daiichi
2009-2010 A Randomized Double-Blind Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128 a Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Interventions (INNOVATE-PCI) Portola Pharmaceuticals
2010-2012 TReatment with ADPreceptor iNhibitorS Longitudinal Assessment ofTreatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS)
Eli Lilly Company 2010-2013 RADAR Randomized Partially-Blinded Multi-Center Active-Controlled Dose-Ranging Study
Assessing the Safety Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome Regado Bioscience Inc
2011-2013 A Phase IIa Multi-center Randomized Sponsor-unblinded Placebo-controlled Single Ascending Dose Study to Investigate the Safety Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Adults Taking Aspirin and a P2Y12 Platelet Inhibitor
AEGIS CSL Research Program BuildingLeadership 1991-1995 Director Interventional Cardiology Research University of Maryland Medical System 1998-2015 Director Sinai Center for Thrombosis Research 2001-2015 Director Cardiovascular Research Lifebridge Health 2002-2015 Director Therapeutics Research and Technology Development for the Cardiac Catheterization Program Sinai Hospital of Baltimore 2007-2015 Associate Chief for Research Department of Medicine Sinai Hospital of Baltimore 2015-current Director Interventional Cardiology and Cardiovascular Medicine Research INOVA Health 2015-Current Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute EDUCATIONAL ACTIVITIES
Curriculum Vitae Paul A Gurbel MD Page 19
Peer Reviewed Publications-Consensus Statements Expert Opinions 1 Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C
Rao AK The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 200531309-11
2 Hoekstra J Cohen M Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Saucedo JF Pollack CV Jr Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention-an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective report on a roundtable discussion Am J Emerg Med 200927720-8
3 Bonello L Tantry US Marcucci R Blindt R Angiolillo DJ Becker R Bhatt DL Cattaneo M Collet JP Cuisset T Gachet C Montalescot G Jennings LK Kereiakes D Sibbing D Trenk D Van Werkum JW Paganelli F Price MJ Waksman R Gurbel PA Working Group on High On Treatment Platelet Reactivity Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 201056919-33
4 Gurbel PA Tantry US Shuldiner AR Kereiakes DJ Genotyping one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 201056112-6
5 Gurbel PA Tantry US Antiplatelet therapy Clopidogrel-PPI interaction an ongoing controversy Nat Rev Cardiol 201187-8
6 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
7 Gurbel PA Nolin TD Tantry US Clopidogrel efficacy and cigarette smoking status JAMA 20123072495-6 8 Tantry US Bonello L Aradi D Price MJ Jeong YH Angiolillo DJ Stone GW Curzen N Geisler T Ten Berg J
Kirtane A Siller-Matula J Mahla E Becker RC Bhatt DL Waksman R Rao SV Alexopoulos D Marcucci R Reny JL Trenk D Sibbing D Gurbel PA Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding J Am Coll Cardiol 2013622261-73
9 Gurbel PA Tantry US Antiplatelet and anticoagulant agents in heart failure Current status and future perspectives JACC Heart Fail 201421-14
10 Gurbel PA Tantry US Antiplatelet therapy What have we learned from the ANTARCTIC trial Nat Rev Cardiol 201613639-640
Invited Review Articles 1 Gurbel PA Midwall JA Brodie BR Angioplasty and adjunctive intra-aortic balloon pump counterpulsation Current
clinical considerations Todays Therapy Trends 19951363-78 2 OrsquoConnor CM Gurbel PA Serebruany VL Depression and ischemic heart disease Am Heart J 200014063-69 3 Gurbel PA Serebruany VL Oral IIbIIIa inhibitors From initial promise to clinical failures J Thromb and
Thrombolysis 200010217-20 4 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Atar D Serebruany VL Platelets and
Thrombolysis Cooperation or Contrariety Heart Drug 20011281-290 5 McKenzie ME Gurbel PA The potential of monoclonal antibodies to reduce reperfusion injury in myocardial
infarction BioDrugs 200115395-404 6 Gurbel PA Bliden KP Hayes K Tantry U Platelet activation in myocardial ischemic syndromes Expert Rev of
Cardiovasc Ther 20052535-45 7 Tantry US Bliden KP Gurbel PA Resistance to antiplatelet drugs Current status and future research Expert
Opin Pharmacother 200562027-45 8 Gurbel PA Lau WC Bliden KP Tantry US Clopidogrel resistance Implications for coronary stenting Curr Pharm
Des 2006121261-9 9 Gurbel PA Tantry US Drug insight Clopidogrel non-responsiveness Nature ClinPract Cardiovasc Med
20063387-95 10 Gurbel PA Tantry US Aspirin and Clopidogrel Resistance Considerations and management J Interv Cardiol
200619439-48 11 Lau WC Gurbel PA Antiplatelet drug resistance and drug-drug interactions Role of cytochrome P450 3A4
Pharm Res 2006232691-708 12 Wiviott SD Tantry US Gurbel PA Clinical applications of antiplatelet therapy Rev Cardiovasc Med 20067
Curriculum Vitae Paul A Gurbel MD Page 20
130-46 13 Tantry US Bliden KP Gurbel PA Prasugrel Expert Opin Investig Drugs 2006151627-33 14 Gurbel PA Tantry US Clopidogrel Resistance Thromb Res 2007120311-21 15 Tantry US Etherington A Bliden KP Gurbel PA Antiplatelet therapy Current strategies and future trends Future
Cardiology 20072343-366 16 Gurbel PA Tantry US The relationship of platelet reactivity to the occurrence of post-stenting ischemic events
emergence of a new cardiovascular risk factor Rev Cardiovasc Med 2006Suppl 4S20-8 17 Tantry US Bliden KP Gurbel PA AZD6140 Expert Opin Investig Drugs 200716225-9 18 Gurbel PA Tantry US Stent thrombosis role of compliance and non-responsiveness to antiplatelet therapy Rev
Cardiovasc Med 20078S19-S26 19 Gurbel PA Kandzari DE Stent thrombosis associated with first-generation drug-eluting stents issues with
antiplatelet therapy Neth Heart J 200715148-50 20 Gurbel PA Tantry US The role of clopidogrel in cardiovascular diseases Pol Arch Med Wewn 2007117207-9 21 Gurbel PA DiChiara J Tantry US Antiplatelet therapy after implantation of drug-eluting stents duration
resistance alternatives and management of surgical patients Am J Cardiol 200710018M-25M 22 Gurbel PA Becker R Mann KG Steinhubl SR Michelson AD Platelet function monitoring in patients with
coronary artery disease J Am Coll Cardiol 2007501822-34 23 Gurbel PA Tantry US Prasugrel a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig
Drugs 20089324-36 24 Gurbel PA Bilden KP Tantry US Diagnostics for aspirin resistance Mol Diagn Ther 20081255-6 25 Gurbel PA Antonino MJ Tantry US Antiplatelet treatment of cardiovascular disease a translational research
perspective Pol Arch Med Wewn 2008118289-97 26 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831I36 27 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention Clin Cardiol 200831I28-I35
28 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches Clin Cardiol 200831I21-I27
29 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention Clin Cardiol 200831I17-I20
30 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Assessing the Current Role of Platelet Function Testing Clin Cardiol 200831I10-I16
31 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831136
32 Keriakes DJ Gurbel PA Periprocedural platelet function in percutaneous coronary intervention JACC Cardiovasc Interv 2008suppl 1111ndash121
33 Gurbel PA Tantry US The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome J Interv Cardiol 200821Suppl 1S10-7
34 Gurbel PA Tantry US Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 20091122-322
35 Gurbel PA Aspirin scope and limitations Br J Cardiol 200917 (Suppl 1)S8-S9 36 Cohen M Hoekstra J Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Pollack CV Jr
Saucedo JF Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion J Interv Cardiol 200821283-99
37 Angiolillo DJ Bhatt DL Gurbel PA Jennings LK Advances in antiplatelet therapy agents in clinical development Am J Cardiol 2009103(3 Suppl)40A-51A
38 Gurbel PA Mahla E Antonino MJ Tantry US Response variability and the role of platelet function testing J Invasive Cardiol 200921172-8
39 Gurbel PA Antonino MJ Tantry US Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug MetabToxicol Expert Opin Drug Metab Toxicol 20095989-1004
40 Gurbel PA Tantry US Antiplatelet resistance- Fact or Myth Am Hosp J 2009750-57 41 Gurbel PA Mahla E Tantry US Aspirin resistance Prog Cardiovasc Dis 200952141-52 42 Tantry US Gurbel PA Platelet monitoring for PCI Is it really necessary Haemostaseologie 200929 368-75 43 Gurbel PA Aspirin-scope and limitations Br J Cardiol 200917(Suppl 1)S8-S9
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 18
2004-2005 A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions ENDEAVOR IV Medtronic
2004-2005 A Randomized Trial to evaluate the relative protection against POST-PCI microvasculat obstruction among antiplatelet and anti-thrombotic medications (TIMI-30) TIMI group
2004-2006 A Double-blind Double-dummy Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI 33 AstraZeneca Lp
2005-2006 Strategy To Reduce Atherosclerosis Development Involving Administration of Rimonabant - The Intravascular Ultrasound Study (STRADIVARIUS) EFC5827 Sanofi Synthelabo Research
2006 A Multicenter Randomized Double-Blind Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (TRASM-PCI) Schering Plough
2006-2007 A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel -SWAP (SWitching Anti Platelet study) Eli Lilly amp Company and Sankyo Company Limited
2006-2007 A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2008-2010 A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary InterventionTIMI-38 Eli Lilly Company Daiichi
2009-2010 A Randomized Double-Blind Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128 a Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Interventions (INNOVATE-PCI) Portola Pharmaceuticals
2010-2012 TReatment with ADPreceptor iNhibitorS Longitudinal Assessment ofTreatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS)
Eli Lilly Company 2010-2013 RADAR Randomized Partially-Blinded Multi-Center Active-Controlled Dose-Ranging Study
Assessing the Safety Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome Regado Bioscience Inc
2011-2013 A Phase IIa Multi-center Randomized Sponsor-unblinded Placebo-controlled Single Ascending Dose Study to Investigate the Safety Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Adults Taking Aspirin and a P2Y12 Platelet Inhibitor
AEGIS CSL Research Program BuildingLeadership 1991-1995 Director Interventional Cardiology Research University of Maryland Medical System 1998-2015 Director Sinai Center for Thrombosis Research 2001-2015 Director Cardiovascular Research Lifebridge Health 2002-2015 Director Therapeutics Research and Technology Development for the Cardiac Catheterization Program Sinai Hospital of Baltimore 2007-2015 Associate Chief for Research Department of Medicine Sinai Hospital of Baltimore 2015-current Director Interventional Cardiology and Cardiovascular Medicine Research INOVA Health 2015-Current Director Inova Center for Thrombosis Research and Drug Development Inova Heart and Vascular Institute EDUCATIONAL ACTIVITIES
Curriculum Vitae Paul A Gurbel MD Page 19
Peer Reviewed Publications-Consensus Statements Expert Opinions 1 Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C
Rao AK The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 200531309-11
2 Hoekstra J Cohen M Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Saucedo JF Pollack CV Jr Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention-an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective report on a roundtable discussion Am J Emerg Med 200927720-8
3 Bonello L Tantry US Marcucci R Blindt R Angiolillo DJ Becker R Bhatt DL Cattaneo M Collet JP Cuisset T Gachet C Montalescot G Jennings LK Kereiakes D Sibbing D Trenk D Van Werkum JW Paganelli F Price MJ Waksman R Gurbel PA Working Group on High On Treatment Platelet Reactivity Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 201056919-33
4 Gurbel PA Tantry US Shuldiner AR Kereiakes DJ Genotyping one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 201056112-6
5 Gurbel PA Tantry US Antiplatelet therapy Clopidogrel-PPI interaction an ongoing controversy Nat Rev Cardiol 201187-8
6 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
7 Gurbel PA Nolin TD Tantry US Clopidogrel efficacy and cigarette smoking status JAMA 20123072495-6 8 Tantry US Bonello L Aradi D Price MJ Jeong YH Angiolillo DJ Stone GW Curzen N Geisler T Ten Berg J
Kirtane A Siller-Matula J Mahla E Becker RC Bhatt DL Waksman R Rao SV Alexopoulos D Marcucci R Reny JL Trenk D Sibbing D Gurbel PA Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding J Am Coll Cardiol 2013622261-73
9 Gurbel PA Tantry US Antiplatelet and anticoagulant agents in heart failure Current status and future perspectives JACC Heart Fail 201421-14
10 Gurbel PA Tantry US Antiplatelet therapy What have we learned from the ANTARCTIC trial Nat Rev Cardiol 201613639-640
Invited Review Articles 1 Gurbel PA Midwall JA Brodie BR Angioplasty and adjunctive intra-aortic balloon pump counterpulsation Current
clinical considerations Todays Therapy Trends 19951363-78 2 OrsquoConnor CM Gurbel PA Serebruany VL Depression and ischemic heart disease Am Heart J 200014063-69 3 Gurbel PA Serebruany VL Oral IIbIIIa inhibitors From initial promise to clinical failures J Thromb and
Thrombolysis 200010217-20 4 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Atar D Serebruany VL Platelets and
Thrombolysis Cooperation or Contrariety Heart Drug 20011281-290 5 McKenzie ME Gurbel PA The potential of monoclonal antibodies to reduce reperfusion injury in myocardial
infarction BioDrugs 200115395-404 6 Gurbel PA Bliden KP Hayes K Tantry U Platelet activation in myocardial ischemic syndromes Expert Rev of
Cardiovasc Ther 20052535-45 7 Tantry US Bliden KP Gurbel PA Resistance to antiplatelet drugs Current status and future research Expert
Opin Pharmacother 200562027-45 8 Gurbel PA Lau WC Bliden KP Tantry US Clopidogrel resistance Implications for coronary stenting Curr Pharm
Des 2006121261-9 9 Gurbel PA Tantry US Drug insight Clopidogrel non-responsiveness Nature ClinPract Cardiovasc Med
20063387-95 10 Gurbel PA Tantry US Aspirin and Clopidogrel Resistance Considerations and management J Interv Cardiol
200619439-48 11 Lau WC Gurbel PA Antiplatelet drug resistance and drug-drug interactions Role of cytochrome P450 3A4
Pharm Res 2006232691-708 12 Wiviott SD Tantry US Gurbel PA Clinical applications of antiplatelet therapy Rev Cardiovasc Med 20067
Curriculum Vitae Paul A Gurbel MD Page 20
130-46 13 Tantry US Bliden KP Gurbel PA Prasugrel Expert Opin Investig Drugs 2006151627-33 14 Gurbel PA Tantry US Clopidogrel Resistance Thromb Res 2007120311-21 15 Tantry US Etherington A Bliden KP Gurbel PA Antiplatelet therapy Current strategies and future trends Future
Cardiology 20072343-366 16 Gurbel PA Tantry US The relationship of platelet reactivity to the occurrence of post-stenting ischemic events
emergence of a new cardiovascular risk factor Rev Cardiovasc Med 2006Suppl 4S20-8 17 Tantry US Bliden KP Gurbel PA AZD6140 Expert Opin Investig Drugs 200716225-9 18 Gurbel PA Tantry US Stent thrombosis role of compliance and non-responsiveness to antiplatelet therapy Rev
Cardiovasc Med 20078S19-S26 19 Gurbel PA Kandzari DE Stent thrombosis associated with first-generation drug-eluting stents issues with
antiplatelet therapy Neth Heart J 200715148-50 20 Gurbel PA Tantry US The role of clopidogrel in cardiovascular diseases Pol Arch Med Wewn 2007117207-9 21 Gurbel PA DiChiara J Tantry US Antiplatelet therapy after implantation of drug-eluting stents duration
resistance alternatives and management of surgical patients Am J Cardiol 200710018M-25M 22 Gurbel PA Becker R Mann KG Steinhubl SR Michelson AD Platelet function monitoring in patients with
coronary artery disease J Am Coll Cardiol 2007501822-34 23 Gurbel PA Tantry US Prasugrel a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig
Drugs 20089324-36 24 Gurbel PA Bilden KP Tantry US Diagnostics for aspirin resistance Mol Diagn Ther 20081255-6 25 Gurbel PA Antonino MJ Tantry US Antiplatelet treatment of cardiovascular disease a translational research
perspective Pol Arch Med Wewn 2008118289-97 26 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831I36 27 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention Clin Cardiol 200831I28-I35
28 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches Clin Cardiol 200831I21-I27
29 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention Clin Cardiol 200831I17-I20
30 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Assessing the Current Role of Platelet Function Testing Clin Cardiol 200831I10-I16
31 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831136
32 Keriakes DJ Gurbel PA Periprocedural platelet function in percutaneous coronary intervention JACC Cardiovasc Interv 2008suppl 1111ndash121
33 Gurbel PA Tantry US The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome J Interv Cardiol 200821Suppl 1S10-7
34 Gurbel PA Tantry US Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 20091122-322
35 Gurbel PA Aspirin scope and limitations Br J Cardiol 200917 (Suppl 1)S8-S9 36 Cohen M Hoekstra J Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Pollack CV Jr
Saucedo JF Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion J Interv Cardiol 200821283-99
37 Angiolillo DJ Bhatt DL Gurbel PA Jennings LK Advances in antiplatelet therapy agents in clinical development Am J Cardiol 2009103(3 Suppl)40A-51A
38 Gurbel PA Mahla E Antonino MJ Tantry US Response variability and the role of platelet function testing J Invasive Cardiol 200921172-8
39 Gurbel PA Antonino MJ Tantry US Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug MetabToxicol Expert Opin Drug Metab Toxicol 20095989-1004
40 Gurbel PA Tantry US Antiplatelet resistance- Fact or Myth Am Hosp J 2009750-57 41 Gurbel PA Mahla E Tantry US Aspirin resistance Prog Cardiovasc Dis 200952141-52 42 Tantry US Gurbel PA Platelet monitoring for PCI Is it really necessary Haemostaseologie 200929 368-75 43 Gurbel PA Aspirin-scope and limitations Br J Cardiol 200917(Suppl 1)S8-S9
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 19
Peer Reviewed Publications-Consensus Statements Expert Opinions 1 Michelson AD Cattaneo M Eikelboom JW Gurbel P Kottke-Marchant K Kunicki TJ Pulcinelli FM Cerletti C
Rao AK The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance Position paper of the Working Group on Aspirin Resistance J Thromb Haemost 200531309-11
2 Hoekstra J Cohen M Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Saucedo JF Pollack CV Jr Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention-an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective report on a roundtable discussion Am J Emerg Med 200927720-8
3 Bonello L Tantry US Marcucci R Blindt R Angiolillo DJ Becker R Bhatt DL Cattaneo M Collet JP Cuisset T Gachet C Montalescot G Jennings LK Kereiakes D Sibbing D Trenk D Van Werkum JW Paganelli F Price MJ Waksman R Gurbel PA Working Group on High On Treatment Platelet Reactivity Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 201056919-33
4 Gurbel PA Tantry US Shuldiner AR Kereiakes DJ Genotyping one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 201056112-6
5 Gurbel PA Tantry US Antiplatelet therapy Clopidogrel-PPI interaction an ongoing controversy Nat Rev Cardiol 201187-8
6 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
7 Gurbel PA Nolin TD Tantry US Clopidogrel efficacy and cigarette smoking status JAMA 20123072495-6 8 Tantry US Bonello L Aradi D Price MJ Jeong YH Angiolillo DJ Stone GW Curzen N Geisler T Ten Berg J
Kirtane A Siller-Matula J Mahla E Becker RC Bhatt DL Waksman R Rao SV Alexopoulos D Marcucci R Reny JL Trenk D Sibbing D Gurbel PA Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding J Am Coll Cardiol 2013622261-73
9 Gurbel PA Tantry US Antiplatelet and anticoagulant agents in heart failure Current status and future perspectives JACC Heart Fail 201421-14
10 Gurbel PA Tantry US Antiplatelet therapy What have we learned from the ANTARCTIC trial Nat Rev Cardiol 201613639-640
Invited Review Articles 1 Gurbel PA Midwall JA Brodie BR Angioplasty and adjunctive intra-aortic balloon pump counterpulsation Current
clinical considerations Todays Therapy Trends 19951363-78 2 OrsquoConnor CM Gurbel PA Serebruany VL Depression and ischemic heart disease Am Heart J 200014063-69 3 Gurbel PA Serebruany VL Oral IIbIIIa inhibitors From initial promise to clinical failures J Thromb and
Thrombolysis 200010217-20 4 Callahan KP Malinin AI Gurbel PA Alexander JH Granger CB Atar D Serebruany VL Platelets and
Thrombolysis Cooperation or Contrariety Heart Drug 20011281-290 5 McKenzie ME Gurbel PA The potential of monoclonal antibodies to reduce reperfusion injury in myocardial
infarction BioDrugs 200115395-404 6 Gurbel PA Bliden KP Hayes K Tantry U Platelet activation in myocardial ischemic syndromes Expert Rev of
Cardiovasc Ther 20052535-45 7 Tantry US Bliden KP Gurbel PA Resistance to antiplatelet drugs Current status and future research Expert
Opin Pharmacother 200562027-45 8 Gurbel PA Lau WC Bliden KP Tantry US Clopidogrel resistance Implications for coronary stenting Curr Pharm
Des 2006121261-9 9 Gurbel PA Tantry US Drug insight Clopidogrel non-responsiveness Nature ClinPract Cardiovasc Med
20063387-95 10 Gurbel PA Tantry US Aspirin and Clopidogrel Resistance Considerations and management J Interv Cardiol
200619439-48 11 Lau WC Gurbel PA Antiplatelet drug resistance and drug-drug interactions Role of cytochrome P450 3A4
Pharm Res 2006232691-708 12 Wiviott SD Tantry US Gurbel PA Clinical applications of antiplatelet therapy Rev Cardiovasc Med 20067
Curriculum Vitae Paul A Gurbel MD Page 20
130-46 13 Tantry US Bliden KP Gurbel PA Prasugrel Expert Opin Investig Drugs 2006151627-33 14 Gurbel PA Tantry US Clopidogrel Resistance Thromb Res 2007120311-21 15 Tantry US Etherington A Bliden KP Gurbel PA Antiplatelet therapy Current strategies and future trends Future
Cardiology 20072343-366 16 Gurbel PA Tantry US The relationship of platelet reactivity to the occurrence of post-stenting ischemic events
emergence of a new cardiovascular risk factor Rev Cardiovasc Med 2006Suppl 4S20-8 17 Tantry US Bliden KP Gurbel PA AZD6140 Expert Opin Investig Drugs 200716225-9 18 Gurbel PA Tantry US Stent thrombosis role of compliance and non-responsiveness to antiplatelet therapy Rev
Cardiovasc Med 20078S19-S26 19 Gurbel PA Kandzari DE Stent thrombosis associated with first-generation drug-eluting stents issues with
antiplatelet therapy Neth Heart J 200715148-50 20 Gurbel PA Tantry US The role of clopidogrel in cardiovascular diseases Pol Arch Med Wewn 2007117207-9 21 Gurbel PA DiChiara J Tantry US Antiplatelet therapy after implantation of drug-eluting stents duration
resistance alternatives and management of surgical patients Am J Cardiol 200710018M-25M 22 Gurbel PA Becker R Mann KG Steinhubl SR Michelson AD Platelet function monitoring in patients with
coronary artery disease J Am Coll Cardiol 2007501822-34 23 Gurbel PA Tantry US Prasugrel a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig
Drugs 20089324-36 24 Gurbel PA Bilden KP Tantry US Diagnostics for aspirin resistance Mol Diagn Ther 20081255-6 25 Gurbel PA Antonino MJ Tantry US Antiplatelet treatment of cardiovascular disease a translational research
perspective Pol Arch Med Wewn 2008118289-97 26 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831I36 27 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention Clin Cardiol 200831I28-I35
28 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches Clin Cardiol 200831I21-I27
29 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention Clin Cardiol 200831I17-I20
30 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Assessing the Current Role of Platelet Function Testing Clin Cardiol 200831I10-I16
31 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831136
32 Keriakes DJ Gurbel PA Periprocedural platelet function in percutaneous coronary intervention JACC Cardiovasc Interv 2008suppl 1111ndash121
33 Gurbel PA Tantry US The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome J Interv Cardiol 200821Suppl 1S10-7
34 Gurbel PA Tantry US Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 20091122-322
35 Gurbel PA Aspirin scope and limitations Br J Cardiol 200917 (Suppl 1)S8-S9 36 Cohen M Hoekstra J Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Pollack CV Jr
Saucedo JF Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion J Interv Cardiol 200821283-99
37 Angiolillo DJ Bhatt DL Gurbel PA Jennings LK Advances in antiplatelet therapy agents in clinical development Am J Cardiol 2009103(3 Suppl)40A-51A
38 Gurbel PA Mahla E Antonino MJ Tantry US Response variability and the role of platelet function testing J Invasive Cardiol 200921172-8
39 Gurbel PA Antonino MJ Tantry US Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug MetabToxicol Expert Opin Drug Metab Toxicol 20095989-1004
40 Gurbel PA Tantry US Antiplatelet resistance- Fact or Myth Am Hosp J 2009750-57 41 Gurbel PA Mahla E Tantry US Aspirin resistance Prog Cardiovasc Dis 200952141-52 42 Tantry US Gurbel PA Platelet monitoring for PCI Is it really necessary Haemostaseologie 200929 368-75 43 Gurbel PA Aspirin-scope and limitations Br J Cardiol 200917(Suppl 1)S8-S9
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 20
130-46 13 Tantry US Bliden KP Gurbel PA Prasugrel Expert Opin Investig Drugs 2006151627-33 14 Gurbel PA Tantry US Clopidogrel Resistance Thromb Res 2007120311-21 15 Tantry US Etherington A Bliden KP Gurbel PA Antiplatelet therapy Current strategies and future trends Future
Cardiology 20072343-366 16 Gurbel PA Tantry US The relationship of platelet reactivity to the occurrence of post-stenting ischemic events
emergence of a new cardiovascular risk factor Rev Cardiovasc Med 2006Suppl 4S20-8 17 Tantry US Bliden KP Gurbel PA AZD6140 Expert Opin Investig Drugs 200716225-9 18 Gurbel PA Tantry US Stent thrombosis role of compliance and non-responsiveness to antiplatelet therapy Rev
Cardiovasc Med 20078S19-S26 19 Gurbel PA Kandzari DE Stent thrombosis associated with first-generation drug-eluting stents issues with
antiplatelet therapy Neth Heart J 200715148-50 20 Gurbel PA Tantry US The role of clopidogrel in cardiovascular diseases Pol Arch Med Wewn 2007117207-9 21 Gurbel PA DiChiara J Tantry US Antiplatelet therapy after implantation of drug-eluting stents duration
resistance alternatives and management of surgical patients Am J Cardiol 200710018M-25M 22 Gurbel PA Becker R Mann KG Steinhubl SR Michelson AD Platelet function monitoring in patients with
coronary artery disease J Am Coll Cardiol 2007501822-34 23 Gurbel PA Tantry US Prasugrel a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig
Drugs 20089324-36 24 Gurbel PA Bilden KP Tantry US Diagnostics for aspirin resistance Mol Diagn Ther 20081255-6 25 Gurbel PA Antonino MJ Tantry US Antiplatelet treatment of cardiovascular disease a translational research
perspective Pol Arch Med Wewn 2008118289-97 26 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831I36 27 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD
Peterson E Wiviott S Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention Clin Cardiol 200831I28-I35
28 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches Clin Cardiol 200831I21-I27
29 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention Clin Cardiol 200831I17-I20
30 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Assessing the Current Role of Platelet Function Testing Clin Cardiol 200831I10-I16
31 Braunwald E Angiolillo D Bates E Berger PB Bhatt D Cannon CP Furman MI Gurbel P Michelson AD Peterson E Wiviott S Antiplatelet Therapy and Platelet Function Testing Clin Cardiol 200831136
32 Keriakes DJ Gurbel PA Periprocedural platelet function in percutaneous coronary intervention JACC Cardiovasc Interv 2008suppl 1111ndash121
33 Gurbel PA Tantry US The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome J Interv Cardiol 200821Suppl 1S10-7
34 Gurbel PA Tantry US Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease Curr Treat Options Cardiovasc Med 20091122-322
35 Gurbel PA Aspirin scope and limitations Br J Cardiol 200917 (Suppl 1)S8-S9 36 Cohen M Hoekstra J Giugliano R Granger CB Gurbel PA Hollander JE Manoukian SV Pollack CV Jr
Saucedo JF Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion J Interv Cardiol 200821283-99
37 Angiolillo DJ Bhatt DL Gurbel PA Jennings LK Advances in antiplatelet therapy agents in clinical development Am J Cardiol 2009103(3 Suppl)40A-51A
38 Gurbel PA Mahla E Antonino MJ Tantry US Response variability and the role of platelet function testing J Invasive Cardiol 200921172-8
39 Gurbel PA Antonino MJ Tantry US Recent developments in clopidogrel pharmacology and their relation to clinical outcomes Expert Opin Drug MetabToxicol Expert Opin Drug Metab Toxicol 20095989-1004
40 Gurbel PA Tantry US Antiplatelet resistance- Fact or Myth Am Hosp J 2009750-57 41 Gurbel PA Mahla E Tantry US Aspirin resistance Prog Cardiovasc Dis 200952141-52 42 Tantry US Gurbel PA Platelet monitoring for PCI Is it really necessary Haemostaseologie 200929 368-75 43 Gurbel PA Aspirin-scope and limitations Br J Cardiol 200917(Suppl 1)S8-S9
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 21
44 Gurbel PA and Tantry US Combination antithrombotic therapies Circulation 2010121569-83 45 Becker RC MD Gurbel PA Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics A
foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies Thromb Haemost 2010103535-44
46 Gurbel PA Kereiakes DJ Tantry US Ticagrelor for the treatment of arterial thrombosis Expert Opin Pharmacother 2010112251-9
47 Mahla E Metzler H Tantry US Gurbel PA Controversies in oral antiplatelet therapy in patient undergoing aortocoronary bypass surgery Ann Thorac Surg 2010901040-51
48 Tantry US Kereiakes DJ Gurbel PA Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations JACC Cardiovasc Interv 20114365-80
49 Gurbel PA Mahla E Tantry US Peri-operative platelet function testing The potential for reducing ischaemic and bleeding risks Thromb Haemost 2011106248-52
50 Gurbel PA Tantry US Kereiakes DJ Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Saf 20102233-40
51 Gurbel PA Jeong YH Tantry US Vorapaxar a novel protease-activated receptor-1 inhibitor Expert Opin Investig Drugs 2011201445-53
52 Bergmeijer TO1 van Werkum JW Tantry US Gurbel PA ten Berg JM Platelet Function Testing in Clinical Practice ndash Experience and Views from Europe and the US European Cardiology 201171-11
53 Tantry US Gurbel PA Current options in oral antiplatelet strategies during percutaneous coronary interventions Rev Cardiovasc Med 201112 Suppl 1S4-13
54 Gurbel PA Tantry US Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 20121251276-87 discussion 1287
55 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
56 Tantry US Budaj A Gurbel PA Antiplatelet therapy beyond 2012 role of personalized medicine Pol Arch Med Wewn 2012122298-305
57 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12receptor inhibitors Expert Rev Cardiovascular Ther 2012 (in press)
58 Gurbel PA Jeong YH Tantry US Personalzied antiplatelet therapyState of the art JRSM Cardiovasc Disease 2012 (in press)
59 Jeong YH Tantry US Gurbel PA Importance of potent P2Y(12) receptor blockade in acute myocardial infarction focus on prasugrel Expert Opin Pharmacother 2012131771-96
60 Tantry US Navarese EP Kubica J Jeong Y-H Gurbel PA Ticagrelor in the treatment of coronary artery disease patients Clin Pract 20129373ndash390
61 Gurbel PA Jeong YH Tantry US Personalized antiplatelet therapy state of the art JRSM Cardiovasc Dis 2012 Sep 241(6)
62 Antonino MJ Jeong YH Tantry US Bliden KP Gurbel PA Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors Expert Rev Cardiovasc Ther 2012101011-22
63 Dahlen JR Price MJ Parise H Gurbel PA Evaluating the clinical usefulness of platelet function testing Considerations for the proper application and interpretation of performance measures Thromb Haemost 2012 Dec 20109(2) [Epub ahead of print]
64 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
65 Swiger KJ Yousuf O Bliden KP Tantry US Gurbel PA Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 201315361
66 Tantry US Jeong YH Navarese EP Kubica J Gurbel PA Influence of genetic polymorphisms on platelet function response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 201311447-62
67 Tantry US Gurbel PA Antiplatelet Drug Resistance and Variability in Response The Role of Antiplatelet Therapy Monitoring Curr Pharm Des 2012 Dec 26 [Epub ahead of print]
68 Curzen N Gurbel PA Myat A Bhatt DL Redwood SR What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention Lancet 2013382633-43
69 Doraiswamy VA Slepian MJ Gesheff MG Tantry US Gurbel PA Potential role of oral anticoagulants in the treatment of patients with coronary artery disease focus on dabigatran Expert Rev Cardiovasc Ther 2013 Aug 22 [Epub ahead of print]
70 Tantry US Gurbel PA The next 10 years in personalized medicine in cardiology Expert Rev Cardiovasc Ther 2013 11933-5 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GY
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 22
71 Myat A Ahmad Y Haldar S Tantry US Redwood SR Gurbel PA Lip GYIs bleeding a necessary evil The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation Expert Rev Cardiovasc Ther 2013111029-49
72 Kalra K Franzese CJ Gesheff MG Lev EI Pandya S Bliden KP Tantry US Gurbel PA Pharmacology of antiplatelet agents Curr Atheroscler Rep 201315371
73 Tantry US Mahla E Gesheff MG Gurbel PA Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease an historical account Expert Rev Cardiovasc Ther 2013 111547-56
74 Bliden KP Brener M Gesheff MG Franzese CJ Tabrizchi A Tantry U Gurbel PA PA tablets investigational compounds combining aspirin and omeprazole for cardioprotection Future Cardiol 2013 Nov9(6)785-97 doi 102217fca1367
75 Kubica J Kozinski M Navarese EP Tantry U Kubica A Siller-Matula JM Jeong YH Fabiszak T Andruszkiewicz A Gurbel PA Cangrelor an emerging therapeutic option for patients with coronary artery diseaseCurr Med Res Opin 201430813-28
76 Gurbel PA Rafeedheen R Tantry US Personalized Antiplatelet Therapy Rev Esp Cardiol 201467480-487 77 Gurbel PA Kuliopulos A Tantry U G-ProteinndashCoupled Receptors Signaling Pathways in New Antiplatelet
Drug Development Atheroscl Thromb Vasc Biol 2015 online ISSN1524-4636 78 Liu F Tantry US Gurbel PA P2Y12 receptor inhibitors for secondary prevention of ischemic stroke Expert Opin
Pharmacother 2015161149-65 79 Rafeedheen R Bliden KP Liu F Tantry US Gurbel PA Novel antiplatelet agents in cardiovascular medicine
Curr Treat Options Cardiovasc Med 201517383 80 Jung JH Tantry US Gurbel PA Jeong YH Current antiplatelet treatment strategy in patients with diabetes
mellitus Diabetes Metab J 2015 3995-113 81 Gurbel PA Navarese EP Tantry US What is the best anticoagulant therapy during primary percutaneous
coronary intervention for acute myocardial infarction Pol Arch Med Wewn 2015125461-70 82 Bliden KP Patrick J Pennell AT Tantry US Gurbel PA Drug delivery and therapeutic impact of extended-
release acetylsalicylic acid Future Cardiol 2015 Sep 10 [Epub ahead of print] 83 Tantry US Liu F Chen G Gurbel PA Vorapaxar in the secondary prevention of atherothrombosis Expert
Rev Cardiovasc Ther 2015131293-305 84 Bliden KP Tantry US Chaudhary R Byun S Gurbel PA Extended-release acetylsalicylic acid for secondary
prevention of stroke and cardiovascular events Expert Rev Cardiovasc Ther 2016 Jun 21-13 [Epub ahead of print]
85 Myat A Tantry US Kubica J Gurbel PA Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events Expert Rev Cardiovasc Ther 2016 Oct 14
86 Kim JH Shah P Tantry US Gurbel PA Coagulation Abnormalities in Heart Failure Pathophysiology and Therapeutic Implications Curr Heart Fail Rep 2016 Nov 4 [Epub ahead of print]
Editorials 1 Nair GV Gurbel PA OConnor CM Gattis WM Murugesan SR Serebruany VL Depression coronary events
platelet inhibition and serotonin reuptake inhibitors (editorial) Am J Cardiol 199984321-323 2 Gurbel PA Serebruany VL Adhesion molecules platelet activation and cardiovascular risk Am Heart J
2002143196-8 3 Gurbel PA Lau WC Tantry US Omeprazole a possible new candidate influencing the antiplatelet effect of
clopidogrel J Am Coll Cardiol 200851261-3 4 Mahla E Antonino MJ Tantry US Gurbel PA Point-of-care platelet function analysis Ready for prime time J
Am Coll Cardiol 200853857-9 5 Lau WC Gurbel PA The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009180
699-700 6 Gurbel PA Tantry US Shuldiner AR The worry about clopidogrel ldquononresponsivenessrdquo Identification and
treatment in the post-PCI patient JACC Interv 200921102-4 7 Gurbel PA Tantry US Delivery of GPIIbIIIa Inhibitor Therapy for PCIWhy Not Take the IC Highway Circulation
2010121739-41 8 Gurbel PA Tantry US Acceptance of high platelet reactivity as a risk factor now what do we do about it JACC
Cardiovasc Interv 201031008-10 9 Bliden KP Tantry US Dichiara J Gurbel PA Further ex vivo evidence supporting higher aspirin dosing in patients
with coronary artery disease and diabetes Circ Cardiovasc Interv 20114118-20 10 Gurbel PA Tantry US An initial experiment with personalized antiplatelet therapy the GRAVITAS trial JAMA
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 23
20113051136-7 11 Gurbel PA Jeong YH Tantry US Clopidogrel hypersensitivity give steroids and donrsquot stop the clopidogrel J
Am Coll Cardiol 2011581455-6 12 Jeong Y-H Tantry US Bliden KP Gurbel PA Cilostazol to overcome high on-treatment platelet reactivity in
Korean patients treated with clopidogrel and calcium channel blocker Circ J October 5 2011 (epub ahead of print)
13 Gurbel PA Ohman EM Jeong YH Tantry US Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 2012331187-9]
14 Tantry US Jeong YH Navarese EP Gurbel PA Platelet function measurement in elective percutaneous coronary intervention patients exploring the concept of a P2Y12 inhibitor therapeutic window JACC Cardiovasc Interv 20125290-2
15 Gurbel PA Tantry US Triple antithrombotic therapy with prasugrel in the stented patient concern for more bleeding J Am Coll Cardiol 2013 Mar 21 doipii S0735-1097(13)01110-8 101016jjacc201302032 [Epub ahead of print]
16 Gurbel PA Tantry US P2Y12 Receptor Blockade and Myocardial Perfusion JACC Cardiovasc Interv 20136684-6
17 Gurbel PA Mahla E Udaya US The Enigmatic Search for Optimal DAPT Duration Eur Heart J 201435951-4
18 Tantry US Jeong YH Gurbel PA The clopidogrel-statin interaction Circ J 2014 Feb 2578592-4 19 Mahla E Tantry US Gurbel PA Platelet Function Testing Before CABG is Recommended in the Guidelines
But Do We Have Enough Evidence J Interv Cardiol 201528233-5 20 Gurbel PA Tantry US Inhibited and uninhibited platelet deposition within a thrombus Does it depend on the
antiplatelet drug Arterioscler Thromb Vasc Biol 2015352081-2 21 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2015 Nov 3 pii ehv573 [Epub ahead of print] 22 Gurbel PA Tantry US A Bigger Look Into the ldquoTherapeutic Windowrdquo of Platelet Reactivity to ADP JACC
Cardiovasc Interv 201581988-9 23 Gurbel PA Tantry US Deciding about prolonged ticagrelor therapy in coronary clot formers an ongoing
dilemma Eur Heart J 2016371143-4 24 Tantry US Gurbel PA Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary
Artery Disease Circ Cardiovasc Interv 201710 pii e004881 25 Gurbel PA deFilippi CR Bliden KP Tantry US HIV infection ACS PCI and high platelet reactivity
ingredients for a perfect thrombotic storm Eur Heart J 2017 Jan 12 pii ehw630 doi 01093eurheartjehw630 [Epub ahead of print]
26 Gurbel PA Tantry US GEMINI-ACS-1 toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes Lancet 20173891773-1775
Case Reports 1 Haber R Oddone E Gurbel PA Stead WW Acute pulmonary decompensation due to amphotericin B in the
absence of granulocyte transfusions N Engl J Med 4996315836 2 Navetta F Barber M Gurbel PA Moreadith R Bernstein R Hlatky MA Coleman RE Bashore TM Myocardial
ischemia in constrictive pericarditis Am Heart J 19881161107 3 Gurbel PA Davidson CJ Smith JE Ohman EM Stack RS Selective infusion of thrombolytic therapy in the acute
myocardial infarct related coronary artery as an alterative to rescue percutaneous angioplasty Am J Cardiol 1990661021
4 Hurwitz JL Davidson CJ Gurbel PA Greenfield R Kassell JH Kanter RJ AV nodal blockade via selective AV nodal artery injection in a human Am Heart J 1990120986
5 Benitez RM Gurbel PA Chong H Rajasingh MC Penetrating atherosclerotic ulcer of the aortic arch resulting in extensive and fatal dissection Am Heart J 1995129821-3
6 Pimentel CX Schreiter SW Gurbel PA The use of the Trackerreg catheter as a guidewire support device in angioplasty of angulated and tortuous circumflex coronary arteries J Invas Cardiol 1995766-71
7 Gurbel PA Criado FJ Curnutte EA Patten P Secada-Lovio J Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent Cathet Cardiovasc Diagn 19984075-78
8 Serebruany VL Gurbel PA Shustov AR Dalesandro M Gumbs SI Grabletz BS Bahr RD Ohman EM Topol EJ Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction Stroke 199829235-238
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 24
9 Gurbel PA Austin B Cho PW Sequeira AJ Correction of a saphenous vein graft to coronary vein anastomosis resulting in a steal by selective coil induced occlusion to ldquoarterialize ldquo the native vein A case of mistaken identity caused by coronary venous atherosclerosis Catheter Cardivasc Interven 200257541-4
Letters Correspondence 1 Gurbel PA Angioplasty and adjunctive intra-aortic balloon pump counter-pulsation Cardiac Assists 199571-4 2 Gurbel PA OrsquoConnor CM Zofenopril after anterior myocardial infarction N Engl J Med 19953321715 3 Gurbel PA Functional characteristics of a new perfusion balloon comparison with the Flowtrack 40 in a closed
chest swine Cathet Cardiovasc Diagn 199536377-378 4 Gurbel PA Serebruany VL Myths and realities of P-Selectin plasma levels in patients with acute myocardial
infarction Thromb Res 199788343-344 5 Gurbel PA Dalesandro MR Serebruany VL Reteplase but not alteplase affects early soluble PECAM-1 and P-
selectin release in patients with acute myocardial infarction Thromb Haemost 199880725 6 Gurbel PA McKenzie ME Serebruany VL Initial platelet activity may predict efficacy after chronic oral
glycoprotein IIbIIIa blockade Should we still consider uniform treatment regimens Thromb Res 200099105-7 7 Serebruany VL McKenzie ME Levine DJ Gurbel PA Monitoring platelet inhibition during chronic oral platelet
Glycoprotein IIb IIIa blockade Are we missing something Thromb Haemost 200083356-7 8 Cummings CC McKenzie ME Horowitz ED Oshrine BR Callahan KP Gurbel PA Serebruany VL Platelet
function and total length of intracoronary stents Is there a correlation Thromb Res 2001101105-7 9 Serebruany VL Malinin AI Bell CR Gurbel PA Heparin prevents Xylum clot signature analyzer to detect platelet
inhibition with clopidogrel during coronary stenting Thromb Res 200110295-7 10 Serebruany VL Malinin AI Callahan KP Gurbel PA Steinhubl SR Statins do not affect platelet inhibition with
clopidogrel during coronary stenting Atherosclerosis 2001159239-41 11 Gurbel PA Bliden KP Interpretation of platelet inhibition by clopidogrel and the effect of non-responders J
Thromb Haemost 200311318-19 12 Tantry US Bliden KP Gurbel PA What is the best predictor of thrombotic events Pre-treatment platelet
aggregation clopidogrel responsiveness or post-treatment aggregation Cathet Cardiovasc Interv 200566597-8 13 Gurbel P Singh D Balloon angioplasty and repeat stenting may have similar long-term outcomes for people with
in-stent restenosis Evid Based Cardiovasc Med 20061047-8 14 Gurbel PA Bliden KP Tantry US Evidence that pre-existent variability in platelet response to ADP accounts for
lsquoclopidogrel resistancersquo a rebuttal J Thromb Haemost 200751087-88 15 Gurbel PA Bliden KP Navickas I Cohen E Post - coronary intervention recurrent ischemia in the presence of
adequate platelet inhibition by dual antiplatelet therapy what are we overlooking J Thromb Haemost 20075 2300-1
16 Gurbel PA Tantry US Shuldiner AR Letter by Gurbel et al regarding article Cytochrome 2C1917 allelic variant platelet aggregation bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement Circulation 2010122e478
17 Jeong YH Bliden KP Tantry US Kim IS Park Y Gurbel PA We need further studies for the development of optimized antiplatelet therapy based on ethnicity J Am Coll Cardiol 201158198
18 Jeong YH Bliden KP Tantry US Gurbel PA Do East Asians have different hypercoagulable states compared with Western population Am Heart J 2011162e19-20
19 Navarese EP Kubica J Gurbel PA Sirolimus or paclitaxel drug eluting stent in left main disease The winner ishellip Int J Cardiol 2011 Sep 10 [Epub ahead of print]
20 Jeong YH Bliden KP Tantry US Gurbel PA The role of platelet function testing and genotyping in the stented patient treated with clopidogrel J Am Coll Cardiol 2011582701-2
21 Jeong YH Bliden KP Tantry US Gurbel PA High on-treatment platelet reactivity assessed by various platelet function tests Is the consensus-defined cutoff of VASP-P platelet reactivity index too low J Thromb Haemost 2011 Dec 25 doi 101111j1538-7836201104604x [Epub ahead of print]
22 Jeong YH Park Y Bliden KP Tantry US Gurbel PA High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype Heart 2011 Nov 10 [Epub ahead of print]
23 Navarese EP Gurbel PA Tantry U Obonska K Sukiennik A Kubica J Caution in interpreting the findings from small observational studies Int J Cardiol 2012 Jun 15 [Epub ahead of print]
24 Mahla E Suarez TA Bliden KP Sequeira AJ Cho P Sell J Fan J Antonino MJ Tantry US Gurbel PA Rehak P Metzler H Response to Letter Regarding Article Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 20125e48
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 25
25 Jeong Y-H Bliden KP Park Y Tantry US Gurbel PA Pharmacogenetic guidance for antiplatelet treatment Lancet 2012 380(9843)725 author reply 725-6
26 Gurbel PA Nolin T Tantry US Response to letter to the editor by Sibbing et al on clopidogrel efficacy and cigarette smoking status JAMA 2012 (in press)
27 Gurbel PA Bliden KP Tantry US Letter by Gurbel et al regarding article administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome Circ Cardiovasc Interv 20147273
28 Ahn JH Tantry US Kim KH Gurbel P Jeong YH PRASFIT-ACS Important Evidence Against a One-Guideline-Fits-All-Races Approach to Antiplatelet Therapy Circ J 2014 Sep 16 [Epub ahead of print]
29 Gurbel PA Kreutz RP Bliden KP Tantry US Platelet activation and pneumonia is soluble p-selectin the right marker J Am Coll Cardiol 2015 651492-3
30 Jeong YH Smith SC Jr Gurbel PA Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015 243731273-4
31 Gurbel PA Bliden KP Baker BA Dahlen J Tantry US Cigarette Smoking Clopidogrel Responsiveness and Hemoglobin Level JACC Cardiovasc Interv 201692364
32 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
33 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
34 Ahn J-H Gurbel PA Jeong Y-H Ticagrelor versus Clopidogrel in Peripheral Artery Disease N Engl J Med 20173761487-8
35 Gurbel PA Price MJ Dahlen JR Tantry US ANTARCTIC platelet function testing to adjust therapy Lancet 20173891193
Books Book Chapters Monographs 1 Fedeerici R Tengalia A Hillegass W Harrington R Gurbel PA Ohman EM Prevention and management of
abrupt closure In Strategic Approaches in Coronary Intervention Ellis SG Homes DR Jr (editors) Williams amp Wilkins Baltimore Maryland pp 626-645 1996
2 Gurbel PA Kologie F Serebruany VL Mergner WJ Myocardial cell injury during ischemia and reflow In Principles of Medical Biology Bittar EE Bittar N (editors) JAI Press Inc Greenwich Connecticut pp 127-166 1998
3 Herzog WR Schlossberg L Serebruany VL Gurbel PA Schneider AI Pou S Edgeworth N Rosen G Intracoronary delivery of a nitric oxide donor ameliorates myocardial stunning in a swine model In International Society for Heart Research pp 619-622 1994
4 Serebruany VL Ordonez JV Herzog WR Rohde M Mortensen SA Folkers K Gurbel PA Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51CD61) receptor expression In 9th
International Symposium n Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 37 1996 5 Serebruany VL Herzog WR Gurbel PA Rohde M Mortensen SA Folkers K Hemostatic changes after dietary
coenzyme Q10 supplementation in swine In 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q Ancona Italy p 54 1996
6 Gurbel PA Tantry US Resistance to antiplatelet drugs In Textbook of Interventional Cardiovascular Pharmacology Kipshidze NN Fareed J Moses JW and Serruys PW (editors) Informa Healthcare London England pp 139-154 2007
7 Gurbel PA Tantry US Non-COX-1-mediated effects of aspirin implications for aspirin responsiveness In A Published Proceedings From The Inflammation Aspirin Information Summit Libby P Knappertz V (editors) Bayer HealthCare Morristown New Jersey pp 53-56 2007
8 Gurbel PA Suarez T Tantry US Thienopyridine response variability and resistance In Antiplatelet Therapy In Ischemic Heart Disease Wiviott SD (editor) American Heart Association Dallas Texas pp 77-93 2008
9 Gurbel PA Tantry US Markers of platelet function In New Thrombolytic Agents in Thrombosis and Thrombolysis Freedman JE and Loscalzo J (editors) Informa Healthcare USA New York New York pp 409-428 2009
10 Gurbel PA DiChiara J Antonino M Tantry US CRP and its role in coronary heart disease New research developments In C-Reactive Protein Satoshi Nagasawa (editor) Nova Science Publications Inc Hauppauge New York pp 39-41 2009
11 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 8 Rao S (section editor) Elsevier New York New York 2012 and 2014
12 Gurbel PA Tantry US Monitoring Antiplatelet Therapy In Platelets Michelson AD (editor) Academic Press San Diego California 2012
13 Becker RC Lohrmann J Gurbel P Antiplatelet Therapy In Acute Coronary Syndromes A Companion to
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 26
Braunwaldrsquos Heart Disease Theroux P (editor) Elsevier Saunders Philadelphia Pennsylvania 2011 14 Gurbel PA and Tantry US Resistance to Antiplatelet Therapy In Development of Therapeutic Agents
Handbook Gad SC (editor) John Wiley and Sons Hoboken New Jersey 2012 15 Gurbel PA Kereiakes D Tantry US Thrombosis haemostasis and platelet biology InLandmark papers in
cardiovascular medicine Oxford University Press Oxford England 2012 16 Gurbel PA Tantry US Antiplatelet Drug Resistance and Variability in ResponseThe Role of Antiplatelet
Therapy Monitoring InAntiplatelet and Anticoagulation Therapy Current Cardiovascular Therapy Ferro A and Garcia DA (eds) Springer-Verlag London UK 2013
17 Gurbel PA Tantry US Huber K Fast Facts Acute Coronary Syndromes Health Press Oxford England 2014 18 Gurbel PA Tantry US Platelet Pathophysiology and its Role in Thrombosis In Antiplatelet Therapy in
Cardiovascular Disease Ed Ron Waksman Paul A Gurbel and Michael A Gaglia Jr Wiley Balckwell Oxford England 2014
19 Gurbel PA Tantry US Antiplatelet Therapy for NSTE ACS In ACCSAP 9 Rao S (section editor) Elsevier New York New York 2016
20 Gurbel PA Tantry US Interventional PharmacotherapiesOral Antiplatelet Agents Aspirin and P2Y12 Receptor Inhibitors In CATHSAP 5 Kirtane A (Section editor) Elsevier New York New York 2017
Peer-Reviewed Media Slide DecksVideosCD ROMsInternet (2005-present) 1 Gurbel PA Solutions to a Sticky Problem Overcoming Platelet Resistance in the Cath Lab North American
Center for Continuing Medical Education Med Reviews CME- certified program (video-slide deck) 7-16-2005 2 Mixed Thoughts on Generic Clopidogrel TheHeartorg (interview) August 15 2006 3 Gurbel PA Clopidogrel Resistance Brigham and Womenrsquos Grand Rounds
CardioTrendsorg CME-certified program (video-slide deck) March 2 2006 4 Diabetes Ups Aspirin Resistance MedPageToday (interview) March 27 2007 5 Gurbel PA Gibson CM Resistance to Antiplatelet Therapy A Field in Evolution Program 1 Resistance to
Antiplatelet Agents Where Are We Medical Education Solutions Group CME- certified program (video-slide deck) August 8 2007
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007 7 Gurbel PA Peterson ED New Insights into the Evolving Care and Management of Acute Coronary
Syndromes CME-certified program (slide deck) AKH Inc Orange Park FL and Medical Communications Media Wrightstown PA 2007
8 Kereaikes DJ Gurbel PA Post-ACS and Post-PCI Antiplatelet Therapy CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2008
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008 10 Smoking and Clopidogrel Response (interview) TheHeartorg August 5 2008 11 Prasugrel Bests Clopidogrel Without Bleeding Risk (interview) TheHeartorg March 5 2009 12 Differentiating antiplatelet therapy in ACS (video) TheHeartorg 3-14-2010 13 Stents Cheaper Than By-Pass in Low Risk Patients (interview) MedPageToday March 28 2009 14 Identifying Clopidogrel Non-Responders (interview) TheHeartorg March 28 2009 15 Evidence growing for personalized antiplatelet therapy (interview) TheHeartorg March 28 2009 16 Does point-of-care monitoring have a role today facts to consider Accelmed May 7 2009 17 Ticagrelor Data Promising TheHeartorg May 13 2009 18 Prasugrel also reduces cardiovascular events in patients who receive GP IIbIIIa inhibitors (interview)
TheHeartorg August 11 2009 19 Ticagrelor Shows More Rapid Powerful Platelet Inhibition Than Clopidogrel (interview) TCT MD -12309 20 Ticagrelor effects unraveled in new phase 2 trials TheHeartorg November 18 2009 21 Ticagrelor Bests Clopidogrel (interview) TheHeartorg March 10 2010 22 Reaction to FDA clopidogrel hyporesponder warning (interview) TheHeartorg March 16 2010 23 PPIclopidogrel and MI risk (interview) TheHeartorg April 27 2010 24 Personalizing antiplatelet therapy Could platelet-function tests help (interview) TheHeartorg May 14 2010 25 Clopidogrel genes and PPI (interview) TheHeartorg July 6 2010 26 Platelet responsiveness to antiplatelet therapy with Dr Paul Gurbel (interview) TheHeartorg Radio 8210 27 Platelet assay betters clopidogrel gene testing (interview) TheHeartorg August 11 2010 28 Publication on platelet assay vs clopidogrel gene testing (interview) TheHeartorg August 12 2010 29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 27
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010 31 Demystifying antiplatelet therapy in ACS Digging into P2Y12 inhibition Video program for ldquotheheartorgrdquo
Stockholm Sweden August 30 2010 32 Personalized antiplatelet therapynew antiplatelet therapies Video interview with Prof Frans Van de Werf
European Society of Cardiology Stockholm Sweden September 1 2010 33 Stone G Gurbel PA Cannon CP Bhatt DL Mahaffey K Van de Werf F Managing Atherothrombotic Disease
Preventing Adverse Outcomes With Optimal Use of Antiplatelet Therapies mdash Weighing the Evidence CME-certified program (video-slide deck) Theheartorg December 22 2010
34 Berger P Price M Gurbel PA Antiplatelet Therapy The Role of Platelet-Function Testing CME-certified program (video-slide deck) Theheartorg November 17 2010
35 Bhatt DL Gurbel PA Goldstein JL Gastrointestinal Endpoints and CV Risk A Multidisciplinary Panel CME-certified program (video-slide deck) Theheartorg December 10 2010
36 Gurbel PA Angiolillo Clarifying Oral Antiplatelet Therapy A Straightforward Approach For Todayrsquos Practitioners CME-certified program (slide deck) Potomac Center for Medical Education A Rockpointe Company Columbia MD 2011
37 Bhatt DL Becker R Verheugt F Kereiakes D Gurbel PA Price M Antiplatelet Therapy for Atherothrombotic Disease Unmasking the Data CME-certified program (video-slide deck) Theheartorg June 23 2011
38 No PPI attenuation of clopidogrel antiplatelet effects MI registry analysis TheHeartorg Jan 26 2011 39 FAST-MI registry on clopidogrel-PPI interaction (interview) TheHeartorg January 27 2011 40 GRAVITAS Published (interview) TheHeartorg March 16 2011 41 FDA Approval of Ticagrelor - Researchers Respond (interview) TheHeartorg July 21 2011 42 Clopidogrel hypersensitivity treated successfully with steroids TheHeartorg September 29 2011 43 Ohman EM Gurbel PA Steg GP PPIs Platelets and Outcomes A Data Drill Down CME-certified program
(video-slide deck) Theheartorg May 04 2011 44 Gurbel PA Reducing the Risk of Ischemic Events in Patients Undergoing PCI (slide deck) Peer-
directPVupdates 2011 45 Interview with Gaglia MA on the impact of GRAVITAS on clinical practice Cardiovascular research
technologies Washington DC Clinicaltrialresultsorg (video) 2-27-2011 46 Gurbel PA Relations of CYP2C19 genotype to on-treatment platelet reactivity Implications of GRAVITAS and
TRIGGER-PCI for personalized antiplatelet therapy in stable CAD Personalized antiplatelet therapy in pts with ACS ndash how can genetic testing and on-treatment platelet function testing contribute Videotape brief w Cardiovascular Clinician ACC Scientific Sessions 2011 New Orleans LA 3-1-2011
47 Gurbel PA Onsetoffset study results (Slides) wwwclinicaltrialresultsorgSlidesONSET-OFFSETppt 48 Gurbel PA CLEAR PLATELETS study results (video-Slide)
wwwclinicaltrialresultsorgCLEAR20PLATELETS-220AHAfinalppt 49 Gurbel PA The association of ciggerette smoking with enhanced platelet inhibition (Slides)
wwwclinicaltrialresultsorgSlidesSMOKING-GIBSONppt 50 Gurbel PA Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients (Slides)
wwwclinicaltrialresultsorgFilesdiabeteshtm 51 Gurbel PA Dr Paul Gurbel discusses clopidogrel response variability and resistance (video)
clinicaltrialresultsorgvideosVideo20Archive(2007)htm 52 Drs Gurbel and Gibson review the dose-related effects of aspirin on platelet function and the results observed
in the ASPECT Trial (video) wwwclinicaltrialresultsorgFilesaspirinhtm 53 Gurbel PA TRIP Thrombotic Risk Progression Paul A Gurbel MD (video) wwwclinicaltrialresultsorg 54 Gurbel PA Dr Paul Gurbel discusses antiplatelet resistance and newer antiplatelet therapies such as
Prasugrel (video) wwwclinicaltrialresultsorg 55 Gurbel PA Dr Paul Gurbel and Dr Stephen Wiviott Give an Update on the TRITON- TIMI 38 Trial (video)
httpclintrialresultsorgvideosAHA06_Gurbel_Wiviottwmv Lay Media (2006-present) Television
1 Docs Develop New Heart Attack Test University of Maryland WBAL TV January 23 2006 2 Blood-Thinner Plavix Works Harder in Smokers ABC NewsHealth August 4 2008 3 Sicky blood Do You Have It WBAL TVcom Baltimore Maryland November 8 2008 4 Sticky Blood ndash Do You Have It WBAL TV November 6 2008 5 Sticky Blood ndash Do You Have It KSBW TV November 6 2008 6 Sticky Blood ndash Do You Have It KOKO TV November 6 2008 7 Sticky Blood ndash Do You Have It Good Morning Maryland WMAR TV May 21 2009 8 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WJZ-TV 2009
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 28
9 Feature Story on Platelet Reactivity as Heart Attack Risk Factor WBFF TV 2009 10 Doctor Outlines Risk of Sticky Blood KOAT TV KOATcom Albuquerque NM November 18 2008 WPXI TV
wpxicom Pittsburgh Pennsylvania October 27 2010 11 MD Doc Helps Develop New Heart Disease Drug WBAL TV August 2 2011 12 Local docrsquos heart medication wins FDA approval WBAL TVcom August 2 2011
1 Hopkins UMMC Offer New Heart Procedure Baltimore Business Journal October 13 2003 2 Suddenly Yoursquore Much Less Healthy ndash Guidelines Create New Worry Baltimore Sun June 15 2003 3 Newsmakers Baltimore Messenger November 8 2005 4 Setback in cholesterol fight Some drugs boost HDL levels but dont lower plaque One even raises death risk
study finds Los Angeles Times April 2 2007 5 Landmark Study on Aspirin Resistance Medical News Today June 17 2007 6 Aspirin Effective Resistance is Rare United Press International June 20 2007 7 A Change of Heart Baltimore Sun June 21 2007 8 Sinai Opens Schapiro Cardiac Diagnostic Center Carroll County Times July 28 2007 9 The Goldilocks Factor - SCIENTISTS TRY TO FIGURE OUT WHICH ASPIRIN DOSAGE IS BEST FOR
THOSE TRYING TO AVOID HEART ATTACKS Baltimore Sun February 14 2008 10 Drug Coated Stents Safe for Heart Attack Patients Study Finds Bloomberg News March 30 2008 11 From the Heart ndash Cardiologist Paul Gurbel Baltimore Examiner August 10 2008 12 JampJrsquos High-Wire Heart Drug Forbes October 11 2008 13 FDA Considers Updating Plavix Label Wall Street Journal December 31 2008 14 Novartis AG to Pay Portola Pharmaceuticals $75 Million for Anti-clotting Drug
Fierce Biotech February 12 2009 15 Mixing Plavix and Heartburn Drugs Seen as Risky Wall Street Journal May 7 2009 16 New Cardiac Biomarkers Target Plaque Protein amp Platelets Cardiovascular Business July 8 2009 17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009 18 JAMA Researchers home in on gene variant for Plavix responsiveness Cardiovascular Business 8262009 19 Brilinta Data Fuels AZrsquos Hopes for Megablockbuster FireceBiotech August 31 2009 20 Advances in Heart Disease Treatment Continental Air Magazine September 2009 21 4 Foods to Help Boost Good Cholesterol Readers Digest September 2009 22 AZ wows analysts with new Brilinta data FierceBioTech November 18 2009 23 New Blood Thinners May Outperform Old Standbys US News and World Report November 18 2009 24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009 25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010 26 How Sticky Is Your Blood MDMd Magazine ndash January 2010 27 Sinai Doctorrsquos Research May Lead to Rival Plavix Drug Baltimore Business Journal July 19 2010 28 TARGET-PCI trial to assess value of genetic amp platelet function testing Cardiovascular Business 862010 29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010 30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010 31 Platelet Function Testing Time to Get Personal Cardiovascular BusinessNovember 1 2010 32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010 33 PPIs and antiplatelets Consensus TheHeartorg November 8 2010 34 Pharmacodynamics back up PLATO genetics substudy TheHeartorg November 15 2010 35 Ticagrelor may negate the need to assess genetic variations Cardiovascular Business November 14 2010 36 AstraZenecarsquos Plavix Rival Brilique Wins EU Approval Bloomberg News December 6 2010 37 FDA Is Set Decide the Fate of AstraZenecas Heart Drug Brilinta Daily Finance December 15 2010 38 FDA gives ticagrelor thumbs up (finally) Cardiovascular Business July 20 2011 39 FDA Approves Heart Drug Backed by Sinai Doctorrsquos Research Baltimore Business Journal July 22 2011 40 Plavix heart drug priced higher than local roots rivalrsquos Baltimore Business Journal August 5 2011 Teaching Classroom Instruction 1980 Pathology lecturer Dept of Pathology University of Maryland School of Medicine 1985 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1988-89 Internal Medicine Core Lecture Series lecturer Duke University Medical Center 1990-95 Physiology lecturer Department of Physiology University of Maryland School of Medicine 1991-96 Pathology lecturer Department of Pathology University of Maryland School of Medicine
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 29
1990-95 Internal Medicine Lecture Series for Housestaff lecturer Dept of Medicine University of Maryland Hospital and Baltimore Veterans Administration Hospital
1998-present Internal Medicine Noon Conference Lectures lecturer Dept Of Medicine Sinai Hospital of Maryland Clinical Instruction 1988-89 Internal Medicine Training Program directed education as Chief Resident Duke University 1988 Chief of Medicine Rounds instituted and was organizer Duke University 1988-89 Second Year Rotation and Sub-internship in Medicine directed education as Chief Resident Duke University 1990 Interventional Cardiovascular Fellowship teacher Duke University 1990-95 Interventional Cardiology Research Laboratory director educated all fellows and students conducting research in the laboratory University of Maryland 1991 Interventional Cardiology Fellowship instituted formal training program directed the education of all Interventional fellows University of Maryland 1990-95 Internal Medicine training program teacher University of Maryland 1995-99 Coronary Care Unit Teaching Rounds teacher Union Memorial Hospital Baltimore MD 1998-2006 Coronary Care Unit Teaching Rounds teacher Johns Hopkins UniversitySinai Hospital Program in Internal Medicine Sinai Hospital Baltimore MD 1998-present Sinai Center for Thrombosis Research teacher educate medical students and house staff during rotations in the Center Sinai Hospital Baltimore MD CME Instruction (see above and Invited Talks) 1988-89 Medicine Grand Rounds organizer Duke University Medical Center 41103 9th Annual Interventional Cardiology Course lecturer San Jose CA Mentoring Advisees 1991 Mark Leithe MD assistant professor Division of Cardiology Duke University 1993-94 Christopher MacCord MD emergency medicine private practice Alabama 1993-95 R David Anderson MD director interventional cardiology University of Florida 1994 Joel Gogard MD cardiologist Cleveland Clinic 1994 Maureen E Collins MD cardiologist private practice Maryland 1994 Alan I Schneider MD cardiologist private practice Maryland 1994 Carlos Pimental MD interventional cardiologist private practice Texas 1994 Steven W Schreiter interventional cardiologist Mayo Clinic Health Program 2001 Marcus McKenzie MD director clinical research Legacy Heart Center Texas Awards- Sinai
Hospital Resident Research Symposium best investigation 2005 Kevin A Hayes DO cardiologist Florida 2003-2004 Jason Yoho MD cardiologist private practice Alabama 2004 Robert Poston MD chief Division of Cardiothoracic Surgery University of Arizona 2005 Mulughetta Fissha MD cardiology fellow Georgia Health Sciences University 2004-2005 Rolf Kreutz MD interventional cardiologist assistant professor Department of Medicine University of Indiana 2008 Oscar Bailon MD cardiology fellow University of Texas San Antonio 2008-present Anand Singla MD cardiology fellow Guthrie ClinicRobert Packer Sayre PA Beth Israel Medical Center Boston MA 2009-10 Miruais Hamed MD cardiology fellow Oregon Health and Science University OR 2009 Spaz Kotev MD cardiology fellow Newark Beth Israel Hopital NJ 2009-10 Elisabeth Mahla MD director Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine Head of Research Unit Forschungseinheit fuumlr Perioperative Thrombozytenfunktion University of Graz Graz Austria 2010-present Young-Hoon Jeong MD PhD assistant professor division of cardiology Gyeong-Sang
National University Hospital Jinju Korea Awards - Journal of the American College of Cardiology Young Investigator
2011 Jacek Kubica professor Department of Cardiology Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
2013 Julia Kubica medical student Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 30
2013 Karolina Obonska MD Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland 2013 Eli Lev MD associate professor Tel Aviv University Tel Aviv Israel 2014-15 Geiling Chen MD Department of Cardiology China-Japan Friendship Hospital Beijing China 2014-15 Fang Liu MD Department of Neurology Beijing Hospital Beijing China EDUCATIONAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Interventional Cardiology Fellowship Training Program Founder and Director UMMS EDUCATIONAL EXTRAMURAL FUNDING - none CLINICAL ACTIVITIES Licensures and Registrations 102286 State of Maryland D34366 091715 Commonwealth of Virginia 0101259105 Board Certification 7284 National Board of Medical Examiners 278234 91086 American Board of Internal Medicine Internal Medicine 108658 1988 Board Eligible in Pulmonary and Critical Care Medicine 11889 American Board of Internal Medicine Cardiovascular Disease 108658 1999-2009 American Board of Internal Medicine Added Qualifications in Interventional Cardiology 2010-2020 American Board of Internal Medicine Added Qualifications in Interventional Cardiology Clinical Responsibilities 1998-present Interventional cardiologist at Sinai Hospital of Baltimore and Inova 60 1998-present Clinical cardiology 20 CLINICAL PROGRAM BUILDINGLEADERSHIP 1991-1995 Director Interventional Cardiology University of Maryland Medical System 2002-2015 Director of Therapeutics Research and Technology Development Cardiac Catheterization Program Sinai Hospital of Baltimore 2005-2006 Director Division of Cardiology Sinai Hospital of Baltimore 2015-present Director Inova Center for Thrombosis Research and Drug Development 2015-present Director Interventional Cardiology Inova Health 2015-present Director Cardiovascular Medicine Research Inova Health CLINICAL EXTRAMURAL FUNDING -none SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (Not Appropriate) ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments 1988-1989 Duke University School of Medicine Admissions Committee Residency Program in Medicine 1988-1990 University of Maryland School of Medicine Pharmacy and Therapeutics Committee 1998-2009 Sinai Hospital of BaltimoreLifebridge Health Member Institutional Review Board 2004-2009 Sinai Hospital of BaltimoreLifebridge Health Member Medical Executive Committee Editorial Activities Editorial Board Appointments
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 31
2001-2002 Member Editorial Board Heartdrug 2004-2007 Member Editorial Board Clinical Geriatrics 2008-2010 Member Editorial Board Journal of Medicine 2010-present Editorial Consultant Journal of the American College of Cardiology 2010-present Editorial Board Member Cardiology Today Intervention 2012- Editorial Board Member JRSM Cardiovascular Disease 2014- Editorial Board Member Expert Opinion in Pharamcotherapy Journal Peer Review Activities (present) Arteriosclerosis Thrombosis and Vascular Biology American Heart Journal American Journal of Cardiology BioDrugs Blood Coagulation and Fibrinolysis Coronary Artery Disease Circulation Circulation Interventions
Circulation Genetics Circulation Journal
Catheterization and Cardiovascular Interventions European Heart Journal
JAMA Nature Cardiovascular Medicine Journal of the American College of Cardiology Journal of the American College of Cardiology Interventions
Journal of the American College of Cardiology Imaging Journal of Thrombosis and Haemostasis Journal of the American Medical Association Lancet New England Journal of Medicine Platelets Thrombosis and Haemostasis Scientific Abstract Reviewer (present) American College of Cardiology
Transcatheter Cardiovascular Therapeutics International Society of Thrombosis and Haemostasis American Heart Association
Cardiovascular Research Therapeutics Advisory Committees Review GroupsStudy Sections 1999-2000 Member Adjudication Committee A Randomized Double-Blinded Placebo-Controlled Multicenter Trial
of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) King Pharma
2005-present Member The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Aspirin resistance ISTH
2006-2007 National Coordinator A Randomized Double-blind Parallel Group Phase 3 Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) ndash PLATO Trial AstraZeneca LP
2007-present Member Steering Committee TRILOGY Trial Eli Lilly and Company 2007-2010 Member Executive Committee CHAMPION Trail Medicines Company 2007-present Member Steering Committee TRA TIMI 2PTrial Merck 2008-present Chairman Adjudication Committee The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial BayerHealthcare 2008 Advisor Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES) Trial Accumetrics Volcano 2009-present Member Steering Committee TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 32
manage Acute Coronary Syndromes (TRILOGY ACS) Director TRILOGY Platelet Function Substudy Eli Lilly and Company
2009-present Member Advisory Committee The Dual Antiplatelet (DAPT) Study Medtronic Boston Scientific Abbott BMS Cordis Daiichi Sankyo Eli Lilly 2011-present Member Technical Expert Panel Comparative Effectiveness Review of Pharmacogenetic Testing for
CYP2C19 Variants for Guiding Antiplatelet Treatment Tufts Evidence-based Practice Center Tufts Medical Center Boston MA
2012 Member NHLBI Working Group Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care 2013 American Heart Association peer grant reviewer Thrombosis Clinical group 2014 NHLBI Member Onsite Tools and Technologies for Heart Lung and Blood Clinical Research Point- of-Care SBIR Advisory Boards for PharmaceuticalDevice Companies 1992-1998 Medtronic Inc member 1992-1999 Datascope Inc member 1998-2000 Dupont Merck Pharmaceuticals member 1998-present Bristol Myers SquibbSanofiAventis member 1999-2001 Genentech Inc member 2001-2006 Cordis Corporation member 2002 ndash 2005 Millennium Pharmaceuticals member 2002-present Sanofi Aventis member 2005-2009 Schering Plough member 2005-present Daiichi SankyoLilly member 2007-present Pozen Pharmaceuticals chairman 2008-2010 Portola Pharmaceuticals member 2009-present Merck member 2009-present Boehringer Ingleheim member 2010-present Novartis member Professional Societies 1983-1995 American College of Physicians member 1986-1991 American College of Chest Physicians member 1987-1995 American Thoracic Society member 1990-present Duke University Clinical Cardiology Society member 1991-1994 American Federation for Clinical Research member 1992-present Council on Clinical Cardiology American Heart Association fellow 1992-present American College of Chest Physicians fellow 1992-present American College of Cardiology fellow 2004-present Society for Cardiovascular Angiography and Interventions fellow Conference Organizer Session Chair 2003-present Transcatheter Cardiovascular Therapeutics organizing Committee member and session chair Selected Sessions 2003 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2004 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2005 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2006 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2007 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2008 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2009 Platelet inhibition I Physiology and thienopyridine Transcatheter Cardiovascular Therapeutics 2010 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 92210 Adjunct pharmacotherapy ldquoblack boxrdquo Transcatheter Cardiovascular Therapeutics 2011 Practicalities and pitfalls of platelet function testing Transcatheter Cardiovascular Therapeutics 2005-2011 Cardiovascular Research Technologies faculty session chair Washington DC
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 33
Selected Sessions 22710 Antiplatelet responsiveness and resistance Cardiovascular Research Technologies Washington DC 22711 How will GRAVITAS impact clinic practice Cardiovascular Research Technologies Washington DC 22811 What else can be done to minimize stent thrombosis Cardiovascular Research Technologies Washington DC 2005-present American College of Cardiology ACCi2 Summit session chair panelist Selected Sessions 2006 Aspirin and Clopidogrel Resistance Fact or Fiction 31507 Drug Eluting Stent Complications and Tough Calls 31509 i2Featured Clinical Studies Orlando Florida 2009 31510 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome ACC Meet the Experts Altanta Georgia 31610 Oral Antiplatelet Therapy Case Reviews i2 Meet the Experts Co-Chair Atlanta Georgia 3111 Cardiovascular pharmacogenomics Bench to bedside and dyslipidemia in special populations New Orleans LA 3111 I2 Platelet inhibition therapy in 2011 Current state of the art with practical applications and
presentation New Orleans LA 3511 Genetics and Cardiovascular Outcomes ACC Oral Contributions Co-chair New Orleans LA 2005-present American Heart Association session chair Selected Sessions 2008 Understanding Variability in antiplatelet drug effects in acute coronary syndromes Abstract oral sessions 2009 Drug responsiveness and management of Anti-platelet therapy after DES Why the resistance to
testing Orlando FL 111610 Controversies in antiplatelet therapy Digital dialogue Chicago 111411 Whatrsquos is in the pipeline Adjunct Pharmacotherapeutics for Coronary Interventions Orlando FL 2005-present Society for Cardiovascular Angiography and Interventions session chair Selected sessions 2010 Emerging therapy antiplatelet drugs Las Vegas NV 5511 Platelet inhibition Optimizing and individualizing therapy SCAI 34th annual scientific session 5511 Putting it all together What is practicing clinician to do Baltimore MD 2006 ADP 2006 Drug resistance- new drug targets session chair Strasbourg FR 2007 2009 International Society on Thrombosis and Haemostasis
Congress International Advisory Board member Geneva Switz and Boston MA
Other Conferences
10307 Antiplatelet Resistance 3rd Thrombosis Quorum Advisory Summit Meeting Perguia Italy Co-chair 82810 Managing patients with ACS Current challenges and emerging solutions European Society of
Cardiology Meetings (Spotlight Session) Astra Zeneca Stockholm Sweden Co-chair 2011 2011 Workshop for Invasive Cardiology Zabre Poland Co-chair 61011 Presence and future of antiplatelet therapy Collegium Meddicum of Nicolas Coppernicus University
Bydgaszcz Poland Co-chair 2011 Does one antiplatelet agent fit all SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do
Estado De Sao Paulo Brazil Co-chair 72211 Seoul Platelet Research Group Seoul Korea Co-chair 72311 Platelet Research Group Busan South Korea Co-chair
Consultanships 2009-present CSL Haemonetics Novartis Accumetrics PlaCor Takeda Bayer International Grants Reviewed (2010-2011) 1 Grant Name ldquoCost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients
with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 34
with stent implantation optimization of treatmentrdquo Program DoelmatigheidsOnderzoek Netherlands Applicant Dr VHM Deneer Sint Antonius Ziekenhuis Klinische farmacie ostbus 2500 3430 EM NIEUWEGEIN Netherlands
2 Grant Name Platelet hyperreactivity project- A network biology approach to identify activation pathways involved in the modulation of platelet reactivity in cardiovascular patients Program Biology and Medicine grant Swiss National Foundation Switzerland
Applicant Pierre Fontana
3 Grant Namerdquo The Staphylothrombin trial-From Bench to Bedsiderdquo Program Clinical Research in Austria Department of Biological and Medical Sciences Applicant Bernd Jilma AoUniversity Professor Austria
4 Grant Name Biomedical Diagnostics Institute Proposal for Second Term of Funding International Platelet Research Expert Reviewers DrUdaya S Tantry Dr Paul a Gurbel Program Centres for Science Engineering amp Technology Science Foundation Ireland Applicant Professor Brian MacCraith Bilogical Diagnostic Institute Dublin City University
5 Project Name ldquoPharmacogenetic approach to personalize oral antiplatelet agent therapiesrdquo Program Application for Prix Jean Valade Applicant Jean-Philippe Collet Paris France
RECOGNITION Awards Honors 1979 Phi Beta Kappa Johns Hopkins University 1983 Alpha Omega Alpha University of Maryland School of Medicine 1991 DuPont Pharmaceuticals American College of Chest Physicians Young Investigator Award 2004 Faculty Research Award Sinai Hospital of Baltimore 2006 Daily Record Health Care Heroes Award Advancement in Health Care 2007 Best Poster award Transition to an unstable coronary syndrome is marked by hypercoagulability
platelet activation heightened platelet reactivity and inflammation results of the thrombotic rIsk progression (TRIP) study American College of Cardiology Scientific Sessions 2007 New Orleans
2008 Josef Strus Memorial Lecture Polish Society of Internal Medicine Warsaw Poland 2009 Red ribbon award Effect of epifibatide added to bivalirudin on periprocedural inflammation and
platelet function in elective stenting ISTH Boston 2009 Red ribbon award The antiplatelet effect of a new direct acting reversible P2Y12 inhibitor elinogrel
(PRT060128) in patients with high platelet reactivity during clopidogrel therapy ISTH Boston 2009 Red ribbon award PA32520 (single-tablet of immediate-release omeprazole 20 mg + enteric-coated
aspirin 325 mg) Safer aspirin therapy with greater thromboxane suppression ISTH Boston 2011-14 SuperDoctors Washington DC Baltimore Northern Virginia 2011-14 Best Doctors US News and World Report 2011-14 Top Doctors Best physicians as chosen by their peers The Washington Post Magazine 2015 Top Doctors Baltimore Magazine 2011 Consumersrsquo Checkbookrsquos Top Doctors 2012 2014 Elite Reviewer Award JACC Journals 2015 Elite Reviewer Award JACC Journals 2013 Simon Dack Award for Outstanding Scholarship in support of the JACC Journals 2016 Honorary Doctorate Causa Honora Nicolaus Copernicus University Invited Talks Panels Invited Talks-International 2004 ndash present 4-5-04 Restenosis Endocoronaire Platelet inhibition by clopidogrel importance of resistance Marseille France 6-18-04 Clopidogrel resistance Scientific Subcommitte Session Platelet Physiology The 50th Scientific and
Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis Venice Italy
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 35
9-16-04 Resistance to clopidogrel 3rd International meeting ADP 2004rdquoon P2 receptors and other new targets for antithrombotic drugs Tuscany Italy
10-1-04 Aspirin Roundtable 3rd International Experts Forum Obidos Portugal 4-22-05 Clopidogrel resistance Does it really exist VII International symposium update on antithrombotic
management in acute coronary syndrome Madrid Spain 10-1-05 Variable response to antiplatelet agents Clinical impact or laboratory curiosity Bayerrsquos 4th International
expert forum Bayer Healthcare Sitges Spain 10-5-06 Clopidogrel resistance and its detection ADP 2006 Strasbourg France 9-23-07 Aspirin resistance clopidogrel resistance and clinical relevance The 2nd Amsterdam symposium on
acute coronary syndrome Amsterdam Netherlands 10-3-07 Antiplatelet Resistance Co-chairman and Speaker 3rd Thrombosis Quorum Advisory Summit Meeting
2007 Perguia Italy 10-6-07 The ARRIVE Trial North America Aspirin Consultants Roundtable Aspirin in the 21st century
Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy 10-6-07 Dose dependent inhibition of COX-1- ldquoVariable Responserdquo North America Aspirin Consultants
Roundtable Aspirin in the 21st century Cardiovascualr disease epidemic Realizing the potential 6th International Experts Forum Rome Italy
4-24-08 Antiplatelet Treatment in Cardiovascular Diseases Perspectives of a Translational Researcher 36th Congress of the Polish Society of Internal Medicine Strus Memorial Lecture Warsaw Poland
4-16-09 Measurement of platelet function 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
9-24-09 Optimizing Platelet Aggregation Inhibition (PAI) in CAD State of the Art 13th Congress of the Polish Cardiac Society Poznan Poland
10-15-09 Aspirin Scope and Limitations Aspirin Foundation BayerHealthcare The British Journal of Cardiology issued the proceedings of this meeting as a special supplement London UK
5-22-10 Antiplatelet treatment in 2010 and beyond XVII Annual Congress on Acute Coronary Syndrome Silesian Center for Heart Diseases Zabrze Poland
6-24-10 Case Presentations Rabin Heart Center Petah Tikva Israel 6-25-10 The New Antiplatelet Agents How Significant Are the Differences Beyond Standard and High-Dose
Clopidogrel Therapy The Israeli Working Group on Cardiology and the Working Group on Cardiovascular Pharmacology Tel Aviv Israel
8-11-10 First Analysis of The Relation Between CYP2C19 Genotype and Pharmacodynamics in Ticagrelor Versus Clopidogrel Treated Patients The ONSETOFFSET and RESPOND Genotype Study Antiplatlet Summit Astra Zeneca London UK
8-30-10 Role of platelet function testing Does it have a clinical impact Hot Topics in ACS European Society of Cardiology Meetings Stockholm Sweden
9-2-10 P2Y12 and its inhibition in ACS ADP2010 Platelet Receptors Meeting From basic science to clinical practice P2Y12 and its inhibition in ACS Gazzada Schianno Italy
9-17-10 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy Platelets and acute coronary syndromes 2010 Workshop for Invasive Cardiology The Department of Cardiology Collegium Meddicum of Nicolas Copernicus University in Torun Torun Poland
2-6-10 Ticagrelor Focus on off target effects International Antiplatelet Symposium Astra Zeneca Amsterdam Netherlands
2-6-10 Enhanced Effect of Ticagrelor Added to Clopidogrel Data from ONSET-OFFSET and RESPOND Studies PLATO Investigators Meeting Astra Zeneca Amsterdam Netherlands
4-16-10 New antiplatelet agents 10th Annual NATA (Network for Advancement of Transfusion Alternatives) Symposium Linz Austria
6411 How new anti-thrombotic therapy will influence the risk for bleeding in the future 2011 Workshop for Invasive Cardiology Silesian Center for Heart Diseases Zabre Poland
61111 Is it time for tailored treatment Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
61111 Personalized antiplatelet therapy current and future status Presence and future of antiplatelet therapy The Department of Cardiology Collegium Meddicum of Nicolas Coppernicus University in Torun Bydgoszcz Poland
6-22-11 Pharmacogenomics of clopidogrel and the interaction with PPIrsquos Is there a real safety issue Grand Rounds Heart Institute (InCor HCFMUSP) University of Sao Paulo Sao Paulo Brazil
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 36
6-24-11 Antiplatelet therapy pharmacokinetics pharmacodynamics and pharmacogenomics SOCESP 2011 XXXII Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Satellite Symposium Astra Zeneca Sao Paulo Brazil
6-24-11 Personalized antiplatelet therapy for the PCI patient SOCESP 2011 XXX Congresso Da Sociedade De Cardiologia Do Estado De Sao Paulo Brazil
7-1-11 Ticagrelor A new chemical class International Speaker Summit Astra Zeneca Brussels Belgium 72111 Antiplatelet therapy past current and future perspective Asan Medical Center Seoul South Korea 7-21-11 Antiplatelet therapy past current and future perspective St Mary Hospital Seoul South Korea 7-22-11 Concept of antiplatelet therapy and role of pharmacogenomics Seoul platelet research group Seoul
South Korea 7-22-11 Antiplatelet therapy past current and future perspective Seoul National University Hospital Seoul
South Korea 7-23-11 Concept of antiplatelet therapy and role of pharmacogenomics South Korea platelet research group
Busan South Korea 7-24-11 Genetic influences on platelet function New insights International society on thrombosis and hemostasis
conference 2011 Astra Zeneca sponsored CME-certified symposium Kyoto Japan 7-25-11 New P2Y12 inhibitors for the treatment of CAD XXIII Congress of The International Society on
Thrombosis and Haemostasis International Society on Thrombosis and Hemostasis Kyoto Japan 10-31-11 The time has come for personalized antiplatelet therapy Protagonist 7th International Meeting on Acute
Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Debate Bivalirudin for all ACS patients during PCI Protagonist 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society
10-31-11 Advances in antiplatelet therapy for the ACS patient From basic mechanisms to evidence-based guidelines Luncheon Symposium at the 7th International Meeting on Acute Cardiac Care Working Group on Acute Cardiac Care of the European Society of Cardiology and the Israel Heart Society Astra Zeneca
Invited Talks- United States 2003- present 4-11-03 Interventional Pharmacology III ASA and thienopyridines in ACS and PCI 9th Annual Interventional
Cardiology Course San Jose CA 9-15-03 Aspirin and thienopyridine resistance Incidence detection and relevance Transcatheter
Cardiovascular Therapeutics Washington DC 9-28-04 Overview Platelet Physiology Reactivity Receptors Inhibition Transcatheter Cardiovascular
Therapeutics Washington DC 3-17-04 Platelet inhibitions by clopidogrel What is known What is new Visiting Professor Grand Rounds
University of North Carolina Chapel Hill NC 5-7-04 Critical pathways and discharge plans for ACS Implementing evidence based medicine in clinical
practice Medical Ground Rounds STRIVE (Strategies and Therapies for Educing Ischemic and Vascular Events) Harbor Hospital Center Baltimore MD
5-12-04 Early treatment guidelines Grand Rounds Mercy Hospital Baltimore MD 7-22-04 Platelet inhibitions by clopidogrel What is known What is new National Institutes of Health ASTRA
Pearls Lecture Series National Institutes of Health National Institute on Aging Intramural Research Program Clinical Research Branch Harbor Hospital Center Baltimore MD
9-28-04 Platelet inhibition INew insights into aspirin and thienopyridine applications Transcatheter Cardiovascular Technologies Washington DC
9-30-04 Management dilemmas in interventional patients approach to aspirin resistance Transcatheter Cardiovascular Therapeutics Washington DC
10-22-04 Clopidogrel resistance and platelet inhibition Morristown Memorial Hospital Morristown NJ 10-22-04 Clopidogrel resistance and platelet inhibition Newark Beth Israel Medical Center Newark NJ 10-29-04 Clopidogrel resistance Millennium Scientific Advisory meeting IIS Investigator Forum Millennium
Pharmaceuticals Boston MA 12-2-04 Atherothrombosis Challenges in managing the highest risk patient Grand Rounds Coatesville VA
Medical Center Coatesville PA 1-12-05 Clopidogrel response variability and drug resistance Antiplatelet therapy conference Pfizer StLouis
MO
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 37
1-26-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of percutaneous coronary intervention Cardiology Grand Rounds George Washington University Washington DC
2-2-05 Clopidogrel Resistance Cardiology Grand Gounds Massachusetts General Hospital Boston MA 2-4-05 Clopidogrel Resistance Relevance for coronary stenting Strategic Council Presentation Millenium
Pharmaceuticals Cambridge MA 3-5-05 Optimal treatment of patients with ACS throughout the spectrum of risk ldquoCLEAR platelets studyrdquo
Antiplatelet Therapy Symposium American College of Cardiology Annual Scientific Sessions Orlando FL
3-8-05 Defining the future of antiplatelet therapy Antiplatelet Therapy Symposium at the American College of Cardiology Scientific Sessions Daiichi Sankyo Orlando FL
3-31-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Moristown Hospital Grand Rounds Livingston NJ
4-6-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention University of Mississippi Jackson MS
4-13-05 Consideration on the use of GPIIbIIIa inhibitors in the setting of setting of percutaneous coronary intervention Carolinas Medical Center Charlotte NC
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for Advanced cardiac care St Josephrsquof Hospital Mt Clemens MI
4-16-05 Advances in percutaneous intervention for coronary artery disease Symposium for advanced cardiac care Mt Clemens MI
5-4-05 Implementing critical pathways for cardiovascular disease Strategies and therapies for reducing ischemic and vascular events Medicine Grand Rounds St Maryrsquos Health Center St Louis MO
5-9-05 Clopidogrel and aspirin resistance Clinical impact or just another in vitro phenomenon Society of Cardiac Angiography and Interventions 28th Annual scientific session Ponte Verda Beach FL
5-9-05 The discovery of clopidogrel resistanceresponse variability Duke Cliniocal Research Institute Durham NC
6-7-05 The discovery of clopidogrel resistanceresponse variability Daiichi pharmaceutical corporation scientific colloquium Cardiac catherization conference Cardiovascualr Research Institute Washington Hospital Center Washington DC
7-16-05 Solutions to a sticky problem Overcoming platelet resistance in the cath lab North American Center for Continuing Medical Education Med Reviews Cambridge MA
8-25-05 The future of antiplatelet therapy Schering-Plough leadership council for improving cardiovascular care general council Boston MA
9-14-05 Clopidogrel for coronary stenting Cardiac catherization conference Fairfax Hospital Fairfax VA 10-6-05 Defining the future of antiplatelet therapy Medicine Grand Rounds StVincents Hospital Erie PA 10-7-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Current concepts
in cardiovascular management Internal Medicine Society Kaleida Health Buffalo NY 10-9-05 Resistance to antiplatelet therapy What dose it mean to patients undergoing stenting Cardiology
section meeting Riverside Methodist Hospital Columbus OH 10-11-05 Antiplatelet therapy resistance 2nd Global Cardiovascular Summit Schering Plough Dallas TX 10-13-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Catherization
laboratory conference High Point Regional Hospital High Point NC 10-17-05 Variability in response to antiplatelet agents Definitions implications and therapeutic strategies
Transcatheter Cardiovascular Therapeutics Washington DC 10-18-05 Resistance to thienopyridines and issues surrounding dosing thienopyridines in the setting of PCI
Transcatheter Cardiovascular Therapeutics Washington DC 11-13-05 Platelet Physiology for the Clinician Bench to Bedside American Heart Association Scientific
Sessions Dallas TX 11-14-05 Defining Resistance to Antiplateletagents American Heart Association Scientific Sessions 11-14-05 Aspirin response variability in platelets Evolving evidence of aspirin effectiveness American Heart
Association Scientific Sessions Dallas TX 10-20-05 Resistance to antiplatelet therapy What does it mean for patients undergoing stenting Grand Rounds
Sinai Hospital of Baltimore MD 1-4-06 Antiplatelet therapy response variability and clinical consequences Cardiology Grand Rounds California
Pacific Medical Center San Francisco CA 1-19-06 A hard look at correlating measures of inter-patient variability in platelet function and clinical outcomes
Thrombosis and bleeding Platelet Colloquium University of Kentuky and Duke Clinical Research Institute Miami FL
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 38
2-17-06 The role of platelets in atherothrombosis Vascular Biology Working Group Summit Chicago IL 3-2-06 Response variability to antiplatelet therapy Relevance of ex vivo platelet function measurements to
clinical outcomes in patients undergoing PCI Grand Rounds Brigham and Womenrsquos Hospital Boston MA
3-14-06 Antiplatelet Resistance Is It Real American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Aspirin and Clopidogrel resistance Considerations and Management American College of Cardiology Annual Scientific Sessions Atlanta GA
3-13-06 Clopidogrel Resistance American College of Cardiology Annual Scientific Sessions Atlanta GA 10-9-06 Plavix and aspirin resistance Everything you need to know in 10 minutes ACE Meeting New York NY 10-9-06 CTOrsquos and vulnerable plaque ACE Meeting New York NY 12-15-06 New insights into the evolving care and management of acute coronary syndrome (ACS) Townhall
meeting NJ 3-23-07 Aspirin and clopidogrel resistance Core concepts and relation to adverse DES outcomes Drug Eluting
Stent Revolution Cardiovascular research Foundation Symposium at the American College of Cardiology Scientific Sessions New Orleans LA
3-24-07 Time is muscle STEM strategies to match patients with therapy The central role of the platelet Symposium at American College of Cardiology Annual Scientific Sessions Medtronic New Orleans LA
3-24-07 Balancing reduction of ischemia and risk of bleeding in moderate to high-risk Non-ST-Elevation ACS Satellite Symposium Schering Plough ACS Symposium at ACC New Orleans LA
5-31-07 Drug Eluting stents or not American College of Cardiology-Alabama chapter Destin FL 7-23-07 Antiplatelet therapy resistance and therapeutic strategies Vascular Biology Working Group Meetings
Baltimore MD 8-13-07 Future of antiplatelet therapy Duke University Medical Center Cardiology Grand Rounds Durham NC 2007 Assessing platelet physiology in translational research studies Bayview Hospital Baltimore MD 10-12-07 Optimal antiplatelet treatment strategies for percutaneous coronary intervention Christiana Hospital
Christiana DE 10-22-07 Antiplatelet therapy for ACS Weighing long-term outcomes vs short-term risk Rockpointe symposium
Transcatheter Cardiovascular Therapeutics Washington DC 10-22-07 New cardiovascular risk factor Rockpointe symposium Transcatheter Cardiovascular Therapeutics
Washington DC 10-24-07 Platelet inhibition II New insights into GPIIbIIIa inhibitor use- Stent thrombosis and GPIIbIIIa inhibitor
Transcatheter Cardiovascular Therapeutics Washington DC 11-2-07 Current and evolving role of antiplatelet agents 4th Annual Global CV Summit Schering Plough Orlando
FL 1-29-08 Updates in ACS Grand Rounds Loma Linda University Medical Center Loma Linda CA 1-29-08 Updates in ACS Grand Rounds University of Southern California County Hospital Los Angeles CA 1-31-08 Assessing Platelet Physiology in Translational Research Studies Grand Rounds Mayo Clinic
Rochester MN 2-11-08 How to detect Aspirin Resistance and Lack of Platelet Inhibition Cardiovascular Research
Technologies 2008 Washington DC 3-27-08 Assessing Platelet Physiology in Translational Research Studies Identification and Optimal Treatment of
the Atherothrombotic Patient American College of Cardiology Annual Scientific Sessions Chicago IL
3-29-08 SCAI-ACCi2 Late-Breaking Clinical Trials I PCI Commentator on Bonello Study American College of Cardiology Annual Scientific Sessions Chicago IL
3-31-08 Aspirin and clopidogrel resistance measurement and relevance Pharmacology for Percutaneous Coronary Intervention And Acute Coronary Syndrome Symposium American College of Cardiology Annual Scientific Sessions Chicago IL
9-10-08 An Oral direct acting P2Y12 receptor antagonist AZD6140 Properties and Clinical Trial Update Transcatheter Cardiovascular Therapeutics Washington DC
9-10-08 PAR-1 Inhibitors Rationale and Clinical Update Transcatheter Cardiovascular Therapeutics Washington DC
10-3-08 Antiplatelet therapy current and future perspectives from translational research Maryland General Hospital Grand rounds Baltimore MD
11-9-08 A Case-based Approach to PCI and Antiplatelet Therapy and in Ischemic Heart Disease Symposium Schering Plough New Orleans LA
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 39
11-9-08 Resistance to Oral Antiplatelet Drugs American Heart Association Scientific Sessions New Orleans LA
11-9-08 Platelet Function Assays What is Their Current and Potential Future Clinical Utility Global Cardiovascular Summit at American Heart Association Scientific Sessions Schering Plough New Orleans LA
11-9-08 The Central Role of the Platelet in ThrombosismdashWhat Do We Know American Heart Association Scientific Sessions New Orleans LA
11-9-08 Oral Antiplatelet Therapy Thienopyridine Use American Heart Association Scientific Sessions New Orleans LA
3-4-09 Aspirin and clopidogrel responsiveness Cardiovascular Research Technologies Washington DC 3-4-09 Should patients undergoing DES implantation routinely test their responsiveness to aspirin and
clopidogrel Cardiovascular Research Technologies Washington DC 3-18-09 Antiplatelet Therapy and Stent Choice Major Controversies in Interventional Cardiology Reading PA 3-28-09 Aspirin and Clopidogrel Resistance Measurement and Relevance Pharmacology for Percutaneous
Coronary Intervention And Acute Coronary Syndrome American College of Cardiology Scientific Sessions Orlando Florida
3-29-09 Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicentre Randomized Prospective Study Commentator SCAI-ACCi2 Late-Breaking Clinical Trials I PCI American College of Cardiology Scientific Sessions Orlando FL
3-29-09 Antiplatelet Agent Resistance and The Potential for New Antiplatelet Agents i2 Plenary Sessions American College of Cardiology Scientific Sessions Orlando FL
4-27-09 Future developments where is the opportunity for new antiplatelet agents SanofiBMS advisory board meeting Philadelphia PA 4-27-2009
5-6-09 Tailored Antiplatelet Therapy and Antithrombotic Therapies Specific to Diabetic (PCI) Patient Society for Cardiac Angiography and Interventions Las Vegas NE
5-6-09 Platelet Physiology and Blockade for Interventionalist Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Measuring Platelet Reactivity in the Individual Patient Is it Ready for Prime Time Society for Cardiac Angiography and Interventions Las Vegas NV
5-6-09 Does Point-of-Care Monitoring Have a Role Today Factors to Consider Accumetrics Society for Cardiac Angiography and Interventions Las Vegas NV
6-17-09 Role of Oral Antiplatelet Therapy in ACS Which One How Much and When Complex cardiovascular catheter therapeutics annual conference Baltimore MD
6-17-09 Dual Antiplatelet Therapy and Antiplatelet Drug Resistance Impact on the Outcomes of DES and New Clinical Evidence Complex Cardiovascular Catheter Therapeutics Annual Conference Baltimore MD
7-11-09 Antiplatelet Response Variability A Review of the Literature International Society on Thrombosis and Hemostasis Boston MA
7-11-09 Emerging Antiplatelet Therapies The potential impact on response variability International Society on Thrombosis and Hemostasis Boston MA
7-30-09 Antiplatelet Therapy in the PCI Patient Perspectives of a Translational Platelet Physiology Researcher Christiana Hospital Christiana DE
8-20-09 Emerging Antiplatelet Agents and Personalized Therapy Improving Outcomes in the PCI Patient Lynchburg Hospital Lynchburg VA
9-21-09 The drug eluting stent summit part I Appropriate utilization of current generation devices session III DES safety considerations Discussant Transcatheter Cardiovascular Therapeutics San Francisco CA
9-21-09 Overcoming Clopidogrel Hyporesponsiveness with New Antiplatelet Agents Preclinical Insights Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Antiplatelet agent utilization and resistance sessionII Antiplatelet drug resistance Current knowledge and future perspectives Transcatheter Cardiovascular Therapeutics San Francisco CA
9-23-09 Aspirin and Clopidogrel ldquoResistancerdquo Definitions Prognostic Implications and Potential Solutions Transcatheter Cardiovascular Therapeutics San Francisco CA
11-15-09 Thrombosis in CVD Resistance Genetics and Drug Interactions American Heart Association Scientific Sessions Orlando FL
11-15-09 Changing Role of GPIIbIIIa Blockers with Contemporary Antithrombotic Drug Regimens Bench-to-bedside success storiesGPIIbIIIa blocker American Heart Association Scientific Sessions Orlando FL
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 40
11-15-09 Response Variability and Point-Of-Care Platelet Function Testing At American Heart Association Scientific Sessions Accelmed Orlando FL
11-15-09 Drug Responsiveness and Management of Anti-Platelet Therapy After DES Why Resistance to Testing American Heart Association Scientific Sessions Orlando FL
11-15-09 Pharmacogenetics Pharmacodynamics and Antiplatelet Therapy American Heart Association Scientific Sessions Orlando FL
11-30-09 The New Antiplatelet Agents Focus on Oral P2Y12 Blockade Duke University Durham NC 1-14-10 Current Landscape of P2Y12 Receptor Antagonists Duke Clinical research Institute Astra Zeneca
Durham NC 1-28-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy Sinai Hospital
Cath Lab Conference Baltimore MD 2-4-10 Antiplatelet Therapy Coagulation Conference New Orleans LA 2-21-10 Insights to factors affecting responsiveness to ASA and clopidogrel Interactions with other medications
and platelet turnover rate Cardiovascular Research Technologies Washington DC 2-21-10 Genotyping Which one should we perform How to interpret the data and is it ready for clinical practice
Cardiovascualar Research Technologies Washington DC 2-22-10 Will personalized antiplatelet therapy reduce stent thrombosis Emerging Drugs and Polymers
Cardiovascular Research Technologies Washington DC 3-13-10 Clopidogrel Resistance and Genetic Polymorphisms Time to Measure and React pro Cardiovascular
Research Roundation CME Symposia at the Americamn College of Cardiology Altanta GA 3-15-10 Individualized Antiplatelet Therapy Where Are We Industry-Expert Theater Presentation 4
Accumetrics American College of Cardiology Scientific Sessions Altanta GA 4-9-10 Recent Research in Antiplatelet Therapy Related to the Practice of Interventional Cardiology Maryland
Association of Cardiac and Pulmonary Rehabilitation Physicians Baltimore MD 4-10-10 New Guidelines for the Evaluation amp Treatment of ACS Focus on Antiplatelet Therapy St Joseph
Medical Center Reading PA 4-12-10 Pharmacogenomics of Plavix Is There a Real Safety Issue Drug Information Association Meetings 4-28-10 Antiplatelet Therapy New P2Y12 Antagonists and Non-Thienopyridine Alternatives Duke University
sponsored meeting Washington DC 5-5-10 The role of genetic testing and antiplatelet resistance in treatment choices during ACS and AMI New
Treatment Pathways for ACS and STEMI PCI Focus on Pharmacology Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
5-6-10 Mechanisms of antiplatelet therapy how do the different drugs work Advances in Antiplatelet Therapy Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions San Diego CA
7-22-10 Everything you ever wanted to know about clopidogrel genotyping and phenotyping Food and Drug Administration Silver Spring MD
9-22-10 Pharmacogenetics and the PCI patient-The advent of real time genotyping Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Optimal antiplatelet therapy in patients post-PCI A case-based round table with the experts Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 Personalized Antiplatelet Therapy with Point-of-Care Genotyping Nanosphere Transcatheter Cardiovascular Therapeutics Washington DC
9-22-10 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Role of Platelet Inhibition Assessment And Genotype Testing Discussant Transcatheter Cardiovascular Therapeutics Washington DC
9-24-10 Platelet Function Testing and the CYP2C19 Genotype Fact vs Fiction Transcatheter Cardiovascular Therapeutics Washington DC
10-1-10 Antiplatelet strategies to protect ACS patient and minimize risk A CME certified visiting professor grand rounds program DSL mini conference
10-9-10 Gurbel PA Personalized Antiplatelet Therapy-Now Robert Wood Johnson Hospital UMDNJ New Brunswick NJ
11-13-10 Pharmacokinetics Pharmacodynamics and Pharmacogenetics of Antiplatelet Therapy Taking A Closer Look Symposium at the Amercian Heart Association Scientific Sessions Astra Zeneca Chicago IL
11-19-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Sinai Cath Lab Conference Baltimore MD
12-1-10 Advances in Antiplatelet Therapy for The PCI Patient Getting to the Core of the Problem of Coronary Thrombosis Virginia Commonwealth University Cath Conference Richmond VA
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 41
12-8-10 Update on ACS and antiplatelet therapy Maryview Medical Center Schering Plough Portsmouth VA 2-26-11 Platelet function testing and the role of genetic testing 15th Annual Coastal Cardiovascular Conference
CME certified program Hyatt Regency Hotel Cambridge MD 2-27-11 Insights into factors affecting responsiveness to aspirin and clopidogrel Interactions with other
medications and platelet turnover rate Cardiovascualar Research Technologies Washington DC 2-27-11 Debate II We should tailor antiplatelet therapy based on platelet function testing and genotyping
Cardiovascular Research Technologies Washington DC 2-27-11 Do we need personalized antiplatelet therapy in the era of new potent antiplatelet therapy
Cardiovascualar Research Technologies Washington DC 3-1-11 Advances in anti-platelet therapy for the PCI patient Getting to the core of the problem of coronary
thrombus Cardiology Grand Rounds Winthrop Hospital NY 3-1-11 Update in nntiplatelet therapy and ACS Cardiology Fellows Conference Daiichi Sankyo Newark Beth
Israel Hospital Newark NJ 3-3-11 Antiplatelet therapy The Oral Anticoagulants Panel KutcherCiti Investment Research Citibank New
York NY 3-15-11 Relative merits of four thienopyridines Interventional cardiology 2011 26th International Symposium
Snowmass CO 3-30-11 Updates on ACS management University of Rochester Medical Center Rochester NY 4-1-11 The landscape of antiplatelet agents Which drug for whom and Why Women in Innovations at ACC
Society for Cardiovascular Angiography and Interventions New Orleans LA 4-1-11 Pharmacogenomic assessment is not ready for prime time American College of Cardiology Scientific
Sessions 2011 New Orleans LA 4-1-11 Is there practical utility to genomic testing for platelet function or corresponding drug responsivity i2
symposium A look into the black boxPPI and genomic testing i2American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-3-11 Genetic testing and antiplatelet therapy Antiplatelet Therapy for Aterothrombotic Disease Voxmedia New Orleans LA
4-3-11 Pharmacogenomic assessment Is not ready for prime time ACC Symposium Pharmacogenomic- or pharmacodynamic-tailored antiplatelet therapy Is it time for personalized medicine American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Assessing response to antiplatelet agents A Practicing clinicianrsquos perspective on why testing should be done now Expo learning destinations American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-4-11 Benefits beyond standard clopidogrel therapy Do pharmacokinetics and pharmacodynamics make a difference Platelet Inhibition Therapy in 2011 Current State of the Art with Practical Applications i2 Symposium American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-5-11 Genetics and cardiovascular outcomes Session summary American College of Cardiology Scientific Sessions 2011 New Orleans LA
4-14-11 Is parasugrel and ticagrelor really better than standard clopidogrel or is PLATO just a philosopher TRITON a mythical god and the oasis just a mirage Debate National Cardiovascular Controversies Piedmont Heart institute Greensboro GA
4-18-11 Role of genotyping and platelet function assessment in the PCI patient Monthly PreventionVascular Disease Conference Johns Hopkins Hospital Baltimore MD
4-20-11 Platelet function testing in clinical practice and drug development Pitfalls and opportunities Novartis Grand Rounds Novartis East Hanover NJ
4-30-11 Antiplatelet therapy Update on rapidly evolving field Ponte Vedra Cardiovascular Symposium American College of Cardiology Foundation CME-certified program Jacksonville FL
5-5-11 Platelet inhibition Optimizing and individualizing therapy The genetic basis of clopidogrel response variability Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-5-11 Glycoprotein IIbIIIa inhibitions during PCI Current status and novel approaches Society for Cardiovascular Angiography and Interventions 34th Annual Scientific Sessions Baltimore MD
5-12-11 Update on antiplatelet therapy Department of Cardiovascular Surgery Visiting professor lecture East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-12-11 Individualized management of ACS and PCI patients A case based approach East Carolina Heart Institute East Carolina University School of Medicine Greenville NC
5-23-11 Advances in antiplatelet therapy Medicine Grand Pounds Mercy Medical Center Baltimore MD 5-25-11 Antiplatelet therapy for ACS Fellows Conference Henry Ford Hospital Detroit MI
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
Curriculum Vitae Paul A Gurbel MD Page 42
5-25-11 ACS Update on antiplatelet therapy 12th Annual Antithrombotic Therapy Symposium Henry Ford Health System Detroit MI
6-16-11 Challenges and new strategies for antiplatelet therapy in atherothrombosis CME certified Medicine Grand Rounds Maryland General Hospital Baltimore MD
8-10-11 Clopidogrel and PPI interaction Is there a real safety and efficacy issue Takeda Pharmaceuticals Deerfield IL
8-23-11 Update on antiplatelet therapy for ACS Deborah Heart and Lung Center Merck Brown Mills NJ 9-22-11 Platelet function and bleeding Department of Anesthesiology CME Grand Rounds Sinai Hospital of
Baltimore Baltimore MD 9-23-11 Advances in antiplatelet drug therapy Monthly Cardiovascular CME Conference Sinai Hospital of
Baltimore Baltimore MD 9-27-11 Personalized Antiplatelet Therapy Rationale and the effects of the new drugs Newark grandrounds
Newark NJ 11-8-11 ACC11 Highlights for the Interventional Invasive and General Cardiologist Session V Genetics and
Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA 11-8-11 What is the optimal strategy genetic polymorphism and platelet function testing ACC11 Highlights for
the Interventional Invasive and General Cardiologist Session V Genetics and Pharmacokinetic Assessment Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 Late Breaking Clinical Trials and First Report Investigations I Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-9-11 The Pharmacodynamic Platform for Improved Antiplatelet Regimens Is There Any Role of Platelet Inhibition Assessment and Genetic Testing Optimal Antiplatelet Therapy in Undergoing PCI A Case-Based Roundtable with the Experts Speaker and panel discussant Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Clopidogrel Prasugrel and Ticagrelor During Primary PCI Pharmacokinetic and Pharmacodynamic Differences At the Razors Edge Establishing a New Standard of Care in Acute Myocardial Infarction Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-10-11 Practicalities and Pitfalls of Platelet Function Testing Assessing the Prognostic and Predictive Value of Platelet Function Testing in Patients Undergoing PCI Is It a Meaningful Test Viewpoint 2 Yes If You Know How to Interpret the Test Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-11-11 Point-Counterpoint Pro Point-of-Care Assays for Clopidogrel Responsiveness Offer Important Clinical Information and Should Be Used Difficult Patients in Interventional Cardiology The Art of Clinical Decision-Making Clinical Decisions I The Poor Responder to Clopidogrel Transcatheter Cardiovascular Therapeutics 2011 San Francisco CA
11-13-11 Is There Still a Role for Point-of-Care Platelet Function Testing Sunday Morning Program entitled Interventional Cardiology Bench to Bedside Controversy Complications and Landmark Studies American Heart Association Scientific Sessions 2011 San Francisco CA
Peer-Reviewed Abstracts 2004-present available upon request
6 Platelet tests More studies needed (interview) TheHeartorg October 30 2007
9 Clopidogrel dosing in PCI takes a step forward (interview) TheHeartorg March 30 2008
29 High Platelet Reactivity and Clopidogrel Dose (interview) TheHeartorg August 22 2010
30 New PLATO data No need for gene testing in PCI patients (interview) TheHeartorg - August 28 2010
17 Gene Variant Linked To Effectiveness Of Popular Anti-clotting ScienceDaily August 26 2009
24 Studies give AstraZeneca blood clot drug boost over competitor Wilmington News Journal ndash 11192009
25 Onsetoffset and respond studies Interview at the ACC meeting Cardiovascular Business 3-13-2010
29 Plavix Less Effective In Certain Patients Wall Street Journal August 25 2010
30 Research Could Unlock Key to Heart Attacks Baltimore Messenger September 23 2010
32 Double-dose clopidogrel helpful for some patients TheHeartorg October 22 2010
